[
{"protocolSection":{"identificationModule":{"nctId":"NCT02326129","briefTitle":"Novel Biomarker for Development of T2D"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Duke University"},"collaborators":[{"name":"Children's Miracle Network"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Type II"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01713764","briefTitle":"A Pilot Study of the Effects of Diet and Behavioral Interventions on Health in Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Francisco"}},"conditionsModule":{"conditions":["Diabetes Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low Carbohydrate Diet"},{"name":"American Diabetes Association Diet"},{"name":"Mindfulness and Positive Affect Skills"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01121315","briefTitle":"A Retrospective Study of Cardiovascular Events Related to the Use of Glucose Lowering Drug Treatment in Primary Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Type II"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04011904","briefTitle":"The Role of Traditional or Western Diet in the TBC1D4 Gene on Glucose Homeostasis in Greenland Inuits"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Copenhagen"},"collaborators":[{"name":"Steno Diabetes Center Copenhagen"},{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["T2D"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cross-over study"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05767372","briefTitle":"Effect of Coherent Breathing on Elderly Quality of Life"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cairo University"}},"conditionsModule":{"conditions":["Stable Diabetes Mellitus","Geriatrics","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Coherent Breathing Exercise"},{"name":"Inspiratory muscle training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03194152","briefTitle":"Peanut Consumption and Cardiovascular Disease Risk in a Chinese Population"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Harvard School of Public Health (HSPH)"}},"conditionsModule":{"conditions":["T2D"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Peanut"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04790526","briefTitle":"Dose Response of Eccentric Exercise on Glycemic Control in Type II Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Riphah International University"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Eccentric Exercises Dose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02446054","briefTitle":"A Study to Evaluate the Effect of Musashino Diabetes Diet in Type II Diabetes Mellitus Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Celio Technology Inc."}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Musashino T2DM diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04665284","briefTitle":"Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Getz Pharma"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Usual care group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05252728","briefTitle":"Altered Faecal Microbiome and Metabolome in CT1D, AT1D and T2D"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Second Xiangya Hospital of Central South University"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus Maturity Onset"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01868646","briefTitle":"Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type II Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Materia Medica Holding"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Subetta"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02879383","briefTitle":"Effect of Duodenal Mucosal Resurfacing (DMR) Using the Revita System in the Treatment of Type 2 Diabetes (T2D)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fractyl Health Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Noninsulin-Dependent Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DMR Procedure"},{"name":"Sham Procedure"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00960791","briefTitle":"Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD1656"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02091193","briefTitle":"Effects of Krill Oil on Endothelial Function in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Danbury Hospital"},"collaborators":[{"name":"Prograde Nutrition"}]},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Krill Oil (Supplement A)"},{"name":"Placebo (Supplement B)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02805361","briefTitle":"Real World Assessment of Clinical Outcome Changes -Including Month of Ramadan-for Dapagliflozin in Management of Type II Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03047486","briefTitle":"Smartguard Use in Real Life : a Longitudinal Study in Patients With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Caen"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus Maturity Onset"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06645418","briefTitle":"Relative Hand Grip Strength and Functional Fitness in Diabetic Patient in Egypt"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Beni-Suef University"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"relative Hand grip strength"},{"name":"senior fitness test"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01252524","briefTitle":"Effect of Calcium Polycarbophil on Type II Diabetes Mellitus Control: a Randomized Double-blind Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"East Carolina University"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Calcium polycarbophil"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01020123","briefTitle":"Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD1656"},{"name":"Placebo"},{"name":"Glipizide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03258840","briefTitle":"EPA Supplementation on Vascular Inflammation, and Gene Expression of PON2 in Patients With Type II Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tehran University of Medical Sciences"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EPA Supplement"},{"name":"EPA Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03084965","briefTitle":"Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03059719","briefTitle":"Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"PegBio Co., Ltd."}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide injection(Byetta)"},{"name":"PB-119 injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00825383","briefTitle":"Effect of Dietary Fiber on Glucose & Lipids in Non Insulin Dependent Diabetes Mellitus (NIDDM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Texas Southwestern Medical Center"}},"conditionsModule":{"conditions":["Non-Insulin-Dependent Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High Fiber and Moderate Fiber Diets"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06386328","briefTitle":"A Clinical Trial to Evaluate the Food Effect of CKD-378"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-378, QD, PO"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00995787","briefTitle":"Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD1656"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01261494","briefTitle":"Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Genfit"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GFT505 80mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05719155","briefTitle":"Pharmacokinetics and Safety/Tolerability of CKD-379"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-379"},{"name":"D759+D745+D150"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05544214","briefTitle":"Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-371"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05452525","briefTitle":"Pharmacokinetics and Safety/Tolerability Profile of CKD-379"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-379 I"},{"name":"CKD-379 II"},{"name":"D759+D745+D150"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05364476","briefTitle":"Development and Exploration of the Effectiveness and Feasbility of a Digital Intervention for Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"EVYD Technology"},"collaborators":[{"name":"Raja Isteri Pengiran Anak Saleha Hospital"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"16 weeks digital intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05274880","briefTitle":"Study to Evaluate the Food Effect on Pharmacokinetics Profile and Safety of CKD-393"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-393"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02144948","briefTitle":"Investigation of the Effect of E.-Coli-Nissle as Supporting Therapy to Standard Care of Diabetes Mellitus Type II"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GWT-TUD GmbH"},"collaborators":[{"name":"Ardeypharm GmbH"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"e.-coli-nissle"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01972724","briefTitle":"Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"Metformin"},{"name":"Sulfonylurea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00306176","briefTitle":"Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aristotle University Of Thessaloniki"},"collaborators":[{"name":"University of Athens"}]},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01969084","briefTitle":"The Effect of Linagliptin on Mitochondrial and Endothelial Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Beth Israel Deaconess Medical Center"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Linagliptin"},{"name":"Placebo"},{"name":"Microcirculation testing"},{"name":"Macrocirculation testing"},{"name":"MRI Scans"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01523405","briefTitle":"A Non-Interventional Study To Evaluate Diabetes Related Quality Of Life, Frequency And Impact Of Hypoglycemia In T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01262586","briefTitle":"Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03478202","briefTitle":"GOLO Open-Label Pilot 1"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Golo"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GOLO RELEASE"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02184455","briefTitle":"Feasibility Study of DermGEN for Diabetic Foot Ulcer Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dr. Paul F. Gratzer"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"},{"name":"Nova Scotia Health Authority"}]},"conditionsModule":{"conditions":["Diabetes Type I","Diabetes Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DermGEN"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00481663","briefTitle":"A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Placebo to sitagliptin"},{"name":"Metformin"},{"name":"Rescue"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00863954","briefTitle":"Application of Magnetic Fields as Adjunctive Treatment for Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"pico-tesla Magnetic Therapies, LLC"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Resonator Device"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05662332","briefTitle":"A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes","T2D"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Efsitora Alfa"},{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00131287","briefTitle":"The Supplementary Effects of the Extract of Agaricus Blazei Murril on Type II Diabetes Mellitus (DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"ECbiotech Taiwan"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Extract of Agaricus blazei Murill"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01552005","briefTitle":"Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2D)"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02592421","briefTitle":"SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01076829","briefTitle":"Effects of a Spiced Meat Patty on Inflammation in Men With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, Los Angeles"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Spice polyphenols"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02036372","briefTitle":"Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Insulin bolus"},{"name":"GIK infusion"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01505426","briefTitle":"A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ASP1941"},{"name":"metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02761018","briefTitle":"Using Technology to Share Fitness Goals and Results to Improve Diabetes Outcomes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mike O'Callaghan Military Hospital"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Behavioral: Fitness Tracker"},{"name":"Fitness Tracker"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00309751","briefTitle":"Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kowa Research Europe"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus","Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pitavastatin"},{"name":"Atorvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04632862","briefTitle":"The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daewoong Pharmaceutical Co. LTD."}},"conditionsModule":{"conditions":["T2DM (Type 2 Diabetes Mellitus)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DWP16001"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04654390","briefTitle":"The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daewoong Pharmaceutical Co. LTD."}},"conditionsModule":{"conditions":["T2DM (Type 2 Diabetes Mellitus)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DWP16001 Amg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02156349","briefTitle":"A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"},"collaborators":[{"name":"Roche Diabetes Care Deutschland GmbH"}]},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Accu-Chek Smart Pix Software"},{"name":"Accu-Chek Smart Pix readout Device"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02012478","briefTitle":"Using a Motivational Interviewing (MI) Informed Text Messaging Program to Lower Blood Sugar in Diabetic Patients."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pennsylvania"},"collaborators":[{"name":"Center for Healthcare Improvement and Patient Safety"},{"name":"Leonard Davis Institute"}]},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MI- informed SMS program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03616392","briefTitle":"Clinical Trial to Evaluate the Drug Drug Interaction of CKD-501 and D308"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"D308, CKD-501"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01952535","briefTitle":"A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral HMS5552 in Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hua Medicine Limited"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HMS5552"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01648244","briefTitle":"The Use of a Computer Program to Help Primary Care Providers Treat Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Walter Reed National Military Medical Center"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Computer-Assisted Decision Support"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01566981","briefTitle":"E-health Care Process Support for Diabetes Type II Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Primorska"},"collaborators":[{"name":"University of Ljubljana School of Medicine, Slovenia"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type II,"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Computerised support to the Diabetes type II patients"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04218305","briefTitle":"Fetuin-A as a Marker in Obesity and Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Minia University"}},"conditionsModule":{"conditions":["Diabete Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Serum Level Of Fetuin A"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00344370","briefTitle":"Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kowa Research Europe"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus","Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pitavastatin"},{"name":"Atorvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00086515","briefTitle":"Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin (MK0431)"},{"name":"Placebo/Glipizide 5 mg"},{"name":"Metformin"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02175121","briefTitle":"Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"PF-06291874"},{"name":"PF-06291874"},{"name":"PF-06291874"},{"name":"PF-06291874"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00162175","briefTitle":"PPAR-COMBO With Sulfonylurea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristol-Myers Squibb"}},"conditionsModule":{"conditions":["Metabolics Diabetes Nos"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Muraglitazar"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00929539","briefTitle":"Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Akros Pharma Inc."}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"JTT-130"},{"name":"JTT-130 Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01088711","briefTitle":"Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes (T2D)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omarigliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01165190","briefTitle":"Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Arizona State University"},"collaborators":[{"name":"Takeda"}]},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01196728","briefTitle":"Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"CellMed AG, a subsidiary of BTG plc."}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CM3.1-AC100"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05376930","briefTitle":"Study to Evaluate the Long Term Safety and Efficacy of DWP16001 Compared to Placebo in the Treatment of T2DM."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daewoong Pharmaceutical Co. LTD."}},"conditionsModule":{"conditions":["T2DM (Type 2 Diabetes Mellitus)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DWP16001 Amg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04843592","briefTitle":"SOKARY Mobile Application With Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Magda Bayoumi"}},"conditionsModule":{"conditions":["Type II Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SOKARY Mobile"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00952445","briefTitle":"A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"InteKrin Therapeutics, Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"T0903131 Besylate"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03467932","briefTitle":"A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oramed, Ltd."},"collaborators":[{"name":"Integrium"}]},"conditionsModule":{"conditions":["T2DM (Type 2 Diabetes Mellitus)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cohort A: ORMD-0801"},{"name":"Placebo oral capsule"},{"name":"Cohort B: ORMD-0801"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03112382","briefTitle":"Effect of SLC30A8 rs13266634 Genetic Polymorphism on Zinc Supplementation and Glycemic Control in Egyptian Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cairo University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"zinc supplement plus vitamin A and E"},{"name":"vitamin A and E"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05376969","briefTitle":"Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daewoong Pharmaceutical Co. LTD."}},"conditionsModule":{"conditions":["T2DM (Type 2 Diabetes Mellitus)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DWP16001"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04270656","briefTitle":"Liver and Metabolic Effects of Insulin Pump Therapy in Diabetics Type 2 with Non-alcoholic Hepatic Steatosis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nantes University Hospital"},"collaborators":[{"name":"University Hospital, Angers"}]},"conditionsModule":{"conditions":["Type 2 Diabetes (T2D)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin pump therapy"},{"name":"Multi-injection treatment ( MDI )."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03829514","briefTitle":"Fenofibrate in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of South Carolina"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fenofibrate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03155087","briefTitle":"PRKAA2 Genetic Polymorphisms and Its Susceptibility to Chinese Type 2 Diabetes Mellitus and Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"People's Hospital of Zhengzhou University"}},"conditionsModule":{"conditions":["T2DM (Type 2 Diabetes Mellitus)"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05455242","briefTitle":"Habit Formation for Diabetes Self-Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Des Moines University"}},"conditionsModule":{"conditions":["Diabete Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Habit formation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00577590","briefTitle":"Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Washington University School of Medicine"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Rosiglitazone"},{"name":"Lovaza"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04634500","briefTitle":"The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daewoong Pharmaceutical Co. LTD."}},"conditionsModule":{"conditions":["T2DM (Type 2 Diabetes Mellitus)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06224803","briefTitle":"Evaluation of Effects of Dibifree® on Regulation of Blood Sugar and HbA1c in Patients With Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Global Preventive Medicine Biotech Co., Ltd."}},"conditionsModule":{"conditions":["Type II Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Compound plant extracts"},{"name":"Indigestible dextrin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05983289","briefTitle":"Single Escalating Dose Study Of HSK7653 In Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Haisco Pharmaceutical Group Co., Ltd."}},"conditionsModule":{"conditions":["T2DM (Type 2 Diabetes Mellitus)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HSK7653"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06055582","briefTitle":"To Study the Effects of Mango Ingestion in T2DM and Non-diabetic Subjects."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diabetes Foundation, India"},"collaborators":[{"name":"Indian Council of Medical Research"}]},"conditionsModule":{"conditions":["Normoglycemia","T2DM (Type 2 Diabetes Mellitus)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bread"},{"name":"Mango"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01654120","briefTitle":"Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mountain Diabetes and Endocrine Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00701090","briefTitle":"A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus, Non Insulin Dependent","Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin"},{"name":"Comparator: glimepiride"},{"name":"open-label metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02957721","briefTitle":"Diabetes Engagement and Activation Platform"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Virginia Commonwealth University"}},"conditionsModule":{"conditions":["Type 2 Diabetes (T2D)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00151697","briefTitle":"LANN-study: Lantus, Amaryl, Novorapid, Novomix Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rijnstate Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Novomix 30"},{"name":"Novorapid and Amaryl"},{"name":"Lantus"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04120844","briefTitle":"Effectiveness of Motivational Interviewing on Improving Care for Type 2 Diabetes Mellitus Patients in China"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Hong Kong-Shenzhen Hospital"}},"conditionsModule":{"conditions":["Diabete Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Motivational interviewing (MI)-based patient empowerment program (PEP)"},{"name":"Traditional lecture style health education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01194258","briefTitle":"Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Halozyme Therapeutics"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin lispro"},{"name":"Insulin aspart"},{"name":"Recombinant human hyaluronidase PH20"},{"name":"Insulin glulisine"},{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01596244","briefTitle":"Jordan Diabetes Microclinic Project"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Microclinic International"},"collaborators":[{"name":"Ministry of Health Jordan"},{"name":"Royal Health Awareness Society (RHAS), Jordan"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Microclinic"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06642467","briefTitle":"BGEM Use as Blood Glucose Prediction Model in T2DM Population of Indonesia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Krida Wacana Christian University"},"collaborators":[{"name":"Actxa"},{"name":"Lif"}]},"conditionsModule":{"conditions":["Diabete Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BGEM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03012074","briefTitle":"Episodic to Real-Time Care in Diabetes Self-Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Duke University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Type 2 Diabetes Self-Management"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02824874","briefTitle":"CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Duvie Tab. 0.5mg"},{"name":"Duvie Tab. 0.5mg + Januvia Tab. 100mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04970940","briefTitle":"The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AJU Pharm Co., Ltd."}},"conditionsModule":{"conditions":["T2DM (Type 2 Diabetes Mellitus)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Treatment A"},{"name":"Treatment B"},{"name":"Treatment C"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00081328","briefTitle":"Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Rosiglitazone"},{"name":"Lifestyle Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02685774","briefTitle":"A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500mg in Healthy Male Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg"},{"name":"CKD-395 0.25/500mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00660790","briefTitle":"Multifactorial Treatment of Cardiovascular Risk in Diabetic Patients: Identification of Treatment Non-Responders"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Graz"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intensified Treatment of risk factors"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02648854","briefTitle":"Investigate the Effect of Food on the Pharmacokinetic Characteristics of CKD-395 in Healthy Male Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T"},{"name":"CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02627027","briefTitle":"A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/750 mg in Healthy Male Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Duvie Tab. 0.5mg, Glucodaun OR Tab. 750mg"},{"name":"CKD-395 0.25/750mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02565368","briefTitle":"A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg"},{"name":"CKD-395 0.5/1000mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05904847","briefTitle":"The Effect of Theory-Based Education on Patient Empowerment and Self-Efficacy in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sakarya University"}},"conditionsModule":{"conditions":["Diabete Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Application of The Theory of Planned Behaviour for Diabetes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06188572","briefTitle":"The Effect of Peripheral Neuropathy Symptoms on Temporomandibular Joint Functionality"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bandırma Onyedi Eylül University"}},"conditionsModule":{"conditions":["Diabete Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Michigan Neuropathy Screening Instrument"},{"name":"Numeric Pain Scale"},{"name":"Mandibular Function Disorder Questionnaire"},{"name":"Fonseca Anamnestic Index"},{"name":"Ferrans&Powers Quality of Life Index Diabetes Version"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00563225","briefTitle":"20 Week Bridging Study in Type II DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00482079","briefTitle":"A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks"},{"name":"Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02028091","briefTitle":"Diabetes Mellitus - A Diagnosis Trial by Means of Non Invasive Measurements"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Vienna"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type II"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02471794","briefTitle":"Personalized Health Planning in Shared Medical Appointments for Individuals With Type II Diabetes Pilot Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Duke University"}},"conditionsModule":{"conditions":["Type II Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Personalized Health Planning Shared Medical Appointment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05359341","briefTitle":"Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sadat City University"},"collaborators":[{"name":"Beni-Suef University"}]},"conditionsModule":{"conditions":["Diabete Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin 50 mg"},{"name":"Empagliflozin 12.5 MG"},{"name":"Sitagliptin 50 mg + Empagliflozin 12.5 MG"},{"name":"Empagliflozin 12.5 MG + Sitagliptin 50 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01728740","briefTitle":"Bioequivalence Study for Acarbose / Metformin FDC"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acarbose/Metformin FDC (BAY81-9783)"},{"name":"Acarbose (Glucobay, BAYG5421)"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01301092","briefTitle":"A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2189265"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01247896","briefTitle":"Single Dose Escalation Study of PF-05190457 in Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-05190457"},{"name":"PF-05190457"},{"name":"PF-05190457"},{"name":"PF-05190457"},{"name":"PF-05190457"},{"name":"PF-05190457"},{"name":"PF-05190457"},{"name":"PF-05190457"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00231387","briefTitle":"Rosiglitazone And Plaque Study for Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Non-insulin-dependent Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rosiglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01025999","briefTitle":"Mechanisms of Glycemic Improvement After Gastrointestinal Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Washington"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00649909","briefTitle":"Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hadassah Medical Organization"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04893135","briefTitle":"Impact of the Rapid Normalization of Chronic Hyperglycemia and the Practice of Moderate Physical Activity on the \"Receptor Activator of Nuclear Factor-kappa B Ligand / Osteoprotégérine (RANKL / OPG) System in Patients Living With Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Sud Francilien"}},"conditionsModule":{"conditions":["Type II Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pratice physical activity"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00528918","briefTitle":"Comparison of Apidra to Regular Insulin in Hospitalized Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Carl T. Hayden VA Medical Center"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glulisine (Apidra)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03727854","briefTitle":"Effect of Premeal Protein-bar on Glycemic Control in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Hospital"}},"conditionsModule":{"conditions":["Patients With Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Premeal protein enriched bar"},{"name":"Dietary modification"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01782092","briefTitle":"Activator and Type II Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Life University"}},"conditionsModule":{"conditions":["Type II Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Chiropractic Adjustment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04768673","briefTitle":"A Study to Investigate the PK and Safety of CKD-393"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Type II Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-393 formulation I"},{"name":"CKD-393 formulation II"},{"name":"D501, D759, H053"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01735253","briefTitle":"Prospective Observatonal Study for Effect of Duodenojejunal Bypass and Gastric Bypass on T2DM Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Inha University Hospital"}},"conditionsModule":{"conditions":["Non Insulin Dependent Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"laparoscopic roux en Y gastric bypass / open duodenojejunal bypass"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00889785","briefTitle":"Situational Problem Solving in Adolescents With Type 2 Diabetes: Enhancing a Randomized Controlled Trial (RCT)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Adolescents With Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Comprehensive intervention (disease management program)"},{"name":"Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01373814","briefTitle":"Nutritional Therapy for Diabetic Cardiomyopathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Washington University School of Medicine"}},"conditionsModule":{"conditions":["T2DM (Type 2 Diabetes Mellitus)"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00985114","briefTitle":"Safety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and Obesity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Morphic Medical Inc."}},"conditionsModule":{"conditions":["Type II Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EndoBarrier"},{"name":"Diet + Lifestyle Counseling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01610934","briefTitle":"The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"},"collaborators":[{"name":"Novo Nordisk A/S"},{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Maturity-onset Diabetes of the Young"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05881213","briefTitle":"Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-378 and Co-administration of D745, D150, D029 in Healthy Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Type II Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-378 (low-dose)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01980459","briefTitle":"Magnesium Treatment of Inflammation in Disorders of Glucose Homeostasis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"George Washington University"},"collaborators":[{"name":"Nadia Zghoul, PhD, Dept of Clinical Research"},{"name":"Dasman Diabetes Institute"}]},"conditionsModule":{"conditions":["Non-Insulin Dependent Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"magnesium lactate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05741437","briefTitle":"A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-378"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Type II Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-378, QD, PO Drug: D745, D150, QD, PO"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03596177","briefTitle":"A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"MedImmune LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MEDI0382"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04639492","briefTitle":"Postbiotic MBS and Metformin Combination in Patients With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Microbio Co Ltd"}},"conditionsModule":{"conditions":["Type-II Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MBS oral solution"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00359112","briefTitle":"AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Non-Insulin-Dependent Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"metformin"},{"name":"sulphonylurea"},{"name":"Avandamet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00318656","briefTitle":"24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Non-Insulin-Dependent Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rosiglitazone-metformin fixed dose combination"},{"name":"metformin + glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01384045","briefTitle":"Outreach for Diabetes Cure"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Denver"}},"conditionsModule":{"conditions":["Type II Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Health promotion outreach"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01342939","briefTitle":"Pathophysiological Implications of the Incretin Hormones in Maturity Onset of Diabetes of the Young (MODY)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"},"collaborators":[{"name":"University of Copenhagen"},{"name":"Steno Diabetes Center Copenhagen"}]},"conditionsModule":{"conditions":["Maturity-onset Diabetes of the Young"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral Glucose Tolerance Test (OGTT)"},{"name":"iso glycaemic intravenous (iv) glucose infusion (IIGI)"},{"name":"Meal test"},{"name":"Sitagliptin"},{"name":"Incretin effect on sulphonyl urea treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04499846","briefTitle":"Educational Intervention Targeting Statin Therapy and Compliance in Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lille Catholic University"}},"conditionsModule":{"conditions":["Type II Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Therapeutic education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00269061","briefTitle":"Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Non-Insulin-Dependent Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06006468","briefTitle":"Evaluating ImmuNe Changes in the Evolution of Pre Type 1 Diabetes With Adult ONset"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Royal Devon and Exeter NHS Foundation Trust"},"collaborators":[{"name":"University of Exeter"}]},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 1 Diabetes Mellitus Maturity Onset"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High genetic risk for type 1 diabetes"},{"name":"High gentic risk for Coeliac disease"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01207934","briefTitle":"Recombinant Human Leptin Therapy Effects on Insulin Action"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Washington University School of Medicine"},"collaborators":[{"name":"Amgen"},{"name":"National Institutes of Health (NIH)"}]},"conditionsModule":{"conditions":["Type Two Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo"},{"name":"low-dose leptin"},{"name":"high-dose leptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05711602","briefTitle":"The Physical and Mental Health of People With Type II Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Jaén"}},"conditionsModule":{"conditions":["Adult ALL","Diabete Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pilates"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05789706","briefTitle":"Use of a Smart-phone Based Medication Adherence Platform to Improve Outcomes in Uncontrolled Non-insulin Dependent Diabetes Among Veterans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VA Sierra Nevada Health Care System"}},"conditionsModule":{"conditions":["Diabetes","Diabete Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dayamed Arthur a novel intelligent medication adherence platform"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04540016","briefTitle":"Mass Balance and Biotransformation of [14C]HSK7653 in Human"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sichuan Haisco Pharmaceutical Group Co., Ltd"},"collaborators":[{"name":"First Affiliated Hospital of Suzhou Medical College"}]},"conditionsModule":{"conditions":["Type II Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"[14C]HSK7653"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00156897","briefTitle":"Efficacy and Safety of ATL-962 in Obese Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Alizyme"}},"conditionsModule":{"conditions":["Non-Insulin-Dependent Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ATL-962"},{"name":"Orlistat"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00856908","briefTitle":"Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type II Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD1656"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02556840","briefTitle":"Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Assistance Publique - Hôpitaux de Paris"}},"conditionsModule":{"conditions":["Maturity-Onset Diabetes of the Young"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01698528","briefTitle":"Evaluation of a Prototype Diabetes Management System Applied to Insulin Initiation and Titration"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Joslin Diabetes Center"},"collaborators":[{"name":"Massachusetts Institute of Technology"}]},"conditionsModule":{"conditions":["Type II Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tablet Computer"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01927562","briefTitle":"Initial Clinical Evaluation of an Endoscopic Therapy for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fractyl Health Inc."}},"conditionsModule":{"conditions":["Type II Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fractyl Duodenal Remodeling System"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03498001","briefTitle":"Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire Dijon"}},"conditionsModule":{"conditions":["Type II Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLP-1 agonists"},{"name":"Cardiac MRI"},{"name":"Follow up by phone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01619332","briefTitle":"Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type II Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Sitagliptin"},{"name":"LEZ763"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06377657","briefTitle":"Oxidative and Antioxidant Indices to HIIT and Aloe Vera Supplementation in Patients With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Nis"}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise"},{"name":"Aloe vera"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00703482","briefTitle":"A Randomised, Double-Blind, Placebo-Controlled Study Assessing the Effect of Fenofibrate, Coenzyme Q10 and Their co-Administration on Ventricular Diastolic Function in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Solvay Pharmaceuticals"}},"conditionsModule":{"conditions":["Patients With Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fenofibrate/CoQ10"},{"name":"Fenofibrate/CoQ10"},{"name":"Fenofibrate/CoQ10"},{"name":"Fenofibrate/CoQ10"},{"name":"Fenofibrate/CoQ10"},{"name":"Fenofibrate/CoQ10"},{"name":"Fenofibrate/CoQ10"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02984644","briefTitle":"Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"}},"conditionsModule":{"conditions":["Type II; Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00819884","briefTitle":"To Evaluate 24-hr Glucose After OD vs BD AZD1656"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type II Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD1656"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01330251","briefTitle":"The Effect of Gastric Bypass Surgery on Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Oulu"},"collaborators":[{"name":"Oulu University Hospital"}]},"conditionsModule":{"conditions":["Type II Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02429258","briefTitle":"Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type II Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Farxiga"},{"name":"Placebo"},{"name":"Metformin"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01206725","briefTitle":"Exercise Study on Cardiac Function in Patients With Diabetes Mellitus Type 2 and Diastolic Dysfunction"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Norwegian University of Science and Technology"}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03784703","briefTitle":"Type 2 Diabetic Patients Maintained on Statin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Damanhour University"},"collaborators":[{"name":"Tanta University"}]},"conditionsModule":{"conditions":["Dyslipidemia Associated With Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Atorvastatin 40 Mg Oral Tablet"},{"name":"Rosuvastatin 10 Mg Oral Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03437109","briefTitle":"Efficacy of Androgen Substitution for Hypogonadism in Men With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Besins Healthcare"}},"conditionsModule":{"conditions":["T2DM (Type 2 Diabetes Mellitus)","Hypogonadism"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Laboratory tests"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02084251","briefTitle":"Clinical Trial for PB-119 in Healthy Subjects (Phase I)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"PegBio Co., Ltd."}},"conditionsModule":{"conditions":["Type II Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PB-119"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02726217","briefTitle":"NYULMC CareSmarts Pilot"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NYU Langone Health"}},"conditionsModule":{"conditions":["Diabetes","Type 2 Diabetes (T2D)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CareSmarts Mobile Health Diabetes Program"},{"name":"Standard of Care Reminders and Self Assessments"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00882882","briefTitle":"To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sandoz"}},"conditionsModule":{"conditions":["Type II Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC"},{"name":"Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC"},{"name":"GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb"},{"name":"GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02496000","briefTitle":"Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oramed, Ltd."},"collaborators":[{"name":"Integrium"}]},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ORMD-0801"},{"name":"Placebo Comparator"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00887302","briefTitle":"Metabolomics of Roux-en-Y Gastric Bypass (RYGB) With Gastrostomy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"East Carolina University"},"collaborators":[{"name":"Johnson & Johnson"}]},"conditionsModule":{"conditions":["Type II Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gastric Band"},{"name":"Gastric Sleeve"},{"name":"Gastrostomy Tube"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04830969","briefTitle":"Impact of Periodontal Therapy on Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"State University of New York at Buffalo"},"collaborators":[{"name":"Sunstar, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II","Periodontitis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Chlorhexidine gluconate oral rinse"},{"name":"Scaling & Root Planing"},{"name":"Soft Picks"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01652729","briefTitle":"Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide once weekly suspension"},{"name":"Sitagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00561171","briefTitle":"Phase IIa Study to Investigate the Efficacy and Safety of SPP635 in Diabetic and Hypertensive Patients With Albuminuria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Speedel Pharma Ltd."}},"conditionsModule":{"conditions":["Hypertension","Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SPP635"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06476990","briefTitle":"Food Rx + Community Health Worker"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Kansas Medical Center"},"collaborators":[{"name":"Blue Cross Blue Shield"}]},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Healthy food box"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04289818","briefTitle":"The Effectiveness of \"CARE Coaching Model\" as an Effort to Empower Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Indonesia University"}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Health Coaching"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04233229","briefTitle":"Evaluation of a Closed-loop Insulin Delivery System at Home With Tailored Home Care Services in Poorly Controlled Type 2 Diabetes Patients (T2D)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Air Liquide Santé International"},"collaborators":[{"name":"International Clinical Trials Association"}]},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"t:slim X2 with Control-IQ"},{"name":"home healthcare services"},{"name":"usual care for daily insulin treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02759289","briefTitle":"Arsenic, Disordered Glucose Homeostasis and Atherosclerosis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NYU Langone Health"}},"conditionsModule":{"conditions":["Atherosclerosis","Type 2 Diabetes (T2D)"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05107063","briefTitle":"An Observational Study Investigating the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo"},"collaborators":[{"name":"Daiichi Sankyo Korea Co., Ltd."}]},"conditionsModule":{"conditions":["Dyslipidemia Associated With Type II Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pravastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06005519","briefTitle":"The Short and Long-term Effects of Low Advanced Glycation End Product* Diet"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Marmara University Pendik Training and Research Hospital"}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"low AGE diet education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01066039","briefTitle":"Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck KGaA, Darmstadt, Germany"},"collaborators":[{"name":"Merck Ltd."}]},"conditionsModule":{"conditions":["Hypertension","Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bisoprolol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04887077","briefTitle":"Digital Intervention Promoting Physical Activity Among Obese People (DIPPAO)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Clermont-Ferrand"},"collaborators":[{"name":"SENS laboratory, Univ. Grenoble Alpes"},{"name":"INRAE, UNH, CRNH Auvergne, Clermont Auvergne University"},{"name":"Kiplin"},{"name":"I-SITE Clermont Auvergne Project 20-25"}]},"conditionsModule":{"conditions":["Obesity","Diabete Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Kiplin"},{"name":"face-to-face"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05266742","briefTitle":"Investigation of the Effect of Web-based Education on Self-Care Management and Family Support in Women With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ankara Yildirim Beyazıt University"}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"web based education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01336738","briefTitle":"Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"150 mg PF-04991532"},{"name":"450 mg PF-04991532"},{"name":"750 mg PF-04991532"},{"name":"Sitagliptin 100 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04971252","briefTitle":"Type 2 Diabetes Mellitus and Chronic Kidney Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sohag University"}},"conditionsModule":{"conditions":["Renal Disorder Associated With Type II Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hematologic tests for patients with diabetes mellitus and chronic kidney disease"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05399134","briefTitle":"Glycemic Evaluation of Novel Staple Foods"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National University of Singapore"}},"conditionsModule":{"conditions":["Diabete Type 2","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Modified Functional Foods"},{"name":"Control Functional Foods"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02041234","briefTitle":"Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Khoo Teck Puat Hospital"}},"conditionsModule":{"conditions":["Type II Diabetes in Subjects BMI 27 to 32"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Roux-en-Y Gastric Bypass (RYGB)"},{"name":"Incretin analogues"},{"name":"Xenical"},{"name":"SGLT2 inhibitors"},{"name":"DPP-4 Inhibitors"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04946188","briefTitle":"Translating Biometric Data Into Blood Glucose Levels"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Scimita Operations Pty Ltd."}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Opuz NICGM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05752929","briefTitle":"Comparison of 2 Hyperglycemia-correction Scales in Hospitalized Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital Universitario Clinica San Rafael"}},"conditionsModule":{"conditions":["Diabete Type 2","Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin"},{"name":"insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00637546","briefTitle":"Gait and Balance of Diabetes Type 2 Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Geneva"},"collaborators":[{"name":"Maastricht University Medical Center"},{"name":"Swiss Federal Institute of Technology"},{"name":"Ecole Polytechnique Fédérale de Lausanne"}]},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physiotherapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02529982","briefTitle":"Curcumin Supplementation and Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Nutrition and Food Technology Institute"}},"conditionsModule":{"conditions":["Non Insulin Dependent Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Curcumin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01845064","briefTitle":"A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"DiaMedica Therapeutics Inc"}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DM199"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04910178","briefTitle":"Follow-up of NAFLD Patients With MRI-PDFF"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Asmaa Abdelfattah Elsayed"}},"conditionsModule":{"conditions":["Diabetes Type 2","NAFLD"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin 25 MG"},{"name":"Ursodeoxycholic acid"},{"name":"Pentoxifylline 400 MG"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05276128","briefTitle":"Effects of Plant Based Lipids on Glucose Regulation and Cognitive Variables"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lund University"}},"conditionsModule":{"conditions":["Diabete Type 2","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"lipids"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03714451","briefTitle":"Investigating the Effect of Onyx Sorghum on Blood Glucose in Individuals With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yale University"},"collaborators":[{"name":"Silver Palate Kitchens Inc."}]},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"onyx sorghum"},{"name":"whole wheat flour"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01193179","briefTitle":"A Phase 3 Study of OPC-262 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kyowa Kirin Co., Ltd."}},"conditionsModule":{"conditions":["Diabetes, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"OPC-262"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01359904","briefTitle":"Effect of Dialysis Glucose Bath on Glycemic Control in Hemodialysis (HD)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"McGill University Health Centre/Research Institute of the McGill University Health Centre"}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High Dialysate bath"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03179254","briefTitle":"Type 2 Diabetes and Ambulatory Surgery Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Texas Southwestern Medical Center"}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin continue"},{"name":"Metformin discontinue"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01617603","briefTitle":"A Comparison Chocolate With and Without High Cocoa Solids in Patients With Type 2 Diabetes in a Randomised Clinical Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Société des Produits Nestlé (SPN)"}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cocoa Polyphenols"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01472328","briefTitle":"Effects of HBO Therapy on Muscular Insulin Resistence in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"German Diabetes Center"},"collaborators":[{"name":"Heinrich-Heine University, Duesseldorf"}]},"conditionsModule":{"conditions":["Obesity","Non-insulin-dependent Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HBO therapy"},{"name":"Hyperbaric room air"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02093234","briefTitle":"Changing the Healthcare Delivery Model"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"George Washington University"}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"mobile health care application"},{"name":"CHWs and mobile health care application"},{"name":"Community Health Worker (CHW)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04076384","briefTitle":"Effectiveness of a Team-based Follow-up Program in General Practice Among People With Chronic Conditions"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bergen University College"},"collaborators":[{"name":"University of Bergen"},{"name":"University of Stavanger"}]},"conditionsModule":{"conditions":["Diabetes Type 2","COPD"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Guided Self-Determination"},{"name":"Standard care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04115657","briefTitle":"The Effect of Different Starches of Boba Pearls and Sugar Substitutes Used in Milk Tea on Glycaemia, Insulinaemia and Appetite Control (Pearl Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Singapore Institute of Food and Biotechnology Innovation"}},"conditionsModule":{"conditions":["Diabete Type 2","Obese"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Starch 1"},{"name":"Starch 2"},{"name":"Starch 3"},{"name":"Starch 4"},{"name":"Sugar 1"},{"name":"Sugar 2"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02586129","briefTitle":"Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yuhan Corporation"}},"conditionsModule":{"conditions":["Dyslipidemia","Type II Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"YH14755"},{"name":"Metformin"},{"name":"Rosuvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00881543","briefTitle":"\"Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients\""},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Sao Paulo General Hospital"},"collaborators":[{"name":"University of Sao Paulo"}]},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dipeptidyl Peptidase IV inhibitors"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05072990","briefTitle":"Type 2 Diabetes Mellitus With Obesity and Dyslipidemia Treated by Chinese Herbal Medicine"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus in Obese","Dyslipidemia Associated With Type II Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Chinese herb medicine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03380416","briefTitle":"Effects of a Portfolio Diet on NAFLD in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Federico II University"}},"conditionsModule":{"conditions":["Diabetes Type 2","NAFLD"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Portfolio Diet"},{"name":"MUFA Diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02809963","briefTitle":"Mineralocorticoid Receptor Antagonists in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Herlev Hospital"}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Eplerenone"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02947620","briefTitle":"Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daewoong Pharmaceutical Co. LTD."}},"conditionsModule":{"conditions":["Type II Diabetes","Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin/Atorvastatin 1500mg/40mg, QD"},{"name":"Metformin 1500mg, QD"},{"name":"Atorvastatin 40mg, QD"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01076842","briefTitle":"Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"},"collaborators":[{"name":"BodyMedia"}]},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin-Levemir"},{"name":"Exenatide-Bayetta"},{"name":"Insulin-Levemir and Exenatide-Bayetta"},{"name":"SenseWear Pro3® armband"},{"name":"DexCom CGM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02648685","briefTitle":"The Study to Investigate the Contribution of Basal and Postprandial Glucose to Overall Hyperglycemia in T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"West China Hospital"}},"conditionsModule":{"conditions":["Diabetes, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00539890","briefTitle":"Comparison Between Technosphere/Insulin Inhalation Powder Versus Rapid Acting Insulin in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mannkind Corporation"}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Technosphere Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03551925","briefTitle":"Effect of Occupational Therapy in Promoting Medication Adherence"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Indianapolis"},"collaborators":[{"name":"University of Missouri, Kansas City"},{"name":"Missouri State University"}]},"conditionsModule":{"conditions":["Hypertension","Diabete Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Treatment as Usual Plus Occupational Therapy"},{"name":"Treatment as Usual"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02569684","briefTitle":"Effects of Prebiotics on GLP-1 in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oslo University Hospital"},"collaborators":[{"name":"Norwegian Diabetes Association"},{"name":"Norwegian Extra Foundation for Health and Rehabilitation"}]},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Prebiotic fibers: oligofructose and inulin"},{"name":"Maltodextrin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02559843","briefTitle":"Effects of Pomegranate Juice on Oxidative Stress in Patients With type2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Nutrition and Food Technology Institute"}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pomegranate juice"},{"name":"lifestyle modification"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00714441","briefTitle":"Reducing Distress and Improving Self-Care in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Francisco"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle and Activities Education Program (LEAP-AHEAD)"},{"name":"Computer Automated Self-Management (CASM)"},{"name":"Computer Automated Self-Management and Problem Solving Therapy (CAPS)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03550378","briefTitle":"A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well Tolerated"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"MedImmune LLC"}},"conditionsModule":{"conditions":["Type II Diabetes Mellitus","Renal Insufficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MEDI0382"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01889095","briefTitle":"Biphasic Insulin Aspart Versus NPH Plus Regular Human Insulin in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tehran University of Medical Sciences"}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BIAsp 30"},{"name":"NPH/Reg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01953393","briefTitle":"The Acute Effects of Low-dose TNF-α on Glucose Metabolism and β-cell Function in Humans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rigshospitalet, Denmark"},"collaborators":[{"name":"Copenhagen Muscle Research Centre, Rigshospitalet, Copenhagen, Denmark"},{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low-dose TNF-alpha"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01704612","briefTitle":"Evaluation of Block Duration in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pierre and Marie Curie University"},"collaborators":[{"name":"Centre Hospitalier Universitaire de Nīmes"}]},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ropivacaine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03081676","briefTitle":"The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"}},"conditionsModule":{"conditions":["Maturity-Onset Diabetes of the Young, Type 3"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glimepiride 1Mg Tablet"},{"name":"Glucagon-like Peptide-1"},{"name":"Glucose-Dependent Insulinotropic Polypeptide"},{"name":"Placebo Oral Tablet"},{"name":"Placebo infusion"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01624116","briefTitle":"Comparison of Hypoglycaemic Regimens During Ramadan Fasting in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Services Hospital, Lahore"}},"conditionsModule":{"conditions":["Diabetes, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acarbose"},{"name":"Diet and lifestyle"},{"name":"Metformin"},{"name":"Metformin/ Glimepride"},{"name":"Metformin/Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01634282","briefTitle":"Along-term Study of OPC-262 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kyowa Kirin Co., Ltd."}},"conditionsModule":{"conditions":["Diabetes, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"OPC-262"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01728714","briefTitle":"Better Diabetes Control, Quality - Educate to Achieve Compliance."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01799850","briefTitle":"The Impact of Actos Treatment of Diabetes on Glucose Transporters in Muscle"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"East Tennessee State University"},"collaborators":[{"name":"Takeda Pharmaceuticals North America, Inc."}]},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03038789","briefTitle":"XIGDUO Extended Release (XR) Post Marketing Surveillance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Adult Patients With Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01427660","briefTitle":"iDecide.Decido: Diabetes Medication Decision Support Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"},"collaborators":[{"name":"Agency for Healthcare Research and Quality (AHRQ)"}]},"conditionsModule":{"conditions":["Diabetes, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Community Health Worker Diabetes Education: Print media"},{"name":"CHW Diabetes Education: tailored web site"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06475586","briefTitle":"Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Banja Luka"}},"conditionsModule":{"conditions":["Psoriasis Vulgaris","Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00940472","briefTitle":"Study on DMMET-01 Versus Metformin on Improvement of Metabolic Control in Naive Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Laboratorios Silanes S.A. de C.V."}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DMMET-01"},{"name":"Metformin Hydrochloride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00997282","briefTitle":"A Study of OPC-262 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kyowa Kirin Co., Ltd."}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"OPC-262 2.5 mg"},{"name":"OPC-262 5 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01046422","briefTitle":"Safety Study of BMS-770767 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristol-Myers Squibb"}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BMS-770767"},{"name":"BMS-770767"},{"name":"BMS-770767"},{"name":"BMS-770767"},{"name":"Placebo"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02935712","briefTitle":"Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Parexel"},{"name":"Spandauer Damm 130"},{"name":"14050"},{"name":"Berlin, Germany"}]},"conditionsModule":{"conditions":["Male Subjects With Type II Diabetes (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD8601+Placebo (SAD)"},{"name":"AZD8601+Placebo"},{"name":"Placebo+Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00857558","briefTitle":"A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kyowa Kirin Co., Ltd."}},"conditionsModule":{"conditions":["Diabetes, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"saxagliptin"},{"name":"saxagliptin"},{"name":"saxagliptin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00934414","briefTitle":"Clamp Study Comparing Inhalation of Technosphere®/Insulin in Smokers and Non-Smokers With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mannkind Corporation"}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Technosphere Insulin Inhalation Powder"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01040806","briefTitle":"Peer Coaching for Low-Income Patients With Diabetes in Primary Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Francisco"},"collaborators":[{"name":"American Academy of Family Physicians"}]},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Usual care"},{"name":"Health coaching"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00898950","briefTitle":"Effects of Different Doses of Aspirin on Pathophysiological Markers in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Portsmouth"}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aspirin"},{"name":"Aspirin"},{"name":"Aspirin"},{"name":"placebo tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00940797","briefTitle":"Effect of DMMET-01 on Insulin Sensitivity in Naive Type 2 Diabetes Patients (CLAMP)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Laboratorios Silanes S.A. de C.V."}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DMMET-01"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01165983","briefTitle":"The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Beth Israel Deaconess Medical Center"},"collaborators":[{"name":"Novartis Pharmaceuticals"}]},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Aliskiren"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03781232","briefTitle":"Non-invasive Glucose Measurement With Raman Technology in Patients With Type 1 and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"RSP Systems A/S"}},"conditionsModule":{"conditions":["Diabete Mellitus","Medical Device"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Prototype 0.3"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05336019","briefTitle":"The Effect of a Diabetes Self-management Coaching Program for Type 2 Diabetes Patients in the Ethiopian PC."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Queen's University"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes self-management Coaching"},{"name":"Usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00518427","briefTitle":"Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00461136","briefTitle":"Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aliskiren"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00246987","briefTitle":"A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristol-Myers Squibb"}},"conditionsModule":{"conditions":["Diabetes, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Muraglitazar"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00376038","briefTitle":"Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK189075 oral tablets"},{"name":"metformin tablets"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00309244","briefTitle":"Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mannkind Corporation"}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Technosphere® Insulin Inhalation Powder"},{"name":"70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00141232","briefTitle":"Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc."},"collaborators":[{"name":"Churchill Hospital"}]},"conditionsModule":{"conditions":["Diabetes, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Atorvastatin and Omega-3 fatty acids"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00464880","briefTitle":"Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aliskiren"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00349427","briefTitle":"A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone 4 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00044447","briefTitle":"Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01608724","briefTitle":"The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02923453","briefTitle":"Effect of Ginseng in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Unity Health Toronto"}},"conditionsModule":{"conditions":["Type II Diabetes Control"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CNT 2000 American ginseng extract"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03764280","briefTitle":"The Efficacy of MDI Treatment With an Optimization Algorithm Adjusting Basal-Bolus Parameters in Children and Adolescents With Type 1 Diabetes at a Diabetes Camp"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"McGill University"}},"conditionsModule":{"conditions":["Diabete Mellitus","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Multiple Daily Injections: Slow acting insulin and Rapid acting insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02722499","briefTitle":"Financial Incentives Telephone Education and Skills Trial in African Americans With Diabetes (FITEST)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"State University of New York at Buffalo"},"collaborators":[{"name":"Medical University of South Carolina"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Type 2 Diabetes Mellitus","Adult-Onset Diabetes Mellitus","Non-Insulin-Dependent Diabetes Mellitus","Noninsulin Dependent Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High Frequency Financial Incentive"},{"name":"Moderate Frequency Financial Incentive"},{"name":"Low Frequency Financial Incentive"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05706506","briefTitle":"A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05360147","briefTitle":"Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Third Military Medical University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Oral antidiabetic drugs: Metformin, Sulfonylureas (2nd generation), Thiazolidinediones, α-Glucosidase inhibitors, and Glinides"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02961192","briefTitle":"Social Incentives to Improve Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pennsylvania"}},"conditionsModule":{"conditions":["Type II; Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Supportive social incentive"},{"name":"Competitive social incentive"},{"name":"Collaborative social incentive"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00259896","briefTitle":"In-patient Study in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04449120","briefTitle":"HOME COOKING: Health Empowerment Strategy in People With Type II Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Basque Culinary Center Fundazioa"},"collaborators":[{"name":"University of Navarra"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mediterranean diet-based culinary intervention"},{"name":"Mediterranean diet-based nutritional education intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00035542","briefTitle":"A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristol-Myers Squibb"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glucovance (metformin HCl/glyburide)"},{"name":"metformin HCl"},{"name":"glyburide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00044694","briefTitle":"Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo 0.01 mL"},{"name":"Placebo 0.02 mL"},{"name":"Placebo 0.03 mL"},{"name":"Placebo 0.04 mL"},{"name":"AC2993 2.5 mcg"},{"name":"AC2993 5.0 mcg"},{"name":"AC2993 7.5 mcg"},{"name":"AC2993 10.0 mcg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02158741","briefTitle":"Comparison Study of Usual Care vs. Usual Care Plus Community Intervention to Manage Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"McMaster University"},"collaborators":[{"name":"Ontario Ministry of Health and Long Term Care"},{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","NIDDM","Non-insulin Dependent Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Home Visits and Lifestyle Education Support"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06617767","briefTitle":"The Effect of Reiki in Patients With Type-II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Osmaniye Korkut Ata University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Reiki"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02537470","briefTitle":"Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"BHV Pharma"},"collaborators":[{"name":"Integrium"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Biphasic Remogliflozin Etabonate"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05127291","briefTitle":"Dual-Task Effects on Hand Functions in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kutahya Health Sciences University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dual-task"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05359432","briefTitle":"Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Getz Pharma"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00291356","briefTitle":"GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Non-Insulin-Dependent Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK189075 oral tablets"},{"name":"GW869682 oral tablets"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00411554","briefTitle":"A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin phosphate"},{"name":"Comparator: voglibose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06687811","briefTitle":"Carbohydrate Loading in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Indonesia University"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"preoperative carbohydrate loading"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03707171","briefTitle":"Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Third Military Medical University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04930679","briefTitle":"Evaluating Safety of Andiabet on Diabetes Mellitus Type II Patients, Phase I CT."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre of Clinical Pharmacology, Hanoi Medical University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Andiabet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00035984","briefTitle":"Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AC2993"},{"name":"AC2993"},{"name":"Placebo"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05048719","briefTitle":"A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3502970"},{"name":"Dulaglutide"},{"name":"Placebo"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00837577","briefTitle":"MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Comparator: Placebo"},{"name":"Sitagliptin"},{"name":"Voglibose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05158244","briefTitle":"Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-07081532"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00189774","briefTitle":"Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"},"collaborators":[{"name":"Ajinomoto USA, INC."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"nateglinide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01752842","briefTitle":"Lipid Biomarkers for Diabetic Heart Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Washington University School of Medicine"},"collaborators":[{"name":"National Institutes of Health (NIH)"},{"name":"National Heart, Lung, and Blood Institute (NHLBI)"},{"name":"Leducq Foundation"}]},"conditionsModule":{"conditions":["Type II Diabetes Mellitus","Diabetes Complications"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fenofibrate"},{"name":"Placebo for fenofibrate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05943886","briefTitle":"A Phase 1 Study of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dongguan HEC Biopharmaceutical R&D Co., Ltd."}},"conditionsModule":{"conditions":["Healthy Subjects","Obesity","T2DM (Type 2 Diabetes Mellitus)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HEC88473 injection"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00039026","briefTitle":"Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AC2993"},{"name":"AC2993"},{"name":"Placebo"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05878587","briefTitle":"Burger Allen Exercises in Knee OA With Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Riphah International University"}},"conditionsModule":{"conditions":["Knee Osteoarthritis","Type II Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"thermotherapy+ TENS+ low intensity high repetition exercises and Buerger Allen"},{"name":"thermotherapy+ TENS+ low intensity high repetition exercises"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01005069","briefTitle":"Efficacy of DLBS-32 in Subjects With Type-II Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dexa Medica Group"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DLBS-32"},{"name":"DLBS-32"},{"name":"DLBS-32"},{"name":"DLBS-32"},{"name":"Placebo capsule"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01007097","briefTitle":"Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TAK-875"},{"name":"TAK-875"},{"name":"TAK-875"},{"name":"TAK-875"},{"name":"TAK-875"},{"name":"Glimepiride"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02689362","briefTitle":"Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eurofarma Laboratorios S.A."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Evogliptin"},{"name":"Sitagliptin"},{"name":"Placebo Evogliptin"},{"name":"Placebo Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06169982","briefTitle":"A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3209590"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05491252","briefTitle":"A Randomized Controlled Trial of Patient-Centered Self-Management Intervention in Adults With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shifa Tameer-e-Millat University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PAtient CEntered Self-Management Intervention (PACE-SMI)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03552991","briefTitle":"Effects of Dietary Fiber on Glucose Control in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Samsung Medical Center"},"collaborators":[{"name":"Bukwang Pharmaceutical, Co., Ltd."},{"name":"ChunLab, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Agiocur Pregranules"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02801448","briefTitle":"Clinical Trial With Broccoli Sprout Extract to Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Anders Rosengren, MD PhD"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sulforaphane"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04622722","briefTitle":"Efficacy and Safety of Diabetes-specific Formula in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Société des Produits Nestlé (SPN)"},"collaborators":[{"name":"Ramathibodi Hospital"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nutren Diabetes"},{"name":"Isocaloric"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04124484","briefTitle":"DBPR108 Tablets in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)"},{"name":"DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)"},{"name":"DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)"},{"name":"Placebo matching DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01406717","briefTitle":"Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sun Pharmaceutical Industries Limited"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SPIL1033"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06256523","briefTitle":"A Study of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gan and Lee Pharmaceuticals, USA"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GZR18"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04744636","briefTitle":"Vascular Function and Biomarker Assessments in Healthy Volunteers and in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institut de Recherches Internationales Servier"},"collaborators":[{"name":"ADIR, a Servier Group company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Other"},{"name":"Other"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06229847","briefTitle":"Mindful Eating and Current Glycemic Control in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Goztepe Prof Dr Suleyman Yalcın City Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02661906","briefTitle":"A Pilot Study on Effect of SKY on Psychosocial Parameters of Type 2 Diabetic Patients After a 6 Days"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dasman Diabetes Institute"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SKY"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03195400","briefTitle":"Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yale University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["IGT - Impaired Glucose Tolerance","T2D"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral Glucose Tolerance Test"},{"name":"Hyperglycemic Clamp"},{"name":"Isoglycemic Intravenous Glucose Test"},{"name":"Hyperinsulinemic Euglycemic Clamp and 2H20"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00256867","briefTitle":"A Study In Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK523338"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05596747","briefTitle":"A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3209590"},{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06517602","briefTitle":"Effect of Moringa Oleifera Leaves on Glycemic Control of Women With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Milan"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Supplementation of Moringa oleifera leaf powder"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02685345","briefTitle":"A Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus Receiving Sitagliptin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo Co., Ltd."},"collaborators":[{"name":"Mediscience Planning, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DS-8500a 25 mg"},{"name":"DS-8500a 75 mg"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01657227","briefTitle":"Tertiary Prevention in Type II Diabetes Mellitus in Canary Islands Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Servicio Canario de Salud"},"collaborators":[{"name":"Instituto de Salud Carlos III"},{"name":"Asociación para la Diabetes de Tenerife"},{"name":"Asociación de Diabéticos de Gran Canaria"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intervention to patients"},{"name":"Intervention to professionals"},{"name":"Usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03176056","briefTitle":"The Effectiveness of Low Carbohydrate Diet in Reducing Polypharmacy for Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Taiwan University Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low carbohydrate diet"},{"name":"Calori restricted diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05150041","briefTitle":"The Efficacy of Guardian Connect to Modify Lifestyle in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kangbuk Samsung Hospital"},"collaborators":[{"name":"Medtronic"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Guardian connect"},{"name":"iPro2"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04318184","briefTitle":"Effects of Exercise on Metabolic Parameters in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Marmara University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aerobic exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05451147","briefTitle":"A Comparative Study of the Effect of Ayurvedic Drugs and Metformin in the Management of Diabetes Mellitus (Type II)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"A & U Tibbia College Karol Bagh"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Chhinnavahni Kashaya Vati along with Agnimantha Kwatha"},{"name":"Metformin Hydrochloride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06290947","briefTitle":"BFR Walking for Insulin and Aerobic Improvement in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Arab American University (Palestine)"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BFR Cuffs for Intervention Group"},{"name":"Standard Walking Training Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05383859","briefTitle":"Diet and Physical Activity Program for Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Oviedo"},"collaborators":[{"name":"Servicio de Salud del Principado de Asturias. Área Sanitaria III"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01346046","briefTitle":"Evaluation of SCOUT DS in Subjects With Type 2 Diabetes #2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VeraLight, Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin Dependent"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02647320","briefTitle":"12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin 100 mg"},{"name":"DS-8500a 25mg"},{"name":"Placebo Tablet"},{"name":"Placebo Capsule"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04847219","briefTitle":"Efficacy and Safety of Premixed Insulin Treatment in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nanjing First Hospital, Nanjing Medical University"},"collaborators":[{"name":"Wuxi Hospital of Traditional Chinese Medicine"},{"name":"Wuxi People's Hospital Affiliated to Nanjing Medical University"},{"name":"Huai'an Second People's Hospital and the Affiliated Huai'an Hospital of Xuzhou Medical University"},{"name":"The Affiliated Suqian First People's Hospital of Nanjing Medical University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Professional flash glucose mornitoring"},{"name":"Personal flash glucose mornitoring"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04450394","briefTitle":"A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3209590"},{"name":"Insulin Degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04810507","briefTitle":"MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"JW Pharmaceutical"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Anagliptin BID Treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04217902","briefTitle":"VOIES-D-ql - Qualitative Study on Experiences of Diabetes Care Delivery and Planning"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospices Civils de Lyon"}},"conditionsModule":{"conditions":["Diabete Type 1","Diabete Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Description of patients' experiences of diabetes care delivery and planning"},{"name":"Description of health care professionals needs and experiences in diabetes care delivery and planning"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01309620","briefTitle":"Zinc Supplementation in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National University Hospital, Singapore"},"collaborators":[{"name":"National University of Singapore"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Zinc gluconate"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05407961","briefTitle":"A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3532226"},{"name":"Placebo"},{"name":"Dulaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05404178","briefTitle":"Turkish Validity-Reliability Study of the Diabetic Foot Self-Care Questionnaire"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Harran University"}},"conditionsModule":{"conditions":["Diabete Type 2","Diabetic Foot"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Type 2 diabetes group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00309712","briefTitle":"Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Intermountain Health Care, Inc."},"collaborators":[{"name":"Abbott"},{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Type II Diabetes Mellitus","Mixed Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"fenofibrate 160 mg and placebo"},{"name":"simvastatin 20 mg and placebo"},{"name":"fenofibrate 160 mg and simvastatin 20 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05202470","briefTitle":"Effectiveness of Telehealth Program in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Muğla Sıtkı Koçman University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TE"},{"name":"CE"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05134662","briefTitle":"ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Altimmune, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ALT-801"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00875394","briefTitle":"Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin phosphate"},{"name":"Comparator: metformin"},{"name":"Comparator: metformin"},{"name":"Comparator: Antidiabetic Standard of Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02585505","briefTitle":"Tissue Distribution of F18-FDG Labeled ABMSCT in Patients With Type2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Post Graduate Institute of Medical Education and Research, Chandigarh"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"stem cells"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01812122","briefTitle":"Effects of Vildagliptine and Glimepiride on Glucose Variability"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glimepiride"},{"name":"Vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00071422","briefTitle":"Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Exsulin Corporation"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INGAP-Peptide"},{"name":"INGAP-Peptide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04168541","briefTitle":"Glycemic Response in Persons With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Société des Produits Nestlé (SPN)"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral Nutrition Supplement"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01472185","briefTitle":"Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gilead Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ranolazine"},{"name":"Placebo"},{"name":"Diet"},{"name":"Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00335712","briefTitle":"Pilot Study of ONO-5129 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ono Pharma USA Inc"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ONO-5129"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05362071","briefTitle":"Remotely Supervised Exercise Program in Individuals With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Federal University of Pelotas"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Remote Exercise Group"},{"name":"Group control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02189135","briefTitle":"Making Ramadhan Fasting a Safer Experience With Technology Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Monash University"},"collaborators":[{"name":"Segi University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Telemedicine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01694758","briefTitle":"OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00871572","briefTitle":"A Study for Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2409021"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03249506","briefTitle":"Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin"},{"name":"Empagliflozin"},{"name":"Dapagliflozin"},{"name":"Dipeptidyl Peptidase-4 Inhibitor (DPP-4)"},{"name":"Glucagon-Like Peptide-1 Agonist (GLP-1)"},{"name":"Thiazolidinedione (TZD)"},{"name":"Sulfonylureas"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03745937","briefTitle":"A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"MedImmune LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MEDI0382"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03014479","briefTitle":"Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Trelagliptin"},{"name":"Daily DPP-4 inhibitor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05327595","briefTitle":"A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3549492"},{"name":"Placebo"},{"name":"Atorvastatin"},{"name":"Midazolam"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05659537","briefTitle":"A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dulaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03694470","briefTitle":"Characteristics of Patients With Type 2 Diabetes Mellitus (CVD-RNDR)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04296825","briefTitle":"Effect of Camel Milk With Probiotic on Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"China Agricultural University"},"collaborators":[{"name":"Beijing Chinese Medicine Hospital-Pinggu Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Camel milk containing Bifidobacterium animalis A6"},{"name":"Camel milk"},{"name":"Bifidobacterium animalis A6"},{"name":"Cow milk"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02662400","briefTitle":"Assessment of Insulin Sensitivity and β Cell Function by Clamps Studies"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Post Graduate Institute of Medical Education and Research, Chandigarh"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MNCs"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03416127","briefTitle":"Effect of Propolis or Metformin Administration on Glycemic Control in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Guadalajara"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Propolis"},{"name":"Metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04914559","briefTitle":"Glucose Response in Persons with Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Société des Produits Nestlé (SPN)"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral nutrition supplement - control"},{"name":"Oral nutrition supplement - test"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04535700","briefTitle":"Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone 30 mg"},{"name":"standard of care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00545584","briefTitle":"Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin phosphate"},{"name":"Comparator: Diet"},{"name":"Comparator: Physical Activity"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05086445","briefTitle":"A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3502970"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02771093","briefTitle":"An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Trelagliptin"},{"name":"Alogliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05629117","briefTitle":"Personalized Diabetes Text Messaging (DB-TEXT) Combined With Peer Support Education in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Taipei Medical University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Personalized Diabetes Text Messaging (DB-TEXT) combined with Peer Support Education"},{"name":"Personalized Diabetes Text Messaging (DB-TEXT)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01001611","briefTitle":"An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-501 0.5mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00905528","briefTitle":"TRENDY Follow-up: Study on Endothelial Function in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Erlangen-Nürnberg Medical School"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Telmisartan 80 mg/d"},{"name":"Ramipril 10 mg/d"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03829891","briefTitle":"Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Xijing Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Beinaglutide"},{"name":"glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02847091","briefTitle":"Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ipragliflozin"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01865474","briefTitle":"Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dexa Medica Group"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DLBS1033"},{"name":"placebo tablet of DLBS1033"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01105429","briefTitle":"Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristol-Myers Squibb"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BMS-820132"},{"name":"BMS-820132"},{"name":"BMS-820132"},{"name":"BMS-820132"},{"name":"BMS-820132"},{"name":"BMS-820132"},{"name":"BMS-820132"},{"name":"BMS-820132"},{"name":"BMS-820132"},{"name":"Placebo"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04823208","briefTitle":"A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3437943"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02717078","briefTitle":"The LoBAG Diet and Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Minnesota"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diet Therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01299844","briefTitle":"Impact of Type 2 Diabetes Peer Counseling on Behavioral, Metabolic, and Health Outcomes Among Latinos"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Connecticut"},"collaborators":[{"name":"Hartford Hospital"},{"name":"Hispanic Health Council, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Peer Counseling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04208620","briefTitle":"Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"MedImmune LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Cotadutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00035568","briefTitle":"A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristol-Myers Squibb"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glucovance (metformin HCl/glyburide)"},{"name":"or Metformin HCl alone"},{"name":"or Glyburide alone."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05130463","briefTitle":"Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"empagliflozin/linagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02143765","briefTitle":"Efficacy and Safety of Mitiglinide vs Acarbose in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Zhongda Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mitiglinide"},{"name":"Acarbose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04529317","briefTitle":"Beneficial Effects of Quinoa (Chenopodium Quinoa Willd) in the Prevention of Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institut d'Investigacions Biomèdiques August Pi i Sunyer"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Quinoa and quinoa-based food"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04957914","briefTitle":"A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine"},{"name":"LY3209590"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04413357","briefTitle":"Glycemic Response in Persons with Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Société des Produits Nestlé (SPN)"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Balanced Nutritional Drink"},{"name":"Diabetes Specific, Balanced Nutritional Drink (DMA)"},{"name":"Diabetes Specific, Balanced Nutritional Drink DMB"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01494987","briefTitle":"Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gilead Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ranolazine"},{"name":"Placebo"},{"name":"Glimepiride"},{"name":"Diet"},{"name":"Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04240171","briefTitle":"Dapagliflozin Versus Glimepiride Effect in Patient With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Damanhour University"},"collaborators":[{"name":"Tanta University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin 5Mg Tab"},{"name":"Glimepiride 4Mg Tab"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03951753","briefTitle":"A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Semaglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04217291","briefTitle":"The Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Suzhou Yabao Pharmaceutical R&D Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SY-004"},{"name":"SY-004 matching placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04755660","briefTitle":"Home-based Resistance Training to Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Taipei University of Nursing and Health Sciences"},"collaborators":[{"name":"Taiwan Nurses Association"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise behavior change for resistance exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00952991","briefTitle":"The Effects of LAF237 on Gastric Function in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"},"collaborators":[{"name":"Novartis Pharmaceuticals"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LAF237 = vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00817778","briefTitle":"Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD1656"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01578096","briefTitle":"Stress Management Among Latinos With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yale University"},"collaborators":[{"name":"Hartford Hospital"},{"name":"UConn Health"},{"name":"Hispanic Health Council, Inc."},{"name":"National Institute on Minority Health and Health Disparities (NIMHD)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"stress management"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00044707","briefTitle":"Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pramlintide acetate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03538743","briefTitle":"4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"PF-06882961"},{"name":"PF-06882961"},{"name":"PF-06882961"},{"name":"PF-06882961"},{"name":"PF-06882961"},{"name":"PF-06882961"},{"name":"PF-06882961"},{"name":"PF-06882961"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03495908","briefTitle":"Regular Insulin vs Rapid Insulin Delivered by V-Go"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"East Coast Institute for Research"},"collaborators":[{"name":"Valeritas, Inc."},{"name":"Dallas Diabetes Research Center"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"VGo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05407233","briefTitle":"Reusing Needles for Subcutaneous Insulin Injection in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital de Clinicas de Porto Alegre"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Does not reuse the syringe for insulin application"},{"name":"Uses the syringe for insulin delivery five times"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02222350","briefTitle":"Phase 2 Study of DS-8500a in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"10mg DS-8500a tablet"},{"name":"75mg DS-8500a tablet"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06264661","briefTitle":"Effect of Cognitive Behavioral Therapy and Phototherapy on Glycosylated Hemoglobin, CLOCK Genes and Quality of Life in Patients With Type 2 Diabetes Mellitus and Insomnia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centro Interdisciplinario de Ciencias de la Salud Unidad Santo Tomás"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Effect of Cognitive Behavioral Therapy with Phototherapy in glycated hemoglobin, CLOCK genes and quality of life in patients with type 2 diabetes mellitus and insomnia"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04143802","briefTitle":"A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3437943"},{"name":"Dulaglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03736785","briefTitle":"A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3209590"},{"name":"Insulin Degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04276428","briefTitle":"A Study of LY3209590 in Japanese Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3209590"},{"name":"Insulin Degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06202079","briefTitle":"A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gan and Lee Pharmaceuticals, USA"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GZR4 Injection"},{"name":"Insulin Degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05170880","briefTitle":"Effect of Primary Non-surgical Endodontic Therapy on Glycaemic Control in Type 2 Diabetic Patients With Asymptomatic Apical Periodontitis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Postgraduate Institute of Dental Sciences Rohtak"}},"conditionsModule":{"conditions":["Diabete Type 2","Apical Periodontitis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Primary endodontic treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01669616","briefTitle":"Point of Service Diabetes Screening Evaluation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VeraLight, Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin Dependent"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03131687","briefTitle":"A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"tirzepatide"},{"name":"Dulaglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00791661","briefTitle":"MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK-1006"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06411275","briefTitle":"A Phase 2 Study of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Diet and Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HighTide Biopharma Pty Ltd"},"collaborators":[{"name":"Shenzhen HighTide Biopharmaceutical Ltd."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HTD1801"},{"name":"Placebo"},{"name":"HTD1801"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04161430","briefTitle":"A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DBPR108; Placebo matching sitagliptin"},{"name":"Placebo matching DBPR108; Sitagliptin; DBPR108"},{"name":"Placebo matching DBPR108; Placebo matching sitagliptin; DBPR108"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00835861","briefTitle":"Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of North Carolina, Chapel Hill"},"collaborators":[{"name":"WakeMed Health and Hospitals"}]},"conditionsModule":{"conditions":["Non Insulin Dependent Diabetes","Pregnancy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00754130","briefTitle":"MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011)."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"MK-0941"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05802927","briefTitle":"Diabetes-specific Formula (DSF) in Individuals With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Nutrition"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DSF"},{"name":"Breakfast 1"},{"name":"Breakfast 2"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04556760","briefTitle":"Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Parexel"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD9567"},{"name":"Prednisolone"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01554618","briefTitle":"Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Children and Adolescent With Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide Once Weekly"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05145673","briefTitle":"Effect of Aqueous Cinnamon Extract on the Postprandial Glycaemia Levels in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Egas Moniz - Cooperativa de Ensino Superior, CRL"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo (OGTT)"},{"name":"Cinnamon (OGTT plus aqueous cinnamon extract)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04235959","briefTitle":"A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03625856","briefTitle":"The Effect of Chlorella Supplementation on Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dr. Behnood Abbasi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Chlorella Vulgaris"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04412798","briefTitle":"Orange Juice and Glycaemic Control in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hasselt University"},"collaborators":[{"name":"Hochschule Geisenheim University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"orange juice concentrate"},{"name":"Sugar-sweetened orange-flavoured beverage"},{"name":"Whole orange juice with skin removed"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01435616","briefTitle":"A Study in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glargine"},{"name":"LY2605541"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00237952","briefTitle":"Environmental Exposure to Lead and Progressive Renal Insufficiency in Type II Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chang Gung Memorial Hospital"}},"conditionsModule":{"conditions":["Diabetic Nephropathies","Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EDTA chelating agents"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02292433","briefTitle":"A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-04937319 high dose"},{"name":"PF-04937319 low dose"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03138746","briefTitle":"Insulin Sensitivity During Hyperbaric Oxygen Compared to Hyperbaric Air"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Adelaide"},"collaborators":[{"name":"Royal Adelaide Hospital"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II","Insulin Resistance"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HBO"},{"name":"Hyperbaric air"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04313829","briefTitle":"Pharmacist Counseling on the Health-related Quality of Life of Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universitas Padjadjaran"},"collaborators":[{"name":"Ministry of Research, Technology and Higher Education of the Republic of Indonesia"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pharmacist Counseling Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02851849","briefTitle":"A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ligand Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LGD-6972-5 mg"},{"name":"LGD-6972-10 mg"},{"name":"LGD-6972-15 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02954601","briefTitle":"A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oramed, Ltd."},"collaborators":[{"name":"Integrium"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ORMD-0801 (qd)"},{"name":"ORMD-0801 (bid)"},{"name":"ORMD-0801 (tid)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03050229","briefTitle":"SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jichi Medical University"},"collaborators":[{"name":"Boehringer Ingelheim"},{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Nocturnal Hypertension","T2DM (Type 2 Diabetes Mellitus)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00094796","briefTitle":"Rosiglitazone to Reverse Metabolic Defects in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise cardiopulmonary metabolic testing"},{"name":"Skeletal muscle biopsy"},{"name":"Brachial artery reactivity testing"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04100473","briefTitle":"Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dance Biopharm Inc."},"collaborators":[{"name":"Profil Institut für Stoffwechselforschung GmbH"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Inhaled Human Insulin"},{"name":"Insulin Lispro (Humalog U-100)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03233178","briefTitle":"Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LMC Diabetes & Endocrinology Ltd."}},"conditionsModule":{"conditions":["T2DM (Type 2 Diabetes Mellitus)","Fatty Liver","NAFLD"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Non-interventional"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00949091","briefTitle":"Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TAK-875"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02889510","briefTitle":"Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lecube, Albert, M.D."},"collaborators":[{"name":"Dynamic Solutions"},{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03407196","briefTitle":"Dapagliflozin in Type 2 Diabetes Patients, a Retrospective Cohort Study From Turkey"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca Turkey"},"collaborators":[{"name":"Optimum Contract Research Organization, Turkey"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Forxiga"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00363519","briefTitle":"Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ono Pharmaceutical Co. Ltd"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Sitagliptin phosphate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01862939","briefTitle":"A Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DS-7309"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00501592","briefTitle":"Study of INT-747 in Patients With Diabetes and Presumed NAFLD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Intercept Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II","Fatty Liver"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INT-747"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04564846","briefTitle":"A Study to Evaluate the Effect of ORMD-0801 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oramed, Ltd."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ORMD-0801"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00363948","briefTitle":"Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ono Pharmaceutical Co. Ltd"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Sitagliptin phosphate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00363844","briefTitle":"Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ono Pharmaceutical Co. Ltd"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin phosphate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05342012","briefTitle":"The Effect of Nitrate on Brown Fat"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bournemouth University"},"collaborators":[{"name":"University of Portsmouth"},{"name":"Institute of Bioengineering and Bioimaging (IBB)"},{"name":"Loughborough University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Concentrated beetroot juice"},{"name":"Nitrate depleted beetroot juice"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02346175","briefTitle":"Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jiangsu HengRui Medicine Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SHR3824"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00506298","briefTitle":"Study of CRx-401 on Glucose Levels in Subjects With Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Zalicus"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"bezafibrate + diflunisal"},{"name":"bezafibrate + placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01669473","briefTitle":"A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Northwestern University"},"collaborators":[{"name":"University of Illinois at Chicago"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type I","Diabetes Mellitus Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EHR Based Strategy to promote Safe and Appropriate Drug Use"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03840850","briefTitle":"Type 2 Diabetes: Risk Perceptions and Self-management Behaviour"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Oxford"},"collaborators":[{"name":"NIHR Collaboration for Leadership in Applied Health Research and Care (Oxford)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Personalized Risk Communication for People with Type 2 Diabetes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00758069","briefTitle":"Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin phosphate"},{"name":"Comparator: Placebo"},{"name":"Comparator: Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04264793","briefTitle":"Skills for Change: Nutrition Education Program for Emirati Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"United Arab Emirates University"},"collaborators":[{"name":"Ambulatory Healthcare Services, Al Ain, UAE"},{"name":"Sheikh Hamdan bin Rashid Al Maktoum Award for Medical Sciences"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Behavioral Lifestyle Intervention"},{"name":"Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06228911","briefTitle":"Increased Blood Glucose Levels After Steroid Injection"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Syrian Private University"}},"conditionsModule":{"conditions":["Osteoarthritis, Knee","Diabete Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"steroid (triamcinolone)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00069784","briefTitle":"The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"},"collaborators":[{"name":"Population Health Research Institute"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glargine (HOE901)"},{"name":"omega-3 polyunsaturated fatty acids (PUFA)"},{"name":"placebo"},{"name":"reusable pen device for insulin injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04924777","briefTitle":"Effects of Moderate Physical Activity on Glycemic Control in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Riphah International University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Brisk Walk"},{"name":"Strength training"},{"name":"Aerobic Exercises"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00422357","briefTitle":"Effect of Urtica Dioica on Glycemic Control in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shahid Beheshti University of Medical Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Urtica Dioica (Tea bag)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02419859","briefTitle":"A Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"CeQur Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PaQ® Insulin Delivery Device"},{"name":"Insulin, Asp(B28)-"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01293669","briefTitle":"Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Targacept Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TC-6987"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05478525","briefTitle":"A Study Evaluating the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Glyscend, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLY-200"},{"name":"GLY-200"},{"name":"GLY-200"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06517784","briefTitle":"Insulin Initiation and Adherence Behaviours: a Cross Sectional Survey of Indian HCPs & Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05956743","briefTitle":"Progressive Relaxation Exercise on Sleep Quality in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mersin University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"progressive relaxation exercise sessions"},{"name":"Sham"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04387045","briefTitle":"Perceived Stress and Negative Thoughts With Biomarkers in People With Type 2 Diabetes Mellitus and Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Francisco Carlos López Marquez"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Guilty feelings"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04077216","briefTitle":"Effect of Extra Virgin Olive Oil on Postprandial Blood Glucose in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Makati Medical Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Extra Virgin Olive Oil (EVOO)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03230786","briefTitle":"Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"KeyBioscience AG"},"collaborators":[{"name":"Nordic Bioscience A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Daily injection of KBP/placebo for 12 weeks as add-on to metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01449747","briefTitle":"Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Catholic University of Korea"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00642798","briefTitle":"An Open-Label, Single- & Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects (0431-108)(COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus Non-insulin-dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin phosphate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04342845","briefTitle":"Effectiveness of Motivational Interviewing on Improving Care for Patients With Type 2 Diabetes in China"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Hong Kong"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Experimental: Motivational interviewing Placebo Comparator: Traditional lectures"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01241448","briefTitle":"A Study of LY2409021 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2409021"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01798238","briefTitle":"Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Handok Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MP-513"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05015946","briefTitle":"Handball-based Exercise and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University College of Northern Denmark"},"collaborators":[{"name":"Danish Handball Federation"},{"name":"The Danish Diabetes Association"},{"name":"Research Unit for General Practice in Aalborg"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Small-sided team handball training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06351748","briefTitle":"Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04515576","briefTitle":"A Study of LY3493269 in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3493269"},{"name":"Dulaglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01188863","briefTitle":"Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lexicon Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"300 mg LX4211 (150 mg tablets)"},{"name":"300 mg LX4211 (50 mg tablets)"},{"name":"300 mg LX4211 (liquid)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00065312","briefTitle":"An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"naveglitazar"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03861052","briefTitle":"A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Dulaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05516966","briefTitle":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fujian Shengdi Pharmaceutical Co., Ltd."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HRS9531"},{"name":"Placebo"},{"name":"Dulaglutide Injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02010827","briefTitle":"Endogenous Glucoseproduction in Patients With Type 2 Diabetes Mellitus During Oral Glucose and iv. Glucose Infusion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"isoglycemic intravenous glucose infusion and Glucagon infusion, day C"},{"name":"Oral glucose tolerance test, day A"},{"name":"intravenous iv glucose infusion, day B"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06020846","briefTitle":"Effect of Soleus Pushup Exercise in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Riphah International University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Soleus Pushup Exercise"},{"name":"treadmill walk group 2"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04345120","briefTitle":"Multiple Ascending Doses of SY-008 in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Suzhou Yabao Pharmaceutical R&D Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SY-008"},{"name":"SY-008 matching placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04345107","briefTitle":"Multiple Ascending Doses of SY-009 in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Suzhou Yabao Pharmaceutical R&D Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SY-009"},{"name":"SY-009 matching placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00513214","briefTitle":"Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"XOMA (US) LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"XOMA 052"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00004983","briefTitle":"Education and Group Support for Diabetic Hispanics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"diabetes self-management education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05606913","briefTitle":"A Study of IBI362 in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Innovent Biologics (Suzhou) Co. Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"dulaglutide"},{"name":"IBI362"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00006432","briefTitle":"Acute Glycemic Effects of a Very Low Fat Diet in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Center for Research Resources (NCRR)"},"collaborators":[{"name":"Duke University"},{"name":"Procter and Gamble"},{"name":"Jenny Craig, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"very low fat diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06327503","briefTitle":"Salivary Signal Molecules for Neural and Vascular Homeostasis in T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Belgrade"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"saliva samples collecting"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03338010","briefTitle":"A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2963016"},{"name":"Lantus®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04759469","briefTitle":"Effect of Exercise on Cardiometabolic Risk Factors in Type II Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cairo University"},"collaborators":[{"name":"Kasr El Aini Hospital"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High-intensity interval training"},{"name":"Moderate intensity interval training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02773095","briefTitle":"Evaluation of Novartis Access; a Non-communicable Disease (NCD) Access Initiative"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boston University"},"collaborators":[{"name":"Innovations for Poverty Action"}]},"conditionsModule":{"conditions":["Cardiovascular Disease","Diabetes Type II","Breast Cancer","Asthma"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Novartis Access"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03311724","briefTitle":"A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01468181","briefTitle":"A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2189265"},{"name":"Sulfonylureas (SU)"},{"name":"Biguanides (BG)"},{"name":"alpha-glucosidase inhibitor (a-GI)"},{"name":"Thiazolidinedione (TZD)"},{"name":"Glinides"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04426474","briefTitle":"A Study of LY3502970 in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3502970"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01095991","briefTitle":"Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD1656"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04403841","briefTitle":"Effect of Group Patient Education on Glycemic Control Among People Living With Type 2 Diabetes in Vietnam"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hanoi Medical University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"patient education and self-management intervention in a low-resource setting on diabetes knowledge and levels of blood glucose control"},{"name":"Usual diabetes care alone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05478252","briefTitle":"A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide J"},{"name":"Semaglutide B"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00943917","briefTitle":"Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Intarcia Therapeutics"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ITCA 650"},{"name":"Exenatide Injection"},{"name":"Ex Inj/ITCA 650"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03363386","briefTitle":"Effects Of Resistive Exercise or Proprioceptive Exercise Training Among Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yeditepe University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Proprioceptive Exercises"},{"name":"Resistive Exercises"},{"name":"Aerobic Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01609088","briefTitle":"Pilot Study of the Effects of Erythritol on Endothelial Function in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boston University"},"collaborators":[{"name":"Cargill"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Erythritol-containing beverage"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03793855","briefTitle":"Nutritional Strategy for Glycemic Control in Patients With Type 2 Diabetes Mellitus (NUGLIC)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital do Coracao"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nutritional Strategy"},{"name":"Dietary Prescription"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03810846","briefTitle":"Feasibility and Safety of Walking Football in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidade do Porto"},"collaborators":[{"name":"Federação Portuguesa de Futebol, Portugal"},{"name":"Administração Regional de Saúde do Norte, Portugal"},{"name":"Fédération Internationale de Football Association"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Walking football exercise program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04867785","briefTitle":"A Study of LY3437943 in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3437943"},{"name":"Dulaglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01498367","briefTitle":"Life-long Tele-monitoring of Patients With Type 2 Diabetes Mellitus in Central Greece"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Regional Health Authority of Sterea & Thessaly"},"collaborators":[{"name":"Ministry for Health and Social Solidarity, Greece"},{"name":"Municipality of Trikala, Greece"},{"name":"e-Trikala S.A."},{"name":"Cities Net SA"},{"name":"Institute of Biomedical Research & Technology, Larissa, Greece"},{"name":"Institute of Communications and Computer Systems, Athens, Greece"},{"name":"Alexander Technological Educational Institute, Thessaloniki, Greece"},{"name":"University of Macedonia, Thessaloniki, Greece"},{"name":"University of Thessaly"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Telemonitoring of patients with diabetes type 2"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02554643","briefTitle":"Soccer and Health: Diet and Exercise on Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Sao Paulo General Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diet"},{"name":"Soccer"},{"name":"Running"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03334773","briefTitle":"Nutrition Education Intervention for Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pretoria"},"collaborators":[{"name":"South African Sugar Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nutrition education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05533632","briefTitle":"Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05749029","briefTitle":"An Online, Compassion Intervention for Adults with Type 1 and Type 2 Diabetes Mellitus (T1DM; T2DM)."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Canterbury Christ Church University"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Four Week Self-Compassion Course"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03766308","briefTitle":"The Clinical Study of the Effect of Highland Barley Diet on Blood Glucose in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Xuefeng Yu"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Highland Barley Diet"},{"name":"ADA diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02794792","briefTitle":"A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Europe B.V."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ipragliflozin L-proline"},{"name":"Metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02683746","briefTitle":"Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lyophilized albiglutide DCC pen injector"},{"name":"Lyophilized albiglutide DCC pen injector matching placebo"},{"name":"Albiglutide liquid auto-injector"},{"name":"Albiglutide liquid auto-injector matching placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03666546","briefTitle":"Blood Glucose Response After Oral Intake of Lactulose in Mildly Constipated Patients With Diabetes Mellitus Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fresenius Kabi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lactulose crystals 20 g"},{"name":"Lactulose crystals 30 g"},{"name":"Lactulose liquid 20 g"},{"name":"Lactulose liquid 30 g"},{"name":"Glucose"},{"name":"Still water"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00361946","briefTitle":"The Role of Amylin and Incretins on Postprandial Metabolisms in Adolescents With Type 2 Diabetes Mellitus (T2DM)."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baylor College of Medicine"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03960424","briefTitle":"Diabetes Management Program for Hispanic/Latino"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Northwell Health"},"collaborators":[{"name":"Patient-Centered Outcomes Research Institute"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Comprehensive Outpatient Management"},{"name":"Diabetes Telemonitoring"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05542420","briefTitle":"A Research Study, Looking at the Characterization of Treatment Intensified (Add on to Metformin) Real-world Adult Population With Type 2 Diabetes Mellitus in India, Pakistan and Thailand."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00644241","briefTitle":"Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Post Graduate Institute of Medical Education and Research, Chandigarh"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"stem cell harvest"},{"name":"angiographic transplantation of stem cells"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02128815","briefTitle":"Evaluating the Effect of a Diabetes Health Coach in Individuals With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"McMaster University"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Coaching"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01175811","briefTitle":"A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Lispro Premix"},{"name":"Insulin Glargine"},{"name":"Insulin Lispro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01144975","briefTitle":"Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"XOMA (US) LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"XOMA 052"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02452632","briefTitle":"A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Korea, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ASP1941"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05937737","briefTitle":"Serum FGF21 Levels and Dietary Total Antioxidant Capacity in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hacettepe University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Type 2 Diabetes Diet Modification"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03387787","briefTitle":"Evaluation of Glycaemic Control Using GlucoTab® With Insulin Degludec in Hospitalized Patients With Diabetes Mellitus Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Insel Gruppe AG, University Hospital Bern"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GlucoTab"},{"name":"Insulin Degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04980014","briefTitle":"A Post-Marketing Surveillance Study on NesinaAct® Tablet Use Among Type 2 Diabetes Mellitus Participants in Korea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NesinaAct® Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02636192","briefTitle":"Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03314246","briefTitle":"Development and Implementation of Ramadan Fasting Algorithm for Singaporeans With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Joyce Lee"},"collaborators":[{"name":"National University of Singapore"},{"name":"Tan Tock Seng Hospital"},{"name":"National Healthcare Group, Singapore"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FAST"},{"name":"Standard of care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04642378","briefTitle":"Study to Assess the Efficacy and Safety of iNCDSS in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Zhongshan Hospital"},"collaborators":[{"name":"Shanghai Fifth People's Hospital,Fudan University"},{"name":"XuHui Central Hospital of Shanghai, Shanghai, China"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"iNCDSS based insulin regime"},{"name":"routine insulin treatment regime"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03231709","briefTitle":"Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Trelagliptin"},{"name":"Alogliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01240759","briefTitle":"Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shionogi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"S-707106 Dose A"},{"name":"S-707106 Dose B"},{"name":"S-707106 Dose C"},{"name":"Placebo A tablet"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06120556","briefTitle":"Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLP-1 receptor agonist"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04383639","briefTitle":"Cocoa/Carob Polyphenols and Postprandial Changes in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Research Council, Spain"},"collaborators":[{"name":"Ministerio de Economía y Competitividad, Spain"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No product (A)/mixture of coca and carob together with breakfast (B)/mixture of coca and carob 10 h before breakfast (C)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01933256","briefTitle":"Study of Subcutaneous Doses of HIP2B in Subjects With Type 2 Diabetes Mellitus Treated With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"CureDM"},"collaborators":[{"name":"Profil Institute for Clinical Research, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HIP2B"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04657939","briefTitle":"Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Leeds"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04166760","briefTitle":"Metabolic Effects of Whey Compounds in Patients With Diabetes Mellitus Type 2."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"speWHE"},{"name":"WHE"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00694057","briefTitle":"Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Harbor Therapeutics"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HE3286"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04303754","briefTitle":"Diabetes-Specific Formula in Individuals With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Nutrition"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes-Specific Formula"},{"name":"Bread with Spread"},{"name":"Rice Porridge"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00013910","briefTitle":"NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Center for Research Resources (NCRR)"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NNC 90-1170"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03318913","briefTitle":"Vascular Function, Fish Protein Hydrolysates and Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidade Federal do Rio de Janeiro"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Fish protein hydrolysates"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01072331","briefTitle":"Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MP-513"},{"name":"MP-513"},{"name":"Placebo of MP-513"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04305587","briefTitle":"Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-07081532"},{"name":"Placebo"},{"name":"Clopidogrel"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04889157","briefTitle":"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-06882961"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03751735","briefTitle":"Efficacy of Wharton Jelly in Erectile Dysfunction"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sophia Al-Adwan"}},"conditionsModule":{"conditions":["Erectile Dysfunction Associated With Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Wharton Jelly Mesenchymal stem cells"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03944616","briefTitle":"Study Of Drinks With Artificial Sweeteners in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, Irvine"},"collaborators":[{"name":"University of Minnesota"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diet Beverage"},{"name":"Water"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01421459","briefTitle":"A Study in Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"},"collaborators":[{"name":"Boehringer Ingelheim"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2963016"},{"name":"Lantus"},{"name":"OAMs"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02229227","briefTitle":"Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"},"collaborators":[{"name":"PPD DEVELOPMENT, LP"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Albiglutide"},{"name":"Insulin Glargine and Insulin Lispro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04663282","briefTitle":"A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jiangsu HengRui Medicine Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INS068 injection"},{"name":"Insulin Degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03555591","briefTitle":"Specified Drug-Use Survey of Trelagliptin Tablets \"Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus\""},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Trelagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04191525","briefTitle":"Phase II Clinical Trial to Evaluate the Efficacy and Safety of the Treatment With BPL-1 in Adult Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mónica Marazuela Azpíroz"},"collaborators":[{"name":"Alba Garcimartín Álvarez"},{"name":"Carolina Knott Torcal"},{"name":"Nerea Aguirre Moreno"},{"name":"Miguel Antonio Sampedro Núñez"},{"name":"María Caldas"},{"name":"Belén Ruiz-Rosso"},{"name":"Ana María Ramos Levi"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BPL-1 Probiotic capsules"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04701424","briefTitle":"Closed-loop in Adults With T2D Not Requiring Dialysis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Cambridge"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CamAPS HX Closed-loop"},{"name":"Multiple Daily Insulin Injections (Control)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01038089","briefTitle":"Pilot Study Of The Effects Of Resveratrol On Endothelial Function In Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boston University"},"collaborators":[{"name":"DSM Nutritional Products, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Resveratrol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03189407","briefTitle":"Effect of Moringa Oleifera on Metformin Plasma Level in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Titilayo O Fakeye"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Moringa oleifera tea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04386187","briefTitle":"Glutathione-rich Foods for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Diego"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSH Foods"},{"name":"Nutrition education about glutathione sources in the diet"},{"name":"Standard of care nutrition education for type 2 diabetes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02077452","briefTitle":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HMS5552 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hua Medicine Limited"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HMS5552"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01719640","briefTitle":"MSC and MC in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fuzhou General Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"infusion of MSCs"},{"name":"infusion MCs"},{"name":"insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04564872","briefTitle":"HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sichuan Haisco Pharmaceutical Group Co., Ltd"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HSK7653 10 mg Q2W"},{"name":"HSK7653 25 mg Q2W"},{"name":"Linagliptin 5 mg QD"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05963022","briefTitle":"A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01677013","briefTitle":"Autologous Bone Marrow Mononuclear Cell Transplantation in Treating Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Peking University Aerospace Centre Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BMMCT"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04591782","briefTitle":"Investigation of PJ vs. Sugar on Glucose Levels in Healthy and Prediabetic Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, Los Angeles"}},"conditionsModule":{"conditions":["Diabete Type 2","Pre Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PomJuice"},{"name":"Water"},{"name":"Sugar Water"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01029704","briefTitle":"Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Theracos"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EGT0001442"},{"name":"Placebo capsules to match EGT0001442"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00494013","briefTitle":"Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Lispro Protamine Suspension"},{"name":"Detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05553145","briefTitle":"The Prevalence of Autoimmune Antibodies in Patients with Type 2 Diabetes Managed by Endocrinology Vs. Primary Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Cleveland Clinic"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Autoimmune Antibody Assays"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03928379","briefTitle":"A Study of LY3305677 in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3305677"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02152371","briefTitle":"A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dulaglutide"},{"name":"Placebo"},{"name":"Insulin Glargine"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03315780","briefTitle":"A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dulaglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02371239","briefTitle":"SIT LESS 2: Effect of Sitting Less on Glucose Regulation in People With Diabetes Mellitus Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physical activity intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05386849","briefTitle":"Closed Loop Glucose Control in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ideal Medical Technologies"},"collaborators":[{"name":"Emory University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FUSION closed loop glucose control system"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04023539","briefTitle":"Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidad de Sonora"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cinnamomum zeylanicum"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00160017","briefTitle":"Effectiveness and Cost-effectiveness of the Diabetes Integrated Care Breakthrough Collaborative"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Radboud University Medical Center"},"collaborators":[{"name":"ZonMw: The Netherlands Organisation for Health Research and Development"},{"name":"Dutch Institute for HealthCare Improvement (CBO)"},{"name":"College of Health Insurances CVZ"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Breakthrough collaborative"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03343782","briefTitle":"Outcomes of Expanded Autologous Bone Marrow-derived Mesenchymal Stem Cells Therapy in Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vinmec Research Institute of Stem Cell and Gene Technology"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Expanded autologous bone marrow-derived mesenchymal stem cell"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02597049","briefTitle":"A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dulaglutide"},{"name":"Placebo"},{"name":"SGLT2 inhibitor"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00923962","briefTitle":"Endothelial and Metabolic Effects of Glucagon-like Peptide-1 (GLP-1) in Coronary Circulation in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glucagon like peptide-1"},{"name":"Adenosine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04491253","briefTitle":"Social Support Intervention for Self-management of Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidad de Antioquia"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Social support for diabetes self-management"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01258075","briefTitle":"Colesevelam for Children With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High-dose colesevelam"},{"name":"Low-dose colesevelam"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04136067","briefTitle":"A Study to Look at How Safe NNC0268-0965 is in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NNC0268-0965"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02180646","briefTitle":"Impact of Breakfast Composition on Glycemic and Incretin Responses in Individuals With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Missouri-Columbia"},"collaborators":[{"name":"American Egg Board"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High protein breakfast"},{"name":"High carb breakfast"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04945109","briefTitle":"Wolffia Globosa (Mankai) and Glycemic Control Among Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ben-Gurion University of the Negev"},"collaborators":[{"name":"Sheba Medical Center"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mankai beverage"},{"name":"Water (control)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01230749","briefTitle":"A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"JNJ-41443532"},{"name":"Pioglitazone 30 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03199053","briefTitle":"Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Saxagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02737891","briefTitle":"Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Saniona"},"collaborators":[{"name":"Profil Institut für Stoffwechselforschung GmbH"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tesofensine/Metoprolol"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04552470","briefTitle":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"PF-06882961"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01387334","briefTitle":"The Effectiveness of Resistance Exercise for Glycemic Control in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Prince of Songkla University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Resistance Exercise Training Program With Rubber Bands"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04153981","briefTitle":"A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04108299","briefTitle":"Family Intervention for Chinese Americans With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NYU Langone Health"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Wait-list control group"},{"name":"SMS intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05373212","briefTitle":"A Trial Investigating the Dose Linearity and Safety of BC Combo THDB0207 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Adocia"},"collaborators":[{"name":"Tonghua Dongbao Pharmaceutical Co.,Ltd"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Euglycemic clamp with BC Combo THDB0207"},{"name":"Euglycemic clamp with Humalog® Mix25"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02964585","briefTitle":"Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"George Washington University"},"collaborators":[{"name":"Janssen Scientific Affairs, LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00790660","briefTitle":"A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ASP1941"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02680457","briefTitle":"Effect of Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Guadalajara"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Degludec"},{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05333822","briefTitle":"Effects of Bashan on Glucose in Type 2 Diabetes Patients and Its Related Mechanisms"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Zhongda Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bashan"},{"name":"water"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01381887","briefTitle":"A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Canagliflozin 300mg/Placebo"},{"name":"Canagliflozin 300mg/Canagliflozin 150mg"},{"name":"Canagliflozin 300mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04965506","briefTitle":"A Study of IBI362 in Chinese Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Innovent Biologics (Suzhou) Co. Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IBI362"},{"name":"placebo"},{"name":"Dulaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05375695","briefTitle":"Feasibility of Time-Restricted Eating in the Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kristine Færch"},"collaborators":[{"name":"Hvidovre University Hospital"},{"name":"University of Leeds"},{"name":"Salk Institute for Biological Studies"},{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Time-restricted eating"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01597154","briefTitle":"Lifestyle Therapy for Youth With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Manitoba"},"collaborators":[{"name":"Manitoba Institute of Child Health"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle Counselling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03922750","briefTitle":"A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin icodec"},{"name":"Insulin glargine U100"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02973321","briefTitle":"A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SAR425899"},{"name":"Placebo"},{"name":"Liraglutide"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01933672","briefTitle":"Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-04937319 once-daily"},{"name":"PF-04937319 split-dose"},{"name":"Sitagliptin once-daily"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02201550","briefTitle":"Study of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hvidovre University Hospital"},"collaborators":[{"name":"Zealand Pharma"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04595968","briefTitle":"Electrical Vestibular Nerve Stimulation (VeNS) Compared to Sham Control As a Means of Improving Glycemic Control in Adults with Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Neurovalens Ltd."},"collaborators":[{"name":"University College Dublin"},{"name":"CS Lifescience"},{"name":"Clinical Trial Mentors"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vestal DM Active device"},{"name":"Lifestyle modification"},{"name":"Vestal DM Sham device"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04617795","briefTitle":"Omnipod® 5 Automated Insulin Delivery System in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Insulet Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omnipod 5 Automated Insulin Delivery System"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00680849","briefTitle":"Enhancing Support for Women With Type 2 Diabetes: Follow-Up"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oregon Research Institute"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02211261","briefTitle":"A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-06293620"},{"name":"Placebo"},{"name":"PF-06293620"},{"name":"Placebo"},{"name":"PF-06293620"},{"name":"Placebo"},{"name":"PF-06293620"},{"name":"Placebo"},{"name":"PF-06293620"},{"name":"Placebo"},{"name":"PF-06293620"},{"name":"Placebo"},{"name":"PF-06293620"},{"name":"Placebo"},{"name":"PF-06293620"},{"name":"Placebo"},{"name":"PF-06293620"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03992248","briefTitle":"Effect of Eating Within a Limited Time on Sugar Sensitivity and Liver Sugar Stores of People With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University"},"collaborators":[{"name":"ZonMw: The Netherlands Organisation for Health Research and Development"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Time restricted feeding"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03367377","briefTitle":"A Study of LY3209590 in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3209590"},{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01441921","briefTitle":"Effect of Pistachio Intake on Insulin Resistance and Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institut Investigacio Sanitaria Pere Virgili"},"collaborators":[{"name":"Western Pistachio Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pistachios"},{"name":"control diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05125185","briefTitle":"The Effect of USM-IAM-based Counselling"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universiti Sains Malaysia"}},"conditionsModule":{"conditions":["Diabetes Type 2 on Insulin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"The Effectiveness of USM-Insulin Adherence Module (U-IAM) for Type 2 Diabetes in Improving Insulin Adherence, Glycemic Control and Inflammation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01276106","briefTitle":"Study of AC-201 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"TWi Biotechnology, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AC-201, 25mg"},{"name":"AC-201, 50mg"},{"name":"AC-201, 75mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00320853","briefTitle":"A Study to Evaluate the Effect of Vitamin D Supplementation on Insulin Sensitivity and Secretion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sitaram Bhartia Institute of Science and Research"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin D"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06461871","briefTitle":"Combined Effects of BT With Moderate Intensity Aerobic Versus RT in Type 2 DM."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Riphah International University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BALANCE TRAINING WITH MODERATE INTESITY AEROBIC VERSUS RESISTED TRAINING (RT)"},{"name":"Moderate intensity resistance exercises in combination with balance training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01023945","briefTitle":"A Study of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ASP1941"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01733758","briefTitle":"A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Albiglutide 30 mg weekly"},{"name":"Albiglutide 50 mg weekly"},{"name":"Placebo"},{"name":"Liraglutide 0.9 mg daily"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01066715","briefTitle":"Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"XOMA (US) LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"XOMA 052"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01528254","briefTitle":"VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo of vildagliptin"},{"name":"vildagliptin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04374578","briefTitle":"Effect of Dulaglutide on Glycemic Variability in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Zhongshan Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dulaglutide 1.5 MG/ML"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02346344","briefTitle":"Outpatient Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Foundation for the National Institutes of Health"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"Juvenile Diabetes Research Foundation"},{"name":"Amylin Pharmaceuticals, LLC."},{"name":"Merck Sharp & Dohme LLC"},{"name":"Pfizer"},{"name":"Eli Lilly and Company"},{"name":"Takeda"},{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."},{"name":"Novartis"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02960659","briefTitle":"Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},"collaborators":[{"name":"Children's National Research Institute"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02294526","briefTitle":"A Sardine Diet Intervention Study to Assess Benefits to the Metabolic Profile in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sardine diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01387165","briefTitle":"Epidemiologic Survey to Describe the Current Medical Practice of General Practitioners Treating Subjects With Type 2 Diabetes Mellitus in Latina"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00734474","briefTitle":"A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"},"collaborators":[{"name":"United BioSource, LLC"},{"name":"Tessella Inc."},{"name":"Berry Consultants"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2189265"},{"name":"Sitagliptin"},{"name":"Placebo solution"},{"name":"Placebo tablet"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01786707","briefTitle":"Autologous Stem Cell and Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rodolfo Alejandro"},"collaborators":[{"name":"Diabetes Research Institute Foundation"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Autologous stem cells"},{"name":"Hyperbaric oxygen therapy"},{"name":"Insulin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02434744","briefTitle":"Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Response Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"KD026"},{"name":"Placebo"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01699737","briefTitle":"Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Akros Pharma Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"JTT-851"},{"name":"Glimepiride"},{"name":"Placebo for Active"},{"name":"Placebo for comparator"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04465877","briefTitle":"Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Akros Pharma Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"JTT-662"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02426541","briefTitle":"Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Antaros Medical"},{"name":"Bioventure Hub"},{"name":"43183 Mölndal"},{"name":"Sweden"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02627898","briefTitle":"Effect of Green Tea Extract on Arterial Stiffness in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centro Universitario de Ciencias de la Salud, Mexico"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"green tea extract"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01558271","briefTitle":"A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2189265"},{"name":"Placebo"},{"name":"Liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00232583","briefTitle":"Preservation of Beta-cell Function in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Texas Southwestern Medical Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Insulin"},{"name":"Metfomin"},{"name":"Pioglitazone"},{"name":"glyburide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02730754","briefTitle":"Emotional Disorders and Outcomes in Adults With Type 2 Diabetes Mellitus at Primary Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universiti Putra Malaysia"},"collaborators":[{"name":"Ministry of Health, Malaysia"},{"name":"UMC Utrecht"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05806502","briefTitle":"Arginase Inhibition in Type 1 and Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Karolinska Institutet"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nω-hydroxy-nor-arginine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05737810","briefTitle":"Attitudes and Unmet Needs Among Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00484198","briefTitle":"Study of Rivoglitazone in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"Placebo"},{"name":"Rivoglitazone"},{"name":"Rivoglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01509001","briefTitle":"Study of Metabolic and Haemodynamic Effects of Metformin and Glimepiride in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Sao Paulo"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03914326","briefTitle":"A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"},{"name":"Placebo (semaglutide)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02663245","briefTitle":"INTEGRA Study: Primary Care Intervention in Type 2 Diabetes Patients With Poor Glycaemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intervention 1"},{"name":"Intervention 2"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02891382","briefTitle":"Feasibility Study on the Impact of Economic Incentives to Improve the Management of Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidad Peruana Cayetano Heredia"},"collaborators":[{"name":"Johns Hopkins Bloomberg School of Public Health"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes education"},{"name":"Goal setting"},{"name":"Companion Support"},{"name":"Individual Reward"},{"name":"Shared Reward"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02009488","briefTitle":"Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin, 100 mg"},{"name":"Canagliflozin, 300 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06624553","briefTitle":"Satisfaction With FreeStyle Libre 2 Monitoring Versus Capillary Blood Glucose Monitoring in People With DM2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FreeStyle Libre 2, flash glucose monitoring"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04013581","briefTitle":"Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yonsei University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TZD group"},{"name":"SGLT-2 group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02205996","briefTitle":"The Effects of Hypoglycaemia in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Hull"},"collaborators":[{"name":"Hull University Teaching Hospitals NHS Trust"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin (Humulin S)"},{"name":"Euglycaemic Hypoglycaemic Insulin clamp"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01881074","briefTitle":"Periodontal Treatment Response in Type II Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Florida"},"collaborators":[{"name":"Colgate Palmolive"}]},"conditionsModule":{"conditions":["Type II Diabetes","Periodontal Disease"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Triclosan containing toothpaste"},{"name":"Non-triclosan containing toothpaste"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03322631","briefTitle":"A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00642278","briefTitle":"An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II","Diabetes Mellitus, Non Insulin Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin (JNJ-28431754)"},{"name":"Sitagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00299871","briefTitle":"Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LIXISENATIDE (AVE0010)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03758742","briefTitle":"Effect of Whole Fruit on Glycemic Control in Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alabama at Birmingham"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High-Fruit Diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01475461","briefTitle":"Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"PF-04937319 - 3mg"},{"name":"PF-04937319 - 20mg"},{"name":"PF-04937319 - 50mg"},{"name":"PF-04937319 - 100mg"},{"name":"Sitagliptin - 100mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04230382","briefTitle":"The Proportion of Patients With Non-diagnosed Diabetes Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nutrition Institute, Slovenia"},"collaborators":[{"name":"National Institute of Public Health, Slovenia"},{"name":"Ministry of Health of Republic of Slovenia"},{"name":"Slovenian Research Agency"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diagnosis of diabetes (OGTT)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01902316","briefTitle":"Clinical Verification of Peptide Biomarkers for Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Beijing Institute of Technology"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00942188","briefTitle":"A Study of LY2189102 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2189102"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02456064","briefTitle":"Impact of a Program of Non-pharmacological Intervention in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Equipo Multidisciplinar Sanitario CS Foietes"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle counseling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02121717","briefTitle":"Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chipscreen Biosciences, Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Chiglitazar"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03861039","briefTitle":"A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Oral antihyperglycemic medication (OAM)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05666128","briefTitle":"Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hyundai Pharm"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HD-6277"},{"name":"HD-6277"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04427488","briefTitle":"The Effect of Exercises Performed According to Circadian Rhythm in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Istanbul Medipol University Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Morning Chronotype group"},{"name":"Evening Chronotype group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00032487","briefTitle":"Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VA Office of Research and Development"},"collaborators":[{"name":"National Eye Institute (NEI)"},{"name":"SmithKline Beecham"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin"},{"name":"Glimepiride"},{"name":"Rosiglitazone"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03603704","briefTitle":"A Study of LY3209590 in Japanese Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3209590"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01885260","briefTitle":"Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ionis Pharmaceuticals, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ISIS-GCGRRx - Dose Level 1"},{"name":"ISIS-GCGRRx - Dose Level 2"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01082120","briefTitle":"Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD1656"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03244800","briefTitle":"A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"MedImmune LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MEDI0382"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05083767","briefTitle":"Effect of Whole Body Vibration Training on Glycemic Control in Type II Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ameen Medical and Dental Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Experimental"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01649466","briefTitle":"Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LAF237"},{"name":"Protaphane"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05074667","briefTitle":"Use of Continuous Glucose Monitors in Publicly-Insured Youth With Type 2 Diabetes - A Pilot and Feasibility Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Stanford University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous Glucose Monitor"},{"name":"Patient Reported Outcome Questionnaires"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01071850","briefTitle":"A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ipragliflozin"},{"name":"Metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04424888","briefTitle":"Evaluating Use of Continuous Glucose Monitors in a Short-term 2x2-Crossover Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pendulum Therapeutics"}},"conditionsModule":{"conditions":["Diabetes Type 2","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"WB-011"},{"name":"Placebo"},{"name":"Continuous Glucose Monitor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05564039","briefTitle":"A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Dulaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04004793","briefTitle":"Remission of Type 2 Diabetes With Dapagliflozin (READ Trial)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Zhongshan Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intensive lifestyle intervention"},{"name":"Dapagliflozin 10 MG Oral Tablet"},{"name":"Placebo Oral Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02004886","briefTitle":"A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK-0893"},{"name":"Metformin"},{"name":"Placebo"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00302224","briefTitle":"A Phase 1/2a Study of the 2S,4R Enantiomer of Ketoconazole in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"DiObex"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"2S, 4R Ketoconazole (DIO-902)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02206607","briefTitle":"Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-04937319 IR MST"},{"name":"PF-04937319 MR 1"},{"name":"PF-04937319 MR 2"},{"name":"PF-04937319 MR 3"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01990300","briefTitle":"Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin/Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01584232","briefTitle":"A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2189265"},{"name":"Insulin glargine"},{"name":"Sulfonylureas (SU)"},{"name":"Biguanide (BG)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05162014","briefTitle":"To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"empagliflozin"},{"name":"Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05380232","briefTitle":"Physical Activity and Mortality in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aarhus University Hospital"},"collaborators":[{"name":"University of Aarhus"},{"name":"The Danish Diabetes Association"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Leisure-time physical activity"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01582230","briefTitle":"Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01663220","briefTitle":"Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Foundation for the National Institutes of Health"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"Juvenile Diabetes Research Foundation"},{"name":"Amylin Pharmaceuticals, LLC."},{"name":"Merck Sharp & Dohme LLC"},{"name":"Pfizer"},{"name":"Eli Lilly and Company"},{"name":"Takeda"},{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."},{"name":"Novartis"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00851019","briefTitle":"Dance Dance Revolution (DDR) in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Charles Drew University of Medicine and Science"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DDR"},{"name":"Treadmill"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02899949","briefTitle":"Health Outcomes of Patients With Type 2 Diabetes Treated With Dapagliflozin in Conjunction With Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lawson Health Research Institute"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02688075","briefTitle":"An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04916093","briefTitle":"Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Beni-Suef University"},"collaborators":[{"name":"Minia University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin 50 MG"},{"name":"Sitagliptin 100mg"},{"name":"MetFORMIN 1000 Mg Oral Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06560541","briefTitle":"Rice Intervention in Chronic Health Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Taylor's University"},"collaborators":[{"name":"National University of Malaysia"},{"name":"Universiti Putra Malaysia"},{"name":"National Institutes of Health, Ministry of Health Malaysia"},{"name":"University of Nottingham Malaysia"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"UKMRC9"},{"name":"White rice"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05801627","briefTitle":"SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled by Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shenzhen Salubris Pharmaceuticals Co., Ltd."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SAL067"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03018938","briefTitle":"A Study of Basal Insulin Analog and Insulin Analog Mid Mixture in Chinese Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Analog Mid Mixture"},{"name":"Basal Insulin Analog"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02220907","briefTitle":"Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Teneligliptin/Canagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05284344","briefTitle":"The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Adelaide"},"collaborators":[{"name":"The First Affiliated Hospital with Nanjing Medical University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Anti-Diabetics"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03371108","briefTitle":"Gan & Lee Insulin Glargine Target Type (2) Evaluating Research"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gan and Lee Pharmaceuticals, USA"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gan & Lee Insulin Glargine Injection"},{"name":"Lantus®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01614769","briefTitle":"Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus (MK-0000-253)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Glimepiride 2 mg"},{"name":"Glimepiride 4 mg"},{"name":"Hypoglycemic Clamp"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05146869","briefTitle":"A Single-dose and Multiple-dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of DBPR108 Tablets in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DBPR108 tablets"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03645421","briefTitle":"Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MEDI0382 100 μg"},{"name":"MEDI0382 200 μg"},{"name":"MEDI0382 300 μg"},{"name":"PlaceboA"},{"name":"MEDI0382 50 ug"},{"name":"PlaceboB"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02367131","briefTitle":"Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"JARDIANCE®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00824694","briefTitle":"Impact of Accu-Chek 360 in Veterans With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Biomedical Research Institute of New Mexico"},"collaborators":[{"name":"New Mexico VA Healthcare System"},{"name":"Carl T. Hayden VA Medical Center"},{"name":"Southern Arizona VA Health Care System"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Targeted Self-Monitoring Of Blood Glucose (SMBG)"},{"name":"Provider Training"},{"name":"Patient Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02441023","briefTitle":"Nutritional Therapy and Education With Multimedia Application in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Coordinación de Investigación en Salud, Mexico"},"collaborators":[{"name":"National Council of Science and Technology, Mexico"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nutritional therapy and education"},{"name":"Nutritional therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01346033","briefTitle":"Evaluation of SCOUT DS in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VeraLight, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00957268","briefTitle":"Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02945449","briefTitle":"Safety of Wharton Jelly in Erectile Dysfunction"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sophia Al-Adwan"}},"conditionsModule":{"conditions":["Erectile Dysfunction Associated With Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Wharton Jelly Mesenchymal stem cells"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02002975","briefTitle":"Pioglitazone Special Drug Use Surveillance \"Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus\""},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06425705","briefTitle":"Impact of Silymarin Adjunct Therapy on Proteinuria in Type 2 Diabetic Patients on RAS Inhibitors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lahore General Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Silymarin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01273558","briefTitle":"A Study of Two Methods for Determining the Renal Threshold for Glucose in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00607945","briefTitle":"Dietary Fatty Acids As Complementary Therapy in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ohio State University"},"collaborators":[{"name":"National Center for Complementary and Integrative Health (NCCIH)"},{"name":"GlaxoSmithKline"},{"name":"Bunge Loders Croklaan"},{"name":"LifeScan"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant"},{"name":"conjugated linoleic acid (CLA)"},{"name":"conjugated linoleic acid (CLA)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00850096","briefTitle":"Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"CPEX Pharmaceuticals Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo for Nasulin"},{"name":"Nasulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04980027","briefTitle":"Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine (U300)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05514080","briefTitle":"A Study to Evaluate Eli Lilly's Insulin Dosing Algorithm to Control Glycemia in Insulin-treated Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"McGill University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin closed-loop"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01044537","briefTitle":"A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"PF-04937319"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02528695","briefTitle":"Adipose Tissue Imaging in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Radboud University Medical Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"18F-FDG PET/CT"},{"name":"euglycemic clamp"},{"name":"hypoglycemic clamp"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03951805","briefTitle":"A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin icodec"},{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02098733","briefTitle":"Long-term Use of Sonias Combination Tablets in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone/glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03663738","briefTitle":"Impact Evaluation of a Mobile Health App to Improve Self-control and Health Outcomes of Patients With Type 2 Diabetes Mellitus (T2DM): Pilot Study \"NOVAME\""},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Servicio Canario de Salud"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"mobile app NOVAME"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04605991","briefTitle":"A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY900014"},{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04682067","briefTitle":"Diabetes Smoking Cessation Incentives Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Oklahoma"}},"conditionsModule":{"conditions":["Smoking Cessation","Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Contingency Management"},{"name":"Usual Care smoking cessation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01869608","briefTitle":"Postpartum Screening of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Université de Sherbrooke"},"collaborators":[{"name":"The Lawson Foundation"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"oral glucose tolerance test 2 days post-partum"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04012775","briefTitle":"Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Geropharm"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Humulin® NPH"},{"name":"Insulin Rinsulin® NPH"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02059187","briefTitle":"The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK-1293"},{"name":"Lantus™"},{"name":"Prandial insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00067951","briefTitle":"A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rosiglitazone/metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00804986","briefTitle":"A Study for Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2428757"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01915849","briefTitle":"Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LIK066"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06659848","briefTitle":"the Effect of Fasted Versus Post-meal HIIT on Glycemic Control in Men With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Prince Sattam Bin Abdulaziz University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"high intensity interval training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00931372","briefTitle":"Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"},"collaborators":[{"name":"Profil GmbH, Neuss, Germany"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide (AVE0010)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04445714","briefTitle":"To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"dapagliflozin and saxagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05550870","briefTitle":"Effect of Raw Versus Roasted Fenugreek Seed Powder in Reducing Blood Glucose Levels in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Veterinary and Animal Sciences, Lahore - Pakistan"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Raw fenugreek seed powder"},{"name":"Roasted fenugreek seed powder"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03985293","briefTitle":"A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"PF-06882961"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01195090","briefTitle":"Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and Sulfonylurea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sung-Chen Liu"},"collaborators":[{"name":"Mackay Memorial Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02052037","briefTitle":"Egg Ingestion in Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Griffin Hospital"},"collaborators":[{"name":"American Egg Board"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Egg inclusion"},{"name":"Egg exclusion"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03555994","briefTitle":"A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"MedImmune LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MEDI0382"},{"name":"Placebo"},{"name":"Liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02489942","briefTitle":"Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Jardiance"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01128985","briefTitle":"A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin 50 mg"},{"name":"Canagliflozin 100 mg"},{"name":"Canagliflozin 300 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04237493","briefTitle":"Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Jordan"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin and Glimepiride (Low Dosage)"},{"name":"Metformin and Vildagliptin (Low Dosage)"},{"name":"Metformin and Insulin Glargine U100 (Low Dosage)"},{"name":"Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage)"},{"name":"Metformin and Glimepiride (Regular Dosage)"},{"name":"Metformin and Vildagliptin (Regular Dosage)"},{"name":"Metformin and Insulin Glargine U100 (Regular Dosage)"},{"name":"Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00962065","briefTitle":"Study of LX4211 in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lexicon Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LX4211 Low Dose"},{"name":"LX4211 High Dose"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02000700","briefTitle":"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin 100 mg"},{"name":"Canagliflozin 50 mg"},{"name":"Canagliflozin 300 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01076075","briefTitle":"A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin phosphate"},{"name":"Comparator: placebo to pioglitazone"},{"name":"Comparator: placebo to Sitagliptin"},{"name":"Comparator: pioglitazone"},{"name":"Glimepiride or gliclazide"},{"name":"Metformin"},{"name":"Pioglitazone rescue therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04439474","briefTitle":"Determining the Effect of Vitamin D, Dyslipidemia and Microvascular in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baqiyatallah Medical Sciences University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin D3"},{"name":"Routine treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05252793","briefTitle":"Effect of Education Based on The Health Belief Model on Healthy Lifestyle Behaviors in Individuals With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gazi University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Education based on the health belief model"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00329225","briefTitle":"Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rosiglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01037842","briefTitle":"Effect of Combination of Mitiglinide and Metformin on Glycemic Control in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Hospital"},"collaborators":[{"name":"Seoul St. Mary's Hospital"},{"name":"The Catholic University of Korea"},{"name":"Uijeongbu St. Mary Hospital"},{"name":"Korea University"},{"name":"Kyungpook National University Hospital"},{"name":"Pusan National University College of Medicine"},{"name":"Sungkyunkwan University"},{"name":"Yonsei University"},{"name":"Eulji University"},{"name":"Chonnam National University"},{"name":"Chonbuk National University"},{"name":"Chungnam National University"},{"name":"Hallym University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mitiglinide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00668954","briefTitle":"Antioxidant Effects of Pomegranate Juice Versus Placebo in Adults With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Denver"},"collaborators":[{"name":"POM Wonderful LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pomegranate Juice"},{"name":"Placebo Juice"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00530309","briefTitle":"Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK716155 for injection"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01091909","briefTitle":"Post-extraction Wound Healing in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Sao Paulo"},"collaborators":[{"name":"Fundação de Amparo à Pesquisa do Estado de São Paulo"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dental extractions"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02194608","briefTitle":"Telemonitoring System Study in Participants With Type 2 Diabetes Mellitus (MK-0000-347)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Home telehealth system"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00287807","briefTitle":"Effect of Self-monitoring of Blood Glucose in Patients With Type 2 Diabetes Mellitus Not Using Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical Research Foundation, The Netherlands"},"collaborators":[{"name":"Langerhans Foundation, the Netherlands"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Self-monitoring of blood glucose (SMBG)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00198926","briefTitle":"Type 2 Diabetes Controlled Eating Experiment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johns Hopkins Bloomberg School of Public Health"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"covert v overt nutrition labeling"},{"name":"varying meal nutrition manipulation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04484883","briefTitle":"Performance of Six Equations for Estimating Resting Energy Expenditure in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Observational"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03421301","briefTitle":"Dietary Intervention Modifies Gut Microbiota in Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran"},"collaborators":[{"name":"University of Connecticut"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"dietary portfolio"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02435693","briefTitle":"Pharmaceutical Care Program for Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"TABREJ MUJAWAR"}},"conditionsModule":{"conditions":["DIABETES MELLITUS, TYPE 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PHARMACEUTICAL CARE programe"},{"name":"Without PHARMACEUTICAL CARE programe"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04591626","briefTitle":"A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dulaglutide"},{"name":"Placebo"},{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03510624","briefTitle":"Acute Effect of Rebaudioside A on Glucose Excursion During an Oral Glucose Tolerance Test in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universitaire Ziekenhuizen KU Leuven"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rebaudioside A"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01680926","briefTitle":"Metabolic Activation With Almased for Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"West German Center of Diabetes and Health"},"collaborators":[{"name":"Almased Wellness GmbH"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Almased"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04017832","briefTitle":"A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral semaglutide"},{"name":"Sitagliptin"},{"name":"Placebo (oral semaglutide)"},{"name":"Placebo (sitagliptin)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01968265","briefTitle":"Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ionis Pharmaceuticals, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ISIS-GCCRRx"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03829800","briefTitle":"Formulas for Diabetes With Sucromalt & Isomaltulose on Glycemic Index, Hormones & Subjective Appetite in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidad del Zulia"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ensure® Abbott Nutrition"},{"name":"Glucerna® Abbott Nutrition"},{"name":"Diasip® Nutricia Advanced"},{"name":"Glicolab®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02524782","briefTitle":"A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"MedImmune LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MEDI-4166"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05110703","briefTitle":"Study to Assess Safety and Effect of a Prebiotic Fiber Meal Replacement Shake in Individuals With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Uplifting Results Labs Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Supergut"},{"name":"Placebo"},{"name":"Dietary guidelines"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02091362","briefTitle":"A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2409021"},{"name":"Placebo"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04582435","briefTitle":"A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Insulin Icodec in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Icodec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02359461","briefTitle":"Evaluation of the Effect of Pulsatile Cuts Stendo3 on Vascular Function Patients With Diabetes Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Clermont-Ferrand"},"collaborators":[{"name":"STENDO, 17 rue du port 27400 LOUVIERS"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Combination pulsatile Stendo3"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00660309","briefTitle":"A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aliskiren"},{"name":"Irbesartan"},{"name":"Captopril"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04003194","briefTitle":"Pinto Beans and Glycemic Control in Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Colorado Springs"},"collaborators":[{"name":"Iowa State University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pinto Beans"},{"name":"Green Beans - control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04014582","briefTitle":"Taking Action: a Care for Type 2 Diabetes Intervention for Couples"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Carnegie Mellon University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Communal Coping Intervention"},{"name":"Diabetes Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02926950","briefTitle":"Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lexicon Pharmaceuticals"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sotagliflozin (SAR439954)"},{"name":"Placebo"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05377333","briefTitle":"A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3457263"},{"name":"Placebo"},{"name":"Dulaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01427257","briefTitle":"Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"PhaseBio Pharmaceuticals Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Single Dose PB1023"},{"name":"Single Dose PB1023"},{"name":"Single Dose PB1023"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01387984","briefTitle":"YKL-40 and Complications in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Taiwan University Hospital"},"collaborators":[{"name":"National Science Council, Taiwan"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01387737","briefTitle":"Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TA-7284-Low"},{"name":"TA-7284-High"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06111508","briefTitle":"The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Virginia"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03363100","briefTitle":"Diabetes Coaching Program for Medicare Advantage Members With Type 2 Diabetes - Impact on A1c"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Evidation Health"},"collaborators":[{"name":"Humana Co.Ltd."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Digital health Partnership program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01263496","briefTitle":"Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin"},{"name":"Alogliptin"},{"name":"Alogliptin"},{"name":"Alogliptin"},{"name":"Voglibose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05066152","briefTitle":"The Effect of Single Probiotic on Metabolic Control in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Istanbul University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lactobacillus rhamnosus GG (ATCC 53103)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03598855","briefTitle":"Ischemic Preconditioning and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Liverpool John Moores University"},"collaborators":[{"name":"Liverpool University Hospitals NHS Foundation Trust"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ischemic Preconditioning"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03989232","briefTitle":"A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"},{"name":"Placebo (semaglutide)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03353350","briefTitle":"Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hanmi Pharmaceutical Company Limited"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"efpeglenatide (SAR439977)"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02622113","briefTitle":"Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin (TA-7284)"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00814190","briefTitle":"Effect of Internet Therapeutic Intervention on A1C Levels in Type 2 Diabetes Mellitus (DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Endocrine Research Society"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Internet Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02317211","briefTitle":"Purified Anthocyanins Supplementation in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sun Yat-sen University"},"collaborators":[{"name":"Shaoguan University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus，Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Anthocyanin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05502562","briefTitle":"A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05684341","briefTitle":"A Randomized Controlled Trial to Compare the Glycemic Control, With or Without the Connected Solution, of Adult Type 2 Diabetic Participants on Basal Insulin in Taiwan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Connected Solution with H2S app which connects with blood glucose meter (BGM)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02803918","briefTitle":"A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide (AVE0010)"},{"name":"Placebo"},{"name":"Basal Insulin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03480945","briefTitle":"Glycemic Control and Endothelial Function in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Karolinska Institutet"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"serotonin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02098746","briefTitle":"Pioglitazone/Glimepiride (Sonias) Combination Tablets Special Drug Use Surveillance Survey in Patients With Type 2 Diabetes Mellitus Who Respond Poorly to Pioglitazone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone/glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03620890","briefTitle":"Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center, Houston"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Neutral Protamine Hagedorn (NPH)"},{"name":"Detemir insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01732705","briefTitle":"High Intensity Interval Training (HIT) in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Copenhagen"},"collaborators":[{"name":"The Ministry of Science, Technology and Innovation, Denmark"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High intensity interval training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04982575","briefTitle":"Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide 2.4 mg"},{"name":"Cagrilintide 2.4 mg"},{"name":"Placebo (semaglutide)"},{"name":"Placebo (cagrilintide)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04109547","briefTitle":"A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral semaglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01908348","briefTitle":"Dose-Dependent Effects of Erythritol on Endothelial Function in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boston University"},"collaborators":[{"name":"Cargill"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Erythritol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00829699","briefTitle":"Metabolic Causes of Thrombosis in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Maryland, Baltimore"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"euinsulinemic euglycemic glucose clamp"},{"name":"euinsulinemic hyperglycemic glucose clamp"},{"name":"Hyperinsulinemic euglycemic glucose clamp"},{"name":"Hyperinsulinemic hyperglycemic glucose clamp"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02173457","briefTitle":"Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chipscreen Biosciences, Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Chiglitazar"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01247363","briefTitle":"A Study of LY2608204 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2608204"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04935554","briefTitle":"My Type 2 Diabetes: Person-centred Health Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Norwegian University of Science and Technology"},"collaborators":[{"name":"The Centre for Health Innovation"},{"name":"The Dam Foundation"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Person centred care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04707508","briefTitle":"Effect of Adding Renin-Angiotensin System Inhibitors to Standard Antidiabetic Therapy on Glycemic Control in Patients With Type 2 Diabetes Ellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nantou Christian Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Valsartan 80 mg and metformin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02848833","briefTitle":"JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"JARDIANCE 10mg"},{"name":"JARDIANCE 25mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01650259","briefTitle":"Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"OAD"},{"name":"Trazenta"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00972244","briefTitle":"Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05016375","briefTitle":"Perceptions of Passive Heating in Individuals With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Portsmouth"},"collaborators":[{"name":"Portsmouth Hospitals NHS Trust"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Interview"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03560271","briefTitle":"A Phase 2 Study of Cyclo-Z in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NovMetaPharma Co., Ltd."},"collaborators":[{"name":"InClin, Inc."},{"name":"FGK Clinical Research GmbH"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cyclo-Z"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00111800","briefTitle":"A New Oral Treatment For Type II Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"DEN 2.5 mg"},{"name":"DEN 7.5 mg"},{"name":"DEN 15 mg"},{"name":"DEN 30 mg"},{"name":"DEN 45 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03760991","briefTitle":"Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INSULIN GLARGINE (U300)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01876849","briefTitle":"An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03761797","briefTitle":"A Long-term Study on the Side Effects of TRADIANCE in Japanese Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TRADIANCE® Combination Tablets AP"},{"name":"TRADIANCE® Combination Tablets BP"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01765517","briefTitle":"Study to Explore the Effects of Probiotics on Endotoxin Levels in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"King Saud University"},"collaborators":[{"name":"Warwick Medical School"},{"name":"Winclove Bio Industries BV"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Probiotics"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03531944","briefTitle":"Impact of Community Pharmacist-Involved Collaborative Care Model for the Management of Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National University of Singapore"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Community pharmacist-involved collaborative care"},{"name":"Usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02293577","briefTitle":"Continuous Glucose Monitoring in Youth With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yale University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"continuous glucose monitor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04980040","briefTitle":"A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin Benzoate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00690326","briefTitle":"Behavioral Change Communication (BCC) to Promote Physical Activity Among Females With Type 2 Diabetes Mellitus Attending Diabetic Clinic"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Thiruvananthapuram Medical College"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Behavioral change communication to promote physical activity"},{"name":"Behavioral change communication to promote physical activity"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04765631","briefTitle":"Type 2 Diabetes and Bone Microarchitecture"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospices Civils de Lyon"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Patients with Type 2 diabetes"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00391209","briefTitle":"Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"},"collaborators":[{"name":"Alkermes, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder"},{"name":"intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01177384","briefTitle":"Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin phosphate"},{"name":"Comparator: Placebo"},{"name":"Acarbose"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04857398","briefTitle":"A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People From China With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin icodec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05823948","briefTitle":"A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Icodec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04892069","briefTitle":"Investigating the Effect of Ryzodeg® in Adult Patients With Type 2 Diabetes in Lebanon"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Degludec/Insulin Aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02542722","briefTitle":"Type 2 Diabetes Prevention"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud"},"collaborators":[{"name":"Hospital Regional de Malaga"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Control"},{"name":"Intensive Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01163721","briefTitle":"Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gilead Sciences"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ranolazine"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02401243","briefTitle":"Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INSULIN GLARGINE (U300)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02302716","briefTitle":"A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"},"collaborators":[{"name":"Boehringer Ingelheim"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2963016"},{"name":"LANTUS®"},{"name":"Oral Antihyperglycemic Medication"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02561078","briefTitle":"An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"},"collaborators":[{"name":"Insulet Corporation"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Human regular U-500 insulin (CSII)"},{"name":"Human regular U-500 insulin (MDI)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00353691","briefTitle":"Glimepiride vs Metformin as Monotherapy in Pediatric Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"glimepiride"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00907075","briefTitle":"Pilot Study to Assess Adherence to a Novel Eating System in Men and Women With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mondelēz International, Inc."},"collaborators":[{"name":"Provident Clinical Research"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NES With Energy Restriction"},{"name":"NES Without Energy Restriction"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05341063","briefTitle":"New Diagnosed Type 2 Diabetes - Online Education"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mehmet Akif Ersoy University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Online Education"},{"name":"Control Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02175784","briefTitle":"A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ipragliflozin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05144984","briefTitle":"A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NNC0480-0389"},{"name":"Semaglutide"},{"name":"Placebo (NNC080-0389)"},{"name":"Placebo (semaglutide)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00754988","briefTitle":"A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Placebo (matching sitagliptin)"},{"name":"Placebo (matching taspoglutide)"},{"name":"Sitagliptin"},{"name":"Taspoglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01189890","briefTitle":"Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin phosphate"},{"name":"Glimepiride"},{"name":"Placebo to Sitagliptin"},{"name":"Placebo to Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02804932","briefTitle":"Nitrate Supplementation and Exercise Tolerance in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Darren P Casey"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Super Beets"},{"name":"Super Beets Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03732690","briefTitle":"The Interaction Between Protein Intake, Gut Microbiota and Type 2 Diabetes in Subjects With Different Ethnic Backgrounds"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Assistance Publique - Hôpitaux de Paris"},"collaborators":[{"name":"ICAN Nutrition Education and Research"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diet HP"},{"name":"Diet LP"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04646746","briefTitle":"Acute Studies on the Glycemic Index After Intake of Different Sorts of Barley in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"Innovation Fund Denmark"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"100% wheat"},{"name":"50% nude barley and 50% wheat"},{"name":"75% nude barley and 25% wheat"},{"name":"50% gene-modified high-amylose barley and 50% wheat"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03882970","briefTitle":"A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Insulin Degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03078049","briefTitle":"Characteristics of Patients With Type 2 Diabetes Mellitus Receiving Treatment With Dapagliflozin Versus Sitagliptin: An Analysis of Commercial Claims and Linked Laboratory Data"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Optum, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01316861","briefTitle":"Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"EMS"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EMS Acarbose"},{"name":"Bayer Acarbose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04031417","briefTitle":"Effect of a Simulated Flight in Patients With Type 2 Diabetes and Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hull University Teaching Hospitals NHS Trust"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hypoxia"},{"name":"Low Humidity"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00854035","briefTitle":"MK-0431/ONO-5435 Phase III Clinical Trial - Insulin Add-on Study for Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ono Pharmaceutical Co. Ltd"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK-0431/ONO-5435"},{"name":"MK-0431/ONO-5435"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03681691","briefTitle":"The Interaction Between Diabetes and Estradiol on Human Brain Metabolism in Postmenopausal Women"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Wake Forest University Health Sciences"},"collaborators":[{"name":"National Institute on Aging (NIA)"}]},"conditionsModule":{"conditions":["Diabetes Type 2","Dementia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Estradiol patch"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02322762","briefTitle":"DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04917926","briefTitle":"Behavioural Economics-based Incentives in Adults With Type 2 Diabetes (BET2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Hong Kong"},"collaborators":[{"name":"University Grants Committee, Hong Kong"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Financial and social incentives"},{"name":"Financial incentives"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00816218","briefTitle":"Molecular Mechanisms of Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"},"collaborators":[{"name":"Takeda"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01468987","briefTitle":"A Study in Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2605541"},{"name":"Insulin Glargine"},{"name":"Insulin Lispro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01092663","briefTitle":"The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"KineMed"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Colesevelam HCl"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01474083","briefTitle":"A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"vTv Therapeutics"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GK1-399 (formerly TTP399)"},{"name":"GK1-399 (formerly TTP399)"},{"name":"GK1-399 (formerly TTP399)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02291874","briefTitle":"Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ipragliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01827826","briefTitle":"Call-2-Health: Preventing Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kaiser Permanente"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Telephonic intervention to prevent Diabetes Mellitus, Type 2"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00924053","briefTitle":"Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Theracos"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EGT0001474"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01275794","briefTitle":"Screening Epidemiological Program on Compensation Evaluation of Diabetes Mellitus Type 2 (DMT2) Patients on Oral Anti-diabetic (OAD) Monotherapy and Physicians Satisfaction of Their Usage"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01991795","briefTitle":"A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ticagrelor 60 mg"},{"name":"Ticagrelor placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00551590","briefTitle":"Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ludwig-Maximilians - University of Munich"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo tablet"},{"name":"Sitagliptin tablet"},{"name":"Saline infusion"},{"name":"Exendin(9-39) infusion"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02078440","briefTitle":"Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VeroScience"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bromocriptine mesylate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05362058","briefTitle":"A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Efsitora Alfa"},{"name":"Insulin Degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01263470","briefTitle":"Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin"},{"name":"Alogliptin"},{"name":"Alogliptin"},{"name":"Alogliptin"},{"name":"Voglibose"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02906709","briefTitle":"Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omarigliptin"},{"name":"Placebo"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03102424","briefTitle":"Transcutaneous Electrical Nerve Stimulator to Improve Blood Glucose Control in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Taiwan Resonant Waves Research Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Transcutaneous Electrical Nerve Stimulator (DW1330)"},{"name":"Sham DW1330 device"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01582243","briefTitle":"Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02430870","briefTitle":"TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TAK-648"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03552523","briefTitle":"The Set-Point Study for Type 2 Diabetes: Evaluating the Use of an Insulin Only Bionic Pancreas System in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Massachusetts General Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bionic Pancreas"},{"name":"Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04707469","briefTitle":"Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03209089","briefTitle":"Type 2 Diabetes Mellitus Patients' Characteristics and Management by General Practitioners and Endocrinologists"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02226822","briefTitle":"DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Ono Pharmaceutical Co. Ltd"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03870724","briefTitle":"Women and Risk of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Oslo"},"collaborators":[{"name":"Norwegian Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01373450","briefTitle":"Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oxyntomodulin"},{"name":"Liraglutide 0.6 mg"},{"name":"Liraglutide 1.2 mg"},{"name":"Placebo for Oxyntomodulin"},{"name":"Placebo for Liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02926937","briefTitle":"Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lexicon Pharmaceuticals"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sotagliflozin (SAR439954)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05523362","briefTitle":"Feasibility and Clinical Utility of the Dexcom G6 Continuous Glucose Monitoring Device for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ian J. Neeland, MD"},"collaborators":[{"name":"DexCom, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dexcom continuous glucose monitor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05331339","briefTitle":"Real-life Efficacy of Insulia® Tool in Patients Living With Type 2 Diabetes Treated With Basal Insulin Therapy as Part of a National Telemedicine Program (ETAPES)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Sud Francilien"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00145093","briefTitle":"Effects of Chromium Supplementation on Parameters of the Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical Research Foundation, The Netherlands"},"collaborators":[{"name":"Pharma Nord"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Baker's yeast (Bio Chromium)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01289119","briefTitle":"Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin"},{"name":"Placebo to alogliptin"},{"name":"Metformin"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02409329","briefTitle":"Improving Medication Adherence Among Underserved Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University Medical Center"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"REACH"},{"name":"Helpline and A1c results"},{"name":"REACH + FAMS"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00744367","briefTitle":"A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"metformin"},{"name":"pioglitazone"},{"name":"placebo"},{"name":"taspoglutide"},{"name":"taspoglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03940183","briefTitle":"Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Trelagliptin Succinate"},{"name":"Placebo Oral Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05951569","briefTitle":"Loop T2D Observational Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jaeb Center for Health Research"},"collaborators":[{"name":"Embecta Medical"},{"name":"Tidepool Project"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Community-Derived Open-Source Automated Insulin Delivery Loop System"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05816057","briefTitle":"A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hangzhou Jiuyuan Gene Engineering Co. Ltd.,"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01030679","briefTitle":"Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-501 0.5mg"},{"name":"CKD-501 1mg"},{"name":"CKD-501 2mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00882726","briefTitle":"A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centocor, Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CNTO 3649 IV (Healthy participants)"},{"name":"CNTO 3649 SC (Healthy participants)"},{"name":"CNTO 3649 SC (Diabetic patients)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01522157","briefTitle":"A Randomized Cross-over Trial of the Postprandial Effects of Three Different Diets in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vårdcentralen Lyckorna"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low-fat Diet"},{"name":"Low-carbohydrate Diet"},{"name":"Mediterranean Diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00303394","briefTitle":"Treatment of Patients With Type 2 Diabetes With an Interleukin-1 Antagonist"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Zurich"},"collaborators":[{"name":"Steno Diabetes Center Copenhagen"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IL-1Ra"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02703337","briefTitle":"A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY900014"},{"name":"Insulin Lispro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02031341","briefTitle":"Peripheral Insulin Uptake in Type 2 Diabetes Mellitus and in Non-Diabetic Individuals"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Amsterdam UMC, location VUmc"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01106651","briefTitle":"A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin 100 mg"},{"name":"Canagliflozin 300 mg"},{"name":"Antihyperglycemic agent(s)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04556851","briefTitle":"HSK7653 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sichuan Haisco Pharmaceutical Group Co., Ltd"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HSK7653 10 mg Q2W"},{"name":"HSK7653 25 mg Q2W"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03235219","briefTitle":"A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"JNJ-64565111"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02836873","briefTitle":"Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Theracos"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bexagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03005288","briefTitle":"Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BYM338 10 mg/kg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02183324","briefTitle":"BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low dose of BI 1356 BS"},{"name":"Medium dose of BI 1356 BS"},{"name":"High dose of BI 1356 BS"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01353391","briefTitle":"Metformin in Women With Type 2 Diabetes in Pregnancy Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mount Sinai Hospital, Canada"},"collaborators":[{"name":"University Health Network, Toronto"},{"name":"Sunnybrook Research Institute"},{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Placebo Comparator"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02025907","briefTitle":"A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin, 100 mg"},{"name":"Canagliflozin, 300 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02585674","briefTitle":"Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine (U300)"},{"name":"MyStar DoseCoach"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04153929","briefTitle":"A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 456906"},{"name":"Placebo"},{"name":"Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02413762","briefTitle":"The Role of Gut Hormones and Hepcidin in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Imperial College London Diabetes Centre"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00638716","briefTitle":"A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus Who Are Currently on Metformin Monotherapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"ConjuChem"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CJC-1134-PC"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05319496","briefTitle":"isCGM With Education and Feedback for Non-Insulin Dependent Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alberta"},"collaborators":[{"name":"Epidemiology Coordinating and Research Centre, Canada"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intermittently scanned continuous glucose monitor (isCGM)"},{"name":"Education and coaching"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02367066","briefTitle":"A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AR-C165395XX"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00518115","briefTitle":"Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Albiglutide (GSK716155) or exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00654056","briefTitle":"Severe Insulin Resistance in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"Aarhus University Hospital"},{"name":"Regionshospitalet Silkeborg"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Actrapid (human insulin)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03952143","briefTitle":"A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY900014"},{"name":"Insulin Lispro"},{"name":"Insulin Glargine"},{"name":"Insulin Degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05495451","briefTitle":"Feasibility and Impact of an Intensive Team-based Intervention on Type 2 Diabetes Reversal"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Montreal Heart Institute"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Moderate-carbohydrate Mediterranean diet, Personalized exercice prescription and training, Intermittent fasting"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03468283","briefTitle":"Smartphone Application for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kangbuk Samsung Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"mobile application for diabetes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00874809","briefTitle":"Diabetes Mellitus Type 2 Basal Insulin Dosing Requirements Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diabetes Care Center"},"collaborators":[{"name":"Animas Corporation"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CGMS with an insulin pump using rapid acting insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00495469","briefTitle":"Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK189075"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02701569","briefTitle":"Effect of Rebound Exercise in Individuals With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of KwaZulu"},"collaborators":[{"name":"Aminu Kano Teaching Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rebound exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01022112","briefTitle":"An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TA-7284-Low"},{"name":"TA-7284-Low-middle"},{"name":"TA-7284-High-middle"},{"name":"TA-7284-High"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01701570","briefTitle":"Barriers to Physical Activity in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Denver"},"collaborators":[{"name":"Colorado Clinical & Translational Sciences Institute"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo Attention Control"},{"name":"Supervised Exercise Training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01152385","briefTitle":"Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD1656"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02294474","briefTitle":"Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SAR342434"},{"name":"Humalog"},{"name":"insulin glargine HOE901"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03335930","briefTitle":"Exercise-induced Blood Glucose Response in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tri-Service General Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"a 12-week moderate-intensity exercise training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04667728","briefTitle":"Professional Continuous Glucose Monitoring as an Adjuvant Educational Tool for Improving Glycemic Control in Patients With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado"},"collaborators":[{"name":"Medtronic, PLC"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Professional continuous glucose monitoring (CGM) sensor (iPro™2)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00541983","briefTitle":"Single-dose, Dose-escalation Study of Safety, PK, and Preliminary Efficacy of XOMA 052 in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"XOMA (US) LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"XOMA 052"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04927858","briefTitle":"A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02836015","briefTitle":"Shared Medical Visits for Spanish-speaking Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Nebraska"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Shared Medical Visit"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05486065","briefTitle":"A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04770532","briefTitle":"A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin degludec"},{"name":"Insulin Icodec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05151276","briefTitle":"Mobile Phone-based Video Education on Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Balikesir University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"mobile phone-based distance video education group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02093702","briefTitle":"Impact of Structured Physical Activity Education Delivery in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Royal Victoria Hospital, Canada"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physical activity and exercise education and behaviour counseling from a Registered Kinesiologist and a YMCA Wellness Coach"},{"name":"Unstructured Physical Activity and Exercise Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00196989","briefTitle":"Study In People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"GW677954"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04369664","briefTitle":"CHOlesterol Lowering and Residual Risk in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NYU Langone Health"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Statin"},{"name":"PCSK9 inhibitor"},{"name":"Ezetimibe 10mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02713477","briefTitle":"Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010"},{"name":"Insulin glargine HOE901"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01964963","briefTitle":"Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02256332","briefTitle":"Plant-based Ingredient on Post Prandial Glucose in Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Unilever R&D"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low dose plant based ingredient"},{"name":"High dose plant based ingredient"},{"name":"Reference food format"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05275400","briefTitle":"A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Efsitora Alfa"},{"name":"Insulin Degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03170518","briefTitle":"A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin 100 mg"},{"name":"Canagliflozin 300 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00523913","briefTitle":"A Study Of BRL49653C For The Treatment Of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rosiglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06391983","briefTitle":"The Impact of Moderate Resistance Training on IMAT in Elderly Diabetes Patients Without Obesity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lou Qingqing"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"resistance training (elastic band)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04807348","briefTitle":"Chiglitazar Added to Metformin for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chipscreen Biosciences, Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Chiglitazar 32mg"},{"name":"Chiglitazar 48mg"},{"name":"Placebo"},{"name":"Metformin Hydrochloride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00290927","briefTitle":"Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glulisine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03495102","briefTitle":"A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dulaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01869959","briefTitle":"A Study of LY2405319 in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2405319"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00392678","briefTitle":"Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Joslin Diabetes Center"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Salsalate"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01582451","briefTitle":"A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2605541"},{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01971554","briefTitle":"Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK-8666"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01182948","briefTitle":"Effects of Different Types of Exercise in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universita di Verona"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aerobic Training"},{"name":"Resistance Training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03473262","briefTitle":"Empagliflozin-based Quadruple Combination vs Insulin Glarine-based Combination Therapy in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chungbuk National University Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00263276","briefTitle":"A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"dapagliflozin"},{"name":"dapagliflozin"},{"name":"dapagliflozin"},{"name":"dapagliflozin"},{"name":"dapagliflozin"},{"name":"placebo"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02227849","briefTitle":"Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin (TA-7284)"},{"name":"GLP-1 analogue"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01535612","briefTitle":"Study of PaQ™ (a Simple Patch on Insulin Delivery Device) in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"CeQur Corporation"},"collaborators":[{"name":"International Diabetes Center at Park Nicollet"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PaQ™ insulin infusion device"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02390050","briefTitle":"A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Theracos"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bexagliflozin tablets"},{"name":"Bexagliflozin tablets, placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02955875","briefTitle":"Pharmaceutical Care Service in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pusan National University"},"collaborators":[{"name":"Pusan National University Hospital"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pharmaceutical care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02220920","briefTitle":"Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin (TA-7284)"},{"name":"Placebo"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03203278","briefTitle":"Web-based Exercise for South Asian People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NHS Greater Glasgow and Clyde"},"collaborators":[{"name":"University of Glasgow"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Web-based exercise programme"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00425009","briefTitle":"Therapeutic Effects of Berberine in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Jiao Tong University School of Medicine"},"collaborators":[{"name":"National Institutes of Health (NIH)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Berberine"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05261776","briefTitle":"The Effects of Pilates on Functional Capacity and Blood Glucose Levels in Adults With Diabetes Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Riphah International University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pilates exercise"},{"name":"brisk walk"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05435677","briefTitle":"A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IcoSema"},{"name":"insulin icodec"},{"name":"semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01536808","briefTitle":"Premature Aging and Type 2 Diabetes Mellitus: an Increased Risk of Cardiomyopathy?"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospices Civils de Lyon"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cardiac RMI"},{"name":"Analysis telomere"},{"name":"Stress test"},{"name":"echocardiography"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00069836","briefTitle":"Study Of AVANDAMET® With Or Without Insulin In Type II Diabetes Mellitus Patients. AVANDAMET® is a Registered Trademark of the GSK Group of Companies."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone/metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04531462","briefTitle":"A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01977560","briefTitle":"Diet and Exercise Intervention in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Washington University School of Medicine"},"collaborators":[{"name":"National Dairy Council"},{"name":"American Egg Board"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intensive Lifestyle Intervention"},{"name":"Standard Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00388050","briefTitle":"Diabetes Medication Choice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Medication Choice decision aid"},{"name":"Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01640873","briefTitle":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK-8655"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05443191","briefTitle":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01318109","briefTitle":"Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin and metformin"},{"name":"Alogliptin and metformin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05468632","briefTitle":"A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00266240","briefTitle":"A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GK Activator (2)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02151461","briefTitle":"Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NuSirt Biopharma"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low Metformin"},{"name":"Metformin"},{"name":"Mid Metformin"},{"name":"High Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05988957","briefTitle":"Nutrition-Focused Approach During CGM Initiation: A Qualitative Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HealthPartners Institute"},"collaborators":[{"name":"Academy of Nutrition and Dietetics"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semi-structured interviews using an IRB-approved interview guide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06099067","briefTitle":"Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin"},{"name":"DPP4 inhibitor"},{"name":"Liraglutide"},{"name":"Saxagliptin"},{"name":"2nd generation Sulfonylurea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06313164","briefTitle":"The Impact of Oral Glutathione on Oxidative Damage and Glycated Hemoglobin (HbA1c) Levels in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"S.LAB (SOLOWAYS)"},"collaborators":[{"name":"Center of New Medical Technologies"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"enhanced glutathione"},{"name":"placebo comparator"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00073268","briefTitle":"Prevention of Type 2 Diabetes Mellitus in Children"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05782192","briefTitle":"SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shenzhen Salubris Pharmaceuticals Co., Ltd."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SAL067"},{"name":"Alogliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00328627","briefTitle":"Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin"},{"name":"Alogliptin placebo"},{"name":"Pioglitazone"},{"name":"Pioglitazone placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04795531","briefTitle":"A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin icodec"},{"name":"Placebo insulin icodec"},{"name":"Insulin degludec"},{"name":"Placebo insulin degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01103622","briefTitle":"Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD1656"},{"name":"Digoxin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05187806","briefTitle":"Motivational Interviewing With Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Istanbul University - Cerrahpasa (IUC)"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"motivational interview"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01298726","briefTitle":"Pharmaceutical Care in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidade Federal de Ouro Preto"}},"conditionsModule":{"conditions":["DIABETES MELLITUS, TYPE 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PHARMACEUTICAL CARE"},{"name":"HEALTH USUAL CARE"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01832181","briefTitle":"MiTy Kids (Metformin in Women With Type 2 Diabetes in Pregnancy Kids Trial)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mount Sinai Hospital, Canada"},"collaborators":[{"name":"Sunnybrook Research Institute"},{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04731142","briefTitle":"Type 2 Diabetes Exemplar: A Remote Care Service for North West London"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Imperial College London"},"collaborators":[{"name":"AstraZeneca"},{"name":"Huma"},{"name":"North West London Collaboration of CCGs (NWL CCGs)"},{"name":"Imperial College Health Partners (ICHP)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Huma"},{"name":"Video group consultations"},{"name":"KNOW Diabetes"},{"name":"Standard of care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01028963","briefTitle":"A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"ChemoCentryx"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"pioglitazone"},{"name":"CCX140-B"},{"name":"CCX140-B"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03196895","briefTitle":"Treating Type 2 Diabetes by Reducing Postprandial Glucose Elevations: A Paradigm Shift in Lifestyle Modification"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Virginia"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Weight reduction training"},{"name":"PPG training"},{"name":"discrete BG feedback"},{"name":"continuous BG feedback"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00801164","briefTitle":"Exploratory Study of Iocide Oral Rinse in a Diabetic Population"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Biomedical Development Corporation"},"collaborators":[{"name":"Methodist Healthcare Ministries of South Texas"},{"name":"Foundation Of Collaborative Unique Science (FOCUS)"}]},"conditionsModule":{"conditions":["Diabetes Type 2","Periodontitis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Frio Mouth Rinse Placebo"},{"name":"Frio Mouth Rinse"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03422263","briefTitle":"Performance Under SGLT-2-Inhibitors in Humans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Berner Klinik Montana"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02655627","briefTitle":"Internet Based Exercise Training in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Biruni University"},"collaborators":[{"name":"Istanbul University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Internet based exercise training"},{"name":"group exercise training"},{"name":"Physical activity counselling via a brochure"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01789788","briefTitle":"A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"RO6811135"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01318083","briefTitle":"Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin and glimepiride"},{"name":"Alogliptin and glimepiride"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01340664","briefTitle":"An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin 50 mg"},{"name":"Placebo"},{"name":"Canagliflozin 150 mg"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00454233","briefTitle":"A Safety and Efficacy Study With YM543 in Type 2 Diabetes Mellitus Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"YM543"},{"name":"Metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00110864","briefTitle":"Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Wellstat Therapeutics"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PN2034"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02185755","briefTitle":"Internet Monitoring vs Medication to Control Blood Sugar in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Endocrine Research Society"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Internet-Based Glucose Monitoring System"},{"name":"Normal Medication Positive Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04371497","briefTitle":"Switch From U-100 Insulin Analog to U-500 Regular Insulin in Pumps for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Caen"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00289848","briefTitle":"MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin phosphate"},{"name":"Comparator: placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04236206","briefTitle":"Short Message Service for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Alexandria University"},"collaborators":[{"name":"High Institute of Public Health, Egypt"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mobile Phone Short Message Service"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04946799","briefTitle":"The Effect of Blood Flow Restriction Training on Glycemic Control Among Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Uppsala University"},"collaborators":[{"name":"Nanjing Sport Institute"},{"name":"Nanjing Maigaoqiao Community Health Service Center"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low-intensity training combined with blood flow restriction (LI-BFR)"},{"name":"High-intensity aerobic exercise (HI)"},{"name":"Low intensity exercise (LI)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04042441","briefTitle":"A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Degludec/Insulin Aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04867707","briefTitle":"Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Missouri-Columbia"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Zanamivir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00542633","briefTitle":"An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Biodel"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"VIAject™"},{"name":"Regular Human Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01715649","briefTitle":"Telehealth Remote Patient Monitoring Study in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sutter Health"},"collaborators":[{"name":"LifeScan"},{"name":"GE Healthcare"},{"name":"University of California, Davis"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05316662","briefTitle":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04582448","briefTitle":"A Study Looking at How Insulin Icodec is Taken up in the Blood When Administered in Different Injection Sites in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin icodec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00963768","briefTitle":"A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"JNJ 28431754"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02715258","briefTitle":"Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Theracos"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bexagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03039569","briefTitle":"Assessing Home Food Environment and Diabetes Self-management Among Adult Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Nebraska Lincoln"},"collaborators":[{"name":"The Methodist Hospital Research Institute"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Text messaging"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00982371","briefTitle":"An Investigation Into Bone Micro-architecture in Women With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hamilton Health Sciences Corporation"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"},{"name":"McMaster University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02081599","briefTitle":"Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Teneli (Teneligliptin)"},{"name":"Placebo"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00605475","briefTitle":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canakinumab"},{"name":"Placebo"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05114590","briefTitle":"Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine/Lixisenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03074383","briefTitle":"Improvement of Care for Outpatients With Type 2 Diabetes Through Self-Care Multidisciplinary Workshop for Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital de Clinicas de Porto Alegre"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Workshop"},{"name":"Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02564211","briefTitle":"Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ipragliflozin"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05918068","briefTitle":"Pyridoxine Effect on the Blood Glucose Level in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Al-Rasheed University College"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin 500 mg/day"},{"name":"Metformin 500 mg/day plus vitamin B6 300 mg/day"},{"name":"non-pharmacological therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01099163","briefTitle":"Effect of Conjugated Linoleic Acid Alone and in Conjunction With Vitamin E in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shahid Beheshti University of Medical Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tonalin SG1000T FFA"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00422487","briefTitle":"Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gilead Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MBX-2044"},{"name":"MBX-2044"},{"name":"MBX-2044"},{"name":"MBX-2044"},{"name":"MBX-2044"},{"name":"MBX-2044"},{"name":"Placebo for MBX-2044"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03359837","briefTitle":"Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INSULIN GLARGINE (HOE901)"},{"name":"Insulin Glulisine"},{"name":"Biphasic insulin aspart 30"},{"name":"Repaglinide"},{"name":"Acarbose"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05205005","briefTitle":"Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VA Office of Research and Development"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Endocalyx"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04745780","briefTitle":"Evaluation of Efficacy and Safety of a Combination Containing Myo-inositol, D-chiro-inositol, Alpha-lactalbumin, Zinc and Extract of Gymnema Sylvestre in Subjects Diabetic Patients."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lo.Li.Pharma s.r.l"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Myo-inositol, D-chiro-inositol, Gymnema sylvestre, Zinc and Alpha-lactalbumin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00361153","briefTitle":"Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Colesevelam hydrochloride"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00500331","briefTitle":"Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK189075"},{"name":"pioglitazone"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01117103","briefTitle":"A Prospective, Observational Study to Assess and Evaluate the Use of Glucophage XR Therapy in the Management of Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck KGaA, Darmstadt, Germany"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02318693","briefTitle":"Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Glibenclamide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04072523","briefTitle":"An Observational Study to Assess the Prevalence of Heart Failure in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04315688","briefTitle":"A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Russia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01341067","briefTitle":"Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rocky Mountain Diabetes and Osteoporosis Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02963766","briefTitle":"A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dulaglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01381900","briefTitle":"A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Canagliflozin 100mg"},{"name":"Canagliflozin 300mg"},{"name":"Metformin"},{"name":"Sulphonylurea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01318122","briefTitle":"Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin and pioglitazone"},{"name":"Alogliptin and pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01841697","briefTitle":"Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omarigliptin"},{"name":"Sitagliptin"},{"name":"Placebo to omarigliptin"},{"name":"Placebo to Sitagliptin"},{"name":"Open-label Metformin"},{"name":"Open-label Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04677127","briefTitle":"Effect of HBM Based Education on Glycemic Control of Type 2 Diabates Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hacettepe University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Health Belief Model and Health Literacy Level based Education and Counseling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03767543","briefTitle":"Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04460885","briefTitle":"A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin icodec"},{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01218256","briefTitle":"Secondary Prevention in Type 2 Diabetes: Comparison of Two Different Resistance Exercise Training Protocols"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Paracelsus Medical University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physical exercise training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01126580","briefTitle":"A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"LY2189265"},{"name":"Placebo (oral)"},{"name":"Placebo (subcutaneous)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02250222","briefTitle":"Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ligand Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LGD-6972"},{"name":"Placebo (Captisol ®)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05002933","briefTitle":"A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine 300 U/ml"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02021695","briefTitle":"DNA Methylation and Gene Expression in Qataris With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Weill Medical College of Cornell University"},"collaborators":[{"name":"Hamad Medical Corporation"},{"name":"Weill Cornell Medical College in Qatar"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05230615","briefTitle":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03194945","briefTitle":"Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sun Yat-sen University"},"collaborators":[{"name":"The Seventh Affiliated Hospital of Sun Yat-sen University"},{"name":"Guangdong Provincial Hospital of Traditional Chinese Medicine"},{"name":"Guangdong Provincial People's Hospital"},{"name":"The First Affiliated Hospital with Nanjing Medical University"},{"name":"Dongguan People's Hospital"},{"name":"Clifford Hospital"},{"name":"Guangzhou Panyu Central Hospital"},{"name":"Nanfang Hospital, Southern Medical University"},{"name":"Chinese PLA General Hospital"},{"name":"Peking University People's Hospital"},{"name":"Shanghai 10th People's Hospital"},{"name":"Shanghai Changzheng Hospital"},{"name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University"},{"name":"Huizhou Municipal Central Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CSII followed by Lina+MET"},{"name":"CSII followed by Lina"},{"name":"CSII followed by MET"},{"name":"CSII alone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00377858","briefTitle":"Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin lispro mid mixture (MM)"},{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01277471","briefTitle":"Effect of Meal Frequency on Insulin Resistance in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institute for Clinical and Experimental Medicine"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Meal frequency (6 meals vs. 2 meals/day)"},{"name":"6 meals/day followed by 2 meals/day"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03893422","briefTitle":"Placebo-Controlled Clinical Nutrition Study of the Safety and Metabolic Effects of Two Medical Foods in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pendulum Therapeutics"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"WB-010"},{"name":"WB-011"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01456806","briefTitle":"Educative Intervention to Improve Type 2 Diabetes Mellitus Control in Corrientes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centro de Endocrinologia Experimental y Aplicada"},"collaborators":[{"name":"National Council of Scientific and Technical Research, Argentina"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01677611","briefTitle":"Effects of Resveratrol in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Khoo Teck Puat Hospital"},"collaborators":[{"name":"National Medical Research Council (NMRC), Singapore"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Trans-resveratrol extract from Polygonum Cuspidatum"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00510952","briefTitle":"Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Lispro Protamine Suspension"},{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02154347","briefTitle":"Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kissei Pharmaceutical Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"KAD-1229"},{"name":"Placebo"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02843399","briefTitle":"Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Truven health"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00791479","briefTitle":"Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2189265 and Lifestyle Measures"},{"name":"Placebo solution and Lifestyle Measures"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00135330","briefTitle":"An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"rosiglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01050803","briefTitle":"Effectiveness of the Farsi Diabetes Self-management Education (FDSME) Program for People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tehran University of Medical Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FDSME group"},{"name":"FDSME"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04443842","briefTitle":"Behavioural Economics-based Incentives in Adults With Type 2 Diabetes Pilot Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Hong Kong"},"collaborators":[{"name":"University Grants Committee, Hong Kong"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Financial and social incentives"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02338921","briefTitle":"Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Bundang Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Dapagliflozin"},{"name":"Lobeglitazone"},{"name":"Glimepirde"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01191268","briefTitle":"A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine"},{"name":"LY2189265"},{"name":"Insulin Lispro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04466904","briefTitle":"Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Innovent Biologics (Suzhou) Co. Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IBI362"},{"name":"Placebo"},{"name":"Dulaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01644500","briefTitle":"A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dulaglutide"},{"name":"Glimepiride"},{"name":"Placebo as Capsules"},{"name":"Placebo as SC Injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02481141","briefTitle":"Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"SBI Pharmaceuticals Co, Ltd."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"5-ALA-SFC"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03444584","briefTitle":"Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"MedImmune LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MEDI0382"},{"name":"Placebo"},{"name":"Dapaglifozin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02725593","briefTitle":"Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Parexel"},{"name":"Q2 Solutions"},{"name":"PRA Health Sciences"},{"name":"Covance Laboratories, Inc"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Dapagliflozin placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02252965","briefTitle":"Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck KGaA, Darmstadt, Germany"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin IR"},{"name":"Metformin XR"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03819790","briefTitle":"The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LMC Diabetes & Endocrinology Ltd."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Basal insulin glargine and lixisenatide"},{"name":"Basal insulin Basaglar/Lantus + gliclazide MR"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03299153","briefTitle":"The Effects of Barberry Juice Consumption in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Nutrition and Food Technology Institute"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"barberry juice"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01396187","briefTitle":"Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-05231023"},{"name":"PF-05231023"},{"name":"PF-05231023"},{"name":"PF-05231023"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03406377","briefTitle":"Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"OPKO Health, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"OPK-88003"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01154244","briefTitle":"Insulin Resistance as Primary Pathogenesis in Newly Diagnosed, Drug naïve Type 2 Diabetes Patients in Korea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HOMA-IR"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03484689","briefTitle":"MBCT for DM Distress: a Pilot Qusai-experimental Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chinese University of Hong Kong"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mindfulness-based cognitive therapy MBCT"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01067924","briefTitle":"Motivational Interviewing to Promote Maintenance of Physical Activity in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Calgary"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Motivational interviewing"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03144505","briefTitle":"Comparing Moderate and High-intensity Interval Training Protocols on Biomarkers in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Lisbon"},"collaborators":[{"name":"Associação Protectora dos Diabéticos de Portugal"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MCT combined with RT Group"},{"name":"HIIT combined with RT Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02562326","briefTitle":"A Trial to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Adocia"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BioChaperone insulin lispro"},{"name":"Humalog®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01809327","briefTitle":"A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin 100 mg"},{"name":"Canagliflozin 300 mg"},{"name":"Metformin XR"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01338870","briefTitle":"Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"25 mg PF-04991532"},{"name":"75 mg PF-04991532"},{"name":"150 mg PF-04991532"},{"name":"300 mg PF-04991532"},{"name":"Sitagliptin 100 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01154933","briefTitle":"Exeantide in Type 2 Diabetes on Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University at Buffalo"},"collaborators":[{"name":"Amylin Pharmaceuticals, LLC."}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide 5 mcg"},{"name":"exenatide 10 mcg"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06684912","briefTitle":"Acute Effects of Aerobic Exercise on Flow Mediated Slowing and Flow Mediated Dilation in Adults with and Without Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Egas Moniz - Cooperativa de Ensino Superior, CRL"},"collaborators":[{"name":"Faculdade de Motricidade Humana"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High-intensity interval exercise"},{"name":"Moderate continuous exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01237314","briefTitle":"The Impact of Food on Blood Sugar in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HealthPartners Institute"},"collaborators":[{"name":"International Diabetes Center at Park Nicollet"},{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02121483","briefTitle":"Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"empagliflozin medium dose"},{"name":"empagliflozin high dose"},{"name":"empagliflozin low dose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01215955","briefTitle":"Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin lispro"},{"name":"Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03799796","briefTitle":"Combining Flash Glucose Monitoring and Online Peer Support to Improve Outcomes in Hispanics With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Utah"},"collaborators":[{"name":"La Trobe University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Flash Glucose Monitoring with Online Peer Support"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01758380","briefTitle":"Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"Gliclazide"},{"name":"Metformin"},{"name":"Placebo to Gliclazide"},{"name":"Placebo to Vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03267576","briefTitle":"An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin 300 mg"},{"name":"Sitagliptin 100 mg"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03350984","briefTitle":"Insulin Schemes for Type 2 Diabetes Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidad de Guanajuato"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NPH insulin"},{"name":"Glargine and Lispro insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02341690","briefTitle":"Intervention Study - Effectiveness of Smartphone Delivered Interval Walking Training to Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Copenhagen"},"collaborators":[{"name":"Center for Physical Activity Research (CFAS)"},{"name":"The Danish Center for Strategic Research on Type 2 Diabetes"},{"name":"The Danish Diabetes Association"},{"name":"Copenhagen University Hospital Bispebjerg"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Interval walking training"},{"name":"control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00765817","briefTitle":"Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo"},{"name":"exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00241605","briefTitle":"AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rosiglitazone/metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03214380","briefTitle":"A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY900014"},{"name":"Insulin Lispro"},{"name":"Insulin Glargine"},{"name":"Insulin Degludec"},{"name":"Metformin"},{"name":"SGLT2 inhibitor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01263483","briefTitle":"Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin and voglibose"},{"name":"Alogliptin and voglibose"},{"name":"Voglibose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02450097","briefTitle":"Metabolic and Hormonal Effects of 5:2 Intermittent Fasting"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Karolinska University Hospital"}},"conditionsModule":{"conditions":["Obesity","Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Caloric restriction"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05790681","briefTitle":"A Study to Test How New Long-acting Insulin (Insulin Icodec) Works in the Body of Children and Teenagers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin icodec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05230589","briefTitle":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01469065","briefTitle":"A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-04991532"},{"name":"PF-04991532"},{"name":"PF-04991532"},{"name":"PF-0499132"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01208012","briefTitle":"Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"ikfe-CRO GmbH"},"collaborators":[{"name":"Novo Nordisk A/S"},{"name":"IKFE Institute for Clinical Research and Development"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Victoza®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01377155","briefTitle":"A Comparison of Two Initial Dosing Formulas"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diabetes Care Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04383041","briefTitle":"Study to Learn More About Outcomes Reported by Patients Suffering From Type 2 Diabetes Using a Digital Data Collection Tool"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01495013","briefTitle":"A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"1mg Glimepiride/10mg Atorvastatin FDC"},{"name":"2mg Glimepiride/10mg Atorvastatin FDC"},{"name":"3mg Glimepiride/10mg Atorvastatin FDC"},{"name":"4mg Glimepiride/10mg Atorvastatin FDC"},{"name":"1mg Glimepiride/20mg Atorvastatin FDC"},{"name":"2mg Glimepiride/20mg Atorvastatin FDC"},{"name":"3mg Glimepiride/20mg Atorvastatin FDC"},{"name":"4mg Glimepiride/20mg Atorvastatin FDC"},{"name":"1mg Glimepiride"},{"name":"2mg Glimepiride"},{"name":"3mg Glimepiride"},{"name":"4mg Glimepiride"},{"name":"10mg Atorvastatin"},{"name":"20mg Atorvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04222686","briefTitle":"Evaluation of Losartan and Perindopril in Blacks Type 2 Diabetics Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yaounde Central Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Perindopril Arginine"},{"name":"Losartan Potassium"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01451398","briefTitle":"Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mannkind Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Technosphere® Insulin"},{"name":"Technosphere Powder"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03156985","briefTitle":"Multi-center, Single Arm, Observational Study to Evaluate the Safety of Dapagliflozin in Type 2 Diabetes Mellitus Patients in China"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00532935","briefTitle":"MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin phosphate (+) metformin hydrochloride"},{"name":"Comparator: pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02132637","briefTitle":"A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Peglispro"},{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02159846","briefTitle":"Effects of Mixed Herbs on Blood Glucose and Lipid Profile in T2DM Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"International Islamic University Malaysia"},"collaborators":[{"name":"Ministry of Health, Malaysia"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01408888","briefTitle":"A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2189265"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01357135","briefTitle":"An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Sitagliptin"},{"name":"Sulfonylurea"},{"name":"Antihyperglycemic Medication"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05335889","briefTitle":"Wearable Sensors and Artificial Intelligence for Carbohydrate Counting"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NYU Langone Health"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"eButton"},{"name":"Continuous Glucose Monitoring (CGM)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01919684","briefTitle":"Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ligand Pharmaceuticals"},"collaborators":[{"name":"Beckloff Associates, Inc."},{"name":"Medpace, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LGD-6972"},{"name":"Placebo (Captisol®)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04233801","briefTitle":"A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00961909","briefTitle":"A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"RO5095932"},{"name":"RO5095932"},{"name":"metformin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01455441","briefTitle":"The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tina Vilsboll"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Training and liraglutide"},{"name":"Training and placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01936025","briefTitle":"A Study to Investigate the Glucose Lowering Effects of Dextromethorphan Alone or in Combination With Sitagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance Test"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Profil Institut für Stoffwechselforschung GmbH"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dextromethorphan"},{"name":"Sitagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01075282","briefTitle":"A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine"},{"name":"LY2189265"},{"name":"Metformin"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00085969","briefTitle":"Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo 0.04 mL twice daily"},{"name":"Placebo 0.04 mL once daily"},{"name":"Placebo 0.08 mL once daily"},{"name":"B - Exenatide 10 mcg twice daily"},{"name":"C - Exenatide 10 mcg once daily"},{"name":"Exenatide 20 mcg once daily"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05727592","briefTitle":"An Intervention Study on the Effect of Brazilian Spinach Supplementation on Health Outcomes Among Type 2 Diabetes Patients in Hospital Universiti Sains Malaysia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universiti Sains Malaysia"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Althernanthera Sissoo"},{"name":"Dietary Consultation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02589639","briefTitle":"Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Placebo"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01165268","briefTitle":"Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04314622","briefTitle":"A Study of Supaglutide in Chinese Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd."},"collaborators":[{"name":"Shanghai 6th People's Hospital"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Supaglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02987348","briefTitle":"Clinical Outcomes of Exenatide Versus Basal Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide once weekly"},{"name":"exenatide twice daily"},{"name":"basal insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01318135","briefTitle":"Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin and glimepiride"},{"name":"Alogliptin and glimepiride"},{"name":"Alogliptin and metformin"},{"name":"Alogliptin and metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03689374","briefTitle":"A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"},{"name":"Insulin aspart"},{"name":"Insulin glargine U100"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01263509","briefTitle":"Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin and voglibose"},{"name":"Alogliptin and voglibose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02513641","briefTitle":"Effect of 2-Week Nightly Moderate Hypoxia on Glucose Tolerance in Individuals With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pennington Biomedical Research Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hypoxico Altitude Training Systems"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04838743","briefTitle":"GOAL: A Research Study Looking at Long Term Blood Sugar Control in People With Type 2 Diabetes Treated With Xultophy® in Local Clinical Practice in Japan."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IDegLira"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02497170","briefTitle":"Implementation of A Patient Centered Self-Management Program for Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rutgers, The State University of New Jersey"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Education of goal setting and achievement"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03811288","briefTitle":"An International Survey of the Occurrence of Cardiovascular Disease Among Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01159249","briefTitle":"Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05579119","briefTitle":"SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital de Especialidades, Centro Medico Nacional \"La Raza\", Instituto Mexicano del Seguro Social"},"collaborators":[{"name":"National Polytechnic Institute, Mexico"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin 100mg"},{"name":"Glargine"},{"name":"Lispro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03908281","briefTitle":"Fasted Exercise Training in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alberta"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fasted Exercise"},{"name":"Postprandial Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00630825","briefTitle":"A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2189265"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00998881","briefTitle":"Monotherapy Study of MP-513 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Teneligliptin 20 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00121966","briefTitle":"South Danish Diabetes Study: Evaluation of the Antidiabetic Treatment of Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Odense University Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Aspart"},{"name":"Insulin NPH"},{"name":"Metformin"},{"name":"Rosiglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01064687","briefTitle":"A Study in Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2189265"},{"name":"Exenatide"},{"name":"Placebo"},{"name":"Metformin"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03954834","briefTitle":"A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01006590","briefTitle":"Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00558909","briefTitle":"4 Weeks Treatment of Type II Diabetic Patients With BI 44847"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 44847"},{"name":"placebo for BI 44847"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00458133","briefTitle":"Health Benefits of Aerobic and Resistance Training in Individuals With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pennington Biomedical Research Center"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01582308","briefTitle":"A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin 100 mg"},{"name":"Saxagliptin 5 mg"},{"name":"Vildagliptin 50 mg"},{"name":"Vildagliptin 50 mg BID"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00477581","briefTitle":"A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02317484","briefTitle":"Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan"},"collaborators":[{"name":"Osaka Saiseikai Nakatsu Hospital"},{"name":"Astellas Pharma Inc"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ipragliflozin (SGLT2 inhibitor)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01023581","briefTitle":"Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin"},{"name":"Metformin"},{"name":"Alogliptin Placebo"},{"name":"Metformin Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03115099","briefTitle":"A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3325656"},{"name":"Placebo"},{"name":"Liraglutide"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00094757","briefTitle":"An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Comparator: sitagliptin 100 mg"},{"name":"Comparator: sitagliptin 200 mg"},{"name":"Comparator: placebo"},{"name":"Comparator: pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01253278","briefTitle":"A Multiple-Ascending Dose Study in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2393910"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01995656","briefTitle":"A Study of LY3108743 in Healthy Participants and Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo - Capsule"},{"name":"LY3108743 - Capsule"},{"name":"Placebo - Solution"},{"name":"LY3108743 - Solution"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03817463","briefTitle":"A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor"},{"name":"Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01103609","briefTitle":"Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Warfarin"},{"name":"Placebo"},{"name":"AZD1656"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01426802","briefTitle":"Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03092882","briefTitle":"Digital Self-Management Program for Medicare Advantage Members With Type 2 Diabetes- Impact on A1c"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Evidation Health"},"collaborators":[{"name":"Humana Co.Ltd."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Self-Management Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02106104","briefTitle":"Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Amsterdam UMC, location VUmc"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Linagliptin 5 mg QD (N=24)"},{"name":"Glimepiride 1 mg QD (N=24)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00795704","briefTitle":"Impact of Mulberry Leaf on Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Mississippi Medical Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mulberry Leaf Extract"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04886388","briefTitle":"Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Better Therapeutics"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BT-001"},{"name":"Physician-guided Standard of Care for type 2 diabetes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01856595","briefTitle":"PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-06291874"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01940302","briefTitle":"Dietary Supplement of LEHEL for the Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shaoguan University"},"collaborators":[{"name":"Sun Yat-sen University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LEHEL multi-nutrients supplement"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05004948","briefTitle":"Exercise Intervention Combined With Metformin in the Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Prince Sattam Bin Abdulaziz University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00490854","briefTitle":"A Study for Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"},"collaborators":[{"name":"Alkermes, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Human Insulin Inhalation Powder"},{"name":"Neutral protamine hagedorn insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00400491","briefTitle":"Vitamin D Supplementation to Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Tromso"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cholecalciferol (vitamin D)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01039532","briefTitle":"Comparison of Thrice Daily Biphasic Human Insulin With Basal Bolus Regimen in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Post Graduate Institute of Medical Education and Research, Chandigarh"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01845831","briefTitle":"Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"},{"name":"Temple University"},{"name":"University of Michigan"},{"name":"Ohio University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Basal Bolus"},{"name":"Metformin and Sitagliptin"},{"name":"Glargine"},{"name":"Glargine 50%"},{"name":"Glargine 80%"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05035849","briefTitle":"Comparison of the FGM Profiles in Patients of Type 2 Diabetes Treated With Sitagliptin and Acarbose"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nanjing First Hospital, Nanjing Medical University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin and acarbose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00097786","briefTitle":"Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Valsartan 160 mg + nateglinide 60 mg"},{"name":"Valsartan 160 mg + nateglinide placebo"},{"name":"Nateglinide 60 mg + valsartan placebo"},{"name":"Valsartan placebo + nateglinide placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02548585","briefTitle":"A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"MedImmune LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MEDI0382"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02607566","briefTitle":"Yoga as a Complementary Therapy for Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Miriam Hospital"},"collaborators":[{"name":"University of Massachusetts, Lowell"},{"name":"Rhode Island Hospital"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Yoga"},{"name":"Standard Exercise Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03620357","briefTitle":"Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"DexCom, Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CGM"},{"name":"SMBG"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03987919","briefTitle":"A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01184768","briefTitle":"HBA1c and Diagnosis of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Tromso"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03482596","briefTitle":"The Effects of Reducing Prolonged Sitting Bouts in Individuals at High Risk of or With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Leicester"},"collaborators":[{"name":"University Hospitals, Leicester"},{"name":"Loughborough University"},{"name":"Baker Heart and Diabetes Institute"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Reducing/breaking prolonged sitting"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01920256","briefTitle":"Provider-Initiated Regular Remote Interventions for Optimal Type 2 Diabetes Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Remote, personalized type 2 diabetes care."},{"name":"Usual Endocrine care."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02666807","briefTitle":"Effects of Ginger Supplementation on NF-KB in Peripheral Blood Mononuclear Cells in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tehran University of Medical Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ginger"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03730662","briefTitle":"A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00810823","briefTitle":"The Effect of Gastric Bypass Surgery on the Glucose Metabolism Seen in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hvidovre University Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05465317","briefTitle":"Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Dipeptidyl Peptidate-4 inhibitors"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02737657","briefTitle":"An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen-Cilag International NV"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02973100","briefTitle":"A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dulaglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01301833","briefTitle":"Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"teneligliptin"},{"name":"glinide"},{"name":"biguanide"},{"name":"alpha-glucosidase inhibitor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04878393","briefTitle":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Japan, as Part of Local Clinical Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01339520","briefTitle":"Diabetes Scorecard Educational Intervention Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"George Washington University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Scorecard"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00950677","briefTitle":"The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baylor College of Medicine"},"collaborators":[{"name":"National Institutes of Health (NIH)"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Byetta (exenatide)"},{"name":"Symlin (pramlintide)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00372060","briefTitle":"MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin phosphate"},{"name":"Comparator: sitagliptin phosphate (MK0431)"},{"name":"Comparator: pioglitazone"},{"name":"Comparator: placebo (unspecified)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03862716","briefTitle":"Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Population Health Research Institute"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IDegLira"},{"name":"insulin degludec"},{"name":"Metformin"},{"name":"Lifestyle Therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03785379","briefTitle":"A Trial Evaluating the Effects of a One-year Lifestyle Intervention in Obese Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Padova"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Caloric restriction"},{"name":"Exercise training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00458016","briefTitle":"Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ligand Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MB07803"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04093752","briefTitle":"A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00653510","briefTitle":"The Metabolic Effects of Acute Hyperglycemia in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"Aarhus University Hospital"},{"name":"Regionshospitalet Silkeborg"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Actrapid (human insulin)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01606397","briefTitle":"A Study of Multiple Increasing Doses of LY2409021 in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"LY2409021"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01874483","briefTitle":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 187004 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"BI 187004"},{"name":"BI 187004"},{"name":"BI 187004"},{"name":"BI 187004"},{"name":"BI 187004"},{"name":"BI 187004"},{"name":"BI 187004"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03332771","briefTitle":"Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lexicon Pharmaceuticals"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sotagliflozin (SAR439954)"},{"name":"Glimepiride"},{"name":"Metformin"},{"name":"Placebo"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04533945","briefTitle":"Feasibility of Using the CGM During TOC From in Persons With T2D Using Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Northwell Health"}},"conditionsModule":{"conditions":["Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FreeStyle Libre"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04261933","briefTitle":"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02750410","briefTitle":"A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dulaglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00280865","briefTitle":"GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tesaglitazar"},{"name":"Pioglitazone"},{"name":"Dietary and Lifestyle Modification Counseling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04489966","briefTitle":"Effects of Aerobic Training on Pancreatic Fat and Cognitive Function in T2DM Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nanjing University of Traditional Chinese Medicine"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aerobic training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02065544","briefTitle":"Remission Rates of New Type 2 Diabetes With Weight Loss and Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Vermont"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"behavioral weight loss and exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02653599","briefTitle":"A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"vTv Therapeutics"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TTP273"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02653209","briefTitle":"TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Royal Devon and Exeter NHS Foundation Trust"},"collaborators":[{"name":"University of Exeter"},{"name":"NHS Tayside"},{"name":"University of Dundee"},{"name":"University of Glasgow"},{"name":"Newcastle University"},{"name":"King's College London"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin - DPP4i"},{"name":"Canagliflozin - SGLT2i"},{"name":"Pioglitazone - TZD"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05259033","briefTitle":"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IcoSema"},{"name":"Semaglutide 1 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00722371","briefTitle":"MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin phosphate"},{"name":"Pioglitazone hydrochloride"},{"name":"Matching placebo to sitagliptin"},{"name":"Matching placebo to pioglitazone"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03945656","briefTitle":"A Research Study of How Overdosing of a New Once Weekly Medicine NNC0148-0287 C (Insulin 287) Influences the Blood Sugar Level in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin icodec"},{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01717313","briefTitle":"A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omarigliptin"},{"name":"Placebo to Omarigliptin"},{"name":"Metformin"},{"name":"Placebo to metformin"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02676648","briefTitle":"Web-Delivered Interventions for Blood Sugar Control for Individuals With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Multicomponent online program"},{"name":"Breath meter"},{"name":"Text messages"},{"name":"Diet-appropriate foods and cookbooks"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04862923","briefTitle":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01897532","briefTitle":"Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Linagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02553382","briefTitle":"Fibre Grain Herb Trial in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Unity Health Toronto"},"collaborators":[{"name":"Canadian Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dietary, Herbal"},{"name":"Positive Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04196231","briefTitle":"Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Campania \"Luigi Vanvitelli\""}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IDegLira"},{"name":"IGlarLixi"},{"name":"Insulin/Canaglifozin"},{"name":"Insulin/Dapaglifozin"},{"name":"Insulin/Empaglifozin"},{"name":"Basal Bolus"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04285983","briefTitle":"Specified Drug-Use Survey of Trelagliptin Tablets \"Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease\""},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Trelagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05036876","briefTitle":"Degludec Glargine U300 Hospital Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medanta, The Medicity, India"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Degludec"},{"name":"Glargine U300"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04880850","briefTitle":"A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin icodec"},{"name":"Insulin glargine"},{"name":"Insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00941161","briefTitle":"Effect of Oral Combination Therapy in a Single Dosage Form in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Laboratorios Silanes S.A. de C.V."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"metformin/glimepiride combination"},{"name":"metformin"},{"name":"glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05026424","briefTitle":"Glycemic Response in Adults with Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Société des Produits Nestlé (SPN)"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Balance oral nutritional drink - control"},{"name":"Balance oral nutritional drink - test"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03653091","briefTitle":"Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fractyl Health Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Duodenal Mucosal Resurfacing (DMR)"},{"name":"Duodenal Mucosal Resurfacing Sham (Sham)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02545842","briefTitle":"Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INSULIN GLARGINE"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00237237","briefTitle":"Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01682759","briefTitle":"A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omarigliptin"},{"name":"Placebo to Omarigliptin"},{"name":"Glimepiride"},{"name":"Glimepiride Placebo"},{"name":"Metformin"},{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04738799","briefTitle":"The Impact of Food Order on Glycemic Excursions in Type 2 Diabetes Assessed by Continuous Glucose Monitoring"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Weill Medical College of Cornell University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Carbohydrate-Last Meal Sequence"},{"name":"Carbohydrate-First Meal Sequence"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03207893","briefTitle":"Benefits of Continuous Glucose Monitoring With GEM Lifestyle Modification for Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Virginia"},"collaborators":[{"name":"DexCom, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GEM lifestyle modification & continuous glucose monitoring"},{"name":"Routine Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02292511","briefTitle":"Mind-motor Exercise in Older Adults With Type 2 Diabetes and Self-reported Cognitive Complaints"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lawson Health Research Institute"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Square-stepping exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04039503","briefTitle":"A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01169779","briefTitle":"Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide (AVE0010)"},{"name":"Placebo"},{"name":"Pen auto-injector"},{"name":"Metformin"},{"name":"Sulfonylurea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00530881","briefTitle":"Randomized, Double-Blind, Placebo-Controlled, With PHX1149 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Phenomix"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PHX1149"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01798264","briefTitle":"Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Intarcia Therapeutics"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ITCA 650 (exenatide in DUROS)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00628212","briefTitle":"Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Teneligliptin 10mg"},{"name":"Teneligliptin 20 mg"},{"name":"Teneligliptin 40 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04876274","briefTitle":"Social Media-Delivered Patient Education in Enhancing Type 2 Diabetics Self-Management and Attitudes During the COVID-19 Pandemic"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Taipei Medical University"},"collaborators":[{"name":"Taipei Medical University WanFang Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TMU-LOVE"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04601753","briefTitle":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02397447","briefTitle":"Effect of Momordica Charantia Administration on Type 2 Diabetes Mellitus, Insulin Sensitivity and Insulin Secretion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Guadalajara"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Momordica charantia"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00106340","briefTitle":"Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"},{"name":"glimepiride"},{"name":"Metformin"},{"name":"Vildagliptin matching placebo"},{"name":"Glimepiride matching placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01376323","briefTitle":"A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK256073 1mg"},{"name":"GSK256073 5mg"},{"name":"GSK256073 10mg"},{"name":"GSK256073 25mg"},{"name":"Placebo"},{"name":"Sitagliptin 100mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02490085","briefTitle":"Closed-loop Control of Glucose Levels (Artificial Pancreas) for 24 Hours in Adults With Type 2 Diabetes Under Intensive Insulin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institut de Recherches Cliniques de Montreal"},"collaborators":[{"name":"Réseau de recherche en santé cardiométabolique, diabète et obésité"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"24-hour intervention with multiple daily injections"},{"name":"24-hour intervention with closed-loop strategy"},{"name":"Insulin"},{"name":"Insulin pump Accu-Chek Combo"},{"name":"Dexcom G4 Platinum"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02049814","briefTitle":"Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Voglibose"},{"name":"Acarbose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03786406","briefTitle":"An International Survey of the Occurrence of Diseases That Affects the Heart and Blood Vessels Among People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01835678","briefTitle":"Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Erlangen-Nürnberg Medical School"}},"conditionsModule":{"conditions":["Type 2-diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Linagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00982254","briefTitle":"Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Profil Institut für Stoffwechselforschung GmbH"},"collaborators":[{"name":"Emisphere Technologies, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral insulin"},{"name":"regular human insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00822367","briefTitle":"Blood Sugar Response to Commercial Nutritional Supplements in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Walter Reed Army Medical Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glucerna; Ensure; SlimFast"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02910141","briefTitle":"Individual Patient Data Meta-analysis of CSII vs. MDI in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"King's College London"},"collaborators":[{"name":"University of Leicester"},{"name":"University Hospital, Caen"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous subcutaneous insulin infusion"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02462863","briefTitle":"Treatment of Type 2 Diabetes With Immunonutrients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Christ Hospital"},"collaborators":[{"name":"Shriners Hospitals for Children"},{"name":"University of Cincinnati"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Arginine and fish oil"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01425866","briefTitle":"Two Years Maintenance of Structured Group Self-management Education in Type 2 Diabetes : a Randomized Controlled Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire de la Réunion"},"collaborators":[{"name":"Ministry of Health, France"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Structured self-management group education during 2 years"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04559815","briefTitle":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04666987","briefTitle":"A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in Italy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin degludec and liraglutide (IDegLira)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04083820","briefTitle":"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05155410","briefTitle":"Examining the Effect of Exogenous Ketone Supplementation on Glucose Control in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of British Columbia"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exogenous Ketone Monoester"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04094415","briefTitle":"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03785522","briefTitle":"A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Saudi Arabia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01944449","briefTitle":"Effects of Whey Protein in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tel Aviv University"},"collaborators":[{"name":"Hospital de Clinicas Caracas"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Whey Protein (WPC) at breakfast"},{"name":"Other Protein Sources at breakfast"},{"name":"Low Protein at breakfast"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04537637","briefTitle":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04537624","briefTitle":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01046318","briefTitle":"A Study of OPC-262 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kyowa Kirin Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"OPC-262"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01947855","briefTitle":"Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Empagliflozin"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Empagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02082184","briefTitle":"An Evaluation of a Novel Glucose Sensing Technology in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Diabetes Care"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sensor Based Glucose Monitoring System"},{"name":"Standard Blood Glucose Monitoring"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00733577","briefTitle":"A Study to Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus After 6 Days of Dosing."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SB756050"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01963663","briefTitle":"Metformin and Pioglitazone Effects on YKL-40 Concentrations in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tehran University of Medical Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00877890","briefTitle":"A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide once weekly"},{"name":"exenatide twice daily"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04067999","briefTitle":"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01545388","briefTitle":"Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Metformin"},{"name":"Metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01871428","briefTitle":"A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"aleglitazar"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04780425","briefTitle":"Structured Diabetes Self-Management Education and Care Outcomes in Adults liVIng With Type 2 Diabetes in Accra, Ghana"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Korle-Bu Teaching Hospital, Accra, Ghana"},"collaborators":[{"name":"University of Leicester"},{"name":"Utrecht University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DESMOND"},{"name":"usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00102466","briefTitle":"Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"},{"name":"Gliclazide"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03798080","briefTitle":"Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine/Lixisenatide (HOE901/AVE0010)"},{"name":"Insulin glargine (HOE901)"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00736879","briefTitle":"Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00087516","briefTitle":"Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin (MK0431)"},{"name":"Sitagliptin"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Metformin - Rescue"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04702672","briefTitle":"High-amylose Barley (HIAMBA) in the Regulation and Prevention of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"Innovation Fund Denmark"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"100% wheat (control)"},{"name":"100% Lean-baking barley®"},{"name":"100% regular barley"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05628311","briefTitle":"A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Innovent Biologics (Suzhou) Co. Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo"},{"name":"IBI362"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01449019","briefTitle":"The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ludwig-Maximilians - University of Munich"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exendin(9-39)amide"},{"name":"saline"},{"name":"duodenal meal"},{"name":"duodenal saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02488785","briefTitle":"Impact of a Virtual Diabetes Self-Care and Education Program on Diabetes-related Outcomes in Latinos With T2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Joslin Diabetes Center"},"collaborators":[{"name":"Verizon Foundation"},{"name":"DHR Health Institute for Research and Development"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Virtual Diabetes Self-Care and Education Program"},{"name":"Fitbit"},{"name":"Smartphone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01257451","briefTitle":"Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02543684","briefTitle":"Post-prandial Glucose and Insulin Levels in Type 2 Diabetes Mellitus Patients After Consumption of Ready-to-eat Mixed Meals"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Harokopio University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ready to eat mixed meal 1"},{"name":"ready to eat mixed meal 2"},{"name":"ready to eat mixed meal 3"},{"name":"oral glucose load"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02890745","briefTitle":"The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Henrik Enghusen Poulsen"},"collaborators":[{"name":"University Hospital, Gentofte, Copenhagen"},{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02752412","briefTitle":"Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine/Lixisenatide (HOE901/AVE0010)"},{"name":"Insulin glargine U100 (HOE901)"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00380445","briefTitle":"Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01065298","briefTitle":"Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus-2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Post Graduate Institute of Medical Education and Research, Chandigarh"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"stem cell transplantation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00671424","briefTitle":"A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hydrochlorothiazide (HCTZ)"},{"name":"Remogliflozin etabonate (GSK189075)"},{"name":"Furosemide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04537923","briefTitle":"A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Insulin Lispro (U100)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03130426","briefTitle":"Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Population Health Research Institute"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"iGlarLixi"},{"name":"Insulin Glargine"},{"name":"Metformin"},{"name":"Lifestyle therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01055808","briefTitle":"Observational Study in Japanese Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulins"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00254254","briefTitle":"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide - Exenatide - Placebo"},{"name":"Exenatide - Placebo - Exenatide"},{"name":"Placebo - Exenatide - Exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01357109","briefTitle":"Effect of Bosentan on Endothelial Function in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Karolinska Institutet"},"collaborators":[{"name":"Swedish Heart Lung Foundation"},{"name":"The Swedish Research Council"},{"name":"Actelion"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bosentan"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04601740","briefTitle":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01059825","briefTitle":"Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo to Ertugliflozin"},{"name":"Ertugliflozin 1 mg"},{"name":"Ertugliflozin 5 mg"},{"name":"Ertugliflozin 25 mg"},{"name":"Sitagliptin 100 mg"},{"name":"Placebo to Sitagliptin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00297063","briefTitle":"BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00325429","briefTitle":"Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03336528","briefTitle":"Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Degludec"},{"name":"Glargine"},{"name":"Aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01175408","briefTitle":"Blood Monitoring and Data Acquisition and Utilization in Patients With Type 2 Diabetes Treated With Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Endocrine Research Society"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Remote Blood Glucose Monitoring"},{"name":"Continuous Glucose Monitoring"},{"name":"SMBG"},{"name":"SMBG With Knowledge"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00924534","briefTitle":"A Safety PK/PD Study of SLV337 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Products"},"collaborators":[{"name":"Quintiles, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"SLV337"},{"name":"SLV337"},{"name":"SLV337"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01027871","briefTitle":"A Study for Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2605541"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01215968","briefTitle":"A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2189265"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02577016","briefTitle":"Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Placebo"},{"name":"Ipragliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02577003","briefTitle":"Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ipragliflozin"},{"name":"Placebo"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01026194","briefTitle":"Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo / Teneli (Teneligliptin) + pio (pioglitazone)"},{"name":"Teneli / Teneli + pio"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02687152","briefTitle":"Arginase Inhibition and Microvascular Endothelial Function in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Karolinska Institutet"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"N-hydroxy-nor-L-arginine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00913367","briefTitle":"Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Handok Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"glimepiride + insulin glargine (Amaryl + Lantus)"},{"name":"glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03066830","briefTitle":"Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lexicon Pharmaceuticals"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sotagliflozin (SAR439954)"},{"name":"Placebo"},{"name":"Metformin"},{"name":"Sulfonylurea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03864562","briefTitle":"Gastric Emptying - Implications for the Pathogenesis of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Nottingham"},"collaborators":[{"name":"University of Adelaide"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03929679","briefTitle":"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01814787","briefTitle":"Computer Automation for Diagnosis and Management of Childhood Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Indiana University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CHICA Type 2 Diabetes Module"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02669524","briefTitle":"Dissection of the Gastrointestinal-mediated Glucose Disposal and Incretin Defect in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2409021"},{"name":"LY2409021 placebo"},{"name":"OGTT"},{"name":"IIGI"},{"name":"Standardised liquid meal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03918148","briefTitle":"Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Campania \"Luigi Vanvitelli\""}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SGLT-2i"},{"name":"DPP-4i"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00532610","briefTitle":"A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK189075"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00458029","briefTitle":"Middle-School Based Primary Prevention Trial of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},"collaborators":[{"name":"George Washington University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"integrated program of nutrition, activity, behavior, and promotion"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02661165","briefTitle":"How Does the Spirituality of Patients With Type 2 Diabetes Influence Their Self-management?"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Natasha Duke"},"collaborators":[{"name":"University of Southampton"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01281605","briefTitle":"Comparison of Two Titration Programs of Adding Insulin Detemir to OADs in Poorly Controlled Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mackay Memorial Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Active titration algorithm"},{"name":"Usual titration algorithm"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02194595","briefTitle":"Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mount Sinai Hospital, Canada"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"},{"name":"University of Toronto"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Basal insulin and exenatide"},{"name":"Basal insulin only"},{"name":"Basal insulin and bolus insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00679939","briefTitle":"Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01571622","briefTitle":"Whey Protein on Posprandial Glucose, Insulin GLP-1, GIP and DPP4 in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tel Aviv University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Whey before Breakfast"},{"name":"Water before breakfast"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03705260","briefTitle":"Quality Initiative to Improve Glucose Control in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"},"collaborators":[{"name":"Twine Clinical Consulting"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Usual Care"},{"name":"Intensive Behavioral Intervention"},{"name":"Monthly Screening for Risk"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00974090","briefTitle":"Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)"},{"name":"Teneli / Teneli + SU"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00501930","briefTitle":"A Study to Evaluate and Study Drug Levels in Blood Plasma When Giving High Doses of GSK189075 to Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK189075"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04528212","briefTitle":"Fenofibrate Versus Curcumin in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rehab Werida"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glimepiride Tablets"},{"name":"glimepiride plus fenofibrate"},{"name":"glimepiride plus curcumin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03888157","briefTitle":"A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01999218","briefTitle":"Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ertugliflozin 5 mg"},{"name":"Ertugliflozin 10 mg"},{"name":"Glimerpiride"},{"name":"Placebo to Ertugliflozin"},{"name":"Placebo to Glimepiride"},{"name":"Metformin"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01707147","briefTitle":"A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Trajenta tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00124397","briefTitle":"Atorvastatin and Endothelial Function in Type 2 Diabetes Mellitus (ATTEND-Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Southern Denmark"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Atorvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00099944","briefTitle":"Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"},{"name":"Glimepiride"},{"name":"LAF237 placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02130401","briefTitle":"Examining the Effects of Neuromodulation on Glucose Metabolism in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Scion NeuroStim"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TNM (thermoneuromodulation device)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01512849","briefTitle":"A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TA-7284 Low"},{"name":"TA-7284 High"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03071016","briefTitle":"Usage of Dapagliflozin in the Management of Type-2 Diabetes Mellitus: A Real World Evidence Study in Indian Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02123901","briefTitle":"The Effect of Walking Meditation Training on Glycemic Control and Vascular Function in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chulalongkorn University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Walking Meditation"},{"name":"Walking"},{"name":"No exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01182935","briefTitle":"Elevated Triglyceride Levels and Later Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Tromso"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03751657","briefTitle":"A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin icodec"},{"name":"Placebo (insulin 287)"},{"name":"Metformin"},{"name":"Dipeptidyl peptidase-4 inhibitors"},{"name":"Insulin glargine"},{"name":"Placebo (insulin glargine)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00354536","briefTitle":"In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK716155 subcutaneous injections"},{"name":"placebo injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01413204","briefTitle":"Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TA-7284 Low"},{"name":"TA-7284 High"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01691755","briefTitle":"A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"aleglitazar"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02853630","briefTitle":"A Clinical Trial to Study the Effects of Two Drugs, Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals"}},"conditionsModule":{"conditions":["TYpe 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01140542","briefTitle":"Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Proof of Concept Clinical Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Roflumilast"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04175665","briefTitle":"Real-world Health Outcomes in Canadian Patients Using Semaglutide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LMC Diabetes & Endocrinology Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00101673","briefTitle":"Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00099931","briefTitle":"Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00099892","briefTitle":"Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00099853","briefTitle":"Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"pioglitazone"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00682097","briefTitle":"A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"RO4998452"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03823339","briefTitle":"A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin degludec/liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03876015","briefTitle":"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01177163","briefTitle":"A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"JNJ 28431754 300 mg/placebo"},{"name":"JNJ 28431754 100 mg/placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04426422","briefTitle":"Effect of Metformin on Gut Microbiota Changes and Glycemic Control of Newly Diagnosed Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shenzhen People's Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin Hydrochloride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03798054","briefTitle":"Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine/Lixisenatide (HOE901/AVE0010)"},{"name":"Insulin glargine (HOE901)"},{"name":"Lixisenatide (AVE0010)"},{"name":"Metformin"},{"name":"SGLT2 inhibitor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00753896","briefTitle":"Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04057248","briefTitle":"Digital Self-Management and Health Coaching for Type 2 Diabetes - Impact on Diabetes Clinical and Wellness Indicators"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LabStyle Innovations Ltd."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dario Blood Glucose Monitoring System"},{"name":"CDE"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01648582","briefTitle":"A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dulaglutide"},{"name":"Insulin glargine"},{"name":"Metformin"},{"name":"Sulfonylureas"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00520065","briefTitle":"Comparison of Nutritional Products for People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Nutrition"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"enteral nutritional formula"},{"name":"Diabetes specific enteral product"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02716610","briefTitle":"Dose-Response and Variability of Inhaled Insulin in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dance Biopharm Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INH 69 U (low)"},{"name":"INH 69 U (high)"},{"name":"INH 139 U"},{"name":"INH 208 U"},{"name":"LIS 18 U"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01414920","briefTitle":"Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"TAK-875"},{"name":"TAK-875"},{"name":"Sitagliptin"},{"name":"TAK-875 and Sitagliptin"},{"name":"TAK-875 and Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00500955","briefTitle":"Rosiglitazone on Microalbuminuria in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01055652","briefTitle":"Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00888836","briefTitle":"Diet and Medical Therapy Versus Bariatric Surgery in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Catholic University of the Sacred Heart"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bariatric surgery: Gastric bypass"},{"name":"Bariatric surgery: Bilio-pancreatic diversion"},{"name":"anti-diabetic drugs and behavioral suggestions"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05352815","briefTitle":"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IcoSema"},{"name":"Insulin icodec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02586545","briefTitle":"Shared Care for Patients With Type 2 Diabetes Across the Primary and Secondary Health Care Sector"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"},"collaborators":[{"name":"Metropolitan University College"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Shared care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02129946","briefTitle":"The Effect of Resistant Starch Bagels on Risk Factors of Type 2 Diabetes and Colorectal Cancer"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Guelph"},"collaborators":[{"name":"Ontario Ministry of Agriculture, Food and Rural Affairs"},{"name":"Maple Leaf Foods, Canada Bread"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Resistant Starch"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00432679","briefTitle":"A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone (BRL49653C)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02453555","briefTitle":"Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Linagliptin"},{"name":"Empagliflozin placebo + linagliptin placebo low dose"},{"name":"Empagliflozin + linagliptin low dose"},{"name":"Linagliptin placebo"},{"name":"Empagliflozin + linagliptin high dose"},{"name":"Empa + lina highdose placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01285518","briefTitle":"Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-05231023"},{"name":"PF-05231023"},{"name":"PF-05231023"},{"name":"PF-05231023"},{"name":"PF-05231023"},{"name":"PF-05231023"},{"name":"PF-05231023"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03091517","briefTitle":"A Single Arm Feasibility Study of GlycoLeap, an On-line Lifestyle Modification and Self-management Program for People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Duke-NUS Graduate Medical School"},"collaborators":[{"name":"SingHealth Polyclinics"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GlycoLeap"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03932721","briefTitle":"EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Campinas, Brazil"}},"conditionsModule":{"conditions":["Dyslipidemia Associated With Type II Diabetes Mellitus","Diabetes Mellitus, Type 2","Hypertension Arterial"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Evolocumab 140 MG/ML"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02206074","briefTitle":"The Effect of Dietary Nitrate Supplementation on Ability of Individuals With Type 2 Diabetes to Perform Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Exeter"},"collaborators":[{"name":"Diabetes UK"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Beetroot"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00310297","briefTitle":"Insulin Glulisine in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glulisine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00785005","briefTitle":"What Makes Exercise Feel More Difficult to Women With and Without Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Denver"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00824616","briefTitle":"A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK-0941"},{"name":"Placebo"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02583919","briefTitle":"Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ionis Pharmaceuticals, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ISIS-GCGRRx- Dose Level 1"},{"name":"ISIS-GCGRRx- Dose Level 2"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00789737","briefTitle":"Welchol as Monotherapy for Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Welchol"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00795691","briefTitle":"Diabetes Dietary Study- Low Carbohydrate and Low-Fat Diets in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Albert Einstein College of Medicine"},"collaborators":[{"name":"Robert C. Atkins Foundation"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"low-carbohydrate diet"},{"name":"low-fat diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00799643","briefTitle":"Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Joslin Diabetes Center"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Salsalate"},{"name":"Salsalate Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03285750","briefTitle":"Expression of G-protein Coupled Receptor 120 Receptor in Adipose Tissue of German Diabetes Center Cohort Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"German Diabetes Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01580852","briefTitle":"The Effects of Immersion in Dead Sea Water on Glucose Levels in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Victor Novack"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dead Sea water"},{"name":"Pool water"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00695526","briefTitle":"Effects of Cranberry Extractive on the Lipid Profiles in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Taichung Veterans General Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"cranberry"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02738151","briefTitle":"Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine, 300U/mL"},{"name":"Insulin degludec, 100 U/mL"},{"name":"Non-insulin anti-diabetic treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05516797","briefTitle":"IGNITE (Impact of Glucose moNitoring and nutrItion on Time in rangE)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HealthPartners Institute"},"collaborators":[{"name":"Virta Health"},{"name":"Abbott Diabetes Care"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous Glucose Monitoring (CGM)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02227303","briefTitle":"A Pilot Open Label Clinical Trial to Evaluate the Combined Impact of Two Mobile Health Products on Health Outcomes in Overweight Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medidata Solutions"},"collaborators":[{"name":"Miami Research Associates"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"lifestyle modification instructional and motivational sessions"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01034111","briefTitle":"A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin phosphate"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02910089","briefTitle":"ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Brigham Women's Health"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Shared Decision Making"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03278158","briefTitle":"A Single-dose Trial to Investigate the Safety and Tolerability of XEN-D0501 in Patients With Diabetes Mellitus Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pila Pharma"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"XEN-D0501, 1 mg/tablet"},{"name":"XEN-D0501, 2 mg/tablet"},{"name":"XEN-D0501, 4 mg/tablet"},{"name":"XEN-D0501, 8 mg/tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00910507","briefTitle":"The Impact of Exercise Counseling on Exercise Behavior in People With Type 2 Diabetes: A Randomized Clinical Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Central Arkansas"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise counseling"},{"name":"Supervised exercise training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05174975","briefTitle":"Effectiveness of App-based Positive Psychological Intervention on Patients Newly Diagnosed With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tri-Service General Hospital"},"collaborators":[{"name":"Kaohsiung Medical University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"App-based Positive Psychological Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03115112","briefTitle":"Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Theracos"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bexagliflozin"},{"name":"Sitagliptin"},{"name":"Placebo for sitagliptin"},{"name":"Placebo for bexagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05011292","briefTitle":"Well-child Visit Video Project"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Educational Video about SCB"},{"name":"Survey on child feeding and related knowledge and practices"},{"name":"Educational Video other than SCB"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01318070","briefTitle":"Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin and pioglitazone"},{"name":"Alogliptin and pioglitazone"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00120536","briefTitle":"Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00147745","briefTitle":"Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Colesevelam"},{"name":"Colesevelam matching placebo"},{"name":"Insulin glargine (Lantus)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00110240","briefTitle":"Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02286128","briefTitle":"Effect of NF-кB Dependent Proinflammation on Osteogenic Differentiation of the Mesenchymal Stem Cells in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chiang Mai University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00284609","briefTitle":"Rehabilitation of Type 2 Diabetes Patients."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bispebjerg Hospital"},"collaborators":[{"name":"National Board of Health, Denmark"},{"name":"The Health and Care Committee, Copenhagen City Council"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Group based non-pharmacological rehabilitation"},{"name":"Individual non-pharmacological rehabilitation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00102388","briefTitle":"Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"},{"name":"Gliclazide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03724526","briefTitle":"Text Messaging and Cardiovascular Health in Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nanfang Hospital, Southern Medical University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Text messaging"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00099918","briefTitle":"Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00099866","briefTitle":"Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"},{"name":"Metformin Comparator"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00198900","briefTitle":"Diabetes Knowledge Assessment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johns Hopkins Bloomberg School of Public Health"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"survey of information"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04515745","briefTitle":"The Effects of an Intensive Lifestyle Intervention for Type 2 Diabetes on Disability Insurance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Minnesota"},"collaborators":[{"name":"University of Southern California"},{"name":"Wake Forest University"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intensive lifestyle intervention (ILI)"},{"name":"Diabetes support and education (DSE)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02607410","briefTitle":"Sitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2D"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Sao Paulo General Hospital"},"collaborators":[{"name":"Fundação de Amparo à Pesquisa do Estado de São Paulo"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin"},{"name":"NPH insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03982238","briefTitle":"Effects of Hypoglycemic Drugs on Testosterone Levels in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Majianhua"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin"},{"name":"Metformin"},{"name":"Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01580475","briefTitle":"Training, Detraining, Retraining and Glycemic Control in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Democritus University of Thrace"},"collaborators":[{"name":"Aristotle University Of Thessaloniki"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Training - detraining - retraining"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02366416","briefTitle":"Effects of Physical Exercise on Blood Glucose and Pain From the Musculoskeletal System in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nordsjaellands Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01224366","briefTitle":"Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03194100","briefTitle":"Serum METRNL Concentration in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chungnam National University Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04656106","briefTitle":"A Study Investigating the Clinical Parameters Associated With the Use of Ryzodeg® (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in South Korea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ryzodeg®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00359762","briefTitle":"Exenatide Versus Glimepiride in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02797314","briefTitle":"Comparison of Bone Quality in Type 2 Diabetic Patients With a Non-diabetic Control Population"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospices Civils de Lyon"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bone biopsies"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00674466","briefTitle":"A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Who Are Currently on Metformin Monotherapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"ConjuChem"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"1.5 mg or 2.0 mg CJC-1134-PC"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00993187","briefTitle":"Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin/Metformin FDC"},{"name":"Comparator: Glimepiride"},{"name":"Matching placebo to Sitagliptin/Metformin FDC"},{"name":"Matching placebo to glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05427890","briefTitle":"Diabetes Risk Communication Tool Evaluation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National University of Singapore"},"collaborators":[{"name":"National Medical Research Council (NMRC), Singapore"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"T2D Risk Communication Tool: Relative Risk"},{"name":"T2D Risk Communication Tool: Metabolic Age"},{"name":"T2D Risk Communication Tool: Traffic Light"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02809365","briefTitle":"FreeStyle Libre- Effect on QOL in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Wolfson Medical Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FreeStyle Libre"},{"name":"personal glucometer"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00388518","briefTitle":"A Study of Aleglitazar in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Actos"},{"name":"Placebo"},{"name":"aleglitazar"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02941367","briefTitle":"Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide (AVE0010)"},{"name":"Sulfonylurea"},{"name":"metformin"},{"name":"basal insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01006603","briefTitle":"Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01960179","briefTitle":"Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"lixisenatide AVE0010"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04219124","briefTitle":"The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Leicester"},"collaborators":[{"name":"Royal Surrey County Hospital NHS Foundation Trust"},{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IMP oral tablet"},{"name":"Placebo oral tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00797069","briefTitle":"Comparison of Nutritional Products for People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Nutrition"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"standard nutritional product (medical food)"},{"name":"nutritional product for diabetes (medical food)"},{"name":"diabetes specific experimental nutritional product (medical food)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05317845","briefTitle":"An International Chart Review and Survey for the Prevalence and Clinical Management of Atherosclerotic Cardiovascular Diseases in Patients With Type 2 Diabetes Across Countries in the Middle East and Africa"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00509223","briefTitle":"GLYCOSA Study:Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"ResMed"},"collaborators":[{"name":"Royal North Shore Hospital"},{"name":"Baker Heart and Diabetes Institute"},{"name":"International Diabetes Center at Park Nicollet"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Positive Airway Pressure therapy"},{"name":"Lifestyle counseling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01995539","briefTitle":"Use of iPro™2 in Real Life Diabetes Management of Type 2 Patients in India"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medtronic Diabetes"},"collaborators":[{"name":"Medtronic"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"therapy regimen"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00451620","briefTitle":"Effect of GlucoNorm vs Glyburide on Post-Prandial Hyperglycemia in Elderly Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of British Columbia"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"glyburide"},{"name":"GlucoNorm"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00372957","briefTitle":"Study Of GW823093 In Japanese Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GW823093 15mg"},{"name":"GW823093 placebo capsule"},{"name":"GW823093 30mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03598738","briefTitle":"The Effect of Esomeprazole on Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baskent University Ankara Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Esomeprazole 40mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02749890","briefTitle":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine/Lixisenatide (HOE901/AVE0010)"},{"name":"Lixisenatide (AVE0010)"},{"name":"Oral anti-diabetic drugs"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00174668","briefTitle":"Insulin Glulisine in Diabetes Mellitus, Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glulisine"},{"name":"Insulin Therapy"},{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04356742","briefTitle":"Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dong-A ST Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin 10mg"},{"name":"Placebo"},{"name":"Evogliptin 5mg"},{"name":"Metformin≥1000mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01785524","briefTitle":"Dietary Nitrate and Exercise to Augment Exercise Training Benefits in Subjects With DM+PAD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Duke University"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Peripheral Arterial Disease","Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Beetroot Juice (Beet-It Stamina Shot) and Exercise Training"},{"name":"Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01843127","briefTitle":"A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gilead Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ranolazine"},{"name":"Placebo"},{"name":"Exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04538352","briefTitle":"Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Cleveland Clinic"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"},{"name":"Insulin Degludec"},{"name":"Insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04030091","briefTitle":"Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sciema UG"},"collaborators":[{"name":"Innovative Diabetes Treatment Studies LLC."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"3 hours humulin R 100 IU/mL PIT"},{"name":"2 hours humulin R 100 IU/mL PIT"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02033889","briefTitle":"A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007)."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ertugliflozin 5 mg"},{"name":"Ertugliflozin 15 mg"},{"name":"Placebo to Ertugliflozin"},{"name":"Glimepiride"},{"name":"Placebo to Glimepiride"},{"name":"Basal Insulin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02764021","briefTitle":"Cut Down on Carbohydrate Usage in the Diet of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bispebjerg Hospital"},"collaborators":[{"name":"University of Copenhagen"},{"name":"University of Aarhus"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Carbohydrate-Restricted Diet"},{"name":"Standard Antidiabetic Diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02435277","briefTitle":"An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NuSirt Biopharma"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low Metformin"},{"name":"Mid Metformin"},{"name":"High Metformin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03566693","briefTitle":"Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"DexCom, Inc."},"collaborators":[{"name":"Jaeb Center for Health Research"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dexcom G6 CGM System"},{"name":"Blood glucose meter"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02227875","briefTitle":"Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mylan Inc."},"collaborators":[{"name":"Mylan GmbH"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mylan's insulin glargine"},{"name":"Lantus®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00924105","briefTitle":"Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cytos Biotechnology AG"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CYT013-IL1bQb"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01474538","briefTitle":"Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Lispro"},{"name":"Insulin Aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01606371","briefTitle":"A First-in-Human Study of LY2409021 in Healthy Participants and Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"LY2409021"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03457012","briefTitle":"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03745157","briefTitle":"RESILIENT: A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in Local Clinical Practice in Japan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Degludec/Insulin Aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02340260","briefTitle":"Time Efficient Exercise in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Norwegian University of Science and Technology"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High intensity interval training"},{"name":"Sprint interval training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03789578","briefTitle":"A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NNC0148-0287sema"},{"name":"Semaglutide"},{"name":"NNC0148-0287"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03235050","briefTitle":"A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"MedImmune LLC"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MEDI0382 low dose"},{"name":"MEDI0382 mid dose"},{"name":"MEDI0382 high dose"},{"name":"Placebo"},{"name":"Liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00371007","briefTitle":"MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks"},{"name":"Comparator : placebo (unspecified) / Duration of Treatment: 12 Weeks"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01414556","briefTitle":"GIP Effects at Insulin Induced Hypoglycemia in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mikkel Christensen"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glucose-dependent Insulinotropic polypeptide"},{"name":"saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01735643","briefTitle":"Lifestyle Intervention With an Interactive Video Game for Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"West German Center of Diabetes and Health"},"collaborators":[{"name":"Novartis Pharmaceuticals"},{"name":"Nintendo of Europe GmbH"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"interactive videogame Wii Fit Plus"},{"name":"waiting"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00351585","briefTitle":"A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00238498","briefTitle":"A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02354235","briefTitle":"Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Teneligliptin"},{"name":"Canagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02354222","briefTitle":"Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin"},{"name":"Teneligliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00511602","briefTitle":"Study of the Efficacy and Safety of Inhaled Technosphere Insulin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mannkind Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Technosphere Insulin"},{"name":"Technosphere Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03285594","briefTitle":"Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lexicon Pharmaceuticals"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sotagliflozin"},{"name":"Insulin glargine (HOE901)"},{"name":"Placebo"},{"name":"Oral Antidiabetes Drugs (OADs)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04285450","briefTitle":"The Clinical Effect of Vitamin K Administration in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cairo University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin K"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01001104","briefTitle":"A Study of LY2189265 in Japanese Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2189265"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04227431","briefTitle":"A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in China"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00086502","briefTitle":"Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Comparator: Sitagliptin"},{"name":"Comparator: Placebo"},{"name":"Comparator: Pioglitazone"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02113332","briefTitle":"Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vastra Gotaland Region"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01665352","briefTitle":"A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"vTv Therapeutics"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TTP054"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03090464","briefTitle":"A 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Use of digital disease management tool"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00856284","briefTitle":"Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin"},{"name":"Metformin"},{"name":"Glipizide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04738591","briefTitle":"mHealth Intervention to Support Diabetes Medication Adherence (Pilot Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fundació d'investigació Sanitària de les Illes Balears"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DIABE-TEXT"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01593371","briefTitle":"Comparison of Metformin and Pioglitazone Effects on Adipokines Concentrations in Newly Diagnosed Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tehran University of Medical Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00562029","briefTitle":"Study of Duodenal-Jejunal Bypass(DJB) as a Potential Cure for Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sound Shore Medical Center of Westchester"},"collaborators":[{"name":"Maffucci L, Rangraj M"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Duodenal-jejunal Bypass"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05716724","briefTitle":"O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00389415","briefTitle":"Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00612794","briefTitle":"A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide once weekly"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02039934","briefTitle":"Effect of High-intensity Low-volume Training on Insulin Sensitivity in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"German Diabetes Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High intensity interval training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00971659","briefTitle":"Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Profil Institut für Stoffwechselforschung GmbH"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glargine + exenatide + preexisting metformin"},{"name":"insulin glargine + sitagliptin + preexisting metformin"},{"name":"insulin glargine + preexisting metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00103935","briefTitle":"Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo"},{"name":"placebo"},{"name":"Exenatide LAR"},{"name":"Exenatide LAR"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01149421","briefTitle":"A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2189265"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03644134","briefTitle":"A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rashid Centre for Diabetes and Research"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Assessment of physiological stress and sleep pattern"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00690638","briefTitle":"Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Phenomix"},"collaborators":[{"name":"Forest Laboratories"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PHX1149T"},{"name":"PHX1149T"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01217073","briefTitle":"A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omarigliptin"},{"name":"Placebo to omarigliptin"},{"name":"Pioglitazone"},{"name":"Metformin"},{"name":"Placebo to metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02024971","briefTitle":"Special Drug Use Surveillance of Pioglitazone/Metformin Hydrochloride Combination Tablets Survey on Long-term Use for Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone/metformin hydrochloride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01993121","briefTitle":"Exercise and Type 2 Diabetes: Gender and Endothelial Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Denver"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Supervised Exercise Training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00995345","briefTitle":"Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"ActivX Biosciences, Inc."},"collaborators":[{"name":"Kyorin Pharmaceutical Co.,Ltd"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"KRP-104"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01456650","briefTitle":"R230C and C230C Variants of ABCA1 and Glyburide Response"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glyburide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04908904","briefTitle":"Acute Effects of Cafestol on Glucose Metabolism in Subjects With Type-2-diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"Aarhus University Hospital"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cafestol"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03732209","briefTitle":"A Remotely Delivered Episodic Future Thinking Intervention to Improve Management of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Virginia Polytechnic Institute and State University"},"collaborators":[{"name":"Carilion Clinic"},{"name":"University at Buffalo"},{"name":"National Institute of Nursing Research (NINR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Episodic future thinking"},{"name":"Control Thinking"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00666458","briefTitle":"18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"saxagliptin"},{"name":"sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02040246","briefTitle":"Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"RenJi Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Repaglinide"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03631186","briefTitle":"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00101803","briefTitle":"Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02248714","briefTitle":"The Efficacy of Glucerna SR in Chinese Drug-naïve Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Jiao Tong University Affiliated Sixth People's Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glucerna SR"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02561130","briefTitle":"Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Population Health Research Institute"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glargine"},{"name":"metformin"},{"name":"Forxiga"},{"name":"Lifestyle therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00639080","briefTitle":"Necessity for Lipid Lowering Therapy in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Endocrine Research Society"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Stop lipid lowering therapy (statin)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00472095","briefTitle":"Fotonovela for Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Francisco"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fotonovela"},{"name":"Placebo Fotonovela"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00103857","briefTitle":"MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily)"},{"name":"Comparator: MK0431 100 mg q.d. (q.d. = once daily)"},{"name":"Comparator: Placebo (Phase A)/Metformin (Phase B)"},{"name":"Comparator: Metformin 500 mg b.i.d."},{"name":"Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d."},{"name":"Comparator: Metformin 1000 mg b.i.d."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00575471","briefTitle":"Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rivoglitazone HCl"},{"name":"rivoglitazone HCl"},{"name":"rivoglitazone HCl"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01376557","briefTitle":"Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lexicon Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"75 mg LX4211"},{"name":"200 mg LX4211"},{"name":"400 mg LX4211"},{"name":"200 mg LX4211"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01297049","briefTitle":"I-care: Stimulating Self-management in Patients With Type 2-diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oslo Metropolitan University"},"collaborators":[{"name":"University of Oslo"}]},"conditionsModule":{"conditions":["Diabetes Type 2","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cognitive behavior therapy (CBT)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01907113","briefTitle":"Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 10773"},{"name":"BI 10773"},{"name":"BI 10773"},{"name":"BI 10773"},{"name":"BI 10773"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02669732","briefTitle":"An Exploratory Study of DS-8500a on Beta Cell Function Using Hyperglycemic Clamp"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DS-8500a"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01755156","briefTitle":"A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omarigliptin"},{"name":"Matching placebo to omarigliptin"},{"name":"Glimepiride"},{"name":"Matching placebo to glimepiride"},{"name":"Insulin glargine"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03351478","briefTitle":"Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lexicon Pharmaceuticals"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sotagliflozin"},{"name":"Empagliflozin"},{"name":"Placebo"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01546558","briefTitle":"Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gilead Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Ranolazine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01774968","briefTitle":"Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Human Regular U-500 Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01704261","briefTitle":"Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omarigliptin"},{"name":"Matching placebo to Omarigliptin"},{"name":"Glimepiride"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02813759","briefTitle":"Sucralose in Subjects With Diabetes Mellitus Insulin Requesting"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidad de Valparaiso"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sucralose"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02769481","briefTitle":"Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Theracos"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bexagliflozin"},{"name":"Placebo for Bexagliflozin"},{"name":"Glimepiride"},{"name":"Placebo for Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04141111","briefTitle":"Retrospective and Prospective Study on Professional Continuous Glucose Monitoring in Insulin-treated Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Associacao Protectora dos Diabeticos de Portugal"},"collaborators":[{"name":"Medtronic"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous Glucose Monitoring (CGM)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01529541","briefTitle":"Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"JW Pharmaceutical"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Anagliptin"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01702298","briefTitle":"A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin 100 mg/simvastatin 40 mg FDC"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01769378","briefTitle":"Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Dulaglutide"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00767260","briefTitle":"Bone Marrow Mononuclear Cell and Hyperbaric Oxygen Therapy in Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fuzhou General Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BM-MNC+HOT"},{"name":"BM-MNC"},{"name":"HOT"},{"name":"SMT"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04823442","briefTitle":"Activation of Brown Adipose Tissue Metabolism Using Mirabegron"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Université de Sherbrooke"},"collaborators":[{"name":"Laval University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mirabegron"},{"name":"Bisoprolol Fumarate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01070238","briefTitle":"Metabolic Response of Slow Released Carbohydrates in Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Giessen"},"collaborators":[{"name":"Numico Research"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Isomaltulose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01839344","briefTitle":"Effects of Quercetin on Blood Sugar and Blood Vessel Function in Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bastyr University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Quercetin"},{"name":"Acarbose"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02157298","briefTitle":"Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin 5 mg"},{"name":"Placebo tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01207349","briefTitle":"Type 2 Diabetes Secondary Prevention"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institut National de la Santé Et de la Recherche Médicale, France"},"collaborators":[{"name":"Groupe Hospitalier Sud Réunion"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Secondary prevention intervention trial"},{"name":"standard follow up"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01886989","briefTitle":"Cocoa Polyphenols and Postprandial Metabolism in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Arpita Basu"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cocoa polyphenols"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03555565","briefTitle":"Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets \"Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age\""},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin and Metformin hydrochloride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02408120","briefTitle":"Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine"},{"name":"Insulin aspart"},{"name":"Supplemental insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01085292","briefTitle":"NOX-E36 Multiple Ascending Dose Study in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"TME Pharma AG"},"collaborators":[{"name":"Profil Institut für Stoffwechselforschung GmbH"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NOX-E36"},{"name":"NOX-E36"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03064841","briefTitle":"Clinical Characteristics, Anti-hyperglycaemic Treatment Pattern and Target Attainment of Type 2 Diabetes Mellitus Patients in Older Population With or Without Albuminuria in China"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No Treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01738802","briefTitle":"The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Walter Reed National Military Medical Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Anti-oxidant and micronutrient"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00559884","briefTitle":"A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK189075 (Modified and immediate release formulations)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01793909","briefTitle":"Type 2 Diabetes and Exercise Function in Single Leg Exercises"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Denver"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Single Leg Exercise Training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03993132","briefTitle":"A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03819153","briefTitle":"A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"},{"name":"Placebo (semaglutide)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05754424","briefTitle":"AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Arecor Limited"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AT278"},{"name":"NovoRapid"},{"name":"Humulin R 500 UNT/ML Injectable Solution"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02411825","briefTitle":"Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SAR425899"},{"name":"placebo"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00471549","briefTitle":"Simvastatin Reduces Circulating Osteoprotegerin Levels in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Statin (simvastatin)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01117584","briefTitle":"A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ipragliflozin"},{"name":"Placebo"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02588859","briefTitle":"Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01249677","briefTitle":"Chronic Reduction of Fasting Glycaemia With Insulin Glargine Improves First and Second Phase Insulin Secretion in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ruhr University of Bochum"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02752113","briefTitle":"Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institut für Pharmakologie und Präventive Medizin"},"collaborators":[{"name":"University of Erlangen-Nürnberg Medical School"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin and Linagliptin"},{"name":"Metformin and Insulin sc"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02639130","briefTitle":"GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diabeteszentrum Bad Lauterberg im Harz"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exendin [9-39]"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02036515","briefTitle":"Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ertugliflozin 5 mg"},{"name":"Ertugliflozin 15 mg"},{"name":"Placebo for ertugliflozin 5 mg"},{"name":"Metformin"},{"name":"Sitagliptin"},{"name":"Glimepiride"},{"name":"Insulin"},{"name":"Placebo for ertugliflozin 10 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01284465","briefTitle":"Type 2 Diabetes Self-management Intervention for Low-income Women"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Meharry Medical College"},"collaborators":[{"name":"National Center for Research Resources (NCRR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Education and patient liaison combination"},{"name":"Control group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01237301","briefTitle":"Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HealthPartners Institute"},"collaborators":[{"name":"Roche Diagnostics GmbH"},{"name":"International Diabetes Center at Park Nicollet"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CGM Group"},{"name":"SMBG Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01475734","briefTitle":"Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"albiglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00544206","briefTitle":"Comparison of Enteral Products for Tube Fed Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Nutrition"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"standard enteral feeding product"},{"name":"Diabetes specific feeding product"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01097681","briefTitle":"A Study to Assess the Pharmacokinetics, Pharmacodynamics of ASP1941 in Diabetes Mellitus Patients With Renal Impairment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ASP1941"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02192424","briefTitle":"Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Main Trial)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mount Sinai Hospital, Canada"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin alone"},{"name":"Metformin + Intermittent Insulin Therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02752828","briefTitle":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine/lixisenatide (HOE901/AVE0010)"},{"name":"Insulin glargine (HOE901)"},{"name":"Oral anti-diabetic drugs"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00256646","briefTitle":"Markers and Mechanisms of Vascular Disease in Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"US Department of Veterans Affairs"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00272077","briefTitle":"Insulin Glargine in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insuline glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01188200","briefTitle":"Four-Hour Evaluation of a Medical Food in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Nutrition"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Experimental nutritional formula #M979"},{"name":"Standard food"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00504816","briefTitle":"A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK189075"},{"name":"Brevicon"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00501683","briefTitle":"A Single Dose Of GSK189075 Taken By Mouth Containing Small Amounts Of Radioactivity Studied In Healthy Male Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Radiolabelled GSK189075"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00501397","briefTitle":"A Study of the Effects of Ketoconazole Taken Orally Has on the PK Profiles of a Dose of GSK189075 in Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ketoconazole"},{"name":"GSK189075"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02310724","briefTitle":"TODAY2 Phase 2 Follow-up"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"},{"name":"National Eye Institute (NEI)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TODAY cohort"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04905589","briefTitle":"Medium Chain Triglycerides (MCT) and Whey Protein Isolate (WPI) for Type 2 Diabetes Patients (Combine)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Société des Produits Nestlé (SPN)"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BetaQuik™"},{"name":"WheyBasics"},{"name":"Iso-voluminous water"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00570466","briefTitle":"Computer Based Intervention for Type 2 Diabetes in Youth"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},"collaborators":[{"name":"Baylor College of Medicine"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Video Games"},{"name":"Web and DVD knowledge"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00497198","briefTitle":"Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MCI-196"},{"name":"Placebo of MCI-196 Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01497522","briefTitle":"Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01515657","briefTitle":"Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"PLx Pharma"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PL2200 Aspirin Capsules"},{"name":"Immediate-Release Aspirin Tablets"},{"name":"Enteric-coated aspirin caplets"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00985361","briefTitle":"Effect of Vitamin D Supplementation on Hemoglobin A1c in Patients With Uncontrolled Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"ProMedica Health System"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin D3 2000 international units daily"},{"name":"Vitamin C 500mg daily"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00361738","briefTitle":"Dose-Ranging Study Evaluating AVE2268 in Patients With Type 2 Diabetes Not Adequately Controlled by a Metformin Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AVE2268"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01187069","briefTitle":"A Practice-nurse Addressed Intervention to Improve Type 2 Diabetes Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"TrygFonden, Denmark"},{"name":"Sygekassernes Helsefond"},{"name":"Lundbeck Foundation"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Training course for practice nurses in autonomy support"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02053272","briefTitle":"A Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jazz Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GWP42004"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01499082","briefTitle":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HOE901-U300 (new formulation of insulin glargine)"},{"name":"Lantus (insulin glargine)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00276939","briefTitle":"Plant-Based Dietary Intervention in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Physicians Committee for Responsible Medicine"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"Diabetes Action Research and Education Foundation"},{"name":"George Washington University"},{"name":"University of Toronto"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low-fat, low-Glycemic Index, vegan diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00482729","briefTitle":"MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin phosphate (+) metformin hydrochloride"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01243424","briefTitle":"CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"linagliptin"},{"name":"glimepiride"},{"name":"linagliptin placebo"},{"name":"glimepiride placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04654676","briefTitle":"DPP4 Inhibitor on Glycemic Variability"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Malaysia Sarawak"},"collaborators":[{"name":"Sarawak General Hospital"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00266253","briefTitle":"A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GK Activator (2)"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03138447","briefTitle":"A Digital Health Tool for Insulin Titration (DHIT) Individuals With Type 2 Diabetes: A Prospective Outcomes Study With a Retrospective Control Group"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Amalgam Rx, Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Basal Insulin Titration Application"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02333734","briefTitle":"Investigation of the Effect of 8-week Controlled High Intense Interval Training in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aarhus University Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physical training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01697592","briefTitle":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omarigliptin"},{"name":"Matching placebo to omarigliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01555164","briefTitle":"A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gilead Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ranolazine"},{"name":"Placebo to match ranolazine"},{"name":"Metformin"},{"name":"Placebo to match metformin"},{"name":"Diet"},{"name":"Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00516074","briefTitle":"A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01871415","briefTitle":"A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"aleglitazar"},{"name":"metformin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03164538","briefTitle":"A Psychological-behavioral Intervention to Increase Activity in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Massachusetts General Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Positive Psychology + Motivational Interviewing"},{"name":"Diabetes Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03180710","briefTitle":"A Trial to Investigate the Dose-linearity of BioChaperone® Combo 75/25 and the Safety at Three Different Doses in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Adocia"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BioChaperone® Combo 75/25 at 0.6 U/kg"},{"name":"BioChaperone® Combo 75/25 at 0.8 U/kg"},{"name":"BioChaperone® Combo 75/25 at 1.0 U/kg"},{"name":"Humalog® Mix25 at 0.8 U/kg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04132934","briefTitle":"Observational Study of Effectiveness and Tolerability of Gliclazide MR 60mg in Diabetic Patients Fasting During RAMADAN"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Servier Affaires Médicales"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00333723","briefTitle":"AVANDIA With Glyburide In African American And Hispanic Patients With Type 2 Diabetes Not Controlled by Glyburide Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00838916","briefTitle":"A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"albiglutide"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04279444","briefTitle":"Effects of BKR-017 on Insulin Resistance in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"BioKier Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BKR-017"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02881164","briefTitle":"Glycemic Index in Subjects With Diabetes Mellitus Insulin Requesting"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidad de Valparaiso"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low glycemic index"},{"name":"High glycemic index"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03202563","briefTitle":"Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LG Chem"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gemigliptin 50mg"},{"name":"Dapagliflozin 10mg"},{"name":"Diet/exercise questionnaire"},{"name":"Continuous Glucose Monitoring System(CGMS)"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00390520","briefTitle":"Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01010035","briefTitle":"Cholesterol Metabolism and Lipid Transfer in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Sao Paulo General Hospital"},"collaborators":[{"name":"Fundação de Amparo à Pesquisa do Estado de São Paulo"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Plasma kinetic study"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02273050","briefTitle":"Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin 5 mg"},{"name":"Placebo 5 mg for Saxagliptin"},{"name":"Placebo 500 mg for metformin (with titration)"},{"name":"Metformin 500 mg with titration"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01729403","briefTitle":"A Study of The Effect of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"aleglitazar"},{"name":"metformin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02081586","briefTitle":"mHealth Skill Enhancement Plus Phone CBT for Type 2 Diabetes Distress Medication Nonadherence: Pilot Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pittsburgh"},"collaborators":[{"name":"National Institutes of Health (NIH)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CBT"},{"name":"Smartphone app"},{"name":"Standard Diabetes Care at PCP"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03168633","briefTitle":"Lifestyle Advises Sent Via Email in Attempt of Improving A1C in DM2 Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rambam Health Care Campus"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"web-based DM2 information pages"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01368081","briefTitle":"Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"BI 10773"},{"name":"Placebo (low dose)"},{"name":"BI 10773"},{"name":"Placebo (high dose)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03596450","briefTitle":"Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"},{"name":"Standard of care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00099957","briefTitle":"A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02855684","briefTitle":"Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine (U300)"},{"name":"Insulin glargine"},{"name":"Non-insulin antihyperglycemic drugs"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01159938","briefTitle":"A Study of Postprandial Hyperglycemia in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lispro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00287404","briefTitle":"Measuring Cholesterol in the Fasting and Postmeal State in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of North Carolina"},"collaborators":[{"name":"LipoScience, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02630706","briefTitle":"A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ertugliflozin 5 mg"},{"name":"Ertugliflozin 15 mg"},{"name":"Placebo matching ertugliflozin"},{"name":"Metformin"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02868788","briefTitle":"Anti-inflammatory Effects of the Fiber"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University at Buffalo"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"dietary fiber"},{"name":"HFHC meal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00901979","briefTitle":"A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LCQ908A"},{"name":"LCQ908A"},{"name":"LCQ908A"},{"name":"LCQ908A"},{"name":"LCQ908A"},{"name":"Placebo"},{"name":"Sitagliptin"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00147758","briefTitle":"WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Colesevelam hydrochloride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00147719","briefTitle":"WelChol® With Metformin in Treating Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Colesevelam hydrochloride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03648281","briefTitle":"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02413398","briefTitle":"A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin 10 mg"},{"name":"Matching Placebo for Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00101712","briefTitle":"Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild Hyperglycemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"},{"name":"Vildagliptin Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04285554","briefTitle":"Evaluation of the Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Metavention"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"iRF System Hepatic Denervation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03095651","briefTitle":"Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK-5160 16 nmol/kg"},{"name":"MK-5160 32 nmol/kg"},{"name":"MK-5160 64 nmol/kg"},{"name":"Glargine 0.4 U/kg"},{"name":"Placebo to Glargine"},{"name":"Placebo to MK-5160"},{"name":"Dextrose"},{"name":"Glargine 0.6 U/kg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02863328","briefTitle":"Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"empagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01626053","briefTitle":"The Efficacy and Treatment Adherence With an Integrated Program on HbA1c Scores in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"KRJG Services Inc."},"collaborators":[{"name":"K21 Health Foundation"},{"name":"Kosciusko County Health Department"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ASMART"},{"name":"Control Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00449930","briefTitle":"Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin phosphate"},{"name":"Comparator: metformin hydrochloride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02104804","briefTitle":"Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin 5mg"},{"name":"Placebo for Saxagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00941447","briefTitle":"Development of Self-Regulation in Individuals With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Tennessee, Knoxville"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"Abbott Diabetes Care"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dietary"},{"name":"Physical Activity"},{"name":"Self-Regulatory Approaches"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02836704","briefTitle":"Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INSULIN GLARGINE"},{"name":"metformin"},{"name":"acarbose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03848793","briefTitle":"A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jiangsu HengRui Medicine Co., Ltd."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HS-20004"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03952728","briefTitle":"The Long-term Effects of an Intensive Lifestyle Intervention for Type 2 Diabetes on Medicare Outcomes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Minnesota"},"collaborators":[{"name":"University of Southern California"},{"name":"Wake Forest University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intensive lifestyle intervention"},{"name":"Diabetes support and education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01438814","briefTitle":"Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"metformin placebo"},{"name":"linagliptin placebo"},{"name":"metformin"},{"name":"metformin"},{"name":"linagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00272064","briefTitle":"ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glulisine"},{"name":"Insulin glargine"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03437902","briefTitle":"Impact of Rutin and Vitamin C Combination on Oxidative Stress, Insulin Sensitivity and Lipid Profile in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ain Shams University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rutin in combination with Vitamin C"},{"name":"Vitamin C"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04692415","briefTitle":"Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Split, School of Medicine"},"collaborators":[{"name":"Pavle Vrebalov Cindro"},{"name":"Jonatan Vuković"},{"name":"Darko Modun"},{"name":"Božo Smajić"},{"name":"Gordan Kardum"},{"name":"Tina Tičinović Kurir"},{"name":"Doris Rušić"},{"name":"Ana Šešelja Perišin"},{"name":"Josipa Bukić"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Degludec"},{"name":"Glargine U300"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01057628","briefTitle":"A Study to Assess the Efficacy and Safety of ASP1941 in Japanese Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ipragliflozin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02911792","briefTitle":"Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Metformin"},{"name":"Glipizide 5 MG"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01037647","briefTitle":"VLDL-triglyceride Kinetics in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"The Danish Medical Research Council"},{"name":"The Novo Nordic Foundation"},{"name":"The Danish Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hyperinsulinemic euglycemic glucose clamp"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04163757","briefTitle":"The Effects of Crocin Supplementation on Metabolic Parameters, Oxidative Stress, AMP- Activated Protein Kinase and Inflammation-promoting Genes Expression in Peripheral Blood Mononuclear Cells in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Nutrition and Food Technology Institute"},"collaborators":[{"name":"Vahideh Behrouz"},{"name":"Ali Dastkhosh"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"crocin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06059326","briefTitle":"Multiple-dose Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of HSK7653 in T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Haisco Pharmaceutical Group Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HSK7653 10 mg"},{"name":"HSK7653 25 mg"},{"name":"HSK7653 50 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03305822","briefTitle":"A Study of LY900014 in Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY900014"},{"name":"Insulin Lispro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02638805","briefTitle":"Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Intarcia Therapeutics"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ITCA 650 Osmotic Mini Pump 20/60 mcg/day"},{"name":"ITCA 650 Osmotic Mini Pump 60 mcg/day"},{"name":"Metformin"},{"name":"Liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03226210","briefTitle":"Comparison of Efficacy and Safety of Prandilin and NovoRapid in Newly Diagnosed Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nanjing First Hospital, Nanjing Medical University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"aspart insulin or lipro insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00279201","briefTitle":"The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine"},{"name":"Lispro Low Mix"},{"name":"Lispro Mid Mix"},{"name":"Lispro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00351507","briefTitle":"A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03890900","briefTitle":"T2DXcel Mobile Application"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Montefiore Medical Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"T2DXcel mobile application"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02830048","briefTitle":"Low dosE GlibENclamide in Diabetes Part A"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Oxford"},"collaborators":[{"name":"Oxford University Hospitals NHS Trust"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glibenclamide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03616171","briefTitle":"A Sleep Intervention (SLEEP-Extend) for Young Adults At-Risk for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SLEEP-Extend intervention"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02415556","briefTitle":"Memory Aid by Intranasal Insulin in Diabetes (MemAID)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Beth Israel Deaconess Medical Center"},"collaborators":[{"name":"Novo Nordisk A/S"},{"name":"Medtronic"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Regular Human Insulin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00519142","briefTitle":"Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Elixir Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo for mitiglinide"},{"name":"mitiglinide"},{"name":"mitiglinide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04665570","briefTitle":"A Study to Learn More About How Acarbose and Metformin Work When Taken Together and How Safe They Are in Indian Patients Who Were Recently Diagnosed With Type 2 Diabetes (T2D)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BAY81-9783 (Acarbose/Metformin)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01593215","briefTitle":"Randomized Study of Yohimbine Treatment for Type 2 Diabetes Patients Carrying a Specific Genetic Risk Variant"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Anders Rosengren, MD PhD"},"collaborators":[{"name":"Region Skane"},{"name":"Lund University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Yohimbine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02551900","briefTitle":"A Comparison of the Effect of Warm and Cold Water Exercise Training on Vascular Function in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chulalongkorn University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Warm water exercise"},{"name":"Cold water exercise"},{"name":"Land based cycling exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01324921","briefTitle":"Effect of Nutritional Products on Metabolic Parameters in Subjects With Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Nutrition"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No breakfast/beverage only"},{"name":"Breakfast"},{"name":"10004RF"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03610412","briefTitle":"Cinnamomum Cassia Effect on IGF1 and Metabolic Control in Patients With DM2 Without Glycemic Control Metformin Treated"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Coordinación de Investigación en Salud, Mexico"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cinnamomum Cassia"},{"name":"Placebo (calcined magnesia)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01938521","briefTitle":"Effects of Red Grape Cells (RGC) Powder in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tel Aviv University"},"collaborators":[{"name":"Wolfson Medical Center"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Red Grape Cells (RGC)"},{"name":"Placebo (for Red Grape Cells (RGC))"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02355145","briefTitle":"Non-inteRvEntional Study to Observe rAtionaLe to Select add-on TherapY for Type 2 Diabetes Inadequately Controlled With Metformin."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02049034","briefTitle":"Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Surrey"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05221580","briefTitle":"China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ryzodeg®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00707954","briefTitle":"Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TA-7284"},{"name":"Placebo of TA-7284"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01086189","briefTitle":"Does Green Tea Affect Postprandial Glucose, Insulin and Satiety in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Skane University Hospital"}},"conditionsModule":{"conditions":["Diabetes Type 2","Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01413542","briefTitle":"Pharmacogenetics of Ace Inhibitor-Associated Angioedema"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University"}},"conditionsModule":{"conditions":["Hypertension","Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin (DPP4 inhibitor)"},{"name":"Substance P,"},{"name":"bradykinin"},{"name":"enalaprilat (ACE inhibitor)"},{"name":"Glucagon-like peptide 1"},{"name":"brain natriuretic peptide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01499108","briefTitle":"Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Peter Rossing"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00260156","briefTitle":"A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01951235","briefTitle":"A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Poxel SA"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Imeglimin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00321321","briefTitle":"The Beta Cell Responsiveness to Glucose-dependent Insulinotropic Polypeptide (GIP) With and Without Sulfonylurea in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sulfonylurea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02292290","briefTitle":"Trial for People With Established Type 2 Diabetes During Ramadan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Leicester"},"collaborators":[{"name":"University Hospitals, Leicester"},{"name":"University Hospital Birmingham"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Liraglutide"},{"name":"Sulfonylurea or Pioglitazone"},{"name":"Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00849017","briefTitle":"Safety and Efficacy Study of Albiglutide in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"albiglutide"},{"name":"albiglutide uptitration"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00984750","briefTitle":"Acetyl-L-Carnitine in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mario Negri Institute for Pharmacological Research"},"collaborators":[{"name":"Leadiant Biosciences, Inc."}]},"conditionsModule":{"conditions":["Diabetes Type 2","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"acetyl-L-carnitine/statin (simvastatin)"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02686177","briefTitle":"Effect of GLP-1 on Angiogenesis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Assistance Publique - Hôpitaux de Paris"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Metformin or sulfonylurea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00618007","briefTitle":"Effect of PF-00734200 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-00734200 30 mg QD"},{"name":"PF-00734200 20 mg QD"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00308139","briefTitle":"Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide, long acting release"},{"name":"exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01264497","briefTitle":"Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Theratechnologies"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TH9507"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04760626","briefTitle":"A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin icodec"},{"name":"Insulin Glargine 100U/mL"},{"name":"Insulin Degludec"},{"name":"Insulin Glargine 300U/mL"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01128621","briefTitle":"A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK1292263"},{"name":"GSK1292263 matching placebo"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00099905","briefTitle":"A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00111540","briefTitle":"Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01986881","briefTitle":"Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ertugliflozin"},{"name":"Placebo"},{"name":"Glycemic Rescue"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00906919","briefTitle":"The Effectiveness of Diabetes Patient Education and Self-Management Education in Persons With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Victoria"},"collaborators":[{"name":"Vancouver Foundation"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Regular diabetes patient education"},{"name":"Augmented diabetes patient education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01153048","briefTitle":"Trial on an Educative Structured Intervention by Peer Educators to Improve HbA1c of Patients With Type 2 Diabetes in the Sikasso Region in Mali"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sante Diabete Mali"},"collaborators":[{"name":"Société Francophone du Diabète"},{"name":"French Development Agency"},{"name":"Centre hospitalo-universiaire du Point G de Bamako (CHU Pt G)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intensification of education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00315718","briefTitle":"Long-Term Effects of Sucontral(TM) on Mild and Moderate Cases of Diabetes Mellitus (Type 2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Harras Pharma Curarina GmbH"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Extract from Hintonia latiflora bark"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00753181","briefTitle":"Effects of Nutritional Products on Blood Glucose in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Nutrition"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nutritional Formula"},{"name":"Usual diet"},{"name":"Diabetes Meal Plan with experimental diabetes-specific nutritional shake, diabetes specific cereal, and diabetes specific snack bars."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05668442","briefTitle":"Feasibility of an Online Exercise Community Among Individuals With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mathias Ried-Larsen"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Type2diabetes","Diabetes Mellitus, Type 2","Type2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Online exercise and group meetings"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00998335","briefTitle":"Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Florida"},"collaborators":[{"name":"VA Office of Research and Development"},{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Long-acting bedtime insulin detemir (Levemir)"},{"name":"Insulin detemir and pre-meal insulin aspart."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01811485","briefTitle":"Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LMF237 50/250 mg"},{"name":"LMF237 50/500 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00138580","briefTitle":"Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02827669","briefTitle":"One Drop Experts Program for Type 2 Diabetes Self-Management: Impact on A1c"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Evidation Health"},"collaborators":[{"name":"One Drop"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"One Drop Experts Program"},{"name":"One Drop Experts Program + Apple Watch"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03509324","briefTitle":"Effectiveness of Glucose Control, β Cell Function in Response to Short-term Insulin Pump Therapy in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sun Yat-sen University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin LISPRO"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05822674","briefTitle":"Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Diyala"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin/metformin ( 50/500mg) Oral Tablet"},{"name":"Empagliflozin/metformin(10/500mg) Oral Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01847144","briefTitle":"MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Royal Devon and Exeter NHS Foundation Trust"},"collaborators":[{"name":"University of Exeter"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gliclazide 80mg OD"},{"name":"Sitagliptin 100mg OD"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04219215","briefTitle":"Acute Hyperbaric Oxygen Treatment Increases Hepatic Insulin Sensitivity and Muscle Reactive Oxygen Species in T2D"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"German Diabetes Center"}},"conditionsModule":{"conditions":["Type 2-diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"100% O2 in oxygen chamber"},{"name":"21% O2 in oxygen chamber"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03170544","briefTitle":"Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK-1092, 4.0 nmol/kg"},{"name":"MK-1092, 8.0 nmol/kg"},{"name":"MK-1092, 16 nmol/kg"},{"name":"MK-1092, 32 nmol/kg"},{"name":"MK-1092, 64 nmol/kg"},{"name":"Glargine 3.0 nmol/kg"},{"name":"Lispro 1.2 nmol/kg"},{"name":"Placebo to glargine"},{"name":"Placebo to MK-1092"},{"name":"Dextrose"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01760447","briefTitle":"A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin plus metformin"},{"name":"Placebo to metformin"},{"name":"Metformin"},{"name":"Placebo to sitagliptin plus metformin"},{"name":"Sitagliptin plus metformin XR"},{"name":"Placebo to metformin XR"},{"name":"Insulin"},{"name":"Placebo to sitagliptin plus metformin XR"},{"name":"Metformin XR"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00106704","briefTitle":"Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Comparator: Sitagliptin"},{"name":"Comparator: Placebo"},{"name":"Comparator: Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04577274","briefTitle":"Impact of High Protein and Low Carbohydrate Smoothie Drinks in Type-2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mahidol University"},"collaborators":[{"name":"National Research Council of Thailand"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"smoothie with regular formulas (SM)"},{"name":"smoothie with low carbohydrate formulas (SMLS)"},{"name":"conventional diabetic enteral drinks (Glucerna)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01040468","briefTitle":"Surgery Or Lifestyle Intervention for Type 2 Diabetes (SOLID)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pennsylvania"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Roux-en-Y Gastric Bypass surgery"},{"name":"Laparoscopic Adjustable Gastric Banding surgery"},{"name":"Intensive Lifestyle Modification"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00380380","briefTitle":"A Study to Assess the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00635492","briefTitle":"CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"any human insulin or analog insulin(s) given in any regimen by subcutaneous injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01541956","briefTitle":"Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00792935","briefTitle":"A Study to Test MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-0941-017)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK-0941"},{"name":"Glimepiride"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01128205","briefTitle":"Nationwide Assessment of Cardiovascular Risk Factors: in Chinese Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"China Cardiometabolic Registries"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"},{"name":"China Gerontological Society"},{"name":"VitalStrategic Research Institute"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01044017","briefTitle":"A Study of Single Doses of RO4998452 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"RO4998452"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01154348","briefTitle":"Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shionogi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"S-707106"},{"name":"Placebo"},{"name":"Metformin, S-707106 plus metformin"},{"name":"Metformin, placebo plus metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01790438","briefTitle":"A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2605541"},{"name":"Human Insulin NPH"},{"name":"Oral Antihyperglycemic Medications (OAM)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00239187","briefTitle":"A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"OPKO Health, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"E1 and G1"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02887898","briefTitle":"Efficacy of Automated Bolus Calculation in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hvidovre University Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Automated bolus calculator"},{"name":"Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00127192","briefTitle":"A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin phosphate"},{"name":"Comparator: placebo (unspecified)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03452085","briefTitle":"The Artificial Saliva Spray Reduces Xerostomia in Diabetes Type II"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Certmedica International GmbH"}},"conditionsModule":{"conditions":["Xerostomia Due to Hyposecretion of Salivary Gland","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"artificial saliva spray (AS)"},{"name":"maritime throat spray (TT)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05409924","briefTitle":"First-in-human Single and Multiple Dose Trial of ATR-258"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Atrogi AB"},"collaborators":[{"name":"Key2Compliance"},{"name":"CRS Clinical Research Services"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ATR-258"},{"name":"ATR-258"},{"name":"ATR-258"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01417845","briefTitle":"The Effect of Exercise Training Intensity in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Central Arkansas"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High Intensity Exercise Training"},{"name":"Moderate Intensity Exercise Training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03223129","briefTitle":"Insulin Sensitivity and Metabolomics During Oral Administration of Glucose and Graded Intravenous Infusion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Catholic University of the Sacred Heart"},"collaborators":[{"name":"Steno Diabetes Center Copenhagen"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral glucose tolerance test"},{"name":"Graded intravenous glucose infusion"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02489968","briefTitle":"Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"empagliflozin 10 mg + linagliptin 5 mg"},{"name":"empagliflozin 10 mg"},{"name":"empagliflozin 25 mg + linagliptin 5 mg"},{"name":"empagliflozin 25 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02533453","briefTitle":"A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bydureon"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03687827","briefTitle":"A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin degludec"},{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01386671","briefTitle":"Metformin Glycinate on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Laboratorios Silanes S.A. de C.V."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin glycinate"},{"name":"Metformin hydrochloride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02948777","briefTitle":"Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Marja-Riitta Taskinen"},"collaborators":[{"name":"Göteborg University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Evolocumab"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00138606","briefTitle":"Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00138554","briefTitle":"Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"},{"name":"pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00138541","briefTitle":"Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00138515","briefTitle":"Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00106808","briefTitle":"Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristol-Myers Squibb"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Muraglitazar"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00783744","briefTitle":"Insulin Glargine Combination Therapies in Type II Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine"},{"name":"Glimepiride"},{"name":"Metformin"},{"name":"Insulin monotherapy with premixed insulin NPH 30/70"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04891887","briefTitle":"Diabetes Mellitus and microRNA as Risk Factors for Mild Cognitive Impairment: Impact of Life Style Modification"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Research Centre, Egypt"},"collaborators":[{"name":"Science and Technology Development Fund (STDF)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Health education program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05132335","briefTitle":"A Repeatability Study of Fatty Acid Uptake Using PET/MR Imaging in Patients With T2DM and Non-diabetic Control Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Turku University Hospital"},"collaborators":[{"name":"Antaros Medical"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Imaging Biomarkers"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02058160","briefTitle":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine/lixisenatide (HOE901/AVE0010)"},{"name":"Insulin glargine (HOE901)"},{"name":"Metformin (Background Drug)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05256706","briefTitle":"SomaSignal Tests on Medical Management and Change in Risk in Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"},"collaborators":[{"name":"SomaLogic, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SomaSignal Informed Medical Management SSCVD"},{"name":"Standard of Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04120259","briefTitle":"Effect of Apple Cider Vinegar and Metformin Combination vs Metformin Alone in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ziauddin University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin Oral Tablet"},{"name":"Vinegar"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04446026","briefTitle":"A Randomized, Placebo-controlled Clinical Trial of Teneligliptin as Quadruple Oral Combination Therapy for Type 2 DM After Failure of an Oral Triple Anti-diabetic Regimen"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yonsei University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"teneligliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03430310","briefTitle":"Return of First-phase Insulin Secretion in Type 2 Diabetes is Associated With Depletion of Pancreas Lipid"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alabama at Birmingham"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low Glycemic Diet"},{"name":"Control Diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03365180","briefTitle":"Starter Kit Study in Insulin naïve Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Signe Schmidt"},"collaborators":[{"name":"Technical University of Denmark"},{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Starter Kit Algorithm"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01649297","briefTitle":"A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"empagliflozin (low dose qd)"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Empagliflozin (high dose qd)"},{"name":"empagliflozin (high dose bid)"},{"name":"Placebo"},{"name":"empagliflozin (low dose bid)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00972322","briefTitle":"Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK-8245"},{"name":"Comparator: placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01654341","briefTitle":"Multi-Modal Intervention In Frail And Prefrail Older People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital Universitario Getafe"},"collaborators":[{"name":"Cardiff University"},{"name":"Igen Biotech SL"},{"name":"University Hospital, Bordeaux"},{"name":"Hexabio Sarl"},{"name":"University of Campania \"Luigi Vanvitelli\""},{"name":"University Hospital, Toulouse"},{"name":"University of Ulm"},{"name":"University Ghent"},{"name":"University of Castilla-La Mancha"},{"name":"Univerzita Karlova v Praze"},{"name":"Niche Science & Technology Ltd"},{"name":"Catholic University of the Sacred Heart"},{"name":"Vrije Universiteit Brussel"},{"name":"Diabetes Frail Ltd"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise, dietary and educational program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02119819","briefTitle":"A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"OPKO Health, Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2944876"},{"name":"Exenatide extended-release"},{"name":"Placebo"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05324462","briefTitle":"Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IDegLira"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05013229","briefTitle":"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IcoSema"},{"name":"Insulin glargine"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00305604","briefTitle":"Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin phosphate"},{"name":"Comparator: Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01901861","briefTitle":"Effect of the DPP-4 Inhibitor Sitagliptin on Islet Function After Mixed Meal in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lund University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03076112","briefTitle":"Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Bundang Hospital"},"collaborators":[{"name":"Astellas Pharma Korea, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ipragliflozin"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01652716","briefTitle":"Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide once weekly suspension"},{"name":"Exenatide twice daily"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02057172","briefTitle":"Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hanmi Pharmaceutical Company Limited"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HM11260C"},{"name":"liraglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02832999","briefTitle":"Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yaounde Central Hospital"},"collaborators":[{"name":"University of Yaounde 1"},{"name":"University of Buea"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sub cutaneous liraglutide"},{"name":"Oral Vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01824017","briefTitle":"Validation of an RLIP76 Assay in Humans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"City of Hope Medical Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Blood Draw"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00094991","briefTitle":"Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristol-Myers Squibb"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Muraglitazar"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04712916","briefTitle":"Pharmacist-led Intervention in Treatment Non-adherence in Southwestern Nigeria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Ibadan"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Health education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01409213","briefTitle":"A Study of the Current Medical Practice and Outcomes in the Treatment of Type 2 Diabetes Mellitus in an Office Setting (MK-0431-199)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02235298","briefTitle":"Dapagliflozin Effects on Epicardial Fat"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Miami"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05654831","briefTitle":"FTIH of ECC5004 in Healthy and Diabetic Participants"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eccogene"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"ECC5004"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01958671","briefTitle":"A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ertugliflozin 5 mg"},{"name":"Ertugliflozin 10 mg"},{"name":"Placebo to Ertugliflozin"},{"name":"Metformin"},{"name":"Placebo to Metformin"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01940965","briefTitle":"Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"lixisenatide AVE0010"},{"name":"biguanide"},{"name":"TZD"},{"name":"alpha-GI"},{"name":"glinide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05135676","briefTitle":"Time in Glucose Hospital Target"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jaeb Center for Health Research"},"collaborators":[{"name":"DexCom, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Blinded CGM"},{"name":"real-time CGM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05476016","briefTitle":"Safety and Performance of the Glyconics-SX System (ANODE02)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Glyconics Ltd"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Near-infrared (NIR)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02895867","briefTitle":"Effect of Dairy Consumption on Glycemic Control, Body Weight and Cardiovascular Risk in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Joslin Diabetes Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Full fat dairy"},{"name":"Low fat dairy"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03092752","briefTitle":"Clinical Characteristics and Practice Patterns of Type 2 Diabetes Mellitus Patients Treated With OADs in Japan: Analysis of Medical and Health Care Database of the MDV"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"oral antidiabetic drugs"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01883258","briefTitle":"Effect of Aerobic Interval Training on Cardiovascular Function in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Florida"},"collaborators":[{"name":"National Institute on Aging (NIA)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High intensity aerobic interval training"},{"name":"Continuous moderate intensity exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01755468","briefTitle":"Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Pilot Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mount Sinai Hospital, Canada"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intermittent insulin therapy"},{"name":"Continuous metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02506296","briefTitle":"Glucose Response, Excursions And Treatment (GREAT) Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Royal Devon and Exeter NHS Foundation Trust"},"collaborators":[{"name":"NIHR Exeter Clinical Research Facility"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DPPIV inhibitor -"},{"name":"Continuous glucose monitoring system."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01736865","briefTitle":"Vitamin D for Established Type 2 Diabetes (DDM2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tufts Medical Center"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cholecalciferol"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00368134","briefTitle":"To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00789750","briefTitle":"Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Colesevelam"},{"name":"Placebo"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02748239","briefTitle":"Evaluation of a Diabetes Self-Management Education Program for Non-Intensified Insulin Therapy in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Forschungsinstitut der Diabetes Akademie Mergentheim"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MEDIAS 2 CT"},{"name":"Current CT program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01822548","briefTitle":"Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Azienda Ospedaliero-Universitaria di Parma"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"Glibenclamide"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00138619","briefTitle":"Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00138567","briefTitle":"Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04149067","briefTitle":"Study of Real-world Evidence With SGLT2i (Dapagliflozin) and DPP4i (Sitagliptin) in Type 2 Diabetes Patients in Spain"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01043965","briefTitle":"Myocardial Perfusion in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Sao Paulo General Hospital"},"collaborators":[{"name":"Fundação de Amparo à Pesquisa do Estado de São Paulo"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01529528","briefTitle":"A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"JW Pharmaceutical"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Anagliptin"},{"name":"Anagliptin"},{"name":"Placebo of Anagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01276288","briefTitle":"Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 10773"},{"name":"hydrochlorothiazide"},{"name":"torasemide"},{"name":"BI 10773"},{"name":"torasemide"},{"name":"BI 10773"},{"name":"hydrochlorothiazide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01144338","briefTitle":"Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide Once Weekly"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01511900","briefTitle":"A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Catabasis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CAT 1004"},{"name":"Placebo"},{"name":"CAT 1004"},{"name":"CAT 1004"},{"name":"CAT 1004"},{"name":"CAT 1004"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01333592","briefTitle":"Long-term Study of KAD-1229 in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kissei Pharmaceutical Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"KAD-1229"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01472341","briefTitle":"Beta-Cell Dysfunction and Insulin Resistance Among Italian Patients With Type 2 Diabetes (MK-0000-113)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00330330","briefTitle":"Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ionis Pharmaceuticals, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ISIS 113715"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02314637","briefTitle":"Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Teneligliptin"},{"name":"Teneligliptin + Sulfonylurea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02623998","briefTitle":"Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Population Health Research Institute"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glargine"},{"name":"sitagliptin/metformin"},{"name":"lifestyle therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00455598","briefTitle":"Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ionis Pharmaceuticals, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ISIS 113715"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00372463","briefTitle":"Internet Diabetes Self-Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Robert Wood Johnson Foundation"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"6-week Online Diabetes Self-Management Educational Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01290575","briefTitle":"Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristol-Myers Squibb"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Placebo"},{"name":"BMS-820132"},{"name":"BMS-820132"},{"name":"BMS-820132"},{"name":"BMS-820132"},{"name":"BMS-820132"},{"name":"BMS-820132"},{"name":"BMS-820132"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04025281","briefTitle":"Post-prandial Effects of Extra Virgin Olive Oil on Endothelial Function in Adults at Risk for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Griffin Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Extra Virgin Olive Oil"},{"name":"Refined Olive Oil"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01813708","briefTitle":"Intensive Life-Style Intervention in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Coordinación de Investigación en Salud, Mexico"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intensive Life-Style"},{"name":"Collaborative Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00351832","briefTitle":"A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01703221","briefTitle":"Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omarigliptin"},{"name":"Sitagliptin"},{"name":"Placebo to omarigliptin"},{"name":"Placebo to sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00903500","briefTitle":"Controlled Outcome Evaluations of a Daily Physical Activity Intervention for Individuals With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Ghent"},"collaborators":[{"name":"BOF"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Daily physical activity, pedometer and counseling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01656850","briefTitle":"The Effect of Whole Almonds on Biomarkers of Cardiovascular Disease in Chinese Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Taipei Medical University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Almond diet first, then NCEP Diet"},{"name":"NCEP diet first, then Almond diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00499148","briefTitle":"Efficacy Study Testing Herbal Extract on Metabolic Parameters in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Nutrition"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"herbal extract; root of woody shrub grown in India/Sri-Lanka"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00138593","briefTitle":"Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11%"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01087567","briefTitle":"INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ohio University"},"collaborators":[{"name":"Western University of Health Sciences"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intensive insulin"},{"name":"Routine Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03711682","briefTitle":"Reducing Plasma Glucose Effect of Cinnamon in Type 2 Diabetic Patients in the Municipality of Comasagua"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidad Dr. José Matías Delgado"},"collaborators":[{"name":"Hospital Nacional Rosales"},{"name":"Unidad Comunitaria de Salud Familiar Intermedia de Comasagua (UCSFI-Comasagua)"},{"name":"Asociación Salvadoreña de Diabetes (ASADI)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cinnamon"},{"name":"Wheat Flour"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01182493","briefTitle":"OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medtronic Diabetes"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Pump (Medtronic Minimed Paradigm® VEO)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00717457","briefTitle":"A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"taspoglutide"},{"name":"taspoglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03778580","briefTitle":"Advanced Glycation Endproducts and Bone Material Strength in T2D Treated With Pyridoxamine"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Columbia University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pyridoxamine Dihydrochloride"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04098575","briefTitle":"A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01206712","briefTitle":"Beta Cell Relieving and Cardiovascular Protective Effects of LANTUS Treatment in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"ikfe-CRO GmbH"},"collaborators":[{"name":"Sanofi"},{"name":"IKFE Institute for Clinical Research and Development"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06483243","briefTitle":"Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02327429","briefTitle":"Pilot Test of a Chinese Menu Plan for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alberta"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"A Chinese menu plan for type 2 diabetes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00517283","briefTitle":"A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide and placebo"},{"name":"Exenatide and placebo"},{"name":"Exenatide and placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06192121","briefTitle":"Web-Based Education for Individuals With Type-2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Near East University, Turkey"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Web Based Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00191178","briefTitle":"Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin lispro protamine suspension:insulin lispro rDNA origin low mix"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01029886","briefTitle":"Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide once weekly"},{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01572415","briefTitle":"Evaluation of SCOUT DS Device in the Diagnosis of Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VeraLight, Inc."},"collaborators":[{"name":"Greece National Social Insurance Institute"},{"name":"Laikο General Hospital, Athens"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01689142","briefTitle":"Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine new formulation (HOE901)"},{"name":"Insulin glargine (HOE901)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02914743","briefTitle":"Providing Preventive Periodontal Treatment to Hospitalized Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Massachusetts General Hospital"},"collaborators":[{"name":"Harvard School of Dental Medicine"}]},"conditionsModule":{"conditions":["Type II Diabetes","Periodontal Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Motivational Interviewing"},{"name":"Dental cleaning"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00567905","briefTitle":"Effect of Green Tea Extract on Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Taipei Hospital, Taiwan"},"collaborators":[{"name":"National Science Council, Taiwan"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Green tea extract"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00994266","briefTitle":"Diamel in the Treatment of Type 2 Diabetic Patients Receiving Insulin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Catalysis SL"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diamel"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00609102","briefTitle":"Antioxidant Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"n-aceylcysteine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02917057","briefTitle":"Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide once weekly"},{"name":"basal insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01018017","briefTitle":"A Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT2104 Capsules Administered for 28 Days to Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"SRT2104"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00575874","briefTitle":"Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rivoglitazone HCl"},{"name":"rivoglitazone HCl"},{"name":"rivoglitazone HCl"},{"name":"pioglitazone HCl"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02112721","briefTitle":"Can Vitamin D Supplementation Prevent Type 2 Diabetes?"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Monash University"},"collaborators":[{"name":"University of Victoria"},{"name":"University of Auckland, New Zealand"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin D"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01176149","briefTitle":"Role Of Self-monitoring of Blood Glucose and Intensive Education in Patients With Type 2 Diabetes Not Receiving Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Consorzio Mario Negri Sud"},"collaborators":[{"name":"LifeScan"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SMBG plus intensive education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01334229","briefTitle":"Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Laval University"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02772926","briefTitle":"Benfotiamine Effect on Advanced Glycation End Products(AGEs) and Soluble Receptor for AGEs(sRAGE) in Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidad de Guanajuato"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Benfotiamine"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01396564","briefTitle":"Pioglitazone and Metformin in Diabetic Children"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Coordinación de Investigación en Salud, Mexico"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02752880","briefTitle":"YH1 in Poorly Controlled Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chang Gung Memorial Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"YH1 group"},{"name":"placebo group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00590226","briefTitle":"Insulin Detemir Versus NPH Insulin In Hospitalized Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Detemir + aspart insulin before meals"},{"name":"NPH insulin + regular insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04244110","briefTitle":"Pilot for the Analysis of Usability in the Use of the Diacare Platform for People With Type 2 DM and Their Professionals"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina"},"collaborators":[{"name":"Fundació TicSalut"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00976261","briefTitle":"A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK1614235"},{"name":"Sitagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00324363","briefTitle":"Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02288273","briefTitle":"Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bydureon"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00418522","briefTitle":"This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine"},{"name":"Inhaled Insulin (Exubera)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03752567","briefTitle":"New Patient Support Program in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Farmacia La Regina s.r.l."},"collaborators":[{"name":"Federfarma Campania"},{"name":"Federfarma Salerno"},{"name":"HTN - Health Telematic Network srl"},{"name":"BSI - Biochemical Systems International spa"},{"name":"Next Sight srl"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Follow up"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02811575","briefTitle":"Type 2 Diabetes and Alteration of Immune System of Intestinal Mucosa : Proof of Concept"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Toulouse"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Biopsy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03960814","briefTitle":"A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03675919","briefTitle":"TeLIPro Health Program - Active With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"West German Center of Diabetes and Health"},"collaborators":[{"name":"AOK Rheinland/Hamburg"},{"name":"German Institute for Telemedicine and Health Promotion"},{"name":"German Diabetes Center"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Scale"},{"name":"Step counter"},{"name":"Blood glucose meter with test stripes"},{"name":"Access to the online portal"},{"name":"Telemedical coaching"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05368454","briefTitle":"Evaluation of a Digital Diabetes Self-Management Education and Support Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Omada Health, Inc."},"collaborators":[{"name":"Abbott Diabetes Care"},{"name":"Evidation Health"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Online Diabetes Self-Management Education and Support (DSMES) Program"},{"name":"Standard of Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00330473","briefTitle":"A Concordance Study Comparing Insulin Treatments in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Human Insulin Inhalation Powder"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00663260","briefTitle":"Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Dapagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05544435","briefTitle":"Motivational Interviewing on Self-Care Activities in T2DM: The Sample of Turkey"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Erzurum Technical University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Motivational İnterviewing"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01420692","briefTitle":"The Effects of Insulin Detemir and Gliclazide-MR Treatments on Endothelial Functions in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ankara University"},"collaborators":[{"name":"Hacettepe University"},{"name":"The Scientific and Technological Research Council of Turkey"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gliclazide MR"},{"name":"Insulin Detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03529123","briefTitle":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)"},{"name":"INSULIN GLARGINE (HOE901)"},{"name":"Metformin"},{"name":"Insulin Glulisine (HMR1964)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02094846","briefTitle":"Evaluation of an Intervention Based on Cell Phones"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Instituto Nacional de Salud Publica, Mexico"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Voice messages"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01601990","briefTitle":"Phase 3 Trial to Evaluate the Efficacy and Safety of LC15-0444 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LG Life Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo group(once daily)"},{"name":"LC15-0444 50mg qd"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04032197","briefTitle":"A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"},{"name":"Placebo (semaglutide)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01984489","briefTitle":"Efficacy and Safety Study of SHR117887 in Combination With Metformin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jiangsu HengRui Medicine Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"SHR117887"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02388113","briefTitle":"Effect of Exercise Frequency on Metabolic Control and Heart Function in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Norwegian University of Science and Technology"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"accumulated exercise"},{"name":"traditional exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01315756","briefTitle":"Self-management in Type 2 Diabetes Patients Using the Few Touch Application"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital of North Norway"},"collaborators":[{"name":"Oslo University College"},{"name":"European Commission"},{"name":"The Research Council of Norway"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Use of Few Touch Application (FTA)"},{"name":"Use of FTA and health counseling based on TTM and CBT"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02311075","briefTitle":"Mechanisms of Endothelial Dysfunction in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Rouen"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Blood samples"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00560417","briefTitle":"Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Lispro Protamine Suspension"},{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05198895","briefTitle":"Safety and Performance of the Glyconics-SX System"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Glyconics Ltd"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Near-infrared (NIR)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01042106","briefTitle":"Safety, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Patients With Type 2 Diabetes Mellitus and Healthy Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sumitomo Pharma America, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DSP-8658"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01969318","briefTitle":"Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jiangsu HengRui Medicine Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo /Metformin"},{"name":"SP2086(50 mg q.d.)/Metformin"},{"name":"SP2086 (100 mg q.d.)/Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05423938","briefTitle":"Efficacy of Two ONS in Patients at Nutritional Risk With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud"},"collaborators":[{"name":"Adventia Pharma"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Malnutrition"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetic"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05210504","briefTitle":"Determinants of Alpha-aminoadipic Acid (2-AAA) and Relationship to Diabetes: Study 3"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University Medical Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"L-Lysine"},{"name":"Normal Saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01590797","briefTitle":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Placebo"},{"name":"Insulin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01590771","briefTitle":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Placebo"},{"name":"Gliclazide"},{"name":"Glimepiride"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03700801","briefTitle":"Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Zhujiang Hospital"},"collaborators":[{"name":"The Sixth Affiliated Hospital of Guangzhou Medical University"},{"name":"Third Affiliated Hospital, Sun Yat-Sen University"},{"name":"Peking University Shenzhen Hospital"},{"name":"Dongguan Kanghua Hospital"},{"name":"First People's Hospital, Shunde China"},{"name":"The First Affiliated Hospital of Guangdong Pharmaceutical University"},{"name":"The Fifth Affiliated Hospital of Zunyi Medical College"},{"name":"Shenzhen Sixth People's Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Triple combination therapy group"},{"name":"Premixed insulin therapy group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00642538","briefTitle":"A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mannkind Corporation"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MKC253 Inhalation Powder"},{"name":"Technosphere Inhalation Powder"},{"name":"subcutaneous injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01357252","briefTitle":"Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00603239","briefTitle":"Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00993824","briefTitle":"Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HealthPartners Institute"},"collaborators":[{"name":"International Diabetes Center at Park Nicollet"},{"name":"Daiichi Sankyo"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"colesevelam HCl"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00574912","briefTitle":"Characteristics of Glargine in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University Medical Center"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Insulin Glargine 0.5 u/kg body wt SC"},{"name":"Insulin Glargine 1.0 u/kg body wt SC"},{"name":"Insulin Glargine 1.5 u/kg body wt SC"},{"name":"Insulin Glargine 2.0 u/kg body wt SC"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00823992","briefTitle":"A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo"},{"name":"taspoglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04311853","briefTitle":"Evidence-Based Nutrition Practice Guidelines of Toolkit and Preliminary Outcomes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Academy of Nutrition and Dietetics"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03037528","briefTitle":"Examination of Psychological Tools and Tracking in an Online Intervention for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"diet and lifestyle program"},{"name":"positive affect informational materials"},{"name":"mindfulness informational materials"},{"name":"dietary tracking"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00744926","briefTitle":"A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo"},{"name":"taspoglutide"},{"name":"taspoglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03324451","briefTitle":"The Effectiveness of Intervention on Insulin Injection"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kaohsiung Medical University Chung-Ho Memorial Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TTM Intervention for Insulin Initiation"},{"name":"Usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00399724","briefTitle":"A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02751398","briefTitle":"Impact of Dapagliflozin on DIAstolic Dysfunction in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yonsei University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin 10mg"},{"name":"Placebo 10mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00846898","briefTitle":"Is There a Metabolic Effect of Cinnamon on HbA1c, Blood Pressure and Serum Lipids in Type 2 Diabetes Mellitus?"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Thames Valley University"},"collaborators":[{"name":"Wembley Health Care centre, NHS, UK."},{"name":"Monks Park Primary care centre, NHS UK."},{"name":"Willesden Health centre, NHS, UK."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"cinnamon 2g per day for 12 weeks"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03811587","briefTitle":"Clinical Feasibility and Efficacy of Intermittent Use of a Fasting Mimicking Diet in the Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Leiden University Medical Center"},"collaborators":[{"name":"Dutch Diabetes Research Foundation"},{"name":"Health Holland"},{"name":"IFOM ETS - The AIRC Institute of Molecular Oncology"},{"name":"L-Nutra"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fasting Mimicking diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01557504","briefTitle":"A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin/metformin XR"},{"name":"Placebo"},{"name":"Metformin"},{"name":"Thyroid hormone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00639613","briefTitle":"The Role of Small Intestinal Endocrine Cells in Type 2 Diabetic Hyperglucagonemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Double-balloon enteroscopy"},{"name":"Standard meal test"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01031108","briefTitle":"A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sirtris, a GSK Company"},"collaborators":[{"name":"GlaxoSmithKline"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"SRT2104"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02315495","briefTitle":"Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Zilin Sun"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Acarbose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01060059","briefTitle":"Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"basal insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01517321","briefTitle":"MK-0431/ONO-5435 Phase III Clinical Trial-Rapid-acting Insulin Secretagogue Add-on Study in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ono Pharmaceutical Co. Ltd"},"collaborators":[{"name":"MSD K.K."}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK-0431/ONO-5435"},{"name":"Placebo, MK-0431/ONO-5435"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04053959","briefTitle":"Artificial Intelligence Assisted Insulin Titration System"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Zhongshan Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AI assisted insulin system"},{"name":"Physician based insulin regime"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01757587","briefTitle":"Galvus (Vildagliptin) vs Placebo in Combination With Metformin and Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02317796","briefTitle":"Adult Subjects With Uncontrolled Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Melior Pharmaceuticals"},"collaborators":[{"name":"Bukwang Pharmaceutical, Co., Ltd."}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MLR-1023"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01462266","briefTitle":"Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Comparator: Placebo"},{"name":"Insulin Glargine"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01183104","briefTitle":"START-J: SiTAgliptin in eldeRly Trial in Japan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Japan Association for Diabetes Education and Care"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00849056","briefTitle":"Safety and Efficacy of Albiglutide in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"albiglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02736084","briefTitle":"Boosting Emotions & Happiness in Outpatients Living With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Massachusetts General Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Positive Psychology"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00813995","briefTitle":"A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Comparator: Sitagliptin phosphate"},{"name":"Comparator: Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02916706","briefTitle":"Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Teneligliptin 20mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01698775","briefTitle":"A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omarigliptin"},{"name":"Placebo to omarigliptin"},{"name":"Glipizide"},{"name":"Placebo to glipizide"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02122250","briefTitle":"Web-based Support for People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Southampton"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Interactive web-based materials"},{"name":"Static web-based materials"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04673656","briefTitle":"Dose-Response Study to Evaluate the Effect of BKR-017 on Insulin Resistance and Other Metabolic Parameters in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"BioKier Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BKR-017"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01456026","briefTitle":"Effects of Food Advanced Glycation Endproducts on Vascular Function in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Profil Institut für Stoffwechselforschung GmbH"},"collaborators":[{"name":"Heart and Diabetes Center North-Rhine Westfalia"},{"name":"Icahn School of Medicine at Mount Sinai"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glycated beta-lactoglobulins."},{"name":"Non-glycated beta-lactoglobulins"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05448105","briefTitle":"My Diabetes Care: A Scalability and Usability Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University Medical Center"},"collaborators":[{"name":"National Institutes of Health (NIH)"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"My Diabetes Care (MDC) Mobile"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03517527","briefTitle":"The Effect of The Walking Exercise Training Given According to Transtheoretical Model, and Follow-Up on Improving Exercise Behavior and Metabolic Control in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emine KAPLAN SERIN"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00971243","briefTitle":"Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MP-513 Lowest Dose and Metformin"},{"name":"MP-513 Low Dose and Metformin"},{"name":"MP-513 Medium Dose and Metformin"},{"name":"MP-513 High Dose and Metformin"},{"name":"Placebo and Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00202033","briefTitle":"Impact of Self-Monitoring Blood Glucose Frequency on Glycemic Control in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HealthPartners Institute"},"collaborators":[{"name":"International Diabetes Center at Park Nicollet"},{"name":"LifeScan"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"frequency of self monitoring blood glucose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04563598","briefTitle":"The Effects of an Intensive Lifestyle Intervention on Employment, Earnings, and Retirement"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Minnesota"},"collaborators":[{"name":"University of Southern California"},{"name":"Wake Forest University"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intensive lifestyle intervention (ILI)"},{"name":"Diabetes support and education (DSE)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03099928","briefTitle":"Developing a Positive Psychology Intervention to Improve Health Behaviors in Type 2 Diabetes: Qualitative Research"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Massachusetts General Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01571661","briefTitle":"A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK189075A"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02110979","briefTitle":"Validation of a Patient Decision Aid for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"EPI-Q"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Use of a PDA to assist shared decision making"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02970838","briefTitle":"Therapy of Obesity and Diabetes Mellitus Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Medicine Greifswald"}},"conditionsModule":{"conditions":["Obesity","Diabetes Type 2","Weight Loss"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Structured weight-loss program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02033876","briefTitle":"Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ursodiol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01192659","briefTitle":"Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01017302","briefTitle":"A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Placebo"},{"name":"RO5095932"},{"name":"RO5095932"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02942914","briefTitle":"A Study of LY3209590 in Healthy Participants and Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3209590"},{"name":"Placebo"},{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02765204","briefTitle":"A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Uppsala University"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Saxagliptin"},{"name":"Glucose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00549874","briefTitle":"Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"},"collaborators":[{"name":"GlaxoSmithKline"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone"},{"name":"Glyburide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04129268","briefTitle":"Determining the Minimal Amount of Exercise to Improve Glycaemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lancaster University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cycle ergometry exercise at 60% VO2max"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02274272","briefTitle":"Effects of Genmont Probiotic on Improve the Level of Blood Glucose and Other Diabetic Associate Parameter in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GenMont Biotech Incorporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ADR-1"},{"name":"GMNL-263"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06289920","briefTitle":"A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of \"BR3005\" and Co-administration of \"BR3005-1\" and \"BR3005-2\" Under Fasting Conditions in Healthy Adult Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boryung Pharmaceutical Co., Ltd"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BR3005"},{"name":"BR3005-1"},{"name":"BR3005-2"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02709577","briefTitle":"A Study of the GI Sleeve for the Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Morphic Medical Inc."},"collaborators":[{"name":"Hospital Dipreca"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EndoBarrier Gastrointestinal Liner"},{"name":"Sham: endoscopy and standard of care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00099320","briefTitle":"Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01890629","briefTitle":"Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LG Life Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01342484","briefTitle":"Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo"},{"name":"BI1356 low dose"},{"name":"BI1356 high dose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00039013","briefTitle":"Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AC2993"},{"name":"AC2993"},{"name":"Placebo"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01798706","briefTitle":"Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide (AVE0010)"},{"name":"Placebo"},{"name":"Antidiabetic background therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04345497","briefTitle":"Diabetes-Specific Formula on Long Term Glycemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Nutrition"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes-Specific Formula"},{"name":"Standard Of Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00957060","briefTitle":"Superiority of Glimepiride Over Sitagliptin in Naive Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLIMEPIRIDE (HOE490)"},{"name":"SITAGLIPTIN"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00383578","briefTitle":"Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin 100 mg qd"},{"name":"Metformin 1500 mg daily"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04575181","briefTitle":"A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NNC0268-0965"},{"name":"Insulin glargine"},{"name":"Placebo (NNC0268-0965)"},{"name":"Placebo (insulin glargine)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00631007","briefTitle":"A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"InteKrin Therapeutics, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INT131 besylate"},{"name":"Pioglitazone HCl"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01508481","briefTitle":"Vitamin D Inadequacy is Associated With Incidence of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Bundang Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00976495","briefTitle":"Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Astra Zeneca, Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo"},{"name":"Hydrochlorothiazide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06132126","briefTitle":"A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Healthy","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3938577"},{"name":"Placebo"},{"name":"Insulin degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01175473","briefTitle":"Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide (AVE0010)"},{"name":"Pen auto-injector"},{"name":"Liraglutide"},{"name":"Pre-filled pen injector"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02863419","briefTitle":"Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00094770","briefTitle":"An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin (MK0431)"},{"name":"Comparator: glipizide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04737499","briefTitle":"Culturally Appropriate Strategies for Chinese Americans With Diabetes (CASCADe)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Claremont Graduate University"},"collaborators":[{"name":"AHMC Health Foundation"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CASCADe"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01932775","briefTitle":"Efficacy, Usability Study of the GlucoTab System for Glycaemic Management in Type 2 Diabetic Patients at General Wards"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Graz"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GlucoTab System"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02532855","briefTitle":"A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Dapagliflozin"},{"name":"Metformin"},{"name":"Matching placebo to sitagliptin"},{"name":"Matching placebo to dapagliflozin"},{"name":"Sulfonylurea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02027753","briefTitle":"Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INSULIN GLARGINE"},{"name":"Metformin"},{"name":"DPP-4 inhibitor"},{"name":"Sulphonylurea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01135433","briefTitle":"A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ipragliflozin"},{"name":"Placebo"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05413369","briefTitle":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine/Lixisenatide"},{"name":"IDegAsp"},{"name":"Metformin"},{"name":"SGLT2 inhibitor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00700908","briefTitle":"Impact of an Automated Telephone Intervention on Glycosylated Hemoglobin (HbA1c) in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Minnesota"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"automated telephone intervention vs. usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00044460","briefTitle":"Efficacy and Safety In Poorly Controlled Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rosiglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00786500","briefTitle":"Anti-diabetic Effect of Gynostemma Pentaphyllum Tea in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hanoi Medical University"},"collaborators":[{"name":"Karolinska Institutet"},{"name":"Swedish International Development Cooperation Agency (SIDA)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gynostemma pentaphyllum tea"},{"name":"Placebo tea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02681497","briefTitle":"Use of Canagliflozin in Conjunction With Insulin in a Real-world Setting"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lawson Health Research Institute"},"collaborators":[{"name":"Janssen Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01242215","briefTitle":"A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ipragliflozin"},{"name":"Placebo"},{"name":"Sulfonylurea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04926623","briefTitle":"Freestyle Libre-based Education on MDI in T2DM (FreEdoM-2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daewoong Pharmaceutical Co. LTD."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FreeStyle Libre 24 weeks"},{"name":"SMBG (22 weeks) and blind CGM (2 weeks)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01510093","briefTitle":"Diurnal Variation of Exogenous Peptides (Endogenous Insulin Jurgita II)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aarhus University Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Aspart 100 IE/ml"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01003184","briefTitle":"Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide once weekly"},{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02967237","briefTitle":"Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glargine (U300)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00511732","briefTitle":"18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mannkind Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Technosphere Insulin"},{"name":"Technosphere Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01461577","briefTitle":"Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INSULIN GLARGINE HOE 901"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01225081","briefTitle":"A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ipragliflozin"},{"name":"Placebo"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01393808","briefTitle":"Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mario Negri Institute for Pharmacological Research"},"collaborators":[{"name":"Abbott"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Paricalcitol"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01113671","briefTitle":"Type 2 Diabetes Haptoglobin Phenotype and Vitamin E"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Technion, Israel Institute of Technology"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin E (d-alpha-tocopheryl acetate)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01889667","briefTitle":"Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oramed, Ltd."},"collaborators":[{"name":"Integrium"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ORMD-0801 Dose # 1"},{"name":"ORMD-0801 Dose # 2"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01812811","briefTitle":"Twentyfour Ambulatory Pulse Wave Velocity and Central Augmentation Index in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"Regionshospitalet Silkeborg"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01340768","briefTitle":"Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Sulfonylurea"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03258268","briefTitle":"Easy Diabetes Treatment Study 1"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Läkarexpressen AB"},"collaborators":[{"name":"Region Skane"},{"name":"Lund University"},{"name":"Region Halland"},{"name":"Västra Götalandsregionen"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Standard of Care with EASY DSS"},{"name":"Standard of Care without EASY DSS"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06235762","briefTitle":"The Effects of Nutritional Intervention on Health Parameters in Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sao Jose do Rio Preto Medical School"},"collaborators":[{"name":"Fundação de Amparo à Pesquisa do Estado de São Paulo"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Diabetes Mellitus Type 2 in Obese","Diabetes","Diabetes Mellitus Non-insulin-dependent","Hypertension","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nutritional Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00481117","briefTitle":"Safety, Tolerability, and Effect of LY2405319 After Multiple Injections in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2405319"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00574665","briefTitle":"Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 1"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hyperinsulinemic Hyperglycemic Clamp"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00528879","briefTitle":"A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01456195","briefTitle":"Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Fasiglifam"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00541229","briefTitle":"Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin phosphate"},{"name":"sitagliptin phosphate"},{"name":"Comparator: Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00311818","briefTitle":"Insulin Glargine in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01115205","briefTitle":"Supervised Walking Groups as a Model to Increase Physical Activity in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universita di Verona"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Supervised walking"},{"name":"Standard counselling procedure"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01412710","briefTitle":"Vitamin D Supplementation on Cardiovascular Risk Factors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Florida International University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cholecalciferol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00901992","briefTitle":"Evaluation of a Self-management Oriented Diabetes Education Program for Intensified Insulin Therapy in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Forschungsinstitut der Diabetes Akademie Mergentheim"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MEDIAS 2 ICT"},{"name":"Current ICT program (ACC-ICT)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00616811","briefTitle":"Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00916188","briefTitle":"Effects of Black Tea on Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Nutrition and Food Technology Institute"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Black Tea Extract"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00353834","briefTitle":"The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Joslin Diabetes Center"},"collaborators":[{"name":"Amylin Pharmaceuticals, LLC."},{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide"},{"name":"Glargine Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01579981","briefTitle":"The Importance of GLP-1 in Post RYGB Improvement in Glycaemic Control Type 2 Diabetic Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hvidovre University Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Roux-en-Y Gastric Bypass"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02536248","briefTitle":"Sitagliptin Therapy and Kinetics of Inflammatory Markers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Laval University"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03403582","briefTitle":"Raspberries and Postprandial Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oklahoma State University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Raspberries"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00646542","briefTitle":"Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03406663","briefTitle":"The Korean TITRATION Study: Comparison of the Self-titration Methods for Glargine-300"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Hospital"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Group 1"},{"name":"Group 2"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05887544","briefTitle":"Towards Objective Dietary Assessment in Large-scale Studies"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Copenhagen"},"collaborators":[{"name":"Aarhus University Hospital"},{"name":"University of Aarhus"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exposure: Plant-based diet pattern"},{"name":"Intervention: Fermented dairy products"},{"name":"Exposure: individual foods and food groups"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00658021","briefTitle":"Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Quintiles, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Exenatide"},{"name":"Exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00821977","briefTitle":"Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"Vildagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01127269","briefTitle":"Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INSULIN GLARGINE"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04937296","briefTitle":"Effects of Home-based Physical Activity in Saudi Arabian Type-2 Diabetes Mellitus Patients."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jonathan Sinclair"},"collaborators":[{"name":"University of Hertfordshire"},{"name":"University of Jazan"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physical activity"},{"name":"Usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00379769","briefTitle":"RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone"},{"name":"Sulfonylurea"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01546597","briefTitle":"Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gilead Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Ranolazine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01086280","briefTitle":"Risk of Cardiovascular Events in Patients With Type 2 Diabetes Initiating Oral Antidiabetic Treatments"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"},{"name":"University of Pennsylvania"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02150824","briefTitle":"Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"BI 187004"},{"name":"Placebo"},{"name":"BI 187004"},{"name":"BI 187004"},{"name":"BI 187004"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00231725","briefTitle":"Complaints Associated With Use of Pre-Filled Pen B With Type 2 Diabetics on Twice-Daily Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin lispro injection [rDNA origin] Low Mix"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00135096","briefTitle":"Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glulisine"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02090673","briefTitle":"Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01415726","briefTitle":"Stem Cell Educator Therapy in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Illinois at Chicago"},"collaborators":[{"name":"Chinese government"},{"name":"Jinan Tianhe Stem Cell Biotechnologies Co Ltd"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Stem Cell Educator"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01870297","briefTitle":"A Study of LY3025876 in Participants With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3025876"},{"name":"Placebo"},{"name":"Liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01309698","briefTitle":"Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin (LAF237)"},{"name":"Voglibose"},{"name":"Vildagliptin and Voglibose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02510521","briefTitle":"Effects of Neuro-myo-electrical Stimulation on Insulin Sensitivity in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Caen"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"acute muscle exercise by NMES"},{"name":"daily workout sequence with NMES in one week"},{"name":"rest situation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04698018","briefTitle":"A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Faster Aspart"},{"name":"Novo Rapid"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03313856","briefTitle":"Effect of Oral Administration of a Herbarium Mixture (Guazuma Ulmifolia and Tecoma Stans) on Metabolic Profile in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centro Universitario de Ciencias de la Salud, Mexico"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Guazuma Ulmifolia plus Tecoma Stans"},{"name":"Calcinaned magnesia"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00574340","briefTitle":"Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 4"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Maryland, Baltimore"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hyperinsulinemic Hypoglycemic Clamp"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00396071","briefTitle":"Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00566358","briefTitle":"Surgical Treatment of Non-obese Type 2 Diabetic Patients With Duodenal Exclusion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Campinas, Brazil"},"collaborators":[{"name":"Ethicon Endo-Surgery"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Duodenal exclusion surgery"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00839527","briefTitle":"A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo to match albiglutide"},{"name":"albiglutide"},{"name":"metformin"},{"name":"glimepiride"},{"name":"pioglitazone"},{"name":"placebo to match pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03078764","briefTitle":"The Adaptation, Usability, and Feasibility of a Mobile Health (mHealth) System to Improve Type 2 Diabetes Self-management in Thailand"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"},"collaborators":[{"name":"Mahidol University"},{"name":"Fogarty International Center of the National Institute of Health"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mobile health system"},{"name":"E-mail reports and technical support for mHealth system"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01676220","briefTitle":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HOE901-U300 (new formulation of insulin glargine)"},{"name":"Lantus (insulin glargine)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03207269","briefTitle":"Impact of Bedtime Snacks on Glucose Control in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of British Columbia"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dietary"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00133718","briefTitle":"A 2 Year Trial of Patients With Type 2 Diabetes Focusing on Cardiovascular Diagnostics and Metabolic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Asker & Baerum Hospital"},"collaborators":[{"name":"Rikshospitalet University Hospital"},{"name":"University Hospital, Aker"},{"name":"Sahlgrenska University Hospital, Sweden"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Combined lifestyle intervention and optimisation of pharmacological treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00870194","briefTitle":"A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide and sitagliptin"},{"name":"exenatide and placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00351884","briefTitle":"Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin AM"},{"name":"vildagliptin pm"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02691273","briefTitle":"Applicability of Cellular Application in Diabetes Type 2 Patients."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hadassah Medical Organization"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"cellular application treating diabetes using breathing technique"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01469104","briefTitle":"Metabolic Response to 3-day Fast Versus Carbohydrate-free Diet in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Minneapolis Veterans Affairs Medical Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"3 day fast"},{"name":"3 day CHO-free diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01193218","briefTitle":"Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo (low dose)"},{"name":"Placebo (low dose)"},{"name":"Placebo (mid dose)"},{"name":"Placebo (high dose)"},{"name":"BI 10773"},{"name":"Placebo (mid dose)"},{"name":"Placebo (high dose)"},{"name":"Placebo (high dose)"},{"name":"BI 10773"},{"name":"BI 10773"},{"name":"Placebo (mid dose)"},{"name":"Placebo (high dose)"},{"name":"Placebo (low dose)"},{"name":"Placebo (low dose)"},{"name":"BI 10773"},{"name":"Placebo (mid dose)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02183350","briefTitle":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 1356 BS - single rising dose"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01880476","briefTitle":"Interprofessional Community-Based Diabetes Intervention for Older Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"McMaster University"},"collaborators":[{"name":"Diabetes Care Guelph"},{"name":"Guelph Wellington Seniors Association"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Home visits and group program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01427699","briefTitle":"A Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"T2-18C3 therapeutic antibody"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00362011","briefTitle":"Effect of Chia Seeds (Salvia Hispanica L.) on Glucose Control in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Unity Health Toronto"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Salba diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03341013","briefTitle":"A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"MedImmune LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MEDI0382 Formulation 2"},{"name":"MEDI0382 Formulation 3"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01279317","briefTitle":"Vinegar Co-ingestion in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo co-ingestion"},{"name":"vinegar co-ingestion"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02183415","briefTitle":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 1356 BS, low dose"},{"name":"BI 1356 BS, medium dose"},{"name":"BI 1356 BS, high dose"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00168519","briefTitle":"Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baker Heart Research Institute"},"collaborators":[{"name":"National Health and Medical Research Council, Australia"},{"name":"Hoffmann-La Roche"},{"name":"Life for a Child Program, Diabetes Australia"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"nitroprusside, pentalong, imdur, AICAR, isoptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00935532","briefTitle":"Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide once weekly"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01937598","briefTitle":"Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Michael A. Nauck"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Mixed meal test"},{"name":"Liraglutide"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00908921","briefTitle":"Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono-therapy in Chinese Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLIMEPIRIDE"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00742547","briefTitle":"Type 2 Diabetes Mellitus: New Approaches to Optimize Medical Care in General Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"German Cancer Research Center"},"collaborators":[{"name":"Heidelberg University"},{"name":"German Federal Ministry of Education and Research"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Telephone counseling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00423215","briefTitle":"LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine (LANTUS)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00367055","briefTitle":"Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rosiglitazone-metformin"},{"name":"Metformin"},{"name":"metformin+ gliclazide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01107171","briefTitle":"Trial of Tang-min-ling Pills in the Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences"},"collaborators":[{"name":"Tasly Pharmaceuticals, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tang-min-ling pills low dosage"},{"name":"Tang-min-ling pills high dosage"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01432405","briefTitle":"Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baylor College of Medicine"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02824003","briefTitle":"Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ionis Pharmaceuticals, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ISIS-GCGRRx"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01404676","briefTitle":"The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Samsung Medical Center"},"collaborators":[{"name":"Novartis"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Add Vildagliptin"},{"name":"Add Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02915250","briefTitle":"A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Adocia"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BioChaperone® Combo"},{"name":"Humalog® Mix25"},{"name":"Humalog®"},{"name":"Lantus®"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02831361","briefTitle":"Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LG Life Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gemigliptin"},{"name":"Gemigliptin placebo"},{"name":"Metformin"},{"name":"Diet/exercise questionnaire"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02440555","briefTitle":"Evaluation of the Targeted Screening of Type 2 Diabetes by Capillary Blood Glucose"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire de Saint Etienne"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"fulfill the self-administered questionnaire"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00212641","briefTitle":"A Phase II Study to Evaluate the Effects of Oral ONO-5129 in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ono Pharma USA Inc"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ONO-5129"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03842267","briefTitle":"A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LG Chem"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gemigliptin 50mg"},{"name":"Gemigliptin Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00975065","briefTitle":"Galvus on Met Phase 4 Study : Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Handok Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin 50 mg bid plus metformin 1500mg (Galvus+Diabex)"},{"name":"metformin 1500mg plus metformin 500mg or 1000mg (Diabex)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02381119","briefTitle":"Effects of Personalized Dietary Advice on Health Status of Diabetes Type 2 Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"TNO"},"collaborators":[{"name":"Vitas"},{"name":"SwissAnalysis"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Personalized Dietary Advice Services"},{"name":"Regular care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00194896","briefTitle":"Preferred Treatment of Type 1.5 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Washington"},"collaborators":[{"name":"Seattle Institute for Biomedical and Clinical Research"},{"name":"GlaxoSmithKline"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rosiglitazone"},{"name":"glyburide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00252525","briefTitle":"Correlation of Plasma Endothelial Cell Activity With Cardiovascular Events in Patients With Diabetes Mellitus Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"US Department of Veterans Affairs"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00877851","briefTitle":"Evaluation of a Computer-Based, Self-Management Tool for People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Queen's University, Belfast"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Computer-based Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02320526","briefTitle":"Interval-training in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rigshospitalet, Denmark"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Control"},{"name":"Continuous walking"},{"name":"Interval walking"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00822211","briefTitle":"Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin 50 mg bid"},{"name":"Vildagliptin 50 mg qd"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00308373","briefTitle":"Effects of Fats on Blood Glucose in People With and Without Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin vs Thiazolidinedione (Pioglitazone)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00833677","briefTitle":"Community Based Participatory Research With Immigrant Chinese With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Francisco"},"collaborators":[{"name":"National Institute of Nursing Research (NINR)"},{"name":"University of San Francisco"},{"name":"Donaldina Cameron House"},{"name":"North East Medical Services"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Chinese Coping Skills Training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01581658","briefTitle":"Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI10773"},{"name":"BI10773"},{"name":"BI10773"},{"name":"BI10773"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00948168","briefTitle":"Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide (Byetta)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03382015","briefTitle":"Effect of BKR-013 on Average Daily Glucose Levels"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"BioKier Inc."},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BKR-013 or Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00325364","briefTitle":"Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"},"collaborators":[{"name":"Alkermes, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Human Insulin Inhalation Powder"},{"name":"Injectable insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00729326","briefTitle":"Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"sitagliptin"},{"name":"placebo"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01632163","briefTitle":"Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide (AVE0010)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01864174","briefTitle":"Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristol-Myers Squibb"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin XR"},{"name":"Metformin IR"},{"name":"Placebo matching with Metformin XR"},{"name":"Placebo matching with Metformin IR"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01473147","briefTitle":"Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chang Gung Memorial Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide"},{"name":"Normal saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00151749","briefTitle":"WelChol® and Insulin in Treating Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Colesevelam hydrochloride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01580813","briefTitle":"Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Denver"},"collaborators":[{"name":"US Department of Veterans Affairs"},{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acipimox"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02606357","briefTitle":"Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INSULIN GLARGINE"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02001753","briefTitle":"Impact of Cardiac Magnetic Resonance Imaging on Endothelial Function in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Xiang Guang-da"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CMR"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00394875","briefTitle":"The Diabetes Specialist Nurse as Delegated Main Care Provider for Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical Research Foundation, The Netherlands"},"collaborators":[{"name":"Netherlands: Ministry of Health, Welfare and Sports"},{"name":"Langerhans Foundation, the Netherlands"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Treated and educated by nurses specialized in diabetes."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01206322","briefTitle":"Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Beth Israel Deaconess Medical Center"},"collaborators":[{"name":"Boston University"},{"name":"Joslin Diabetes Center"},{"name":"Peking University"},{"name":"University of Washington"},{"name":"University of Arkansas"},{"name":"VA Boston Healthcare System"},{"name":"University of Massachusetts, Worcester"},{"name":"Wake Forest University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intranasal insulin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00951899","briefTitle":"The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"},"collaborators":[{"name":"Daiichi Sankyo"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"National Center for Research Resources (NCRR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Colesevelam"},{"name":"Placebo"},{"name":"Diet"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01236846","briefTitle":"Vitamin D Receptor Polymorphisms and Efficacy of Vitamin D-Fortified Yogurt Drink in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tirang R. Neyestani"},"collaborators":[{"name":"Tehran University of Medical Sciences"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fortified Yogurt Drink"},{"name":"Plain Yogurt Drink"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01107886","briefTitle":"Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02290925","briefTitle":"The Effect of Biscuit Containing Kothala Himbutu on Blood Glucose in Patients With Diabetes. A Randomized Control Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rajarata University, Sri Lanka"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Kothala Himbutu Biscuit"},{"name":"Placebo Biscuit"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03798717","briefTitle":"To Bathe or Not to Bathe"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Portsmouth"},"collaborators":[{"name":"Portsmouth Hospitals NHS Trust"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Heating"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03837405","briefTitle":"(R33 Phase) Delish Study: Diabetes Education to Lower Insulin, Sugars, and Hunger"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Francisco"},"collaborators":[{"name":"National Center for Complementary and Integrative Health (NCCIH)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Carbohydrate-restricted diet"},{"name":"Mindfuless"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01119846","briefTitle":"A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK1292263"},{"name":"GSK1292263 matching placebo"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01282970","briefTitle":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 135585"},{"name":"Placebo to BI 135585"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01137474","briefTitle":"A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo-matching dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01196546","briefTitle":"Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin/metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01364428","briefTitle":"Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"insulin degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00516048","briefTitle":"An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00490867","briefTitle":"Effect of Long Term α-Lipoic Acid Treatment on Endothelial Function in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Vienna"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alpha lipoic acid"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00885378","briefTitle":"Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin plus metformin IR"},{"name":"Placebo plus metformin IR"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01111955","briefTitle":"Safety Study of BMS-823778 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristol-Myers Squibb"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BMS-823778"},{"name":"BMS-823778"},{"name":"BMS-823778"},{"name":"Placebo"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00577824","briefTitle":"Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"exenatide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01986855","briefTitle":"A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ertugliflozin 5 mg"},{"name":"Placebo 5 mg"},{"name":"Ertugliflozin 10 mg"},{"name":"Placebo 10 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01891955","briefTitle":"Alimentation and Diabetes in Lanzarote - ADILAN: a Pilot Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lund University"},"collaborators":[{"name":"Cabildo de Lanzarote"},{"name":"Ayuntamiento de Teguise"},{"name":"Ayuntamiento de Arrecife"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Healthy diet A"},{"name":"Healthy diet B"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02455076","briefTitle":"Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide"},{"name":"Glargine"},{"name":"Rapid-acting insulin analogs"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04586907","briefTitle":"A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Healthy","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3537021"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01382303","briefTitle":"Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ajou University School of Medicine"},"collaborators":[{"name":"Bundang CHA Hospital"},{"name":"Hallym University Medical Center"},{"name":"Gangnam Severance Hospital"},{"name":"Yonsei University"},{"name":"Myongji Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pentoxifylline"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00377442","briefTitle":"A Drug-Drug Interaction Study of GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GK Activator (2)"},{"name":"Simvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00879125","briefTitle":"Effect of Gastric Bypass on Patients With Type 2 Diabetes and/or Dyslipidemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02196350","briefTitle":"P4 Approach in Diabetes Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"W.J. Pasman"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intervention A: Diet"},{"name":"Intervention B: Exercise"},{"name":"Intervention C: Diet and Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00902161","briefTitle":"A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK0893"},{"name":"MK0893-matched Placebo"},{"name":"Propranolol Hydrochloride (HCL)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01226043","briefTitle":"Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02343926","briefTitle":"Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GEMIGLIPTIN LS15-0444"},{"name":"vildagliptin"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02445911","briefTitle":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kaneq Bioscience Limited"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"KQ-791"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03341312","briefTitle":"A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY900014"},{"name":"Insulin Lispro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00960661","briefTitle":"A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"insulin lispro"},{"name":"Metformin"},{"name":"Insulin/ Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01181674","briefTitle":"Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Population Health Research Institute"},"collaborators":[{"name":"Hamilton Health Sciences Corporation"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glargine"},{"name":"metformin"},{"name":"acarbose"},{"name":"lifestyle therapy"},{"name":"insulin glargine"},{"name":"metformin"},{"name":"acarbose"},{"name":"lifestyle therapy"},{"name":"Standard glycemic care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02449603","briefTitle":"Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Xijing Hospital"},"collaborators":[{"name":"Air Force Military Medical University, China"},{"name":"First Affiliated Hospital Xi'an Jiaotong University"},{"name":"Second Affiliated Hospital of Xi'an Jiaotong University"},{"name":"Shaanxi Provincial People's Hospital"},{"name":"Chang'An Hospital"},{"name":"Xi'an Gaoxin Hospital"},{"name":"Xi'an Central Hospital"},{"name":"Shaanxi Aerospace Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide"},{"name":"Biphasic insulin Aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01396161","briefTitle":"A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-05175157 or Placebo"},{"name":"PF-05175157 or Placebo"},{"name":"PF-05175157 or Placebo"},{"name":"PF-05175157 or Placebo"},{"name":"PF-05175157 or Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00241423","briefTitle":"Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01680133","briefTitle":"Regulation of Tissue Lipolysis by Insulin in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"},"collaborators":[{"name":"Netherlands Organisation for Scientific Research"},{"name":"European Foundation for the Study of Diabetes"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hyperinsulinemic euglycemic clamp"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01855321","briefTitle":"Effects of Treating Vitamin D Deficiency in Poorly Controlled Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Florida"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin D"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02406443","briefTitle":"The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Health Network, Toronto"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitaglitpin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02211963","briefTitle":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 44847 in Female and Male Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 44847"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00377676","briefTitle":"Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VeroScience"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cycloset"},{"name":"Usual Diabetes Therapy plus placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01976858","briefTitle":"A Phase I Study of 8-week Continuous Treatment With Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jiangsu HengRui Medicine Co., Ltd."},"collaborators":[{"name":"Beijing Tongren Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PEX168"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01195662","briefTitle":"A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo matching Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00167115","briefTitle":"Metabolic Effects of Alcohol"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bantle, John P., MD"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alcohol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00942318","briefTitle":"Efficacy of Continuous Subcutaneous Insulin Infusion Versus Basal-bolus Multiple Daily Injections Regimen in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Toulouse"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Detemir insulin, Aspart insulin, Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00174681","briefTitle":"Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01086306","briefTitle":"Risk of Hospitalized Infections Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"},{"name":"University of Pennsylvania"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00960674","briefTitle":"Tactile Massage in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Karolinska Institutet"},"collaborators":[{"name":"Region Stockholm"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tactile massage"},{"name":"Relaxation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00485758","briefTitle":"Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ER niacin/laropiprant"},{"name":"Comparator : placebo (unspecified)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02542735","briefTitle":"Incidence of Type 2 Diabetes in the di@Bet.es Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud"},"collaborators":[{"name":"Instituto de Salud Carlos III"},{"name":"Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00442884","briefTitle":"Effect of Acute Psychological Stress on Glucose Concentrations in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Zurich"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Trier Social Stress Test (TSST)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00690287","briefTitle":"A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD6370"},{"name":"AZD6370"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01499095","briefTitle":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lantus (Insulin glargine)"},{"name":"HOE901-U300 (new formulation of insulin glargine)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01965509","briefTitle":"A PK/PD Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jiangsu HengRui Medicine Co., Ltd."},"collaborators":[{"name":"China-Japan Friendship Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PEX168 or placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00548158","briefTitle":"Effect of Pioglitazone Therapy for Type 2 Diabetes on Vision"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Diego"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00860288","briefTitle":"Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"Metformin"},{"name":"Placebo"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02298192","briefTitle":"A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00457093","briefTitle":"A Comparison Between Glargine and Detemir Insulin in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diabetes Care Center"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"glargine"},{"name":"detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01167881","briefTitle":"Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 10773"},{"name":"Glimepiride"},{"name":"Placebo"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01223196","briefTitle":"Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02311244","briefTitle":"The Sapienza University Mortality and Morbidity Events Rate (SUMMER) Study in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Roma La Sapienza"},"collaborators":[{"name":"Campus Bio-Medico University"},{"name":"Ospedale Sandro Pertini, Roma"},{"name":"Azienda Ospedaliera San Camillo Forlanini"},{"name":"University of Cagliari"},{"name":"Casa Sollievo della Sofferenza IRCCS"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01449773","briefTitle":"Effects of N-3 Polyunsaturated Fatty Acids On Chylomicron Secretion And Expression Of Genes That Regulate Intestinal Lipid Metabolism In Men With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Laval University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"n-3 PUFAs"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02864914","briefTitle":"Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"DPP-4 inhibitors"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03862963","briefTitle":"Lifestyle Intervention to Treat Diabetes in the Marshall Islands"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alabama at Birmingham"},"collaborators":[{"name":"United States Department of Defense"},{"name":"Loma Linda University"},{"name":"Brenda Davis Nutrition Consultation Services"},{"name":"Canvasback Missions, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Standard of diabetes care"},{"name":"Lifestyle Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01341717","briefTitle":"Effects of Sitagliptin on Type 2 Diabetes Mellitus Patients on Treatment With Metformin and Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jothydev's Diabetes and Research Centre"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Glimepiride"},{"name":"Metformin"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00902616","briefTitle":"Effect of Arginine on Microcirculation in Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tameside Hospital NHS Foundation Trust"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"L-arginine"},{"name":"Placebo Lactose powder"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02026024","briefTitle":"Incretin Based Therapy for Poorly Controlled Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chang Gung Memorial Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02542631","briefTitle":"Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Calibra Medical, Inc."},"collaborators":[{"name":"Medpace, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bolus Insulin Patch (Calibra Finesse)"},{"name":"Insulin Pen (Novo-Nordisk FlexPen®)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04632849","briefTitle":"The Use of Libre to Improve Metabolic Control and Reduce Reliance on Medication"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Virginia"},"collaborators":[{"name":"University of Colorado, Denver"},{"name":"West Virginia University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GEM + CGM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04894916","briefTitle":"My Diabetes Care Mobile: A Usability Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University Medical Center"},"collaborators":[{"name":"National Institutes of Health (NIH)"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"My Diabetes Care Mobile (MDC-m)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00110851","briefTitle":"Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Wellstat Therapeutics"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rosiglitazone"},{"name":"metformin"},{"name":"PN2034"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01965496","briefTitle":"A Phase I Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jiangsu HengRui Medicine Co., Ltd."},"collaborators":[{"name":"People's Liberation Army General Hospital of Chengdu Military Region"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PEX168"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00499707","briefTitle":"Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rosiglitazone maleate/metformin hydrochloride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00803920","briefTitle":"Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HealthPartners Institute"},"collaborators":[{"name":"Amylin Pharmaceuticals, LLC."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03604224","briefTitle":"A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johnson & Johnson Private Limited"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin 300 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02688920","briefTitle":"Intraluminal Imaging of Duodenal Layer Morphometry in Patients With and Without Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Victoria Gomez"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EUS and OCT imaging"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02924064","briefTitle":"Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Teneligliptin 20mg"},{"name":"Placebo"},{"name":"Metformin ≥ 1000 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00541697","briefTitle":"Eze/Simva Switch Study in Diabetics (0653A-807)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Organon and Co"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks"},{"name":"Comparator: atorvastatin / Duration of Treatment: 6 Weeks"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00673231","briefTitle":"Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Dapagliflozin"},{"name":"Dapagliflozin"},{"name":"Placebo"},{"name":"Dapagliflozin"},{"name":"Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00151762","briefTitle":"Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Colesevelam hydrochloride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00831779","briefTitle":"Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Astra Zeneca, Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00859898","briefTitle":"Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Metformin XR"},{"name":"Metformin XR"},{"name":"dapagliflozin matching Placebo"},{"name":"metformin HCl Modified Release matching Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01236404","briefTitle":"Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"PhaseBio Pharmaceuticals Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)"},{"name":"Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00308737","briefTitle":"Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mannkind Corporation"}},"conditionsModule":{"conditions":["Diabetes, Type 1","Diabetes, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Technosphere® Insulin Inhalation Powder"},{"name":"Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01316107","briefTitle":"A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ipragliflozin"},{"name":"nateglinide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01572649","briefTitle":"Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide (AVE0010)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01364584","briefTitle":"Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Denver"},"collaborators":[{"name":"Amylin Pharmaceuticals, LLC."},{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02081573","briefTitle":"Brief CBT Interventions Delivered by Nurse Care Managers to Improve Type 2 Diabetes Outcomes: Pilot Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pittsburgh"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Brief CBT"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06370494","briefTitle":"Testing New Models of Diabetes Self-Management to Improve Population Health"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Texas A&M University"},"collaborators":[{"name":"Blue Cross Blue Shield"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Living Healthier with Diabetes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00325117","briefTitle":"To Assess the Efficacy and Safety of Vildagliptin as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02895672","briefTitle":"GLP-1/Basal Insulin Combination Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Albany College of Pharmacy and Health Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLP-1 therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01084005","briefTitle":"Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"linagliptin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00508287","briefTitle":"Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristol-Myers Squibb"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BMS-686117"},{"name":"Byetta"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01098539","briefTitle":"A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"albiglutide"},{"name":"sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00736515","briefTitle":"Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Servier (Tianjin) Pharmaceutical Co. LTD."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gliclazide MR and Insulin Glargine Injection"},{"name":"Biosynthetic Human Insulin Injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02268929","briefTitle":"A German Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Type 2 Diabetes Patients."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"},"collaborators":[{"name":"Roche Diabetes Care Deutschland GmbH"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Accu-Chek Smart Pix Software"},{"name":"Accu-Chek Smart Pix readout Device"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02860611","briefTitle":"Comparison of Th1 Cytokine Levels Between Type 1 and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Istanbul Medeniyet University"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04531631","briefTitle":"Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chinese University of Hong Kong"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dorzagliatin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01375270","briefTitle":"Glucolipotoxicity and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rigshospitalet, Denmark"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glucotoxicity"},{"name":"Lipotoxicity"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01151293","briefTitle":"Personality of Diabetic Patients Will Influence Their Medical compliance-a 5 Years Cohort Follow up With Type D Personality"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Far Eastern Memorial Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02787551","briefTitle":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine/lixisenatide fixed ratio combination"},{"name":"liraglutide"},{"name":"exenatide"},{"name":"exenatide extended-release"},{"name":"albiglutide"},{"name":"dulaglutide"},{"name":"Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00111670","briefTitle":"A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DPP-IV Inhibitor"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00728351","briefTitle":"Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin + metformin"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02806349","briefTitle":"Konjac-Glucomannan Fibre Blend and American Ginseng in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vladimir Vuksan"},"collaborators":[{"name":"Canadian Diabetes Association"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"American Ginseng"},{"name":"Konjac-glucomannan fiber blend"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01541735","briefTitle":"Pantoprazole on Insulin Secretion in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Coordinación de Investigación en Salud, Mexico"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pantoprazole"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00637273","briefTitle":"A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide once weekly"},{"name":"sitagliptin"},{"name":"pioglitazone"},{"name":"placebo tablet"},{"name":"placebo once weekly"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00548808","briefTitle":"A Study for Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin lispro low mixture"},{"name":"Insulin glargine"},{"name":"Insulin lispro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01186354","briefTitle":"Understanding of Genetic Risk Information for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Duke University"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Receiving results via genetic counselor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00423501","briefTitle":"A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"taspoglutide"},{"name":"taspoglutide"},{"name":"taspoglutide"},{"name":"taspoglutide"},{"name":"taspoglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01353118","briefTitle":"The Effects of Glycemic Optimization Before Gastric Bypass Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Imperial College London"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"gastric bypass"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00521378","briefTitle":"A Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diasome Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01358929","briefTitle":"A Study of RO6807952 in Patients With Diabetes Mellitus Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"RO6807952"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00382096","briefTitle":"Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"Metformin"},{"name":"Vildagliptin + Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03807440","briefTitle":"DIA_CENTRAL:T2D Treatment Pattern in Central Europe"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Sodium Glucose Transporter 2 inhibitor"},{"name":"Dipeptidyl-peptidase 4 inhibitor"},{"name":"Glucagon-like peptide 1 agonist"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06423872","briefTitle":"A SAD Study of ZT002 Injection in Healthy Participants"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Beijing QL Biopharmaceutical Co.,Ltd"},"collaborators":[{"name":"Beijing Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ZT002"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02312063","briefTitle":"Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kansai Electric Power Hospital"},"collaborators":[{"name":"Saiseikai Noe Hospital Osaka"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00366379","briefTitle":"A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GK Activator (2)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03261895","briefTitle":"Effectiveness of a Nurse-led Integrative Health and Wellness Programme Among Newly Diagnosed Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chinese University of Hong Kong"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nurse-led Integrative health and wellness programme"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03013985","briefTitle":"Glargine U300 Hospital Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glargine U300"},{"name":"Glargine U100"},{"name":"Glulisine Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00838903","briefTitle":"Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"albiglutide"},{"name":"sitagliptin"},{"name":"glimepiride"},{"name":"metformin"},{"name":"placebo albiglutide"},{"name":"placebo sitagliptin"},{"name":"placebo glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01576328","briefTitle":"Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mesoblast, Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mesenchymal Precursor Cells (MPCs)"},{"name":"Mesenchymal Precursor Cells (MPCs)"},{"name":"Mesenchymal Precursor Cells (MPCs)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03626155","briefTitle":"Does Exercise Timing Affect Glucose Levels in People With Diabetes?"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alberta"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Walking"},{"name":"Seated Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02285881","briefTitle":"Shared Decision Making Between Patients and GPs in the Treatment of Type 2 Diabetes in Primary Care."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"UMC Utrecht"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Shared decision making"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03464045","briefTitle":"Empa PASS on Urinary Tract Malignancies"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"empagliflozin"},{"name":"DPP-4 inhibitors"},{"name":"SGLT-2 inhibitors"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00300287","briefTitle":"A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01513798","briefTitle":"Diet and Exercise in Type 2 Diabetes - a Randomized Controlled Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Umeå University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Modified paleolithic diet and exercise under observation"},{"name":"Modified paleolithic diet and general advice on exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00734669","briefTitle":"Risk of Hypoglycemia in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Giessen"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glibenclamide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02122926","briefTitle":"Intensive Discharge Intervention in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Brigham and Women's Hospital"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type II Diabetes","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intensive discharge intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04885621","briefTitle":"Telehealth and Meal Replacement Pilot Program for Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Virginia"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"nutrisystem-D"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00686634","briefTitle":"Sitagliptin in Combination With Metformin and Sulfonylurea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Charles Drew University of Medicine and Science"},"collaborators":[{"name":"National Center for Research Resources (NCRR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02252224","briefTitle":"Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00786019","briefTitle":"Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Denver"},"collaborators":[{"name":"American Diabetes Association"},{"name":"National Institutes of Health (NIH)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise program"},{"name":"Ascorbic Acid (Vitamin C)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01569893","briefTitle":"Life-Long Monitoring of Diabetes Mellitus in Veneto Region"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Regione Veneto"},"collaborators":[{"name":"European Commission"},{"name":"Azienda ULSS 4 Alto Vicentino"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Self-monitoring for patients with Dibetes mellitus"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00357370","briefTitle":"A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02514850","briefTitle":"A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Adocia"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Biochaperone Combo"},{"name":"Humalog Mix25"},{"name":"Humalog"},{"name":"Lantus"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00743002","briefTitle":"A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"OPKO Health, Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TT223 with Metformin and/or TZD"},{"name":"Placebo with Metformin and/or TZD"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00097500","briefTitle":"Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"Insulin glargine"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03674866","briefTitle":"A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00873821","briefTitle":"A Pharmacokinetic Study of MK-0941 After Multiple Daily Doses in Subjects With Type 2 Diabetes (MK-0941-012)(COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK-0941"},{"name":"Comparator: Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00396357","briefTitle":"Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01455896","briefTitle":"A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Intarcia Therapeutics"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ITCA 650"},{"name":"ITCA placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01204775","briefTitle":"Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Placebo (Saxagliptin)"},{"name":"Metformin IR"},{"name":"Placebo (Metformin)"},{"name":"Metformin (Active Rescue)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01269996","briefTitle":"JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chinese University of Hong Kong"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Janumet, Lantus"},{"name":"metformin, gliclazide, protaphane"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00622284","briefTitle":"Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo identical to BI 1356 5mg"},{"name":"Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg"},{"name":"BI 1356"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04726657","briefTitle":"Comparison of Two Biphasic Insulin Regimens"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aristotle University Of Thessaloniki"},"collaborators":[{"name":"University Hospital Tuebingen"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Premixed Human Isophane Insulin Suspension + Human Insulin Injection"},{"name":"Premixed Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02949739","briefTitle":"Prevention of Type 2 Diabetes Amongst South Asians With Central Obesity and Prediabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Imperial College London"},"collaborators":[{"name":"London North West Healthcare NHS Trust"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intensive lifestyle modification"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04757233","briefTitle":"Personalizing Self-management in Diabetes - Pilot Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Columbia University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GlucoType"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02512068","briefTitle":"A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Trelagliptin 25 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02386982","briefTitle":"Beta Cell Function and Related Pharmacodynamics of HMS5552 in T2DM Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hua Medicine Limited"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HMS5552"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01270789","briefTitle":"LIraglutide and Beta-cell RepAir (LIBRA) Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mount Sinai Hospital, Canada"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01131676","briefTitle":"BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME)."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 10773 low dose"},{"name":"Placebo BI 10773 high dose"},{"name":"BI 10773 high dose"},{"name":"Placebo BI 10773 low dose"},{"name":"Placebo BI 10773 low dose"},{"name":"Placebo BI 10773 high dose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01455857","briefTitle":"A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Intarcia Therapeutics"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ITCA 650"},{"name":"ITCA placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00667732","briefTitle":"How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oregon Health and Science University"},"collaborators":[{"name":"Amylin Pharmaceuticals, LLC."},{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01345435","briefTitle":"Effects of Telemonitoring and Telemedicine Service for Type 2 Diabetes Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"CHANGHEE LEE"},"collaborators":[{"name":"LG Electronics Inc."},{"name":"Purdue University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Telemonitoring group"},{"name":"Telemonitoring & Telemedicine"},{"name":"SMBG"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00922649","briefTitle":"Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Animas Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Pump therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02798172","briefTitle":"The Effect of Alogliptin on Pulmonary Function in Obese Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fourth People's Hospital of Shenyang"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin and Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00871936","briefTitle":"A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Response Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SLx-4090"},{"name":"Placebo"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00540488","briefTitle":"Glucose/Insulin Responses:Subjects With Type 2 Diabetes Consuming Diabetes-Specific vs Standard Nutritional Formulas"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Nutrition"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Adult enteral formula"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01882907","briefTitle":"Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pusan National University Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05548218","briefTitle":"Care Companion Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NorthShore University HealthSystem"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Automated health education using a digital health pathway"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06293742","briefTitle":"ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eccogene"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ECC5004"},{"name":"Midazolam"},{"name":"Rosuvastatin"},{"name":"Digoxin"},{"name":"Atorvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02475070","briefTitle":"Vildagliptin Versus Dapagliflozin on Glucagon"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lund University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03313297","briefTitle":"Glucocorticoids and Skin Healing in Diabetes (GC-SHealD)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Leeds"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD4017"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01646320","briefTitle":"Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo matching with Dapagliflozin"},{"name":"Saxagliptin"},{"name":"Metformin immediate release (IR)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03254849","briefTitle":"Empagliflozin and Sympathetic Nerve Traffic"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Profil Institut für Stoffwechselforschung GmbH"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Hydrochlorothiazide 25 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02117154","briefTitle":"Relationship Between HbA1c, Fasting Plasma Glucose, Post-prandial Glucose and Other Measures of Glycemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Malaya"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"6-day Continuous Glucose Monitoring System"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01638351","briefTitle":"Resistance Training in Diabetic Elder Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Taiwan University Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Resistance exercise"},{"name":"Usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00473525","briefTitle":"12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"PF-00734200 10 mg QD"},{"name":"PF-00734200 20 mg QD"},{"name":"PF-00734200 5 mg QD"},{"name":"PF-00734200 2 mg QD"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01177813","briefTitle":"Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo identical to BI10773 high dose"},{"name":"BI 10773"},{"name":"BI 10773 open label"},{"name":"Placebo identical to BI10773 low dose"},{"name":"Placebo identical to BI10773 low dose"},{"name":"Placebo identical to BI10773 high dose"},{"name":"Placebo identical to Sitagliptin 100mg"},{"name":"Placebo identical to Sitagliptin 100mg"},{"name":"BI10773"},{"name":"Sitagliptin"},{"name":"Placebo identical to Sitagliptin 100mg"},{"name":"Placebo identical to BI10773 low dose"},{"name":"Placebo identical to BI10773 high dose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00394030","briefTitle":"Injection Site Study In Patients With Type 2 Diabetes Mellitus (T2DM) And Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK716155 subcutaneous injections"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06268145","briefTitle":"ECC5004 RBA FE Study in Healthy Participants"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eccogene"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ECC5004"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04023344","briefTitle":"Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Geropharm"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Humalog Mix25"},{"name":"Insulin Lispro Biphasic 25"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01619059","briefTitle":"Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Dapagliflozin"},{"name":"Metformin IR"},{"name":"Placebo matching with Saxagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01083212","briefTitle":"To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD1656"},{"name":"Gemfibrozil"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00174824","briefTitle":"Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00494884","briefTitle":"Vildagliptin 100 mg Once Daily vs. Placebo as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01672762","briefTitle":"A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ipragliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01778049","briefTitle":"Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 10773"},{"name":"BI 10773 Placebo"},{"name":"BI 10773 / BI 1356"},{"name":"BI 10773"},{"name":"BI 10773 / BI 1356"},{"name":"BI 10773 / BI 1356 Placebo"},{"name":"BI 10773"},{"name":"BI 10773"},{"name":"BI 10773"},{"name":"BI 10773 / BI 1356 Placebo"},{"name":"BI 10773 Placebo"},{"name":"BI 10773 / BI 1356 Placebo"},{"name":"BI 10773"},{"name":"BI 10773 / BI 1356 Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00135083","briefTitle":"Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glulisine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01836796","briefTitle":"Metabolic Effects of Lactobacillus Reuteri DSM 17938 in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vastra Gotaland Region"},"collaborators":[{"name":"BioGaia AB"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lactobacillus Reuteri"},{"name":"Lactobacillus Reuteri DSM17938"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02099838","briefTitle":"Effectiveness and Safety of Adding Compound Preparation of Pioglitazone and Metformin for Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Huazhong University of Science and Technology"},"collaborators":[{"name":"Wuhan Iron and Steel Workers' Hospital"},{"name":"Wuhan Pu-Ai Hospital"},{"name":"Hubei Xinhua Hospital"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone and Metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02472951","briefTitle":"Cut Down on Carbohydrate Usage in the Diet of Type 2 Diabetes - Mechanisms of Effective Therapy of Diabetes by Selective Choice of Macronutrients - The Phenotype Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bispebjerg Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low carbohydrate meals"},{"name":"Standard carbohydrate meals"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00808860","briefTitle":"Anti-Diabetic Effect of Gynostemma Pentaphyllum Tea as add-on Therapy With Sulfonylureas in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hanoi Medical University"},"collaborators":[{"name":"Karolinska Institutet"},{"name":"Swedish International Development Cooperation Agency (SIDA)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GP group"},{"name":"Placebo group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00374907","briefTitle":"A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Placebo"},{"name":"Metformin (blinded)"},{"name":"Metformin (open-label)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00937222","briefTitle":"Effects of Peanut and Peanut Butter Consumption on Blood Lipids and Glycemic Control in Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Loma Linda University"},"collaborators":[{"name":"National Peanut Board"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Peanuts and peanut butter"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00437112","briefTitle":"Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"},"collaborators":[{"name":"Alkermes, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Human Insulin Inhalation Powder"},{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01596504","briefTitle":"Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide (AVE0010)"},{"name":"Liraglutide"},{"name":"Insulin Glargine"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02291666","briefTitle":"Evaluation of CYP450 Activities in Diabetic Patients vs. Non-diabetic Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre hospitalier de l'Université de Montréal (CHUM)"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CRCHUM-MT cocktail"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02474147","briefTitle":"Processed Meat and Brain Regions Related to Reward and Addiction"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institute for Clinical and Experimental Medicine"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Processed meat hamburger"},{"name":"Vegan sandwich"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00515632","briefTitle":"Efficacy and Safety of Treatment With Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rheoscience A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Balaglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06204107","briefTitle":"A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-379(Empagliflozin+sitagliptin+metformin) Test drug"},{"name":"CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01377935","briefTitle":"Risk of Acute Kidney Injury Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"},{"name":"University of Pennsylvania"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00143520","briefTitle":"Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rivoglitazone"},{"name":"Pioglitazone"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00411411","briefTitle":"Long Term Effects of DPP-IV Inhibitor Treatment in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Januvia"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00402909","briefTitle":"Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nateglinide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03185689","briefTitle":"Diabetes Self-Management Education (DSME) and Its Effect on Clinical, Psychosocial, and Behavioral Outcomes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jimma University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Effectiveness of an intensified DSME in T2D adult patients"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04948931","briefTitle":"The Effect of Aromatherapy on Cognitive Functions, Anxiety and Sleep"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abant Izzet Baysal University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lavender aromatherapy"},{"name":"Rosemary aromatherapy"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02774733","briefTitle":"Correlation Between the Pulmonary Function Parameters and the Circulatory Parameters (PSV, EDV, RI) of Retrobulbar Blood Vessels (CRA, PCA, and OA) in 48 T2DM Patients Did Not Combinate With DR"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fourth People's Hospital of Shenyang"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"spirometer;Intraocular pressure;Color doppler imaging"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00660907","briefTitle":"Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"dapagliflozin"},{"name":"glipizide"},{"name":"metformin hydrochloride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00749190","briefTitle":"BI 10773 add-on to Metformin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 10773"},{"name":"placebo"},{"name":"sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04260100","briefTitle":"Diabetic Care Self-Management Mobile Health Application Among Diabetes Mellitus Clients in Malaysia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mohd Khairul Zul Hasymi Firdaus"},"collaborators":[{"name":"Prince of Songkla University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Care Self-Management Mobile Health Application"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00359879","briefTitle":"Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00353587","briefTitle":"Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gilead Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MBX-102"},{"name":"MBX-102"},{"name":"MBX-102"},{"name":"Placebo"},{"name":"Actos"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00815399","briefTitle":"Pioglitazone Versus Metformin in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Campania \"Luigi Vanvitelli\""}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02386930","briefTitle":"Behavioral Lifestyle Intervention Study (BLIS) in Patients With Type 2 Diabetes in UAE: A Randomized Controlled Trial in Real Life Setting"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rashid Centre for Diabetes and Research"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Behvarioal lifestyle modification"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00710008","briefTitle":"Effect of Short-Term Exercise Training on ATP Synthesis in Relatives of Type 2 Diabetic Humans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Landsteiner Institut"},"collaborators":[{"name":"Mein Hanusch-Krankenhaus"},{"name":"Karl-Landsteiner Institute for Endocrinology and Metabolism"},{"name":"Medical University of Vienna"},{"name":"Lund University Hospital"},{"name":"Fondazione C.N.R./Regione Toscana \"G. Monasterio\", Pisa, Italy"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exercise training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01624259","briefTitle":"A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2189265"},{"name":"Liraglutide"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01203111","briefTitle":"Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INSULIN GLARGINE"},{"name":"INSULIN GLULISINE"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02299050","briefTitle":"Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"},"collaborators":[{"name":"VeroScience"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cycloset"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04218734","briefTitle":"A Study of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DBPR108"},{"name":"metformin hydrochloride"},{"name":"placepo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00954447","briefTitle":"Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Linagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00918879","briefTitle":"Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01903356","briefTitle":"A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Trajenta duo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05819749","briefTitle":"Diabetes Homelessness Medication Support Program in Spanish"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hennepin Healthcare Research Institute"},"collaborators":[{"name":"National Institutes of Health (NIH)"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"University of Minnesota"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Homelessness Medication Support Program in Spanish"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01159353","briefTitle":"Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin Aspart"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glulisine"},{"name":"Insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02004366","briefTitle":"Linagliptin Inpatient Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"},"collaborators":[{"name":"Boston Medical Center"},{"name":"Rush University"},{"name":"University of Denver"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Linagliptin"},{"name":"Basal Bolus"},{"name":"Linagliptin"},{"name":"Linagliptin + 50% Glargine dose on discharge"},{"name":"Linagliptin + 80% Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02786823","briefTitle":"Effect of Folic Acid and Vitamin B12 Supplementation in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"All India Institute of Medical Sciences, Bhubaneswar"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Folic acid"},{"name":"Vitamin B12"},{"name":"Oral hypoglycemic agents [Metformin +/- Sulfonylurea]"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00460941","briefTitle":"A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Taspoglutide 20mg"},{"name":"Taspoglutide 20mg-30mg"},{"name":"Taspoglutide 20mg-40mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02906930","briefTitle":"Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04126603","briefTitle":"Impact of Semaglutide on CD34+ EPC and Fat Derived MSC"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sabyasachi Sen"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"},{"name":"Placebos"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02243176","briefTitle":"24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Acarbose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03086330","briefTitle":"Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02564926","briefTitle":"Foxiga Korea Local Phase 4 Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01422590","briefTitle":"Pharmacodynamics of Mitiglinide/Sitagliptin Compared to Mitiglinide and Sitagliptin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Samsung Medical Center"},"collaborators":[{"name":"JW Pharmaceutical"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Mitiglinide"},{"name":"Sitagliptin, Mitiglinide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03797885","briefTitle":"A Study of People With Type 2 Diabetes Who Have Diseases That Affect the Heart and Blood Vessels. The Study Will Also Look at the Treatment of a Group of These People in Hospitals in Portugal"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03374774","briefTitle":"A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BIAsp 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02251301","briefTitle":"Milk Plus Exercise: A Novel Strategy to Treat Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of British Columbia"},"collaborators":[{"name":"Dairy Farmers of Canada"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Skim Milk"},{"name":"High intensity interval training"},{"name":"Placebo"},{"name":"Macronutrient isoenergetic control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06084156","briefTitle":"A Study to Evaluate the DDI of HSK7653 With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Haisco Pharmaceutical Group Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HSK7653"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01855087","briefTitle":"Safety and Efficacy of Sitagliptin Added to Insulin Therapy for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kanagawa Physicians Association"},"collaborators":[{"name":"The Japan Kidney Foundation"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00760578","briefTitle":"A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Metabolic Solutions Development Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Pioglitazone"},{"name":"MSDC-0160 90 mg"},{"name":"MSDC-0160 220 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02282046","briefTitle":"Diabetes Effects on Long-Term Implant Survival and Success"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"},"collaborators":[{"name":"National Institute of Dental and Craniofacial Research (NIDCR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05974878","briefTitle":"The Effect of the Physiotherapy Program for Diabetic Individuals on Dexterity, Proprioception, and Functionality"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hasan Kalyoncu University"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise"},{"name":"Conventional Physiotherapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00511667","briefTitle":"A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK0941"},{"name":"Comparator: Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01867216","briefTitle":"A Study of Multiple Doses of LY2922470 in Participants With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"LY2922470"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03487887","briefTitle":"Secondary Care - Continuous Glucose Monitoring"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Croatian Society for Endocrinology and Diabology"},"collaborators":[{"name":"Takeda"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"continuous glucose monitoring (CGM) iPro™2 Medtronic"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02872922","briefTitle":"Effects of Low Intensity Therapeutic Ultrasound on Endothelial Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidade Federal de Santa Maria"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low intensity therapeutic ultrasound"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01790724","briefTitle":"Regulating Efficacy and Wellness in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Illinois at Urbana-Champaign"},"collaborators":[{"name":"National Institute on Aging (NIA)"}]},"conditionsModule":{"conditions":["Diabetes Type 2","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Walking exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00964587","briefTitle":"Cardiovascular Disease Education and Problem-Solving Training in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johns Hopkins University"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Education + Problem-Solving Training Self-Study"},{"name":"Education + Group Problem-Solving Training"},{"name":"Education + Individual Problem-Solving Training"},{"name":"Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01956357","briefTitle":"Chronic Effects of Two Aerobic-training Models Performed in Water and on Dry Land in Patients With Type 2 Diabetes Mellitus (T2DM)."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital de Clinicas de Porto Alegre"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aquatic exercise"},{"name":"Land Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00111631","briefTitle":"A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DPP-IV Inhibitor"},{"name":"Metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01254084","briefTitle":"Effect of Gynostemma Pentaphyllum Tea in Insulin Sensitivity in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hanoi Medical University"},"collaborators":[{"name":"Karolinska Institutet"},{"name":"Swedish International Development Cooperation Agency (SIDA)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gynostemma Pentaphyllum tea"},{"name":"Placebo tea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01768559","briefTitle":"Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide (AVE0010)"},{"name":"Insulin glulisine QD"},{"name":"Insulin glulisine TID"},{"name":"Insulin Glargine (Mandatory background drug)"},{"name":"Metformin (Background drug)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03520972","briefTitle":"Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"PegBio Co., Ltd."},"collaborators":[{"name":"Tigermed Consulting Co., Ltd"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PB-119 75ug"},{"name":"PB-119 150ug"},{"name":"PB-119 200ug"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01929863","briefTitle":"Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"},"collaborators":[{"name":"Elite Research Institute"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK2330672"},{"name":"Placebo"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03349944","briefTitle":"Effect of Training Intensity on Health Outcomes in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Morten Hostrup, PhD"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00774553","briefTitle":"To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD1656"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00502710","briefTitle":"A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in Patients With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"RO4876904"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00316758","briefTitle":"A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GK Activator (2)"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00768105","briefTitle":"To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD1656"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01398267","briefTitle":"A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"aleglitazar"},{"name":"lisinopril"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00857870","briefTitle":"Insulin Glargine First Line vs Metformin in Type 2 Diabetic Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GWT-TUD GmbH"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03124043","briefTitle":"Get In Touch Phase 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Massachusetts, Worcester"},"collaborators":[{"name":"Livongo Health"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Livongo for Diabetes program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02730078","briefTitle":"Value-based Emotion-focused Educational Programme to Reduce Diabetes-related Distress"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universiti Putra Malaysia"},"collaborators":[{"name":"Ministry of Health, Malaysia"},{"name":"UMC Utrecht"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"VEMOFIT"},{"name":"Attention-meetings (AG)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01212133","briefTitle":"A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00396227","briefTitle":"Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"},{"name":"thiazolidinedione (TZD)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00855166","briefTitle":"Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Metformin"},{"name":"Sitagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00375388","briefTitle":"The HOME Trial: Hyperinsulinaemia: the Outcome of Its Metabolic Effects, a Randomized Controlled Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bethesda General Hospital, Hoogeveen"},"collaborators":[{"name":"Takeda"},{"name":"LifeScan"},{"name":"Merck KGaA, Darmstadt, Germany"},{"name":"Dupont Merck"},{"name":"Merck Sharp & Dohme LLC"},{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin on top of intensive insulin therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00546325","briefTitle":"REASSURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic Agents"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rimonabant"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01176097","briefTitle":"To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD5658"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00747175","briefTitle":"A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD1656"},{"name":"AZD1656"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03387683","briefTitle":"A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"dapagliflozin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00986349","briefTitle":"Study of EndoBarrier Liner for Treatment of Type 2 Diabetes Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Morphic Medical Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EndoBarrier Liner"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02673554","briefTitle":"The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of GIP"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diabeteszentrum Bad Lauterberg im Harz"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GIP Bolus"},{"name":"GIP Clamp"},{"name":"Oral glucose tolerance test (OGTT)"},{"name":"hyperglycemic clamp"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02290301","briefTitle":"An Observational Study to Evaluate Cardiovascular Outcomes of T2DM PatientsTreated With Gemigliptin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LG Life Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"gemigliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00240253","briefTitle":"A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pramlintide acetate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02558296","briefTitle":"Bexagliflozin Efficacy and Safety Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Theracos"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bexagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00517465","briefTitle":"A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"RG1511"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00511472","briefTitle":"An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK-0941"},{"name":"Placebo"},{"name":"LANTUS insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01242202","briefTitle":"A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ipragliflozin"},{"name":"alpha glucosidase inhibitor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00424411","briefTitle":"Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Inhaled human insulin (EXUBERA™)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00725257","briefTitle":"Dietary Control of Type 2 Diabetes: Low-Carbohydrate Mediterranean Diet Versus Low-Fat Diet"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Campania \"Luigi Vanvitelli\""}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mediterranean diet"},{"name":"Low-fat diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00829569","briefTitle":"n-3 Fatty Acid Infusion and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"St. Olavs Hospital"},"collaborators":[{"name":"Norwegian University of Science and Technology"},{"name":"Norwegian Foundation for Health and Rehabilitation"},{"name":"Novo Nordisk A/S"},{"name":"Norwegian Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intralipid +/- Omegaven"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00952198","briefTitle":"A Safety Study of ARRY-403 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Array Biopharma, now a wholly owned subsidiary of Pfizer"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ARRY-403, glucokinase activator; oral"},{"name":"Placebo; oral"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04431687","briefTitle":"A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD 501"},{"name":"D759, D150"},{"name":"CKD-501, D759, D150"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03021187","briefTitle":"Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"semaglutide"},{"name":"semaglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02990299","briefTitle":"mHealth for Diabetes Adherence Support"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Illinois at Chicago"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"mHealth for Diabetes Adherence Support"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02089438","briefTitle":"DPP-4 Inhibition, Incretins and Islet Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lund University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Vildagliptin"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01013766","briefTitle":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK1362885"},{"name":"GSK1362885"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02714660","briefTitle":"The Work of Being a Patient With Diabetes: Data Collection Via a Smartphone Application"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"none, observational study"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01512979","briefTitle":"Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"metformin"},{"name":"linagliptin"},{"name":"metformin placebo"},{"name":"metformin placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01724645","briefTitle":"Beneficial Effects of Korean Traditional Diets in Subjects With Hypertension and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chonbuk National University Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Korean traditional diets"},{"name":"Control group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01386099","briefTitle":"A PK-PD Study of PSN821 in Type 2 Diabetes Patients (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Prosidion Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PSN821"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02324569","briefTitle":"A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SYR-472"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00916604","briefTitle":"To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD1656"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00612144","briefTitle":"Study Comparing Efficacy and Safety of Amaryl M and Metformin Uptitraion to Type 2 DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Handok Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glimepiride/metformin fixed combination"},{"name":"Metformin HCl"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02946541","briefTitle":"A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dong-A ST Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"evogliptin 5mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01919489","briefTitle":"Liraglutide Hospital Discharge Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide + OADs"},{"name":"Glargine + OADs"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01081834","briefTitle":"The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin"},{"name":"Placebo"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01402388","briefTitle":"Lifestyle Intervention in Patients With New Onset Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Royal Bournemouth Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Group lifestyle programme"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01606007","briefTitle":"Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Metformin XR"},{"name":"Dapagliflozin"},{"name":"Placebo matching with Dapagliflozin"},{"name":"Placebo matching with Saxagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02180620","briefTitle":"Pre-dinner vs. Post-dinner Exercise on Glycemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Missouri-Columbia"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No exercise"},{"name":"Meal then exercise"},{"name":"exercise then meal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00558571","briefTitle":"4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 10773 low dose"},{"name":"placebo to BI 10773"},{"name":"BI 10773 medium dose"},{"name":"BI 10773 high dose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00420511","briefTitle":"Beta-Cell Function and Sitagliptin Trial (BEST)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Placebo"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03392961","briefTitle":"Effect of Dosing Time and Meal on IN-105 (Insulin Tregopil) PK and PD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Biocon Limited"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IN-105 (Insulin Tregopil)"},{"name":"Placebo comparator"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00368368","briefTitle":"A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GK Activator (2)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01242228","briefTitle":"A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ipragliflozin"},{"name":"DPP-4 inhibitor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00082407","briefTitle":"Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"biphasic insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01602003","briefTitle":"Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LG Life Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LC15-0444 25mg bid"},{"name":"LC15-0444 50mg qd"},{"name":"Sitagliptin 100mg qd"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01043029","briefTitle":"A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"aleglitazar"},{"name":"pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01699932","briefTitle":"Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glimepiride+metformin (Amaryl M®) - HOE4900"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00541450","briefTitle":"A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Comparator: sitagliptin phosphate (sitagliptin)"},{"name":"sitagliptin phosphate (+) metformin hydrochloride"},{"name":"Comparator: pioglitazone"},{"name":"Matching placebo to pioglitazone"},{"name":"Matching placebo to sitagliptin"},{"name":"Matching Placebo to Sita/Met FDC"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01194830","briefTitle":"Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Linagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00859755","briefTitle":"A Safety Study of ARRY-403 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Array BioPharma"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ARRY-403, glucokinase activator; oral"},{"name":"Placebo; oral"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00809705","briefTitle":"A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"taspoglutide"},{"name":"taspoglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02849080","briefTitle":"Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00382239","briefTitle":"A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide (LY2148568)"},{"name":"exenatide (LY2148568)"},{"name":"exenatide (LY2148568)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00871507","briefTitle":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (Explores What the Body Does to the Drug), and Pharmacodynamics (Explores What a Drug Does to the Body) of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"JNJ-38431055 Dose 1"},{"name":"Sitagliptin 100 mg"},{"name":"Placebo"},{"name":"JNJ-38431055 Dose 2"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03165877","briefTitle":"Effect of Low-glycemic Index Meals Intake on DM2 Women Under Metformin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidad de Valparaiso"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low-glycemic index"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01740921","briefTitle":"GLP-1 and Microvascular Function in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Royal Devon and Exeter NHS Foundation Trust"},"collaborators":[{"name":"University of Exeter"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"diet"},{"name":"Aspirin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01956305","briefTitle":"Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DS-7309"},{"name":"placebo"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03508323","briefTitle":"Tenelia Elderly CGMS Study(TEDDY)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Handok Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Teneligliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05577728","briefTitle":"Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Brigham and Women's Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"New use of semaglutide injection"},{"name":"New initiation of \"standard of care\" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02949193","briefTitle":"Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dong-A ST Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"evogliptin"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01409330","briefTitle":"German Diabetes-Diet-Intervention and Energy Restriction-Trial (DDIET)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"German Diabetes Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"diet intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01011868","briefTitle":"Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 10773 placebo"},{"name":"BI 10773 low dose"},{"name":"BI 10773 high dose"},{"name":"BI 10773 placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02727790","briefTitle":"Effect of Short Peripheral Electrical Stimulation (PES) on Blood Glucose"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Assaf-Harofeh Medical Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Stimulator"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00643474","briefTitle":"PRISMA Study (Prospective, Randomized Trial on Intensive Self-Monitoring Blood Glucose Management Added Value in Non-Insulin Treated Type 2 Diabetes Mellitus Patients)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Accu-Chek Aviva Meter"},{"name":"Accu-Chek Aviva Meter"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01951651","briefTitle":"Effect of Exenatide on Liver and Heart Fat and Inflammation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baylor College of Medicine"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide"},{"name":"Glipizide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00479791","briefTitle":"Lipid, Glycemic, and Insulin Responses to Meals Rich in Different Fatty Acids"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Texas Southwestern Medical Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Test meals rich in different fatty acids"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00641056","briefTitle":"Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide Once Weekly"},{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01727349","briefTitle":"Validation of a Predictive Risk Equation for Type 2 Diabetes in Families With Risk"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HbA1c measurement"},{"name":"Oral Glucoce Tolerance Test"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00722397","briefTitle":"TODAY Genetics Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00699426","briefTitle":"The Effect of Nexium and Probiotics on Insulin Secretion and Cardiovascular Risk Factors in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lise Tarnow"},"collaborators":[{"name":"Novo Nordisk A/S"},{"name":"Chr Hansen"},{"name":"Statens Serum Institut"},{"name":"Steno Diabetes Center Copenhagen"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"nexium"},{"name":"nexium"},{"name":"Yoghurt"},{"name":"placebo+placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02221284","briefTitle":"Alogliptin Tablets Specified Drug-use Survey \"Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)\""},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01611363","briefTitle":"A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Europe B.V."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ASP1941"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02135549","briefTitle":"Study of the Effectiveness and Safety of SugarDown vs. Placebo in Type 2 Diabetic Subjects Treated With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boston Therapeutics"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SugarDown"},{"name":"Placebo Oral Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01703286","briefTitle":"Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Linagliptin"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01969357","briefTitle":"A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jiangsu HengRui Medicine Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"50 mg SP2086"},{"name":"100 mg SP2086"},{"name":"200 mg SP2086"},{"name":"100 mg Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00676338","briefTitle":"Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide once weekly"},{"name":"metformin"},{"name":"sitagliptin"},{"name":"pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02197520","briefTitle":"A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Peglispro"},{"name":"Insulin Glargine"},{"name":"Insulin Lispro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00688363","briefTitle":"Blood Glucose Self Monitoring and HbA1c Effects on Glucose Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Deutsche Diabetes Gesellschaft"},"collaborators":[{"name":"Bayer"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"weekly blood glucose profile"},{"name":"three-monthly haemoglobin A1c"},{"name":"no blood-glucose self-control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00567112","briefTitle":"Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"10 mg MK-0941 DFC (fasted)"},{"name":"10 mg MK-0941 OCT (after meal)"},{"name":"10 mg MK-0941 OCT (before meal)"},{"name":"10 mg MK-0941 OCT (fasted)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03429543","briefTitle":"Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Insulin"},{"name":"Placebo"},{"name":"Linagliptin"},{"name":"Empagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01042769","briefTitle":"A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aleglitazar"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01537120","briefTitle":"Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00680745","briefTitle":"Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"dapagliflozin"},{"name":"Glimepiride"},{"name":"metformin hydrochloride"},{"name":"pioglitazone hydrochloride"},{"name":"Rosiglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05182359","briefTitle":"Pragmatic Impact of Proteomic Risk Stratification in Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospitals Cleveland Medical Center"},"collaborators":[{"name":"SomaLogic, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) Test and SomaSignal Metabolic Factors test"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00905255","briefTitle":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide (AVE0010)"},{"name":"Pen auto-injector"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01734785","briefTitle":"Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Linagliptin"},{"name":"Empagliflozin + Linagliptin"},{"name":"Empagliflozin + Linagliptin"},{"name":"Empagliflozin + Linagliptin"},{"name":"Empagliflozin placebo + Linagliptin placebo"},{"name":"Empagliflozin + Linagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00355849","briefTitle":"Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"},"collaborators":[{"name":"Alkermes, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Human Insulin Inhalation Powder"},{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01244971","briefTitle":"Exercise and Acarbose in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Karolinska Institutet"},"collaborators":[{"name":"The Swedish Research Council"},{"name":"Bayer"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acarbose"},{"name":"Exercise"},{"name":"Exercise + Acarbose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02601989","briefTitle":"Effects on Insulin Resistance With Tadalafil in Type 2 Diabetes - a Double-blind, Placebo-controlled Crossover Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Göteborg University"},"collaborators":[{"name":"Vastra Gotaland Region"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tadalafil"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02324842","briefTitle":"Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"},"collaborators":[{"name":"Janssen Scientific Affairs, LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin"},{"name":"Liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00347100","briefTitle":"Insulin Glargine in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine"},{"name":"Glyburide"},{"name":"Glyclazide"},{"name":"Glimiperide"},{"name":"Glipizide"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00705952","briefTitle":"Group Lifestyle Intervention for People With New Onset Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Royal Bournemouth Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01906359","briefTitle":"Effects of Triacylglycerol Structure on Gut Hormones and Haemostatic Markers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Malaysia Palm Oil Board"},"collaborators":[{"name":"Universiti Putra Malaysia"},{"name":"Ministry of Health, Malaysia"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Native palm olein (IV56)"},{"name":"Chemically interesterified palm olein (IV56)"},{"name":"High oleic sunflower oil"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02417012","briefTitle":"Lifestyle and Glucose Lowering Medication in T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rigshospitalet, Denmark"},"collaborators":[{"name":"TRYG Foundation"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"U-TURN"},{"name":"Standard care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02548000","briefTitle":"Diabetes Resistance Training Adaptations in Elderly"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital de Clinicas de Porto Alegre"},"collaborators":[{"name":"Federal University of Rio Grande do Sul"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Resistance training"},{"name":"Stretching control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01169818","briefTitle":"Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01316341","briefTitle":"Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI10773"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"BI10773"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01303302","briefTitle":"The TANTALUS® II for the Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"MetaCure (USA), Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tantalus System"},{"name":"TANTALUS system"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03207711","briefTitle":"Delish Study: Diabetes Education to Lower Insulin, Sugars, and Hunger"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Francisco"},"collaborators":[{"name":"National Center for Complementary and Integrative Health (NCCIH)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Carbohydrate-restricted diet"},{"name":"Mindfulness"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03088670","briefTitle":"Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"SatRx LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gosogliptin"},{"name":"Vildagliptin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02421393","briefTitle":"Study to Weigh the Effect of Exercise Training on BONE (SWEET-BONE) Quality and Strength in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Metabolic Fitness Association, Italy"},"collaborators":[{"name":"University of Roma La Sapienza"},{"name":"S. Andrea Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"supervised exercise training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01289990","briefTitle":"Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 10773"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"BI 10773"},{"name":"Placebo"},{"name":"Placebo"},{"name":"BI 10773"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"BI 10773"},{"name":"BI 10773"},{"name":"BI 10773"},{"name":"Placebo"},{"name":"BI 10773"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Sitagliptin 100mg"},{"name":"BI 10773"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00082381","briefTitle":"Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide (AC2993)"},{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01921322","briefTitle":"Sensor Augmented Pump Therapy Versus Multiple Daily Injection Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medtronic Diabetes"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pump"},{"name":"CGMS Gold"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00467168","briefTitle":"Optimal Dietary Fat Pattern to Prevent Cardiovascular Disease Among Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sun Yat-sen University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03463629","briefTitle":"Multidisciplinary Team Approach: Working Together to Improve Glycemic Control in Hispanic Adults Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center, Houston"},"collaborators":[{"name":"DHR Health Institute for Research and Development"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Specialized multidisciplinary diabetes team (SMDT) approach"},{"name":"Traditional model of care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00653341","briefTitle":"Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glargine"},{"name":"NPH human insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00461058","briefTitle":"A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Actos"},{"name":"aleglitazar"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01069549","briefTitle":"Association of AGTR1 and ACACB Gene Polymorphism and Diabetic Nephropathy in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Post Graduate Institute of Medical Education and Research, Chandigarh"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01234155","briefTitle":"Exercise Training and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rigshospitalet, Denmark"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise Training - Interval Walking"},{"name":"Exercise - Continuous Walking"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05304975","briefTitle":"Border Region Area Lifestyle Intervention Study for Healthy Neurocognitive Ageing Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Queen's University, Belfast"},"collaborators":[{"name":"Western Health and Social Care Trust"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"diet"},{"name":"cognitive stimulation"},{"name":"physical activity"},{"name":"risk factor management"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01353469","briefTitle":"Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin human/Insuman Comb 25 (HR1799)"},{"name":"Insulin human/Novolin® 30R"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01000519","briefTitle":"Effects of Different Mode of Exercise Training on Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Singapore General Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aerobic Training"},{"name":"Progressive resistance training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01748552","briefTitle":"A Study of LY2922083 in Healthy Participants and Participants With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"LY2922083"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01746017","briefTitle":"A Study of LY2922470 in Healthy Participants and Participants With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"LY2922470"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01521624","briefTitle":"Metformin Effects on Oxidative Stress Parameters in Newly Diagnosed Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tehran University of Medical Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06141590","briefTitle":"A Clinical Study to Evaluate the Safety and the Pharmacokinetics of UI068 in Healthy Adult Volunteers Under Fed Conditions"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Korea United Pharm. Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"administration of UI068"},{"name":"administration of UIC202205, UIC202206"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00551356","briefTitle":"Lispro Mix 25 vs. Glargine in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin lispro mix 25"},{"name":"Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00467649","briefTitle":"A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pramlintide acetate (Symlin)"},{"name":"rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])"},{"name":"basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01441232","briefTitle":"A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lexicon Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LX4211"},{"name":"Januvia®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01991769","briefTitle":"Negative Postprandial Effect on Endothelium After a Not-healthy Meal in Type 2 Diabetes as Affected by Training"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Norwegian University of Science and Technology"},"collaborators":[{"name":"St. Olavs Hospital"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"47 min moderate intensity training"},{"name":"exercise healthy volunteers"},{"name":"control; no exercise training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00663884","briefTitle":"Glufast On Insulin Glargine Trial in Type 2 DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"JW Pharmaceutical"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mitiglinide"},{"name":"Voglibose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00881530","briefTitle":"Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 10773"},{"name":"Metformin"},{"name":"BI 10773"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01217892","briefTitle":"Evaluation of Dapagliflozin Taken Twice-daily"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"dapagliflozin"},{"name":"dapagliflozin"},{"name":"dapagliflozin"},{"name":"metformin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00135057","briefTitle":"Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glulisine"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00698932","briefTitle":"Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04743778","briefTitle":"Online Diabetes Education Project (ODEP)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Virtual Diabetes Self-Management Education and Support"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05411965","briefTitle":"A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boryung Pharmaceutical Co., Ltd"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BR3003(T)"},{"name":"BR3003B(R1)"},{"name":"BR3003C(R2)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02754817","briefTitle":"A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01086293","briefTitle":"Risk of Acute Liver Failure Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"},{"name":"University of Pennsylvania"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03549390","briefTitle":"Investigating the Acute Effect of Alternative Forms of Physical Activity in a Multi-ethnic Population"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Leicester"},"collaborators":[{"name":"University Hospitals, Leicester"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physical activity"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01086319","briefTitle":"Risk of Hospitalization for Severe Hypersensitivity (Including Severe Skin Reactions) in Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"},{"name":"University of Pennsylvania"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00763451","briefTitle":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide (AVE0010)"},{"name":"Placebo"},{"name":"Pen auto-injector"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00688701","briefTitle":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide (AVE0010)"},{"name":"Placebo"},{"name":"Pen auto-injector"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01135992","briefTitle":"Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00461006","briefTitle":"A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Actos"},{"name":"aleglitazar"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03764631","briefTitle":"Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Dipeptidyl-peptidase 4 (DPP-4) inhibitors"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01229891","briefTitle":"Comparison of Efficacy of Vitamin D and Vitamin D-calcium Fortified Yogurt Drink in Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Nutrition and Food Technology Institute"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"plain yogurt drink"},{"name":"vitamin D fortified yogurt drink"},{"name":"vitamin D-calcium yogurt drink"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00960076","briefTitle":"An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Metformin XR"},{"name":"Metformin XR"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00909597","briefTitle":"A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pioglitazone"},{"name":"taspoglutide"},{"name":"taspoglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02476760","briefTitle":"Incretin-based Drugs and Acute Pancreatitis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Canadian Network for Observational Drug Effect Studies, CNODES"},"collaborators":[{"name":"Drug Safety and Effectiveness Network, Canada"},{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DPP-4 inhibitors"},{"name":"GLP-1 analogs"},{"name":"Insulins"},{"name":"Biguanides"},{"name":"Sulfonylureas"},{"name":"Thiazolidinediones"},{"name":"Alpha-glucosidase inhibitors"},{"name":"Meglitinides"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05046873","briefTitle":"A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL"},{"name":"semaglutide 1.34 mg/mL (placebo)"},{"name":"Semaglutide 1.34 mg/mL"},{"name":"NNC0480-0389 A 10 mg/mL"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01319357","briefTitle":"Effects of Saxagliptin on Endothelial Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Erlangen-Nürnberg Medical School"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00704236","briefTitle":"Improvement of Insulin Resistance With Traditional Chinese Treatment in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Jiao Tong University School of Medicine"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Coptis Chinensis, Astragalus mambranesceus, Lonicera Japonica (Traditional Chinese Treatment)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00373178","briefTitle":"Metabolic Effects of Treatment in Patients With Recently Diagnosed Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aristotle University Of Thessaloniki"},"collaborators":[{"name":"University of Athens"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rosiglitazone"},{"name":"metformin"},{"name":"Anti-diabetic medications"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05497674","briefTitle":"Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sunshine Lake Pharma Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rongliflozin"},{"name":"Rifampin"},{"name":"Rongliflozin"},{"name":"Probenecid"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01095666","briefTitle":"A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"AstraZeneca, Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Dapagliflozin"},{"name":"Metformin"},{"name":"Dapagliflozin Placebo"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00351546","briefTitle":"A Study to Assess the Effects of DPP-4 Inhibition on Insulin Sensitivity in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00268645","briefTitle":"Insulin Glargine in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01181986","briefTitle":"The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Carl T. Hayden VA Medical Center"},"collaborators":[{"name":"American Diabetes Association"},{"name":"Amylin Pharmaceuticals, LLC."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide SC"},{"name":"Exenatide IV"},{"name":"Placebo SC"},{"name":"Exendin-9"},{"name":"Placebo IV"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03338803","briefTitle":"Real World Glycemic Effectiveness of Linagliptin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Linagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02280486","briefTitle":"Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"},"collaborators":[{"name":"The First Affiliated Hospital with Nanjing Medical University"},{"name":"Zhongda Hospital"},{"name":"Nanjing PLA General Hospital"},{"name":"Changzhou No.2 People's Hospital"},{"name":"The First Affiliated Hospital of Soochow University"},{"name":"Wuxi People's Hospital"},{"name":"The First Affiliated Hospital of Anhui Medical University"},{"name":"Huai'an First People's Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02111967","briefTitle":"Study to Identify Adequate Biomarker to Detect Vitamin B12 Deficiency in Type 2 Diabetic Patients Treated With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Basel, Switzerland"},"collaborators":[{"name":"University of Basel"},{"name":"Solothurner Spitäler AG"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Questionnaire administration"},{"name":"Laboratory biomarker analysis"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02683135","briefTitle":"Lifestyle Control of Postprandial Hyperglycemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of British Columbia"},"collaborators":[{"name":"Medtronic"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High-carbohydrate diet"},{"name":"Low-carbohydrate diet"},{"name":"Low-carbohydrate diet with post-meal walking"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00099619","briefTitle":"Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide/insulin glargine"},{"name":"insulin glargine/exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00350779","briefTitle":"Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin"},{"name":"Comparator: Placebo"},{"name":"rosiglitazone"},{"name":"metformin"},{"name":"glipizide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02974244","briefTitle":"Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide once weekly"},{"name":"basal insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02058147","briefTitle":"Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine/lixisenatide Fixed Ratio Combination"},{"name":"Insulin glargine (HOE901)"},{"name":"Lixisenatide (AVE0010)"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04831775","briefTitle":"Cognitive Training for Diabetes Self-Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Texas at Austin"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Memory, Attention, and Problem Solving Skills for Diabetes"},{"name":"Brain Games"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00497133","briefTitle":"Alpha-Cell Sensitivity to GLP-1 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Copenhagen"},"collaborators":[{"name":"Novo Nordisk A/S"},{"name":"The Danish Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02081118","briefTitle":"Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hanmi Pharmaceutical Company Limited"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HM11260C"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04760444","briefTitle":"Michigan Men's Diabetes Project"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"},"collaborators":[{"name":"Blue Cross Blue Shield of Michigan Foundation"},{"name":"National Institutes of Health (NIH)"},{"name":"National Institute on Aging (NIA)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Peer Leader Diabetes Self-Management Support"},{"name":"Virtual Diabetes Self-Management Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02026310","briefTitle":"Efficacy/Safety Study of Glimepiride to Type 2 Diabetes Patients Based on Metformin And Basal Insulin Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Qifu Li"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"glimepiride"},{"name":"glargine and metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03642717","briefTitle":"Regulatory Request NIS in Korea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"JARDIANCE DUO®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00975286","briefTitle":"24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide (AVE0010)"},{"name":"Placebo"},{"name":"Insulin glargine"},{"name":"Pen auto-injector"},{"name":"Metformin"},{"name":"Thiazolidinedione (TZD)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02607306","briefTitle":"A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/liraglutide"},{"name":"insulin degludec"},{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00381342","briefTitle":"Safety and Efficacy of Exenatide as Monotherapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"exenatide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05415644","briefTitle":"Study of the Bioequivalence and Food Effects of HRX0701 Tablets in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shandong Suncadia Medicine Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"hrx0701 tablets、Metformin hydrochloride tablets、Retagliptin phosphate tablets"},{"name":"hrx0701 tablets"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01128153","briefTitle":"Saxagliptin Triple Oral Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02597400","briefTitle":"Drug-Drug Interaction Study of Glucokinase Activator HMS5552 and Metformin in T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hua Medicine Limited"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"HMS5552"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01095653","briefTitle":"A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"AstraZeneca, Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Dapagliflozin"},{"name":"Metformin"},{"name":"Dapagliflozin Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01955031","briefTitle":"Effectiveness and Cost-effectiveness of a Telemonitoring Program for Diabetic People at Home"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Toulouse"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"telemonitoring"},{"name":"Usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01474018","briefTitle":"QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Texas Southwestern Medical Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"QR-bromocriptine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00886821","briefTitle":"A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CVX-096"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02152852","briefTitle":"Peer Support for Achieving Independence in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Public Health - Seattle and King County"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Community Health Worker Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00661362","briefTitle":"Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Placebo"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02757937","briefTitle":"Reaching Better Health Study: A Website to Improve Type 2 Diabetes Self-Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Children's Hospital of Philadelphia"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"},{"name":"University of Pennsylvania"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Health & Wellness Website"},{"name":"Control Arm"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00350701","briefTitle":"Effect of Androgel on Type 2 Diabetic Males With Hypogonadism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University at Buffalo"},"collaborators":[{"name":"Solvay Pharmaceuticals"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"androgel"},{"name":"androgel 10g"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02420262","briefTitle":"A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/liraglutide"},{"name":"insulin glargine"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01517373","briefTitle":"Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"PF-04937319 10 mg"},{"name":"PF-04937319 50 mg"},{"name":"PF-04937319 100 mg"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00553020","briefTitle":"Assessment of Duration of Metabolic Effect of a Single Bolus of sc Injected Lantus Compared to NPH Insulin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02612805","briefTitle":"The Diabetes and Aquatic Training Study (DATS)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital de Clinicas de Porto Alegre"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aerobic training"},{"name":"Combined training"},{"name":"Training placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03686917","briefTitle":"Validation of a CREATION Health Assessment Tool for Patients in a Diabetic Outpatient Population"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AdventHealth"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CHAT-P"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02666924","briefTitle":"Cooking Classes for Chinese Canadian Patients Living With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vancouver General Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Chinese-canadian specific cooking classes"},{"name":"Diabetes educational classes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05870670","briefTitle":"A Research Study of a New Medicine NNC0519-0130 in Japanese and Non-Japanese Men"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NNC0519-0130"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01175824","briefTitle":"Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Lispro Low Mixture (LM)"},{"name":"Insulin Glargine"},{"name":"Prandial Insulin Lispro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01241370","briefTitle":"Skin and Retina Microvascular Endothelial Function in Healthy, Insulin Resistant and Type 2 Diabetic Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"ELAB-Logistics"},"collaborators":[{"name":"Institute for Clinical Research and Development (ikfe) GmbH"},{"name":"Johannes Gutenberg University Mainz"},{"name":"University of Erlangen-Nürnberg Medical School"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03947333","briefTitle":"Evaluation of a Patient Portal Intervention for Diabetes: A Pilot Randomized Controlled Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University Medical Center"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"My Diabetes Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02361138","briefTitle":"The PK/PD Study of Multiple Dose of SHR3824 in Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jiangsu HengRui Medicine Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SHR3824"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02202161","briefTitle":"A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK2330672"},{"name":"Placebo"},{"name":"Sitagliptin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02356224","briefTitle":"The PK/PD Study of Single Dose of SHR3824 in Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jiangsu HengRui Medicine Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SHR3824"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02650726","briefTitle":"Purified Anthocyanins Supplementation and High-Density Lipoprotein (HDL) Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sun Yat-sen University"}},"conditionsModule":{"conditions":["Diabetes Mellitus，Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Anthocyanin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01144078","briefTitle":"Exercise Intensity, Glycemic Control and Abdominal Fat in People With Type 2 Diabetes: A Pilot Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alberta"},"collaborators":[{"name":"Alberta Diabetes Institute"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Traditional Intensity Exercise"},{"name":"High Intensity Interval Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00525330","briefTitle":"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"ActivX Biosciences, Inc."},"collaborators":[{"name":"Kyorin Pharmaceutical Co.,Ltd"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"KRP-104 QD Drug: Placebo Drug: Metformin"},{"name":"Placebo Drug: Metformin"},{"name":"KRP-104 BID Drug: Placebo Drug: Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02372630","briefTitle":"The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University at Buffalo"},"collaborators":[{"name":"Kaleida Health"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Linagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00656864","briefTitle":"Pioglitazone Incretin Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Vermont"},"collaborators":[{"name":"Takeda"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03027726","briefTitle":"Prevention of Diabetes in Overweight/Obese Preadolescent Children"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of the Basque Country (UPV/EHU)"},"collaborators":[{"name":"Ministerio de Economía y Competitividad, Spain"},{"name":"Universidad Pública de Navarra"}]},"conditionsModule":{"conditions":["Overweight Children With Type 2 Diabetes Risk"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"lifestyle and psycho-educational program"},{"name":"Exercise plus lifestyle and psycho-educational program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01358981","briefTitle":"A Study of LY2881835 in Healthy People and People With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2881835"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00849563","briefTitle":"Effect of Type 2 Diabetes Genetic Risk Information on Health Behaviors and Outcomes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Duke University"},"collaborators":[{"name":"deCODE genetics"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Standardized Risk Assessment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00542698","briefTitle":"Changing Physical Activity Behavior in Individuals With Type 2 Diabetes Using Counceling and Information From Continuous Glucose Monitoring"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Nursing Research (NINR)"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Effect of Physical Activity on Type II Diabetes Mellitus"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02455011","briefTitle":"Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"REMD Biotherapeutics, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"REMD-477"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00968812","briefTitle":"CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glimepiride"},{"name":"Canagliflozin (JNJ-28431754)"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00901043","briefTitle":"Effects of Walnut Consumption on Endothelial Function in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Griffin Hospital"},"collaborators":[{"name":"California Walnut Commission"}]},"conditionsModule":{"conditions":["DIABETES MELLITUS TYPE 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Walnut supplementation"},{"name":"Ad lib diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02316054","briefTitle":"Evaluation of Myocardial Perfusion Heterogeneity Imaging in Diabetes Patients (EVADIAB)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Grenoble"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MPHI"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01804842","briefTitle":"Assessing the Effect of Met DR on Plasma Glucose and PK in Subjects With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Elcelyx Therapeutics, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Met DR"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00463502","briefTitle":"The Effect of Metformin Treatment on Thyroid Hormone Metabolism in Euthyroid Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Haydarpasa Numune State Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02974816","briefTitle":"Glooko mHealth Advantage Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Glooko"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glooko's mobile application"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02432391","briefTitle":"Lifestyle Modification for Type 2 Diabetes Involving Reduction of After-meal Blood Glucose Elevations"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Virginia"},"collaborators":[{"name":"LifeScan"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GEM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04829045","briefTitle":"Effects of Acupuncture as Adjunctive Therapy in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universiti Putra Malaysia"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Acupuncture"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SEIRIN PYONEX Acupuncture Needles"},{"name":"PYONEX Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00885846","briefTitle":"Effects of Qigong on Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bastyr University"},"collaborators":[{"name":"Seattle Foundation"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Qigong therapy"},{"name":"Progressive resistance training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00713830","briefTitle":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide (AVE0010)"},{"name":"Placebo"},{"name":"Pen auto-injector"},{"name":"Sulfonylurea"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02464462","briefTitle":"The Role of Vitamin D3 and Calcium Supplementation in Attenuating T2DM Severity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"York University"},"collaborators":[{"name":"Women's Health in Women's Hands Community Health Center"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vitamin D3 and calcium"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00853151","briefTitle":"A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"},"collaborators":[{"name":"OPKO Health, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2428757"},{"name":"TT223"},{"name":"Placebo for LY2428757"},{"name":"Placebo for TT223"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00388986","briefTitle":"A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GK Activator (2)"},{"name":"Glyburide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02401880","briefTitle":"Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Profil Institut für Stoffwechselforschung GmbH"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Linagliptin"},{"name":"Placebo"},{"name":"Empagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02497313","briefTitle":"Effect of Metformin and Cholecystokinin-mediated Gallbladder Emptying on GLP-1 Secretion in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Isotonic saline"},{"name":"Metformin placebo"},{"name":"Cholecystokinin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01356381","briefTitle":"Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03350191","briefTitle":"A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"},"collaborators":[{"name":"Antaros Medical"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SAR425899"},{"name":"[68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer)"},{"name":"[68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00987285","briefTitle":"Linking Self-Management and Primary Care for Diabetes 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kaiser Permanente"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"InterVision"},{"name":"Oregon Research Institute"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CASM +"},{"name":"CASM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01159600","briefTitle":"Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo identical to BI 10773 high dose"},{"name":"Placebo identical to BI 10773 low dose"},{"name":"BI 10773"},{"name":"BI 10773"},{"name":"Placebo identical to BI 10773 low dose"},{"name":"BI 10773"},{"name":"Placebo identical to BI 10773 high dose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02186080","briefTitle":"Effect of Gemigliptin on Metabolic Endotoxemia and Lipemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Hospital"},"collaborators":[{"name":"LG Life Sciences"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gemigliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01455870","briefTitle":"A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Intarcia Therapeutics"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ITCA 650 60 mcg/day"},{"name":"sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01759823","briefTitle":"Bone Marrow Derived Stem Cell Transplantation in T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Post Graduate Institute of Medical Education and Research, Chandigarh"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"mesenchymal stem cell transplantation"},{"name":"control"},{"name":"MNC's TRANSPLANTATION"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02309424","briefTitle":"The Effect of Vinegar on Glucose and Lipid Metabolism in Subjects With Impaired Glucose Tolerance or Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Attikon Hospital"},"collaborators":[{"name":"Hellenic National Diabetes Center"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vinegar"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02993614","briefTitle":"Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01459809","briefTitle":"Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLIMEPIRIDE"},{"name":"METFORMIN"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01349387","briefTitle":"Effect of Treatment With Metformin in Type 2 Diabetes Patients on Alternative Genes Splicing"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00532506","briefTitle":"Phase II Dose-Finding Study of SK-0403 With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanwa Kagaku Kenkyusho Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SK-0403"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01548235","briefTitle":"Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00256607","briefTitle":"Non-traditional Cardiovascular Risk Factors and Atherosclerosis in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"US Department of Veterans Affairs"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03949504","briefTitle":"Diabetes Risk Diagnosis and Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Neuromed IRCCS"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"New Find-risk questionnaire software"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01680978","briefTitle":"A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"aleglitazar"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02375932","briefTitle":"Pre-Visit Prioritization for Complex Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kaiser Permanente"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pre-Visit Tool"},{"name":"Usual Care Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01018173","briefTitle":"A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo"},{"name":"taspoglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05160974","briefTitle":"QTERN (SAXAGLIPTIN/DAPAGLIFLOZIN FDC) Regulatory Post-Marketing Surveillance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00715624","briefTitle":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide (AVE0010)"},{"name":"Placebo"},{"name":"Basal Insulin"},{"name":"Metformin"},{"name":"Pen auto-injector"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00894868","briefTitle":"Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Congestive Heart Failure","Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"},{"name":"placebo of vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04937816","briefTitle":"This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Empagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05260879","briefTitle":"Potential Effectiveness of the Diabetes Prevention Program in the Peri-urban Area of Bamako, Mali"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Clinical Research Center, Mali"},"collaborators":[{"name":"Columbia University"},{"name":"Fogarty International Center of the National Institute of Health"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes prevention program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02289612","briefTitle":"Glycemic and Satiety Response Study of Fibre-Enriched Pudding Products"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Guelph"},"collaborators":[{"name":"Ontario Ministry of Agriculture, Food and Rural Affairs"},{"name":"Natural Sciences and Engineering Research Council, Canada"},{"name":"Dairy Farmers of Ontario"},{"name":"Agriculture and Agri-Food Canada"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Yellow Mustard Gum Fibre"},{"name":"Soluble Flaxseed Gum Fibre"},{"name":"Fenugreek Gum Fibre"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01255085","briefTitle":"Yellow Pea Protein and Fibre and Short Term Food Intake"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Toronto"},"collaborators":[{"name":"Agriculture and Agri-Food Canada"}]},"conditionsModule":{"conditions":["Obesity","Type II Diabetes Mellitus","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"yellow pea protein"},{"name":"yellow pea fiber"},{"name":"Control Tomato Soup"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01821846","briefTitle":"Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01242059","briefTitle":"Yellow Pea Fractions and Short-term Food Intake, Subjective Appetite and Glycemic Response"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Toronto"},"collaborators":[{"name":"Agriculture and Agri-Food Canada"},{"name":"Pulse Canada"}]},"conditionsModule":{"conditions":["Obesity","Type II Diabetes Mellitus","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"yellow pea protein"},{"name":"yellow pea fiber"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00763815","briefTitle":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide (AVE0010)"},{"name":"Placebo"},{"name":"Pen auto-injector"},{"name":"Pioglitazone"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00800176","briefTitle":"A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"RO4998452"},{"name":"RO4998452"},{"name":"RO4998452"},{"name":"RO4998452"},{"name":"RO4998452"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01096940","briefTitle":"Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD1656"},{"name":"simvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00812032","briefTitle":"Evaluation of Antiplatelet Effects of Different Dosages of Aspirin in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Karolinska Institutet"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aspirin"},{"name":"aspirin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06519903","briefTitle":"Anxiety Reduction in Type 2 Diabetes Through Breathing ExercisesPatients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Goztepe Prof Dr Suleyman Yalcın City Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Type 2 Diabetes Treated With Insulin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BREATH technique"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02856113","briefTitle":"Phase 3 Alogliptin Pediatric Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"},"collaborators":[{"name":"Takeda Development Center Americas, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin Benzoate"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02231021","briefTitle":"The Practical Evidence of Antidiabetic Combination Therapy in Korea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kun-Ho Yoon"},"collaborators":[{"name":"Takeda"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"alogliptin"},{"name":"Pioglitazone"},{"name":"alogliptin + pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04857411","briefTitle":"Peers LEAD Plus Healthy Living With Diabetes (HLWD)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Wisconsin, Madison"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Peers LEAD plus HLWD"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00541775","briefTitle":"Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Comparator: Rosiglitazone"},{"name":"Comparator: Placebo"},{"name":"Comparator: Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00849576","briefTitle":"Effect of Treatment With Insulin VIAjectTM Compared to Regular Human Insulin and Insulin Lispro on Mealtime Blood Vessel Stress in Patients With Type 2 Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Biodel"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Regular Human Insulin"},{"name":"Insulin Lispro"},{"name":"Insulin VIAject™ (75%)"},{"name":"Insulin VIAject™ (90%)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01400971","briefTitle":"An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02458495","briefTitle":"The Diabetes Medication Adherence Promotion Intervention Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes MAP Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00044668","briefTitle":"Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AC2993"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00145925","briefTitle":"Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The George Institute"},"collaborators":[{"name":"Institut de Recherches Internationales Servier"},{"name":"University of Sydney"},{"name":"National Health and Medical Research Council, Australia"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Perindopril-indapamide"},{"name":"Gliclazide MR-based glucose lowering"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03389490","briefTitle":"Toujeo Versus NPH Self-titration Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Elaine Chow"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine 300 UNT/ML"},{"name":"Neutral protamine hagedorn insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01630369","briefTitle":"Efficacy and Safety of Insuman Basal/Comb/Rapid in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin human (HR1799)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02971865","briefTitle":"Effect of Manual Medicine or Cognitive Behavioral Therapy With Chronic Uncontrolled Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Community Wellness Center, West Linn, OR"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CBT/CMT"},{"name":"Control group traditional primary care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00601250","briefTitle":"Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"linagliptin"},{"name":"linagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01776788","briefTitle":"Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The First Affiliated Hospital of Xiamen University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin lispro injection, exenatide injection"},{"name":"insulin lispro injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00434954","briefTitle":"Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide twice daily (BID)"},{"name":"premixed insulin aspart twice daily (BID)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00726674","briefTitle":"Basal Insulin for Type 2 Diabetes Patients Treated in Outpatient Clalit Clinics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01357876","briefTitle":"Effect of Metformin on Gut Peptides , Bile Acids and Lipid Profiles in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05207020","briefTitle":"Development and Validation of the Blood Glucose Measurement Device by Air Analysis Expired"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Toulouse"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glycemia estimated by exhaled air analyzer"},{"name":"Questionnaire"},{"name":"Veinous glycemia"},{"name":"Capillary glycemia"},{"name":"constitution biological collection"},{"name":"Blood sample"},{"name":"Test meal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02526524","briefTitle":"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Elcelyx Therapeutics, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Met DR"},{"name":"Met IR"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02842359","briefTitle":"Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Irbesartan/atorvastatin fixed dose combination"},{"name":"Irbesartan SR47436"},{"name":"Atorvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00332488","briefTitle":"Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mannkind Corporation"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Technosphere Insulin"},{"name":"Metformin & Secretagogues"},{"name":"Technosphere Insulin & Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01441986","briefTitle":"Dextromethorphan, Amantadine and Glucose Homeostasis in Diabetes Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Profil Institut für Stoffwechselforschung GmbH"},"collaborators":[{"name":"Heinrich-Heine University, Duesseldorf"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dextromethorphan hydrobromide"},{"name":"Amantadine"},{"name":"Pacebo 1 (placebo for Amantadine)"},{"name":"Placebo 2 (fo Dextromethorphan)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00290394","briefTitle":"Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baskent University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rosiglitazone(drug), blood pressure lowering effect"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05037045","briefTitle":"Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Affiliated Hospital of Xuzhou Medical University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLP-1 receptor agonist"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00593476","briefTitle":"Pilot Study to Assess Pre-packaged, Portion-controlled Meal Plan on Weight Loss"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Temple University"},"collaborators":[{"name":"Nutrisystem, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PCD"},{"name":"DSE"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05031871","briefTitle":"Pharmacokinetics of HR17031 Injection in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jiangsu HengRui Medicine Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HR17031 injection ；INS068 injection；SHR20004 injection"},{"name":"HR17031 injection ；INS068 injection；SHR20004 injection"},{"name":"HR17031 injection ；INS068 injection；SHR20004 injection"},{"name":"HR17031 injection ；INS068 injection；SHR20004 injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02554877","briefTitle":"A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-06291874"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00360698","briefTitle":"Insulin Glulisine in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine"},{"name":"Glimepiride"},{"name":"Insulin Glulisine"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03794336","briefTitle":"Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin"},{"name":"Acarbose"},{"name":"Metformin"},{"name":"Aspirin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01965639","briefTitle":"Southeastern Diabetes Initiative Clinical Intervention"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Duke University"},"collaborators":[{"name":"Centers for Medicare and Medicaid Services"},{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Extension of Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02933853","briefTitle":"A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Faster-acting insulin aspart"},{"name":"Insulin Aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02954692","briefTitle":"A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INSULIN GLARGINE (U300)"},{"name":"metformin"},{"name":"sulfonylurea"},{"name":"meglitinides"},{"name":"thiazolidinediones"},{"name":"alpha-glucosidase inhibitors"},{"name":"GLP1 Receptor Agonist"},{"name":"Dipeptidyl peptidase-IV (DPP-IV) inhibitors"},{"name":"Sodium-glucose transport-2 (SGLT-2) inhibitors"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00707031","briefTitle":"GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide (AVE0010)"},{"name":"Pen auto-injector"},{"name":"Exenatide"},{"name":"Prefilled pen injector"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04597957","briefTitle":"The Fruit and Vegetable Prescription Program Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Henry Ford Health System"},"collaborators":[{"name":"Blue Cross Blue Shield of Michigan Foundation"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fresh Rx Intervention group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00511719","briefTitle":"Bioavailability of Technosphere® Insulin Versus Subcutaneous Regular Human Insulin in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mannkind Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Technosphere Insulin"},{"name":"Actrapid"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00851903","briefTitle":"Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine"},{"name":"Sitagliptin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03930758","briefTitle":"Preventing Diabetic Osteoporosis With Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"},"collaborators":[{"name":"University of Wisconsin, La Crosse"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Behavior intervention of uphill exercise"},{"name":"Dietary intervention of exercise before the meal"},{"name":"Dietary intervention of uphill exercise"},{"name":"Dietary intervention of exercise after the meal"},{"name":"Behavior intervention of downhill exercise"},{"name":"Dietary intervention of exercise before the meal"},{"name":"Behavioral intervention of downhill exercise"},{"name":"Dietary intervention of exercise after the meal"},{"name":"Behavioral intervention of sedentary no-exercise trial"},{"name":"Dietary intervention of eating two meals"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00866658","briefTitle":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide (AVE0010)"},{"name":"Placebo"},{"name":"Pen auto-injector"},{"name":"Sulfonylurea"},{"name":"Basal Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00811460","briefTitle":"A Study of Taspoglutide in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"taspoglutide"},{"name":"taspoglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05417646","briefTitle":"Impact of SGLT2 on Glucosuria in HNF1A-MODY"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Steno Diabetes Center Copenhagen"},"collaborators":[{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Maturity-Onset Diabetes of the Young, Type 3","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hyperglycaemic clamp"},{"name":"Placebo"},{"name":"Empagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05498610","briefTitle":"A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NNC0480 0389"},{"name":"Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02256189","briefTitle":"Sitagliptin and Glucagon Counterregulation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lund University"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01210001","briefTitle":"Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"BI 10773"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"BI 10773"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03027960","briefTitle":"Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yale University"},"collaborators":[{"name":"Boehringer Ingelheim"}]},"conditionsModule":{"conditions":["Heart Failure","Type II; Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Placebo Oral Capsule"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01039116","briefTitle":"Taking Action Together- A Diabetes Prevention Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, Berkeley"},"collaborators":[{"name":"University of California, San Francisco"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High Intensity"},{"name":"Low Intensity"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01585051","briefTitle":"Effect of Vitamin D Supplementation on Blood Pressure and HbA1c Levels in Patients With T2D"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kantonsspital Baselland Bruderholz"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"25(OH) vitamin D"},{"name":"0.9 % NaCl"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02459353","briefTitle":"Effect of Dapagliflozin on Glycemic Variability"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Catholic University of Korea"},"collaborators":[{"name":"AstraZeneca"},{"name":"Severance Hospital"},{"name":"Eulji General Hospital"},{"name":"Kyung Hee University Hospital at Gangdong"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02505334","briefTitle":"A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00528372","briefTitle":"A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Dapagliflozin placebo"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01588366","briefTitle":"The Effects of LY2409021 on the Liver"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"LY2409021"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02501161","briefTitle":"A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/liraglutide"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00121641","briefTitle":"Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Saxagliptin"},{"name":"Saxagliptin"},{"name":"Placebo matching Saxagliptin"},{"name":"Metformin"},{"name":"Placebo matching Metformin"},{"name":"Saxagliptin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01137812","briefTitle":"The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin 100 mg"},{"name":"Canagliflozin 300 mg"},{"name":"Metformin"},{"name":"Sulphonylurea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02581657","briefTitle":"Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"PhaseBio Pharmaceuticals Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PE0139 Injection"},{"name":"Placebo Injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01952145","briefTitle":"A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/liraglutide"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01867307","briefTitle":"Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"BI 10773"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01476475","briefTitle":"Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine /lixisenatide Fixed Ratio Combination"},{"name":"Insulin glargine"},{"name":"Metformin (Background drug)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00464776","briefTitle":"Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aliskiren"},{"name":"Aliskiren"},{"name":"Aliskiren"},{"name":"Aliskiren"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02971241","briefTitle":"Intergenerational mHealth Diabetes Program OPPORTUNITIES PROGRAM IN TAIWAN"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Southern California"},"collaborators":[{"name":"Taipei Fubon Bank Charity Foundation"},{"name":"Taichung Tzu Chi Hospital"},{"name":"Hualien Tzu Chi General Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intergenerational Mobile Technology Opportunities Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03680482","briefTitle":"To Compare the Effects of Non-nutritive Sweeteners Intake in Subjects With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Chile"},"collaborators":[{"name":"Sociedad Chilena de Nutrición"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intervention ingest a 48 mg of sucralose"},{"name":"Intervention ingest a 96 mg of stevia"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01980524","briefTitle":"The Impact of Free Fatty Acid (FFA-) Suppression on Myocardial Lipids and Function in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Vienna"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"acipimox"},{"name":"Placebo Oral Capsule"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02284893","briefTitle":"Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Dapagliflozin"},{"name":"Sitagliptin"},{"name":"Placebo matching with Saxagliptin"},{"name":"Placebo matching with Dapagliflozin"},{"name":"Placebo matching with Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02475499","briefTitle":"Incretin-based Drugs and Pancreatic Cancer"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Canadian Network for Observational Drug Effect Studies, CNODES"},"collaborators":[{"name":"Drug Safety and Effectiveness Network, Canada"},{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DPP-4 inhibitors"},{"name":"GLP-1 analogs"},{"name":"Sulfonylureas"},{"name":"Biguanides"},{"name":"Thiazolidinediones"},{"name":"Alpha-glucosidase inhibitors"},{"name":"Meglitinides"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02540486","briefTitle":"Long Acting Insulin Glargine Titration Web Tool (LTHome) vs Enhanced Usual Therapy of Glargine Titration"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LMC Diabetes & Endocrinology Ltd."},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Long-acting insulin glargine titration web tool (LTHome)"},{"name":"Diabetes Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00257257","briefTitle":"Study Evaluating Rimonabant Efficacy in Drug-NAive DiabEtic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rimonabant (SR141716)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03037099","briefTitle":"Healthy Eating and Active Living for Diabetes: Glycemic Index"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Athabasca University"},"collaborators":[{"name":"University of Alberta"},{"name":"Canadian Foundation for Dietetic Research (CFDR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Enhanced GI Concept Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01520753","briefTitle":"Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 70"},{"name":"biphasic insulin aspart 70"},{"name":"biphasic insulin aspart 50"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01106625","briefTitle":"The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin"},{"name":"Placebo"},{"name":"Metformin"},{"name":"Sulphonylruea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02224118","briefTitle":"Safety, Pharmacokinetics, and Pharmacodynamics Study of Single Dose of CNTO 3649 in Healthy Adult Men and Multiple Doses of CNTO 3649 in Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Pharmaceutical K.K."}},"conditionsModule":{"conditions":["Healthy","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CNTO 3649 10 mcg/kg"},{"name":"CNT0 3649 30 mcg/kg"},{"name":"CNTO 3649 100 mcg/kg"},{"name":"CNTO 3649 300 mcg/kg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01773473","briefTitle":"Comparison of Insulin Mix25 Versus Mix50"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Lispro Mix25"},{"name":"Insulin Lispro Mix50"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04869800","briefTitle":"Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-398"},{"name":"CKD-501, D745"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01529216","briefTitle":"Efficacy Study of the DIAMOND System to Treat Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"MetaCure Limited"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DIAMOND System"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00541437","briefTitle":"Type 2 Diabetes Patients Switched From Sulfonylurea With Metformin to Glyburide/Metformin Combination Tablet"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Genovate Biotechnology Co., Ltd.,"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02925559","briefTitle":"Effect of Anti-diabetic Drugs on Glycemic Variability"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centro de Diabetes Curitiba Ltda"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Gliclazide MR"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04215328","briefTitle":"Facilitated Release of Endogenous Enterokines"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Southern California"},"collaborators":[{"name":"Halyard Health"},{"name":"Wallace H. Coulter Foundation"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mixed-Meal"},{"name":"Electrolyte Solution"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01063361","briefTitle":"Low Glycemic Index Diets (With Pulses) in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Toronto"},"collaborators":[{"name":"Saskatchewan Pulse Growers"},{"name":"Pulse Canada"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low glycemic index diet with pulses"},{"name":"High Cereal Fibre"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00393770","briefTitle":"Acetylcarnitine and Insulin Sensitivity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mario Negri Institute for Pharmacological Research"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"L-acetylcarnitine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00108004","briefTitle":"Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pramlintide acetate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00708578","briefTitle":"Optimal Oral Hypoglycaemic Agents (OHA) for Combination With Insulin Glargine (Sulfonylurea vs. Metformin)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glimepiride"},{"name":"Metformin"},{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02068443","briefTitle":"Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin"},{"name":"Metformin hydrochloride"},{"name":"Metformin hydrochloride Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01589445","briefTitle":"Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Dhaka"},"collaborators":[{"name":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders"},{"name":"University of Dundee"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone hydrochloride"},{"name":"Metformin hydrochloride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02004678","briefTitle":"Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DS-1150b"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02692716","briefTitle":"A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01416649","briefTitle":"Impact of Exenatide on Sleep Duration"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Chicago"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05328726","briefTitle":"Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gan and Lee Pharmaceuticals, USA"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GZR-18"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04080960","briefTitle":"Dining With Diabetes in Pennsylvania"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Penn State University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle modification education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02920801","briefTitle":"Study About Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Zhongshan Hospital"},"collaborators":[{"name":"Chinese Medical Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"saxagliptin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00482768","briefTitle":"Improving Risk Factors for Diabetes Complications in Primary Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Practice Facilitation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01245270","briefTitle":"A Single Supplement of a Standardised Bilberry Extract Modifies Glycaemic Response"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aberdeen"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bilberry capsule first, then control cap"},{"name":"Control capsule first then bilberry cap"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01122979","briefTitle":"Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INSULIN GLARGINE"},{"name":"NPH insulin (insulin isophane)"},{"name":"INSULIN GLULISINE"},{"name":"Regular insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01326026","briefTitle":"Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"insulin degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00643773","briefTitle":"The Effect of Leucine on Body Composition and Muscle Characteristics in Elderly, Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"},"collaborators":[{"name":"Top Institute Food and Nutrition"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Leucine"},{"name":"Wheat flour"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00712673","briefTitle":"GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide (AVE0010)"},{"name":"Placebo"},{"name":"Pen auto-injector"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00666718","briefTitle":"A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine"},{"name":"Insulin Lispro Protamine Suspension (ILPS)"},{"name":"Insulin Lispro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00554450","briefTitle":"Renal Impairment in Type 2 Diabetic Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02791490","briefTitle":"A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Placebo"},{"name":"Metformin IR"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02694263","briefTitle":"Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Leicester"},"collaborators":[{"name":"University Hospital Birmingham"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin"},{"name":"Repaglinide"},{"name":"Pioglitazone"},{"name":"Gliclazide"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01054092","briefTitle":"A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ipragliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01525992","briefTitle":"A Community Pharmacy-based Program to Improve Management of Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tehran University of Medical Sciences"},"collaborators":[{"name":"Research Center for Rational Use of Drugs"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Community pharmacist-led diabetes education program"},{"name":"Usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01664676","briefTitle":"Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"Novo Nordisk A/S"},{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Placebo-liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00230464","briefTitle":"Acute Metabolic Effects of LAF 237 in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"},"collaborators":[{"name":"Novartis"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LAF 237"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03487692","briefTitle":"Medical Care, Education, Social Support, And Goal-setting to Empower Self-management for Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Chicago"},"collaborators":[{"name":"Midwest Clinicians' Network"},{"name":"CareMessage"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes MESSAGES Program"},{"name":"Diabetes MESSAGES Program (second trial)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01517412","briefTitle":"Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide (AVE0010)"},{"name":"Self-injector pen device (OptiClik®)"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03136484","briefTitle":"Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"},{"name":"Canagliflozin"},{"name":"Placebo (canagliflozin)"},{"name":"Placebo (semaglutide)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00716170","briefTitle":"GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Herlev Hospital"},"collaborators":[{"name":"University of Copenhagen"},{"name":"The Danish Medical Research Council"},{"name":"The Danish Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01792518","briefTitle":"MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Linagliptin 5mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01357889","briefTitle":"Pharmacokinetics/Pharmacodynamics of Albiglutide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"albiglutide (GSK716155)"},{"name":"albiglutide (GSK716155)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00894322","briefTitle":"A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide once weekly"},{"name":"exenatide once weekly"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03971838","briefTitle":"Diabetes Prevention Programming for Women With a History of Gestational Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Indiana University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Positive Outcomes for Women"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00110370","briefTitle":"Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lispro Mixture Therapy"},{"name":"Glargine Basal-Bolus Therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00823680","briefTitle":"A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"RO5027838"},{"name":"RO5027838"},{"name":"RO5093151"},{"name":"RO5093151"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04495114","briefTitle":"Pre-operative Carbohydrate Loading Patients With Diabetes Undergoing Elective Colorectal Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alberta"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"40g carbohydrate load (Apple juice)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01817595","briefTitle":"Evaluation of Iphone Technology in Diabetes Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Endocrine Research Society"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BG Star Meter (Conventional) Internet Blood Glucose Reporting"},{"name":"iBG Star (iphone) Internet Blood Glucose Method"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00686712","briefTitle":"Insulin Glargine at Bedtime or in AM Versus NPH"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Charles Drew University of Medicine and Science"},"collaborators":[{"name":"National Center for Research Resources (NCRR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"1- Insulin glargine QHS"},{"name":"2 - Insulin glargine QAM"},{"name":"3 - NPH insulin QHS"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01030952","briefTitle":"Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nateglinide"},{"name":"Acarbose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05159622","briefTitle":"Water Up@ At Home: An Intervention to Replace Sugary Drinks With Water"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"George Washington University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Water Up! at Home"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01408628","briefTitle":"The I-KAN Study: Internet Insulin Education for Kansans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"David Robbins, MD"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Internet Insulin Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05153564","briefTitle":"A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide 1.34 mg/mL"},{"name":"Semaglutide 3.0 mg/mL"},{"name":"NNC0480-0389 10 mg/mL"},{"name":"NNC0480-0389 30 mg/mL"},{"name":"Microgynon®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00121667","briefTitle":"Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin + Metformin"},{"name":"Saxagliptin + Metformin"},{"name":"Saxagliptin + Metformin"},{"name":"Placebo + Metformin"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01904383","briefTitle":"PMS of Trazenta on the Long-term Use as Add-on Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Trazenta"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02024477","briefTitle":"Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"George Washington University"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01950637","briefTitle":"GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"},{"name":"survey"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03304158","briefTitle":"Community Based Management of Diabetes in Nepal"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FCHV visit"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00306644","briefTitle":"Effect Of Rosiglitazone On Carotid Intima Media Thickness In Patients With Insulin Resistance Syndrome And/Or Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01518101","briefTitle":"Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin/ Metformin"},{"name":"Liraglutide"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02518334","briefTitle":"Wine Consumption and Glycemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Missouri-Columbia"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alcohol consumption"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01106690","briefTitle":"The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Canagliflozin"},{"name":"Sitagliptin"},{"name":"Metformin"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02481596","briefTitle":"FAMS Mobile Health Intervention for Diabetes Self-care Support"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University Medical Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"REACH + FAMS"},{"name":"REACH"},{"name":"Helpline & A1c results"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02020629","briefTitle":"Study on Lixisenatide and Counterregulation to Hypoglycemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lund University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00123643","briefTitle":"Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"St. Paul Heart Clinic"},"collaborators":[{"name":"GlaxoSmithKline"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rosiglitazone"},{"name":"glyburide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01457911","briefTitle":"Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glimepiride and Metformin hydrochloride combination (HOE490)"},{"name":"Glimepiride (HOE490)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00841503","briefTitle":"Exploring Buckwheat's Glucose Lowering Potential"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"St. Boniface Hospital"},"collaborators":[{"name":"University of Manitoba"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"buckwheat, rice crackers, glucose, sugar substitute"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03865381","briefTitle":"Onduo Virtual Diabetes Clinic Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Verily Life Sciences LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Onduo App"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02287285","briefTitle":"Determinants of Diabetes Remission After Gastric Bypass Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Blandine Laferrere"},"collaborators":[{"name":"National Institutes of Health (NIH)"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exendin9"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00191464","briefTitle":"Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"premeal insulin lispro mixtures"},{"name":"insulin glargine"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00631488","briefTitle":"A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK-0893"},{"name":"Sitagliptin"},{"name":"Metformin"},{"name":"Placebo for MK-0893"},{"name":"Placebo for Sitagliptin"},{"name":"Placebo for Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02010684","briefTitle":"Mood and Diabetes Empowerment & Improvement Training"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, Los Angeles"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empowerment and CBT Classes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01316094","briefTitle":"A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal Impairment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ASP1941"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00308451","briefTitle":"A 30 Day Acute Efficacy and Safety Study of Chromium Picolinate + Biotin on Glycemic Control in Overweight or Obese Subjects With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nutrition 21, Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00476437","briefTitle":"Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"},{"name":"biphasic human insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02294370","briefTitle":"Variation of Glucose Values at Early Stages of Diabetes - Continuous Glucose Monitoring"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Folkhälsan Researech Center"},"collaborators":[{"name":"Medtronic"},{"name":"University of Padova"},{"name":"Universidad Politecnica de Madrid"},{"name":"University of Pavia"},{"name":"Fondazione Salvatore Maugeri"},{"name":"Asociación Española Para el Desarrollo de la Epidemiologia Clínica"},{"name":"Lund University"},{"name":"Soluciones Tecnologias para la Salud y el Bienestar SA"},{"name":"National Technical University of Athens"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01787396","briefTitle":"Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LG Life Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gemigliptin 50mg"},{"name":"Placebo(Metformin)"},{"name":"Metformin"},{"name":"Placebo(Gemigliptin)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00295633","briefTitle":"A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Saxagliptin"},{"name":"Placebo"},{"name":"pioglitazone"},{"name":"rosiglitazone"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01106677","briefTitle":"The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Canagliflozin"},{"name":"Sitagliptin"},{"name":"Metformin immediate release"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01024790","briefTitle":"Exercise Study to Help Patients Who Have Type 2 Diabetes and Depression."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Massachusetts, Worcester"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01536639","briefTitle":"Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03377127","briefTitle":"Impact of Pharmacy Clinic on Diabetes Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"William Beaumont Hospitals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pharmacy Managed Diabetes Clinic (PMDC)"},{"name":"Standard of Care (SOC)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04075110","briefTitle":"Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sadat City University"}},"conditionsModule":{"conditions":["Obesity; Endocrine; Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Montelukast 10mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03159299","briefTitle":"Yo Puedo! Diabetes Self-Management Education + mHealth in Mexico City"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yale University"},"collaborators":[{"name":"Universidad Iberoamericana"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Yo Puedo + mHealth"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00179400","briefTitle":"Insulin Action in Individuals With Type 2 Diabetes by Natural Fatty Acids or the Medication Pioglitazone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Albert Einstein College of Medicine"},"collaborators":[{"name":"Takeda"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone 45 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00935220","briefTitle":"Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"linagliptin QD (once daily) for 7 days"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01495975","briefTitle":"Impact of a Diabetes Transitions Tool Kit on Post-Hospitalization Glycemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Deborah Wexler, MD"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Transitions Tool Kit"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03414736","briefTitle":"A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SAR425899"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01766752","briefTitle":"Performance of a Tablet Based Workflow and Decision Support System With Incorporated Software Algorithm Used for Glycaemic Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Graz"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GlucoTab System"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04710940","briefTitle":"Development and Feasibility Testing of DM-BOOST Intervention."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daniel Amante"},"collaborators":[{"name":"Worcester Polytechnic Institute"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes BOOST"},{"name":"Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03738449","briefTitle":"The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-387 Under Fed Condition"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-387"},{"name":"D484"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02226003","briefTitle":"Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ertugliflozin"},{"name":"Sitagliptin"},{"name":"Placebo to Ertugliflozin"},{"name":"Placebo to Sitagliptin"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00798161","briefTitle":"Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 1356"},{"name":"BI 1356 + metformin"},{"name":"Bi 1356 + metformin"},{"name":"Metformin"},{"name":"metformin"},{"name":"matching placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05015894","briefTitle":"A Research Study Looking Into Blood Levels of the Medicine NNC0480-0389 in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NNC0480-0389"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03786718","briefTitle":"Usability of Diabetes Dashboard Embedded Within a Patient Web Portal"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University Medical Center"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Patient-facing Diabetes Dashboard"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01040819","briefTitle":"Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baylor College of Medicine"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01484262","briefTitle":"Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02981069","briefTitle":"Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Exenatide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00664534","briefTitle":"Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine"},{"name":"Insulin Lispro Premix (mid-mixture and low-mixture)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00520962","briefTitle":"Screening for Undiagnosed Type 2 Diabetes in New Classes of Subjects at High Risk"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"IRCCS San Raffaele"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00955747","briefTitle":"Naturlose (D-Tagatose) Efficacy Evaluation Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Robert Lodder"},"collaborators":[{"name":"University of Kentucky"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tagatose"},{"name":"Sugar Substitute Splenda"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02773368","briefTitle":"A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/liraglutide"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00602472","briefTitle":"BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"linagliptin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04972539","briefTitle":"Evaluation of Pharmacokinetics and Safety of AJU-A51 in Healthy Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AJU Pharm Co., Ltd."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AJU-A51 Tab."},{"name":"A51R1 Tab. and A51R2 Tab."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02738879","briefTitle":"Randomized Sitagliptin Withdrawal Study (MK-0431-845)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Placebo to sitagliptin"},{"name":"Metformin"},{"name":"Metformin XR"},{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01709305","briefTitle":"A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Sitagliptin"},{"name":"Acarbose"},{"name":"Repaglinide"},{"name":"Glimepiride"},{"name":"Gliclazide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01407289","briefTitle":"A Trial to Investigate Efficacy and Usability of Published Best Practice to Control Glycaemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Graz"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Aspart, Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01691846","briefTitle":"A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"aleglitazar+metformin"},{"name":"placebo+metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04953442","briefTitle":"Fit 24 Technology Intervention YOUTH"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baylor College of Medicine"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fit 24"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00701831","briefTitle":"Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04431141","briefTitle":"Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Handok Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Teneligliptin"},{"name":"Empagliflozin"},{"name":"Teneligliptin and Empagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04426708","briefTitle":"A Clinical Study to Access the Pharmacokinetics of HMS5552 in Hepatic Impaired Subjects and Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hua Medicine Limited"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HMS5552"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01093794","briefTitle":"Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Co-administration of 50 mg sitagliptin and 500 mg metformin"},{"name":"sitagliptin/metformin 50 mg/500 mg tablet"},{"name":"Co-administration of 50 mg sitagliptin and 850 mg metformin"},{"name":"sitagliptin/metformin 50 mg/850 mg tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01434186","briefTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo matching with Saxagliptin"},{"name":"Metformin IR"},{"name":"Metformin XR"},{"name":"Saxagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02027103","briefTitle":"Metformin and Pioglitazone Effects on Fetuin-A and Osteoprotegrin Concentrations in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tehran University of Medical Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03800680","briefTitle":"A Randomized Trial to Slow the Progression of Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Duke-NUS Graduate Medical School"},"collaborators":[{"name":"National Medical Research Council (NMRC), Singapore"},{"name":"SingHealth Polyclinics"},{"name":"Singapore General Hospital"},{"name":"Changi General Hospital"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Management Package (DMP)"},{"name":"M-POWER Rewards"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00147836","briefTitle":"Evaluation of the Effects of Different Interventions on Glycemic Control in Newly-Diagnosed Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sun Yat-sen University"},"collaborators":[{"name":"Ministry of Education, China"},{"name":"Guangdong Science and Technology Bureau, China"},{"name":"Hoffmann-La Roche"},{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Human Insulin (Novolin-R, Novo Nordisk)"},{"name":"H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland"},{"name":"Pre-meal"},{"name":"Novolin-R"},{"name":"Human Insulin NPH (Novolin-N, Novo Nordisk)"},{"name":"Gliclazide (Diamicron, Servier)"},{"name":"Diamicron and Glucophage"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00221234","briefTitle":"Alberta Diabetes and Physical Activity Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alberta"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Print materials, pedometers/logbooks"},{"name":"Print materials, pedometers/logbooks, telephone counselling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04132089","briefTitle":"Mobile Health Application for Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of South Alabama"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"capABILITY"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05360537","briefTitle":"Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Palermo"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Degludec / Liraglutide Injectable Product"},{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00401622","briefTitle":"Clinical Benefits of a Blood Glucose Monitoring System in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LifeScan"},"collaborators":[{"name":"Synexus(UK)"},{"name":"CPS(UK)"},{"name":"Battelle CRO(US)"},{"name":"RPS CRO(US)"},{"name":"Robertson Centre For Biostatistics (UK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"OneTouch® Ultra®2 System"},{"name":"Standard care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04571723","briefTitle":"Health Mindset as a Driver of Efficacy of a Diabetes Prevention Program in the Blackfeet Community"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Montana State University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Prevention Program"},{"name":"Health Mindset modified diabetes prevention program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03438617","briefTitle":"Peer Support To Enhance The Shanghai Integration Model Of Diabetes Care: Extension & Dissemination"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai 6th People's Hospital"},"collaborators":[{"name":"University of North Carolina, Chapel Hill"},{"name":"Asian Center for Health Education"},{"name":"Shanghai Municipal Commission of Health and Family Planning"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Peer Support"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01680341","briefTitle":"Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/insulin aspart"},{"name":"insulin degludec/insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02533648","briefTitle":"Role of Allopurinol on Oxidative Stress and Mitochondrial Alterations in Skeletal Muscle of Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospices Civils de Lyon"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"2 capsules of allopurinol 150 mg daily for 3 month"},{"name":"2 capsules of lactose daily for 3 month"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02607865","briefTitle":"Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"sitagliptin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01366794","briefTitle":"Macronutrients and Gut Hormone Secretion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lund University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Macronutrients"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01779609","briefTitle":"ET-blockade and Exercise-induced Vascular Adaptations in T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Radboud University Medical Center"},"collaborators":[{"name":"Actelion"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bosentan"},{"name":"Placebo"},{"name":"Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03871621","briefTitle":"Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mackay Memorial Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Medicines"},{"name":"Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00612950","briefTitle":"Beta-Cell Function After Near-Normalisation of Blood Glucose"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hvidovre University Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"glucagon-like peptide-1,"},{"name":"glucose dependent insulinotropic polypeptide"},{"name":"Saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02383784","briefTitle":"Effects of Low- or High-glycemic Index Diets on Metabolic and Inflammatory Responses in Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Federal University of Vicosa"},"collaborators":[{"name":"Coordenação de Aperfeiçoamento de Pessoal de Nível Superior."},{"name":"Fundação de Amparo à Pesquisa do estado de Minas Gerais"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low GI index diet"},{"name":"High GI diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02643277","briefTitle":"Effectiveness of Automated Mobile Phone Based Text Messaging on the Improvement of Glycaemic Outcomes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mobile phone text messaging"},{"name":"Conventional care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00095030","briefTitle":"Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristol-Myers Squibb"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"muraglitazar"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00928889","briefTitle":"Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nateglinide 120 mg"},{"name":"Acarbose 50 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02313363","briefTitle":"Patient-Centered Smartphone-Based Diabetes Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"patient-centered smartphone-based diabetes care system"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04324424","briefTitle":"A Clinical Study to Access the Pharmacokinetics of HMS5552 in Renal Impaired Subjects and Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hua Medicine Limited"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HMS5552"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04504396","briefTitle":"Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"PegBio Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLP-1 receptor agonist"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02660736","briefTitle":"Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Albiglutide Liquid Auto-injector"},{"name":"Albiglutide Lyophilized DCC Pen Injector"},{"name":"Placebo Liquid Auto-injector"},{"name":"Placebo Lyophilized DCC Pen injector"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03918525","briefTitle":"Diabetes In Sindhi Families In Nagpur (DISFIN)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lata Medical Research Foundation, Nagpur"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sindhi families"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00885118","briefTitle":"4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo (middle dose)"},{"name":"Placebo"},{"name":"BI 10773"},{"name":"BI 10773"},{"name":"BI 10773"},{"name":"Placebo (high dose)"},{"name":"BI 10773"},{"name":"Placebo (low dose)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04817644","briefTitle":"A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02320721","briefTitle":"Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine (HOE901 - U300)"},{"name":"Insulin Glargine (HOE901 - U100)"},{"name":"Background therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00614939","briefTitle":"Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00976937","briefTitle":"24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide (AVE0010)"},{"name":"Lixisenatide Placebo"},{"name":"Pen auto-injector"},{"name":"Sitagliptin"},{"name":"Sitagliptin Placebo"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01440530","briefTitle":"Technology Intervention for Diabetes Engagement & Self-Care (TIDES)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Geisinger Clinic"},"collaborators":[{"name":"Dlife"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Educational Intervention"},{"name":"Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00279045","briefTitle":"Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone"},{"name":"glyburide"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00551538","briefTitle":"24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lispro mix 75/25"},{"name":"Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01556529","briefTitle":"CDRM Study: Computer-assisted Diabetes Risk Management-for Secondary and Tertiary Prevention of T2DM Complications"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Philipps University Marburg"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"risk profile information"},{"name":"standard DMP care"},{"name":"standard DMP care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01365507","briefTitle":"Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02551874","briefTitle":"A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin, Onglyza"},{"name":"Dapagliflozin, Farxiga"},{"name":"Glargine insulin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02845557","briefTitle":"Glucose Homeostasis and Incretin Effect T2DM in the Youth- a Study of the Malaysian Population"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"RCSI & UCD Malaysia Campus"},"collaborators":[{"name":"Sarawak General Hospital"},{"name":"Putrajaya Hospital, Malaysia"},{"name":"Penang Hospital, Malaysia"},{"name":"Institute of Neuroscience, Padova, Italy"},{"name":"University of Copenhagen"},{"name":"Institute for Medical Research, Malaysia"},{"name":"Seberang Jaya Clinical Research Centre"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"OGTT and IVGTT tests"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01121835","briefTitle":"Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INSULIN GLARGINE"},{"name":"INSULIN GLULISINE"},{"name":"PREMIXED INSULIN"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01280695","briefTitle":"A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Metabolic Solutions Development Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"MSDC-0602 100 mg"},{"name":"MSDC-0602 250 mg"},{"name":"MSDC-0602 250 mg"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00819455","briefTitle":"Use of Information Technology in the Prevention of Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals"},"collaborators":[{"name":"Imperial College London"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Experimental"},{"name":"Control arm (usual care/standard care arm)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01819272","briefTitle":"Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Elcelyx Therapeutics, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Met DR"},{"name":"Met XR"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00065650","briefTitle":"Pilot Study of Vedic Medicine for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Center for Complementary and Integrative Health (NCCIH)"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vedic Medicine"},{"name":"Vedic Medicine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00638313","briefTitle":"Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"PF-04603629"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01106131","briefTitle":"Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-501 0.5mg"},{"name":"Pioglitazone 15mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01221545","briefTitle":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD1656"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04034511","briefTitle":"Food and Education Effects on Diabetes Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johns Hopkins University"},"collaborators":[{"name":"Moveable Feast"},{"name":"Priority Partners MCO"},{"name":"Leonard & Helen R. Stulman Charitable Foundation"},{"name":"France-Merrick Foundation"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Medically-tailored meal delivery and medical nutrition therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01422876","briefTitle":"Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"high dose FDC"},{"name":"BI 10773 high dose"},{"name":"high dose FDC placebo"},{"name":"low dose FDC placebo"},{"name":"high dose FDC placebo"},{"name":"high dose FDC placebo"},{"name":"low dose FDC placebo"},{"name":"low dose FDC placebo"},{"name":"high dose BI 10773 placebo"},{"name":"low dose FDC"},{"name":"high dose FDC placebo"},{"name":"BI 10773 low dose"},{"name":"high dose BI 10773 placebo"},{"name":"high dose BI 10773 placebo"},{"name":"linagliptin"},{"name":"low dose FDC placebo"},{"name":"linagliptin placebo"},{"name":"BI 10773 low dose placebo"},{"name":"linagliptin placebo"},{"name":"low dose BI 10773 placebo"},{"name":"linagliptin placebo"},{"name":"high dose BI 10773 placebo"},{"name":"BI 10773 low dose placebo"},{"name":"low dose BI 10773 placebo"},{"name":"linagliptin placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03692208","briefTitle":"Managing Diabetes to Gain Opportunities for a More Active Life"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Chicago"},"collaborators":[{"name":"National Institutes of Health (NIH)"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"My Diabetes Goal Survey and Optional Care Management"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01659294","briefTitle":"Diabetes Outcomes and Nurse Case Manager Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"BCDiabetes.Ca"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nurse Case Management"},{"name":"standard diabetologist care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01780051","briefTitle":"A Pharmacokinetic Study to Compare Co-administration of Repaglinide and Metformin HCl to Administration of Combination Preparation of Those Two Components"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dalim BioTech Co., Ltd."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Repaglinide/Metformin combination, Repaglinide, Metformin"},{"name":"Repaglinide/Metformin combination, Repaglinide, Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03588000","briefTitle":"The Effect of Remote SMBG Combined With the Application of APP on the Improvement of T2DM Management in the Community"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yuwen Zhang"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Strengthen self-monitoring of blood glucose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02648204","briefTitle":"Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"Dulaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02537834","briefTitle":"Tofogliflozin GLP-1 Analogue Combination Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kowa Company, Ltd."},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tofogliflozin"},{"name":"GLP-1 analogue"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01744236","briefTitle":"SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Amsterdam UMC, location VUmc"},"collaborators":[{"name":"EU FP7: SAFEGUARD consortium"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Sitagliptin"},{"name":"Exenatide"},{"name":"Liraglutide placebo"},{"name":"Sitagliptin placebo"},{"name":"Exenatide placebo"},{"name":"L-NMMA"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00907881","briefTitle":"The OBSTACLE Hypoglycemia Study (MK-0000-158)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sulfonylurea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02181842","briefTitle":"Pioglitazone Tablets Specified Drug-use Survey <Survey on Glycemic Control in Type 2 Diabetic Patients With a History of Cerebral Infarction>"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00995995","briefTitle":"Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prior to the Initiation of Insulin in the UK"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01219582","briefTitle":"GLucobay M OBservation Study for Efficacy and Safety in Treatment of Type-2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glucobay M (Acarbose/Metformin, BAY81-9783)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03387657","briefTitle":"A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sotagliflozin (SAR439954)"},{"name":"Hydrochlorothiazide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00375492","briefTitle":"Effect on Weight Loss of Exenatide Versus Placebo"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01403025","briefTitle":"Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02212951","briefTitle":"Comparison of Postprandial Glucose Control Associated With BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Biodel"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BIOD-531"},{"name":"Humalog Mix 75/25"},{"name":"Humulin R U-500"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00099333","briefTitle":"Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00971997","briefTitle":"A Study of Insulin Lispro Mix in Type 2 Diabetic Asian Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lispro Mix 50/50"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00937326","briefTitle":"Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sirtris, a GSK Company"},"collaborators":[{"name":"GlaxoSmithKline"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SRT2104"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01684709","briefTitle":"Enhancing Informal Caregiving to Support Diabetes Self-Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Telemonitoring + self-management support"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01233622","briefTitle":"Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00391027","briefTitle":"A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine (Lantus®)"},{"name":"Inhaled Human Insulin (Exubera®)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00548782","briefTitle":"Paleolithic Diets vs T2D and Improvements in the Metabolic Syndrome"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Francisco"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Paleolithic diet"},{"name":"ADA ( American Diabetes Association) recommended diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02827708","briefTitle":"Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01434901","briefTitle":"The Effects of Bethanechol on Glucose Homeostasis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Washington University School of Medicine"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Bethanechol (25 mg)"},{"name":"Bethanechol (50 mg)"},{"name":"Bethanechol (100 mg)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01525238","briefTitle":"PK Study of Dapagliflozin in Pediatric Subjects With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Dapagliflozin"},{"name":"Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01515202","briefTitle":"Japanese Phase 1 Multiple Ascending Dose Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristol-Myers Squibb"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BMS-823778"},{"name":"BMS-823778"},{"name":"BMS-823778"},{"name":"BMS-823778"},{"name":"Placebo matching with BMS-823778"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00620282","briefTitle":"The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"placebo"},{"name":"glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00462436","briefTitle":"Innovative Strategies For Risk Reduction Following CABG"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Unity Health Toronto"},"collaborators":[{"name":"Canadian Diabetes Association"}]},"conditionsModule":{"conditions":["Coronary Artery Disease","Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Consumption of Dietary Portfolio"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00892372","briefTitle":"Relationship Between Body Weight and Glycohemoglobin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Saitama Medical University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00501020","briefTitle":"Comparison of the Efficacy and Tolerability of the Addition of AVANDIA to Submaximal Doses of Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02940379","briefTitle":"A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sotagliflozin (SAR439954)"},{"name":"midazolam"},{"name":"metoprolol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03867656","briefTitle":"Effects of Gut Peptides on Bone Remodeling. KS-4-Diabetes-19"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Copenhagen"},"collaborators":[{"name":"Hvidovre University Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLP-2"},{"name":"GIP"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04091373","briefTitle":"A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"MedImmune LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"cotadutide multidose pen injection"},{"name":"cotadutide multidose pen injection"},{"name":"cotadutide multidose pen injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03999268","briefTitle":"Insulin Start Therapy Application With Resources and Training"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pittsburgh"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"I-START"},{"name":"Standard Insulin Administration Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03078478","briefTitle":"A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin degludec"},{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04597697","briefTitle":"A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People With Liver Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin icodec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00732862","briefTitle":"Metabolic Adaptation to Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University"},"collaborators":[{"name":"US Department of Veterans Affairs"},{"name":"Juvenile Diabetes Research Foundation"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"glucose clamp"},{"name":"glucose clamp"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01516320","briefTitle":"Mechanisms of Diabetes Relapse After Bariatric Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Blandine Laferrere"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Roux-en-Y Gastric Bypass"},{"name":"Laparoscopic adjustable gastric banding"},{"name":"Vertical Sleeve Gastrectomy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01248364","briefTitle":"A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 10773"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00793273","briefTitle":"Observational Study to Observe the Efficacy of Levemir® (Insulin Detemir) in Patients With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00403741","briefTitle":"Consultations in Adapted Physical Activity on Behaviours in Physical Exercise by Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Grenoble"},"collaborators":[{"name":"National Institut of Prevention and Health Education"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"motivational interviewing"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02089477","briefTitle":"The Smart-phone as a Physical Fitness Monitor - Validity, Sensitivity and Motivation InterWalk"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Laura Staun Valentiner"},"collaborators":[{"name":"Rigshospitalet, Denmark"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Support group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03191396","briefTitle":"Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"},{"name":"Liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01288326","briefTitle":"Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00398853","briefTitle":"Effect of Chromium Picolinate on Insulin Sensitivity in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pennington Biomedical Research Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"chromium picolinate 1000 mcg daily vs placebo"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00570687","briefTitle":"A Study Comparing Subcutaneous Rapid Acting Insulin and One Formulation of Inhaled Insulin in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mannkind Corporation"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Technosphere Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03189732","briefTitle":"Effect of Metformin on Exercise-induced Lipolysis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Charles University, Czech Republic"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin Oral"},{"name":"Metformin local in AT"},{"name":"Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01476384","briefTitle":"Orthogonal Polarisation Study in Young, Elderly and Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glucose"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00754624","briefTitle":"An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mannkind Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04524832","briefTitle":"Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04521049","briefTitle":"Tubular Markers in Response to Saxagliptin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Beni-Suef University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin 5mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02405260","briefTitle":"Add Glucokinase Activator to Target A1c"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"vTv Therapeutics"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TTP399 400 mg"},{"name":"TTP399 800 mg"},{"name":"Sitagliptin 100 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00961662","briefTitle":"A Clinical Study to Evaluate the Effect of Naturlose (Tagatose)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Robert Lodder"},"collaborators":[{"name":"University of Kentucky"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"D-Tagatose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01413126","briefTitle":"Peanuts Second Meal Glycemic Response"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Federal University of Vicosa"},"collaborators":[{"name":"Coordenação de Aperfeiçoamento de Pessoal de Nível Superior."},{"name":"Fundação de Amparo à Pesquisa do estado de Minas Gerais"},{"name":"United States Agency for International Development (USAID)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Whole peanuts without skins, Peanut butter, or no peanuts (control)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02820298","briefTitle":"Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Theracos"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bexagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00751114","briefTitle":"Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine"},{"name":"Sitagliptin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01894568","briefTitle":"A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Peglispro"},{"name":"Insulin Glargine"},{"name":"Oral Antihyperglycemic Medications (OAMs)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00941369","briefTitle":"Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-Naive Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine (HOE901)/NPH Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01264796","briefTitle":"Community-Based Diabetes Care for Korean American Immigrants"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Texas at Austin"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"culturally tailored diabetes education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01302028","briefTitle":"Renal Impairment Study With ASP1941"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ASP1941"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00949169","briefTitle":"Carotid Intima-media Thickness (IMT) and Large-vessel Atherosclerosis by Multidetector Computed Tomography (MDCT)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eulji University Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01512797","briefTitle":"Treatment of Diabetes After Gastric Bypass With Sitagliptin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Blandine Laferrere"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin phosphate"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02648217","briefTitle":"Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/insulin aspart"},{"name":"biphasic insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03014011","briefTitle":"Effects of Mild Hypoglycaemia on Cognitive Function in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bispebjerg Hospital"},"collaborators":[{"name":"University Hospital, Gentofte, Copenhagen"},{"name":"Psychiatric Centre Rigshospitalet"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II","Hypoglycemia","Cognitive Change"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hypoglycaemic clamp"},{"name":"Euglycaemic clamp"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03066089","briefTitle":"Clinical Evaluation of Fenfuro (Fenugreek Seed Extract) in Type-2 Diabetic Subjects: an add-on Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chemical Resources"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fenfuro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02114814","briefTitle":"A Family-Based Diabetes Intervention for Hispanic Adults in an Emerging Community"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ohio State University"},"collaborators":[{"name":"National Institute on Minority Health and Health Disparities (NIMHD)"},{"name":"University of North Carolina, Greensboro"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes self-management program for Hispanics and their families"},{"name":"General health educational program for Hispanics and their families"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02268916","briefTitle":"Physical Activity and Participation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VA Office of Research and Development"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Counseling"},{"name":"Usual education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01234597","briefTitle":"Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INSULIN GLARGINE (HOE901)"},{"name":"INSULIN GLULISINE (HMR1964)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01677299","briefTitle":"Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Elcelyx Therapeutics, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EFB0027 (metformin delayed release)"},{"name":"EFB0026 (metformin immediate-release)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04413578","briefTitle":"CGM - Reimagine Primary Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Intermountain Health Care, Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dexcom G6"},{"name":"Contour NextOne"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00612625","briefTitle":"Near Normalisation of BG Improves the Potentiating Effect of GLP-1"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hvidovre University Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"glucagon-like peptide-1"},{"name":"Saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01858506","briefTitle":"Diabetes Lifestyle Assessment and Educational Tools"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ofra Kalter-Leibovici MD"},"collaborators":[{"name":"The Gertner Institute"},{"name":"Clalit Health Services"},{"name":"European Foundation for the Study of Diabetes"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"I-ACE intervention"},{"name":"Standard Lifestyle Advice"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00806520","briefTitle":"Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HealthPartners Institute"},"collaborators":[{"name":"Amylin Pharmaceuticals, LLC."}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02762578","briefTitle":"Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/insulin aspart"},{"name":"biphasic insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03169959","briefTitle":"A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Parexel"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"2.5 mg Saxagliptin tablet"},{"name":"5 mg dapagliflozin / 1000 mg metformin XR tablet"},{"name":"Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR"},{"name":"5 mg saxagliptin"},{"name":"10 mg dapagliflozin / 1000 mg metformin XR tablet"},{"name":"Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01283308","briefTitle":"A Randomized Trial of Diabetes Prevention Through Lifestyle Change in India"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"},"collaborators":[{"name":"Madras Diabetes Research Foundation"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle Intervention"},{"name":"Standard of Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00917267","briefTitle":"A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide once weekly"},{"name":"exenatide twice daily"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01595269","briefTitle":"The Clinical and Economic Impacts of e-Heath on Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dr. Danièle Pacaud"},"collaborators":[{"name":"The Lawson Foundation"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"eHealth education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03864432","briefTitle":"An Ascending Dose, Single/Multiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LG Chem"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gemigliptin 25mg"},{"name":"Gemigliptin 50mg"},{"name":"Gemigliptin 100mg"},{"name":"Gemiglptin 50mg multiple dose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01691989","briefTitle":"A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"aleglitazar"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03648424","briefTitle":"Prediction of Findings From the Ongoing CAROLINA Trial Using Healthcare Database Analyses"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Brigham and Women's Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04354090","briefTitle":"Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Beijing Dongfang Biotech Co., Ltd."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"JY09"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03611322","briefTitle":"A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide, 0.25 mg"},{"name":"Semaglutide, 0.5 mg"},{"name":"Semaglutide, 1.0 mg"},{"name":"DV3372"},{"name":"PDS290 pen-injector"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02461589","briefTitle":"Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01703611","briefTitle":"Diabetes in India Nutrition Guidelines Study (DINGS)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Academy of Nutrition and Dietetics"},"collaborators":[{"name":"Indian Institute of Nutritional Sciences"},{"name":"Abbott Healthcare Private Limited (in India)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MNT according to AND EBNPG for Type 2 DM"},{"name":"Usual Nutrition Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00965549","briefTitle":"Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INSULIN GLARGINE (HOE901)"},{"name":"Insulin aspart"},{"name":"Insulin Glulisine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00727896","briefTitle":"\"Information Technology Methodology for Patient Motivation in Diabetes Management.\""},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pre-coded messages"},{"name":"Diabetes Treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01182701","briefTitle":"Cognitive Behavioral Intervention in Diabetes Self-Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Hawaii"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cognitive behavioral training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02541734","briefTitle":"Effect of Gelofusine on GLP1-receptor Imaging"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Radboud University Medical Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gelofusine"},{"name":"111In-exendin 4 SPECT/CT"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01849731","briefTitle":"Effectiveness of Two Interventions in Patients With Low Educational Level With Diabetes to Reduce Inequalities in Self-care Behavior"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Andalusian School of Public Health"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Face-to-face"},{"name":"Face-to-face intervention plus telephone reinforcement"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01339208","briefTitle":"TREAT (Telemedicine for Reach, Education, Access, and Treatment)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pittsburgh"},"collaborators":[{"name":"United States Department of Defense"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Telemedicine diabetes intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01147861","briefTitle":"A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK256073"},{"name":"GSK256073"},{"name":"GSK256073"},{"name":"GSK256073"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01153516","briefTitle":"Diabetes and Gastric By- Pass"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Texas Southwestern Medical Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02805283","briefTitle":"Dapagliflozin Patient Satisfaction Survey"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Optum, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04295005","briefTitle":"A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"DPP-4i"},{"name":"GLP-1-RA"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00736099","briefTitle":"Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"linagliptine 5 mg"},{"name":"linagliptine 5 mg and pioglitazone 30 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01708902","briefTitle":"Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"linagliptin2.5mg/metformin1000mg"},{"name":"linagliptin2.5mg/metformin1000mg"},{"name":"linagliptin 5mg"},{"name":"Metformin 500mg"},{"name":"linagliptin2.5mg/metformin500mg"},{"name":"linagliptin2.5mg/metformin500mg"},{"name":"linagliptin 5mg"},{"name":"Metformin 1000mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01844050","briefTitle":"Traditional Chinese Medicine in Individualized Treatment of Patients With Diabetes Symptoms"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai University of Traditional Chinese Medicine"},"collaborators":[{"name":"Longhua Hospital"},{"name":"Shanghai Putuo District Center Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Chinese herbal medicine"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01272804","briefTitle":"Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","NIDDM"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-04937319"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04260438","briefTitle":"Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T"},{"name":"CKD-393 0.5/100/1000mg formulation 1 Tab. 1T"},{"name":"CKD-393 0.5/100/1000mg formulation 2 Tab. 1T"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06613750","briefTitle":"Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Zhibin Xu"},"collaborators":[{"name":"Nanfang Hospital, Southern Medical University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Glucotoxicity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin and Gliclazide"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03739268","briefTitle":"GLP-1-mediated Gluco-metabolic Effects of Bile Acid Sequestration"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Steno Diabetes Center Copenhagen"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sevelamer"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00674986","briefTitle":"A Clinical Study to Evaluate the Use of Episodic, Intensive Blood Glucose Monitoring in Persons With Non-insulin Treated Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Accu-Chek 360° View Blood Glucose Analysis Tool"},{"name":"Accu-Chek Aviva Glucose Meter"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02713321","briefTitle":"Impact of Medicaid Health Home on Patients With Diabetes in New York City"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Icahn School of Medicine at Mount Sinai"},"collaborators":[{"name":"Patient-Centered Outcomes Research Institute"},{"name":"New York City Clinical Data Research Network"},{"name":"Weill Medical College of Cornell University"},{"name":"The New York Academy of Medicine"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00536549","briefTitle":"Effect of Real Time Continuous Glucose Monitoring System on the Management of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Korea University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Guardian RT"},{"name":"Education about the self monitoring blood glucose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00714844","briefTitle":"Insulin Detemir and Waist Circumference"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Roma La Sapienza"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01486862","briefTitle":"Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00996658","briefTitle":"Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Linagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03705195","briefTitle":"Study of Sulphonylurea Synergy With Incretins"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Dundee"},"collaborators":[{"name":"NHS Tayside"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gliclazide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03704103","briefTitle":"mHealth Insulin Titration and Management (iSage)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Kansas Medical Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"iSage"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00618995","briefTitle":"A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Comparator: ER niacin (+) laropiprant"},{"name":"Comparator: ER niacin"},{"name":"Comparator: laropiprant"},{"name":"Comparator: placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01134224","briefTitle":"A Trial Investigating the Effect of NN5401 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/insulin aspart"},{"name":"insulin degludec/insulin aspart"},{"name":"insulin degludec/insulin aspart"},{"name":"biphasic insulin aspart 30"},{"name":"biphasic insulin aspart 30"},{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03064347","briefTitle":"Targeted Enteral Nutrient Delivery: A Prospective Randomized Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Southern California"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sucrose plus Whole Milk Powder in Enteric Coating"},{"name":"Non coated Sucrose plus Whole Milk"},{"name":"Sucrose in Enteric Coating"},{"name":"Sucrose with Separate Enteric Coating Materials"},{"name":"Whey Protein in Enteric Coating"},{"name":"Whey Protein with Separate Enteric Coating Materials"},{"name":"Pea Protein in Enteric Coating"},{"name":"Pea Protein with Separate Enteric Coating Materials"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04198948","briefTitle":"Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Sarajevo"},"collaborators":[{"name":"General Hospital Prim. Dr. Abdulah Nakas"},{"name":"University of Dundee"},{"name":"Wellcome Trust"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omeprazole"},{"name":"Placebo oral tablet"},{"name":"Gliclazide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00950599","briefTitle":"Study of Multiple Doses of Saxagliptin (BMS-477118)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Saxagliptin"},{"name":"Saxagliptin"},{"name":"Saxagliptin"},{"name":"Saxagliptin"},{"name":"Saxagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02200991","briefTitle":"Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LIXISENATIDE AVE0010"},{"name":"Sitagliptin"},{"name":"Insulin glargine HOE901"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00153179","briefTitle":"Free Fatty Acids and Vascular Function in Subjects With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Brigham and Women's Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"acipimox"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03670641","briefTitle":"Remission Through Early Monitored Insulin Therapy - Duration Month"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sandra Sobel"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glargine"},{"name":"Lispro"},{"name":"Dexcom G6"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02054897","briefTitle":"Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00519480","briefTitle":"A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK189075"},{"name":"Metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00097877","briefTitle":"Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01221090","briefTitle":"Diabetes Self-Management Models to Reduce Health Disparities"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Scott and White Hospital & Clinic"},"collaborators":[{"name":"Texas A&M University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PDA"},{"name":"CDSMP"},{"name":"PDA/CDSMP"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00790153","briefTitle":"To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin"},{"name":"AZD1656"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00551954","briefTitle":"Effects of Acarbose on Endothelial Function After a Mixed Meal in Newly Diagnosed Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Technische Universität Dresden"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"acarbose"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01934686","briefTitle":"A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Indonesia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01934673","briefTitle":"A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Malaysia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02224417","briefTitle":"Trial to Incentivise Adherence for Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Duke-NUS Graduate Medical School"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Educational Program (DEP)"},{"name":"DEP + Process Incentive"},{"name":"DEP + Outcome Incentive"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00143338","briefTitle":"To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Inhaled insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00239707","briefTitle":"GIP: Glucose-dependent Insulinotropic Peptide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute on Aging (NIA)"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GIP"},{"name":"Modified GIP"},{"name":"Normal Saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00419302","briefTitle":"To Compare the Effect of Inhaled Insulin With Subcutaneously Injected Insulin in Subjects With Type 2 Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mannkind Corporation"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Technosphere/Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00842361","briefTitle":"Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/insulin aspart"},{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03202277","briefTitle":"BeWell24: Smartphone-based Diabetes Prevention in the VA"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Arizona State University"},"collaborators":[{"name":"Phoenix VA Health Care System"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BeWell24 smartphone app"},{"name":"Health education app"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00949286","briefTitle":"Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The George Institute"},"collaborators":[{"name":"Servier"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00328172","briefTitle":"Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"BI 1356 dose 3 once daily"},{"name":"BI 1356 dose 2 once daily"},{"name":"BI 1356 dose 1 once daily"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01302145","briefTitle":"Drug to Drug Interaction Study With ASP1941 and Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ASP1941"},{"name":"Metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01296412","briefTitle":"Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin"},{"name":"liraglutide"},{"name":"glimepiride"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03270436","briefTitle":"Diabetes Prevention Program Lifestyle Intervention in the Marshallese Population"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Arkansas"},"collaborators":[{"name":"Patient-Centered Outcomes Research Institute"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program"},{"name":"Partnership for Improving Lifestyle Intervention Diabetes Prevention Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00283777","briefTitle":"Chromium and Insulin Action"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pennington Biomedical Research Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Chromium Picolinate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03015220","briefTitle":"Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"},{"name":"Dulaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02561338","briefTitle":"A Multi-center 12-week Study of HMS5552 in T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hua Medicine Limited"},"collaborators":[{"name":"Tigermed Consulting Co., Ltd"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HMS5552"},{"name":"HMS5552"},{"name":"HMS5552"},{"name":"HMS5552"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01877200","briefTitle":"A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06178094","briefTitle":"The Effects of Video Training Given to Individuals With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kırklareli University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Training"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Video Training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00435240","briefTitle":"Paleolithic Diet in the Treatment of Diabetes Type 2 in Primary Health Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lund University Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Paleolithic diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06539923","briefTitle":"Sarcopenic Index and Related Factors in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Goztepe Prof Dr Suleyman Yalcın City Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Sarcopenia"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"retrieving data"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01022658","briefTitle":"INSUlin Regimens and VASCular Functions"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Assistance Publique - Hôpitaux de Paris"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02917902","briefTitle":"Assessing Health Outcomes in Low-income Diabetics Who Receive Monthly Boxes of Healthy Food at Clinic"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Diego"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Food boxes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00789035","briefTitle":"12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 10773"},{"name":"placebo"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01868542","briefTitle":"A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03394456","briefTitle":"Technology to Improve the Health of Resource-poor Hispanics With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baylor College of Medicine"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"diabetes program"},{"name":"telehealth training and support for Community Health Workers"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04065581","briefTitle":"Bioequivalence Study for Acarbose/Metformin FDC"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acarbose/Metformin FDC(BAY81-9783)"},{"name":"Glucobay"},{"name":"Glucophage"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05607160","briefTitle":"A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00511108","briefTitle":"Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Comparator: sitagliptin phosphate"},{"name":"Comparator: pioglitazone"},{"name":"Comparator: placebo to pioglitazone"},{"name":"Comparator: placebo to sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02375139","briefTitle":"A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01(Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets) Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg in Healthy Male Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dong-A ST Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DA-1229_01"},{"name":"E+M"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00841919","briefTitle":"Insulin Therapy in the Hospital Comparing Two Protocols"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cook County Health"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glargine insulin"},{"name":"NPH insulin and regular insulin"},{"name":"lispro insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02066831","briefTitle":"Diabetes Coaching Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"West German Center of Diabetes and Health"},"collaborators":[{"name":"German Institute for Telemedicine and Health Promotion"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Telemedical coaching"},{"name":"Telemedicine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01470937","briefTitle":"Early Diabetes Intervention Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Indiana University School of Medicine"},"collaborators":[{"name":"Bayer"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acarbose"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00933972","briefTitle":"A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"RO4998452"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00716092","briefTitle":"The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo (linagliptin)"},{"name":"Placebo (linagliptin)"},{"name":"Sitagliptin"},{"name":"Placebo (sitagliptin)"},{"name":"Placebo (sitagliptin)"},{"name":"Linagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01570660","briefTitle":"Phielix et al.: Hepatic Fat Content and Adipokines"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"German Diabetes Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01173315","briefTitle":"The Impact of Vitamins and Minerals Supplementation on Neuropathy and Nephropathy Complications"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shahid Beheshti University of Medical Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vitamin and mineral supplementation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02092597","briefTitle":"Safety Evaluation of Adverse Reactions in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Charles University, Czech Republic"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide"},{"name":"Linagliptin"},{"name":"Gliclazide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01215435","briefTitle":"Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"},{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00506194","briefTitle":"Short-Term Intensive Insulin Therapy Induction of Long-term Glycemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Taipei Veterans General Hospital, Taiwan"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin"},{"name":"OAD"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02967211","briefTitle":"A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to \"Standard of Care\" Basal Insulin in Patients Already Using Basal Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glargine (U300)"},{"name":"insulin glargine (U100)"},{"name":"NPH insulin"},{"name":"insulin detemir"},{"name":"insulin degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01548222","briefTitle":"CGM Evaluation of Glucose Excursions in Basal Insulin Treated T2DM at Fasting Glucose Target"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diabetes Care Center"},"collaborators":[{"name":"Medtronic"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00984867","briefTitle":"Dapagliflozin DPPIV Inhibitor add-on Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01973231","briefTitle":"Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"lixisenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03355040","briefTitle":"Induction of Labour for LGA fœtus in Women Without Insulin-treated Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Montpellier"}},"conditionsModule":{"conditions":["Macrosomia","Induction of Labour","Non-insulin-dependent Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"induction of labour"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01161030","briefTitle":"Almonds and Diabetes Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Arizona State University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Almonds"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03130699","briefTitle":"Dulce Digital-Me: An Adaptive mHealth Intervention for Underserved Hispanics With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Scripps Whittier Diabetes Institute"},"collaborators":[{"name":"University of California, San Diego"},{"name":"San Diego State University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dulce Digital"},{"name":"Dulce Digital-Me (Automated Delivery)"},{"name":"Dulce Digital-Me (Medical Assistant)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01161797","briefTitle":"1,5-AG as a Marker of Postprandial Hyperglycemia and Glucose Variability in Well-controlled Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kyunghee University Medical Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00541606","briefTitle":"Pharmacist Assisted Medication Program Enhancing the Regulation of Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lahey Clinic"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pharmacist collaboration in diabetes care"},{"name":"Usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01754259","briefTitle":"Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Brigham and Women's Hospital"}},"conditionsModule":{"conditions":["Diabetes, Type I","Diabetes, Type II","Angina","Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ranolazine"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00945204","briefTitle":"Evaluation of Intermediate Care Clinics for Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospitals, Leicester"},"collaborators":[{"name":"Warwick Medical School"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"intermediate care clinics (ICCs)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02980978","briefTitle":"diEtitiaNs Helping pAtieNts CarE for Diabetes (ENHANCED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Minneapolis Heart Institute Foundation"},"collaborators":[{"name":"Academy of Nutrition and Dietetics"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Coaching"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00568074","briefTitle":"Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"repaglinide"},{"name":"Glurenorm®"},{"name":"Glucobay®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02967224","briefTitle":"A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to \"Standard of Care\" Basal Insulins in Insulin Naïve Patients Initiating Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glargine (U300)"},{"name":"insulin glargine (U100)"},{"name":"NPH insulin"},{"name":"insulin detemir"},{"name":"insulin degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01393275","briefTitle":"Effects of Exercise Intervention and Rehabilitation Exercise Intervention in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Giessen"},"collaborators":[{"name":"Sportpark Zwickau, Germany"},{"name":"Sportpark Glauchau, Germany"},{"name":"Comenius University"}]},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rehabilitation exercise intervention"},{"name":"placebo control group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03990844","briefTitle":"Glycemic Evaluation of Okra Seed Noodles"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National University of Singapore"},"collaborators":[{"name":"National University Health System"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Okra seed"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03989908","briefTitle":"Effects of Microfluidic Noodle on Blood Glucose Levels of Healthy Volunteers."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National University of Singapore"},"collaborators":[{"name":"National University Health System"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Microfludic noodle"},{"name":"Control noodle"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02897349","briefTitle":"Linagliptin Add-on to Insulin Background Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo"},{"name":"linagliptin"},{"name":"background therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03985566","briefTitle":"Effects of Fixed Meals With Special Formulated Rice on Blood Glucose Levels of Healthy Volunteers."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National University of Singapore"},"collaborators":[{"name":"Alchemy Foodtech Pte Ltd"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fibre Grain"},{"name":"Jasmine white rice"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01664624","briefTitle":"Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Roflumilast"},{"name":"Alogliptin"},{"name":"Exenatide"},{"name":"Placebo to roflumilast"},{"name":"Placebo to alogliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00790205","briefTitle":"Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"},"collaborators":[{"name":"Duke Clinical Research Institute, Oxford Diabetes Trials Unit"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03447964","briefTitle":"Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Groupe Hospitalier Pitie-Salpetriere"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"dosing of sphingolipids"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00605111","briefTitle":"Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02971618","briefTitle":"Study With Dapagliflozin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03970044","briefTitle":"Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Consano Clinical Research, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide 2 MG"},{"name":"Dapagliflozin 10 MG"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00277277","briefTitle":"In-Home Weight Loss Program for Adults With Type 2 Diabetes Delivered by Interactive Cable Television Technology"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bastyr University"},"collaborators":[{"name":"National Institute for Biomedical Imaging and Bioengineering (NIBIB)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Healthium"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00529165","briefTitle":"The Necessity of an Injection-Meal-Interval in Patients With Type 2 Diabetes Mellitus and Therapy With Human Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Jena"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"injection-meal-interval"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00106366","briefTitle":"Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin glargine"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03018028","briefTitle":"Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"},{"name":"Placebo"},{"name":"Liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03675165","briefTitle":"Can You Reduce Diabetes Symptomatology by Becoming Your 'Best Possible Self': The Role of Stress and Resilience"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Liverpool John Moores University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Best Possible Self"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00251680","briefTitle":"Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lapaquistat acetate and lipid-lowering therapy"},{"name":"Lipid-lowering therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03175120","briefTitle":"A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin degludec/liraglutide"},{"name":"Insulin degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02200627","briefTitle":"Forxiga Tablets Specific Clinical Experience Investigation for Elderly"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02722239","briefTitle":"An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Biocard"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Xigduo XR"},{"name":"Metformin ER (Glucophage® long)"},{"name":"Dapagliflozin (Forxiga)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02201004","briefTitle":"TOFO Insulin Combination Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"},"collaborators":[{"name":"Kowa Company, Ltd."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TOFOGLIFLOZIN CSG452"},{"name":"insulin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01098461","briefTitle":"Dose Ranging Study of Albiglutide in Japanese Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"albiglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00683878","briefTitle":"Add-on to Thiazolidinedione (TZD) Failures"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Astra Zeneca, Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Dapagliflozin"},{"name":"Placebo matching Dapagliflozin"},{"name":"Thiazolidinedione (Pioglitazone)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00968006","briefTitle":"Effect of Sitagliptin on Endothelial Progenitor Cells"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Padova"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03923114","briefTitle":"Imaging Pituitary ActiVation by Exendin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Radboud University Medical Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ga-68-NODAGA-exendin-4 PET/CT"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03349684","briefTitle":"Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acarbose"},{"name":"Metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03921203","briefTitle":"ApoB48 Metabolism in Plasma and Interstitial Fluid"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Karolinska University Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00109720","briefTitle":"Evaluation of Diabetes Self-Management Consultant Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},"collaborators":[{"name":"Detroit Department of Health"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Self-Management Consultant"},{"name":"Enhanced Usual Care Control Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03907423","briefTitle":"Rosuvastatin on Diabetic Patients Treated With Glimepiride/Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rehab Werida"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosuvastatin10 mg tablet"},{"name":"Placebo Oral Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01028391","briefTitle":"30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d."},{"name":"Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d."},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03310749","briefTitle":"An Assessment of Pharmacokinetic Gemigliptin and Metformin Interactions in Healthy Mexican Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Stendhal Americas, S.A."},"collaborators":[{"name":"Universidad Nacional Autonoma de Mexico"},{"name":"LG Chem"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gemigliptin"},{"name":"Gemigliptin 50 mg q.d. + metformin 1000 mg twice a day"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03887403","briefTitle":"The COMUNICARE Study: the Effectiveness of a Multimodal Intervention Based on Person-centered Communication"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gerencia de Atención Primaria, Madrid"},"collaborators":[{"name":"Instituto de Salud Carlos III"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Multimodal Intervention"},{"name":"Usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00621140","briefTitle":"Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"linagliptin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03376802","briefTitle":"A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SAR425899"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01076088","briefTitle":"Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin 50 mg"},{"name":"Metformin 500 mg"},{"name":"Sitagliptin 100 mg"},{"name":"Placebo"},{"name":"Metformin 850 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01397942","briefTitle":"Maximising the Taste and Health Value of Plant Food Products"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aarhus University Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diet intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01710371","briefTitle":"Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Avid Radiopharmaceuticals"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"18F-AV-133"},{"name":"10% Arginine Hydrochloride-R-Gene 10"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01128894","briefTitle":"A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"albiglutide"},{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01565733","briefTitle":"Safety of Treatment Initiation With Biphasic Insulin Aspart 30 in Hospitalised Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03138356","briefTitle":"Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet"},{"name":"2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet"},{"name":"5 mg dapagliflozin / 850 mg metformin XR FDC"},{"name":"5 mg dapagliflozin / 1000 mg metformin XR FDC"},{"name":"2.5 mg ONGLYZA® (saxagliptin) tablet"},{"name":"5 mg Forxiga® (dapagliflozin) tablet"},{"name":"500 mg Glucophage XR®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00118950","briefTitle":"Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Steno Diabetes Center Copenhagen"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Repaglinide"},{"name":"Placebo-Metformin."},{"name":"Placebo-Repaglinide."},{"name":"Diet-only."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03637075","briefTitle":"Raclopride-PET/MRT"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital Tuebingen"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"intranasal insulin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03225339","briefTitle":"Diabetes Intervention Accentuating Diet and Enhancing Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Weill Cornell Medical College in Qatar"},"collaborators":[{"name":"Hamad Medical Corporation"},{"name":"Weill Medical College of Cornell University"},{"name":"Cornell University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low Energy Diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01651117","briefTitle":"Using Peer Mentors to Support PACT Team Efforts to Improve Diabetes Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VA Office of Research and Development"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Peer Mentoring"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00858013","briefTitle":"Study of the Durability of Glycemic Control With Nateglinide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ajou University School of Medicine"},"collaborators":[{"name":"Korea University Guro Hospital"},{"name":"Hanyang University"},{"name":"Inha University Hospital"},{"name":"Kyunghee University Medical Center"},{"name":"Myongji Hospital"},{"name":"Bundang CHA Hospital"},{"name":"Wonju Severance Christian Hospital"},{"name":"Hallym University Medical Center"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nateglinide"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03331432","briefTitle":"Effects of Dietary Supplement Tauroursodeoxycholic Acid on Vascular Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Missouri-Columbia"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tauroursodeoxycholic acid"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03839641","briefTitle":"Novel Approach to Assess Metabolic Flexibility in a Respiratory Chamber"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pennington Biomedical Research Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High fat meal"},{"name":"Low fat meal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03837262","briefTitle":"GLucose Monitoring Programme SingaporeE (GLiMPSE)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Singapore General Hospital"},"collaborators":[{"name":"KK Women's and Children's Hospital"},{"name":"SingHealth Polyclinics"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Flash Glucose Monitoring and structured education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02589626","briefTitle":"Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"empagliflozin 10mg"},{"name":"empagliflozin 25 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02699307","briefTitle":"Lifestyle Intervention for Adults With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Counseling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00551876","briefTitle":"Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Organon and Co"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK0653, ezetimibe / Duration of Treatment: 30 Weeks"},{"name":"Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03305367","briefTitle":"Dose-response Effect of Pine Nut Oil as a Dual FFA1 and FFA4 Agonist on Glucose Tolerance in Healthy Humans."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Odense University Hospital"},"collaborators":[{"name":"University of Southern Denmark"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hydrolyzed pine nut oil"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03296800","briefTitle":"Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Theracos"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bexagliflozin"},{"name":"Probenecid"},{"name":"Rifampin"},{"name":"Verapamil"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01570751","briefTitle":"A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01278485","briefTitle":"Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-402)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sulphonylurea"},{"name":"Metformn"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02040038","briefTitle":"Diabetes Self-Management & Support LIVE"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Duke University"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LIVE"},{"name":"Website"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01326598","briefTitle":"Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Valeritas, Inc."},"collaborators":[{"name":"Integrated Medical Development"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"V-Go™"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00849849","briefTitle":"Comprehensive Postpartum Screening Strategies for Women With Gestational Diabetes Mellitus (GDM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Woman's"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03926806","briefTitle":"Yoghurt Consumption, Body Weight Management and Glycemic Control of T2DM Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Harokopio University"},"collaborators":[{"name":"National and Kapodistrian University of Athens"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Plain yoghurt"},{"name":"Vitamin B yoghurt"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02682680","briefTitle":"Randomized Trial Comparing Colesevelam vs. Ezetimibe"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LMC Diabetes & Endocrinology Ltd."},"collaborators":[{"name":"Bausch Health Americas, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Colesevelam"},{"name":"Ezetimibe"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03151837","briefTitle":"Hypoglycemic Efficacy of Greenyn Momordica Charantia Extracts in Diabetic Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chung Shan Medical University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Greenyn Momordica charantia extracts"},{"name":"Placebo control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03604419","briefTitle":"Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"PegBio Co., Ltd."},"collaborators":[{"name":"Covance"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PB-119 100 μg+ Glucophage®"},{"name":"PB-119 150 μg+ Glucophage®"},{"name":"PB-119 200 μg+ Glucophage®"},{"name":"PB-119 placebo + Glucophage®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00918138","briefTitle":"Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Metformin XR"},{"name":"Placebo matching Metformin XR"},{"name":"Metformin XR"},{"name":"Placebo matching Saxagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00339482","briefTitle":"Prospective Studies of the Natural History of Diabetes Mellitus and Its Complications in the Gila River Indian Community"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04849845","briefTitle":"Afrezza® Dosing Optimization Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mannkind Corporation"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Afrezza Dose 1"},{"name":"Afrezza Dose 2"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00757588","briefTitle":"Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin, 5 mg + insulin"},{"name":"Placebo + insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02148861","briefTitle":"A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin icodec"},{"name":"insulin degludec"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03745885","briefTitle":"A Study of the Efficacy and Safety of Supaglutide in Healthy Participants"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd."},"collaborators":[{"name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Supaglutide injection"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04484779","briefTitle":"A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IIM System"},{"name":"Insulin Lispro and/or Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00552370","briefTitle":"Glycemic Optimization Treatment Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lantus®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03225209","briefTitle":"Medically Reproducing Bariatric Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Moahad S Dar"},"collaborators":[{"name":"Société des Produits Nestlé (SPN)"},{"name":"Durham VA Medical Center"},{"name":"East Carolina University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"OPTIFAST"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01780272","briefTitle":"A Trial to Investigate the Impact of Nocturnal Hypoglycaemia on Sleep in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"glucose clamp"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03724981","briefTitle":"A Study Comparing the Dulaglutide Pen and the Semaglutide Pen"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dulaglutide Pen"},{"name":"Semaglutide Pen"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03723785","briefTitle":"A Research Study of How a New Medicine NNC0148-0287 C (Insulin 287) Works in the Body of People With Kidney Problems"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin icodec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03211195","briefTitle":"Sotagliflozin Bioequivalence Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sotagliflozin (SAR439954)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00888719","briefTitle":"Therapeutic Exploratory Study of CWP-0403"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"JW Pharmaceutical"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CWP-0403 100mg"},{"name":"placebo"},{"name":"CWP-0403 50mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03268005","briefTitle":"Research Study Comparing a New Medicine \"Fast-acting Insulin Aspart\" to Another Already Available Medicine \"NovoRapid\"/\"NovoLog\" in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Faster-acting insulin aspart"},{"name":"Insulin aspart"},{"name":"Insulin degludec"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01183013","briefTitle":"30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone 15 mg"},{"name":"Pioglitazone 45 mg"},{"name":"Pioglitazone 30 mg"},{"name":"Linagliptin 5mg / Pioglitazone 45 mg FDC"},{"name":"Linagliptin 5mg / Pioglitazone 30 mg FDC"},{"name":"Linagliptin 5mg"},{"name":"Linagliptin 5mg / Pioglitazone 15 mg FDC"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04518566","briefTitle":"Empowering Patients With Chronic Disease Using Profiling and Targeted Feedbacks Delivered Through Wearable Device"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Singapore General Hospital"},"collaborators":[{"name":"National University of Singapore"},{"name":"SingHealth Polyclinics"},{"name":"Duke-NUS Graduate Medical School"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nudges"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02135328","briefTitle":"SoLaHmo Radio Stories About Children's Healthy Eating and Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Minnesota"},"collaborators":[{"name":"West Side Community Health Services"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Radio Story"},{"name":"Audio brochure"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03699709","briefTitle":"Cooking for Health"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Washington"},"collaborators":[{"name":"Medstar Health Research Institute"},{"name":"Missouri Breaks Industries Research, Inc."},{"name":"National Institute on Minority Health and Health Disparities (NIMHD)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Budgeting, purchasing and cooking educational intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01345734","briefTitle":"Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00819091","briefTitle":"Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 1356"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00258804","briefTitle":"Insulin Glargine During and After the Period of Fasting in Ramadan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01340079","briefTitle":"Virtual World Health Behavior Counseling for Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boston Medical Center"},"collaborators":[{"name":"University of Massachusetts, Worcester"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"virtual world"},{"name":"face to face"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02200666","briefTitle":"Forxiga Tablets Specific Clinical Experience Investigation for Long-term Use"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01012037","briefTitle":"Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"linagliptin low dose"},{"name":"placebo"},{"name":"linagliptin medium dose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01490918","briefTitle":"Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Catholic University of Korea"},"collaborators":[{"name":"Bayer"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acarbose"},{"name":"Placebo acarbose"},{"name":"placebo metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02834923","briefTitle":"Enhancing Self-Management Support in Diabetes Through Patient Engagement"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Francisco"},"collaborators":[{"name":"University of Colorado, Denver"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Enhanced Engagement Protocol for CTH (EE-CTH)"},{"name":"Connection to Health (CTH)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00282360","briefTitle":"Effect of Metabolic Therapy in Patients With Chronic Ischemic Heart Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"IRCCS San Raffaele"}},"conditionsModule":{"conditions":["Coronary Artery Disease","Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Trimetazidine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00643851","briefTitle":"An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Metformin XR"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03449654","briefTitle":"Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Steno Diabetes Center Copenhagen"},"collaborators":[{"name":"Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet & Cluster for Molecular Imaging, University of Copenhagen, Denmark"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Placebo (for liraglutide)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01923181","briefTitle":"Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"semaglutide"},{"name":"oral placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00915772","briefTitle":"Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Linagliptin + metformin"},{"name":"Linagliptin+metformin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01497301","briefTitle":"Efficacy Study of Diabetes Group Visits"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oregon Health and Science University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Group Visits"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00288236","briefTitle":"Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rimonabant (SR141716)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03249259","briefTitle":"The Effect of Choline Alfoscerate on Improvement of Cognitive Function in Elderly Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Bundang Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Choline alfoscerate"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03646721","briefTitle":"A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dong-A ST Co., Ltd."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DA-1241"},{"name":"Placebo"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02857764","briefTitle":"Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03638778","briefTitle":"Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide 3 mg"},{"name":"Semaglutide 7 mg"},{"name":"Semaglutide B 3 mg"},{"name":"Semaglutide B 7 mg"},{"name":"Semaglutide C 3 mg"},{"name":"Semaglutide C 7 mg"},{"name":"Semaglutide D 3 mg"},{"name":"Semaglutide D 7 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02444910","briefTitle":"Effects of KDT501 on Metabolic Features in Insulin Resistant Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"KinDex Pharmaceuticals, Inc."},"collaborators":[{"name":"University of Kentucky"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"KDT501"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04436900","briefTitle":"Evaluation of Macular Structural and Functional Function Following Extensive Retinal Laser Therapy in Patients With Proliferative Diabetic Retinopathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baqiyatallah Medical Sciences University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Panretinal Photocoagulation (PRP)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00290940","briefTitle":"Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CS-917"},{"name":"metformin hydrochloride"},{"name":"pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03172494","briefTitle":"A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin degludec/liraglutide"},{"name":"Insulin degludec"},{"name":"Liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00099515","briefTitle":"Comparing Intensive and Standard Training for Human Insulin Inhalation Powder (HIIP)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"},"collaborators":[{"name":"Alkermes, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY041001 (HIIP)"},{"name":"LY041001 (HIIP)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03617081","briefTitle":"First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NNC0113-2023"},{"name":"Placebo (NNC0113-2023)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05628090","briefTitle":"A Study of an Existing Database to Assess the Treatment Persistence to Basal Insulin in Type 2 Diabetes Mellitus Patients in a Structured Patient Education Program in India"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01305434","briefTitle":"Mulberry Leaf Extract and Blood Glucose Control in Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Craig, Nancy, M.D."}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mulberry leaf extract effect on post prandial blood glucose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02451137","briefTitle":"A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine, 300 U/ml"},{"name":"Insulin glargine, 100 U/ml"},{"name":"Insulin detemir"},{"name":"Background Therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02827890","briefTitle":"CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Januvia Tab. 100mg"},{"name":"Januvia Tab. 100mg + Duvie Tab. 0.5mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02380521","briefTitle":"Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Palermo"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide once weekly (BYDUREON™)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00360334","briefTitle":"A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02846233","briefTitle":"Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Francisco"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLP1 receptor agonist"},{"name":"basal insulin"},{"name":"SGLT2 inhibitor"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03091712","briefTitle":"Insulin Degludec Titration Using Mobile Insulin Dosing System"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Glooko"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glooko Mobile Insulin Dosing System(MIDS)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03598621","briefTitle":"A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide, 0.5 mg/mL"},{"name":"Semaglutide, 1.0 mg/mL"},{"name":"Semaglutide, 1.34 mg/mL"},{"name":"Semaglutide, 2.0 mg/mL"},{"name":"DV3372, 0.5 mg/mL"},{"name":"DV3372, 1.0 mg/mL"},{"name":"PDS290"},{"name":"NovoPen®4"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00755287","briefTitle":"A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glargine"},{"name":"metformin"},{"name":"taspoglutide"},{"name":"taspoglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02212067","briefTitle":"A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00157586","briefTitle":"Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mario Negri Institute for Pharmacological Research"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Delapril, Delapril-Manidipine Fixed combination"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02886884","briefTitle":"Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Joshua M Hare"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"20 million Allogeneic Mesenchymal Human Stem Cells"},{"name":"100 million Allogeneic Mesenchymal Human Stem Cells"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02411929","briefTitle":"A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Unlabeled ertugliflozin for oral use"},{"name":"14^C-labeled ertugliflozin for IV use"},{"name":"14^C-labeled ertugliflozin for oral use"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01154881","briefTitle":"A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02113163","briefTitle":"PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Thetis Pharmaceuticals LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent","Hypertriglyceridemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin Eicosapentaenoate"},{"name":"Metformin HCl and Vascepa"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00789191","briefTitle":"Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"sitagliptin"},{"name":"metformin"},{"name":"sulphonylurea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02877355","briefTitle":"Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02015299","briefTitle":"Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"dr. DJ Mulder"},"collaborators":[{"name":"Boehringer Ingelheim"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Linagliptin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00393718","briefTitle":"Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"glibenclamide"},{"name":"placebo"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00397631","briefTitle":"Initial Combination With Pioglitazone Study (0431-064)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin 100 mg q.d./pioglitazone 30 mg q.d"},{"name":"Comparator: placebo to match sitagliptin 100 mg q.d./pioglitazone 30 mg q.d."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00386100","briefTitle":"A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Avandamet 6 mg/1500 mg (ttd)"},{"name":"Avandamet 4 mg/1000 mg (ttd)"},{"name":"Avandamet 2 mg/500 mg (ttd)"},{"name":"Avandamet 8 mg/ 2000 mg (ttd)"},{"name":"Metformin 500 mg (ttd)"},{"name":"Metformin 1000 mg (ttd)"},{"name":"Metformin 1500 mg (ttd)"},{"name":"Metformin 2000 mg (ttd)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00405418","briefTitle":"Lantus Versus Levemir Treat-To-Target"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine"},{"name":"Insulin Detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01068678","briefTitle":"Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03534687","briefTitle":"Exercise and the Receptor for Advanced Glycation End Products (RAGE)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aerobic Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00944450","briefTitle":"Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin phosphate anhydrous formulation"},{"name":"Comparator: sitagliptin phosphate monohydrate form"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00607906","briefTitle":"First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SB-756050 immediate release capsule"},{"name":"SB-756050 modified release capsule"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00739336","briefTitle":"Diabetes Prevention and Control in the Workplace: A Pilot Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"State University of New York - Upstate Medical University"},"collaborators":[{"name":"County of Onondaga, NYS"},{"name":"NYS Department of Health"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Prevention and Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01055223","briefTitle":"Fracture Risk With Thiazolidinediones"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Fractures, Bone","Type II Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TZD only (RSG or PIO or troglitazone)"},{"name":"TZD + spironolactone"},{"name":"TZD + amiloride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00747968","briefTitle":"The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"Eli Lilly and Company"},{"name":"Aarhus University Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Byetta, Exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01068665","briefTitle":"Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01117350","briefTitle":"Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine"},{"name":"Liraglutide"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01924767","briefTitle":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 10773 Placebo"},{"name":"BI 10773"},{"name":"BI 10773 Placebo"},{"name":"BI 10773"},{"name":"BI 10773 Placebo"},{"name":"BI 10773 Placebo"},{"name":"BI 10773"},{"name":"BI 10773"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01892020","briefTitle":"Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 50"},{"name":"biphasic human insulin 50"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02254291","briefTitle":"A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"semaglutide"},{"name":"sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04932213","briefTitle":"Effect of Tropicamide 0.5% vs Tropicamide 1% on Intraocular Pressure of Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Semnan University of Medical Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tropicamide Ophthalmic"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03486964","briefTitle":"Use of Incretins in Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pavia"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DPP-4 inhibitors"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04805996","briefTitle":"The eHealth Diabetes Remission Trial - Pilot Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Julia Otten"},"collaborators":[{"name":"Region Västerbotten"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes remission using total diet replacement and eHealth contact with the healthcare provider"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02413567","briefTitle":"Evaluation of Duodenal Mucosal Resurfacing in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fractyl Health Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DMR Procedure (Fractyl)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00683657","briefTitle":"Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01486875","briefTitle":"Observational Study of Safety of NovoMix® 30 Treatment for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03447080","briefTitle":"Co-ingestion of Rice Bran Soymilk or Plain Soymilk With White Bread: Effects on the Glycaemic and Insulinaemic Response"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Singapore Institute of Food and Biotechnology Innovation"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Control"},{"name":"Control"},{"name":"Ricebran soybean milk"},{"name":"Soybean milk"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01917656","briefTitle":"Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"metformin"},{"name":"sulphonylurea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00469105","briefTitle":"Improving Care for Primary Care Patients With Diabetes and Poor Literacy and Numeracy Skills"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University"},"collaborators":[{"name":"University of North Carolina, Chapel Hill"},{"name":"American Diabetes Association"},{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Literacy/Numeracy oriented educational intervention"},{"name":"Control Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00437554","briefTitle":"Phase III Study for Glimepiride + Metformin Hydrochloride (Amaryl M) Slow Release (SR)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Handok Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02240680","briefTitle":"Linagliptin as Add on to Basal Insulin in the Elderly"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo"},{"name":"linagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01398592","briefTitle":"Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01336751","briefTitle":"Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine"},{"name":"75% insulin lispro protamine suspension and 25 % insulin lispro injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02400515","briefTitle":"Influence of Regular Exercise and Detraining on Metabolic and Emotional Parameters in Diabetic Individuals"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Campinas, Brazil"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04970810","briefTitle":"My Diabetes, My Community"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Chicago"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"My Diabetes Goal"},{"name":"My Diabetes Goal + CommunityRx"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02214017","briefTitle":"Telemedicine Strategy With Home Treatment Save Resources"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kolding Sygehus"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"A videotelephone, TandBerg E20,"},{"name":"Behavioral motivation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02147431","briefTitle":"A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02639637","briefTitle":"Effect of DPP4 Inhibition on Vasoconstriction"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Placebo"},{"name":"Neuropeptide Y"},{"name":"Enalaprilat"},{"name":"Valsartan 160mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01072565","briefTitle":"Modal Day Analysis of Self Monitoring Blood Glucose Versus Continuous Glucose Monitoring"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HealthPartners Institute"},"collaborators":[{"name":"International Diabetes Center at Park Nicollet"},{"name":"Abbott Diabetes Care"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SMBG to guide clinical decisions"},{"name":"SMBG and CGM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03362398","briefTitle":"Omarigliptin & Trelagliptin in Twelve Healthy Egyptian Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"British University In Egypt"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omarigliptin 25 mg"},{"name":"Trelagliptin 100 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01135394","briefTitle":"Pharmacogenomics of Thiazolidinediones"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Maryland, Baltimore"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00262548","briefTitle":"C-Reactive Protein (CRP) in Obese Diabetic Women"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Mexican National Institute of Public Health"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosuvastatin; improvement of lipid profile"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01607931","briefTitle":"Exercise, Glucose Kinetics, and the Incretin Effect"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rigshospitalet, Denmark"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03331289","briefTitle":"Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Exenatide"},{"name":"Dapagliflozin"},{"name":"Exenatide and Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00157482","briefTitle":"Ezetimibe and Simvastatin in Dyslipidemia of Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mario Negri Institute for Pharmacological Research"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ezetimibe"},{"name":"Simvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02040337","briefTitle":"Sequencing T-cells in Type I Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seton Healthcare Family"},"collaborators":[{"name":"Cancer Prevention Research Institute of Texas"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03132181","briefTitle":"Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"RWTH Aachen University"},"collaborators":[{"name":"Boehringer Ingelheim"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2 (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03649243","briefTitle":"Propolis as Adjuvant in the Healing of Human Diabetic Foot Wounds"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Talca"},"collaborators":[{"name":"Hospital Regional de Talca"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Propolis spray"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00468039","briefTitle":"A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin + metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01471808","briefTitle":"Effects of Different Early Intensive Therapies on Long-term β-cell Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sun Yat-sen University"},"collaborators":[{"name":"Nanfang Hospital, Southern Medical University"},{"name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University"},{"name":"Peking University Shenzhen Hospital"},{"name":"First People's Hospital of Foshan"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CSII"},{"name":"CSII, Metformin, Pioglitazone"},{"name":"CSII, Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01454973","briefTitle":"Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Foundation for the National Institutes of Health"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"Juvenile Diabetes Research Foundation"},{"name":"Amylin Pharmaceuticals, LLC."},{"name":"Merck Sharp & Dohme LLC"},{"name":"Pfizer"},{"name":"Eli Lilly and Company"},{"name":"Takeda"},{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."},{"name":"Novartis"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01796366","briefTitle":"A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin 338 (GIPET I)"},{"name":"placebo"},{"name":"insulin glargine"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00154401","briefTitle":"Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00344240","briefTitle":"Exercise and Activity Guidance in Older Adults With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"},"collaborators":[{"name":"US Department of Veterans Affairs"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Functional circuit training with lifestyle behavior"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00676819","briefTitle":"Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Insulin in Elderly People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin aspart"},{"name":"human insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00246623","briefTitle":"US Inhaled Insulin Dose Titration Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exubera (inhaled insulin)"},{"name":"8-point glucose diary (to assess pre- and post prandial glucoses)"},{"name":"Meal Tolerance Test"},{"name":"24-hour continuous glucose monitoring (at select sites)"},{"name":"Pulmonary Function Testing"},{"name":"Hypoglycemic Event Monitoring"},{"name":"Laboratory Assessments"},{"name":"Nutritional Counseling and Diabetes Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01526980","briefTitle":"Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"},{"name":"biphasic insulin aspart 70"},{"name":"biphasic human insulin 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02791035","briefTitle":"Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Asan Medical Center"},"collaborators":[{"name":"Severance Hospital"},{"name":"Samsung Medical Center"},{"name":"Kyung Hee University Hospital at Gangdong"},{"name":"Astellas Pharma Korea, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral administration of Ipragliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02140645","briefTitle":"Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"linagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01212913","briefTitle":"Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INSULIN GLARGINE"},{"name":"INSULIN GLULISINE"},{"name":"Insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03286751","briefTitle":"A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY900014"},{"name":"Insulin Lispro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02449213","briefTitle":"A Biobehavioral Model of Diabetes Risk in Chinese Immigrants"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fox Chase Cancer Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00575588","briefTitle":"52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Sulphonylurea"},{"name":"Saxagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00885352","briefTitle":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Comparator: Placebo"},{"name":"Pioglitazone"},{"name":"Metformin"},{"name":"Glipizide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00735501","briefTitle":"Observational Study to Observe the Safety of Levemir® Treatment in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02531776","briefTitle":"Patient Experiences With Injection Needles"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Copenhagen"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Subcutaneous insertions of needles"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01542060","briefTitle":"Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03068273","briefTitle":"Managing Type 1 and High Risk Type 2 Diabetes in the Hospital Setting: Glucose as a Vital Sign"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Scripps Whittier Diabetes Institute"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Real-time CGM data"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01332370","briefTitle":"Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone + Metformin"},{"name":"Sitagliptin + Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00223574","briefTitle":"Canadian Trial of Dietary Carbohydrates in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Toronto"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Control - high carbohydrate, high glycemic index foods"},{"name":"high carbohydrate, low glycemic index foods"},{"name":"low carbohydrate, high monounsaturate fat foods"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00943501","briefTitle":"Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"placebo"},{"name":"liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02479399","briefTitle":"Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ipragliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02911948","briefTitle":"A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin degludec/liraglutide"},{"name":"Insulin degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02496221","briefTitle":"A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Albiglutide 50 mg"},{"name":"Placebo"},{"name":"CCK (Kinevac)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03232983","briefTitle":"A Study of LY900014 Formulation at Different Injection Sites in Healthy Participants"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY900014 (SC)"},{"name":"LY900014 (IV)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00949442","briefTitle":"Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine (HOE901) [Lantus]"},{"name":"Glimepiride"},{"name":"human insulin [NPH]"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01615978","briefTitle":"Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00334503","briefTitle":"Open Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanwa Kagaku Kenkyusho Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Miglitol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02133118","briefTitle":"Weight Trajectory in New Users of Sulfonylureas as Add on Therapy Next to Metformin."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical Research Foundation, The Netherlands"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"individual SUs, insulin, pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02297620","briefTitle":"The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Suglat®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05560386","briefTitle":"TEEN HEED: An Adolescent Diabetes Prevention Intervention Incorporating Novel Mobile Health Technologies"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Icahn School of Medicine at Mount Sinai"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Text messaging"},{"name":"Virtual workshop"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00778622","briefTitle":"Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristol-Myers Squibb"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin XR"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03173391","briefTitle":"Long-term Efficacy and Safety of HMS5552 in T2DM Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hua Medicine Limited"},"collaborators":[{"name":"Tigermed Consulting Co., Ltd"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HMS5552"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03168295","briefTitle":"PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"},"collaborators":[{"name":"National Institutes of Health (NIH)"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin 10mg then Placebo Oral Tablet"},{"name":"Placebo Oral Tablet then Dapagliflozin 10mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01497561","briefTitle":"Pharmacodynamics and Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin NPH"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01535677","briefTitle":"To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin + Glucophage tablet fasted"},{"name":"Dapagliflozin/metformin IR FDC tablet fasted"},{"name":"Dapagliflozin + Glucophage tablet fed"},{"name":"Dapagliflozin/metformin IR FDC tablet fed"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00256633","briefTitle":"Fatty Acid Binding Protein 2 (FABP2) Ancillary Proposal"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"US Department of Veterans Affairs"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03143764","briefTitle":"Cardiorespiratory Fitness Using Electrically Assisted Bicycles"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Bergen"},"collaborators":[{"name":"The GC Rieber Funds"},{"name":"Bergen Council"},{"name":"Helse Stavanger HF"},{"name":"Kristiansand Zoo and Amusement park"},{"name":"National Oilwell Varco Norway AS"},{"name":"General Practitioner-scholarship from the Norwegian Medical Association."},{"name":"Department of Global Public Health and Primary Care, University of Bergen"},{"name":"Department of Education and Sports Science, University of Stavanger"},{"name":"Department of Sports and Physical Activity, Bergen University College"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Commuting with electrically assisted bicycles"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03141073","briefTitle":"Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hua Medicine Limited"},"collaborators":[{"name":"Covance"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HMS5552"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00334399","briefTitle":"Double-Blind Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanwa Kagaku Kenkyusho Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Miglitol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01588639","briefTitle":"To Evaluate Clinical Outcome and Injection Compliance of Scilin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin (Scilin N, BAY81-9924)"},{"name":"Insulin (Scilin R _BAY81-9924"},{"name":"Insulin(Scilin M30_BAY81-9924)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00788827","briefTitle":"Autologous Adult Stem Cells to Patients With Type 1 Diabetes and a Successful Renal Transplant"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Imperial College London"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Autologous CD34+ stem cells"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01658501","briefTitle":"Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"PhaseBio Pharmaceuticals Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"50 mg PB1023"},{"name":"70 mg PB1023"},{"name":"100 mg PB1023"},{"name":"Placebo (0.9% Sodium Chloride)"},{"name":"Victoza®"},{"name":"Diet and Exercise"},{"name":"Metformin"},{"name":"Sulfonylurea"},{"name":"Metformin and Sulfonylurea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01272193","briefTitle":"Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/insulin aspart"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00383877","briefTitle":"Effect of Insulin Detemir on Blood Glucose Control in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin NPH"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01467401","briefTitle":"Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"},{"name":"biphasic human insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00709475","briefTitle":"Observational Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00740051","briefTitle":"A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Linagliptin"},{"name":"Linagliptin Placebo"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02008682","briefTitle":"The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02066766","briefTitle":"A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh, Indonesia, Malaysia, Philippines, Sri Lanka and Vietnam"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02567994","briefTitle":"Tenelia Triple Combination Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Handok Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Teneligliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02563834","briefTitle":"A Novel Positron Emission Tomography (PET) Approach to Measuring Myocardial Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Indiana University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"thiapalmitate tracer"},{"name":"Saline"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01225939","briefTitle":"A Study Conducted Over 3 Periods to Look at the Drug in the Body"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD8329"},{"name":"AZD8329"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01849289","briefTitle":"A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Degludec"},{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03061981","briefTitle":"A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dong-A ST Co., Ltd."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Metformin"},{"name":"DA-1241"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00704132","briefTitle":"Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Comparator: sitagliptin phosphate"},{"name":"Comparator: placebo (unspecified)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00272012","briefTitle":"OPAL - Insulin Glulisine, Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glulisine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01204294","briefTitle":"Comprehensive Add on Study in Japan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Linagliptin"},{"name":"Linagliptin"},{"name":"Metformin"},{"name":"Metformin"},{"name":"Linagliptin"},{"name":"Linagliptin"},{"name":"Linagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00318786","briefTitle":"Efficacy and Safety of Three Times a Day BIAsp-70 Compared to Two Times a Day BIAsp-30 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04691219","briefTitle":"Effects of Mulberry Leaves on Glycemic Control in Patients With Obesity and Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chulalongkorn University"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mulberry leaves powder"},{"name":"Diet control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02002611","briefTitle":"Drug-drug Interaction Study(Lobeglitazone, Warfarin)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lobeglitazone"},{"name":"Warfarin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02538848","briefTitle":"Study of HTD4010 in Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HighTide Biopharma Pty Ltd"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HTD4010"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01906099","briefTitle":"Effects of Legume Intake on Cardiovascular Risk Factors Among Adults at Risk for Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Isfahan University of Medical Sciences"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"nutritional intervention"},{"name":"life style modification"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02347020","briefTitle":"Impact of Sleep and Meal Timing on Food Intake Regulation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Columbia University"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type II","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Normal Sleep/ Normal Meal"},{"name":"Normal Sleep/ Late Meal"},{"name":"Late Sleep/ Normal Meal"},{"name":"Late Sleep/ Late Meal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01046110","briefTitle":"Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00154414","briefTitle":"Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00213070","briefTitle":"Double-Blind Trial of Miglitol in Type 2 Diabetic Patients With Insulin Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanwa Kagaku Kenkyusho Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Miglitol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05290506","briefTitle":"Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National University of Malaysia"}},"conditionsModule":{"conditions":["PreDiabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dipeptidyl-Peptidase IV Inhibitors"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01059799","briefTitle":"Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02247271","briefTitle":"The Role and Effectiveness of Diabetes Coaches in British Columbia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Victoria"},"collaborators":[{"name":"The Lawson Foundation"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes health coach support"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01789957","briefTitle":"Extension Study for 2993-112"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AC2993"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02324036","briefTitle":"The EMPATHy Toolkit: Helping Diabetes Patients Overcome Barriers to Medication Adherence"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, Irvine"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EMPATHy Toolkit"},{"name":"Coached Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00916357","briefTitle":"Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Halozyme Therapeutics"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Humalog"},{"name":"Humulin-R"},{"name":"Recombinant human hyaluronidase PH20 (rHuPH20)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02981966","briefTitle":"Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01285076","briefTitle":"Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-401)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Other: Retrospective chart review; one participant encounter visit."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00677937","briefTitle":"A Diabetes Prevention Study Targeting High Risk Individuals With Education and Ongoing Support"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospitals, Leicester"},"collaborators":[{"name":"National Institute for Health Research, United Kingdom"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Modified DESMOND education and ongoing support"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00982644","briefTitle":"Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00729898","briefTitle":"Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01226966","briefTitle":"Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01806194","briefTitle":"Empowering Rural African American Women and Communities to Improve Diabetes Outcomes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"East Carolina University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle Counseling"},{"name":"Educational Control Arm"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02100475","briefTitle":"A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/liraglutide"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02467920","briefTitle":"Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Huazhong University of Science and Technology"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"glargine + exenatide"},{"name":"aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01613105","briefTitle":"Diabetes Treatment With Glucobay in Combination With Sulfonylurea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acarbose (Precose/Glucobay, BAYG5421)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01612741","briefTitle":"Diabetes Treatment With Glucobay in Combination With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acarbose (Precose/Glucobay, BAYG5421)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02964104","briefTitle":"A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin icodec"},{"name":"placebo"},{"name":"insulin degludec"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00964184","briefTitle":"Phenotypic and Genetic Correlates of Diabetes (Non-Type 1) in Young Non-Obese Asian Indians in North India and A Study to Evaluate the Efficacy of Sitagliptin (DPP-4 Inhibitor) in a Sub-group of the Study Population"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diabetes Foundation, India"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Lifestyle modification"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01959529","briefTitle":"A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01045707","briefTitle":"Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/insulin aspart"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02447601","briefTitle":"Evaluate the Pharmacokinetics of Simvastatin When Coadministered With PEX168 in Healthy Adult Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jiangsu Hansoh Pharmaceutical Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PEX168"},{"name":"Simvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02951260","briefTitle":"The Effects of Metformin on Self-selected Exercise Intensity, Physical Fitness and Exercise-induced AMPK-activation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rigshospitalet, Denmark"},"collaborators":[{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02949037","briefTitle":"Enhancing mHealth Technology to Activate Chronic Care Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Clemson University"},"collaborators":[{"name":"Madigan Army Medical Center"},{"name":"U.S. Army Medical Research and Development Command"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mobile Health Care Environment (MHCE)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01215097","briefTitle":"Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Linagliptin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03061214","briefTitle":"Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide 0.5 mg"},{"name":"Semaglutide 1.0 mg"},{"name":"Sitagliptin placebo"},{"name":"Sitagliptin"},{"name":"Semaglutide placebo 0.5 mg"},{"name":"Semaglutide placebo 1.0 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05599893","briefTitle":"Role of Tele-physical Therapy in Patients With Type 2 Diabetes Mellitus Following COVID-19 Infection."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Prince Sattam Bin Abdulaziz University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","COVID-19"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tele physical therapy"},{"name":"Patient educationa and Conventional exercises"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01715090","briefTitle":"Web-based Insulin Titration - An Efficacy Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Web-based insulin titration"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01945918","briefTitle":"Comparing Strategies for Translating Self-management Support Into Primary Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Denver"},"collaborators":[{"name":"University of California, San Francisco"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Self-management support education"},{"name":"Connection to Health Interactive Behavior Change Technology"},{"name":"Connection to Health plus Coaching (CTH+C)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01779596","briefTitle":"ET-blockade and Exercise Induced Blood Flow in T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Radboud University Medical Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bosentan"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01664247","briefTitle":"The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"placebo"},{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01214239","briefTitle":"Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Linagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00393705","briefTitle":"Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Biphasic Aspart 30/70"},{"name":"insulin lispro LM"},{"name":"insulin lispro MM"},{"name":"insulin lispro LM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01605773","briefTitle":"Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"repaglinide"},{"name":"glyburide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02030600","briefTitle":"A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01511692","briefTitle":"Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"placebo"},{"name":"placebo"},{"name":"glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02373150","briefTitle":"Safety, Tolerability and PK of Imeglimin in Japanese Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Poxel SA"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Imeglimin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00370565","briefTitle":"Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"},"collaborators":[{"name":"Sanofi"},{"name":"Nektar Therapeutics"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Inhaled Human Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01617434","briefTitle":"The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01572740","briefTitle":"Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"placebo"},{"name":"insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00537277","briefTitle":"Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus When Failing on OADs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00696995","briefTitle":"An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05219994","briefTitle":"Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Missouri-Columbia"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hyperoxia Exposure"},{"name":"Normoxia Exposure"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01842620","briefTitle":"OXEMET™ 1000 mg Coated Tablets (Metformin Hydrochloride) Bioequivalence Study. OXEMET (TM) is a Trademark of the GlaxoSmithKline Group of Companies. GLAFORNIL(TM) is a Trademark of Merck."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02336945","briefTitle":"Glucose Variability Pilot Study for the Abbott Sensor Based Glucose Monitoring System-Professional"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Diabetes Care"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Abbott Sensor Based Glucose Monitoring System-Professional"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01990638","briefTitle":"Effects of Exercise Therapy on Ventricular and Endothelial Function in Patients After Coronary Artery Bypass Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Taiwan University Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exercise capacity test"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02168491","briefTitle":"Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Vienna"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide"},{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01508949","briefTitle":"Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00330733","briefTitle":"Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VA Office of Research and Development"},"collaborators":[{"name":"Joslin Diabetes Center"}]},"conditionsModule":{"conditions":["Atherosclerosis","Cardiovascular Disease","Inflammation","Insulin Resistance","Noninsulin-dependent Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Salsalate"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02805543","briefTitle":"The Correlation Between the Retrobulbar Hemodynamics and Intrarenal Hemodynamics in T2DM Patients During the Early Period"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fourth People's Hospital of Shenyang"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Color doppler imaging"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01497600","briefTitle":"Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin NPH"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02798744","briefTitle":"SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Leicester"},"collaborators":[{"name":"Loughborough University"},{"name":"University Hospitals, Leicester"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Diet"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02798198","briefTitle":"The Correlation Between the Pulmonary Function and Intrarenal Hemodynamics in 37 T2DM Patients in Early Period"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fourth People's Hospital of Shenyang"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"T2DM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01570140","briefTitle":"Large Scale Demonstrator, Webportal Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Henk Bilo, MD"},"collaborators":[{"name":"Isala"},{"name":"University Medical Center Groningen"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Web portal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02796950","briefTitle":"The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acipimox"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05977205","briefTitle":"COVID-19 Glycemic Control Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Leiden University Medical Center"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No interventions, observational study"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01907854","briefTitle":"Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"sitagliptin"},{"name":"placebo"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00634842","briefTitle":"Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04529239","briefTitle":"Type 2 Diabetes Glucose Biomarker Study With a Continuous Glucose Monitoring System"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Klick Inc."},"collaborators":[{"name":"Mittal Global Clinical Trial Services"}]},"conditionsModule":{"conditions":["Healthy","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Abbott Freestyle Libre Pro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01861756","briefTitle":"The Diabetes Medication Choice Cards Trial in Greece"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aristotle University Of Thessaloniki"},"collaborators":[{"name":"European Foundation for the Study of Diabetes"},{"name":"Mayo Clinic"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Medication Choice decision aid"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01569243","briefTitle":"Text to Move (TTM)Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Massachusetts General Hospital"},"collaborators":[{"name":"McKesson Foundation"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Text messages"},{"name":"Usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01293578","briefTitle":"Study to Test Use of a Decision Aid in a Clinical Visit to Help Patients Choose a Diabetes Medication"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Medication Choice Cards"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02163278","briefTitle":"A Multiple Ascending Dose Phase I Study of DBPR108 in Healthy Male Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Health Research Institutes, Taiwan"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DBPR108"},{"name":"matching placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02470039","briefTitle":"Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin 338 (GIPET I)"},{"name":"insulin glargine"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01819129","briefTitle":"Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Faster-acting insulin aspart"},{"name":"Insulin aspart"},{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01358994","briefTitle":"Metformin Treatment, Renal Function and Lactic Acidosis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Skane University Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00335465","briefTitle":"Lantus Effect on Myocardial Glucose Metabolism in T2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01156597","briefTitle":"Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Miami"},"collaborators":[{"name":"Takeda Pharmaceuticals North America, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00451113","briefTitle":"Sitagliptin in the Elderly"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of British Columbia"},"collaborators":[{"name":"Merck Frosst Canada Ltd."}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin 100 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02234973","briefTitle":"Transformation of Indigenous Primary Healthcare Delivery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lawson Health Research Institute"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"},{"name":"University of Western Ontario, Canada"},{"name":"First Nation Community Partners"},{"name":"Health Canada"},{"name":"First Nations and Inuit Health Branch"},{"name":"Assembly of First Nations"},{"name":"Canadian Diabetes Association"},{"name":"Ontario Stroke Network"},{"name":"Heart and Stroke Foundation of Canada"},{"name":"Toronto Health Economics and Technology Assessment Collaborative"},{"name":"Tri-Ethnic Research Center Colorado State University"},{"name":"Hindsight Healthcare Strategies"},{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Quality Improvement"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02230501","briefTitle":"Metabolic Activation With Protein-rich Formula Diet"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"West German Center of Diabetes and Health"},"collaborators":[{"name":"Almased Wellness GmbH"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"stringent diet regimen"},{"name":"moderate diet regimen"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02223065","briefTitle":"Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00562172","briefTitle":"Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine"},{"name":"Glimepiride"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00700830","briefTitle":"Observational Study to Evaluate the Safety and Efficacy of Levemir® in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04607915","briefTitle":"Technology-enabled Collaborative Care for Diabetes Management During COVID-19"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre for Addiction and Mental Health"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intervention for TECC Model"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01600937","briefTitle":"Italian Diabetes and Exercise Study 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Metabolic Fitness Association, Italy"},"collaborators":[{"name":"University of Roma La Sapienza"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Theoretical & practical exercise counseling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01527539","briefTitle":"Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00659932","briefTitle":"Dealing With Anxiety: A Cognitive Behavioural Program for Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hunter and New England Health"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Immediate Cognitive behavioural therapy (CBT)"},{"name":"Delayed CBT"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02144909","briefTitle":"Partners in Care With Semi-Structured Support Group"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Hawaii"},"collaborators":[{"name":"National Institute on Minority Health and Health Disparities (NIMHD)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Partners in Care with Semi-Structured Support Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00614120","briefTitle":"Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"placebo"},{"name":"liraglutide"},{"name":"liraglutide"},{"name":"glimepiride"},{"name":"metformin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01045590","briefTitle":"Glibenclamide (Dose to be Titrated From Starting Dose of 5mg om) Plus Rosiglitazone 4mg om (Increased to 8mg om After 6 Months) and vs Glibenclamide (Dose to be Titrated With Starting Dose of 5mg om) Plus Placebo, Administered to Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"titration"},{"name":"titration"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02582242","briefTitle":"Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01517555","briefTitle":"Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"placebo"},{"name":"paracetamol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01076647","briefTitle":"Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00280046","briefTitle":"Effect of Biphasic Insulin Aspart 30 on Blood Glucose Control in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01930188","briefTitle":"Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"sitagliptin"},{"name":"placebo"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00237549","briefTitle":"The ADDITION Study. Intensive Treatment in People With Screen Detected Diabetes in Primary Care."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"Steno Diabetes Centre, Gentofte, Denmark"},{"name":"University of Cambridge"},{"name":"University Hospitals, Leicester"},{"name":"Utrecht University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"optimised treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01512108","briefTitle":"Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"oral anti-diabetic drug"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00395343","briefTitle":"Sitagliptin Added-on to Insulin Study (0431-051)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin phosphate"},{"name":"Comparator : placebo (unspecified)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00139763","briefTitle":"US Inhaled Insulin Therapeutic Choice Questionnaire Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Educational Materials"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02773381","briefTitle":"A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00337610","briefTitle":"Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day"},{"name":"comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00976391","briefTitle":"A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"albiglutide + insulin glargine"},{"name":"insulin glargine + preprandial lispro insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02678676","briefTitle":"An Observational Study of Patient Cohorts Who Previously Received Long-term Treatment With Pioglitazone or Placebo in Addition to Existing Antidiabetic Medications"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No Intervention"},{"name":"No Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02167061","briefTitle":"A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01 Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg, and to Evaluate the Effect of Food on the Pharmacokinetics of DA-1229_01 in Healthy Male Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dong-A ST Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DA-1229_01"},{"name":"E+M"},{"name":"DA-1229_01 fast"},{"name":"DA-1229_01 fed"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00521690","briefTitle":"The Effect of Insulin Detemir on Blood Glucose Control in Taiwanese Patients With Type 2 Diabetes Failing on OAD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01392573","briefTitle":"A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/liraglutide"},{"name":"insulin degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04050553","briefTitle":"A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypoglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02613897","briefTitle":"ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Dapagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02099110","briefTitle":"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Matching Placebo to Ertugliflozin 5 mg"},{"name":"Matching Placebo to Ertugliflozin 10 mg"},{"name":"Matching Placebo to sitagliptin 100 mg"},{"name":"Ertugliflozin 5 mg"},{"name":"Ertugliflozin 10 mg"},{"name":"Sitagliptin 100 mg"},{"name":"Metformin >= 1500 mg/day"},{"name":"Insulin Glargine Rescue Medication"},{"name":"Glimepiride Rescue Medication"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00264901","briefTitle":"Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01324388","briefTitle":"A Study of the Effect of LY2189265 on Two Blood Pressure Drugs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2189265"},{"name":"Metoprolol"},{"name":"Lisinopril"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00006165","briefTitle":"Native Hawaiian Diabetes Intervention Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"'Ohana (Family) Support Lifestyle Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00572806","briefTitle":"Initiation of Insulin Aspart in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00238472","briefTitle":"A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"nateglinide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02587286","briefTitle":"Gather mHealth India RCT for Behavior and Health Outcomes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gather Health India"},"collaborators":[{"name":"DHL Innovation Center, India"},{"name":"Diabetes Action Centre"},{"name":"M.V. Hospital for Diabetes"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gather app"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00800683","briefTitle":"Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 1356"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00252694","briefTitle":"DIabetic Retinopathy Candesartan Trials"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Takeda"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"candesartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02068508","briefTitle":"Pioglitazone Tablets Special Drug Use Surveillance \"Combined Use of Insulin Products / Long-term Treatment\""},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02060201","briefTitle":"Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Dapagliflozin"},{"name":"Saxagliptin/Dapagliflozin FDC"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00384085","briefTitle":"Insulin Glargine \"All to Target\" Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glulisine"},{"name":"Insulin Glargine"},{"name":"Premixed Insulin"},{"name":"Insulin Glulisine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02055547","briefTitle":"A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK-8521 35μg"},{"name":"MK-8521 100μg"},{"name":"MK-8521 125μg"},{"name":"MK-8521 150μg"},{"name":"MK-8521 175μg"},{"name":"MK-8521 200μg"},{"name":"MK-8521 300μg"},{"name":"MK-8521 50/72μg"},{"name":"MK-8521 72/125μg"},{"name":"MK-8521 100/150μg"},{"name":"MK-8521 125/150μg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02305381","briefTitle":"Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01330563","briefTitle":"Drug-drug Interaction Study (CKD-501, Ketoconazole)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"},"collaborators":[{"name":"Severance Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-501, Ketoconazole"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00568984","briefTitle":"Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"repaglinide"},{"name":"metformin"},{"name":"glicazide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01749345","briefTitle":"Social Determinants of Health in Diabetes Outcomes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of South Carolina"},"collaborators":[{"name":"Ralph H. Johnson VA Medical Center"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01541215","briefTitle":"Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"placebo"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04416204","briefTitle":"Effect of High Carbohydrate vs. Low Carbohydrate Diet in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alabama at Birmingham"},"collaborators":[{"name":"Mayo Clinic"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"glycogen loading"},{"name":"No Glycogen Loading"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00229658","briefTitle":"An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pramlintide acetate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02169531","briefTitle":"Ex Vivo Immunotherapy for Hyperglycemia in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"B & Y Technologies"},"collaborators":[{"name":"Guangzhou No.12 People's Hospital"},{"name":"The 12th People's Hospital of Shenzhen City"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ex vivo Activated Immune Cells"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01720446","briefTitle":"Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"semaglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00367445","briefTitle":"A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Inhaled Human Insulin (Exubera)"},{"name":"Insulin Glargine (Lantus)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01087502","briefTitle":"Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glimepiride"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Linagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01043510","briefTitle":"The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01054118","briefTitle":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and Sitagliptin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"JNJ-38431055"},{"name":"Sitagliptin 100 mg"},{"name":"JNJ-38431055 + Sitagliptin 100 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02012166","briefTitle":"A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK-0893 10 mg"},{"name":"MK-0893 40 mg"},{"name":"MK-0893 200 mg"},{"name":"MK-0893 1000 mg"},{"name":"Placebo"},{"name":"Sandostatine®"},{"name":"Insulin"},{"name":"Glucagon"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01330121","briefTitle":"Bridging the Gap by Transitional Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cook County Health"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pharmacist Counseling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02003014","briefTitle":"Pioglitazone Tablets Special Drug Use Surveillance \"Combined Use of Biguanides / Long-term Treatment\""},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00184561","briefTitle":"Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01453842","briefTitle":"Diet Oil Induced Stimulation of GLP-1"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Copenhagen"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diet oil"},{"name":"Olive oil"},{"name":"Carrot"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03196154","briefTitle":"Association Between Insulin Resistance and Beta Cell Function With HbA1C in Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Clinical Research Centre, Malaysia"},"collaborators":[{"name":"Ministry of Health, Malaysia"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fasting insulin level"},{"name":"Plasma drug level"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00486291","briefTitle":"Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VIVUS LLC"},"collaborators":[{"name":"Synteract, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"VI-0521"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01987258","briefTitle":"The Acute Effect of Interval-walking"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rigshospitalet, Denmark"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Interval Walking"},{"name":"Continuous walking"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02255266","briefTitle":"Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00333151","briefTitle":"Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"rosiglitazone"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01972893","briefTitle":"A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Zydus Lifesciences Limited"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ZYD1"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01767688","briefTitle":"A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK-3102"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01620489","briefTitle":"Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01324505","briefTitle":"Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"placebo"},{"name":"Microgyn®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01736124","briefTitle":"Computerized Cognitive Training for Diabetic Elderly Veterans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VA Office of Research and Development"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"computerized cognitive training"},{"name":"control games"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00821795","briefTitle":"Veterans Inpatient Insulin Study and Transition to Outpatient Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dennis G. Karounos, M.D."},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NPH/Regular 70/30 mix"},{"name":"insulin aspart protamine/insulin aspart 70/30 mix"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01850615","briefTitle":"Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Faster-acting insulin aspart"},{"name":"basal insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02207374","briefTitle":"A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"DPP-4 inhibitor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00592527","briefTitle":"Safety and Efficacy of Insulin Detemir in Combination With OADs in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01941199","briefTitle":"Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 and Metformin After Oral Administration in Healthy Male Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dong-A Pharmaceutical Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DA-1229"},{"name":"metformin"},{"name":"DA-1229 + metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00979628","briefTitle":"Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Guillermo Umpierrez, MD"},"collaborators":[{"name":"Sanofi"},{"name":"Medical University of South Carolina"},{"name":"Texas A&M University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sliding scale regular insulin (SSRI)"},{"name":"Basal Bolus"},{"name":"Basal Plus"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02445508","briefTitle":"Effect of Bile Acid Secretion and Sequestration on GLP-1 Secretion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sevelamer"},{"name":"Cholecystokinin"},{"name":"Sevelamer placebo"},{"name":"Isotonic saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01885208","briefTitle":"Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01308008","briefTitle":"Home Exercise to Enhance Mobility for Older Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VA Office of Research and Development"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"home exercise/physical activity (PA) enhancement program with behavioral support"},{"name":"flex and toning health education program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01130558","briefTitle":"Efficacy of Structured Insulin Order"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Massachusetts General Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Management"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02420392","briefTitle":"Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Hospital"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01536652","briefTitle":"Prandial Orientated Biphasic Insulin Aspart 30 Therapy - the Physiological Premix Insulin Therapy for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01511185","briefTitle":"Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02670928","briefTitle":"Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01713530","briefTitle":"A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/insulin aspart"},{"name":"insulin degludec"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00395746","briefTitle":"Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sulfonylurea"},{"name":"liraglutide"},{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00569907","briefTitle":"Observational Study of Interstitial Glucose Monitoring With Continuous Glucose Monitoring to Track Patients Treated With Exenatide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HealthPartners Institute"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02097277","briefTitle":"A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristol-Myers Squibb"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BMS-986036"},{"name":"Placebo (Matching with BMS-986036)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00910923","briefTitle":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-38431055 in Healthy Male Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"JNJ-38431055"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00979368","briefTitle":"Safety Study of BMS-816336 in Healthy Male Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristol-Myers Squibb"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent","Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BMS-816336"},{"name":"BMS-816336"},{"name":"BMS-816336"},{"name":"BMS-816336"},{"name":"BMS-816336"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00780715","briefTitle":"Response To Oral Agents in Diabetes (ROAD)- Pilot Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Dundee"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gliclazide MR"},{"name":"Sitagliptin"},{"name":"Pioglitazone"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01580098","briefTitle":"Medium-term Health Coaching and Life-long Monitoring in Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Landeskrankenanstalten-Betriebsgesellschaft"},"collaborators":[{"name":"European Commission"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Self-monitoring for patients with Diabetes mellitus type 2"},{"name":"Nurse-monitoring for patients with Diabetes mellitus type 2"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00403091","briefTitle":"Internet Intervention to Improve Rural Diabetes Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alabama at Birmingham"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Internet Intervention"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01388361","briefTitle":"Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"insulin aspart"},{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00533494","briefTitle":"The Effect of Patients' Participation in Improving Diabetes Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Soroka University Medical Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"physician feedback (A)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04721158","briefTitle":"CGM Use in Children With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johns Hopkins University"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Hyperglycemia Due to Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous glucose monitor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00354939","briefTitle":"Insulin Analogue With Continuous Glucose Monitoring System (CGMS) Measurement"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00700817","briefTitle":"The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"sitagliptin"},{"name":"metformin"},{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01843881","briefTitle":"The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Adrian Vella"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"National Center for Research Resources (NCRR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exendin 9, 39"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01843855","briefTitle":"The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Adrian Vella"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"National Center for Research Resources (NCRR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exendin 9,39"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00288132","briefTitle":"The Diabetes TeleCare Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},"collaborators":[{"name":"University of North Carolina, Chapel Hill"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intervention"},{"name":"Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00850824","briefTitle":"Community Health Workers in Diabetes Care in American Samoa"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},"collaborators":[{"name":"Brown University"},{"name":"The Miriam Hospital"},{"name":"Tafuna Family Health Center"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Community Health Worker home visits"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02342834","briefTitle":"Effects of a Small Protein and Lipid Preload on Glucose Tolerance in Subjects With Impaired Glucose Homeostasis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Azienda Ospedaliero, Universitaria Pisana"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Small mixed protein and lipid meal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01650324","briefTitle":"A Single-dose Phase 1 Study of DBPR108 in Healthy Male Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Health Research Institutes, Taiwan"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DBPR108"},{"name":"matching placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01832935","briefTitle":"Cost Effectiveness of Glargine Insulin Versus NPH Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tehran University of Medical Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glargine"},{"name":"Insulin NPH"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00658099","briefTitle":"Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard®"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin NPH"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01820871","briefTitle":"Self-Management Using Smartphone Application for Type2 DM in Real siTuation (SMART-DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Inje University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Self-Management Using Smartphone Application for Type2 DM"},{"name":"self-management using booklet for management type 2 DM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01141192","briefTitle":"The Effect of Vitamin D Supplementation on Glucose Metabolism in Non-Diabetic African American Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Augusta University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vitamin D3, cholecalciferol"},{"name":"Inactive comparator"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00924430","briefTitle":"Interaction Study SLV337/Simvastatin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Solvay Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Simvastatin- SLV337 SD beta- SLV337 SD alpha - SLV337 MD beta- SLV337 SD beta+ Simvastatin"},{"name":"Simvastatin - SLV337 SD alpha - SLV337 SD beta - SLV337 MD beta - SLV337 SD beta+ Simvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02046395","briefTitle":"Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tulane University School of Medicine"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"amlodipine, hydralazine, terazosin or hydrochlorothiazide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02128932","briefTitle":"Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00300911","briefTitle":"Effects of Rosiglitazone on Plasma BNP Levels and Left Ventricular Dysfunction"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baskent University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone(drug), cardiac adverse effects"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02257190","briefTitle":"The Features Behind the Beneficial Effects of Interval-walking"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rigshospitalet, Denmark"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Control"},{"name":"IW3"},{"name":"IW1"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00627445","briefTitle":"Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"},{"name":"metformin"},{"name":"biphasic insulin aspart 50"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01493934","briefTitle":"Development of a Fast Measurement Technique of Insulin Resistance in Human"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institut National de la Santé Et de la Recherche Médicale, France"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"injection of 6-DIG"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01193296","briefTitle":"Glycemic Holter Study (Continuous Glucose Monitoring) -"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02227212","briefTitle":"Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine U300 (new formulation of insulin glargine) HOE901"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00715780","briefTitle":"Observational Study to Evaluate Safety and Efficacy of Insulin Therapy in Type 2 Diabetes Mellitus Subjects Failing on Oral Anti-diabetic Agents"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"soluble human insulin"},{"name":"biphasic human insulin"},{"name":"insulin NPH"},{"name":"insulin aspart"},{"name":"biphasic insulin aspart"},{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02769728","briefTitle":"EndoBarrier in Obese Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Graz"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EndoBarrier"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01700868","briefTitle":"Practice Based Nutrition Intervention-2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Physicians Committee for Responsible Medicine"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vegan diet"},{"name":"American Diabetes Association guidelines"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00174642","briefTitle":"Opposing Step-by-step Insulin Reinforcement to Intensified Strategy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine"},{"name":"Insulin Glulisine"},{"name":"Metformin"},{"name":"insulin secretagogue"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01180712","briefTitle":"Study of Oral Anthocyanins on Insulin Resistance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aberdeen"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mirtoselect"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01835730","briefTitle":"Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"PhaseBio Pharmaceuticals Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PE0139 Injection"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02197078","briefTitle":"Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01698931","briefTitle":"Efficacy of Repaglinide in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"repaglinide"},{"name":"glyburide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02486237","briefTitle":"Complications in Central American Diabetic Patients: Historic Cohort"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Clínica Los Yoses"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"None, observational study"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01830569","briefTitle":"Impact of an Evidence-based Electronic Decision Support System on Diabetes Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"KU Leuven"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"The EBMeDS system"},{"name":"Evidence Linker"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00660374","briefTitle":"Safety and Efficacy of Insulin NPH Compared to a New Insulin Formulation in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin NPH"},{"name":"EX1000"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01662999","briefTitle":"Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00614055","briefTitle":"Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/insulin aspart"},{"name":"insulin degludec/insulin aspart"},{"name":"insulin glargine"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00380822","briefTitle":"Double-Blind Study of Miglitol in Japanese With type2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanwa Kagaku Kenkyusho Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"miglitol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00659477","briefTitle":"Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With Oral Antidiabetic Drugs (OADs) in Patients With Diabetes Mellitus, Type 2 (DMT2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01676116","briefTitle":"The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/liraglutide"},{"name":"liraglutide"},{"name":"exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00812539","briefTitle":"Diabetes Connect: Patients and Providers Use of a Secure Website for Blood Glucose Monitoring in Type-2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Massachusetts General Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Subject/Provider Portal \"Diabetes Connected Health\" tool - Deluxe"},{"name":"Subject only Portal \"Diabetes Connected Health Tool\" Basic"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00964262","briefTitle":"A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Peptron, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SR Exenatide (PT302)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00652509","briefTitle":"Journey for Control of Diabetes Study (0431-111)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Interactive Dialogue to Educate and Activate (IDEA)"},{"name":"Individual Education (IE)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00347542","briefTitle":"A Trial to Study the Effect of Vitamin D Supplementation on Glucose and Insulin Metabolism in Centrally Obese Men"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sitaram Bhartia Institute of Science and Research"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin D"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02138097","briefTitle":"Oral and Non-insulin Injected Hypoglycemic Therapy Utilization Patterns"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00848757","briefTitle":"Changing Lifestyles for Better Health"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yale University"},"collaborators":[{"name":"Donaghue Medical Research Foundation"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intensive Lifestyle Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02456428","briefTitle":"Incretin-based Drugs and the Risk of Heart Failure"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Canadian Network for Observational Drug Effect Studies, CNODES"},"collaborators":[{"name":"Drug Safety and Effectiveness Network, Canada"},{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DPP-4 inhibitors"},{"name":"GLP-1 analogs"},{"name":"Insulins"},{"name":"Biguanides"},{"name":"Sulfonylureas"},{"name":"Thiazolidinediones"},{"name":"Alpha-glucosidase inhibitors"},{"name":"Meglitinides"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00836225","briefTitle":"Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ionis Pharmaceuticals, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ISIS 388626"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00949663","briefTitle":"Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Washington University School of Medicine"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Glucose-dependent Insulinotropic Polypeptide (GIP)"},{"name":"Xenin-25"},{"name":"Glucose-dependent Insulinotropic Polypeptide plus Xenin-25"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01045447","briefTitle":"Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/insulin aspart"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00162305","briefTitle":"A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BMS-512148"},{"name":"BMS-512148"},{"name":"BMS-512148"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02383238","briefTitle":"Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Erlangen-Nürnberg Medical School"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00318422","briefTitle":"Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"rosiglitazone"},{"name":"glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02064335","briefTitle":"Effects of Physical Activity Coaching on Health and Behaviour Parameters in Diabetic Persons"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universitaire Ziekenhuizen KU Leuven"},"collaborators":[{"name":"Dutch Health Care Insurance Board"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physical activity coaching"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01684813","briefTitle":"VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla"},"collaborators":[{"name":"Andaluz Health Service"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type II","Acute Coronary Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Prasugrel."},{"name":"Clopidogrel"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01278160","briefTitle":"Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"},{"name":"biphasic insulin aspart 30"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01620424","briefTitle":"Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"},{"name":"biphasic insulin aspart 50"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00909480","briefTitle":"Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00131664","briefTitle":"Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Canadian Heart Research Centre"},"collaborators":[{"name":"GlaxoSmithKline"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Avandamet"},{"name":"Avandia and Amaryl"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00929201","briefTitle":"Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin phosphate/metformin hydrochloride FDC"},{"name":"Sitagliptin phosphate"},{"name":"Metformin hydrochloride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02730377","briefTitle":"Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"alpha-glucosidase inhibitors"},{"name":"DPP-4 inhibitors"},{"name":"meglitinides"},{"name":"SGLT-2 inhibitors"},{"name":"sulphonylurea"},{"name":"thiazolidinediones"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02041598","briefTitle":"DREAM Project Community Health Worker Intervention"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NYU Langone Health"},"collaborators":[{"name":"National Institute on Minority Health and Health Disparities (NIMHD)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CHW Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00654381","briefTitle":"Japanese P III vs Voglibose and Placebo"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 1356"},{"name":"BI 1356"},{"name":"voglibose placebo"},{"name":"BI 1356 placebo"},{"name":"voglibose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00551564","briefTitle":"Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rosiglitazone maleate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05237076","briefTitle":"Carotid Body Function in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Leiden University Medical Center"},"collaborators":[{"name":"Demcon"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypoxia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hyperinsulemic-Euglycemic Clamp & Hypoxic Ventilatory Response (HVR)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00195884","briefTitle":"Diabetes Aerobic and Resistance Exercise (DARE) Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ottawa Hospital Research Institute"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"},{"name":"University of Ottawa"},{"name":"Canadian Diabetes Association"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aerobic and Resistance Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01966978","briefTitle":"The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Texas Southwestern Medical Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Detemir"},{"name":"Liraglutide"},{"name":"Insulin Aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02008942","briefTitle":"Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"PLx Pharma"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PL2200 Aspirin Capsules"},{"name":"Enteric-coated aspirin caplets"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00550329","briefTitle":"Bioequivalence Study Of Glucotrol XL 2.5 Mg Tablets"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent","Hyperglycemia"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glipizide GITS"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01469468","briefTitle":"A Study To Estimate The Effect Of Repeated Dosing of PF-05175157 On The Pharmacokinetics Of A Single Dose Of Simvastatin In Healthy Adult Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Simvastatin"},{"name":"PF-05175157"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01681693","briefTitle":"Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Francisco"}},"conditionsModule":{"conditions":["Healthy","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01123239","briefTitle":"Understanding and Improving Diabetes Care for Ethnic Minorities"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, Irvine"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Coached Care"},{"name":"Standard Diabetes Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01444248","briefTitle":"Compare the Compliance of Patients Treated With Once-daily (od) or Twice-daily (Bid) Glimepiride and Metformin Fixed Combination Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Handok Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glimepiride/ Metformin"},{"name":"Glimepiride/ Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04831697","briefTitle":"Intervention to Improve Diabetes Outcomes in Older African American Women With Multi-Caregiving Burden"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical College of Wisconsin"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Multi-Caregiving Intervention"},{"name":"Diabetes Enhanced Usual Care Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01509742","briefTitle":"Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01513590","briefTitle":"A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01880736","briefTitle":"A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"insulin degludec"},{"name":"insulin degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04347291","briefTitle":"Mobile Phone Support for Adults and Support Persons to Live Well With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University Medical Center"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FAMS 2.0"},{"name":"Print Materials"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00006163","briefTitle":"Computer-assisted Diabetes Self-management Interventions"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Personalized Self-management"},{"name":"Community Resources"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02759484","briefTitle":"Multi-clinic Action Trial to Control Hyperglycemia and Hypertension"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rush University Medical Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Home Based Enhanced Education"},{"name":"Clinic Based Enhanced Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01332071","briefTitle":"Avandamet Bioequivalence Study Brazil - Fed Administration"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone Maleate + Metformin 2 miligrams (mg) + 500 mg"},{"name":"Rosiglitazone Maleate + Metformin 4 miligrams (mg) + 1000 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01033773","briefTitle":"Stop Emergency Room Visits for Hyperglycemia Project - District of Columbia (DC)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medstar Health Research Institute"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Antihyperglycemic medication guideline for management of uncontrolled hyperglycemia presenting to the ED using metformin, sulfonylurea and/or insulin"},{"name":"Diabetes survival skills self-management education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00684086","briefTitle":"English Diabetes Self-Management Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Stanford University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Self Management Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00519727","briefTitle":"Safety Study of ISIS 325568 in Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ionis Pharmaceuticals, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ISIS 325568"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00400283","briefTitle":"A Study Looking Into the Effect of NNC 55-0414 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NNC 55-0414"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01618162","briefTitle":"The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01906086","briefTitle":"Effects of Legume Consumption on Adiponectin and Inflammatory Markers Among Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Isfahan University of Medical Sciences"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"nutritional intervention"},{"name":"life style intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00611884","briefTitle":"Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glargine"},{"name":"insulin degludec"},{"name":"insulin degludec"},{"name":"insulin degludec"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00613951","briefTitle":"Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/insulin aspart"},{"name":"insulin degludec/insulin aspart"},{"name":"biphasic insulin aspart"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01386541","briefTitle":"Multiple Ascending Dose Trial of BYK324677 in Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nycomed"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BYK324677"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04151849","briefTitle":"Effects of Diabetes Medications on Adrenal Function and Intestinal Microbiota"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Tartu"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLP-1 receptor agonist"},{"name":"SGLT2 inhibitor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00402012","briefTitle":"\"TAKE TIME\" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pennington Biomedical Research Center"},"collaborators":[{"name":"Takeda Pharmaceuticals North America, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00687063","briefTitle":"Observational Study of Safety and Efficacy of Levemir® in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00213122","briefTitle":"Effects of Miglitol on Daily Plasma Glucose in type2 Diabetes Treated With Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanwa Kagaku Kenkyusho Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"miglitol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01365091","briefTitle":"Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin/metformin fixed-dose combination (FDC)"},{"name":"Saxagliptin"},{"name":"Metformin extended-release (XR)"},{"name":"Saxagliptin/Metformin FDC"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03885869","briefTitle":"Joint Position Sense, Plantar Sensation, Balance and Dual Task Performance in Individuals With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ankara Yildirim Beyazıt University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Balance"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ankle Joint Position Sensation Evaluation"},{"name":"Knee Joint Position Sensation Evaluation"},{"name":"The Evaluation of Plantar Sensation"},{"name":"The Evaluation of Balance"},{"name":"Evaluation of Dual Task Performance"},{"name":"General Evaluation Form"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00747383","briefTitle":"How Improvement in Control of Diabetes Influences the Production of a Hormone Produced in the Gut Which Improves the Release and Action of Insulin."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Royal Bournemouth Hospital"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glimepiride"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00612599","briefTitle":"Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 50 to Biphasic Insulin Aspart 70 in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01341392","briefTitle":"Drug-drug Interaction Study(CKD-501, Amlodipine)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"},"collaborators":[{"name":"Severance Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-501"},{"name":"amlodiopine"},{"name":"CKD-501 amlodipine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01006291","briefTitle":"Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"insulin degludec"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02192853","briefTitle":"Correlation Between Plasma- and Endothelial DPP-4 Activity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01240252","briefTitle":"Insulin Receptor Substrate 1 (IRS-1) Regulation in Insulin Resistance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Human insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01336023","briefTitle":"Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/liraglutide"},{"name":"insulin degludec"},{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01947595","briefTitle":"Individualized Lifestyle Intervention in Subjects With Prediabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital Tuebingen"},"collaborators":[{"name":"German Diabetes-Center, Leibniz-Institut in Düsseldorf"},{"name":"Endocrinology and Metabolic Diseases, Charité Berlin"},{"name":"German Institute of Human Nutrition"},{"name":"University Hospital Carl Gustav Carus"},{"name":"LMU München, medical clinic IV"},{"name":"University Hospital Heidelberg"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"intensified lifestyle intervention"},{"name":"normal lifestyle intervention"},{"name":"Single lifestyle advice"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02471963","briefTitle":"Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Erlangen-Nürnberg Medical School"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00948584","briefTitle":"Insulin Dose Titration System Using a Short Messaging Service (SMS) Automatically Produced by a Knowledge Matrix"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hallym University Medical Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin dose titration system using a SMS"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01292993","briefTitle":"A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lexicon Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"400 mg LX4211"},{"name":"1000 mg metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00309608","briefTitle":"Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Linagliptin"},{"name":"Linagliptin"},{"name":"Linagliptin"},{"name":"Placebo"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01022762","briefTitle":"Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"repaglinide"},{"name":"gliclazide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00572650","briefTitle":"Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01767389","briefTitle":"Glucagon-like Peptide (GLP) Utilization and Safety"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"The GLP-1 receptor agonist users"},{"name":"DPP-4 inhibitor users"},{"name":"Other ADA users"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01754142","briefTitle":"Korean Post-marketing Surveillance for Kombiglyze XR®"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01697631","briefTitle":"Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00622323","briefTitle":"Post Marketing Surveillance Study of Byetta ™ (Exenatide) Use Among Filipino Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01663207","briefTitle":"Characterization of the Variability Of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Prediabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Foundation for the National Institutes of Health"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"Juvenile Diabetes Research Foundation"},{"name":"Amylin Pharmaceuticals, LLC."},{"name":"Merck Sharp & Dohme LLC"},{"name":"Pfizer"},{"name":"Eli Lilly and Company"},{"name":"Takeda"},{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."},{"name":"Novartis"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04523155","briefTitle":"Effect of Medically-tailored Meal Delivery Service on Changes in Hemoglobin A1c (HbA1c) in Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Medically tailored meals"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00499824","briefTitle":"GIANT: General Practitioner Implementation in Asia of Normoglycaemic Targets"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"International Diabetes Institute, Australia"},"collaborators":[{"name":"GlaxoSmithKline"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Education of general practitioners on the IDF-WPR guidelines"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00179374","briefTitle":"Improving Diabetes Outcomes With Activity, Nutrition and Medication"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Albert Einstein College of Medicine"},"collaborators":[{"name":"National Institutes of Health (NIH)"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tailored telephone intervention of education"},{"name":"Print educational intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00641043","briefTitle":"Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo + pioglitazone (30 mg)"},{"name":"Linagliptin + pioglitazone (30 mg)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01511198","briefTitle":"Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00591227","briefTitle":"Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rush University Medical Center"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin aspart"},{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01467375","briefTitle":"Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04253431","briefTitle":"The Characteristics of Different Personal Lancets on Blood Volume and Perceived Pain in Patients With Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HTL-Strefa S.A."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Droplet lancing device (HTL-Strefa S.A.)"},{"name":"Microlet 2 lancing device (Bayer)"},{"name":"OneTouch Delicia lancing device (LifeScan)"},{"name":"ReliOn lancing device (ReliOn)"},{"name":"Accu-Chek Softclix lancing device (Roche)"},{"name":"BGStar lancing device (Sanofi Aventis)"},{"name":"Ultra-Fine 33G lancets (BD)"},{"name":"Droplet 33G lancets (HTL-Strefa S.A.)"},{"name":"OneTouch Delicia Extra Fine 33G lancets (LifeScan)"},{"name":"HaemoFine 33G lancets (HTL-Strefa S.A.)"},{"name":"Softclix 28 G lancets (Roche)"},{"name":"ReliOn Ultra-Thin Plus 33G lancets (ReliOn)"},{"name":"GlucoJect Dual S lancing device (Menarini)"},{"name":"Microlet 28G lancets (Bayer)"},{"name":"BGStar Ultra-Thin 33G lancets (Sanofi Aventis)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00869362","briefTitle":"Effect of Inpatient Diabetes Management on Outpatient Glycemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Massachusetts General Hospital"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes management team"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01686932","briefTitle":"Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01989754","briefTitle":"A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"},"collaborators":[{"name":"The George Institute for Global Health, Australia"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Albuminuria"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Canagliflozin, 100 mg"},{"name":"Canagliflozin, 300 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00518882","briefTitle":"Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00543621","briefTitle":"An Intervention Program to Control Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Nutrition"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"daily enteral nutritional product and/or behavioral changes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05787067","briefTitle":"The Effect of Mobile Online Training Applied to Patients With Diabetes on Insulin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ataturk University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Health Belief Model-Based Mobile Online Training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05643768","briefTitle":"Inspiratory Muscle Strength Training in Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Arizona"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Inspiratory muscle strength training (IMST)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00151021","briefTitle":"Stepping Up to Health: Feedback to Promote Physical Activity in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"},"collaborators":[{"name":"Michigan Diabetes and Training Center"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tailored web-based walking program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01051245","briefTitle":"Effectiveness of a High-risk Diabetic Patients Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital Italiano de Buenos Aires"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Case manager counseling"},{"name":"Usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01607385","briefTitle":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK2330672"},{"name":"Placebo"},{"name":"GSK1614235"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01507311","briefTitle":"Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05505773","briefTitle":"Systemic Metabolic Rate of Diabetic Patients Before and After Bariatric Gastric Bypass Using the Breezing® Device."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kaiser Clinic and Hospital"}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01594060","briefTitle":"Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical Wards"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HaEmek Medical Center, Israel"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin, regular - act rapid"},{"name":"Insulin glulisine, Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01088594","briefTitle":"A Methodological Study To Evaluate The Effects of Single Oral Doses Of Pioglitazone 45 mg And Rosiglitazone 8 mg On Sodium Balance In Healthy Male Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Solvay Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pioglitazone/rosiglitazone/placebo"},{"name":"rosiglitazone/pioglitazone/placebo"},{"name":"placebo/pioglitazone/rosiglitazone"},{"name":"pioglitazone/placebo/rosiglitazone"},{"name":"rosiglitazone/placebo/pioglitazone"},{"name":"placebo/rosiglitazone/pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04562714","briefTitle":"Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LMC Diabetes & Endocrinology Ltd."},"collaborators":[{"name":"Abbott Diabetes Care"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Glucose"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FreeStyle Libre Flash Glucose Monitor"},{"name":"Diabetes self-management education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00807092","briefTitle":"Comparing the Efficacy and Safety of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 on Blood Sugar Control in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"},{"name":"biphasic human insulin 30"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01588106","briefTitle":"Evaluation of CONTOUR® USB BGMS on Glycaemic Control in Insulin-treated Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GWT-TUD GmbH"},"collaborators":[{"name":"Bayer"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01580904","briefTitle":"Impact of Pharmaceutical Care in Diabetics Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidade Estadual da Paraiba"},"collaborators":[{"name":"Universidade Federal do Rio Grande do Norte"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intervention: Pharmaceutical Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01146886","briefTitle":"Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI135585 XX Administered as Tablet and as Solution in Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo to BI 135585"},{"name":"BI 135585"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01575483","briefTitle":"Korean Post-marketing Surveillance for Onglyza®"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No Intervention (subjects were previously treated with Onglyza®)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01068743","briefTitle":"Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"saxagliptin"},{"name":"metformin"},{"name":"saxagliptin + metformin (FDC tablet)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01068730","briefTitle":"Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"metformin (Diabex)"},{"name":"metformin (Glucophage™)"},{"name":"metformin (Glucophage™)"},{"name":"metformin (Diabex)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01068717","briefTitle":"Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)"},{"name":"Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state)"},{"name":"Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)"},{"name":"Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01062048","briefTitle":"Januvia Re-examination Study (MK-0431-181)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Sulfonylurea"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01013571","briefTitle":"Self Titration With Apidra to Reach Target Study (START)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glargine"},{"name":"Apidra (insulin glulisine)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00698802","briefTitle":"Safety and Efficacy of Biphasic Human Insulin Compared to EX1000 in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EX1000"},{"name":"biphasic human insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01561976","briefTitle":"Evaluation of Food Effect on the Pharmacokinetics of Sustained Release Metformin in Healthy Indian Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin hydrochloride prolonged release"},{"name":"metformin hydrochloride prolonged release"},{"name":"Metformin hydrochloride sustained release/Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01554631","briefTitle":"A 3-fold Crossover Bioequivalence Study Between Glucobay ODT (Orally Disintegrating Tablet) 100 mg and Glucobay Standard Tablet 100 mg"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acarbose (Glucobay ODT, BAYG5421)"},{"name":"Acarbose (Glucobay, BAYG5421)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01553968","briefTitle":"Effects of Acute Exercise on Acetylcarnitine Concentration in Endurance Trained and Untrained Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cycling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01545570","briefTitle":"A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK2376497"},{"name":"0.9% sodium chloride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01537497","briefTitle":"A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-05175157"},{"name":"PF-05175157"},{"name":"PF-05175157"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00787670","briefTitle":"Impact of GBS on CVD in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Duke University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Support and Education"},{"name":"gastric bypass surgery"},{"name":"Tissue Control Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02906917","briefTitle":"A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin degludec/insulin aspart"},{"name":"Insulin glargine"},{"name":"Insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01524770","briefTitle":"A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dulaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01522807","briefTitle":"A Study Of Three PF-05190457 Formulations In Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-05190457"},{"name":"PF-05190457"},{"name":"PF-05190457"},{"name":"PF-05190457"},{"name":"PF-05190457"},{"name":"PF-05190457"},{"name":"PF-05190457"},{"name":"PF-05190457"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01650129","briefTitle":"Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 50"},{"name":"biphasic human insulin 50"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00592969","briefTitle":"Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"metformin"},{"name":"biphasic insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04597229","briefTitle":"Efficacy of Multigrain Supplementation in Type II Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universiti Sains Malaysia"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Instant multigrain supplement"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00704223","briefTitle":"Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00989079","briefTitle":"A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ertugliflozin"},{"name":"Placebo to Ertugliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00254800","briefTitle":"The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ethinyl estradiol and levonorgestrel; exenatide"},{"name":"ethinyl estradiol and levonorgestrel; exenatide"},{"name":"ethinyl estradiol and levonorgestrel; exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02105103","briefTitle":"European, Open-label, Prospective, Multinational, Multicenter Study in Adult Subjects With Type 1 or Type 2 Diabetes Previously on MDI or CSII Therapy. Subjects Home Setting is Considered Routine Practice."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Type 2 Diabetes, Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Accu-Chek® Insight Insulin Pump"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02180334","briefTitle":"The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Hospital"},"collaborators":[{"name":"Daewoong Pharmaceutical Co. LTD."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mosapride citrate"},{"name":"Linagliptin"},{"name":"Acetaminophen (paracetamol)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02710448","briefTitle":"May Metformin be Used in Renal Failure?"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire, Amiens"},"collaborators":[{"name":"Merck Serono International SA"}]},"conditionsModule":{"conditions":["Renal Disorder Associated With Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02205528","briefTitle":"A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Metformin"},{"name":"Placebo"},{"name":"NNC0090-2746"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01477567","briefTitle":"A First-in-Human Study of LY3009385 in Healthy Participants"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3009385"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00600626","briefTitle":"Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"},{"name":"insulin NPH"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01460368","briefTitle":"A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2409021"},{"name":"Placebo"},{"name":"Moxifloxacin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01458210","briefTitle":"A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ortho-Cyclen"},{"name":"Dulaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00951912","briefTitle":"The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sun Yat-sen University"},"collaborators":[{"name":"Chinese Nutrition Society"},{"name":"Danone Institute International"},{"name":"Department of Health of Guangdong Province"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Daidzein"},{"name":"Genistein"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01706211","briefTitle":"A Study to Evaluate the Efficacy and Safety of BRL 49653C in Non-insulin Dependent Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Taiwan University Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus Non Insulin Dependent Oral Agent Therapy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BRL 49653C"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00935467","briefTitle":"Pharmacokinetics and Pharmacodynamics Study of Saxagliptin in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01436201","briefTitle":"A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Digoxin"},{"name":"Dulaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00930865","briefTitle":"Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bumetanide"},{"name":"Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01433380","briefTitle":"A Study To Evaluate PF-05175157 In Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-05175157"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01432938","briefTitle":"A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"dulaglutide"},{"name":"Warfarin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00924573","briefTitle":"Comparative Study of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"placebo"},{"name":"Glimepiride (HOE490)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00669864","briefTitle":"Effect of Biphasic Insulin Aspart 30 Combined With Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01612520","briefTitle":"Telecoaching of People With Type 2 Diabetes in Primary Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"KU Leuven"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Telenursing"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"telecoaching"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01416324","briefTitle":"First Time in Human Study Using GSK2330672"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo"},{"name":"0.1 mg GSK2330672"},{"name":"0.3 mg GSK2330672"},{"name":"1 mg GSK2330672"},{"name":"3 mg GSK2330672"},{"name":"10 mg GSK2330672"},{"name":"30 mg GSK2330672"},{"name":"60 mg GSK2330672"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00185601","briefTitle":"Internet Diabetes Self-Management Workshop"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Stanford University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Internet Diabetes Self-Management Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00908271","briefTitle":"Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00904176","briefTitle":"Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Warfarin"},{"name":"Digoxin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01406262","briefTitle":"Albiglutide Thorough ECG Study in Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Albiglutide"},{"name":"Moxifloxacin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00899470","briefTitle":"Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Co-administration of Saxagliptin and Metformin IR, Fasted"},{"name":"Saxagliptin/Metformin, Fasting"},{"name":"Co-administration of Saxagliptin and Metformin IR, Fed"},{"name":"Saxagliptin/Metformin, Fed"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00897390","briefTitle":"Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Metformin IR (glucophage)"},{"name":"Saxagliptin + Metformin IR (FDC)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00888238","briefTitle":"A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin"},{"name":"Comparator: Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00824668","briefTitle":"Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"},{"name":"insulin glargine"},{"name":"insulin glulisine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01388153","briefTitle":"A 3-fold Crossover Bioequivalence Study Between Glucobay Orally Disintegrating Tablet (ODT) and Glucobay Standard Tablet"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acarbose (Glucobay ODT, BAYG5421)"},{"name":"Acarbose (Glucobay ODT, BAYG5421)"},{"name":"Acarbose (Glucobay, BAYG5421)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00220207","briefTitle":"Determining the Effect on Patients of Internet-Based Diabetes Disease Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Robert Wood Johnson Foundation"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Internet co-management module"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00817271","briefTitle":"To Evaluate the Response to Glucagon During Hypoglycemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD1656"},{"name":"Glucagon"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01383356","briefTitle":"Comparison of the Bioavailability of Metformin Between Medium Dose Linagliptin/Metformin Tablets and Medium Dose Glucophage Tablet Given With Linagliptin Tablet"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin Single Tablet"},{"name":"Linagliptin/Metformin Combo"},{"name":"Linagliptin Single Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00486187","briefTitle":"Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - The ROSITEL Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dr. Milan Gupta"},"collaborators":[{"name":"GlaxoSmithKline"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rosiglitazone"},{"name":"metformin or sulfonylurea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01366287","briefTitle":"A Study Of PF-03882845 Absorption In Healthy Volunteers Given Orally As Tablet Versus Suspension Formulations And Effect Of Food On Its Absorption"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-03882845"},{"name":"PF-03882845"},{"name":"PF-03882845"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01354990","briefTitle":"A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin (JANUVIA®)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01846767","briefTitle":"Exogenous Glucose Oxidation Breath Test"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National University of Ireland, Galway, Ireland"},"collaborators":[{"name":"Irish Endocrine Society"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral glucose breath test"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00842556","briefTitle":"Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Glimepiride"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00839683","briefTitle":"Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"simvastatin"},{"name":"Dapagliflozin"},{"name":"simvastatin"},{"name":"valsartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00537303","briefTitle":"Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin aspart"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01340911","briefTitle":"A Study in Healthy Male Volunteers to Investigate Different Doses of a New Drug for the Treatment of Metabolic Diseases"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sirtris, a GSK Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SRT3025"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00624364","briefTitle":"Efficacy and Safety of Biphasic Insulin Aspart 30 With Metformin in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00830076","briefTitle":"A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin phosphate"},{"name":"metformin hydrochloride"},{"name":"Comparator: placebo sitagliptin"},{"name":"Comparator: placebo metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03211858","briefTitle":"Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin aspart"},{"name":"NovoLog/NovoRapid"},{"name":"Insulin glargine (HOE901)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01326299","briefTitle":"Post Prandial Glucose Control Proof-of-Principle"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Nutrition"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Carbohydrate placebo"},{"name":"Nutritional ingredient"},{"name":"#1 Nutritional ingredient +Fiber"},{"name":"#2 Nutritional ingredient + Fiber"},{"name":"#3 Nutritional ingredient + Fiber"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01560546","briefTitle":"Testosterone Therapy of Men With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Marianne Andersen"},"collaborators":[{"name":"Odense University Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Hypogonadism"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Testosterone"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00455858","briefTitle":"Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01130480","briefTitle":"Accu-Chek missiOn: SMBG in Patients With diAbetes on inSulin Study (COMPASS) - Multiple Center, Open, and Non-randomized Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Accu-Chek Integra Glucometer"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05983120","briefTitle":"Self-management and Quality of Life in Individuals With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Afyonkarahisar Health Sciences University"}},"conditionsModule":{"conditions":["Pre-Existing Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00795600","briefTitle":"Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin NPH"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01300260","briefTitle":"Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2189265"},{"name":"Placebo"},{"name":"Insulin"},{"name":"Glucose"},{"name":"Glucagon"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01294553","briefTitle":"An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of AVANDAMET Between June 2004 and January 2010"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Administration of rosiglitazone/metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01274663","briefTitle":"A Study Of PF-05175157 In Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-05175157 or Placebo"},{"name":"PF-05175157 or Placebo"},{"name":"PF-05175157 or Placebo"},{"name":"PF-05175157 or Placebo"},{"name":"PF-05175157 or Placebo"},{"name":"PF-05175157 or Placebo"},{"name":"PF-05175157 or Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00032474","briefTitle":"Ginkgo Biloba Extract and the Insulin Resistance Syndrome"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Center for Complementary and Integrative Health (NCCIH)"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ginkgo biloba extract"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00757601","briefTitle":"A Study to Test the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK1006 (MK-1006-002)(COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK1006"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00931034","briefTitle":"Effect of South Beach Diet (SBD™) Using SBD™ Products Compared to the American Diabetic Association (ADA) Diabetes Meal Plan on Body Weight and Satiety in Diabetic Women"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mondelēz International, Inc."},"collaborators":[{"name":"KGK Science Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"South Beach Diet with South Beach Diet Products"},{"name":"American Diabetes Association Diabetes Meal Plan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01253304","briefTitle":"A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2189265"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00766298","briefTitle":"Skeletal Muscle Lipid and Insulin Resistance: Effects of Physical Activity and Weight Loss"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pittsburgh"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise"},{"name":"Weight Loss"},{"name":"Exercise and weight loss"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01204580","briefTitle":"ADIponectin and Asymmetric Dimethylarginine (ADMA) Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose Combination"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLIMEPIRIDE + METFORMIN"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00614783","briefTitle":"Screening for Early Evidence of Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VeraLight, Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01236794","briefTitle":"Community-Based Participatory Research to Improve Health and Quality of Life of Latino Youth: Every Little Step Counts"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Arizona State University"},"collaborators":[{"name":"National Institutes of Health (NIH)"},{"name":"St. Vincent de Paul Medical and Dental Clinic"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle Education Sessions and Youth Exercise Sessions"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00771680","briefTitle":"Observational Study to Evaluate the Effectiveness and Safety of Levemir®, NovoMix® 30 and NovoRapid® in Insulin naïve Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"biphasic insulin aspart 30"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01427920","briefTitle":"Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01065766","briefTitle":"Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin/metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02077946","briefTitle":"A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01223339","briefTitle":"Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ertugliflozin"},{"name":"Placebo"},{"name":"Ertugliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01807377","briefTitle":"Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-05175157"},{"name":"Midazolam"},{"name":"Placebo"},{"name":"Midazolam"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01154413","briefTitle":"Implementation of a Diabetes Management Protocol as Compared to Conventional Management in a Heart Hospital's Non-Intensive Care Unit: Randomized Clinical"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Instituto de Cardiologia do Rio Grande do Sul"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intensive education of the doctor/nursing team on the protocol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01211197","briefTitle":"Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"C: BI 10773 / metformin tablet"},{"name":"B: BI 10773 tablet and metformin tablet"},{"name":"A: BI 10773 / metformin tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00711152","briefTitle":"Community Health Worker Reduces Care Utilization"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chinese University of Hong Kong"},"collaborators":[{"name":"Asia Diabetes Foundation"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Protocol-driven care under JADE Program"},{"name":"Additional support by CHW"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00420095","briefTitle":"A Study for Patients With Diabetes Mellitus (IOPA)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Human insulin 30/70"},{"name":"Insulin lispro low mix"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01649570","briefTitle":"Safety and Efficacy of Insulin Aspart in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03446261","briefTitle":"Rosuvastatin/Ezetimibe vs Rosuvastatin in Korean Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yuhan Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Hypercholesterolemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosuvamibe® Tab"},{"name":"Monorova® Tab"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01465152","briefTitle":"Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"metformin"},{"name":"repaglinide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01232491","briefTitle":"Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin detemir"},{"name":"Dietary regimen"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01183715","briefTitle":"A Single Dose Study Of PF-05161704 In Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-05161704 or placebo"},{"name":"PF-05161704 or placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00425490","briefTitle":"Effect of Januvia on Beta Cell Function in Patients With Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sheba Medical Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00673465","briefTitle":"Effect of SCH 497079 on Metabolic Parameters and Influence of Race/Ethnic Origin on Therapeutic Response (Study P05338)(COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SCH 497079"},{"name":"Placebo"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00747149","briefTitle":"A Diabetes Study to Treat A Population Previously Not at Target"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosuvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00022750","briefTitle":"Randomized Trial of Health Events Costs in Diabetic Blacks"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nurse Case Manager and Community Health Worker Team"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01508923","briefTitle":"Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00564668","briefTitle":"Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01147731","briefTitle":"A Drug Interaction Study With Albiglutide and Warfarin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"warfarin plus albiglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01147718","briefTitle":"A Drug Interaction Study of Albiglutide and Digoxin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"digoxin plus albiglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01147692","briefTitle":"A Drug Interaction Study of Simvastatin and Albiglutide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"simvastatin plus albiglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01144728","briefTitle":"Initiation and Titration of Amaryl"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLIMEPIRIDE + METFORMIN"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00119938","briefTitle":"An Online System to Improve Diabetes Self-Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Robert Wood Johnson Foundation"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Access to online patient portal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01704378","briefTitle":"Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00605449","briefTitle":"A Drug Interaction Study Between Simvastatin and GSK376501"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK376501"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00198757","briefTitle":"Efficacy of 2 Diet Plans Designed for People With Type II Diabetes on Weight and Health Measures"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johns Hopkins Bloomberg School of Public Health"},"collaborators":[{"name":"Medifast, Inc."}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Medifast Plus for Diabetics Meal Replacement Supplements"},{"name":"Standard ADA recommended diet for type 2 diabetics"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01101568","briefTitle":"A Study to Investigate the Interaction of GSK1292263 With Rosuvastatin and Simvastatin in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Simvastatin"},{"name":"Rosuvastatin"},{"name":"GSK1292263"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05295160","briefTitle":"Fasting-Associated Immune-metabolic Remission of Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Charite University, Berlin, Germany"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"weight loss by very low energy diet intake which may differ in protein or carbohydrate content"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01077505","briefTitle":"An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide ."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"albiglutide"},{"name":"Oral contraceptive (Brevicon)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00566865","briefTitle":"Drug-Drug Interaction Study of Mitiglinide and Gemfibrozil"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Elixir Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo for gemfibrozil"},{"name":"gemfibrozil"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04092023","briefTitle":"Self-care Management Programme for Type 2 Adult DM Patients With Poor Glycemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chinese University of Hong Kong"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"nursing education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02800668","briefTitle":"Metabolic Effects of Duodenal Jejunal Bypass Liner for Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ruhr University of Bochum"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DJBL (Duodenal jejunal bypass liner, EndoBarrier)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01067092","briefTitle":"MATCH: The Mexican-American Trial of Community Health Workers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rush University Medical Center"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Community Health Worker Intervention"},{"name":"Educational Newsletter"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00856986","briefTitle":"The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"insulin detemir"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01131182","briefTitle":"Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin phosphate"},{"name":"Comparator: Sulfonylurea"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00825643","briefTitle":"Observational Study to Evaluate the Safety of Levemir® in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01030796","briefTitle":"Quitting Caffeine for Better Glucose Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Caffeine abstinence"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00184574","briefTitle":"Comparison of Biphasic Insulin Aspart 70/30, 50/50, and 30/70 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01018628","briefTitle":"A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SRT2379"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05844748","briefTitle":"Motivational Interviewing in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Saglik Bilimleri Universitesi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Motivation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"diabetes education with motivational interview technique"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01720290","briefTitle":"Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"repaglinide"},{"name":"metformin"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00986375","briefTitle":"Online Program Assisting Lifestyle Changes (Asterix 1.0 & Obelix 2.0)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Freie Universität Berlin"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intervention Group (IG)"},{"name":"Active Control Group (ACG)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01562561","briefTitle":"Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"repaglinide"},{"name":"insulin NPH"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04276051","briefTitle":"Cryovagotomy Diabetes Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"}},"conditionsModule":{"conditions":["Diabetes Type 2","Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cryoablation of the Vagus Nerve"},{"name":"Lifestyle Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00970528","briefTitle":"Glucose Reduction by Early Acarbose Treatment in Basal Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acarbose (Glucobay, BAYG5421)"},{"name":"Voglibose (Basen)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01485614","briefTitle":"Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Metformin"},{"name":"Placebo to sitagliptin"},{"name":"Placebo to metformin"},{"name":"Glycemic Rescue 1"},{"name":"Glycemic Rescue 2"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05822648","briefTitle":"Evaluating a Type 2 Diabetes Prevention Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Stanford University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","PreDiabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Project Health"},{"name":"Educational Video Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05462756","briefTitle":"A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Type 2 Diabetes Treated With Insulin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Efsitora Alfa"},{"name":"Insulin Lispro (U100)"},{"name":"Insulin Glargine (U100)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01044602","briefTitle":"Metabolic Surgery Versus Medical Management for Resolution of Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"David Bradley MD"},"collaborators":[{"name":"Medtronic - MITG"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Laboratory evaluations, sleep study"},{"name":"Best Medical Management"},{"name":"Roux-en-Y gastric bypass surgery"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00097279","briefTitle":"Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"},{"name":"pioglitazone"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00104182","briefTitle":"Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin NPH"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00938275","briefTitle":"A Clinical Study to Assess the Effect of Food and Gender on the Pharmacokinetics of SRT2104 Administered as an Oral Suspension or Capsule Formulation to Normal Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sirtris, a GSK Company"},"collaborators":[{"name":"GlaxoSmithKline"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"0.5g SRT2104"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00938158","briefTitle":"A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"albiglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00937872","briefTitle":"A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sirtris, a GSK Company"},"collaborators":[{"name":"GlaxoSmithKline"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"250 mg SRT2104 Suspension"},{"name":"Carbon-14 radio-labeled SRT2104"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00933062","briefTitle":"Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered to Normal Healthy Male Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SRT2104"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00690755","briefTitle":"Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VA Office of Research and Development"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00769275","briefTitle":"Detection of Ischemia in Asymptomatic Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yale University"},"collaborators":[{"name":"Bristol-Myers Squibb"},{"name":"Astellas Pharma US, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02813343","briefTitle":"Evaluate the Value of Telehomecare for Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Women's College Hospital"},"collaborators":[{"name":"North York General Hospital"},{"name":"William Osler Health System"},{"name":"St. Joseph's Care Group"},{"name":"Ontario Telemedicine Network (OTN)"},{"name":"Unity Health Toronto"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BlueStar app"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00605020","briefTitle":"Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin aspart"},{"name":"biphasic insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00504673","briefTitle":"Comparison of Insulin Detemir Versus Insulin NPH on Weight Change in Overweight and Obese With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin NPH"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00289354","briefTitle":"Efficacy and Safety Study of Chromium Picolinate + Biotin on Glucose and Cholesterol Control in T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nutrition 21, Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Chromium Picolinate (600 mcg Cr) + biotin (2 mg)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04899791","briefTitle":"Positive Effects of Daily Consumption of Bread Enriched With Hydroxytyrosol on the Results of a 12-week Dietary Intervention on Subjects With Type 2 Diabetes Mellitus and Overweight/ Obesity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Harokopio University"},"collaborators":[{"name":"National and Kapodistrian University of Athens"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Wheat bread enriched with hydroxytyrosol"},{"name":"Wheat bread"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00598793","briefTitle":"Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"},{"name":"insulin glargine"},{"name":"metformin"},{"name":"pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03987802","briefTitle":"An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Faster-acting insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01509755","briefTitle":"Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo"},{"name":"liraglutide"},{"name":"glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01068652","briefTitle":"Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin aspart"},{"name":"biphasic insulin aspart 30"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00365781","briefTitle":"Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ionis Pharmaceuticals, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ISIS 113715"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00687284","briefTitle":"Observational Study of Glycaemic Control in Patients Uncontrolled on Oral Antidiabetic Agents and Starting With 1 (Once) Daily Levemir® (Insulin Detemir) as the Treatment of Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00358124","briefTitle":"Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glargine"},{"name":"rosiglitazone"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04160078","briefTitle":"Mindfulness IN-home for Diabetes and Sleep Health"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"},"collaborators":[{"name":"Georgia Center for Diabetes Translation Research"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mindfulness-based stress reduction (MBSR) Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01195259","briefTitle":"Malignancy Meta Analysis for BRL49653"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"allocation of treatment with metformin or rosiglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01547897","briefTitle":"NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"TME Pharma AG"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Albuminuria"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NOX-E36"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00841048","briefTitle":"Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD4017"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00657930","briefTitle":"Observational Study in Type 2 Diabetes Treated by an Intensive Insulin Treatment (ICT) Containing Once Daily Levemir® (Insulin Detemir)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04097483","briefTitle":"Treatment Adherence Intervention in Patients With Type 2 Diabetes and Comorbid Depression"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Alicia Monreal Bartolomé"},"collaborators":[{"name":"Universidad de Zaragoza"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Depression"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Telephone Intervention Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00922194","briefTitle":"Metformin in Overweight Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Era's Lucknow Medical College"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Extended Release Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00823940","briefTitle":"A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK1362885"},{"name":"GSK1362885"},{"name":"Glucagon"},{"name":"Glucagon + GSK1362885"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01943357","briefTitle":"Improving Self Management Skills of Older Adults With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Stanford University"},"collaborators":[{"name":"HealthCore, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Self Management Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02806973","briefTitle":"A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"},"collaborators":[{"name":"Locemia Solutions ULC"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nasal Glucagon"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00834262","briefTitle":"Observational Study on Safety and Efficacy of Biphasic Insulin Aspart in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"},{"name":"biphasic insulin aspart 50"},{"name":"biphasic insulin aspart 70"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00775736","briefTitle":"Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"},{"name":"biphasic insulin aspart 50"},{"name":"biphasic insulin aspart 70"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06607224","briefTitle":"Effect of the Use of Continuous Glucose Monitoring Versus Standard Glycemic Control in Hospitalized Patients with Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital General Universitario Gregorio Marañon"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Hospitalization"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Experimental (Decision making guided by CGM)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00753142","briefTitle":"Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intralipid 20%"},{"name":"Glucose infusion"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00194506","briefTitle":"Cyber Disease Management: Using the World Wide Web to Share the Medical Record With Patients at Home"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Washington"},"collaborators":[{"name":"Center for Health Management Research"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Internet co-management module"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01618214","briefTitle":"Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02305355","briefTitle":"Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kuhnil Pharmaceutical Co., Ltd."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertriglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omega-3-acids ethylesters 90 4g"},{"name":"Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02066155","briefTitle":"Ongoing Diabetes Self-Management Support in Church-Based Settings"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Parish nurse"},{"name":"Peer Support"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00791128","briefTitle":"Study for Pre-Surgical Weight Loss in Type II Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Morphic Medical Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GI Liner"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00108225","briefTitle":"Effect of a High Protein Diet on the 24-hour Profile of Ghrelin, GH (Growth Hormone) and IGF-1 (Insulin-like Growth Factor-1)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"US Department of Veterans Affairs"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LoBag Diet - test phase"},{"name":"LoBAG Diet - control phase"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00712478","briefTitle":"Observational Study Describing Conditions for Intensification of Insulin Therapy in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01589653","briefTitle":"Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"},{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01918865","briefTitle":"Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ionis Pharmaceuticals, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obese"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ISIS-PTP1BRx"},{"name":"Placebo"},{"name":"daily OAD (metformin and/or sulfonylurea)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00693771","briefTitle":"Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01257087","briefTitle":"Resolution of Type 2 Diabetes Mellitus: Intensive vs. Conventional Glycaemic Control After Obesity Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Imperial College London"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00704574","briefTitle":"Observational Study to Observe the Safety of Levemir® Treatment in Children and Adolescents With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01697618","briefTitle":"Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"},{"name":"biphasic human insulin 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00331851","briefTitle":"Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"insulin glargine"},{"name":"metformin"},{"name":"glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06071325","briefTitle":"Green Digital Diabetes Waste Project"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Florida State University"},"collaborators":[{"name":"Diabetes Technology Society"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00993304","briefTitle":"A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00184626","briefTitle":"Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"},{"name":"insulin glargine"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00645528","briefTitle":"Do Group Insulin Education Visits Reduce Barriers to Insulin Initiation?"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"US Department of Veterans Affairs"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Education Class"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00625859","briefTitle":"A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK189075"},{"name":"Bupropion"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01834378","briefTitle":"Diabetes Prevention in Clinical Practice."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Göteborg University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low intensity intervention"},{"name":"High intensity intervention."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00615212","briefTitle":"Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK376501"},{"name":"Midazolam"},{"name":"Rosiglitazone"},{"name":"Flurbiprofen"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00282451","briefTitle":"Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02137720","briefTitle":"Translating Telephonic Diabetes Self-management Support to Primary Care Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Albert Einstein College of Medicine"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"New York City Department of Health and Mental Hygiene"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Telephonic Diabetes Self-Management Support"},{"name":"Educational Print Materials"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00562250","briefTitle":"Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Glimepiride"},{"name":"Dapagliflozin + Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00328536","briefTitle":"Omacor for the Treatment of Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ruhr University of Bochum"},"collaborators":[{"name":"Heart and Diabetes Center North-Rhine Westfalia"},{"name":"Solvay Pharmaceuticals"}]},"conditionsModule":{"conditions":["Atherosclerosis","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omacor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01511172","briefTitle":"Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"metformin"},{"name":"placebo"},{"name":"placebo"},{"name":"glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01009580","briefTitle":"Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/insulin aspart"},{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00549887","briefTitle":"An Observational Study Evaluating Patient Satisfaction and Quality of Life Associated With Switching Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Analog or Human Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00538174","briefTitle":"Phase I Multiple-Ascending Dose (Japan)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02226640","briefTitle":"Uncovering the 'ORIGINS' of Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AdventHealth Translational Research Institute"},"collaborators":[{"name":"AdventHealth"},{"name":"Sanford-Burnham Medical Research Institute"},{"name":"UCSF Benioff Children's Hospital Oakland"},{"name":"Duke Univeristy Sarah W. Stedman Nutrition & Metabolism Center"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00537719","briefTitle":"Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK716155"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00791895","briefTitle":"Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00283751","briefTitle":"Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00432887","briefTitle":"Experimental Studies of the Effects of Caffeine on Glucose Regulation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"caffeine administration"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00825253","briefTitle":"Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"},{"name":"biphasic human insulin 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00495014","briefTitle":"Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK376501"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00469092","briefTitle":"Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"},{"name":"insulin glargine"},{"name":"metformin"},{"name":"glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00424762","briefTitle":"Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Texas Southwestern Medical Center"},"collaborators":[{"name":"GlaxoSmithKline"},{"name":"Abbott RDx Cardiometabolic"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rosiglitazone"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00384215","briefTitle":"Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glargine [rDNA origin] injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01355718","briefTitle":"Observational, Safety Study of NovoNorm® (Repaglinide) and Insulin Analogue Combination Therapy in Type 2 Diabetes in Korea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"repaglinide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01131091","briefTitle":"A Multicenter, Open Label, Single Dose Study to Evaluate the Effect of Renal Insufficiency on the Pharmacokinetics of SK 0403"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kowa Research Institute, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SK-0403"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06033664","briefTitle":"Grocery Prescription Program for Medicaid Adults With Hypertension or Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Alison Gustafson"},"collaborators":[{"name":"Instacart Health"},{"name":"Kentucky Association of Health Plans"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fresh Funds"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00488527","briefTitle":"DOMME Dose Optimization Multicentric Mexican Evaluation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00404963","briefTitle":"A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo"},{"name":"GSK376501"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01536600","briefTitle":"Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00761852","briefTitle":"Signaling Mechanisms and Vascular Function in Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Brigham and Women's Hospital"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ruboxistaurin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01720303","briefTitle":"Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"repaglinide"},{"name":"isophane human insulin"},{"name":"insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06552923","briefTitle":"Extension for Community Health Outcomes (ECHO) Diabetes Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Florida"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ECHO Tele-Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01217112","briefTitle":"GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jazz Pharmaceuticals"}},"conditionsModule":{"conditions":["Dyslipidemias","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GWP42003"},{"name":"GWP42003"},{"name":"GWP42004"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01017523","briefTitle":"Diabetes Support Project: Couples Intervention"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"State University of New York - Upstate Medical University"},"collaborators":[{"name":"National Institutes of Health (NIH)"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Telephone support and behavior change"},{"name":"Diabetes self-management education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01519674","briefTitle":"Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"},{"name":"biphasic insulin aspart 30"},{"name":"sitagliptin"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00160160","briefTitle":"Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Solvay Pharmaceuticals"}},"conditionsModule":{"conditions":["Hypertension","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"eprosartan/HCTZ"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00897169","briefTitle":"A Trial Investigating the Possible Difference in Development of Type 2 Diabetes Between Caucasian and Japanese Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral Glucose Tolerance Test (OGTT)"},{"name":"Euglycaemic hyperinsulinaemic clamp"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02662114","briefTitle":"Investigating the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00600366","briefTitle":"Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen® in Insulin Naive Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01059812","briefTitle":"A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/insulin aspart"},{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05747118","briefTitle":"A Feasibility Study of a 12 Week Training Intervention With Patients With Type 2 Diabetes and MODY in Greenland"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Steno Diabetes Center Greenland"},"collaborators":[{"name":"University of Southern Denmark"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","MODY"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physical training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01492166","briefTitle":"Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic human insulin 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01814137","briefTitle":"A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/insulin aspart"},{"name":"insulin degludec"},{"name":"insulin aspart"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05411458","briefTitle":"Effects of Telerehabilitative Aerobic and Relaxation Exercises Patients With Type 2 Diabetes With and Without COVID-19"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bozyaka Training and Research Hospital"}},"conditionsModule":{"conditions":["COVID-19","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aerobic and Relaxation Exercises"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01478399","briefTitle":"Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"PhaseBio Pharmaceuticals Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PB1023 Injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00118963","briefTitle":"Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Steno Diabetes Center Copenhagen"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Insulin BIAsp30 (Novolog 70/30)"},{"name":"Repaglinide"},{"name":"Placebo-Metformin"},{"name":"Placebo-Repaglinide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00619697","briefTitle":"Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"},{"name":"insulin glargine"},{"name":"metformin"},{"name":"glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00399711","briefTitle":"Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"repaglinide and metformin combination tablet"},{"name":"rosiglitazone and metformin combination tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01053195","briefTitle":"Qingdao Diabetes Prevention Project"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Helsinki"},"collaborators":[{"name":"The World Diabetes Foundation"},{"name":"Qingdao Centers for Disease Control and Prevention"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle counseling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02629497","briefTitle":"Role of 12-lipoxygenase in Platelet Reactivity and Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Thrombosis","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Primrose oil"},{"name":"Fish Oil"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00036504","briefTitle":"Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Lispro low mixture"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01123980","briefTitle":"Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"},{"name":"metformin"},{"name":"glimepiride"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03867500","briefTitle":"Effects of Niacin on Intramyocellular Fatty Acid Trafficking in Upper Body Obesity and Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Niacin"},{"name":"Saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00700960","briefTitle":"Observational Study Describing Conditions for Administering Slow-acting Insulin Analogue With Oral Antidiabetic Agents in Type 2 Diabetes on Blood Glucose Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01375686","briefTitle":"Noninvasive Screening for Early Evidence of Diabetes With SCOUT DS"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VeraLight, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01487798","briefTitle":"Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic human insulin 30"},{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00755833","briefTitle":"Observational Study of NovoMix® 50 for Treatment of Type 2 Diabetics for 12 Months"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 50"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04214600","briefTitle":"Cognitive Behavioral Therapy for Adherence in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cairo University"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Depression"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cognitive Behavioral Therapy (CBT)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01186965","briefTitle":"Ehealth: Second Life Impacts Diabetes Education & Self-Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Duke University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"eHealth program in the Virtual Environment (VE) platform Second Life"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02666521","briefTitle":"Hypoglycaemia in People With Type 2 Diabetes in Primary Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Leicester"},"collaborators":[{"name":"Primary Care Diabetes Society, UK"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypoglycemia"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05248841","briefTitle":"A Study to Demonstrate Pharmacokinetic and Pharmacodynamic Biosimilarity Between HEC-Glargine and US-Lantus® in Healthy Male Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lannett Company, Inc."},"collaborators":[{"name":"Parexel"},{"name":"FARMOVS (Pty) Ltd"}]},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HEC-Glargine"},{"name":"US-Lantus"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00313001","briefTitle":"Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"},{"name":"exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01344668","briefTitle":"The Public Private Partnership Addressing Literacy-Numeracy to Improve Diabetes Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Enhanced Diabetes Education"},{"name":"Standard Diabetes Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00709917","briefTitle":"Observational Study of the Switch of Metformin Alone to Metformin Combined With Repaglinide in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"repaglinide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00972283","briefTitle":"Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"insulin glargine"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00657319","briefTitle":"Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05897216","briefTitle":"Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-383"},{"name":"CKD-501, D745, D150, D029"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00762671","briefTitle":"Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Brigham and Women's Hospital"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ebselen"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02574195","briefTitle":"Evolution of Effectiveness of Diabetes Medical Care in Russia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Endocrinology Research Centre, Moscow"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04913909","briefTitle":"Effects of a Probiotic on Oral Microbiota and Glycemic Control in Type 2 Diabetics; A Randomized Clinical Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Istanbul University"}},"conditionsModule":{"conditions":["Diabetes Mellitus,Type 2","Periodontitis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Effects of an oral probiotic or placebo use on oral microbiota and glycemic index in Type 2 diabetic patients"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04274660","briefTitle":"Evaluation of Diabetes and WELLbeing Programme"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Canterbury Christ Church University"},"collaborators":[{"name":"Medway Community Healthcare"},{"name":"Blackthorn Trust"},{"name":"Arteveldehogeschool"},{"name":"Kinetic Analysis"},{"name":"Centre Hospitalier de Douai"},{"name":"The Health and Europe Centre"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Type 2 Diabetes Treated With Insulin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DWELL (Diabetes and WELLbeing) Programme"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00806936","briefTitle":"Observational Study to Investigate the Efficacy and Safety of Human Insulin or Insulin Analogue Treatments in Type 2 Diabetes Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"human insulin"},{"name":"insulin analogue"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03821662","briefTitle":"OT-Led Interdisciplinary Diabetes Self-Management Prgm"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Arizona State University"},"collaborators":[{"name":"Hand Therapy Partners"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"OT Diabetes Self-Management Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02185482","briefTitle":"Physician Led Counseling in Management of Depression in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Adwin Life Care"},"collaborators":[{"name":"NMP Medical Research Institute"}]},"conditionsModule":{"conditions":["Depression","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physician Supported Care"},{"name":"Usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05816759","briefTitle":"Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-383"},{"name":"CKD-501, D744, D150"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00842894","briefTitle":"Safety of NovoMix® 30 or Levemir® for Treatment of Type 2 Diabetics in Macedonia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00696657","briefTitle":"A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"semaglutide"},{"name":"semaglutide"},{"name":"semaglutide"},{"name":"semaglutide"},{"name":"semaglutide"},{"name":"placebo"},{"name":"placebo"},{"name":"placebo"},{"name":"placebo"},{"name":"placebo"},{"name":"liraglutide"},{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04928248","briefTitle":"Design, Implementation and Evaluation of Scalable Decision Support for Diabetes Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Utah"},"collaborators":[{"name":"Hitachi, Ltd."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Dashboard integrated with Disease Manager App"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01354925","briefTitle":"Management of Type-2 Diabetic Patients Treated With Insulin During the Ramadan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Meir Medical Center"}},"conditionsModule":{"conditions":["Diabetes Type 2","Treatment During Ramadan"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin treatment during Ramadan"},{"name":"Standard of care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03397225","briefTitle":"A Lifestyle Intervention for Type 2 Diabetes Patients in Kuwait and Its Impact on Glycaemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Reading"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Noninsulin-Dependent","Diabetes, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00274274","briefTitle":"Efficacy and Safety of a Fixed or a Flexible Supplementary Insulin Therapy in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04588259","briefTitle":"Research Study to Compare a New Medicine \"Fast-acting Insulin Aspart\" to Another Medicine \"Insulin Aspart\" in Chinese People With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Faster aspart"},{"name":"Insulin aspart"},{"name":"Insulin degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01611168","briefTitle":"REMEDIES4D: REdesigning MEDication Intensification Effectiveness Study for Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pittsburgh"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Treatment Algorithms"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04028427","briefTitle":"Impact of ACT-based Interventions on Diabetes-related Outcomes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sophini Logeswaran"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Values-plus-goals intervention"},{"name":"Mindfulness-based intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00097084","briefTitle":"Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin glargine"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03393715","briefTitle":"Effect of Morning Versus Evening Perindopril on Blood Pressure Control in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yaounde Central Hospital"},"collaborators":[{"name":"University of Yaounde 1"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Perindopril Oral Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04043065","briefTitle":"Liver-enriched Antimicrobial Peptide 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"},"collaborators":[{"name":"Gubra ApS"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liver-enriched antimicrobial peptide 2"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00496145","briefTitle":"Spanish Diabetes Self-Management Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Stanford University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Spanish Diabetes Self-Management Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01356953","briefTitle":"Exercise Intensity and Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Catholic University of Brasília"},"collaborators":[{"name":"Conselho Nacional de Desenvolvimento Científico e Tecnológico"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aerobic exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02709915","briefTitle":"Effect of Meal Frequency and Timing on Insulin Dose and Clock Gene in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tel Aviv University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Breakfast Diet (Bdiet)"},{"name":"6Meal Diet (6Mdiet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00675311","briefTitle":"Remote Monitoring in Diabetes Disease Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LifeScan"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DM-Standard"},{"name":"Disease Management Plus"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06673212","briefTitle":"Black Barley Study - Barley to Support Food and Drink Innovation (RI-B7-3)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aberdeen"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Control Wheat Bread"},{"name":"Berneray Bere barley bread"},{"name":"Black Barley bread"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00842192","briefTitle":"An Observational Study in Type 2 Diabetic Patients on Oral Antidiabetic Drugs and Basal Insulin in Near East Countries"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04641312","briefTitle":"A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Healthy","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3457263"},{"name":"Dulaglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01571310","briefTitle":"Effect of Breakfast or Omission of Breakfast in T2D"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tel Aviv University"},"collaborators":[{"name":"Hospital de Clinicas Caracas"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omitted Breakfast"},{"name":"Breakfast"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00715351","briefTitle":"Observational Study of Patients Using Levemir® or Insulatard® as Start Insulin for Treatment of Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin NPH"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02188186","briefTitle":"Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Bundang Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Initial triple combination"},{"name":"Conventional treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04801199","briefTitle":"Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cadila Pharnmaceuticals"},"collaborators":[{"name":"New Millennium Indian Technology Leadership Initiative (NMITLI) program of Council of Scientific and Industrial Research, India"}]},"conditionsModule":{"conditions":["Uncontrolled Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CPL-2009-0031 140 mg"},{"name":"Sitagliptin 100mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05275231","briefTitle":"Better Together Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"},"collaborators":[{"name":"National Institute on Minority Health and Health Disparities (NIMHD)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intensive lifestyle interventions (ILIs)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01545401","briefTitle":"Empowering Primary Care Providers and Patients to Improve Chronic Disease Outcomes: The EMPOWER Participatory Action Research (EMPOWER - PAR)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ministry of Health, Malaysia"},"collaborators":[{"name":"Ministry of Education, Malaysia"},{"name":"Universiti Teknologi Mara"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Hypertension (Without Type 2 Diabetes Mellitus)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EMPOWER-PAR Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04810026","briefTitle":"Transform Type 2: Examining Meal-Delivery and Education for Diabetes Self-Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"UnitedHealth Group"}},"conditionsModule":{"conditions":["PreDiabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Education"},{"name":"Meal delivery"},{"name":"Lifestyle coaching"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01085682","briefTitle":"Application and Effectiveness Analysis of Internet-based Diabetes Prevention Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Catholic University of Korea"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle counseling"},{"name":"Standard care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00604396","briefTitle":"Safety and Efficacy of Insulin Detemir in Combination With OAD in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin NPH"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00604253","briefTitle":"Efficacy and Safety of Insulin Detemir in Type 2 Diabetes Inadequately Controlled on OHA Therapy Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin NPH"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00494988","briefTitle":"Self-control Trial to Evaluate the Remission Rate in Newly Diagnosed Type 2 Diabetes Patients After Treatment With Insulin Aspart"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin aspart"},{"name":"insulin NPH"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01498900","briefTitle":"An Observational Study Evaluating Efficacy, Safety and Convenience of NovoNorm® in Treatment of Type 2 Diabetes in Routine Clinical Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"repaglinide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01478841","briefTitle":"Polyphenols and Insulin Resistance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Montpellier"}},"conditionsModule":{"conditions":["Healthy Volunteers","Insulin Resistance","Type 2 Diabetes (T2D)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"polyphenol"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02002221","briefTitle":"Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin (LAF237)"},{"name":"Placebo"},{"name":"Insulin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00950209","briefTitle":"Acute Effect of Intensive Insulin Infusion on Intestinal Triglyceride-rich-lipoprotein-apoB48 Metabolism in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Assistance Publique Hopitaux De Marseille"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"saline infusion"},{"name":"euglycaemic hyperinsulinic clamp"},{"name":"infusion of Endolipide and heparin"},{"name":"hyperglycaemic hyperinsulinic clamp"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03472846","briefTitle":"MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Vienna"},"collaborators":[{"name":"St. Vincent Hospital, Vienna"}]},"conditionsModule":{"conditions":["Postmenopausal Osteoporosis","Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Prolia, 60 Mg/mL Subcutaneous Solution"},{"name":"Teriparatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00698126","briefTitle":"Observational Study of Patients Using NovoRapid® or Soluble Human Insulin for Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"soluble human insulin"},{"name":"biphasic insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01061216","briefTitle":"Pharmacokinetics/Dynamics of Basal (Continuous) Insulin Infusion Administered Either Intradermally or Subcutaneously"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Becton, Dickinson and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intradermal insulin delivery: BD Research Catheter Set"},{"name":"Subcutaneous insulin delivery:ACCU-CHEK Rapid-D Infusion Set"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02392117","briefTitle":"Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00979823","briefTitle":"Simulated Diabetes Training for Resident Physicians"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HealthPartners Institute"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Early SimCare Diabetes Group"},{"name":"Delayed SimCare Diabetes Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06333977","briefTitle":"A Study of LC542019 in Healthy Subjects and Subjects With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LG Chem"}},"conditionsModule":{"conditions":["Healthy","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LC542019"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05033899","briefTitle":"Enhanced Recovery After Spinal Surgery Protocol Versus Conventional Care in Non Insulin Diabetic Patients ( ERAS )"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Alexandria University"}},"conditionsModule":{"conditions":["ERAS","Surgery","Non Insulin Dependent Diabetes Mellitus","Lumbar Spine Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ERAS protocol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03810378","briefTitle":"Contrasting Ketogenic and Mediterranean Diets in Individuals With Type 2 Diabetes and Prediabetes: The Keto-Med Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Stanford University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","PreDiabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mediterranean Diet (Med-Plus)"},{"name":"Well-Formulated Ketogenic Diet (WFKD)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03983551","briefTitle":"Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Changhua Christian Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Proteinuria"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dipeptidyl Peptidase 4 Inhibitor"},{"name":"Sulfonylurea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02327039","briefTitle":"The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Padova"},"collaborators":[{"name":"Azienda Ospedaliera di Padova"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01163006","briefTitle":"Soluble Dietary Fibres in the Prevention of Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"},"collaborators":[{"name":"Tate and Lyle Ingredients France"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Polydextrose and soluble gluco fibre"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05527847","briefTitle":"Peers EXCEL Trial to Improve Glycemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Wisconsin, Madison"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Peers LEAD"},{"name":"HLWD"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05294536","briefTitle":"A Pharmacokinetic Study Comparing the Liraglutide Injection (RD12014) and Victoza® in Healthy Chinese Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sunshine Lake Pharma Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide injection,RD12014"},{"name":"Liraglutide injection,Victoza"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04818242","briefTitle":"Dexcom Continuous Glucose Monitoring in Long-term Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"},"collaborators":[{"name":"DexCom, Inc."}]},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dexcom G6 CGM with GTS"},{"name":"POC Blood Glucose Test + Blinded CGM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02758275","briefTitle":"Teaching: Individual to Increase Adherence to Therapeutic Regimen in Hypertension Arterial and/or Diabetes Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidad Industrial de Santander"},"collaborators":[{"name":"Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)"},{"name":"Cardiecol"},{"name":"Instituto de Salud de Bucaramanga"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Teaching: Individual (5606)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06132204","briefTitle":"Pharmacokinetic and Safety Studies of HRS-7535 in Subjects With Moderate Renal Insufficiency and Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shandong Suncadia Medicine Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HRS-7535 Tablets"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01063374","briefTitle":"Low Glycemic Index Diet for Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Toronto"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"low glycemic diet instruction"},{"name":"high cereal fibre diet instruction"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01106287","briefTitle":"Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK-0941"},{"name":"Comparator: Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06086912","briefTitle":"A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jiangsu HengRui Medicine Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HR17031"},{"name":"HR17031"},{"name":"HR17031"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00869908","briefTitle":"Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin aspart"},{"name":"insulin detemir"},{"name":"biphasic insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02073058","briefTitle":"Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Diabetes Care"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06629688","briefTitle":"The Effect of Parenterally Administred Semaglutide on Intestinal Iron Absorption in Individuals With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital Dubrava"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Iron Absorption"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00184600","briefTitle":"Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"},{"name":"insulin detemir"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04184947","briefTitle":"Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Padova"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SGLT2 inhibitor"},{"name":"GLP-1 receptor agonist"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00937703","briefTitle":"Multicentric Evaluation of Two Telematics Systems in Type 2 Diabetic Patients in Failure of Oral Treatment and Having to Start Treatment by Basal Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["TYPE 2 DIABETES"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo"},{"name":"IVS"},{"name":"PDAphone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03053336","briefTitle":"App-technology to Increase Physical Activity Among Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Karolinska Institutet"},"collaborators":[{"name":"Region Stockholm"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Exercise"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"App-technology to increase physical activity"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00991380","briefTitle":"Healthy Eating & Active Living for Diabetes in Primary Care Networks"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Alliance for Canadian Health Outcomes Research in Diabetes"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HEALD"},{"name":"Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05893576","briefTitle":"A Relative Bioavailability Study of HRS9531 in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fujian Shengdi Pharmaceutical Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HRS9531"},{"name":"HRS9531"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02453685","briefTitle":"A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"},{"name":"insulin glargine"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02762708","briefTitle":"The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Roux-en-Y Gastric Bypass (RYGB)"},{"name":"Caloric Restriction"},{"name":"Exendin-9,39"},{"name":"Normal Saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02827903","briefTitle":"Metformin/Rosuvastatin Combination Therapy With in Patients With Type 2 Diabetes and Dyslipidemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jeil Pharmaceutical Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes","Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin + Rosuvastatin"},{"name":"Metformin + placebo"},{"name":"placebo + Rosuvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01085773","briefTitle":"Effects of Nordic Walking and Exercise on Glucose Metabolism in Type 2 Diabetes Mellitus: A Randomized Controlled Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Esbjerg Hospital - University Hospital of Southern Denmark"},"collaborators":[{"name":"University of Southern Denmark"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Exercise"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise on Prescription"},{"name":"Nordic Walking"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04363710","briefTitle":"Prospective Interventional Study on Reversibility of Type 2 Diabetes Mellitus With Hypocaloric Diet"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Max Healthcare Insititute Limited"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus in Obese"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low Calorie Diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05979142","briefTitle":"Community-based Primary Care Program Effects on Pharmacotherapy of Type 2 Diabetes and Hypertension in Peru"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Asociación Siempre Salud"},"collaborators":[{"name":"University of Arizona"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Hypertension"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"community-based primary care program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04907006","briefTitle":"A Food-drug Interaction Study of SY-004 in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Suzhou Yabao Pharmaceutical R&D Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SY-004 capsule"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04948918","briefTitle":"Distal Renal Denervation to Prevent Renal Function Decline in Patients With T2DM and Hypertension"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tomsk National Research Medical Center of the Russian Academy of Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Anatomically optimized distal renal denervation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02925312","briefTitle":"MedStar Health Type 2 Diabetes Pathway to Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medstar Health Research Institute"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Pathway"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03826290","briefTitle":"Evaluation of a Dashboard for Diabetes Care Integrated With the Electronic Health Record"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Utah"},"collaborators":[{"name":"Hitachi, Ltd."}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EHR-integrated diabetes dashboard"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01103414","briefTitle":"Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Metabolic Solutions Development Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mitoglitazone"},{"name":"Mitoglitazone"},{"name":"Mitoglitazone"},{"name":"Pioglitazone"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01127997","briefTitle":"The Effect and Mechanisms of the Second-meal Phenomenon in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Catholic University of Korea"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01235429","briefTitle":"Partners in Care Diabetes Self-management Intervention"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Hawaii"},"collaborators":[{"name":"National Institute on Minority Health and Health Disparities (NIMHD)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Partners in Care"},{"name":"Partners in Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00491725","briefTitle":"Efficacy and Safety of Repaglinide and Metformin Combination Therapy in Type 2 Diabetes Failing on Oral Anti-diabetic Drugs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"repaglinide"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00670722","briefTitle":"Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin aspart"},{"name":"insulin detemir"},{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02246582","briefTitle":"Adult Accuracy Study of the Enlite 3 Glucose Sensor"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medtronic Diabetes"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Enlite 3"},{"name":"Guardian Mobile App"},{"name":"640G Insulin Pump"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05692934","briefTitle":"A HR20031 FE Study on Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shandong Suncadia Medicine Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HR20031 FDC"},{"name":"HR20031 FDC"},{"name":"HR20031 FDC"},{"name":"HR20031 FDC"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05682495","briefTitle":"A HR20031 BE Study on Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shandong Suncadia Medicine Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ARM A"},{"name":"ARM B"},{"name":"ARM C"},{"name":"ARM D"},{"name":"ARM E"},{"name":"ARM F"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01674049","briefTitle":"Nutrient Timing Following Resistance Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"George Washington University"},"collaborators":[{"name":"United States Department of Agriculture (USDA)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Immediate Nutrition"},{"name":"Nutrition 3 hours Post-Bout"},{"name":"Resistance Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04847999","briefTitle":"Dark Chocolate and Glucose Levels in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of British Columbia"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dark chocolate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01925248","briefTitle":"Can Whey Protein Improve Glycemic Control in Type 2 Diabetes?"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, Davis"},"collaborators":[{"name":"National Institutes of Health (NIH)"},{"name":"National Center for Complementary and Integrative Health (NCCIH)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Whey protein"},{"name":"Placebo group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03199261","briefTitle":"A Study of Pharmacokinetic Comparison of Two Recombinant Exendin-4 Formulations in Chinese Healthy Male Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rE-4 Injection"},{"name":"rE-4 Freeze-dried Powder"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05576298","briefTitle":"A Clinical Study Comparing the Pharmacokinetics and Pharmacodynamic Characteristics of Insulin Degludec Injection (RD15003) and Insulin Degludec Injection (Tresiba®) in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sunshine Lake Pharma Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin degludec injection, RD15003"},{"name":"Insulin degludec, Tresiba"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03648996","briefTitle":"Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Missouri-Columbia"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hyperuricemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low-fructose diet, isocaloric"},{"name":"Allopurinol"},{"name":"Placebo"},{"name":"Low-fructose, hypocaloric"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01945242","briefTitle":"Alogliptin Tablets Special Drug Use Surveillance \"Type 2 Diabetes Mellitus: Combination Therapy With Thiazolidinediones\""},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Melitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05081817","briefTitle":"Accuracy Comparison of Two CGMs in Hospitalized Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Diego"},"collaborators":[{"name":"DexCom, Inc."}]},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00666094","briefTitle":"A Randomized Controlled Trial of Exercise Training Among Men With Type 2-diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Norwegian University of Science and Technology"},"collaborators":[{"name":"St. Olavs Hospital"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Endurance training"},{"name":"strength training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01837680","briefTitle":"Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"St. Luke's-Roosevelt Hospital Center"}},"conditionsModule":{"conditions":["Diabetes, Gestational","Diabetes, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00501462","briefTitle":"A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2","Renal Insufficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK189075"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01783275","briefTitle":"The Effect of Exercise on Hepatic Glucose Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aerobic exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05459285","briefTitle":"A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sunshine Lake Pharma Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"14028 injection"},{"name":"dulaglutide injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05229445","briefTitle":"A Continuous Glucose Monitor Based Insulin Bolus Calculator"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Welldoc"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"continuous glucose monitor based insulin bolus calculator"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02629263","briefTitle":"The Effect of Viscous Fiber on Glycemic Control in Individuals With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Unity Health Toronto"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Viscous Fiber"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00123604","briefTitle":"Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"St. Paul Heart Clinic"},"collaborators":[{"name":"GlaxoSmithKline"}]},"conditionsModule":{"conditions":["Hypertension","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Carvedilol"},{"name":"Metoprolol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04194450","briefTitle":"Exogenous Ketones in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of British Columbia"}},"conditionsModule":{"conditions":["Ketosis","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ketone monoester"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02799953","briefTitle":"Technology-augmented Self-monitoring Model Among Patients With Type 2 Diabetes and Hypertension"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Hong Kong"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Technology-based self-management model"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00311324","briefTitle":"A Church Based Intervention to Improve Diabetes Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of North Carolina, Chapel Hill"},"collaborators":[{"name":"Centers for Disease Control and Prevention"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Special Intervention"},{"name":"Delayed Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01168297","briefTitle":"Type 2 Diabetes and Obesity in Mexican Pimas: Gene-Environment Interaction"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05385575","briefTitle":"A Study to Evaluate Effects of KN056 in Healthy Participants"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Suzhou Alphamab Co., Ltd."},"collaborators":[{"name":"Novotech (Australia) Pty Limited"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"KN056 (0.1mg)"},{"name":"KN056 (0.3mg)"},{"name":"KN056 (1.0mg)"},{"name":"KN056 (3.0mg)"},{"name":"KN056 (6.0mg)"},{"name":"KN056 (12.0mg)"},{"name":"KN056 (18.0mg)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01121276","briefTitle":"A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Faster-acting insulin aspart"},{"name":"insulin aspart"},{"name":"Faster-acting insulin aspart"},{"name":"Faster-acting insulin aspart"},{"name":"Faster-acting insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03756688","briefTitle":"Penile Length Restoration in Men With Diabetes Mellitus, Type II"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Penile Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"RestoreX PTT - 6 months"},{"name":"RestoreX PTT - 3 months"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02214641","briefTitle":"Resilient, Empowered, Active Living: REAL Diabetes Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Southern California"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Resilient, Empowered, Active Living with Diabetes"},{"name":"Information Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00549133","briefTitle":"Irbesartan Effects on Endothelial Dysfunction in Hypertensive Type II Diabetic Patients Comparing Atenolol"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Hypertension","Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Irbesartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00973960","briefTitle":"A Pilot Trial of the EndoBarrier™ Flow Restrictor for Glycemic Improvement in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Morphic Medical Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00095446","briefTitle":"NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00806897","briefTitle":"Observational Study in Type 2 Diabetics Treated by an Intensive Insulin Treatment of Levemir®"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01939496","briefTitle":"Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Scientific Affairs, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00198913","briefTitle":"Long Term Free Living Study With Modified Foods and Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johns Hopkins Bloomberg School of Public Health"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"lower fat food supplied and education"},{"name":"gift cards for grocery foods and written education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00659711","briefTitle":"The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University at Buffalo"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Januvia (Sitagliptin) 100 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04765358","briefTitle":"Virtual Diabetes Specialty Clinic: A Study Evaluating Remote Initiation of Continuous Glucose Monitoring"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jaeb Center for Health Research"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Virtual Clinic"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05210517","briefTitle":"SGLT2 Inhibition: Uric Acid Excretion Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Amsterdam UMC, location VUmc"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin 25 MG"},{"name":"Benzbromaron"},{"name":"Empagliflozin 25 MG + benzbromarone 100 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00732524","briefTitle":"Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cook County Health"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glipizide"},{"name":"Glipizide and Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01407003","briefTitle":"Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LIK066"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01709929","briefTitle":"Safety of Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02468037","briefTitle":"Effect of Iron Reduction by Phlebotomy for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Utah"},"collaborators":[{"name":"University of Colorado, Denver"},{"name":"University of New Mexico"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Prediabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Phlebotomy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01238289","briefTitle":"Randomized Trial of Peer Led Education-Project Dulce"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Scripps Whittier Diabetes Institute"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"National Center for Research Resources (NCRR)"},{"name":"San Diego State University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Peer Education"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00697450","briefTitle":"Observational Study on the Weight Effect of Insulin Detemir (Levemir®) in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00831194","briefTitle":"Stress, Dietary Lapse and Weight Loss Among Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johns Hopkins Bloomberg School of Public Health"},"collaborators":[{"name":"National Institute on Drug Abuse (NIDA)"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Personalized diet plan and PDA self reporting."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05152277","briefTitle":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fujian Shengdi Pharmaceutical Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HRS9531"},{"name":"placebo"},{"name":"HRS9531"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00490178","briefTitle":"Acceptability Study of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Type 2 Diabetes and Dyslipidemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Solvay Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fenofibrate 80 mg and metformin 1000 mg (fixed combination)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05113693","briefTitle":"Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-393"},{"name":"CKD-501, D759, H053"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03978286","briefTitle":"Vortioxetine vs Sertraline in Mexicans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidad Juárez Autónoma de Tabasco"}},"conditionsModule":{"conditions":["Depression","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vortioxetine"},{"name":"Sertraline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04436822","briefTitle":"Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medtronic Diabetes"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous Glucose Monitoring"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00865397","briefTitle":"Observational Study in Type 2 Diabetics Failing on Oral Antidiabetic Therapy and Starting on Insulin Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00444899","briefTitle":"Clinical and Economic Benefits of Cardiovascular Risk Management by a Dietician in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Université de Sherbrooke"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intensive treatment"},{"name":"Normal follow-up"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04378114","briefTitle":"Impact of Acetaminophen on Performance of Guardian™ Sensor (3) in Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medtronic Diabetes"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. C sensor algorithm applied retrospectively to raw sensor data."},{"name":"Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. Zeus sensor algorithm applied retrospectively to raw sensor data."},{"name":"Acetominophen"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02617693","briefTitle":"Development of Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"lifestyle intervention"},{"name":"standard antenatal care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05039307","briefTitle":"Prevention of Type 2 Diabetes and Gestational Diabetes Among Women in Kisantu, Democratic Republic of Congo"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institute of Tropical Medicine, Belgium"},"collaborators":[{"name":"Memisa, Belgium"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Gestational Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Educational and motivational strategy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05029076","briefTitle":"Human Bioequivalence Test of Liraglutide Injection"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide injection"},{"name":"Victoza"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01370005","briefTitle":"12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"BI 10773"},{"name":"Placebo"},{"name":"BI 10773"},{"name":"Placebo"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00740519","briefTitle":"Observational Study on Safety of Self-titration of Once Daily Levemir®"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04504370","briefTitle":"Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"PegBio Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLP-1 receptor agonist"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01755494","briefTitle":"A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus(T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin 5 mg"},{"name":"Metformin XR 500 mg"},{"name":"Mertformin XR 2 x 500 mg"},{"name":"Komboglyze XR 5/500 mg"},{"name":"Komboglyze XR 5/1000 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01673178","briefTitle":"Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Melliuts, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"25 mg PF-05231023"},{"name":"50 mg PF-05231023"},{"name":"100 mg PF-05231023"},{"name":"150 mg PF-05231023"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04317703","briefTitle":"Bioequivalence Study for Fixed Dose Combination Zemimet® SR Tab. 50/1000 and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LG Chem"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gemigliptin tartrate sesquihydrate and metformin"},{"name":"gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04921306","briefTitle":"Obese Human Beta-2-adrenergic Stimulation and Muscle Glucose Uptake"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University"},"collaborators":[{"name":"Eurostars"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Clenbuterol Hydrochloride"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03771781","briefTitle":"Bioequivalence Study of Empagliflozin Tablet in Healthy Participants."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin Tablets"},{"name":"Empagliflozin Tab 25 MG"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00665808","briefTitle":"Observational Study on Treatment Satisfaction of Levemir® Versus Protaphane® During \"Real-life\" Usage in Germany"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"isophane human insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04907019","briefTitle":"A Drug Interaction Study of SY-004 Capsules in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Suzhou Yabao Pharmaceutical R&D Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rifampicin，SY-004"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00042601","briefTitle":"Evaluation of the Effect of Pramlintide on Satiety and Food Intake"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pramlintide acetate"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01096667","briefTitle":"Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo to Ertuglilflozin 1 or 5 mg"},{"name":"Ertugliflozin 1 mg"},{"name":"Ertugliflozin 5 mg"},{"name":"Ertugliflozin 25 mg"},{"name":"HCTZ 12.5mg"},{"name":"Placebo to HCTZ"},{"name":"Placebo to ertuglilflozin 25 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04261361","briefTitle":"Community-based Cognitive Behavioral Therapy for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Hong Kong Polytechnic University"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Depression"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CBCBT intervention"},{"name":"Adherence counseling"},{"name":"Psycho-education package"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00873223","briefTitle":"Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02711839","briefTitle":"Evaluation of White Sweet Potato Tube Feeding Formula on Type 2 Diabetic Residents in Long-term Care Institutions"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Taipei Medical University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Commercial diabetic formula"},{"name":"White sweet potato formula"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02182830","briefTitle":"24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin low dose"},{"name":"placebo"},{"name":"Empagliflozin high dose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01278823","briefTitle":"Effect of Bariatric Surgery on Mechanisms of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Cleveland Clinic"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"laparoscopic roux en y gastric bypass operation"},{"name":"medical management"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03246828","briefTitle":"Glucagon in MODY (Maturity Onset Diabetes of the Young)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Oxford"},"collaborators":[{"name":"Oxford University Hospitals NHS Trust"}]},"conditionsModule":{"conditions":["MODY1","MODY3"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omission of gliclazide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00304603","briefTitle":"Mode of Action of Topiramate in the Treatment of Obese Patients With and Without Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01527630","briefTitle":"Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Japanese Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 50"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04307797","briefTitle":"Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cambridge University Hospitals NHS Foundation Trust"},"collaborators":[{"name":"Antaros Medical"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"0.9% Sodium-chloride"},{"name":"Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min"},{"name":"Glucagon 12.5ng/kg/min and 0.9% saline"},{"name":"0.9% Sodium-chloride"},{"name":"Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min"},{"name":"Glucagon 12.5ng/kg/min"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01940770","briefTitle":"Specific Clinical Experience Investigation for Long-term Use of Bydureon."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00737347","briefTitle":"Prevention of Weight Gain in Adult Patients With Type 2 Diabetes Treated With Pioglitazone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Northwestern University"},"collaborators":[{"name":"Takeda"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle modification"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04658082","briefTitle":"A Pilot Trial of the Non-invasive H.G.R Glucometer"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Prof. Amir Tirosh"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"H.G.R (GWave) non-invasive glucometer"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00363233","briefTitle":"The Potential Effects and Mechanisms of Flax Lignans on Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chinese Academy of Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Hypercholesterolemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"flax lignans"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01487421","briefTitle":"An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen®) in the Evening or at Bedtime"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin aspart"},{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04159766","briefTitle":"A Study With NLY01 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Neuraly, Inc."}},"conditionsModule":{"conditions":["Type2 Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NLY01"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00659282","briefTitle":"Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02759107","briefTitle":"A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Healthy","Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Placebo"},{"name":"Dulaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04214704","briefTitle":"Assessing the Benefits of a Painless Lancing Device Among Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jothydev's Diabetes and Research Centre"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Genteel lancing device"},{"name":"Conventional lancing device"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01398423","briefTitle":"INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"InVasc Therapeutics, Inc."}},"conditionsModule":{"conditions":["Hypertension","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Active Control"},{"name":"INV-144"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01384058","briefTitle":"Effect of Ezetimibe or Simvastatin or Both on Low Densitiy Lipoprotein -Subfractions in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital Freiburg"},"collaborators":[{"name":"Essex Pharma GmbH"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Hypercholesterolemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ezetimibe"},{"name":"simvastatin"},{"name":"Ezetimibe 10/Simvastatin 20"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00110435","briefTitle":"A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Organon and Co"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Hypercholesterolemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK0653A, ezetimibe (+) simvastatin"},{"name":"Duration of Treatment: 4 wk placebo run in then 6 wk active"},{"name":"Comparator: atorvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01871558","briefTitle":"Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"Metformin"},{"name":"sulfonylurea (SU)"},{"name":"Basal Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04115579","briefTitle":"The Impact of Low Glycaemic Index (GI) Biscuits on Postprandial Glycaemia Using the Continuous Glucose Monitoring System (CGMS™) (Biscuit Study (BIS) Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Singapore Institute of Food and Biotechnology Innovation"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Biscuit 1 Control"},{"name":"Biscuit 2 Test"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04568486","briefTitle":"Social Support Intervention for Older Adults With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Brittany L Smalls"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Empowerment Education Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00698230","briefTitle":"Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Incyte Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INCB013739"},{"name":"INCB013739"},{"name":"INCB013739"},{"name":"INCB013739"},{"name":"INCB013739"},{"name":"Placebo comparator matching INCB013739"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03203694","briefTitle":"Effects of Walking and Heating on Vascular Function in Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Missouri-Columbia"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Walking: Intervention arm in diabetics"},{"name":"Walking: No intervention in diabetics"},{"name":"Walking: Healthy cohort as reference controls"},{"name":"Lower body heating: Intervention arm in healthy subjects"},{"name":"Lower body heating: Intervention arm in diabetics"},{"name":"Lower body heating: Healthy cohort as reference controls"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02796170","briefTitle":"Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tulane University School of Medicine"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04698122","briefTitle":"Establishment of the Human Intestinal and Salivary Microbiota Biobank- Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari"},"collaborators":[{"name":"Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies"},{"name":"University Of Perugia"},{"name":"University of Bari Aldo Moro"},{"name":"University of Salento"},{"name":"Istituti Tumori Giovanni Paolo II"}]},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Biological sample collection"},{"name":"Questionnaire"},{"name":"Medical examination"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00819741","briefTitle":"Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"repaglinide"},{"name":"metformin"},{"name":"repaglinide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04502212","briefTitle":"Pilot Study to Assess the Effects of Hepatic Ultrasound Insonification on Subjects With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"General Electric Research"},"collaborators":[{"name":"ProSciento, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hepatic Ultrasound Insonification"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03125694","briefTitle":"Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tehran University of Medical Sciences"}},"conditionsModule":{"conditions":["Uncontrolled Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin 100mg"},{"name":"Pioglitazone 30 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02643797","briefTitle":"Medical Assistant Health Coaching for Diabetes in Diverse Primary Care Settings"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Scripps Whittier Diabetes Institute"},"collaborators":[{"name":"San Diego State University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Medical Assistant Health Coaching"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03747978","briefTitle":"Short-term Effects of Perindopril-amlodipine Versus Perindopril-indapamide in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yaounde Central Hospital"},"collaborators":[{"name":"University of Yaounde 1"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Perindopril and Amlodipine"},{"name":"Perindopril-indapamide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00130481","briefTitle":"Pediatric Atorvastatin in Diabetes Intervention Trial (PADIT)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Florida"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Atorvastatin 20 mg daily for 3 months"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01073020","briefTitle":"Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Joslin Diabetes Center"},"collaborators":[{"name":"Brigham and Women's Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Allergan Adjustable Gastric Band Surgery"},{"name":"Intensive Medical Diabetes & Weight Management (Why WAIT) - Band Group"},{"name":"Roux-en-Y Gastric Bypass (RYGB) Surgery"},{"name":"Intensive Medical Diabetes & Weight Management (Why WAIT) - Bypass Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01805830","briefTitle":"Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Handok Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MP513"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04334213","briefTitle":"A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-501"},{"name":"D745, D150"},{"name":"CKD-501, D745, D150"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01486680","briefTitle":"Silastic Ring Gastric Bypass Versus Sleeve Gastrectomy for Type 2 Diabetes Mellitus in Obese Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"North Shore Hospital, New Zealand"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Laparoscopic Silastic Ring Roux-en-Y Gastric Bypass"},{"name":"Laparoscopic Sleeve gastrectomy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04304430","briefTitle":"Comparative Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Padova"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"DPP-4 inhibitor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00318461","briefTitle":"To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"metformin"},{"name":"glimepiride"},{"name":"placebo"},{"name":"placebo"},{"name":"liraglutide"},{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03959501","briefTitle":"Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Hong Kong"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Ketonemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin 10 mg"},{"name":"Sitagliptin 100mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01306214","briefTitle":"Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"Placebo"},{"name":"BI 10773"},{"name":"BI 10773"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04466618","briefTitle":"Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Adrian Vella"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Healthy","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saline"},{"name":"Exendin-9,39"},{"name":"Saline + Intralipid/Heparin"},{"name":"Exendin-9,39 + Intralipid/Heparin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00676741","briefTitle":"Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin aspart"},{"name":"biphasic insulin aspart 30"},{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01165684","briefTitle":"Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin aspart"},{"name":"insulin aspart"},{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00738023","briefTitle":"Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"},"collaborators":[{"name":"GlaxoSmithKline"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone"},{"name":"Normal saline 0.9%"},{"name":"Intralipid 20%"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01077570","briefTitle":"An Observational Study Investigating the Safety and Effectiveness of Repaglinide in Chinese Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"repaglinide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04208230","briefTitle":"Progression and Etiology of Cortical Porosity in Diabetic Bone Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Francisco"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"XtremeCT"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04192292","briefTitle":"Study of Sulphonylurea Synergy With DPP4 Inhibitors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Dundee"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sulfonylurea"},{"name":"DPP4 Inhibitor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05382533","briefTitle":"MoKaRi II Intervention Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Jena"}},"conditionsModule":{"conditions":["Decreased Cardovascular Risk","Decreased Risk of Diabetes Mellitus Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Menu plans"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04166032","briefTitle":"Validation Study for the Alertgy Non-invasive Continuous Glucose Monitor (ANICGM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Cleveland Clinic"},"collaborators":[{"name":"Alertgy"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alertgy non-invasive continuous glucose monitoring device (ANICGM)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00803660","briefTitle":"Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Hypertension","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01068197","briefTitle":"Low Glycemic Load Diets in Latino Children at Risk for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nazrat Mirza"},"collaborators":[{"name":"National Center for Research Resources (NCRR)"},{"name":"Consumer Health Foundation"},{"name":"Jessie Ball DuPont Foundation"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low Glycemic Load Diet versus Low Fat Diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04074603","briefTitle":"Comparing the Effects of Insulin Glargine on Blood Glucose Between Needle-free Jet Injection and Insulin Pen"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jian-hua Ma"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"The needle-free jet injector"},{"name":"Conventional insulin pen"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05044130","briefTitle":"Postprandial VLDL-triglyceride Metabolism in Type 2 Diabetes Patients With and Without NAFLD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"Danish Diabetes Academy"}]},"conditionsModule":{"conditions":["NAFLD","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High-fat mixed-meal tolerance test (HF-MMTT)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00339833","briefTitle":"The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Salsalate"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03769883","briefTitle":"Exercise Volume and Beta-cell Function in T2D The DOSE-EX Randomized Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mathias Ried-Larsen"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Type2 Diabetes","Diabetes Mellitus, Type 2","Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise and diet"},{"name":"Diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02316522","briefTitle":"Epigenetic Contribution to the Pathogenesis of Diabetic Nephropathy in Qatari Population"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Weill Medical College of Cornell University"},"collaborators":[{"name":"Hamad Medical Corporation"},{"name":"Weill Cornell Medical College in Qatar"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02729246","briefTitle":"Bariatric Surgery for the Treatment of Type 2 Diabetes - Clinical Effects and Underlying Mechanisms"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Uppsala University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Laparoscopic Gastric Bypass"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02713555","briefTitle":"Effect of Roux-en-Y Gastric Bypass or Gastric Sleeve Surgery on Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Roux-en-Y Gastric Bypass"},{"name":"Gastric Sleeve"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00437918","briefTitle":"The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Inje University"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"nateglinide"},{"name":"acarbose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03310944","briefTitle":"Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sotagliflozin (SAR439954)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01348568","briefTitle":"Low Glycemic Index Diet (With Canola Oil) for Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Toronto"},"collaborators":[{"name":"Canola Council of Canada"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"low glycemic index diet with canola oil bread"},{"name":"High fiber diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00240370","briefTitle":"A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristol-Myers Squibb"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Muraglitazar"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03466567","briefTitle":"A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"},{"name":"Probenecid"},{"name":"Ciclosporin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01538589","briefTitle":"Special Survey for Patients With Type 1 or Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05454059","briefTitle":"Salivary C1P and PGE2 Levels in Periodontitis Patients With T2DM and Effect of Non-Surgical Periodontal Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ondokuz Mayıs University"}},"conditionsModule":{"conditions":["Periodontitis","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Non-surgical periodontal treatment"},{"name":"ELISA Test"},{"name":"Periodontal Examination"},{"name":"Saliva Sample Collection"},{"name":"HbA1c Level"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06516328","briefTitle":"AGE/sRAGE Ratio in Diabetic Periodontitis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hacettepe University"}},"conditionsModule":{"conditions":["Periodontitis, Diabetes Mellitus Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Observational"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00696163","briefTitle":"Observational Study to Assess the Quality of Life and Clinical Outcomes in Subjects Using NovoMix® 30 for the Treatment of Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02672839","briefTitle":"A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ligand Pharmaceuticals"},"collaborators":[{"name":"Medpace, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LGD-6972 Solution"},{"name":"LGD-6972 Capsules"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01984372","briefTitle":"Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00742976","briefTitle":"Effects of Insulin Detemir and NPH Insulin on Renal Handling of Sodium, Fluid Retention, and Weight in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rigshospitalet, Denmark"}},"conditionsModule":{"conditions":["Diabetes Type 2","Weight Gain"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Detemir; Insulin Insulatard"},{"name":"Insulin Detemir, Insulin Insulatard"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01298518","briefTitle":"A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Type 2 Diabetes Patients"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-04620110"},{"name":"PF-04620110"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01542424","briefTitle":"An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"},{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01930136","briefTitle":"Effects of Caloric Restriction in Obesity and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mario Negri Institute for Pharmacological Research"},"collaborators":[{"name":"Istituto Superiore di Sanità"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Calorie restriction (25%)"},{"name":"Ad libitum health diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03292185","briefTitle":"A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/liraglutide"},{"name":"insulin degludec"},{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03288740","briefTitle":"A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide 0.5 mg"},{"name":"Placebo (semaglutide 0.5 mg)"},{"name":"Semaglutide 1.0 mg"},{"name":"Placebo (semaglutide 1.0 mg)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06225154","briefTitle":"Effect of Periodontal Treatment on Adipokine Levels"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Marmara University"},"collaborators":[{"name":"University of Turku"}]},"conditionsModule":{"conditions":["Periodontitis","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Non-surgical periodontal treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00979459","briefTitle":"A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK-1006 DFC"},{"name":"MK-1006 FCT"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03489031","briefTitle":"Basal Insulin And Compensation Glycemic In Diabetic Patients In Basal Bolus Outpatient."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Associazione Medici Endocrinologi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00254501","briefTitle":"Empowering Patients to Better Manage Diabetes Through Self-Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oregon State University"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type I or Type II Diabetes (Excludes Gestational Diabetes)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pharmacist Counseling"},{"name":"Educational materials"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01538511","briefTitle":"Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 70"},{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00101751","briefTitle":"INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"},{"name":"dietary regimen"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01865292","briefTitle":"Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02343471","briefTitle":"The Effect of Whey Protein Consumed as a Pre-meal on Postprandial Lipemia in Healthy and Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aarhus University Hospital"},"collaborators":[{"name":"University of Aarhus"},{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Healthy","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"20 g whey protein"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04344210","briefTitle":"Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Federal University of Rio Grande do Sul"}},"conditionsModule":{"conditions":["COVID","Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tele-interventions related to diabetes management and mental well-being"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03368807","briefTitle":"Assessment of Mealtime Bolus Insulin Behavior"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous Glucose Monitoring"},{"name":"Insulin Lispro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01293396","briefTitle":"Comparison of Premixed Insulins Aspart 30, Aspart 70 and Aspart on Postprandial Lipids"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Graz"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Aspart"},{"name":"Insulin Aspart 30"},{"name":"Insulin Aspart 70"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02388100","briefTitle":"The GRADE Capillary Blood Collection Pilot Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GRADE Study Group"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Capillary HbA1c collection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03479619","briefTitle":"Comparison of Three Lancing Devices Regarding Capillary Blood Volume and Lancing Pain Intensity."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HTL-Strefa S.A."},"collaborators":[{"name":"Medical University of Lodz"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lancing device A"},{"name":"Lancing device B"},{"name":"Lancing device C"},{"name":"28 G lancet"},{"name":"30 G lancet"},{"name":"33 G lancet"},{"name":"Lancing depth setting (1)"},{"name":"Lancing depth setting (5)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00641407","briefTitle":"Bedtime Insulins and Oral Antihyperglycemic Drugs in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Campania \"Luigi Vanvitelli\""}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Hypoglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NPL insulin"},{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01292018","briefTitle":"Management of Dyslipidemia in Adult Type 2 Diabetes Patients in India"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Dyslipidemia","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02883127","briefTitle":"Motivational Interviewing With Focus on Diet and Weight Gain in Pregnant Women With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rigshospitalet, Denmark"},"collaborators":[{"name":"Odense University Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Pregnancy"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Motivational interviewing"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04016415","briefTitle":"Decreasing Stress in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Milton S. Hershey Medical Center"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"National Institutes of Health (NIH)"},{"name":"Rowan University"},{"name":"West Chester University of Pennsylvania"},{"name":"Georgetown University"}]},"conditionsModule":{"conditions":["Stress","Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mindfulness Based Stress Reduction"},{"name":"Stress Management Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01461499","briefTitle":"Shiga Microalbuminuria Reduction Trial-2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shiga University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aliskiren"},{"name":"any angiotensin receptor blockers"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00655200","briefTitle":"Observational Study of Safety and Tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the Treatment of Type 1 and Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03361098","briefTitle":"DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Amsterdam UMC, location VUmc"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin 10mg"},{"name":"Exenatide"},{"name":"placebo exenatide"},{"name":"placebo dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04281069","briefTitle":"Diabetes Type 2 in the Eastern Region of Morocco"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universiteit Antwerpen"},"collaborators":[{"name":"Artesis Plantijn University College, Antwerp"},{"name":"Université Mohammed Premier, Oujda"},{"name":"Vliruos"}]},"conditionsModule":{"conditions":["Quality of Life","Diabetes Mellitus, Type 2","Adherence, Medication","Diet Habit"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02964247","briefTitle":"LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00478322","briefTitle":"Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Incyte Corporation"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"INCB013739"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01817569","briefTitle":"Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01054300","briefTitle":"Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Adult"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ertugliflozin 2 mg single dose"},{"name":"Ertugliflozin 2 mg split into twice daily"},{"name":"Ertugliflozin 4 mg single dose"},{"name":"Ertugliflozin 4 mg split into twice daily"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05535322","briefTitle":"Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ana Palanca"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLP-1RA"},{"name":"SGLT2i"},{"name":"Insulin"},{"name":"Miscellany"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01970319","briefTitle":"Mechanisms and Reversibility of Heart Failure Associated With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dr. Peter Swoboda"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05175677","briefTitle":"Study of the Impact of the COVID-19 Pandemic on the Management of Type 2 Diabetic Patients in a Sample in the Paris Region"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fondation Hôpital Saint-Joseph"}},"conditionsModule":{"conditions":["COVID-19","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02691481","briefTitle":"Diabetes-Specific Nutritional Formulas Versus Oatmeal"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Joslin Diabetes Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oatmeal breakfast"},{"name":"Glucerna formula"},{"name":"Ultra Glucose Control formula"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05131451","briefTitle":"ACCESS: AI for pediatriC diabetiC Eye examS Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johns Hopkins University"},"collaborators":[{"name":"National Eye Institute (NEI)"}]},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Point of Care Autonomous AI diabetic retinopathy exam"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05378282","briefTitle":"Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital Juarez de Mexico"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Type 2 Diabetes With Renal Manifestations"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00699790","briefTitle":"Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristol-Myers Squibb"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CCR2 Antagonist"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01498913","briefTitle":"Observational Study of NovoNorm® in Subjects With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"repaglinide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01666223","briefTitle":"Effect of Bile Acids on GLP-1 Secretion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Colesevelam"},{"name":"Chenodeoxycholic Acid"},{"name":"saline"},{"name":"Colesevelam 3750 mg + chenodeoxycholic acid 1250 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03120299","briefTitle":"The Effect of Omega-3 FA on Hypertriglyceridemia in Patients With T2DM(OCEAN)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Jiao Tong University School of Medicine"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Hypertriglyceridemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omega-3 fatty acid"},{"name":"Placebos"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02322268","briefTitle":"RCT Evaluating Effects of Cosmos Caudatus (Ulam Raja) in T2DM Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universiti Putra Malaysia"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cosmos Caudatus"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02845219","briefTitle":"A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"SNAC"},{"name":"Microgynon®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01687582","briefTitle":"Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Psoriasis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLP-1 analog"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02353975","briefTitle":"Effect of a High-fat Meal on the Pharmacokinetics of SHR3824 and Mass Balance Study in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jiangsu HengRui Medicine Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SHR3824"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00484419","briefTitle":"Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Hyperlipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Colesevelam HCl"},{"name":"rosiglitazone maleate"},{"name":"sitagliptin phosphate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01607450","briefTitle":"Modulation of Human Myocardial Metabolism by GLP-1 Dose Response"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Indiana University"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLP-1 Low Dose"},{"name":"GLP-1 Mid-Range Dose"},{"name":"GLP-1 High Dose"},{"name":"Saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01719003","briefTitle":"Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin 500 mg bid"},{"name":"Metformin 1000 mg bid"},{"name":"Empagliflozin low dose qd"},{"name":"Empagliflozin high dose qd"},{"name":"Empagliflozin low dose bid"},{"name":"Metformin 500 mg bid"},{"name":"Empagliflozin high dose bid"},{"name":"Empagliflozin low dose bid"},{"name":"Metformin 1000 mg bid"},{"name":"Metformin 500 mg bid"},{"name":"Metformin 1000 mg bid"},{"name":"Empagliflozin high dose bid"},{"name":"Metformin 1000 mg bid"},{"name":"Empagliflozin high dose bid"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00417924","briefTitle":"Eye on Diabetes: A Multidisciplinary Patient Education Intervention"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nova Southeastern University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Patient education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03118336","briefTitle":"Impact of Empaglifozine on Cardiac Ectopic Fat"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Assistance Publique Hopitaux De Marseille"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin 10Mg Tab"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01158625","briefTitle":"Nighttime Dosing of Antihypertensive Drugs in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"Regionshospitalet Silkeborg"},{"name":"The Ministry of Science, Technology and Innovation, Denmark"},{"name":"Central Denmark Region"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Change of time of administration"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02608853","briefTitle":"Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03050619","briefTitle":"Characteristics of Empagliflozin Initiators"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Other SGLT2 inhibitors"},{"name":"Other non-insulin GLDs"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06135532","briefTitle":"Chemerin, Fetuin-A, IL-34 and IL-13 Levels in Diabetic Periodontitis Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Marmara University"}},"conditionsModule":{"conditions":["Periodontitis","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Non-Surgical Periodontal Treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03558867","briefTitle":"Personalised Medicine in Pre-diabetes and Early Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Garvan Institute of Medical Research"},"collaborators":[{"name":"Weizmann Institute of Science"}]},"conditionsModule":{"conditions":["Pre Diabetes","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin + Healthy diet"},{"name":"Metformin + Personalized diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01610219","briefTitle":"Lifestyle Modification for Type 2 Diabetes Prevention in Overweight Youth"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pennsylvania"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle Modification for Type 2 Diabetes Prevention"},{"name":"Nutrition and Physical Activity"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00671008","briefTitle":"Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"},{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00212303","briefTitle":"Exercise Training in Type 2 Diabetes and Hypertension"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise training for 6 months"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02360878","briefTitle":"The Endocrine Impact of the Duodenal-jejunal Bypass Sleeve on Type 2 Diabetes - Potential Role of the Incretin Hormones"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Filip Krag Knop"},"collaborators":[{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EndoBarrier Gastrointestinal Liner"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00700765","briefTitle":"Observational Study to Evaluate Safety of Levemir® in Type 1 and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02103595","briefTitle":"A Study Evaluating the Perception of Insertion Pain With Accu-Chek FlexLink and FlexLink Plus Insulin Pump Devices Under Real Life Conditions in Diabetic Patients."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"},"collaborators":[{"name":"Roche Diagnostics GmbH"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2, Diabetes Mellitus Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Accu-Chek FlexLink"},{"name":"Accu-Chek FlexLink Plus"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02248857","briefTitle":"Promoting the Universal Medication Schedule Via Mobile and EHR Technologies"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Northwestern University"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"UMS Strategy"},{"name":"SMS Texting Reminders"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00149331","briefTitle":"The Effects of Two Education Strategies About Insulin on Patient Preferences and Perceptions About Insulin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hamilton Health Sciences Corporation"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Structured education program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01179048","briefTitle":"Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02913703","briefTitle":"Preprandial Ghrelin Effect"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jenny Tong, MD, MPH"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ghrelin"},{"name":"Saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01464346","briefTitle":"A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medtronic Diabetes"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Enlite Sensor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06305351","briefTitle":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kallyope Inc."}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"K-757 and K-833 QD"},{"name":"K-757 and K-833 BID"},{"name":"Matching placebo to K-757 and K-833 QD"},{"name":"Matching placebo to K-757 and K-833 BID"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04081766","briefTitle":"Pharmacist-Led Study in Controlling Hypoglycemia in Older Adults With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Lincoln"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2 With Hypoglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SUGAR Handshake"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00655044","briefTitle":"Evaluation of Levemir® for the Treatment of Type 1 and 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02520050","briefTitle":"The Effect of 3 Different Models of MNT on DM Control in Overweight Patients With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Joslin Diabetes Center"},"collaborators":[{"name":"Metagenics, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Traditional MNT"},{"name":"Structured MNT"},{"name":"Structured MNT plus Weekly Support"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06176443","briefTitle":"Impact of an Increased Restrictive Factor of One Anastomosis Gastric Bypass on Metabolic Outcomes Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Society of Bariatric and Metabolic Surgeons of Kazakhstan"}},"conditionsModule":{"conditions":["Obesity, Morbid","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"One anastomosis gastric bypass with combined fundoplication"},{"name":"One anastomosis gastric bypass without combined fundoplication"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01231984","briefTitle":"Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Becton, Dickinson and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"4 mm x 32G Pen Needle"},{"name":"8mm x 31G Pen Needle"},{"name":"12.7mm x 29G Pen Needle"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02264951","briefTitle":"Fat-induced Release of GLP-1 in Humans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Glostrup University Hospital, Copenhagen"},"collaborators":[{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tributyrin"},{"name":"C8-diet oil"},{"name":"Olive oil"},{"name":"Carrot"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01564550","briefTitle":"The Effect of Type 2 Diabetes and Dietary Regulation on VLDL1-and VLDL2-triglyceride Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Dyslipidemia"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin"},{"name":"insulin"},{"name":"diet"},{"name":"no diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03091920","briefTitle":"Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cyclerion Therapeutics"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IW-1973"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01002807","briefTitle":"Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Metformin XR"},{"name":"Glucophage"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02815787","briefTitle":"The Drug -Drug Interaction of SP2086 and Glyburide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jiangsu HengRui Medicine Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SP2086"},{"name":"Glyburide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02815748","briefTitle":"The Metabolite Identification and Material Balance Study of SP2086"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jiangsu HengRui Medicine Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SP2086"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02815722","briefTitle":"The Drug-drug Interaction of SP2086 and Simvastatin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jiangsu HengRui Medicine Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SP2086"},{"name":"Simvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02815657","briefTitle":"The Drug-drug Interaction of SP2086 and Valsartan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jiangsu HengRui Medicine Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SP2086"},{"name":"Valsartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02813863","briefTitle":"The Drug-drug Interaction of SP2086 and Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jiangsu HengRui Medicine Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SP2086"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02811289","briefTitle":"Pharmacological Activation of Brown Adipose Tissue Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Université de Sherbrooke"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mirbetriq (Mirabegron)"},{"name":"cold exposure"},{"name":"injection of 18FDG"},{"name":"injection of 11C-acetate"},{"name":"[3-3H]-glucose"},{"name":"[U-13C]-palmitate"},{"name":"2H-Glycerol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04591015","briefTitle":"Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Scripps Whittier Diabetes Institute"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Covid19"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hospital: DD-CA"},{"name":"Hospital: Usual Care (UC)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02792400","briefTitle":"The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2403021"},{"name":"LY2403021 placebo"},{"name":"Standardised liquid meal"},{"name":"Linagliptin"},{"name":"Linagliptin placebo"},{"name":"Empagliflozin"},{"name":"Empagliflozin placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02321878","briefTitle":"Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02765399","briefTitle":"The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Helsinki University Central Hospital"},"collaborators":[{"name":"Göteborg University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03659461","briefTitle":"Glucagon-like Peptide-1 Levels, Insulin Resistance and Insulin Sensitivity Index in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National University of Malaysia"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","PreDiabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02753803","briefTitle":"Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dong-A ST Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Evogliptin, Pioglitazone, Evogliptin+Pioglitazone"},{"name":"Pioglitazone, Evogliptin, Evogliptin+Pioglitazone"},{"name":"Evogliptin, Evogliptin+Pioglitazone, Pioglitazone"},{"name":"Pioglitazone, Evogliptin+Pioglitazone, Evogliptin"},{"name":"Evogliptin+Pioglitazone, Evogliptin, Pioglitazone"},{"name":"Evogliptin+Pioglitazone, Pioglitazone, Evogliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03531905","briefTitle":"Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Esperion Therapeutics, Inc."}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Cholesterolemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bempedoic acid + Ezetimibe FDC Oral Tablet"},{"name":"Ezetimibe 10 mg Oral Tablet"},{"name":"Placebo Oral Tablet"},{"name":"Placebo oral capsule"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02749032","briefTitle":"Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) Secretion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Michael A. Nauck"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mixed meal test"},{"name":"Vildagliptin"},{"name":"Sitagliptin"},{"name":"Placebo"},{"name":"Metformin"},{"name":"Diet and exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01508858","briefTitle":"Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal Women"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"placebo"},{"name":"levonorgestrel / ethinylestradiol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01516255","briefTitle":"Effect of Liraglutide on Heart Frequency in Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"placebo"},{"name":"moxifloxacin"},{"name":"placebo"},{"name":"electrocardiogram (ECG)"},{"name":"electrocardiogram (ECG)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06124547","briefTitle":"Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Galenicum Health"}},"conditionsModule":{"conditions":["Bioequivalence","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06124495","briefTitle":"Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Galenicum Health"}},"conditionsModule":{"conditions":["Bioequivalence","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01740778","briefTitle":"Lancing Device Comparison Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Facet Technologies"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06124573","briefTitle":"Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Galenicum Health"}},"conditionsModule":{"conditions":["Bioequivalence","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02190669","briefTitle":"Exercise and Diabetes - an Observational Study of Exercise and Blood Glucose Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sansum Diabetes Research Institute"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06124560","briefTitle":"Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Galenicum Health"}},"conditionsModule":{"conditions":["Bioequivalence","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01267448","briefTitle":"Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cook County Health"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glipizide XL"},{"name":"Saxagliptin + Metformin XR"},{"name":"Metformin XR"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00398060","briefTitle":"GOAL Life-Style Change Intervention to Prevent Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Finnish Institute for Health and Welfare"},"collaborators":[{"name":"Academy of Finland"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cognitive-behavioral life-style counseling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01901952","briefTitle":"Lifestyle Improvement Through Food and Exercise (LIFE)Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rush University Medical Center"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"Cook County Health"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intensive education and lifestyle support"},{"name":"Standard of Care control group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01415115","briefTitle":"Using SCOUT Noninvasive AGE Measurements to Forecast Diabetes Complications"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VeraLight, Inc."},"collaborators":[{"name":"Medstar Health Research Institute"}]},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01892319","briefTitle":"An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"other injectable antidiabetic treatment regimens"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00709683","briefTitle":"Observational Study to Evaluate the Safety of NovoMix® 30 FlexPen®"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02473081","briefTitle":"Minimal Psychological Intervention in Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Cheng-Kung University Hospital"},"collaborators":[{"name":"National Science Council, Taiwan"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Depression"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Minimal psychological intervention"},{"name":"Usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00921882","briefTitle":"Is it Possible to Screen for Type 2 Diabetes at Day 2 in Gestational Diabetes Mellitus Patients Postpartum?"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Université de Sherbrooke"}},"conditionsModule":{"conditions":["Gestational Diabetes Mellitus","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral glucose tolerance test"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06034548","briefTitle":"Diabetes and Hypertension Self Management Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"West Virginia University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"diabetes and hypertension self-management"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02553408","briefTitle":"Patients and Care Providers Perspectives and Experience With Decision Aid Tool for Self-monitoring of Blood Glucose"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lawson Health Research Institute"},"collaborators":[{"name":"Abbott"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FreeStyle Precision Neo-Meter"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01150292","briefTitle":"Effects of Docosahexaenoic Acid (DHA) on Cardiovascular Disease on Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospices Civils de Lyon"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"First period DHA"},{"name":"Second period DHA"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01159184","briefTitle":"Stressors, Coping Methods and Social Support in Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Far Eastern Memorial Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01112696","briefTitle":"An Inpatient Performance Evaluation of a New Subcutaneous Glucose Sensor"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medtronic Diabetes"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sensor wear"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01967992","briefTitle":"Examining the Effects of Diet on Health With an Online Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Francisco"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Behavioral: Low Carbohydrate, Ketogenic Diet"},{"name":"American Diabetes Association Diet"},{"name":"Mindfulness and Positive Affect Skills"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00141492","briefTitle":"Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Solvay Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Hypogonadism"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Androgel (testosterone gel)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02283411","briefTitle":"Effectiveness and Safety Study of the Abbott Sensor Based Glucose Monitoring Systems"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Diabetes Care"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Abbott Sensor Based Glucose Monitoring System"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06063109","briefTitle":"A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"THPharm Corp."}},"conditionsModule":{"conditions":["Hypertension","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"THP-00101 (Dapagliflozin) 10mg"},{"name":"THP-00102 (Telmisartan) 80mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00634673","briefTitle":"Postprandial Fatty Acids and FABP2 in Type 2 Diabetes Mellitus (DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital de Clinicas de Porto Alegre"}},"conditionsModule":{"conditions":["Dyslipidemia","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sandwich"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01942694","briefTitle":"Vitamin D and Type 2 Diabetes Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tufts Medical Center"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"Office of Dietary Supplements (ODS)"},{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Prediabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin D (Cholecalciferol)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02459834","briefTitle":"The Fructose and Allulose Catalytic Effects (FACE) Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Toronto"},"collaborators":[{"name":"Tate & Lyle"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Allulose"},{"name":"Fructose"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00631774","briefTitle":"A Study to Evaluate the Postprandial Metabolic Response After Use of Glucerna SR in Obese Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Taipei Veterans General Hospital, Taiwan"},"collaborators":[{"name":"Abbott"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glucerna SR"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05992545","briefTitle":"Mobile Application for Integrative Diabetes Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Korea University Anam Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Depression"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mobile application 'DangDang Care' under usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02433678","briefTitle":"An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University at Buffalo"},"collaborators":[{"name":"Kaleida Health"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"dapagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00362193","briefTitle":"Glycemic Relapse Prevention: Maintenance Dose Assessment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},"collaborators":[{"name":"Vanderbilt University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Telephonic diabetes care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01607294","briefTitle":"A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Esperion Therapeutics, Inc."}},"conditionsModule":{"conditions":["Hyperlipidemia","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ETC-1002"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01729156","briefTitle":"Effects of Metformin on Hepatic FFA Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lars Christian Gormsen"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03074630","briefTitle":"Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Amsterdam UMC, location VUmc"},"collaborators":[{"name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypercholesterolemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Rosuvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02354027","briefTitle":"The Drug-drug Interaction of SHR3824 and Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jiangsu HengRui Medicine Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SHR3824 metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00653302","briefTitle":"Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lantus (insulin glargine) + Glucophage (Metformin)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01890993","briefTitle":"Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01409239","briefTitle":"Effect of Glycemic Variability on Autonomic Tone in Hospitalized Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kathleen Dungan"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Inpatient"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intravenous insulin"},{"name":"Subcutaneous Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02325960","briefTitle":"A Comparison of Exenatide and Insulin Glargine"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00722241","briefTitle":"Effectiveness and Safety Study of the Next-Generation DexCom™ SEVEN® Continuous Glucose Monitoring System"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"DexCom, Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02320344","briefTitle":"Partnerships to Improve Lifestyle Interventions (PILI) 'Ohana Dissemination Project Partners in Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Hawaii"},"collaborators":[{"name":"Kula No Na Po'e Hawaii"},{"name":"Ke Ola Mamo"},{"name":"Hawai'i Maoli"},{"name":"Kokua Kalihi Valley"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Partners in Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02285985","briefTitle":"Effects of Saxagliptin on Adipose Tissue Inflammation in Humans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Phoenix VA Health Care System"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02815943","briefTitle":"Postprandial Metabolism After Bariatric Surgery in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Université de Sherbrooke"},"collaborators":[{"name":"Laval University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Obese"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biliopancreatic diversion with duodenal switch"},{"name":"sleeve gastrectomy"},{"name":"liquid meal"},{"name":"PET/scan"},{"name":"[7,7,8,8-2H]-palmitate"},{"name":"indirect calorimetry"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02153879","briefTitle":"Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institut Investigacio Sanitaria Pere Virgili"},"collaborators":[{"name":"Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fenofibrate"},{"name":"Niacin plus laropiprant"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01809184","briefTitle":"A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin 287"},{"name":"insulin glargine"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02655757","briefTitle":"Effect of Sitagliptin on Progression of Coronary Intermediate Lesion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Li Bo"}},"conditionsModule":{"conditions":["Atherosclerosis","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02501343","briefTitle":"Alkaline Diet for Insulin Sensitivity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Garvan Institute of Medical Research"}},"conditionsModule":{"conditions":["Dysglycemia","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sodium Bicarbonate Oral Capsule"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00613782","briefTitle":"Reandron in Diabetic Men Witn Low Testosterone Level"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Austin Health"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Hypogonadism"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Reandron 1000"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02235584","briefTitle":"Insulinotropic Effect of GLP-1 and GIP After Dexamethasone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hvidovre University Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dexamethasone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02198989","briefTitle":"Effects of Peer Support and Yoga Music on T2DM With Depression and Sleep Disorders"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Guang Ning"},"collaborators":[{"name":"Ruijin Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"peer support and yoga music therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02906579","briefTitle":"A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cyclerion Therapeutics"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Matching Placebo"},{"name":"IW-1973"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00738153","briefTitle":"An Observational Study on Efficacy and Safety in Subjects Using Levemir® for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02211651","briefTitle":"Maternal Adipose Tissue and Placental Dysfunction Programs the Fetus for Type 2 Diabetes (PlacentA-DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AdventHealth Translational Research Institute"},"collaborators":[{"name":"Sanford-Burnham Medical Research Institute"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00879710","briefTitle":"Effect of Diabetes Mellitus on Cholesterol Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical College of Wisconsin"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus","Hypercholesterolemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"simvastatin or ezetimibe"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00432809","briefTitle":"Advanced Medical Therapy Versus Advanced Medical Therapy Plus Bariatric Surgery for the Resolution of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Cleveland Clinic"},"collaborators":[{"name":"Ethicon Endo-Surgery"},{"name":"LifeScan"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gastric bypass"},{"name":"Sleeve Gastrectomy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00745433","briefTitle":"Switch From Metformin Monotherapy to a Bitherapy With Metformin and Repaglinide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"repaglinide"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00945165","briefTitle":"Exercise and Glycemic Control in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"},"collaborators":[{"name":"ZonMw: The Netherlands Organisation for Health Research and Development"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise intervention"},{"name":"No exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02958956","briefTitle":"Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2, Cancer"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01620463","briefTitle":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01852136","briefTitle":"Clinical Evaluation of BD NEXT Pen Needle"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Becton, Dickinson and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BD NEXT 31G x 5 mm pen needle"},{"name":"BD NEXT 31G x 8mm pen needle"},{"name":"BD NEXT 32G x 4mm pen needle"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02061124","briefTitle":"Effect of Bile Acid Sequestration on Postprandial GLP-1 Secretion, Glucose Homeostasis and Gut Microbiota"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sevelamer 1600 mg TID for 7 days"},{"name":"Placebo 1600 mg TID for 7 days"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00374270","briefTitle":"Improving Blood Pressure Management in Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alberta"},"collaborators":[{"name":"Canadian Diabetes Association"},{"name":"Heart and Stroke Foundation of Canada"},{"name":"College and Association of Registered Nurses of Alberta"},{"name":"Alberta Health & Wellness"},{"name":"Medicine Shoppe of Canada"},{"name":"Canadian Council of Cardiovascular Nurses"},{"name":"MED Institute, Incorporated"},{"name":"Capital Health, Canada"},{"name":"Alberta Heritage Foundation for Medical Research"},{"name":"Alberta Medical Association"},{"name":"Merck Frosst Canada Ltd."}]},"conditionsModule":{"conditions":["Hypertension","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle Counselling; Opinion Leader Influence Statements"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01232946","briefTitle":"Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Indiana University"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"insulin detemir"},{"name":"liraglutide plus insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02050074","briefTitle":"The Role of Metformin and Colesevelam in Human GLP-1 Secretion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Colesevelam"},{"name":"Metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06088615","briefTitle":"Feasibility of Non-invasive Glucose Monitoring by Using Photothermal Deflectometry"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diamontech AG"},"collaborators":[{"name":"Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Diabetes Mellitus Type 1","Healthy"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01585506","briefTitle":"Psychosocial Factors Related to Compliance With Treatment With Biphasic Insulin Analogues"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"},{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01820377","briefTitle":"The Aboriginal Youth Mentorship Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Manitoba"},"collaborators":[{"name":"Manitoba Institute of Child Health"},{"name":"The Lawson Foundation"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aboriginal Youth Mentorship Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00946504","briefTitle":"To Demonstrate the Relative Bioequivalency Comparing Geneva's 10 mg Glipizide Tablets To Roerig's 10 mg Glucotrol Tablets"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sandoz"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)"},{"name":"Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00729196","briefTitle":"A Trial of Two Diets for Weight and Diabetes Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},"collaborators":[{"name":"University of Pennsylvania"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle Modification"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01536626","briefTitle":"Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01515592","briefTitle":"Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"liraglutide"},{"name":"liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01089205","briefTitle":"Bioequivalence Study of Metformin Hydrochloride Extended Release 750 mg Tablets Versus Glucophage XR® 750 mg Tablet in Healthy Volunteers Under Fed Conditions."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Torrent Pharmaceuticals Limited"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01089192","briefTitle":"Bioequivalence Study of Metformin Hydrochloride Extended Release 750 mg Tablets Versus Glucophage XR® 750 mg Tablet in Healthy Volunteers Under Fasting Conditions."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Torrent Pharmaceuticals Limited"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01089179","briefTitle":"Bioequivalence Study of Metformin Hydrochloride Extended Release 500 mg Tablet Versus Glucophage XR® 500 mg Tablet in Healthy Volunteers Under Fed Conditions"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Torrent Pharmaceuticals Limited"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01961024","briefTitle":"Postprandial VLDL-TG Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01508806","briefTitle":"Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01507389","briefTitle":"Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01702012","briefTitle":"Almased Multi-Center Diabetes Intervention Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Wake Forest University Health Sciences"},"collaborators":[{"name":"University of Freiburg"},{"name":"University of Campinas, Brazil"},{"name":"London Metropolitan University"},{"name":"University of Mysore"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Almased Meal Replacement Powder"},{"name":"Group-Based Lifestyle Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01490658","briefTitle":"Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"repaglinide"},{"name":"metformin"},{"name":"repaglinide and metformin combination tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01489644","briefTitle":"Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"repaglinide"},{"name":"metformin"},{"name":"repaglinide and metformin combination tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04020822","briefTitle":"Feasibility Study of New Subcutaneous Glucose Sensor With Recording Devices"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medtronic Diabetes"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Guardian Sensor (3)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01921881","briefTitle":"Does the Natural Medicinal Plant St John's Wort Affect the Glucose Tolerance in Healthy Individuals"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Southern Denmark"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"St John's wort"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00675493","briefTitle":"Observational Study of Type 1 and Type 2 Diabetes Patients Having Switched From Human Premixes to NovoMix®30"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00961857","briefTitle":"A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin phosphate (+) metformin hydrochloride"},{"name":"Comparator: metformin 500 mg"},{"name":"Comparator: sitagliptin"},{"name":"Comparator: FMI sitagliptin/metformin 50 mg/500 mg FDC tablet"},{"name":"Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet"},{"name":"Comparator: metformin 1000 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00915954","briefTitle":"Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cedars-Sinai Medical Center"}},"conditionsModule":{"conditions":["Acromegaly","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral Glucose Tolerance Test"},{"name":"Subcutaneous administration of recombinant human IGF-1"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01869621","briefTitle":"Study of Metformin Pharmacogenetics in Twins"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Southern Denmark"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01866462","briefTitle":"Pilot Study of the Effect of MN-504 Cobiotic Formulation on the Efficacy and Tolerability of Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NuMe Health"},"collaborators":[{"name":"Pennington Biomedical Research Center"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NM504"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00728143","briefTitle":"Blood Glucose Response to Highly Viscous Polysaccharide Enriched Biscuits in Healthy and Diabetic Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Unity Health Toronto"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Highly viscous polysaccharide enriched biscuits"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01812590","briefTitle":"Acute Exercise and Pancreatic Endocrine Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rigshospitalet, Denmark"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01512654","briefTitle":"Personalized Glucose Predictive and Therapy Advisory System - DIAdvisor 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Montpellier"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)"},{"name":"Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01169090","briefTitle":"A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kowa Research Institute, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SK-0403"},{"name":"Placebo"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00142922","briefTitle":"Breaking Down Barriers to Diabetes Self-Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Breaking Down Barriers"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00741390","briefTitle":"Evaluation of Blood Volume and Perceived Pain During Fingerstick Monitoring of Blood Glucose"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Becton, Dickinson and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BD/33G"},{"name":"OTM / 33G"},{"name":"OTU/28G"},{"name":"ACC/28G"},{"name":"OTM/28G"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00953498","briefTitle":"Influence of Glitazones on the Vasodilatory Effect of High-density Lipoprotein (HDL) Lipoproteins"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire Dijon"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pioglitazone"},{"name":"rosiglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01771445","briefTitle":"Role of Interleukin-1 in the Regulation of Muscle Derived Interleukin-6 During Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Marc Y.Donath"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IL-1Ra"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00895986","briefTitle":"Using Conversation Maps to Reinforce Self-Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Joslin Diabetes Center"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Conversation Maps Diabetes Education"},{"name":"Heart Healthy Living Diabetes Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04806685","briefTitle":"Diabetes Education and A1c Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Michigan State University"},"collaborators":[{"name":"Blue Cross Blue Shield Foundation of Michigan"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Sleep"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sleep education"},{"name":"Diet only"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01089569","briefTitle":"Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HealthPartners Institute"},"collaborators":[{"name":"International Diabetes Center at Park Nicollet"},{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide"},{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01747083","briefTitle":"Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LG Life Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02176681","briefTitle":"A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Strasbourg, France"},"collaborators":[{"name":"Novartis"}]},"conditionsModule":{"conditions":["Haemodialyzed, Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin (Galvus)"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05969015","briefTitle":"Intensive Self-care on Glycemic Control in Outpatients With Type 2 Diabetes Mellitus: The Diabetes Care (D-CARE) Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude"},"collaborators":[{"name":"Prefeitura Municipal de Criciúma"},{"name":"Conselho Nacional de Desenvolvimento Científico e Tecnológico"},{"name":"Departamento de Promoção da Saúde (DEPROS), Secretaria de Atenção Primária à Saúde (SAPS)"},{"name":"Hospital Universitário São José"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Cardiovascular Diseases","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Prochaska and DiClemente transtheorical model"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01043445","briefTitle":"-Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1 Release in Humans."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Glostrup University Hospital, Copenhagen"},"collaborators":[{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GPR 119 agonist, 2-oleyl glycerol"},{"name":"Oleic acid"},{"name":"Vehicle"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01098253","briefTitle":"Integrating Depression Services Into DM Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pennsylvania"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Depression"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Adherence Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00928057","briefTitle":"Comparison of Glycemic Control Among Diabetics Using Three Different Pen Needles"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Becton, Dickinson and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"4mm x 32G pen needle"},{"name":"8mm x 31G pen needle"},{"name":"5mm x 31G pen needle"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01460446","briefTitle":"ACCU-CHEK® Aviva Expert Study: Does Use of a Bolus Advisor Improve Glycemic Control in Patients Not Achieving Optimal Control Using Multiple Daily Injections (MDI)?"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aviva Expert blood glucose meter"},{"name":"Aviva Nano blood glucose meter"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01625507","briefTitle":"The Alberta Diet: Effectiveness Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alberta"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PANDA intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01610518","briefTitle":"The Glycemic Response Elicited by Beta-glucans of Different Physical Properties and Form"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Guelph Food Research Centre"},"collaborators":[{"name":"University of Toronto"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"oat beta-glucan"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00950898","briefTitle":"The Acute Effects of Coffee on Glucose Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Brooklyn College of the City University of New York"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"decaff"},{"name":"caffcoff"},{"name":"caffeine"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01607944","briefTitle":"Incretins and Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rigshospitalet, Denmark"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01127308","briefTitle":"A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ertugliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04120974","briefTitle":"The Role of Proper Insulin Injection Technique in the Treatment of Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Becton, Dickinson and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1","Lipohypertrophy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Optimal insulin injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02299388","briefTitle":"To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tulane University School of Medicine"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent","Hypertensive Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide or Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00665093","briefTitle":"Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"},{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00688974","briefTitle":"Longitudinal Cohort Study Comparing 2 Surgical Techniques in Patients With Class 3 Obesity and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Lille"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Roux-en-Y gastric bypass"},{"name":"Adjustable gastric band"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01542775","briefTitle":"Effects of Exercise on sRAGE Levels and Cardiometabolic Risk Factors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Korea University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aerobic Exercise Group"},{"name":"Control Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05951140","briefTitle":"Personalised Nutrition for Healthy Living"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Prof. Dr. med. Andreas F. H. Pfeiffer"},"collaborators":[{"name":"European Union"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","PreDiabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Usage of the PROTEIN-Application"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04746781","briefTitle":"The Effect of 360 Video and MAPS on Enrollment in the DPP"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Utah"},"collaborators":[{"name":"Centers for Disease Control and Prevention"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","PreDiabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mobile 360° Video intervention"},{"name":"Motivation and Problem Solving (MAPS)"},{"name":"Risk notification/education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00961480","briefTitle":"A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin phosphate (+) metformin hydrochloride"},{"name":"Comparator: metformin 500mg"},{"name":"Comparator: sitagliptin"},{"name":"Comparator: FMI sitagliptin / metformin 50 mg/500 mg FDC tablet"},{"name":"Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet"},{"name":"Comparator: FMI sitagliptin/metformin 50 mg/850 mg FDC tablet"},{"name":"Comparator: metformin 1000 mg"},{"name":"Comparator: metformin 850 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01524705","briefTitle":"FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Washington"},"collaborators":[{"name":"Eli Lilly and Company"},{"name":"Sanofi"},{"name":"Astra Zeneca, Bristol-Myers Squibb"},{"name":"DexCom, Inc."},{"name":"Bayer"},{"name":"Becton, Dickinson and Company"},{"name":"Medicomp"},{"name":"University of Texas"},{"name":"US Department of Veterans Affairs"},{"name":"Biomedical Research Institute of New Mexico"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine"},{"name":"Metformin"},{"name":"Prandial insulin"},{"name":"Exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05919667","briefTitle":"Dairy and Non-Dairy Alternatives Comparative on Metabolic Outcomes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Toronto"}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dairy and plant-based dairy beverages and solids"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03228706","briefTitle":"Effectiveness of an Intervention in Improving Medication Adherence Among Malay Patients With Underlying Type 2 Diabetes Mellitus in Malaysia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Clinical Research Centre, Malaysia"},"collaborators":[{"name":"University Malaysia Sarawak"}]},"conditionsModule":{"conditions":["Medication Adherence","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Know Your Medicine - Take It For Health (KYM-TIFH)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01494935","briefTitle":"\"Effect of High Fat and High Glycemic Diets"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High Glycemic Diet"},{"name":"Control diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00274118","briefTitle":"DETAIL Study: Diabetes Exposed to Telmisartan and Enalapril"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Hypertension","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"telmisartan"},{"name":"enalapril"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00797888","briefTitle":"Bronx A1c: Bring it Down for Health"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Albert Einstein College of Medicine"},"collaborators":[{"name":"New York City Department of Health and Mental Hygiene"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"telephonic"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02481479","briefTitle":"Saxagliptin and Cardiac Structure and Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Unity Health Toronto"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent","Heart Failure"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Saxagliptin"},{"name":"saxagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05875259","briefTitle":"A Clinical Trial Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1019-1 and BR1019-2 in Healthy Adult Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boryung Pharmaceutical Co., Ltd"}},"conditionsModule":{"conditions":["Hypertension","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BR1019-1"},{"name":"BR1019-2"},{"name":"BR1019-1 + BR1019-2"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01507285","briefTitle":"Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04784130","briefTitle":"Enhancing Diabetes and Hypertension Self-Management Rural Appalachian Patients In Patient-Centered Medical Homes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"West Virginia University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physical Activity"},{"name":"Medication Adherence"},{"name":"Dietary Modification"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03414892","briefTitle":"Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yabao Pharmaceutical Group"}},"conditionsModule":{"conditions":["Hyperglycaemia (Diabetic)","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Globalagliatin Hydrochloride"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00784511","briefTitle":"Vitamin D, Glucose Control and Insulin Sensitivity in African-Americans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tufts University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"cholecalciferol"},{"name":"microcrystalline cellulose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02871882","briefTitle":"Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"},"collaborators":[{"name":"Satiogen Pharmaceuticals, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obese","Overweight"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gastric Emptying test"},{"name":"Mixed Oral Glucose Tolerance test"},{"name":"Conjugated bile acids sodium"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01335763","briefTitle":"Pharmacist Intervention for Glycemic Control in The Community"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alberta"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01360567","briefTitle":"The Effect of Green Tea Extract on Type 2 Diabetes With Hyperlipidemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Taipei City Hospital"},"collaborators":[{"name":"National Yang Ming Chiao Tung University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Hyperlipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Green tea extract"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03109951","briefTitle":"Abnormal Blood Sugar Tests in Diabetic Patients During Colonoscopy Preparation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Catholic Kwandong University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Colonoscopy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Colonoscopy preparation using polyethylene glycol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02664233","briefTitle":"Connecting Smartphones With Electronic Health Record to Facilitate Behavioral Goal Monitoring in Diabetes Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center, Houston"},"collaborators":[{"name":"University of Pittsburgh"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mobile and connected health"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01028404","briefTitle":"A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NN1952"},{"name":"insulin aspart"},{"name":"placebo"},{"name":"NN1952"},{"name":"insulin aspart"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01094899","briefTitle":"Abnormal Structure and Bone Density in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institut National de la Santé Et de la Recherche Médicale, France"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Radiography"},{"name":"Urine and Blood sampling"},{"name":"Echography"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00813020","briefTitle":"A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"semaglutide"},{"name":"semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03815955","briefTitle":"Reducing Sedentary Behaviour in Patients With Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Western University, Canada"},"collaborators":[{"name":"St. Joseph's Health Care London"}]},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Sedentary Lifestyle"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Non-Sedentary Behaviour Modelling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01487408","briefTitle":"Special Survey for Type 1 or Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00859079","briefTitle":"Efficacy of GLP-1 Infusion in Comparison to an Insulin Infusion Protocol to Reach Normoglycemia Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Graz"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLP-1"},{"name":"Human regular insulin intravenously"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01222429","briefTitle":"Practice Based Nutrition Intervention"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Physicians Committee for Responsible Medicine"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vegan diet"},{"name":"diet following ADA guidelines"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01213940","briefTitle":"Vascular Endothelium Changes After Bariatric Surgery (Endothelial Progenitor Cells)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of South Alabama"},"collaborators":[{"name":"American Society for Metabolic and Bariatric Surgery"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pre-bariatric weight loss program"},{"name":"bariatric surgery"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00254124","briefTitle":"Use of a Portion Control Food Tool to Induce Weight Loss in Obese Type 2 Diabetics."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Calgary"},"collaborators":[{"name":"Stewart Diabetes Education Fund"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"The Diet Plate (R) TM portion control plate and bowl"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06247748","briefTitle":"Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Beijing Dongfang Biotech Co., Ltd."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Overweight"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exendin-4 Fc fusion protein (JY09) injection"},{"name":"Metformin Hydrochloride tablet"},{"name":"Rosuvastatin calcium tablets"},{"name":"Digoxin tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01179165","briefTitle":"Noninvasive Methods in Diagnosing Coronary Heart Disease in Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Norwegian University of Science and Technology"},"collaborators":[{"name":"Volda Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diagnostic"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05549570","briefTitle":"Comparative Bioavailability Study of Metformin/Sitagliptin 850 mg/50 mg Tablets in Healthy Male and Female Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Galenicum Health"}},"conditionsModule":{"conditions":["Bioequivalence","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin/Metformin HCl 50/850 mg film-coated tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01135446","briefTitle":"Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"dapagliflozin"},{"name":"dapagliflozin"},{"name":"dapagliflozin"},{"name":"dapagliflozin"},{"name":"dapagliflozin"},{"name":"dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02374788","briefTitle":"Sophia Step Study - a Behaviour Change Program on Physical Activity in Persons With Pre- and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sophiahemmet University"},"collaborators":[{"name":"Karolinska Institutet"},{"name":"Uppsala University"},{"name":"Arizona State University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Prediabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pedometer intervention"},{"name":"Group meetings"},{"name":"Individual consultations"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00950963","briefTitle":"Nurse Telephone Management of Cholesterol in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Denver Health and Hospital Authority"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Phone Counseling"},{"name":"Standard Clinical Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01104701","briefTitle":"A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide once weekly"},{"name":"exenatide once monthly suspension"},{"name":"exenatide once monthly suspension"},{"name":"exenatide once monthly suspension"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01089166","briefTitle":"Study to Compare the Bioavailability of Extended Release Metformin HCl Tablet Versus Glucophage XR® Tablets in Healthy Human Volunteers Under Fasting Condition"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Torrent Pharmaceuticals Limited"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01599338","briefTitle":"Impact of Liraglutide on Sensory Perception, Sensory Specific Satiety, Liking and Wanting in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire Dijon"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Overweight"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00191581","briefTitle":"Local Registration Trial in China Humalog Mix 50"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Humalog Mix 50"},{"name":"Human Insulin Mix 50:50"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04152811","briefTitle":"Cooking Matters for Diabetes - A 6-Week Program for Practical Application of Diabetes Self-Management Education"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ohio State University"},"collaborators":[{"name":"Academy of Nutrition and Dietetics"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cooking Matters for Diabetes"},{"name":"Usual Diabetes Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01046721","briefTitle":"Study Looking at Cardiovascular Effects of Exenatide, Its Blood Pressure Lowering Effect and Its Mechanisms"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Nottingham"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide"},{"name":"Saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00741429","briefTitle":"A 2-Month Safety Follow-Up Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mannkind Corporation"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Technosphere Insulin Inhalation Powder"},{"name":"Comparator"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00813228","briefTitle":"Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 1","Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin (Januvia)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02770235","briefTitle":"Evaluation of Advanced Glycation End-products (AGE) and the Erectile Dysfunction (DE) in Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire, Amiens"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent","Erectile Dysfunction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DE assessment"},{"name":"AGE measurement"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01009528","briefTitle":"Electronic Feedback on Diabetic Care to General Practitioners"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Electronic feedback system on diabetes care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00975052","briefTitle":"A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin phosphate"},{"name":"Comparator: metformin"},{"name":"Comparator: sitagliptin and metformin"},{"name":"Comparator: placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00947024","briefTitle":"To Demonstrate the Effect of Food on the Bioavailability of Glipizide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sandoz"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast."},{"name":"10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast."},{"name":"10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01964833","briefTitle":"PDT and Periodontal Treatment in DMT2 Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Nove de Julho"}},"conditionsModule":{"conditions":["Periodontitis","Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Periodontal treatment"},{"name":"Periodontal treatment and PDT"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00912002","briefTitle":"A Study of Absorption, Metabolism, Excretion and Mass Balance After a Single Dose Administration of MK-0941 (MK-0941-016)(COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK-0941"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05422807","briefTitle":"Behavioral Family Systems Therapy for Teens With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nemours Children's Clinic"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Childhood Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BFST for Teens with Type 2 Diabetes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01114438","briefTitle":"Post Marketing Study in Subjects Who Have Type 2 Diabetes Using the EndoBarrier™ Gastrointestinal Liner"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Morphic Medical Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EndoBarrier Gastrointestinal Liner"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01467323","briefTitle":"Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"},{"name":"biphasic human insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04283318","briefTitle":"Prolonged Fasting on Glucose Metabolism and Hormonal Regulation in Healthy, Obese and Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Graz"}},"conditionsModule":{"conditions":["Healthy","Obesity","Type 2 Diabetes Mellitus","Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"12h fasting"},{"name":"36h fasting"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00865033","briefTitle":"A Relative Bioavailability Study of Metformin HCL Tablets, 1000 mg Under Fasting Conditions"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sandoz"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin HCL Tablets, 1000 mg Sandoz"},{"name":"Glucophage 1000 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00862875","briefTitle":"Levemir-Body Composition and Energy Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institut de Recherches Cliniques de Montreal"},"collaborators":[{"name":"Novo Nordisk A/S"},{"name":"McMaster University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Detemir or Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02667652","briefTitle":"The Curative Effect of the Length of the Jejunum Exclusion in Grstric Bypass Surgery for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Weidong Tong"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"short biliarypancreatic limb"},{"name":"long biliarypancreatic limb"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02320253","briefTitle":"REAL HEALTH-Diabetes: Reach Ahead for Lifestyle and Health-Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Massachusetts General Hospital"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"In Person Group (IP)"},{"name":"Telephone Conference Call Group (TCC)"},{"name":"Medical Nutrition Therapy (MNT)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00790556","briefTitle":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8245 (8245-004)(COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK8245"},{"name":"Comparator: Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02555631","briefTitle":"PowerUp for Health: A Diabetes Prevention Program for Men"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Albert Einstein College of Medicine"},"collaborators":[{"name":"The New York Academy of Medicine"},{"name":"University of Pittsburgh"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Men"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"lifestyle"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00776243","briefTitle":"Short-term Effect of Intensive Insulin Therapy on Incretin Secretion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Catholic University of Korea"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00770302","briefTitle":"Assess Pharmacokinetics, Safety and Tolerability in Healthy Chinese Volunteers After Oral Doses of Saxagliptin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01950650","briefTitle":"GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"},{"name":"survey"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05163964","briefTitle":"Chronotype, Chrononutrition and Glucose Tolerance Among Prediabetic Individuals"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universiti Tunku Abdul Rahman"},"collaborators":[{"name":"National University of Malaysia"}]},"conditionsModule":{"conditions":["PreDiabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00763022","briefTitle":"Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TAK-559"},{"name":"TAK-559"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00593255","briefTitle":"Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"soluble human insulin"},{"name":"insulin aspart"},{"name":"insulin NPH"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03057444","briefTitle":"Resistant Starch, Gut Bacteria and Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Hohenheim"},"collaborators":[{"name":"Institut für Mikroökologie GmbH"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Pre Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SymbioIntest"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00730275","briefTitle":"A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin phosphate"},{"name":"Comparator: matching placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00839150","briefTitle":"Retinal Function in Diabetic Patients Without Retinopathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Assistance Publique - Hôpitaux de Paris"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04600128","briefTitle":"Effect of Pre-meal Serving of Dairy and Dairy Alternatives on Post-meal Satiety and Glycaemia in Healthy Young Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Toronto"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dairy-based greek yogurt"},{"name":"Dairy-based cheddar cheese"},{"name":"Plant-based yogurt"},{"name":"Plant-based cheese"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06666205","briefTitle":"Carbohydrate Quality and Its Impact on Sleep and Depression in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ankara Yildirim Beyazıt University"}},"conditionsModule":{"conditions":["Type 2 DM"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01686945","briefTitle":"Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"semaglutide"},{"name":"semaglutide"},{"name":"placebo"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00673894","briefTitle":"Effects of Glutamine on GLP-1 and Insulin Secretion in Man"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Garvan Institute of Medical Research"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01578837","briefTitle":"Combined Rg3-enriched Korean Red Ginseng and American Ginseng in the Management of Hypertension in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Unity Health Toronto"},"collaborators":[{"name":"Canadian Diabetes Association"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ginseng"},{"name":"Wheat Bran"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00608179","briefTitle":"Glimepiride Induced Insulin Secretion Will be Inhibited by Hypoglycemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glimepiride"},{"name":"glyburide"},{"name":"glucose clamp"},{"name":"glucose clamp"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03786133","briefTitle":"Chronic Periodontitis Microbiota in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Bologna"}},"conditionsModule":{"conditions":["Chronic Periodontitis","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Analysis of microbiological tests"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05492071","briefTitle":"Impact of Regional Vibration Application and Flow Mediated Dilation on Brachial Artery Hemodynamics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Istanbul University"}},"conditionsModule":{"conditions":["Vasodilation","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Local Vibration Application Following Flow Mediated Dilation"},{"name":"Flow mediated dilation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05413330","briefTitle":"Corticosteroid Injection Combined With Cataract Surgery in Diabetic Eyes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Damascus University"}},"conditionsModule":{"conditions":["Diabete Type 2","Cataract","Triamcinolone Acetonide","Intravitreal Injection"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Triamcinolone Acetonide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03416855","briefTitle":"A Regulatory Post Marketing Surveillance (rPMS) Study of Ryzodeg® FlexTouch® (Insulin Degludec /Insulin Aspart) to Evaluate Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice in Korea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin degludec /insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00717223","briefTitle":"A Survey To Elicit The Relationship Between Literacy And Glycemic Control In Pediatric Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baylor College of Medicine"}},"conditionsModule":{"conditions":["Diabetes","Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02377076","briefTitle":"Dietary Calcium Supplementation, Gut Permeability and Microbiota in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Federal University of Vicosa"},"collaborators":[{"name":"Fundação de Amparo à Pesquisa do estado de Minas Gerais"},{"name":"Conselho Nacional de Desenvolvimento Científico e Tecnológico"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Overweight"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dietary calcium supplementation"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04149951","briefTitle":"Effect of VeSTAL Device in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Neurovalens Ltd."},"collaborators":[{"name":"Compliance Solutions Ltd."},{"name":"University College Dublin"},{"name":"Exploristics Ltd"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vestal Device"},{"name":"Placebo device"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01369602","briefTitle":"Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-04991532"},{"name":"PF-04991532"},{"name":"PF-04991532"},{"name":"PF-04991532"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01099865","briefTitle":"High-sensitivity C-reactive Protein and United Kingdom Prospective Diabetes Study (UKPDS) Risk Score in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Korea University"}},"conditionsModule":{"conditions":["Atherosclerosis","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00744237","briefTitle":"Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Forest Laboratories"}},"conditionsModule":{"conditions":["Hypertension","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nebivolol"},{"name":"Metoprolol ER"},{"name":"HCTZ"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01241253","briefTitle":"Glycemic Response of Bean-and-rice Meals in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Arizona State University"},"collaborators":[{"name":"United States Dry Bean Council"}]},"conditionsModule":{"conditions":["Blood Glucose","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Whole cooked beans with rice meals"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01745549","briefTitle":"Efficacy, Safety and Satisfaction of the New Pen Needle 33 Gauge x 4 mm."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Consorzio Mario Negri Sud"},"collaborators":[{"name":"Artsana SpA"}]},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Needle for insulin pen, 4 mm long and with a diameter of 33 gauge"},{"name":"Needle for insulin pen, 4 mm long and with a diameter of 32 gauge"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01865279","briefTitle":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin Degludec"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"placebo"},{"name":"insulin degludec"},{"name":"isophane human insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05691738","briefTitle":"Effects of Modified Otago Exercises in Individuals With Diabetic Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Karamanoğlu Mehmetbey University"},"collaborators":[{"name":"Ankara Yildirim Beyazıt University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Neuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise Group"},{"name":"Control Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02509065","briefTitle":"The Set-Point Study: Evaluating Effects of Changing Glucose Target on Bionic Pancreas Performance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Massachusetts General Hospital"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bionic Pancreas"},{"name":"Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00980187","briefTitle":"A Comparison of Indapamide SR 1.5 mg With HCTZ 25 mg, in Combination With an ACE-inhibitor, in Patients With Mild to Moderate AHT and Type 2 DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LaborMed Pharma S.A."}},"conditionsModule":{"conditions":["Hypertension","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hydrochlorothiazide"},{"name":"Indapamide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01073826","briefTitle":"Role of Interleukin-6 in Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Zurich"},"collaborators":[{"name":"European Foundation for the Study of Diabetes"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sport"},{"name":"Tocilizumab"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00706017","briefTitle":"Observational Study to Evaluate the Safety of Levemir® in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01865305","briefTitle":"Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/insulin aspart 30"},{"name":"insulin degludec/insulin aspart 40"},{"name":"insulin degludec/insulin aspart 50"},{"name":"insulin degludec"},{"name":"insulin aspart"},{"name":"biphasic insulin aspart 30"},{"name":"insulin degludec/insulin aspart 40"},{"name":"insulin degludec/insulin aspart 50"},{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00264589","briefTitle":"Exercise Training and Cardiovascular Function in Obesity and in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire de Nīmes"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"8 weeks individualized training program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03489083","briefTitle":"Heat Shock Response is Blunted in Elderly Diabetic People But Recovered by Strength Training"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Federal University of Rio Grande do Sul"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Aging"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Strength training"},{"name":"No Training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04821921","briefTitle":"The Impact of the COVID-19 Pandemic on Diabetes Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universitätsklinikum Hamburg-Eppendorf"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00285896","briefTitle":"GLP-1 Infusion and Long-Time Fasting"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"}},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glucagon-like-peptide-1 (7-36) amide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01545791","briefTitle":"Observational Study to Evaluate the Safety of Levemir® in Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04883086","briefTitle":"Are Diabetics Type 2 More Prone to Dental Caries?"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Queen Mary University of London"},"collaborators":[{"name":"The Novo Nordisk UK Research Foundation"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Dental Caries"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00717158","briefTitle":"Lifestyle Intervention's Impact on Health Care Costs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Virginia"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Usual medical care"},{"name":"Lifestyle Case management"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00042471","briefTitle":"Evaluation of the Bioavailability of Pramlintide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pramlintide acetate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01542463","briefTitle":"Evaluation of the Use of Levemir® in Insufficiently Controlled Patients With Type 1 or Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00034255","briefTitle":"Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GMP Endotherapeutics"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INGAP Peptide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01980017","briefTitle":"Evaluation of the Ottawa Model for Smoking Cessation in Diabetes Education Programs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ottawa Heart Institute Research Corporation"}},"conditionsModule":{"conditions":["Pre-diabetic","Diabetic Type II Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ottawa Model for Smoking Cessation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02351323","briefTitle":"Novel Type 2 Diabetes Mellitus Preventive Therapies"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boston Medical Center"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glutamine (Pharmacological doses)"},{"name":"Lifestyle change"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02628392","briefTitle":"A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo Co., Ltd."}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DS-8500a"},{"name":"Sitagliptin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05585697","briefTitle":"Bone Turnover in Type 2 Diabetes and Non-diabetes Controls (DiaMarv)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Bone Fragile"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"None - crossectional"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02896140","briefTitle":"Effect of Dairy Consumption on Glycemic Control, Body Weight and Cardiovascular Risk Factors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Joslin Diabetes Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Type 2 diabetes in WhyWAIT Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05472272","briefTitle":"Low-Calorie Diets on Type 2 Diabetes Remission"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Municipal Hospital of Traditional Chinese Medicine"},"collaborators":[{"name":"Shanghai Jiao Tong University School of Medicine"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity","Overweight"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Formula diet"},{"name":"Food-based diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01520818","briefTitle":"Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 50"},{"name":"biphasic insulin aspart 70"},{"name":"biphasic human insulin 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04463277","briefTitle":"A Comparison Between the Effects of Conventional Diets vs Intermittent Fasting Diabetic and Pre-diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Usman Bin Hameed"},"collaborators":[{"name":"World Health Organization"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","PreDiabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Calorie Restriction"},{"name":"Time Restricted Feeding"},{"name":"Time Restricted Feeding with Calorie Restriction"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01135901","briefTitle":"Local Measures to Prevent Diabetes in the Værnes Region."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Norwegian University of Science and Technology"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Behavioural change programme"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01560676","briefTitle":"Reducing Obesity and Type 2 Diabetes in High Risk Youth"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yale University"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HEALTH[e]TEEN"},{"name":"HEALTH[e]TEEN + CST"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01991197","briefTitle":"Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University College Dublin"}},"conditionsModule":{"conditions":["Psoriasis","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Gliclazide"},{"name":"Sitagliptin matched placebo"},{"name":"Gliclazide matched placebo capsule"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04291391","briefTitle":"The Alberta NutrIMM Study - Nutrition and Immunity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alberta"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"North American-type diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00788840","briefTitle":"Detemir Energy Expenditure Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Surrey"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulatard"},{"name":"Detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02235194","briefTitle":"Effects of an Amino Acid and Chromium-picolinate Containing Drink on Glucose Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Stoffwechselzentrum Rhein - Pfalz"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Prediabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Amino Acid and chromium-picolinate containing drink"},{"name":"Placebo Drink"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04527965","briefTitle":"Liver Fat as a Dietary Target for Treating Cardiometabolic Disorders in Prediabetes and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Uppsala University"}},"conditionsModule":{"conditions":["NAFLD","Diabetes Mellitus, Type 2","PreDiabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Customized diet to reduce liver fat"},{"name":"Healthy Nordic diet"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00240422","briefTitle":"Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Telmisartan"},{"name":"Ramipril"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04473326","briefTitle":"Reinforcement Learning in Diabetes Mellitus Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Brigham and Women's Hospital"},"collaborators":[{"name":"National Institute on Aging (NIA)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Medication Adherence"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Reinforcement Learning"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01991548","briefTitle":"User Evaluation of the MiniMed 640G Insulin Pump"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medtronic Diabetes"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MiniMed® 640G Insulin Pump and Guardian® Link Transmitter"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05263232","briefTitle":"Metabolic Effects of Natural Office Light in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University"},"collaborators":[{"name":"Velux Fonden"},{"name":"University of Geneva, Switzerland"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Circadian Dysregulation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Natural or artificial office light exposure"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01202526","briefTitle":"The Effect of Roux-en-Y Gastric Bypass on Insulin Sensitivity in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hvidovre University Hospital"},"collaborators":[{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02126358","briefTitle":"Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LG Life Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gemigliptin and/or Rosuvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01051674","briefTitle":"A Very High Fiber Diet Versus a Low-carbohydrate Diet for Weight Loss"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Loma Linda University"},"collaborators":[{"name":"Lifestyle Center of America"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High fiber vs. low-carbohydrate diets"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00934570","briefTitle":"Activity and Metformin Intervention in Obese Adolescents"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lawson Health Research Institute"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin and standard exercise"},{"name":"Metformin Intensive exercise"},{"name":"Placebo Standard exercise"},{"name":"Intensive exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00001870","briefTitle":"Study of the Effects of Vitamin C on Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Center for Complementary and Integrative Health (NCCIH)"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin Dependent","Non-Insulin Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acetylcholine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03808376","briefTitle":"PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Senseonics, Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous Glucose Monitoring System"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01095965","briefTitle":"Nutrition Education Intervention in Adults With Type 2 Diabetes Mellitus in a Resource Poor Setting"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pretoria"},"collaborators":[{"name":"South African Sugar Association"},{"name":"Nestlè Nutrition Institute Africa"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II [Non-insulin Dependent Type] [NIDDM Type] Uncontrolled"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nutrition education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01238978","briefTitle":"Phase 4 Study in the Elderly Patients With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Elderly"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"\"Usual Care\""}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00775684","briefTitle":"Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pennsylvania"},"collaborators":[{"name":"Pennsylvania Department of Health"}]},"conditionsModule":{"conditions":["Pre-diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide"},{"name":"Sitagliptin"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01773668","briefTitle":"Feasibility Study - Integrated Sensor and Infusion Set. Trial III"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medtronic Diabetes R&D Denmark"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Integrated sensor and infusion set."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02958995","briefTitle":"Epidemiologic Study Of Diabetes And Cancer Risk"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2, Cancer"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02230618","briefTitle":"Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01726621","briefTitle":"User Evaluation of the MiniMed 620G and 640G Insulin Pumps"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medtronic Diabetes"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Medtronic MiniMed 620G or 640G Insulin Pump"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03985098","briefTitle":"Motivational Interviewing (MI) Intervention to Improve Adherence"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Houston"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Motivational interviewing intervention arm"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01980914","briefTitle":"Hypoglycemia (Low Blood Sugar) and the Heart"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of British Columbia"},"collaborators":[{"name":"icentia"}]},"conditionsModule":{"conditions":["Hypoglycemia","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"iPro2 glucose sensor attachment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02715791","briefTitle":"TAPESTRY With Health Connnectors for Diabetes Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"McMaster University"},"collaborators":[{"name":"Ontario Ministry of Health and Long Term Care"},{"name":"Health Canada"},{"name":"McMaster Family Health Team"},{"name":"Volunteer Hamilton"},{"name":"INSPIRE-PHC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TAP-HC-DM"},{"name":"Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01945645","briefTitle":"Ready to Act - Health Education in People With Hyperglycaemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Behavior"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ready to act"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01507597","briefTitle":"The Effect of GLP-1 on the Inhibition of Glucagon Secretion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Native human Glucagon-like Peptide-1 ( GLP-1(7-36))"},{"name":"NaCl"},{"name":"Native human Glucagon-like Peptide-1 ( GLP-1(7-36))"},{"name":"Native human Glucagon-like Peptide-1 ( GLP-1(7-36))"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00659295","briefTitle":"Observational Study to Evaluate the Safety of Levemir® in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05095922","briefTitle":"Effect of HMP on Diabetic Microangiopaemia in T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Affiliated Hospital of Nantong University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetic Angiopathies"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Heart-Protecting Musk Pill"},{"name":"Valsartan Capsules"},{"name":"Calcium Dobesilate Capsules"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04314427","briefTitle":"Early Glycaemic Control in Type 2 Diabetes Patients After Bariatric Surgery; ECODABS"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sahlgrenska University Hospital, Sweden"},"collaborators":[{"name":"University Hospital, Antwerp"},{"name":"Universitair Ziekenhuis Brussel"},{"name":"Karolinska Institutet"},{"name":"Hospital San Carlos, Madrid"},{"name":"University Hospital, Ghent"},{"name":"Imperial College London"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2 in Obese"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Roux-en-Y gastric bypass"},{"name":"Sleeve gastrectomy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04763525","briefTitle":"Efficacy of Pythagorean Self-Awareness for Aging Biomarkers Improvement, in T2D Patients and Healthy Individuals."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National and Kapodistrian University of Athens"},"collaborators":[{"name":"National Hellenic Research Foundation"},{"name":"Laikο General Hospital, Athens"},{"name":"Aghia Sophia Children's Hospital of Athens"},{"name":"University of Thessaly"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Telomere Shortening"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pythagorean Self-Awareness Intervention(PSAI)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00653185","briefTitle":"Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SYR-472"},{"name":"SYR-472"},{"name":"SYR-472"},{"name":"SYR-472"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00486109","briefTitle":"A Prospective, Randomized, Parallel Crossover Study Demonstrating Subject Wearability and Usability of the I-Port Injection Port"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Patton Medical Devices"},"collaborators":[{"name":"Medstar Health Research Institute"},{"name":"Valeritas, Inc."}]},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"I-Port(TM) Injection Port"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01007266","briefTitle":"Partners for Better Health in Adolescent Type 2 Diabetes: The Buddy Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type 2","Abnormal Glucose Metabolism","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Assignment of a Lay Patient Partner"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00698269","briefTitle":"An Observational Study of Efficacy and Safety of Modern Insulin in Diabetes Patients Switched From Anti-diabetic Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"biphasic insulin aspart 30"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03678896","briefTitle":"Creative Writing for Type 2 Diabetes Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Associacao Protectora dos Diabeticos de Portugal"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CrewD Program"},{"name":"Classical structured education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00617565","briefTitle":"Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart"},{"name":"biphasic human insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02684331","briefTitle":"CMR in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Slagelse Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Heart Disease"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cardiac Magnetic Resonance Imaging (CMR)"},{"name":"Echocardiography"},{"name":"Bood samples"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05407454","briefTitle":"Turkish Version of The Diabetes Quality of Life Brief Clinical Inventory Validity and Reliability"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"İlke KARA, PT"},"collaborators":[{"name":"Bitlis Eren University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Questionnaire"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02180191","briefTitle":"Gut Microbiota in Obesity and Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gulhane School of Medicine"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Comparison of the gut microbiota composition"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05256615","briefTitle":"Exercise Timing and Gestational Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alberta"}},"conditionsModule":{"conditions":["Pregnancy Related","Diabetes","Diabete Mellitus","Type 2 Diabetes","Pre-diabetes","Exercise"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"30-minute walking intervention"},{"name":"10-minute"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02117622","briefTitle":"A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05857007","briefTitle":"CGM Utilization With IV Insulin EndoTool and Subcutaneous Insulin in the Neuro ICU"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Wake Forest University Health Sciences"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus","Hyperglycemia"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Libre 2.0 CGM in patients taking subcutaneous insulin with concomitant high dose glucocorticoids"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02373332","briefTitle":"Fatty Acid Regulation of Platelet Function in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Thrombosis","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"omega-3 and -6 fatty acids and their 12-LOX oxylipins"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03251079","briefTitle":"PRECISION Study: Multi-center Study of Performance of a Novel Implanted CGM System Using a Next Generation Transmitter and Algorithm"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Senseonics, Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous glucose monitoring system"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00701155","briefTitle":"Observational Study to Evaluate the Safety While Using Levemir®"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04926415","briefTitle":"Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Obesity and Insulin Resistance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Burrell College of Osteopathic Medicine"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"taVNS"},{"name":"Sham taVNS"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03590561","briefTitle":"Effect of High Caloric Diet on Brain Insulin Sensitivity and Inflammation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital Tuebingen"}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High caloric diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00699179","briefTitle":"Observational Study to Evaluate the Efficacy and Safety of NovoMix® 30 in Type 1 and 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03481335","briefTitle":"Community Health Assessment Program in the Philippines (CHAP-P)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"McMaster University"},"collaborators":[{"name":"Ateneo de Zamboanga University"},{"name":"Université de Montréal"},{"name":"Global Alliance for Chronic Diseases (GACD)"},{"name":"Canadian Institutes of Health Research (CIHR)"},{"name":"International Development Research Centre, Canada"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CHAP-P Sessions"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04076995","briefTitle":"INDIGO-2: The Effect of High Water Intake on Glucose Regulation in Low-drinkers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Arizona State University"}},"conditionsModule":{"conditions":["Dehydration","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Water Intake"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01542489","briefTitle":"Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin aspart"},{"name":"human soluble insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04219514","briefTitle":"Investigating Novel Predictions of Hypoglycemia Occurrence in Real-world Models"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Stewart Harris"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Hypoglycemia","Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05394571","briefTitle":"Conditions Associated With Poorly Controlled Diabetes in Patients With Type 2 Diabetes and HbA1c Changes With Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Goztepe Training and Research Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Poorly Controlled Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01501877","briefTitle":"Smoking Cessation Intervention for Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rhode Island Hospital"}},"conditionsModule":{"conditions":["Smoking","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acceptance and Commitment Therapy"},{"name":"Standard smoking cessation intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05736536","briefTitle":"Behavior Intervention for Weight Loss for Type 2 Diabetes Mellitus Adults With Obesity Problem (BMI of ≥23kg/m2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universiti Teknologi Mara"}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type 2","Behavior"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Chance2Act"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00541879","briefTitle":"Obesity and Diabetes Prevention Through Science Enrichment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Colorado State University"},"collaborators":[{"name":"National Center for Research Resources (NCRR)"},{"name":"Poudre School District, Fort Collins, CO"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Program ENERGY"},{"name":"comparison"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01505803","briefTitle":"The Effect of a Nutritional Supplement in Individuals With Type 2 Diabetes Mellitus: a Pilot Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Sydney"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Zinc supplements"},{"name":"Omega 3 supplements"},{"name":"Placebo supplements"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01967849","briefTitle":"Prevalence of Carbohydrate Intolerance in Lean and Overweight/Obese Children"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yale University"},"collaborators":[{"name":"National Institutes of Health (NIH)"},{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral Glucose tolerance test"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03767608","briefTitle":"Association Between Irisin, Inflammatory Markers and Metabolic Status in Obese Children With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Instituto Tecnologico y de Estudios Superiores de Monterey"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Pediatric Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04626531","briefTitle":"The Effect of Web-Based Education in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mehmet Akif Ersoy University"},"collaborators":[{"name":"Akdeniz University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Educational Problems"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Web-Based Education"},{"name":"Control Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00466518","briefTitle":"Sitagliptin Treatment in Patients With Type 2 DM After Kidney Transplant"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Oklahoma"}},"conditionsModule":{"conditions":["Kidney Transplant","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Administration of sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04286555","briefTitle":"Dietary Approaches to Stop Hypertension for Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johns Hopkins University"},"collaborators":[{"name":"Beth Israel Deaconess Medical Center"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"Sheikh Khalifa Stroke Institute at Johns Hopkins"},{"name":"University of Colorado - Anschutz Medical Campus"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes","Diabetes type2","Type2 Diabetes","Type 2 Diabetes","Type II Diabetes","Hypertension","High Blood Pressure"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DASH4D diet"},{"name":"comparison diet"},{"name":"higher sodium"},{"name":"lower sodium"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03877523","briefTitle":"Cocarnit Effects on Macrophages Polarization"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institute for Atherosclerosis Research, Russia"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes Complications"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cocarnit"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03235362","briefTitle":"A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between YHR1705 and YHR1706"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yuhan Corporation"}},"conditionsModule":{"conditions":["Dyslipidemia","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"YHR1705"},{"name":"YHR1706"},{"name":"YHR1705+YHR1706"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00534014","briefTitle":"Vitamin C and Cardiovascular Risk"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of New Mexico"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Atherosclerosis","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin C"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01548248","briefTitle":"Efficacy and Safety of Levemir® Used as Basal Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00621868","briefTitle":"A Study of ASP1941 in Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ipragliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01729117","briefTitle":"A Trial of Meal Replacement at a Community Diabetes Clinic Serving a Low Socioeconomic Hispanic Population"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Southern California"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Meal Replacement"},{"name":"Standard Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03071432","briefTitle":"QUANtification of Cardiovascular Autonomic Neuropathy (CAN) and the Effects of Anaesthesia on Haemodynamics and Cerebral Perfusion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)"},"collaborators":[{"name":"European Society of Anaesthesiology"}]},"conditionsModule":{"conditions":["Anesthesia","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Paced breathing at 6, 10 and 15 breaths per minute"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00308347","briefTitle":"A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Organon and Co"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK0954, losartan / Duration of Treatment: mean 3.4 years"},{"name":"Placebo / Duration of Treatment: mean 3.4 years"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03814512","briefTitle":"Improving Insulin Resistance and Energy Metabolism Through Sleep Extension in Adolescents"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Denver"}},"conditionsModule":{"conditions":["Sleep","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Extended Sleep Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03064321","briefTitle":"Diabetes Sleep Treatment Trial for Insomnia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pittsburgh"}},"conditionsModule":{"conditions":["Insomnia","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insomnia Intervention"},{"name":"Information Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00334113","briefTitle":"Telerehabilitation Intervention to Promote Exercise for Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"US Department of Veterans Affairs"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TLC-PED"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02491801","briefTitle":"Form of Dairy Products on Satiety, Food Intake and Post-meal Glycaemia in Young and Older Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Toronto"},"collaborators":[{"name":"Dairy Farmers of Canada"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dietary intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02306681","briefTitle":"A Survey on Low Blod Sugar Among Insulin-treated Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01943045","briefTitle":"Phase 2 Study of NGM282 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NGM Biopharmaceuticals, Inc"},"collaborators":[{"name":"NGM Biopharmaceuticals Australia Pty Ltd"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NGM282"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02898766","briefTitle":"Glycemic Response to Two Enteral Formulas in Persons With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Société des Produits Nestlé (SPN)"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Enteral Nutrition Formula"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03159221","briefTitle":"Behavioral Family Systems Therapy (BFST) for Teens With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nemours Children's Clinic"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Childhood Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BFST for Teens with Type 2 Diabetes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02178176","briefTitle":"Participatory Design of Patient-centered Depression and Diabetes Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pennsylvania"}},"conditionsModule":{"conditions":["Depression","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Education, encouragement, card sort"},{"name":"Education, encouragement"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00840307","briefTitle":"Changes in Ectopic Fat Following Surgically Induced Weight Loss"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Texas Southwestern Medical Center"},"collaborators":[{"name":"National Institutes of Health (NIH)"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01832311","briefTitle":"Protein Profile of Immunoregulatory Factors in Diabetic Cataract"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Zagreb"}},"conditionsModule":{"conditions":["Cataract","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ketorolac"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02230631","briefTitle":"A Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04216875","briefTitle":"Best Practice Study of Diabetes Type 2 Management in Primary Care in Switzerland"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"QualiCCare"},"collaborators":[{"name":"Swiss Society of Endocrinology and Diabetology"},{"name":"Roche Diabetes Care, Switzerland"},{"name":"Sanofi"},{"name":"Concordia Versicherungen AG"},{"name":"Novo Nordisk A/S"},{"name":"Galenica"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Primary Care"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Best Practice Diabetes Management in Primary Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00553787","briefTitle":"Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VIVUS LLC"},"collaborators":[{"name":"Medpace, Inc."}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"VI-0521"},{"name":"VI-0521"},{"name":"VI-0521"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01176656","briefTitle":"Hypoglycemia: Physician and Patient Perspectives"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Hypoglycemia"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00723853","briefTitle":"REACH-OUT: Chicago Children's Diabetes Prevention Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Chicago"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Reach-Out Program, nutritional and exercise program"},{"name":"Reach-In Program, standard of care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01857076","briefTitle":"Surgical Treatment in Diabetic Patients With Grade 1 Obesity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital Sirio-Libanes"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gastric bypass surgery"},{"name":"Surgical ileal transposition with sleeve"},{"name":"Clinical"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00339885","briefTitle":"Mapping Genes for Type 2 (Non-Insulin Dependent) Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Human Genome Research Institute (NHGRI)"}},"conditionsModule":{"conditions":["Genetic Variation","Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00670683","briefTitle":"Observational Study of Patients With Diabetes Using Levemir® FlexPen®"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02173834","briefTitle":"Brown Adipose Tissue and Body Mass Index"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"18F- fluorodeoxyglucose-positron emission tomography Computed Tomography scan and 123I-metaiodobenzylguanidine-single-photon emission computed tomography scan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01217905","briefTitle":"Japanese Single and Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic (PK) & Pharmacodynamic (PD) Study of AZD7687"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD7687"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01794052","briefTitle":"To Develop a High Quality Health Care Delivery Model for the Management of Hypertension and Diabetes at CHCs and District Hospitals of Himachal Pradesh."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre for Chronic Disease Control, India"},"collaborators":[{"name":"All India Institute of Medical Sciences, New Delhi"},{"name":"Public Health Foundation of India"}]},"conditionsModule":{"conditions":["Hypertension","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Evidence based, DSS enabled, health care delivery model"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05654727","briefTitle":"Cognitive Functions and BDNF in T2DM and Prediabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bezmialem Vakif University"}},"conditionsModule":{"conditions":["Diabetes Type 2","PreDiabetes","Cognitive Impairment"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01329822","briefTitle":"Effects of Caloric Restriction on Fetuin-A and Cardiovascular Risk Factors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Korea University"},"collaborators":[{"name":"Eulji University Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Overweight"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Caloric restriction"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00010751","briefTitle":"Effects of Reiki on Painful Neuropathy and Cardiovascular Risk Factors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Center for Complementary and Integrative Health (NCCIH)"}},"conditionsModule":{"conditions":["Coronary Disease","Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Reiki"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02130687","briefTitle":"Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Sitagliptin"},{"name":"Aprepitant"},{"name":"Mixed Meal Test (MMT)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03394157","briefTitle":"Randomized Comparative Study of Sleeve Gastrectomy Versus MGB and SASI Bypass , Randomized Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"tarek mahdy"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2 in Obese"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"metabolic surgery"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01724814","briefTitle":"A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hanmi Pharmaceutical Company Limited"}},"conditionsModule":{"conditions":["Healthy","Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HM12460A"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00177398","briefTitle":"Effect of Glargine Insulin on Glucose Control in Hospitalized Patients Who Receive Tube Feedings"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pittsburgh"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glargine insulin vs regular insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00480805","briefTitle":"HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Organon and Co"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks"},{"name":"Comparator : ramipril /Duration of Treatment : 8 Weeks"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01437072","briefTitle":"Changing Diabetes® World Tour"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01483781","briefTitle":"A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Plasma Volume"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02009670","briefTitle":"Inulin,SCFA Production and Metabolic Response"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"},"collaborators":[{"name":"Top Institute Food and Nutrition"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"13C inulin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03259984","briefTitle":"Epigenetics of Muscle Insulin Resistance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Arizona"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02868606","briefTitle":"Physiologic Insulin Therapy for the Management of Hyperglycemia in the Hospital"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Winthrop University Hospital"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hyperglycemia"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physiologic Insulin Therapy"},{"name":"Sliding-Scale Insulin Therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02389127","briefTitle":"Relationship Between HbA1c and Chronic Glycemia in Patients With Cirrhosis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Arkansas"}},"conditionsModule":{"conditions":["Cirrhosis","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous glucose monitor (Dexcom, San Diego, CA)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00444392","briefTitle":"Impact of Gastric Bypass Surgery on Risk of CVD in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University"}},"conditionsModule":{"conditions":["Obese Patients","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Calorie controlled diabetic diet for the control patients"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00004992","briefTitle":"Diabetes Prevention Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},"collaborators":[{"name":"National Institute on Aging (NIA)"},{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)"},{"name":"National Institute on Minority Health and Health Disparities (NIMHD)"},{"name":"Office of Research on Women's Health (ORWH)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent","Glucose Intolerance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intensive lifestyle"},{"name":"Metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02421055","briefTitle":"Longitudinal Phenotyping of Bariatric Surgery Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Imperial College London"}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Laparoscopic Roux-en-Y Gastric Bypass"},{"name":"Laparoscopic Sleeve Gastrectomy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03586830","briefTitle":"A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Obesity and Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"JNJ-64565111 Dose Level 1"},{"name":"JNJ-64565111 Dose Level 2"},{"name":"JNJ-64565111 Dose Level 3"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02947828","briefTitle":"Polyneuropathy in Diabetes Mellitus Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Danish Pain Research Center"},"collaborators":[{"name":"Odense University Hospital"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2 Without Complication","Polyneuropathies, Diabetic","Diabetes Complications","Diabetic Peripheral Neuropathy","Chronic Pain"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01880827","briefTitle":"Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Turku University Hospital"},"collaborators":[{"name":"Lund University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Roux-en-Y"},{"name":"GIP-infusion"},{"name":"GLP-1"},{"name":"MMS"},{"name":"Sleeve gastrectomy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03683784","briefTitle":"Type 2 Diabetes in Fayoum"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fayoum University"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04262661","briefTitle":"A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Healthy Volunteers","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NNC0472-0147"},{"name":"insulin glargine"},{"name":"Placebo (NNC0472-0147)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00001625","briefTitle":"Methods for Measuring Insulin Sensitivity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Center for Complementary and Integrative Health (NCCIH)"},"collaborators":[{"name":"Office of Dietary Supplements (ODS)"}]},"conditionsModule":{"conditions":["Obesity","Hypertension","Diabetes-Mellitus, Non-Insulin Dependent"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06462534","briefTitle":"The Band-Frail Study: A Provincial Intervention to Outweigh Diabetes and Frailty in New Brunswick"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of New Brunswick"},"collaborators":[{"name":"Public Health Agency of Canada (PHAC)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Frailty"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Band-Frail Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00737776","briefTitle":"Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01826162","briefTitle":"Short Chain Fatty Acid Metabolism and Energy Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"},"collaborators":[{"name":"Top Institute Food and Nutrition"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"acetate or placebo infusion"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05589467","briefTitle":"Effects of Potatoes on Blood Pressure in Persons With and Without Type 2 Diabetes Who Follow the DASH Diet for 6 Weeks"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Texas Tech University"},"collaborators":[{"name":"Alliance for Potato Research and Education"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Blood Pressure"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DASH-FP"},{"name":"DASH-NFP"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00648284","briefTitle":"Cardiovascular (CV) Risk Evaluation In Type 2 Diabetes Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","CV Risk"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01696266","briefTitle":"An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05815342","briefTitle":"OP5-005 Using Omnipod 5 in Adults With Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Insulet Corporation"},"collaborators":[{"name":"Jaeb Center for Health Research"}]},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omnipod 5 Automated Glucose Control System"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04094064","briefTitle":"Evaluation of Accuracy of Continuous Glucose Monitoring (CGM) in Patients With End Stage Renal Disease (ESRD) on Intermittent Hemodialysis (iHD)."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Virginia"},"collaborators":[{"name":"DexCom, Inc."}]},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous Glucose Monitor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00957957","briefTitle":"Gut Hormone Profiling in Obese Patients With Type 2 Diabetes (MK-0000-134)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Obesity, Morbid","Diabetes Mellitus Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01542476","briefTitle":"The Impact of Initiating/Switching to Insulin Detemir on Emotional Well-being and Treatment Satisfaction"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01357304","briefTitle":"10 Prescriptions an Hour. Group Treatment and Physical Activity Referral in a Primary Health Care Setting"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Region Skane"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Group treatment and PAR"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00128336","briefTitle":"The Heat Study: 2 Year Lifestyle Intervention in Overweight Women to Encourage Weight Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Otago"},"collaborators":[{"name":"Edgar National Centre for Diabetes Research"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle: diet and exercise intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02682563","briefTitle":"Renoprotective Effects of Dapagliflozin in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"M.H.H. Kramer"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetic Nephropathies"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin 10mg QD"},{"name":"Gliclazide 30mg QD"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00239538","briefTitle":"SMOOTH - Blood Pressure Control in Diabetic/Obese Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Hypertension","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"telmisartan combined with hydrochlorothiazide (80/12.5 mg)"},{"name":"valsartan combined with hydrochlorothiazide (160/12.5mg)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02424500","briefTitle":"Multi-Center Study Comparing Efficacy and Safety of Frequently Modified Insulin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hygieia Research LLC"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypoglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"d-Nav"},{"name":"Blood Glucose Monitoring System"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01505673","briefTitle":"Adding Liraglutide to High Dose Insulin: Breaking the Cycle"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ildiko Lingvay"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05263401","briefTitle":"Keto Drinks as a Meal Primer in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"Aarhus University Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Ketoses, Metabolic"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"3-hydroxybutyrate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00605787","briefTitle":"TTA in Treatment of Diabetes and Dyslipidemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Haukeland University Hospital"},"collaborators":[{"name":"University of Bergen"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tetradecylthioacetic acid (TTA)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01452815","briefTitle":"Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tranzyme, Inc."}},"conditionsModule":{"conditions":["Gastroparesis","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"10mg TZP-102"},{"name":"20mg TZP-102"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00695474","briefTitle":"Vitamin D and Type 2 Diabetes - a Cross Sectional Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"Aarhus University Hospital"},{"name":"Regionshospitalet Silkeborg"}]},"conditionsModule":{"conditions":["Hypovitaminosis D","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02332824","briefTitle":"A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus and Microalbuminuria"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TAK-272"},{"name":"TAK-272 Placebo"},{"name":"Candesartan cilexetil"},{"name":"Candesartan cilexetil Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01798225","briefTitle":"Relationship of Periodontal Disease Treatment and Type 2 Diabetes Mellitus in the Gullah Population"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of South Carolina"},"collaborators":[{"name":"National Center for Research Resources (NCRR)"}]},"conditionsModule":{"conditions":["Periodontal Disease","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Doxycycline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01295229","briefTitle":"Calorie Reduction Or Surgery: Seeking Remission for Obesity And Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Washington"},"collaborators":[{"name":"Kaiser Permanente"},{"name":"Fred Hutchinson Cancer Center"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"laparoscopic Roux-en-Y gastric bypass (RYGB) procedure"},{"name":"Lifestyle Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04064996","briefTitle":"Effectiveness of Foot Exercise People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Istanbul University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Peripheral Neuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Routine rehabilitation program patient education"},{"name":"Routine rehabilitation program + foot exercise training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00450710","briefTitle":"Neuroendocrine Brake for Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medtronic - MITG"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ileal interposition with a sleeve gastrectomy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02167620","briefTitle":"Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre for Addiction and Mental Health"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Schizophrenia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00708266","briefTitle":"The Influence of Fatty-Acids on Systemic and Subcutaneous Cytokines"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Graz"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Openflow microperfusion catheter"},{"name":"Intralipid 20%"},{"name":"0.9% Saline Solution"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02863276","briefTitle":"Modulating the Stress Response in Diabetes Mellitus Type 2 Patients Undergoing Colon Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Basel, Switzerland"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intensified insulin therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01351922","briefTitle":"A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in India"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00789711","briefTitle":"An Observational Study to Compare the Safety and Effectiveness of NovoMix® 30 and Levemir™ for the Treatment of Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"},{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03102801","briefTitle":"A Study to Identify Biomarkers of Hypoglycaemia in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Hull"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus With Hypoglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Humulin S"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03832933","briefTitle":"Comparing High and Normal Protein Diets for the Dietary Remission of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alabama at Birmingham"}},"conditionsModule":{"conditions":["Diabetes Type 2","Obesity","Diet Modification"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High Protein Diet"},{"name":"Standard Protein Diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02043054","briefTitle":"Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Leicester"},"collaborators":[{"name":"Novo Nordisk A/S"},{"name":"University Hospitals, Leicester"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01492218","briefTitle":"Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic human insulin 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02271776","briefTitle":"GOS and Insulin Sensitivity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"},"collaborators":[{"name":"Top Institute Food and Nutrition"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Galactooligosaccharide"},{"name":"maltodextrin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06174129","briefTitle":"Prevalence and Factors Associated With Atrial Fibrillation in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Burapha University"}},"conditionsModule":{"conditions":["Atrial Fibrillation","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Routine examinations"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01547156","briefTitle":"Mobile Sipoo - Telemonitoring With Combined With Active Assistance Technology"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VTT Technical Research Centre of Finland"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intervention group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01724060","briefTitle":"Effects of Obesity Treatments on Food Preferences and Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Imperial College London"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02220751","briefTitle":"Diagnostic Biomarkers Related to Periodontal Disease Activity in Diabetic"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Sao Paulo"},"collaborators":[{"name":"Fundação de Amparo à Pesquisa do Estado de São Paulo"}]},"conditionsModule":{"conditions":["Periodontitis","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"non-surgical periodontal therapy + systemic doxycycline"},{"name":"Non-surgical periodontal therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03902288","briefTitle":"Short-term Effect of Pomegranate Juice on Blood Sugar and Its Controlling Hormones in Pre-diabetic and Type II Diabetic Patients."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jordan University of Science and Technology"}},"conditionsModule":{"conditions":["Patients With Type 2 Diabetes (FSG: More Than 7.1 and Not Higher Than 15.8 mmol/L)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fresh pomegranate juice"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00445627","briefTitle":"Effect of Short-Term Beta-Cell Rest in Adolescents and Young Adults With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Obesity","Overweight","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Insulin"},{"name":"Nutrition counseling"},{"name":"Exercise counseling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00481897","briefTitle":"Worksite Nutrition Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Physicians Committee for Responsible Medicine"}},"conditionsModule":{"conditions":["Overweight","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"low-fat, vegan diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04416841","briefTitle":"Tai Chi Chuan as Rehabilitation Program for Mild Cognitive Impairment in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jing Tao"},"collaborators":[{"name":"Second Affiliated Hospital of Heilongjiang University of Chinese Medicine"},{"name":"Bao'an District People's Hospital of Shenzhen"},{"name":"Xiyuan Hospital of China Academy of Chinese Medical Sciences"},{"name":"Peking University"},{"name":"University of Electronic Science and Technology of China"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Cognitive Dysfunction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tai Chi Chuan"},{"name":"Fitness Walking"},{"name":"Standard Diabetic Care Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03304938","briefTitle":"Lavender Aromatherapy on Sleep Quality and Metabolic Parameters of Type 2 Diabetic Patients With Insomnia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shiraz University of Medical Sciences"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Sleep Disturbance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lavender Oil"},{"name":"Placebos"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03444467","briefTitle":"First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NNC9204-1513"},{"name":"Glucagon"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00867555","briefTitle":"Green Tea, High in Epigallocatechin Gallate (EGCG) and Postprandial Fat Oxidation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"},"collaborators":[{"name":"DSM Nutritional Products, Inc."}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Effect of the green tea extract TEAVIGO, high in EGCG, on postprandial fat oxidation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01475201","briefTitle":"Step Monitoring to Improve ARTERial Health"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"McGill University Health Centre/Research Institute of the McGill University Health Centre"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Step count prescription"},{"name":"Usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00205660","briefTitle":"Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Washington University School of Medicine"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Schizophrenia","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Stayers"},{"name":"Switchers"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06199440","briefTitle":"Azithromycin Versus Doxycycline on Restistin Level in Periodontitis Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"King Abdulaziz University"}},"conditionsModule":{"conditions":["Periodontal Diseases","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Group I"},{"name":"Group II"},{"name":"Group III"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00918151","briefTitle":"A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Korea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00887874","briefTitle":"A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Taiwan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01289145","briefTitle":"Stage-based Exercise Promotion Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Freie Universität Berlin"}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Motivational intervention"},{"name":"Volitional intervention"},{"name":"Active Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00877526","briefTitle":"A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Malaysia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00874159","briefTitle":"A Survey to Evaluate Diabetes Management, Control, Complications and Psychosocial Aspects of Diabetic Patients in Philippines"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00129233","briefTitle":"Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nagoya University"}},"conditionsModule":{"conditions":["Hypertension","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Valsartan"},{"name":"Amlodipine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00737815","briefTitle":"Randomized Crossover Study of Magnesium Supplementation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, Los Angeles"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Inflammation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Magnesium Citrate: a total of 500 mg elemental magnesium"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00836030","briefTitle":"A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Singapore"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05890950","briefTitle":"A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kallyope Inc."}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes Mellitus in Obese"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"K-757 and K-833"},{"name":"Matching placebo to K-757 and K-833"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00839878","briefTitle":"A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Bangladesh"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00713440","briefTitle":"Incretin Physiology Associated With Steroid Hormone Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Glostrup University Hospital, Copenhagen"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Steroids"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral glucose test (OGTT); isoglycaemic iv. clamp; liquid meal test; Gastric Emptying Rate; Prednisolone; Paracetamol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00849342","briefTitle":"Observational Study on Levemir® in Obese Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00805922","briefTitle":"A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Thailand"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02549495","briefTitle":"Impact of Community Health Workers on Adherence to Therapy for Non-Communicable Chronic Disease in Chiapas, Mexico"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Brigham and Women's Hospital"},"collaborators":[{"name":"Harvard University"}]},"conditionsModule":{"conditions":["Hypertension","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00860613","briefTitle":"Medical Nutrition Therapy Program for Pregnant Women With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes"}},"conditionsModule":{"conditions":["Gestational Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"medical nutrition therapy program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00334919","briefTitle":"RCT of the Naturopathic Anti-Inflammatory Diet"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National University of Natural Medicine"},"collaborators":[{"name":"National Center for Complementary and Integrative Health (NCCIH)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Prediabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diet (Anti-Inflammatory or standard diabetic diet)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00788853","briefTitle":"A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Indonesia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04303819","briefTitle":"The Effect of Exenatide on Fasting Bile Acids"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Beijing Chao Yang Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus in Obese"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00872846","briefTitle":"Balance System Study in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Beta-Stim Ltd."},"collaborators":[{"name":"Meditrial Europe Ltd."}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BALANCE System intestinal electrical stimulator"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01578460","briefTitle":"Healthy Moms, Healthy Babies"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Stewart Harris"},"collaborators":[{"name":"Juvenile Diabetes Research Foundation"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Gestational Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous Glucose Monitoring"},{"name":"Glucose Meter"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03987841","briefTitle":"Intervention Mapping to Adapt a Mindfulness-based Intervention for Adults With Diabetes and Emotional Distress"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alabama at Birmingham"},"collaborators":[{"name":"National Center for Advancing Translational Sciences (NCATS)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Stress"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Integrated MBSR/DSME intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00522470","briefTitle":"Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baskent University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rosiglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01281228","briefTitle":"The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Amsterdam UMC, location VUmc"},"collaborators":[{"name":"Eli Lilly and Company"},{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 2","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"exenatide + exendin (9-39)"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03648138","briefTitle":"Testing the Influence of Different Sugary Drink Warning Label Designs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pennsylvania"},"collaborators":[{"name":"Drexel University"},{"name":"New York University"},{"name":"University of Connecticut"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Obesity","Weight Gain","Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sugary drink warning labels"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02014740","briefTitle":"Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Miami"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Overweight","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00007800","briefTitle":"NEW DAY: Nutrition, Exercise, Weight Loss, Diabetes And You"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Behavioral Group Weight Loss Intervention"},{"name":"Motivational Interviewing"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01531569","briefTitle":"Single Oral Dose of BeneFlax to Healthy Young and Older Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Saskatchewan"},"collaborators":[{"name":"Saskatchewan Health Research Foundation"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypercholesterolemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BeneFlax - 38% secoisolariciresinol diglucoside (SDG)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02914691","briefTitle":"Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Peter Rossing"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozine 10 mg once daily tablet treatment"},{"name":"Placebo identical once daily tablet treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00956735","briefTitle":"Effects of Pistachios on Cardiovascular Responses to Stress in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Penn State University"},"collaborators":[{"name":"American Pistachio Growers"}]},"conditionsModule":{"conditions":["Cardiovascular Disease","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pistachio"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02240420","briefTitle":"Diabetes Prevention Among Post-partum Women With History of Gestational Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Francisco"},"collaborators":[{"name":"San Francisco Department of Public Health"},{"name":"San Francisco General Hospital"},{"name":"Sonoma Department of Public Health"}]},"conditionsModule":{"conditions":["Gestational Diabetes Mellitus","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Life Style Counseling (Star-Mama)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02784275","briefTitle":"A Study to Evaluate the Efficacy and Safety of Cyclo-Z in Patients With Obese Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NovMetaPharma Co., Ltd."}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2 in Obese"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cyclo-Z"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00467285","briefTitle":"Effect of Diabetic Medications on Bone Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"US Department of Veterans Affairs"}},"conditionsModule":{"conditions":["Osteoporosis","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00494767","briefTitle":"Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GW869682"},{"name":"GSK189075"},{"name":"GSK189075-Placebo"},{"name":"GW869682-Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03783598","briefTitle":"Person-Centered, Occupation Based Therapy for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Uskudar University"},"collaborators":[{"name":"Hacettepe University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Occupational Therapy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Person centered, occupation based intervention support with problem solving therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02627287","briefTitle":"A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen®"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FlexPen®"},{"name":"DV3316 pen-injector"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01882036","briefTitle":"Bariatric Surgery And Adipose Inflammation Dysfunction and Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Minnesota"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gastric Bypass w/ matched hypocaloric diet"},{"name":"Hypocaloric diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03272074","briefTitle":"Egg Consumption and Glycemic Control in Individuals With Pre- and Type II-diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Florida State University"},"collaborators":[{"name":"Egg Nutrition Center"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity","Pre Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Egg and egg white"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02694172","briefTitle":"Human Faecal Microbiota in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Société des Produits Nestlé (SPN)"},"collaborators":[{"name":"University Hospital, Geneva"},{"name":"Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement"},{"name":"Imperial College London"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Healthy","Overweight"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fiber rich cereal bars"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05363774","briefTitle":"A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Healthy Volunteers (Diabetes Mellitus, Type 2)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NNC0519-0130"},{"name":"Placebo (NNC0519-0130)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04510493","briefTitle":"Canakinumab in Patients With COVID-19 and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Basel, Switzerland"},"collaborators":[{"name":"Novartis"},{"name":"Swiss National Science Foundation"}]},"conditionsModule":{"conditions":["Coronavirus Infection","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canakinumab"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01601574","briefTitle":"Weight Loss Study for People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of South Carolina"},"collaborators":[{"name":"WW International Inc"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Overweight","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Weight Watchers modified program"},{"name":"Standard Care group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00337038","briefTitle":"Endothelial Function as a Marker for Blood Pressure Control Among Hypertensive Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Soroka University Medical Center"}},"conditionsModule":{"conditions":["Hypertension","Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"N-acetylcystein(drug)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03776227","briefTitle":"A Bioequivalence Study Testing Two Formulations of Sotagliflozin in Healthy Male and Female Subjects Under Fasted Conditions"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Healthy Subjects"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sotagliflozin (SAR439954)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04501991","briefTitle":"Short-term Impact of COVID-19 Lockdown on Metabolic Control of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pisa"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Metabolic Control"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"antidiabetic treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01916174","briefTitle":"A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/liraglutide"},{"name":"insulin degludec/liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06528327","briefTitle":"Bioactive Microstructured Anti Microbial Precoated Surface Implant Versus Non-coated Surface Implant in Type 2 Diabetic Patients in the Mandible"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hams Hamed Abdelrahman"}},"conditionsModule":{"conditions":["Dental Implant","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pre coated impants"},{"name":"Non coated implant surface"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00474630","briefTitle":"A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Orexigen Therapeutics, Inc"}},"conditionsModule":{"conditions":["Obesity","Overweight","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Naltrexone SR 32 mg/bupropion SR 360 mg/ day"},{"name":"Placebo"},{"name":"Ancillary therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05870293","briefTitle":"EFFECT OF DIABETES NURSE COACHING ON DIABETES"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tuğba Bilgehan"}},"conditionsModule":{"conditions":["Nurse's Role","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"nurse coaching"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01298882","briefTitle":"Diacerein on Insulin Secretion in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Coordinación de Investigación en Salud, Mexico"},"collaborators":[{"name":"National Council of Science and Technology, Mexico"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Overweight","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diacerein"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01064414","briefTitle":"An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Renal Insufficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02632747","briefTitle":"Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Placebo (matching empagliflozin)"},{"name":"ramipril"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05144750","briefTitle":"Fruit and Vegetable Prescription in the Community Health Center Setting"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Wholesome Wave"},"collaborators":[{"name":"One Community Health"},{"name":"Yale-Griffin Prevention Research Center"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 2","Poverty"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fruit and Vegetable Prescription"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02043886","briefTitle":"Acarbose, Postprandial Hypotension and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of British Columbia"},"collaborators":[{"name":"Canadian Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Postprandial Hypotension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acarbose"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01297738","briefTitle":"Diet, Insulin Sensitivity And the Brain"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)"},"collaborators":[{"name":"Netherlands Organisation for Scientific Research"}]},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Meal size increase with HFHS"},{"name":"Meal size increase with HS"},{"name":"Meal frequency increase with HFHS"},{"name":"Meal frequency increase with HS"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05369871","briefTitle":"Evaluation of a Closed-loop System for the Treatment of Type 2 Diabetes at Home (DT2_2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diabeloop"},"collaborators":[{"name":"Icadom"},{"name":"AGIR à Dom"},{"name":"University Hospital, Grenoble"},{"name":"Centre Hospitalier Annecy Genevois"},{"name":"Centre Hospitalier Metropole Savoie"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2 - Insulin-Treated"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Closed-loop system"},{"name":"Open-loop system"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01931982","briefTitle":"Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bispebjerg Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Microvascular Dysfunction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Victoza"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05688631","briefTitle":"Dietary Antioxidants and Thiol Disulfide Homeostasis in T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ankara Yildirim Beyazıt University"},"collaborators":[{"name":"Baskent University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Antioxidative Stress"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dietary antioxidant intake"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01948986","briefTitle":"Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Renal Impairment","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ertugliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01440257","briefTitle":"A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"ChemoCentryx"}},"conditionsModule":{"conditions":["Diabetic Nephropathy","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"CCX140-B"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00205738","briefTitle":"Janssen - Glucose Regulation/Risp/Olanz"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Washington University School of Medicine"},"collaborators":[{"name":"Janssen, LP"}]},"conditionsModule":{"conditions":["Schizophrenia","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Risperidone, Olanzapine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00205725","briefTitle":"Pfizer/IVGTT/Ziprasidone/Olanzapine"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Washington University School of Medicine"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Schizophrenia","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ziprasidone, Olanzapine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02631902","briefTitle":"Diabetes em Movimento® - Community-based Lifestyle Intervention Program for Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Trás-os-Montes and Alto Douro"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Diabetes-Related Complications"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise"},{"name":"Dietary intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03248401","briefTitle":"Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Bundang Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Carotid Atherosclerosis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cilostazol"},{"name":"Aspirin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03845114","briefTitle":"Insulin-based Strategies to Prevent Hypoglycemia During Two Types of Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institut de Recherches Cliniques de Montreal"},"collaborators":[{"name":"McGill University Health Centre/Research Institute of the McGill University Health Centre"}]},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continous exercise"},{"name":"Interval exercise"},{"name":"Reduction of basal insulin by 40%"},{"name":"Reduction of basal insulin by 80%"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00207233","briefTitle":"Use of MCT Oil for Enhancement of Weight Loss and Glycemic Control in Obese Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boston Medical Center"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MCT oil hypocaloric liquid diet"},{"name":"LCT hypocaloric liquid diet"},{"name":"Subcutaneous abdominal adipose tissue biopsy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01378117","briefTitle":"Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Hospitalization","Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"glargine"},{"name":"lispro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03360604","briefTitle":"Utilizing Glycaemic Index: An Investigation of the Glycaemia and Cognition in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Matthew Grout"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Cognitive Impairment"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low Glycaemic Diet"},{"name":"High Glycaemic Diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01695278","briefTitle":"A Pilot Intervention Study of Health Coaching to Promote Diabetes Self-Care in the Community"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Northwestern University"},"collaborators":[{"name":"Diabetes Action Research and Education Foundation"}]},"conditionsModule":{"conditions":["Diabetes Complications","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Telephone Counseling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01076634","briefTitle":"Comparison of Two NN1250 Formulations in Subjects With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"insulin degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00869128","briefTitle":"A Study of the Efficacy of Prolonged-Release Melatonin Versus Placebo in Diabetic Patients Suffering From Insomnia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Neurim Pharmaceuticals Ltd."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Insomnia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Circadin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00328393","briefTitle":"Effect of Pioglitazone on Ambulatory Blood Pressure"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Erlangen-Nürnberg Medical School"}},"conditionsModule":{"conditions":["Hypertension","Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05624853","briefTitle":"A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic Pain"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yuhan Corporation"}},"conditionsModule":{"conditions":["Neuropathic Pain","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pregabalin sustained release tablet"},{"name":"pregabalin immediate release capsule"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00108927","briefTitle":"Improving Diabetes in Primary Care (IMPACT)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Type 2 Diabetes Mellitus","Hypertension"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TRANSLATE"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04539769","briefTitle":"Impact of the Type of Reconstruction Methods on Diabetes Following Laparoscopic Distal Gastrectomy in Patients With Gastric Cancer and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kyungpook National University Chilgok Hospital"},"collaborators":[{"name":"Kyungpook National University Hospital"}]},"conditionsModule":{"conditions":["Stomach Neoplasms","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"conventional BI"},{"name":"long-limb BII"},{"name":"long-limb RY group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00108459","briefTitle":"Low Carbohydrate Diet Compared to Calorie and Fat Restricted Diet in Patients With Obesity and Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"US Department of Veterans Affairs"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes","Hyperlipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low Carbohydrate Diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01061060","briefTitle":"The Effect of Prostaglandin I2 on the Endothelial Cell Function Disorder in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yonsei University"},"collaborators":[{"name":"Astellas Pharma Korea, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Peripheral Microvascular Symptoms"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Prostaglandin I2"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01812694","briefTitle":"Lifestyle Interventions for Expectant Mothers (LIFE-Moms Phoenix) - Phoenix"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Obesity","Diet Therapy","Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Enhanced standard care"},{"name":"Intensive lifestyle intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01667783","briefTitle":"Improving Diabetes Through Lifestyle and Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johns Hopkins University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gastric Banding"},{"name":"Medical Weight Loss"},{"name":"Gastric Bypass"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02938026","briefTitle":"Changes of Diet, Physical Activity and Sleep Pattern and Their Effects on Glycemic and Weight Control in Hong Kong Chinese Obese Patients With Type 2 Diabetes After Bariatric Surgery Compared to Telephone Intensive Lifestyle Counselling"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chinese University of Hong Kong"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2 in Obese"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bariatric surgery"},{"name":"Telephone Intensive Lifestyle Counselling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01538576","briefTitle":"Paediatric Subjects - Special Survey"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01536613","briefTitle":"Post Marketing Surveillance Study of Biphasic Insulin Aspart 30"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01739205","briefTitle":"Biobehavioral Bases & Management of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Miami"}},"conditionsModule":{"conditions":["Type 2 Diabetes and Depression"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CALM-D Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01492959","briefTitle":"Observational Study With InnoLet® in Daily Clinical Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin human"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01492205","briefTitle":"NovoLet® Acceptance Study Within the Hospital Practise in Indonesia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin human"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01492153","briefTitle":"NovoLet® Surveillance Study on Using Human Insulin System in Indonesia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic human insulin"},{"name":"isophane human insulin"},{"name":"human soluble insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01490112","briefTitle":"Surveillance Study of NovoRapid® for New Drug Re-examination"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01487382","briefTitle":"Special Survey for Paediatric Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01487369","briefTitle":"Special Survey of Production of Insulin Aspart Specific Antibody"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00479986","briefTitle":"Effects of Pioglitazone in Type 2 Diabetes Mellitus and Coronary Heart Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"IKFE Institute for Clinical Research and Development"},"collaborators":[{"name":"Takeda"},{"name":"Johannes Gutenberg University Mainz"},{"name":"Heidelberg University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pioglitazone"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00911625","briefTitle":"Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Loyola University"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Renal Insufficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"0.5 units/kg daily insulin"},{"name":"0.25 units/kg daily insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01628341","briefTitle":"French Observational Survey to Assess Hypoglycaemia in Insulin-treated Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02932436","briefTitle":"Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johannes Gutenberg University Mainz"},"collaborators":[{"name":"Boehringer Ingelheim"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diastolic Dysfunction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03492580","briefTitle":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Cardiovascular Diseases"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin"},{"name":"Empagliflozin"},{"name":"Dapagliflozin"},{"name":"Dipeptidyl Peptidase-4 (DPP-4) Inhibitors"},{"name":"Glucagon-like Peptide-1 (GLP-1) Agonist"},{"name":"Anti-hyperglycemic Agents (AHA)"},{"name":"Thiazolidinediones (TZD)"},{"name":"Sulfonylureas (SU)"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04626453","briefTitle":"Oxygenation Changes After 2-month Exercise in Sedentary Older Adults With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"State University of New York at Buffalo"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Oxygen Deficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"2-month home moderate-intensity exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04569630","briefTitle":"The HEADWIND Study - Part 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Insel Gruppe AG, University Hospital Bern"},"collaborators":[{"name":"ETH Zurich"},{"name":"University of St.Gallen"}]},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Controlled hypoglycaemic state while driving"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02657018","briefTitle":"Mobile Exergaming in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Basel"},"collaborators":[{"name":"Swiss National Science Foundation"}]},"conditionsModule":{"conditions":["Overweight","Obesity","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MOBIGAME"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00576784","briefTitle":"Metabolic Effects of Pioglitazone in Type II Diabetic Patients Previously Treated With Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"IKFE Institute for Clinical Research and Development"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pioglitazone and glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02501876","briefTitle":"Type 2 Diabetes Mellitus as Catalyst for Alzheimer's Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital Universitari Vall d'Hebron Research Institute"}},"conditionsModule":{"conditions":["Alzheimer´s Disease","Diabetes Mellitus Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"There is a retrospectiv observational study. No intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04068272","briefTitle":"Safety of Bosentan in Type II Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Retinset SL"},"collaborators":[{"name":"Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bosentan"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03341117","briefTitle":"Acetylsalicylic Acid and Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centro Universitario de Ciencias de la Salud, Mexico"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Antioxidant Enzyme System"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acetylsalicylic acid"},{"name":"Calcined magnesia"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03002545","briefTitle":"Magnesium Supplementation in Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Protina Pharmazeutische GmbH"}},"conditionsModule":{"conditions":["Effect of Magnesium in Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Magnesium citrate"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04723628","briefTitle":"The Effect of Telephone Consulting on HbA1 and Self-Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aksaray University"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Self-management"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intervention group (telephone counseling)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03150030","briefTitle":"Hypoglycaemia and Cardiac Arrhythmias in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Arrhythmia, Cardiac"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Combined hyper- and hypoglycaemic clamp"},{"name":"Loop recorder (Reveal LINQ, Medtronic, Minneapolis, MN, USA)"},{"name":"Continuous glucose monitoring (iPro2, Medtronic, Minneapolis, MN, USA)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03406910","briefTitle":"Egg Intake and Risk of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Loma Linda University"},"collaborators":[{"name":"American Egg Board"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Heart Diseases"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03144271","briefTitle":"Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00454597","briefTitle":"Effect of the Omentectomy on the Hyperglycemia and the Resistance to the Insulin in Patients With Morbid Obesity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidad de Guanajuato"}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"omentectomy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02650206","briefTitle":"Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Stanford University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes Mellitus, Type II","Diabetes Mellitus, Adult-Onset","Inflammation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Victoza (liraglutide) with dietician monitoring"},{"name":"Placebo with dietician monitoring"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01137058","briefTitle":"Ubiquitous Healthcare for Elderly Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Bundang Hospital"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"U-healthcare service"},{"name":"SMBG group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04410718","briefTitle":"Glycaemia and Cardiac Function in Patients With COVID-19"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Steno Diabetes Center Copenhagen"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1","COVID"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glycaemic levels"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02937987","briefTitle":"Dietary Intake, Eating Behavior, Physical Activity Level and Their Relationships With Glycemic and Weight Control in Hong Kong Chinese Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chinese University of Hong Kong"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus in Obese"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01147627","briefTitle":"Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sun Yat-sen University"},"collaborators":[{"name":"Eli Lilly and Company"},{"name":"Amylin Pharmaceuticals, LLC."},{"name":"Ministry of Health, China"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Newly Diagnosed"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide injection"},{"name":"Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01846377","briefTitle":"Video Games for Obesity and Diabetes Prevention-Diab & Nano"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baylor College of Medicine"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"G4H-Diab-Nano"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04657003","briefTitle":"A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Overweight","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00432276","briefTitle":"Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin"},{"name":"Pioglitazone"},{"name":"Metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05237271","briefTitle":"Clinical Utility Trial for the SomaLogic CVD-T2D Test"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Qure Healthcare, LLC"},"collaborators":[{"name":"SomaLogic, Inc."}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Educational Materials on the Cardiovascular Disease in Type 2 Diabetes (CVD-T2D)"},{"name":"Educational Materials on the CVD-T2D and Bundled Metabolic Panel"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00570739","briefTitle":"Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Hypercholesterolemia","Pre-diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin HCl and Colesevelam Placebo"},{"name":"Metformin HCl tablets and Colesevelam tablets"},{"name":"Colesevelam placebo"},{"name":"Colesevelam"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01128374","briefTitle":"The Effect of Non-Surgical Periodontal Therapy on Glycemic Control and Bacterial Levels in a Mexican-American Population With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center, Houston"},"collaborators":[{"name":"University of Alabama at Birmingham"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Periodontal Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Periodontal Scaling and root planing"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03802487","briefTitle":"Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Healthy Subjects"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sotagliflozin (SAR439954)"},{"name":"14C-microtracer"},{"name":"Charcoal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05004428","briefTitle":"A Study to Learn More About Chronic Kidney Disease (CKD) in Patients With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Chronic Kidney Disease"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02007278","briefTitle":"Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Hypoglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin and metformin (combination)"},{"name":"glimepiride"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02680873","briefTitle":"Efficacy of SASI Bypass for Type-2 Diabetic Obese Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mansoura University"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2 in Obese"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SASI bypass"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06077708","briefTitle":"Diabetes Mellitus and Periodontitis and Vitamin D Supplementation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kırıkkale University"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2 With Periodontal Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin D3K2"},{"name":"Saline Solution"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03262415","briefTitle":"PRECISION Study: Evaluating the Accuracy of the LabPatch Continuous Glucose Monitor"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Joslin Diabetes Center"},"collaborators":[{"name":"Cambridge Medical Technologies, LLC"}]},"conditionsModule":{"conditions":["Type1 Diabetes Mellitus","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LabPatch Continuous Glucose Monitoring (CGM)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04771403","briefTitle":"Two Way Crossover Closed Loop Study MPC vs FMPD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oregon Health and Science University"},"collaborators":[{"name":"Juvenile Diabetes Research Foundation"},{"name":"The Leona M. and Harry B. Helmsley Charitable Trust"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FMPD AP algorithm"},{"name":"MPC AP system"},{"name":"Dexcom G6 Continuous Glucose Monitoring (CGM) System"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02157480","briefTitle":"Effect of Electrostimulation on Glucose Profile of Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Caen"},"collaborators":[{"name":"University Hospital, Rouen"},{"name":"Amiens University Hospital"},{"name":"University Hospital, Lille"},{"name":"General Hospital Roubaix"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Physical Activity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 3 days per week ."},{"name":"electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 5 days per week"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05680207","briefTitle":"Empowerment Training on Type 2 Diabetes Patients on Empowerment Levels and Clinical Findings"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kutahya Health Sciences University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Empowerment","Patient Empowerment"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes self- management education (DSME) program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00700648","briefTitle":"An Observational Study to Assess Safety and Effectiveness of Intravenous NovoRapid® in Hospitalised Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02827630","briefTitle":"Proteus Discover in Subjects With Uncontrolled Hypertension and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Proteus Digital Health, Inc."},"collaborators":[{"name":"Syneos Health"}]},"conditionsModule":{"conditions":["Hypertension","Diabetes Mellitus, Type 2","Hypercholesterolemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Proteus Discover"},{"name":"Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01346527","briefTitle":"Fat Metabolism in Pregnancy and Neonatal Heart Function in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Washington University School of Medicine"},"collaborators":[{"name":"Thrasher Research Fund"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Pregnancy"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00547027","briefTitle":"Promoting Physical Activity Among Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Florida State University"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Physical Activity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"print-based physical activity intervention"},{"name":"usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02699541","briefTitle":"The Effectiveness of Diabetes Self-Management Education Program Based on Behavioural Change Theory"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Nottingham"}},"conditionsModule":{"conditions":["Health Behavior","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Self-Management Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00993603","briefTitle":"Lifestyle Intervention in Obese Non-diabetic Adults With a Family History of Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Royal Bournemouth Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"8-month group lifestyle programme"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00566592","briefTitle":"The Effect of Ethanol on Overnight Glucose Regulation in Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Type 2 Diabetes, Insulin Requiring"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"oral ethanol, overnight"},{"name":"IV ethanol"},{"name":"soda water"},{"name":"soda water"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04243174","briefTitle":"The Use of Short SMS Messaging With Type 2 Diabetes (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Nottingham"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Physical Exercise"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SMS Messaging"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05372471","briefTitle":"Efficacy of the Digital Platform for Diabetes Care Compared to Usual Care in Patients Diagnosed With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital Universitario San Ignacio"}},"conditionsModule":{"conditions":["Type 2 Diabetes Treated With Insulin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"mHealth"},{"name":"Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01087645","briefTitle":"A Two Part Trial Investigating the Safety of NN9925 in Healthy Male Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NN9925 (oral)"},{"name":"NN9925 (i.v.)"},{"name":"placebo"},{"name":"NN9925 (oral)"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00977262","briefTitle":"Postprandial Inflammation and Fatty Acids"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Wageningen University"},"collaborators":[{"name":"Dutch Diabetes Research Foundation"}]},"conditionsModule":{"conditions":["Cardiovascular Disease","Diabetes Type 2","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High saturated fat shake"},{"name":"High monounsaturated fat shake"},{"name":"High polyunsaturated fat shake"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02597101","briefTitle":"Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nick Giannoukakis, PhD"},"collaborators":[{"name":"National Institutes of Health (NIH)"},{"name":"University of Pittsburgh"},{"name":"University of South Florida"},{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"saxagliptin"},{"name":"AZD9668"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01037582","briefTitle":"A Two Part Trial Investigating the Safety of NN9924 in Healthy Male Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NN9924 (oral)"},{"name":"placebo"},{"name":"NN9924 (oral)"},{"name":"placebo"},{"name":"NN9924 (s.c.)"},{"name":"NN9924 (i.v.)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00475371","briefTitle":"A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mannkind Corporation"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Healthy Males"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MKC253 Inhalation Powder"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05260983","briefTitle":"Acceptance and Commitment Therapy Principles for Diabetes Prevention"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Oregon"}},"conditionsModule":{"conditions":["PreDiabetes","Diabetes Mellitus, Type 2","Diabetes","Diabetes type2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Prevention Education and Acceptance and Commitment Therapy"},{"name":"Diabetes Prevention Education Only"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05647083","briefTitle":"The Effect of Massage on Diabetic Parameters"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abant Izzet Baysal University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Peripheral Neuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Massage therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02917031","briefTitle":"Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Heart Failure"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Sitagliptin"},{"name":"Placebo to match saxagliptin"},{"name":"Placebo to match sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01665989","briefTitle":"Improving Diabetes Outcomes Through Lifestyle Change (IDOLc)Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Massachusetts General Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Group Lifestyle Program"},{"name":"Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00309127","briefTitle":"Effects of Disease Management on Development of End Stage Renal Disease in Type 2 Diabetic Patients With Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chinese University of Hong Kong"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","DM Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Multidisciplinary team care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02839044","briefTitle":"A Randomized, Placebo-controlled, Double Blind Trial to Investigate Whether Vitamin K2 Can Influence Arterial Calcification in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"UMC Utrecht"}},"conditionsModule":{"conditions":["Arterial Calcification","Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Menaquinone-7"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02479022","briefTitle":"A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin 320"},{"name":"insulin glargine"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02343107","briefTitle":"E-coaching for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Assistance Publique - Hôpitaux de Paris"}},"conditionsModule":{"conditions":["Abdominal Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"e-coaching"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01555008","briefTitle":"Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lexicon Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Renal Impairment"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LX4211"},{"name":"LX4211 Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03185741","briefTitle":"Regimen Education and Messaging in Diabetes (REMinD)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Northwestern University"},"collaborators":[{"name":"Icahn School of Medicine at Mount Sinai"},{"name":"Emory University"},{"name":"Northwestern Memorial Hospital"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Medication Adherence"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"UMS Strategy"},{"name":"SMS Text Messaging"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06480058","briefTitle":"Predictors of Bariatric Surgery Weight Loss"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kuwait University"},"collaborators":[{"name":"Dasman Diabetes Institute"},{"name":"Jaber Al Ahmad Al Sabah Hospital"}]},"conditionsModule":{"conditions":["Obesity, Mild","Obesity, Morbid","Diabete Mellitus","Diabetes Mellitus, Type 2","Eating Disorders"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02551315","briefTitle":"Microarchitecture, Bone Strength and Fracture Risk in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Basel, Switzerland"},"collaborators":[{"name":"University Hospital Schleswig-Holstein"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Bone Fractures"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01145092","briefTitle":"Effects of Six Months of Moderate Resistance- Versus Endurance-Training on Muscle ATP Synthesis in First-Degree Relatives of Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Landsteiner Institut"},"collaborators":[{"name":"Mein Hanusch-Krankenhaus"},{"name":"Karl-Landsteiner Institute for Endocrinology and Metabolism"},{"name":"Medical University of Vienna"},{"name":"Lund University"},{"name":"Fondazione C.N.R./Regione Toscana \"G. Monasterio\", Pisa, Italy"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exercise training, endurance training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04831216","briefTitle":"Delivering Health: Addressing Diabetes and Food Insecurity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Arkansas"}},"conditionsModule":{"conditions":["Food Insecurity","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Type 2 Diabetes Appropriate Food Boxes + Diabetes Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01588795","briefTitle":"Renal Denervation in Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Assistance Publique - Hôpitaux de Paris"}},"conditionsModule":{"conditions":["Diabetic Nephropathy","Persistent Proteinuria With Type II Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Percutaneous renal denervation and TMNS"},{"name":"Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03728647","briefTitle":"The Effectiveness of Multimedia Education for Patients With Type 2 Diabe Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kaohsiung Medical University Chung-Ho Memorial Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Insulin","Education"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"multimedia health education"},{"name":"regular health education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00760344","briefTitle":"Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SYR-472"},{"name":"SYR-472"},{"name":"SYR-472"},{"name":"SYR-472"},{"name":"Placebo"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00767208","briefTitle":"Diabetes and Metabolic Postprandial Responses"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre de Recherche en Nutrition Humaine Rhone-Alpe"},"collaborators":[{"name":"LESAFFRE SA"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Overweight"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"oral glucose load"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00328965","briefTitle":"Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Essential Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lacidipine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00542113","briefTitle":"Diabetes Virtual Trek: Obesity and Diabetes Prevention Through Science Enrichment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Colorado State University"},"collaborators":[{"name":"Poudre School District, Fort Collins, CO"},{"name":"Montezuma-Cortez School District, Cortez, CO"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DvtProgram ENERGY"},{"name":"DvtProgram ENERGY"},{"name":"DvtProgramENERGY"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02161588","briefTitle":"A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02146079","briefTitle":"A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02526615","briefTitle":"Effects of Rosiglitazone and Metformin on Metabolism in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Turku University Hospital"},"collaborators":[{"name":"SmithKline Beecham"}]},"conditionsModule":{"conditions":["Insulin Sensitivity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone"},{"name":"Metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06489457","briefTitle":"The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Medical Centre Ljubljana"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity","Functional Hypogonadism"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"},{"name":"Testosterone Undecanoate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05083559","briefTitle":"Two Way Crossover Closed Loop Study R-AP vs MPC"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oregon Health and Science University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MPC AP algorithm"},{"name":"Robust R-AP algorithm"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05730634","briefTitle":"The Effect of Statin Treatment on Arterial Wall Inflammation as Assessed With 68Ga-DOTATATE PET-CT"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Vascular Inflammation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Atorvastatin 40 Mg Oral Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02022254","briefTitle":"Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"placebo"},{"name":"metformin"},{"name":"warfarin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01595594","briefTitle":"Comparison Between aPDT and Systemic Doxycycline on Non-surgical Periodontal Therapy in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Sao Paulo"},"collaborators":[{"name":"Fundação de Amparo à Pesquisa do Estado de São Paulo"}]},"conditionsModule":{"conditions":["Periodontal Disease","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Systemic Doxycycline and Sham aPDT"},{"name":"aPDT + Doxycycline Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02016911","briefTitle":"Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00770081","briefTitle":"Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Renal Insufficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"},{"name":"sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03380988","briefTitle":"Fiber-enriched Buckwheat Pasta and Glucose Variability in Patients With Type 1 Diabetes and Celiac Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Federico II University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Celiac Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acute test meal with fiber-enriched buckwheat pasta"},{"name":"Acute test meal with corn pasta"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00765830","briefTitle":"Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Renal Insufficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00317915","briefTitle":"Irbesartan in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Steno Diabetes Center Copenhagen"},"collaborators":[{"name":"Bristol-Myers Squibb"},{"name":"Sanofi-Synthelabo"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Microalbuminuria","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Irbesartan treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01951339","briefTitle":"Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Denver"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Glimepiride"},{"name":"Placebo"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01375322","briefTitle":"ADDM Study - Amtrel and Co-Diovan in Type 2 Diabetes Mellitus Hypertension Patients With Microalbuminuria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"TSH Biopharm Corporation Limited"}},"conditionsModule":{"conditions":["Hypertension","Diabetes Mellitus, Type 2","Albuminuria"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Amlodipine+Benazepril"},{"name":"Valsartan+Hydrochlorothiazide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00057317","briefTitle":"Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ro 205-2349"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04127448","briefTitle":"Exergaming Versus Aerobic Exercises on Mild Cognitive Impairment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Riphah International University"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Cognitive Impairment"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exergaming Training Group"},{"name":"Aerobic Exercise Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04349696","briefTitle":"Pharmacokinetic and Pharmacodynamic Study of Glufast Tablets 10mg(Mitiglinide)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Orient Europharma Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Liver Dysfunction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mitiglinide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01866748","briefTitle":"Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"semaglutide"},{"name":"placebo"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04957589","briefTitle":"VLCD & Adjuvant Exercise Effect in Overweight Diabetic Men"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Nottingham"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2 in Obese"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Very Low Calorie Diet"},{"name":"High Intensity Interval Training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04461405","briefTitle":"INTEGRATE-D: A Pilot Test to Support Integration of Medical and Psychosocial Care for People With Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oregon Health and Science University"}},"conditionsModule":{"conditions":["Type II Diabetes","Primary Health Care","Behavioral Health"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INTEGRATE-D"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04263376","briefTitle":"Bariatric Surgery-Induced Shift in Gut Microbiome and NAFLD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Cleveland Clinic"}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type 2","NAFLD"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01946347","briefTitle":"Endothelial Function in Patients With Type 2 Diabetes Versus Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institute for Clinical and Experimental Medicine"}},"conditionsModule":{"conditions":["Insulin Resistance","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"mixed meal"},{"name":"Acute in vivo induced hyperinsulinemia"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03638349","briefTitle":"Actions & Insights Evaluating a Novel Diabetes Management Solution"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LifeScan Scotland Ltd"}},"conditionsModule":{"conditions":["Diabetes Mellitus ( Type 1 and Type 2)"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00331487","briefTitle":"Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"Rosiglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01186952","briefTitle":"Exercise Program Combined or Not With Nutritional intErvention in Adults With tyPe 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institut de Recherches Cliniques de Montreal"}},"conditionsModule":{"conditions":["Overweight","Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Caloric restriction"},{"name":"Diet intervention and structured exercise training program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03360058","briefTitle":"Obesity and Type 2 Diabetes - Raising the Issue of Weight Management in Primary Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NHS Greater Glasgow and Clyde"},"collaborators":[{"name":"University of Glasgow"}]},"conditionsModule":{"conditions":["Weight Management","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Small Talk Big Difference Immediate access training"},{"name":"Small Talk Big Difference delayed access training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01162876","briefTitle":"A Clinical Pharmacology Study of Saxagliptin in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kyowa Kirin Co., Ltd."}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"saxaglipitin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01690169","briefTitle":"Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NNC0113-0987"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02178501","briefTitle":"Omega-3 Fatty Acids Supplementation and Atherothrombotic Biomarkers in Type 2 Diabetes and Cardiovascular Disease."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jagiellonian University"},"collaborators":[{"name":"National Science Centre, Poland"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Cardiovascular Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omega-3 PUFA"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04407234","briefTitle":"A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Overweight","Obesity","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Acetaminophen"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00972452","briefTitle":"Blood Flow Responses to an Oral Glucose Tolerance Test in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Kansas Medical Center"},"collaborators":[{"name":"US Department of Veterans Affairs"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02694575","briefTitle":"The Impact of Glucose Lowering Therapies on Circulating Endothelial Progenitor Cells and Its Mobilising Factor Stromal Derived Factor-1α in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Leicester"},"collaborators":[{"name":"University Hospitals, Leicester"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Cardiovascular Diseases"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03568409","briefTitle":"ABO-GLYC in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aboca Spa Societa' Agricola"},"collaborators":[{"name":"Latis S.r.l."},{"name":"Fondazione Edmund Mach"}]},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ABO-GLYC"},{"name":"ABO-GLYC Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01597713","briefTitle":"A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NNC 0148-0000-0362"},{"name":"insulin glargine"},{"name":"placebo"},{"name":"NNC 0148-0000-0362"},{"name":"NNC 0148-0000-0362"},{"name":"NNC 0148-0000-0362"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02518581","briefTitle":"Validation of the Doubly Labelled Water Method in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Profil Institut für Stoffwechselforschung GmbH"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Doubly labelled water method"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00821665","briefTitle":"Blood Glucose Homeostasis in Type 2 Diabetes: the Effects of Saccharose"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"},"collaborators":[{"name":"Suikerstichting Nederland (Baarn)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Glycemic Control"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sucrose consumption"},{"name":"water consumption"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04232774","briefTitle":"Neurotronic Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Neurotronic, Inc."},"collaborators":[{"name":"Libra Medical"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus With Circulatory Complciation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"The Neurotronic arterial ablation catheter"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01572753","briefTitle":"Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"semaglutide"},{"name":"semaglutide"},{"name":"semaglutide"},{"name":"semaglutide"},{"name":"semaglutide"},{"name":"semaglutide"},{"name":"semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00286494","briefTitle":"Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin and pioglitazone"},{"name":"Alogliptin and pioglitazone"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02652026","briefTitle":"Effect of Non-surgical Periodontal Treatment on HbA1c in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Barcelona"}},"conditionsModule":{"conditions":["Chronic Periodontitis","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nonsurgical periodontal treatment"},{"name":"Dental Prophylaxis"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01377844","briefTitle":"Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Theracos"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EGT0001442"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03167918","briefTitle":"Lung Function in Patients With Early Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Liaoning University of Traditional Chinese Medicine"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Pulmonary Function"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Calcium Dobesilate"},{"name":"Xuefuzhuyu Decoction"},{"name":"Xuefuzhuyu Decoction & Calcium dobesilate"},{"name":"metformin"},{"name":"Mecobalamin Tablets"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00699023","briefTitle":"Ezetimibe and Statins on Postprandial Lipemia in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Federico II University"}},"conditionsModule":{"conditions":["Postprandial Lipemia","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ezetimibe tablets"},{"name":"simvastatin tablets"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02014259","briefTitle":"Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01473953","briefTitle":"Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide-depot"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02173067","briefTitle":"Anesthesia With Epinephrine in Diabetes Patients is Safe and Effective"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Sao Paulo General Hospital"},"collaborators":[{"name":"Fundação de Amparo à Pesquisa do Estado de São Paulo"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Coronary Disease"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04222738","briefTitle":"The Cardiovascular Effects of Ginger (Zingiber Officinale) in Patients With Type II Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yaounde Central Hospital"},"collaborators":[{"name":"NGATI Denetria NYONGA, Dr"},{"name":"SOBNGWI Eugène, Pr"},{"name":"MBANYA Jean Claude, Pr"}]},"conditionsModule":{"conditions":["Cardiovascular Benefits of Zingiber Officinale Roscoe in Patients With Type 2 Diabetes Mellitus Before and After 6 Weeks of add-on Therapy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GINOFF1"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01405261","briefTitle":"Trial Investigating the Safety of NNC 0113-0987 in Healthy Male Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"oral NNC 0113-0987"},{"name":"oral NNC 0113-0987"},{"name":"I.v. NNC 0113-0987"},{"name":"oral placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05409391","briefTitle":"Insulin Titration System Based on Deep Learning"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Zhongshan Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2 - Insulin-Treated"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Titration System"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03784612","briefTitle":"The Healthy Eating With APP technologY Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Karolinska Institutet"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Dietary Habits"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"App-technology for healthy eating habits"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04319003","briefTitle":"Pilot Sugar Reduction Intervention in Kiritimati Teenagers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Southern California"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sugar-reduction intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00692237","briefTitle":"Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Roma La Sapienza"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Endothelial Dysfunction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sildenafil"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02109094","briefTitle":"Investigating Markers of Energy Metabolism in Pregnant Women With Insulin Resistance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yale University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Gestational Diabetes","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00241085","briefTitle":"Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["PROTEINURIA","Hypertension","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"valsartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01363609","briefTitle":"Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Amsterdam UMC, location VUmc"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide treatment 12 weeks"},{"name":"insulin glargine treatment"},{"name":"GLP-1 receptor antagonist"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01272973","briefTitle":"Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"},{"name":"placebo"},{"name":"semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00558883","briefTitle":"AI(I)DA Acarbose and the Subclinical Inflammation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GWT-TUD GmbH"},"collaborators":[{"name":"Technische Universität Dresden"},{"name":"Diakonissen Krankenhaus Dresden, Germany"},{"name":"University of Regensburg"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Subclinical Inflammation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"acarbose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04791826","briefTitle":"Electronic Alerts for Heart Failure Prevention in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Texas Southwestern Medical Center"}},"conditionsModule":{"conditions":["Heart Failure","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"On-screen electronic alert"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01765894","briefTitle":"Influence of Moderate Exercise on Blood Glucose in Type 2 Diabetics and Healthy Controls"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Copenhagen"},"collaborators":[{"name":"Department of Biomedical Sciences"},{"name":"XLab, Center of Healthy Aging"}]},"conditionsModule":{"conditions":["Type 2 Diabetes and Exercise"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"45 minutes of moderate exercise at the fasted state. Before test day 2: 3 days of carbohydrate loading."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02972996","briefTitle":"Blueberry Consumption and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Albany Research Institute, Inc."}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Blueberry"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00276471","briefTitle":"Evaluation of the Tantalus System in Type 2 Diabetic Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"MetaCure Limited"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Implantable pulse generator and electrodes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02246712","briefTitle":"Influence of Diabetes on Tramadol Pharmacokinetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidade Estadual Paulista Júlio de Mesquita Filho"},"collaborators":[{"name":"University of Sao Paulo"}]},"conditionsModule":{"conditions":["Neuropathic Pain","Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Single oral dose of 100 mg racemic tramadol"},{"name":"CYP2D6 phenotype"},{"name":"CYP3A phenotype"},{"name":"CYP2B6 genotype"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05378295","briefTitle":"Personalized Fiber and Insulin Sensitivity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fermentable oligosaccharide"},{"name":"Personalized fiber mixture"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00843232","briefTitle":"Characterization of the Incretinpathy in Type 2 Diabetes Initiated After Sixty Years Old"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Campinas, Brazil"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Insulin Resistance"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03527667","briefTitle":"Incentivized Smoking Cessation for Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Oklahoma"},"collaborators":[{"name":"Cancer Research UK"},{"name":"University of Strathclyde"},{"name":"University College, London"}]},"conditionsModule":{"conditions":["Smoking Cessation","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Financial incentives"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01464099","briefTitle":"Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin aspart"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00320879","briefTitle":"Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Steno Diabetes Center Copenhagen"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Microalbuminuria"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"irbesartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04322240","briefTitle":"Alpha Lipoic Acid and Diabetes Mellitus: Potential Effects on Peripheral Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Benha University"}},"conditionsModule":{"conditions":["Diabetic Polyneuropathy","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alpha lipoic acid"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01291875","briefTitle":"Periodontal Treatment and Metabolic Control in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Sao Paulo"},"collaborators":[{"name":"Federal University of São Paulo"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Periodontal Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"non-surgical periodontal treatment"},{"name":"Supragingival biofilm control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02517866","briefTitle":"Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Essential Hypertension","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Azilsartan Medoxomil"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05915338","briefTitle":"Training on Using ıInsulin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Inonu University"}},"conditionsModule":{"conditions":["Insulin Dependent Diabetes","Diabetes type2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01164501","briefTitle":"Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Renal Insufficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BI 10773"},{"name":"Placebo"},{"name":"Placebo"},{"name":"BI 10773"},{"name":"Placebo"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00887094","briefTitle":"Aerobic Training, Aerobic-resistance Training and Glucose Profile (CGMS) in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital de Clinicas de Porto Alegre"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Treatment","Exercise"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acute aerobic exercise"},{"name":"Acute aerobic-resistance exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05553184","briefTitle":"Activation of Brown Adipose Tissue Thermogenesis in Humans Using Formoterol Fumarate (GB10)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Université de Sherbrooke"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Formoterol Fumarate 12 micrograms Inhalation Powder"},{"name":"Nicotinic Acid 50 MG Oral Tablet"},{"name":"Acute Cold Exposure"},{"name":"Positron Emission Tomography (PET)"},{"name":"Indirect calorimetry"},{"name":"dual-energy x-ray absorptiometry (DEXA scan)"},{"name":"Biopsy"},{"name":"iv lines"},{"name":"Electromyogram (EMG)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05549583","briefTitle":"Comparative Bioavailability Study of Sitagliptin/Metformin 50 mg/1000 mg Tablets in Healthy Male and Female Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Galenicum Health"}},"conditionsModule":{"conditions":["Bioequivalence","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00268541","briefTitle":"Physical Activity, Insulin Resistance and Function of Fat Tissue in the Offspring of Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NHS Greater Glasgow and Clyde"},"collaborators":[{"name":"British Heart Foundation"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Cardiovascular Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physical activity"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02065791","briefTitle":"Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"},"collaborators":[{"name":"The George Institute for Global Health, Australia"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00760110","briefTitle":"A Cohort Study of Morning Home Blood Pressure Measurement in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nagaoka Red Cross Hospital"}},"conditionsModule":{"conditions":["Hypertension","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"blood pressure measurements based on HBP or CBP"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03208309","briefTitle":"Effect of Diacerein in the Metabolic Control of Patients With DM Type 2 and Secondary Failure to Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"ANS Pharma"},"collaborators":[{"name":"University of Campinas, Brazil"},{"name":"Conselho Nacional de Desenvolvimento Científico e Tecnológico"}]},"conditionsModule":{"conditions":["Complications of Diabetes Mellitus","Diabetes Mellitus","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diacerein"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00693511","briefTitle":"Circuit Training and Motivational Interviewing to Reduce Type 2 Diabetes in Youth"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Obesity and Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Circuit Training"},{"name":"Circuit training + motivational interviewing"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06586775","briefTitle":"Outcome of Complete Pulpotomy in Healthy and Type 2 Diabetic Patients in Permanent Teeth with Irreversible Pulpitis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Postgraduate Institute of Dental Sciences Rohtak"}},"conditionsModule":{"conditions":["Irreversible Pulpitis","Diabetes Mellitus, Type 2","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pulpotomy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00270439","briefTitle":"Omentectomy for the Treatment of Diabetes Mellitus Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University"},"collaborators":[{"name":"United States Surgical Corporation"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Dyslipidemia","Hypercholesterolemia","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"removal of omentum"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01129258","briefTitle":"Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 2","Glucose Metabolism Disorders"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-04991532"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00184613","briefTitle":"Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Delivery Systems"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pump"},{"name":"insulin glargine"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01754662","briefTitle":"Effects of Combining Cocoa and Soy in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hull University Teaching Hospitals NHS Trust"},"collaborators":[{"name":"University of Hull"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Dietary Intervention"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Soy protein"},{"name":"Isoflavones"},{"name":"Cocoa"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04889859","briefTitle":"Impact of Biliopancreatic Limb Length on Diabetes Following Distal Gastrectomy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kyungpook National University Chilgok Hospital"}},"conditionsModule":{"conditions":["Stomach Neoplasm","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"long Roux limb Roux-en-Y reconstruction"},{"name":"long biliopancreatic limb Roux-en-Y reconstruction"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01538290","briefTitle":"Validating Non-invasive Measurements of Central Blood Pressure in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Blood Pressure"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03164187","briefTitle":"Evaluation of Type 2 Diabetes Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Servier Affaires Médicales"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabeton 60 MR"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05689099","briefTitle":"A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Healthy Participants"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide B, 1.34 mg/mL"},{"name":"Semaglutide B, 0.68 mg/mL"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01839370","briefTitle":"Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Virginia"},"collaborators":[{"name":"DexCom, Inc."},{"name":"Tandem Diabetes Care, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Closed Loop with Pramlintide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00508599","briefTitle":"The Effects of Two Days of Bedrest on Insulin Resistance in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of New Mexico"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Study 2 (48 hours of complete bed rest)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00675857","briefTitle":"A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bellus Health Inc. - a GSK company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Metabolic Syndrome X"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NC-503 (eprodisate disodium)"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00665145","briefTitle":"Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sangamo Therapeutics"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Diabetic Polyneuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SB-509"},{"name":"SB-509"},{"name":"Placebo"},{"name":"SB-509"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03903016","briefTitle":"A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Lispro SAR342434"},{"name":"Insulin Lispro SAR342434"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04616027","briefTitle":"STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Renal Impairment","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-06882961 20 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00222846","briefTitle":"Enhancing Adherence in Type 2 Diabetes: The ENHANCE Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pittsburgh"},"collaborators":[{"name":"National Institute of Nursing Research (NINR)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Attention control"},{"name":"Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01086111","briefTitle":"The Effect of a Gastric Bypass on Type 2 Diabetes in the Morbidly Obese Patient"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gasthuisberg"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Morbid Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01060540","briefTitle":"Genetic Testing for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"US Department of Veterans Affairs"},"collaborators":[{"name":"Duke University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"genetic testing for type 2 diabetes"},{"name":"Conventional risk counseling"},{"name":"eye disease counseling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04298229","briefTitle":"Efficacy and Safety of Dapagliflozin in Acute Heart Failure"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University Medical Center"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Heart Failure","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin 10 MG"},{"name":"Protocolized Diuretic Therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04532385","briefTitle":"Effect of Green Tea Extract on Lipids in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centro Universitario de Ciencias de la Salud, Mexico"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Dyslipidemias","Arterial Stiffness"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Green tea extract"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01394952","briefTitle":"Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Cardiovascular Disease","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dulaglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02172716","briefTitle":"Disruption of Immune Homeostasis in Type 2 Diabetics With Generalized Chronic Periodontitis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Sao Paulo"},"collaborators":[{"name":"Augusta University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Type 2 Diabetes Mellitus","Periodontal Diseases","Periodontitis","Chronic Periodontitis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nonsurgical periodontal treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05232708","briefTitle":"A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Healthy Volunteers (Diabetes Mellitus, Type 2)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide B, 1.34 mg/mL"},{"name":"Semaglutide D, 1.0 mg/mL"},{"name":"Semaglutide D, 1.0 mg/mL"},{"name":"Semaglutide B, 1.34 mg/mL"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01467674","briefTitle":"The Effect Of Glycemic Control On Malondialdehyde, Glutathione Peroxidase, Glutathione And Paraoxonase"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Suleyman Demirel University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Chronic Periodontitis"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06226727","briefTitle":"A Study to Evaluate the Pharmacokinetics and the Safety After Administration of \"BR1019\" and Co-administration of \"BR1019-1\" and \"BR1019-2\""},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boryung Pharmaceutical Co., Ltd"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Essential Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BR1019"},{"name":"BR1019-1"},{"name":"BR1019-2"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03302377","briefTitle":"Fit for Two: Incorporating Wearable Trackers Into Clinical Care for Pregnant Women With Diabetes (FFT)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Diego"}},"conditionsModule":{"conditions":["Physical Activity","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"physical activity counseling & Fitbit"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01254552","briefTitle":"Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Guerbet"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Coronary Atherosclerosis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"iobitridol"},{"name":"gadoterate meglumine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02971202","briefTitle":"Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus","Maturity-Onset Diabetes of the Young, Type 2","MODY2","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hyperinsulinemic, euglycemic clamp"},{"name":"20% dextrose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00487240","briefTitle":"Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Lispro Protamine Suspension"},{"name":"Insulin Levemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01741181","briefTitle":"Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tan Tock Seng Hospital"},"collaborators":[{"name":"Duke-NUS Graduate Medical School"},{"name":"National Healthcare Group, Singapore"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Vitamin D Deficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin D supplementation"},{"name":"Placebo Pill"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02662010","briefTitle":"The Relationship Between Advanced Glycation Endproducts and Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Denver"}},"conditionsModule":{"conditions":["Diabetic Retinopathy","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00654745","briefTitle":"18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Amlodipine"},{"name":"amlodipine / olmesartan medoxomil combination"},{"name":"Hydrochlorothiazide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01482481","briefTitle":"Effectiveness of Nursing Care Plans Based in Nursing Diagnoses in Metabolic Control of Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital Carlos III, Madrid"},"collaborators":[{"name":"Gerencia de Atención Primaria, Madrid"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Cardiovascular Risk Factors"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04616066","briefTitle":"Date Fruit Effects in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Royal College of Surgeons in Ireland - Medical University of Bahrain"},"collaborators":[{"name":"King Hamad University Hospital, Bahrain"}]},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dates"},{"name":"Raisins"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02164266","briefTitle":"A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Healthy Volunteer, Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"RO6799477"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03155867","briefTitle":"Glycemic Response to Six Meal Replacements in Persons With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Société des Produits Nestlé (SPN)"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Meal replacement"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02923960","briefTitle":"Effect of Nutritional Products in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Nutrition"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Standard ONS"},{"name":"Diabetes specific ONS 1"},{"name":"Diabetes specific ONS 2"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06615700","briefTitle":"Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Biomed Industries, Inc."}},"conditionsModule":{"conditions":["Overweight or Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NA-931"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01840982","briefTitle":"The Effects of Mixed Grain on Blood Glucose and Insulin in Healthy Male"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chonbuk National University Hospital"}},"conditionsModule":{"conditions":["Healthy People","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mixed grain 1"},{"name":"Mixed grain 2"},{"name":"White rice"},{"name":"Glucose solution"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00306384","briefTitle":"Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01900834","briefTitle":"Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Healthy"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00029848","briefTitle":"Obese Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Non-Insulin-Dependent","Obesity in Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rimonabant (SR141716)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00596687","briefTitle":"Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Inpatient Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine"},{"name":"Regular insulin"},{"name":"Insulin glulisine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05346250","briefTitle":"Long-term Effect of Moderate and Vigorous Exercise on Incident Diabetes in Obese Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Zhongshan Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity, Abdominal"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Non-exercise control"},{"name":"Moderate intensity exercise"},{"name":"Vigorous intensity exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00415688","briefTitle":"Lifestyle Modification for Obesity-Related Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Robert C. Atkins Foundation"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Overweight","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low carbohydrate, ketogenic diet"},{"name":"Low glycemic index, reduced calorie diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05111301","briefTitle":"Control-IQ Technology in Individuals With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tandem Diabetes Care, Inc."},"collaborators":[{"name":"Jaeb Center for Health Research"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Treated With Insulin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Control-IQ technology 1.5"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00806858","briefTitle":"Observational Study of NovoPen® 4 on Treatment Satisfaction of Insulin Therapy in Type 1 or Type 2 Subjects With Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Delivery Systems"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NovoPen® 4"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01375491","briefTitle":"Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Diego"},"collaborators":[{"name":"Ruth L. Kirschstein National Research Service Award"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"National Center for Research Resources (NCRR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Doxycycline"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00606034","briefTitle":"U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mountain Diabetes and Endocrine Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"U-500 Insulin delivered by Omnipod (disposable insulin pump)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03884920","briefTitle":"Glucose Tolerance and Prevention of Diabetes Mellitus Type 2 by Polyherbal Formulation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Islamia University of Bahawalpur"},"collaborators":[{"name":"Hashmi Herbal Pharma (HHP) Registered Bahawalpur"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Pre Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Polyherbal formulation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01588470","briefTitle":"Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"},"collaborators":[{"name":"Takeda Pharmaceuticals North America, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Coronary Heart Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00641251","briefTitle":"DSS: Diabetes Surgery Study - Intensive Medical Management of Type 2 Diabetes, With and Without Gastric Bypass Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medtronic - MITG"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"intensive medical management"},{"name":"RYGB & IMM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01699074","briefTitle":"Acute Dose Response of Korean White Ginseng in Metabolic Syndrome or Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Unity Health Toronto"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"1 gram of White Korean Ginseng"},{"name":"3 grams of White Korean Ginseng"},{"name":"6 grams of White Korean Ginseng"},{"name":"3 grams of Wheat Bran Control"},{"name":"500mg of Korean Red Ginseng"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01594801","briefTitle":"Testing the Effect of the InsuPad Device in Daily Life Conditions"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Insuline Medical Ltd."}},"conditionsModule":{"conditions":["Diabetics Mellitus Type 1","Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"InsuPad"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04107259","briefTitle":"IRAPe, Irisin and IL-34 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Damanhour University"},"collaborators":[{"name":"Tanta University"}]},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Blood sample"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00770952","briefTitle":"Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone and Glimepiride"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04918004","briefTitle":"The Effect of Sleep hygıene traınıng on Blood Sugar regulatıon"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diskapi Yildirim Beyazit Education and Research Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Sleep Hygiene"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sleep Hygiene"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06081413","briefTitle":"Bariatric and Metabolic Surgery in Patients Over 65 Years of Age"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Warmia and Mazury in Olsztyn"}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type 2","Hypertension"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"bariatric surgery"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01394510","briefTitle":"Effect of the Anti-oxidant N-acetylcysteine on Beta-cell Function in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Utzschneider, Kristina, M.D."},"collaborators":[{"name":"VA Puget Sound Health Care System"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Oxidative Stress"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"N-acetylcysteine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05350514","briefTitle":"Preclinical Imaging Biomarkers of Alzheimer's Disease Neuropathology in Young Adults With Youth-onset Diabetes: a Proof-of-concept Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Denver"},"collaborators":[{"name":"American College of Radiology"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Diabetes, Youth Onset"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PI-2620 tracer"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03416270","briefTitle":"ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Health Network, Toronto"},"collaborators":[{"name":"University Medical Center Groningen"},{"name":"Merck Sharp & Dohme LLC"},{"name":"University of Toronto"},{"name":"Toronto General Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Heart Failure"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ertugliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01364350","briefTitle":"TODAY2 Phase 1 Immediate Post-Intervention Observational Follow-up Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2 in Obese"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"standard of care in general clinical practice"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00361023","briefTitle":"Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Jiao Tong University School of Medicine"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"losartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01651065","briefTitle":"Micro-Clinic Obesity and Metabolic Risk Prevention Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Microclinic International"},"collaborators":[{"name":"Bell County Department of Health, Kentucky"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II","Heart Disease","Obesity","Hypertension","Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Microclinic Diabetes Education Program"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05370560","briefTitle":"Plasma Transthyretin Levels and Risk of Type 2 Diabetes Mellitus and Impaired Glucose Regulation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Liegang Liu"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Impaired Glucose Regulation"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Plasma transthyretin concentration"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03234322","briefTitle":"The Impact of a Diabetes Risk Prediction Model in Primary Care."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"German Diabetes Center"},"collaborators":[{"name":"Association of Statutory Health Insurance Physicians North Rhine"},{"name":"German Institute of Human Nutrition"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Primary Prevention"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"external validated risk prediction model"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04678284","briefTitle":"Diabetes Homeless Medication Support Single Arm Treatment Development Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hennepin Healthcare Research Institute"},"collaborators":[{"name":"National Institutes of Health (NIH)"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"University of Minnesota"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Homeless Persons"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Homeless Medication Support (D-Homes)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00115973","briefTitle":"A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Delivery Systems"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pump"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01373489","briefTitle":"Technology-assisted Case Management in Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"State University of New York at Buffalo"},"collaborators":[{"name":"United States Department of Defense"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Technology-Assisted Case Management"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05298111","briefTitle":"Acute Effect of MMT Peel Powder on Glycemic Response, Satiety, and Food Intake in Adults at Risk for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universiti Sultan Zainal Abidin"},"collaborators":[{"name":"National University of Malaysia"},{"name":"Universiti Sains Malaysia"}]},"conditionsModule":{"conditions":["At Risk of Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Formulation 3"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01620125","briefTitle":"Metabolic Control Before and After Supplementation With Lactobacillus Reuteri DSM 17938 in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vastra Gotaland Region"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lactobacillus reuteri DSM 17938"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03908606","briefTitle":"Serum Hs-CRP in Periodontitis Patients With or Without Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cairo University"}},"conditionsModule":{"conditions":["Periodontal Disease","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Scaling and root planing"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03127696","briefTitle":"Randomised Placebo-controlled Study of FMT to Impact Body Weight and Glycemic Control in Obese Subjects With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chinese University of Hong Kong"}},"conditionsModule":{"conditions":["Type2 Diabetes","Type 2 Diabetes Mellitus","Obese"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fecal Microbiota Transplantation"},{"name":"Lifestyle Modification Program"},{"name":"Sham"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00437008","briefTitle":"Effects of Benfotiamine and AGE on Endothelial Function in People With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ruhr University of Bochum"}},"conditionsModule":{"conditions":["Endothelial Dysfunction","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Benfotiamine 1050mg, 3 days"},{"name":"high-AGE vs. low-AGE meal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05291026","briefTitle":"Mobile Health Intervention for Improved Adherence in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Obafemi Awolowo University"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"mobile phone-based health information"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01056367","briefTitle":"Resistant Hypertension in Patients With Type-II-Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Svendborg Hospital"}},"conditionsModule":{"conditions":["Resistant Hypertension","NIDDM"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02500186","briefTitle":"The Clinical Study to Assess the Effect of the Amount of Carbohydrate Intake and Meals Differing in Glycemic Index (GI) in Patients Treated With a Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kansai Electric Power Hospital"},"collaborators":[{"name":"Medical Corporation Heishinkai OCROM Clinic"}]},"conditionsModule":{"conditions":["Diabetes Melltius, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Luseogliflozin"},{"name":"Meal containing different carbohydrate ratio and GI value"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01513369","briefTitle":"Ferric Carboxymaltose in Type 2 Diabetes Mellitus (T2DM) Patients With Iron Deficiency"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GWT-TUD GmbH"},"collaborators":[{"name":"Vifor Pharma"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Iron Deficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ferric carboxymaltose"},{"name":"NaCl (0,9%)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00016835","briefTitle":"Treating Periodontal Infection: Effects on Glycemic"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"},"collaborators":[{"name":"National Institute of Dental and Craniofacial Research (NIDCR)"}]},"conditionsModule":{"conditions":["Periodontal Disease","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Supra-gingival scaling and placebo"},{"name":"Subgingival scaling and metronidazole"},{"name":"Subgingival scaling and doxycycline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04456166","briefTitle":"Safety of Preoperative Carbohydrate Loading in Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Hospital"}},"conditionsModule":{"conditions":["Carbohydrate Intolerance","Diabetes Mellitus Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"noNPO"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02529449","briefTitle":"Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"ASP1941"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00622960","briefTitle":"Effect of High Monounsaturated Fat Diet on Glycemic Control and Cardiovascular Risk Factors in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Cincinnati"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Overweight","Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High-MUFA diet"},{"name":"High-CHO diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01316367","briefTitle":"Effectiveness of PRECEDE Model for Health Education on Changes and Level of Control in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital Carlos III, Madrid"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Cardiovascular Risk Factor"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PRECEDE HPE model"},{"name":"CHPE"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02412774","briefTitle":"Effects of Replacing Diet Beverages With Water on Weight Loss and Plasma Glucose Control in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novindiet Clinic"},"collaborators":[{"name":"University of Nottingham"},{"name":"Tehran University of Medical Sciences"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Overweight","Obese"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DBs at the end of the main meal + Diet"},{"name":"Water at the end of the main meal+ Diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05337644","briefTitle":"Indocyanine Green Test for Evaluation of Perfusion of Staple Line of the Stomach During Laparoscopic Sleeve Gastrectomy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Foggia"}},"conditionsModule":{"conditions":["Obesity, Morbid","Diabete Type 2","Cardiac Disease","Vascular Diseases"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Indocyanine green solution"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04923386","briefTitle":"mRNA Based-Covid-19 Vaccine Effects on Blood Glucose Levels"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Levenson, David I., M.D."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1","Hyperglycemia","Vaccine Adverse Reaction"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"None (not interventional)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00503152","briefTitle":"Preventing Microalbuminuria in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mario Negri Institute for Pharmacological Research"},"collaborators":[{"name":"Agenzia Italiana del Farmaco"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Benazepril"},{"name":"Valsartan"},{"name":"Benazepril/Valsartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04113239","briefTitle":"Study of the Genome, Gut Metagenome and Lifestyle of Patients With Incident Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Atlas Biomed"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Metagenome","Genetic Predisposition"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"16S rRNA gene sequencing"},{"name":"DNA-microarray genotyping"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02700503","briefTitle":"Finding the Patient's Voice Diabetes Prevention Programs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Indiana University"},"collaborators":[{"name":"Indiana University Health"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Prediabetic State"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Encourage 2.0"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01779375","briefTitle":"RISE Pediatric Medication Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"RISE Study Group"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Prediabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01779362","briefTitle":"RISE Adult Medication Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"RISE Study Group"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Prediabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Liraglutide"},{"name":"Glargine"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04283201","briefTitle":"Type 2 Diabetes Mellitus Prevention Ukraine"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Komisarenko Institute of Endocrinology and Metobolism"}},"conditionsModule":{"conditions":["Impaired Fasting Glucose","Impaired Glucose Tolerance","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physical activity"},{"name":"Macronutrient modification"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00286455","briefTitle":"Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin"},{"name":"Alogliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00823849","briefTitle":"Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Otsuka Beijing Research Institute"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Arteriosclerosis Obliterans"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cilostazol"},{"name":"Probucol"},{"name":"Cilostazol+Probucol"},{"name":"Control Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03155412","briefTitle":"Adipose Tissue Expandability and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Charles University, Czech Republic"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02726100","briefTitle":"SMARTHealth Diabetes in China Using Lay Family Health Promoters"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The George Institute for Global Health, China"},"collaborators":[{"name":"Global Alliance for Chronic Diseases (GACD)"},{"name":"National Health and Medical Research Council, Australia"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension","Dyslipidemias"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SMARTHealth Diabetes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05110404","briefTitle":"COMPARISON BETWEEN TWO SUB-TYPES OF HIGH INTENSITY INTERVAL TRAINING"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cairo University"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"The high-volume HIIT"},{"name":"The low-volume HIIT"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00819975","briefTitle":"Differential Effects of Milk Proteins on Postprandial Lipemia in Response to a Fat-Rich Meal in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aarhus University Hospital"},"collaborators":[{"name":"The Danish Obesity Research Centre"},{"name":"Nordic Centre of Excellence"},{"name":"Arla Foods"}]},"conditionsModule":{"conditions":["Postprandial Lipemia","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Casein"},{"name":"Whey Isolate"},{"name":"Whey Hydrolysate"},{"name":"Alphalact-Albumin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04089280","briefTitle":"Probiotics in Metformin Intolerant Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Silesia"},"collaborators":[{"name":"Sanprobi Sp. z o.o., Sp. k., Szczecin, Poland"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Metformin Adverse Reaction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sanprobi Barrier-multispecies probiotic"},{"name":"Placebo Comparator"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01056497","briefTitle":"The Effect of A-lipoic Acid (ALA) on Fatty Acid-induced Impairment of Glucose-stimulated Insulin Secretion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Health Network, Toronto"},"collaborators":[{"name":"Canadian Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Prediabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"alpha lipoic acid"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03282136","briefTitle":"Incretin and CRTd."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Campania \"Luigi Vanvitelli\""}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Heart Failure"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Incretin Effect"},{"name":"Cardiac Resynchronization therapy defibrillator device"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04035395","briefTitle":"Salud y Vida 2.0: Enhancing Integrated Behavioral Health for Diabetics in the Rio Grande Valley"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center, Houston"},"collaborators":[{"name":"Health Resources in Action, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Behavior, Health"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Peer-led Support Group"},{"name":"Behavioral Health Consult"},{"name":"Medication Therapy Management Consult"},{"name":"La Cocina Alegre/ The Happy Kitchen"},{"name":"Mind, Exercise, Nutrition, Do it!"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01000688","briefTitle":"Vildagliptin and Endothelium-dependent Vasodilatation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Radboud University Medical Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Endothelial Dysfunction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin + acarbose"},{"name":"acarbose + vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00585897","briefTitle":"Effect of Discontinuation of Sugar Sweetened Beverages"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Duke University"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"discontinuation of sugar sweetened beverages"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00462046","briefTitle":"Efficacy and Safety of Berberine in the Treatment of Diabetes With Dyslipidemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Jiao Tong University School of Medicine"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Berberine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01191320","briefTitle":"Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Repros Therapeutics Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Secondary Hypogonadism"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Androxal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01778738","briefTitle":"Type 2 Diabetes After Sleeve Gastrectomy and Roux-en-Y Gastric Bypass: A Randomised Single Centre Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sykehuset i Vestfold HF"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Morbid Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bariatric surgery, either gastric bypass surgery or sleeve gastrectomy"},{"name":"Sleeve gastrecomy"},{"name":"Bastric bypass"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05279911","briefTitle":"Effect of Low-level Laser Therapy on Type II Controlled Diabetic Patients After Dental Implant Insertion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sinai University"},"collaborators":[{"name":"Misr International University"},{"name":"Al-Azhar University"},{"name":"Delta University for Science and Technology"}]},"conditionsModule":{"conditions":["T2DM (Type 2 Diabetes Mellitus)","Low-level Laser Therapy","Bone Density Increased"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"low-level laser therapy (LLLT)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03729323","briefTitle":"Motivational Interviewing in the Control of Arterial Hypertension and Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital Nossa Senhora da Conceicao"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Systemic Arterial Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Motivational interviewing"},{"name":"Nursing Consultation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05180721","briefTitle":"A Multi-level Intervention to Increase Access and Use of the Patient Portal"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yale University"},"collaborators":[{"name":"National Institute on Minority Health and Health Disparities (NIMHD)"}]},"conditionsModule":{"conditions":["Patient Education","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Use of patient portal for diabetes management"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05954819","briefTitle":"Effect of Patient Education on Healthy Lifestyle Behaviors and Diabetes Self-management in Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Istanbul University - Cerrahpasa (IUC)"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Myocardial Infarction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Planned patient education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02068300","briefTitle":"The Role of 1.5-anhydro-D-glucitol as Clinical Biomarkers of Hypoglycemia in Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus With Hypoglycemia"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01600690","briefTitle":"Effects of 5-day Statin Withdrawal on Endothelial Progenitor Cells and Inflammatory Markers in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Padova"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Atherosclerosis","Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Statin withdrawal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01447524","briefTitle":"Caloric Restriction and Insulin Secretion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Rome Tor Vergata"}},"conditionsModule":{"conditions":["Morbid Obesity","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Very Low Calorie Diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02856516","briefTitle":"Glycemic Response to Three Oral Nutrition Supplements in Persons With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Société des Produits Nestlé (SPN)"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Boost Glucose Control (A)"},{"name":"Boost Glucose Control (B)"},{"name":"Boost Original"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02174146","briefTitle":"Leptin and Visfatin in Diabetic Patients With Periodontitis Before and After Periodontal Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cairo University"}},"conditionsModule":{"conditions":["Chronic Periodontitis","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"non-surgical periodontal therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03254368","briefTitle":"Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Zafgen, Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Overweight and Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ZGN-1061"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00272831","briefTitle":"The Use of Cilostazol in Patients With Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chinese University of Hong Kong"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes Complications"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cilostazol"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00543595","briefTitle":"MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK0916"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00438698","briefTitle":"Low Glycemic Index Diets vs. High Cereal Fibre Diets in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Toronto"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low Glycemic Index diet"},{"name":"High Cereal Fibre Diets"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06383065","briefTitle":"Respiratory Physiotherapy in Type 2 Diabetes and Bariatric Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Near East University, Turkey"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Bariatric Surgery Candidate"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IMT Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02562573","briefTitle":"Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Liminal BioSciences Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PBI4050"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01983007","briefTitle":"Effect of Physical Exercise on Endothelial Function in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidade Federal do Ceara"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High-intensity exercise"},{"name":"Low-intensity exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02589873","briefTitle":"Getting in Balance: A Workplace Diabetes Prevention Intervention Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kaiser Permanente"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Overweight","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"In-Person Diabetes Prevention Program"},{"name":"Online Diabetes Prevention Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00286468","briefTitle":"Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin and glyburide"},{"name":"Alogliptin and glyburide"},{"name":"Glyburide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04515849","briefTitle":"A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Chronic Kidney Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cotadutide 100 micrograms"},{"name":"Cotadutide 300 micrograms"},{"name":"Cotadutide 600 micrograms"},{"name":"Semaglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00527995","briefTitle":"Acute Effects of Sildenafil on Endothelial Function in People With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ruhr University of Bochum"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Endothelial Dysfunction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sildenafil"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03315988","briefTitle":"The Effects of an 8-week Vegan Diet on TMAO Levels and Post-challenge Glucose Levels in Individuals With Dysglycaemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Leicester"},"collaborators":[{"name":"University Hospitals, Leicester"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Heart Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Adoption of a vegan diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04104711","briefTitle":"Home-Based Intervention to the Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dilay AÇIL,PhD"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Home Visit"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Home visits, health education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03725709","briefTitle":"Metabolomic Profiling of in Patients With type2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chang Gung Memorial Hospital"}},"conditionsModule":{"conditions":["Diagnoses Disease","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"spinal anesthesia"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00950716","briefTitle":"PEARL Program: Empowerment Program for Patients With Type 2 Diabetes (HK4)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chinese University of Hong Kong"},"collaborators":[{"name":"Asia Diabetes Foundation"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Patient Peer Support and Empowerment"},{"name":"Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01635062","briefTitle":"The VALIDATE-D Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Brigham and Women's Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Calcitriol"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01881347","briefTitle":"Effects of Resveratrol on Endothelial Function in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boston University"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Resveratrol"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04630691","briefTitle":"Posterior Narrow Diameter Implants in Hyperglycemic and Normo-glycemic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Witten/Herdecke"},"collaborators":[{"name":"Institut Straumann AG"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Implant Complication"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Implantation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03226457","briefTitle":"SGLT2 Inhibition in Combination With Diuretics in Heart Failure"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Dundee"},"collaborators":[{"name":"British Heart Foundation"}]},"conditionsModule":{"conditions":["Heart Failure","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin 25mg"},{"name":"Placebo oral capsule"},{"name":"Frusemide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00824330","briefTitle":"Home-Based Walking Study in Older Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of British Columbia"}},"conditionsModule":{"conditions":["Cardiovascular","Diabetes","Orthostatic Hypotension","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Control Phase; Exercise Phase"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04316429","briefTitle":"The Impact of Consumption of Eggs in the Context of Plant-Based Diets on Endothelial Function, Diet Quality, and Cardio-Metabolic Risk Factors in Adults at Risk for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Griffin Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Cardiovascular Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Egg included vegan phase"},{"name":"Vegan Phase"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03553862","briefTitle":"Collaborative Care Model on Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National University of Singapore"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"collaborative care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02195856","briefTitle":"Effects of Nitrate on Liver Perfusion and Sugar Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Exeter"},"collaborators":[{"name":"Royal Devon and Exeter NHS Foundation Trust"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Ageing"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Beetroot juice"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00476931","briefTitle":"Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sangamo Therapeutics"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Diabetic Polyneuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SB-509"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01079325","briefTitle":"Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sangamo Therapeutics"},"collaborators":[{"name":"Juvenile Diabetes Research Foundation"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Diabetic Polyneuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SB-509"},{"name":"Saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04739241","briefTitle":"Premixed vs Basal Bolus Insulin Therapy in Older Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Consorci Sanitari Integral"}},"conditionsModule":{"conditions":["Type 2 Diabetes Treated With Insulin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"premixed insulin therapy"},{"name":"basal bolus insulin therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05785832","briefTitle":"A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tandem Diabetes Care, Inc."},"collaborators":[{"name":"Jaeb Center for Health Research"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Treated With Insulin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"t:slim X2 insulin pump with Control-IQ technology 1.5 and Dexcom G6 CGM"},{"name":"Standard Therapy plus continuous glucose monitoring (CGM)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02518503","briefTitle":"High Potency Statins and the Risk of Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Canadian Network for Observational Drug Effect Studies, CNODES"},"collaborators":[{"name":"Drug Safety and Effectiveness Network, Canada"},{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Cardiovascular Disease"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosuvastatin (≥10 mg)"},{"name":"Atorvastatin (≥20 mg)"},{"name":"Simvastatin (≥40 mg)"},{"name":"Fluvastatin"},{"name":"Pravastatin"},{"name":"Lovastatin"},{"name":"Rosuvastatin (<10mg)"},{"name":"Atorvastatin (<20mg)"},{"name":"Simvastatin (<40 mg)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04460326","briefTitle":"Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boston Medical Center"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Treated With Insulin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine"},{"name":"NovoLog"},{"name":"Insulin Fiasp"},{"name":"Standard carbohydrate diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00787839","briefTitle":"Opportunistic Screening for Prediabetes and Early Diabetes in Primary Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"US Department of Veterans Affairs"},"collaborators":[{"name":"Emory University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Prediabetic State"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glucose challenge test"},{"name":"Glucose tolerance test"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00971516","briefTitle":"Healing Profile of Titanium Dental Implants Placed in Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Escola Bahiana de Medicina e Saude Publica"},"collaborators":[{"name":"University of Manitoba"},{"name":"University of Toronto"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Dental Implants"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Implant placement"},{"name":"Implants surgery"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02681874","briefTitle":"Smart and Secure Children Program for Preschool Obesity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baylor College of Medicine"},"collaborators":[{"name":"University of Houston"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SSC Program"},{"name":"Written Handouts"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00095056","briefTitle":"An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Chronic Renal Insufficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin"},{"name":"Placebo to Sitagliptin"},{"name":"glipizide"},{"name":"Placebo to glipizide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00939289","briefTitle":"Concurrent Use of Two Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes Mellitus (T1DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"DexCom, Inc."}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous Glucose Monitoring"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00767351","briefTitle":"Variation in Serum Levels of Metformin in Patients With Reduced Renal Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Skane University Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Metformin","Pharmacokinetics"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02681094","briefTitle":"A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Inadequate Glycaemic Control"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo for Dapagliflozin"},{"name":"Saxagliptin"},{"name":"Placebo for Saxagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06181721","briefTitle":"Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Insulet Corporation"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omnipod 5 Automated Glucose Control System"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00406458","briefTitle":"Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sangamo Therapeutics"},"collaborators":[{"name":"Juvenile Diabetes Research Foundation"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Diabetic Polyneuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SB-509"},{"name":"Normal Saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02269098","briefTitle":"The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medstar Health Research Institute"},"collaborators":[{"name":"American Diabetes Association"},{"name":"Sanofi"},{"name":"Bayer"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Medication Adherence","HYPERGLYCEMIA"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes medication management"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00571506","briefTitle":"Effect of Thiazolidinedione Treatment Vascular Risk Markers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Arkansas"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Vascular Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02289235","briefTitle":"Effects of Ginger on Nonalcoholic Fatty Liver Disease in T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shiraz University of Medical Sciences"}},"conditionsModule":{"conditions":["Fatty Liver","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ginger"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02498002","briefTitle":"Impacts of Intermittent Fasting on Energy Balance and Associated Health Outcomes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Bath"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physical Activity Monitoring (Actiheart)"},{"name":"Energy Intake Monitoring"},{"name":"Body Weight Monitoring"},{"name":"Intravenous Cannulation"},{"name":"Adipose Tissue Biopsy"},{"name":"Lidocaine Hydrochloride"},{"name":"Post-Prandial Meal Tests"},{"name":"DEXA Scan"},{"name":"Actiheart Calibration"},{"name":"Daily Calorie Restriction"},{"name":"Intermittent Fasting with Weight Loss"},{"name":"Intermittent Fasting without Weight Loss"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04152915","briefTitle":"A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Healthy Volunteers","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02122731","briefTitle":"Amiloride for Resistant Hypertension"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ib Abildgaard Jacobsen"}},"conditionsModule":{"conditions":["Hypertension","Type 2 Diabetes Mellitus","Microalbuminuria"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Amiloride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03976271","briefTitle":"Consequences of Hypoglycaemia on Cardiovascular and Inflammatory Responses"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Radboud University Medical Center"},"collaborators":[{"name":"Rigshospitalet, Denmark"}]},"conditionsModule":{"conditions":["Hypoglycemia","Inflammatory Response","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00162357","briefTitle":"Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lantheus Medical Imaging"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Coronary Restenosis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Technetium Tc99m Sestamibi"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02444325","briefTitle":"Diabetes Group Prenatal Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Washington University School of Medicine"},"collaborators":[{"name":"Denver Health Medical Center"}]},"conditionsModule":{"conditions":["Pregnancy","Gestational Diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Group prenatal care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00212290","briefTitle":"Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Insulin Resistance","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pioglitazone"},{"name":"nateglinide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04016974","briefTitle":"A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Healthy Volunteers","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral semaglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01843387","briefTitle":"Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mesoblast, Ltd."}},"conditionsModule":{"conditions":["Diabetic Nephropathy","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mesenchymal Precursor Cells (MPCs)"},{"name":"Mesenchymal Precursor Cells (MPCs)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05577650","briefTitle":"Prevalence of Chronic Kidney Disease in Tunisian Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dacima Consulting"},"collaborators":[{"name":"Tunisian Society for Nephrology, Dialysis and Renal Transplantation"}]},"conditionsModule":{"conditions":["Chronic Kidney Diseases","Diabetes Mellitus","Diabetes Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05984459","briefTitle":"Type 2 Diabetes Treatment and Remission With a Very Low-Calorie Ketogenic Diet (VLCKD) and Lifestyle Changes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cabinet Medical"},"collaborators":[{"name":"Trialance SCCL"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Overweight and Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"VLCKD"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00817973","briefTitle":"Differential Effects of Protein Quality on Postprandial Lipemia in Response to a Fat-Rich Meal in Type 2 Diabetes: Comparison of Whey, Casein, Gluten, and Cod Protein"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aarhus University Hospital"},"collaborators":[{"name":"The Danish Obesity Research Centre"},{"name":"Nordic Centre of Excellence"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Postprandial Lipemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Casein"},{"name":"Whey"},{"name":"Cod"},{"name":"Gluten"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00395512","briefTitle":"Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin"},{"name":"Pioglitazone"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01677936","briefTitle":"Study of Raisins Versus Alternative Snacks in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Louisville Metabolic and Atherosclerosis Research Center"},"collaborators":[{"name":"California Raisin Marketing Board"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Raisins"},{"name":"Snacks"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02471404","briefTitle":"Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Inadequate Glycaemic Control"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Saxagliptin"},{"name":"Glimepiride"},{"name":"Placebo for dapagliflozin"},{"name":"Placebo for saxagliptin"},{"name":"Placebo for glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00997178","briefTitle":"Diabetes and Periodontal Therapy Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Stony Brook University"},"collaborators":[{"name":"University of Alabama at Birmingham"},{"name":"University of Minnesota"},{"name":"The University of Texas Health Science Center, Houston"},{"name":"The University of Texas Health Science Center at San Antonio"},{"name":"National Institute of Dental and Craniofacial Research (NIDCR)"}]},"conditionsModule":{"conditions":["Chronic Periodontitis","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Non-surgical periodontal therapy"},{"name":"Delayed non-surgical periodontal therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03868683","briefTitle":"The Glycemic Effect of Added Sugar on Bake Beans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Singapore Institute of Food and Biotechnology Innovation"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity","PreDiabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glucose Reference 1"},{"name":"Glucose Reference 2"},{"name":"Glucose reference 3"},{"name":"Sucrose"},{"name":"Regular Bake beans in tomato sauce"},{"name":"Bake beans in tomato sauce, reduced sugar"},{"name":"Bake beans in tomato sauce, low GI"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00569426","briefTitle":"Evaluating the Use of Two Different Needles in Subjects With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Delivery Systems"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NovoFine® needle 6 mm"},{"name":"NovoFine® needle 8 mm"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02159144","briefTitle":"Cold Stress Stimulate the Browing of Subcutaneous White Adipose in Healthy Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Xiang Guang-da"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"cold stress"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05998525","briefTitle":"Dapagliflozin Effects on Coronary Calcium and Epicardial Fat Assessed by Cardiotomography"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hilda Elizabeth Macías Cervantes"}},"conditionsModule":{"conditions":["Diabete Type 2","Unstable Angina","Myocardial Infarction","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin 10Mg Tab"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01011062","briefTitle":"Effect of Angiotensin Receptor Blockade on Insulin Resistance and Adipose Tissue Cytokines in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institute for Clinical and Experimental Medicine"},"collaborators":[{"name":"Ministry of Health, Czech Republic"}]},"conditionsModule":{"conditions":["Insulin Resistance","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hyperinsulinaemia"},{"name":"Losartan"},{"name":"Saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00755547","briefTitle":"A Study of the Effects of Exercise Intensity on Insulin Sensitivity in Overweight Youth"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Manitoba"},"collaborators":[{"name":"Manitoba Institute of Child Health"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Adolescent Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aerobic Exercise Training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04565418","briefTitle":"Exercise to Restore 24h Rhythms in Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High-intensity interval training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02009813","briefTitle":"Hyperbaric Oxygen Therapy and Insulin Resistance (HOTAIR2) - Effect of One HBO Session."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Adelaide"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hyperbaric Oxygen Therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05561855","briefTitle":"T2DM Intensity Lifestyle Intervention"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ningbo No. 1 Hospital"},"collaborators":[{"name":"Peking University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Overweight or Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"lifestyle intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03343366","briefTitle":"Glycemic Control in T2DM Through Non-Surgical Periodontal Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dow University of Health Sciences"},"collaborators":[{"name":"Higher Education Commission (Pakistan)"}]},"conditionsModule":{"conditions":["Chronic Periodontitis","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metronidazole"},{"name":"Scaling Root Planing"},{"name":"Oral Hygiene Instructions"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01983046","briefTitle":"Rectal Short Chain Fatty Acids Combinations and Substrate and Energy Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"},"collaborators":[{"name":"Top Institute Food and Nutrition"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Three different mixture of acetate, butyrate and propionate and palcebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03614780","briefTitle":"Pre Post Evaluation of Temperature, Steps, and Glucose With Additional Time Spent Outdoors in an Urban and Rural Setting"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Virginia Polytechnic Institute and State University"},"collaborators":[{"name":"University of Alabama at Birmingham"},{"name":"National Institute of Environmental Health Sciences (NIEHS)"}]},"conditionsModule":{"conditions":["Temperature","Exercise","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"30 minutes outdoors"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03315728","briefTitle":"Pathways for Health Equity Quality Improvement Strategy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Western University, Canada"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"},{"name":"AstraZeneca"},{"name":"Juvenile Diabetes Research Foundation"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2 With Hyperglycemia"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Quality Improvement Strategy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04161859","briefTitle":"Use of Nutraceuticals in Clinical Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pavia"}},"conditionsModule":{"conditions":["Dyslipidemias","Diabetes Mellitus, Type 2","Hypertension"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nutraceutical"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02010242","briefTitle":"Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Calliditas Therapeutics AB"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus With Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GKT137831"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03136471","briefTitle":"Impact of CMS Reimbursement Policy Supporting Care Coordination in Louisiana"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tulane University"},"collaborators":[{"name":"Patient-Centered Outcomes Research Institute"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Chronic Disease"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01864239","briefTitle":"The Medicines Advice Service Evaluation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University College, London"},"collaborators":[{"name":"Pharmacy2U"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Hyperlipidemias"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Medicines Advice Service"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01860547","briefTitle":"Effects of Berries and Berry Fractions on Metabolic Diseases"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Turku"},"collaborators":[{"name":"Pakkasmarja"},{"name":"Saarioinen"},{"name":"Kiantama Ltd."},{"name":"Aromtech Ltd."},{"name":"Fazer"},{"name":"Satakunta Sea Buckthorn Society"},{"name":"Finnish Berry Powders Ltd."}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Atherosclerosis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bilberries"},{"name":"Sea buckthorn berry"},{"name":"Sea buckthorn phenolic extract"},{"name":"Sea buckthorn oil"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01833403","briefTitle":"Metabolomic Analysis of Hepatic Insulin Resistance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Minnesota"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hyperinsulinemic-euglycemic clamp"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01823458","briefTitle":"Behavioral Economics Incentives for Health Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Southern California"},"collaborators":[{"name":"National Institutes of Health (NIH)"},{"name":"National Institute on Aging (NIA)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lottery Insurance"},{"name":"Standard Lottery"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03805412","briefTitle":"Continuous Glucose Monitoring in Diabetes and Prediabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nicole Ehrhardt, MD"},"collaborators":[{"name":"DexCom, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","PreDiabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DEXCOM G6 RT-CGM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01804881","briefTitle":"Effect of Managing Problematic Eating Behaviours With Dietary Management on Chronic Disease Self-management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Toronto Practice Based Research Network"}},"conditionsModule":{"conditions":["Hypertension","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle counseling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06473662","briefTitle":"Study to Evaluate the Safety and Efficacy of Oral Insulin Formulation in Type 2 Diabetes Mellitus Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Roger New"}},"conditionsModule":{"conditions":["Type 2 Diabetes Treated With Insulin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02101151","briefTitle":"Effect of Vitamin D Supplementation on the Metabolic Control and Body Composition of Type 2 Diabetes Subjects in Ajman (UAE)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rashid Centre for Diabetes and Research"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity","Hypovitaminosis D"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin D3(cholecalciferol)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00401453","briefTitle":"OatMeal and Insulin Resistance: OMA-IR"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universitätsmedizin Mannheim"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diet: carbohydrate days. (Name: oatmeal.)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00807976","briefTitle":"Orthostatic Hypotension and Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical Research Foundation, The Netherlands"}},"conditionsModule":{"conditions":["Orthostatic Hypotension","Diabetes Mellitus Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03406975","briefTitle":"Multicenter Endoscopic Sleeve Gastrectomy (ESG) Trial (MERIT Trial)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"},"collaborators":[{"name":"University of Texas"},{"name":"Johns Hopkins University"},{"name":"Brigham and Women's Hospital"},{"name":"NorthShore University HealthSystem"},{"name":"University of Chicago"},{"name":"Orlando Health, Inc."},{"name":"Cornell University"},{"name":"Avera McKennan Hospital & University Health Center"}]},"conditionsModule":{"conditions":["Obesity","Hypertension","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Overstitch Endoscopic Suture System"},{"name":"Lifestyle Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00779363","briefTitle":"A Prospective, Clinical Trial of the TANTALUS® System in Treatment of Obese to Morbidly Obese Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"MetaCure (USA), Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rechargeable TANTALUS II"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05031572","briefTitle":"Energy -Sensing Metabolites in Caloric Restriction"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institut Investigacio Sanitaria Pere Virgili"}},"conditionsModule":{"conditions":["Obesity","Insulin Sensitivity/Resistance","Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"dietary intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01726764","briefTitle":"Interaction Between St John's Wort and Metformin?"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Southern Denmark"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Depression"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"St John's Wort"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03615755","briefTitle":"Short Duration Hyperbaric Oxygen Therapy to Improve HbA1c, Leukocyte, and Serum Creatinine"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hendry Irawan"}},"conditionsModule":{"conditions":["Hyperbaric Oxygen Therapy","Diabetic Foot Ulcer","Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hyperbaric Oxygen Therapy (HBOT)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01677104","briefTitle":"The Microvascular Function of GLP-1 and Its Analogues"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Katarina Kos"},"collaborators":[{"name":"Diabetes UK"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLP-1"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00592735","briefTitle":"Effects of Medical and Surgical Weight Loss on Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Garvan Institute of Medical Research"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"laparoscopic gastric banding"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00855010","briefTitle":"Pioglitazone on Pancreatic Steatosis and Bone Health"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Texas Southwestern Medical Center"},"collaborators":[{"name":"National Institutes of Health (NIH)"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pioglitazone"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00341614","briefTitle":"Exercise Training in Older Diabetic Women"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of San Francisco"},"collaborators":[{"name":"University of California, San Francisco"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"3-month Exercise Training and Diet Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02776696","briefTitle":"Comparison of Two Closed-Loop Strategies for Glucose Control in Type 1 Diabetes The DREMED Trail- 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rabin Medical Center"}},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Advanced Hybrid Closed Loop System"},{"name":"Hybrid Closed Loop System"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03495284","briefTitle":"The Effect of Potatoes on Markers of Cardiometabolic Health"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Penn State University"},"collaborators":[{"name":"Alliance for Potato Research and Education"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Cardiovascular Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Potato-based side dish"},{"name":"Refined grain-based"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04682626","briefTitle":"Effect of Weekly High-dose Vitamin D3 Supplementation on the Association Between Circulatory FGF-23 and A1c Levels"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Applied Science Private University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Kidney Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Soft gelatin capsules each contains 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04251156","briefTitle":"Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Overweight","Obesity","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"},{"name":"Placebo (semaglutide)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00718874","briefTitle":"A Specialized Diet for the Unique Metabolic Characteristics of Peripubertal African American Girls"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alabama at Birmingham"},"collaborators":[{"name":"Thrasher Research Fund"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dietary"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03166852","briefTitle":"Compliance to HIT-program at Home With the Use of Technology"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University College of Northern Denmark"},"collaborators":[{"name":"Aalborg University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Exercise","Technology"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Home-training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00415428","briefTitle":"A Quality Ensuring Project With Focus On Patients With Cardiovascular Diseases As Well As Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc."}},"conditionsModule":{"conditions":["Heart Diseases","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Patient adherence to national educational guidelines."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02088827","briefTitle":"Effects of Sedentary Behaviour on Metabolic Parameters"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of British Columbia"}},"conditionsModule":{"conditions":["Sedentary Lifestyle","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Inactivity"},{"name":"Activity"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03747471","briefTitle":"Conversation Map and Diabetes in Pakistan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rubina Qasim"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes","Self Efficacy","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetic Conversation Map"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00127296","briefTitle":"Reliability of Dosing With NovoLog® Mix 70/30 FlexPen® Compared With Vial and Syringe"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Delivery Systems"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FlexPen®"},{"name":"vial and syringe"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01424891","briefTitle":"Effects on NF-κB Activity: High Dose Simvastatin Versus Combination Therapy With Ezetimibe"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Heidelberg University"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Inflammation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Simvastatin 80 mg"},{"name":"Sim10/Eze10"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04084171","briefTitle":"Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Virginia"},"collaborators":[{"name":"DexCom, Inc."},{"name":"Tandem Diabetes Care, Inc."}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tandem t:slim X2 with Control-IQ Technology + Dexcom G6"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05716308","briefTitle":"The Effect Evaluation of Continuous Nursing Intervention in Patients With Type 2 Diabetic Retinopathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Beijing Tongren Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetic Retinopathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"A continuous nursing intervention group was established."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00572052","briefTitle":"Comparison of Glycemic Control Achieved With 2 Different Needles"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Delivery Systems"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NovoFine® needle 6 mm"},{"name":"Ultra-Fine needle 12.7 mm"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01361971","briefTitle":"Hyperbaric Oxygen Treatment Ameliorates Insulin Resistance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Adelaide"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hyperbaric Oxygen Treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03709966","briefTitle":"Portable Monitoring Device, Physical Activity Motivation and Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Laval University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Physical Activity","Motivation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Portable monitoring device"},{"name":"Routine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00645268","briefTitle":"A Multicenter, Double-blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Sildenafil on the As-Needed Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc."}},"conditionsModule":{"conditions":["Erectile Dysfunction","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sildenafil"},{"name":"placebo"},{"name":"sildenafil"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05904262","briefTitle":"Peripheral Protective Sensation in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Istanbul Kent University"},"collaborators":[{"name":"Bezmialem Vakif University"}]},"conditionsModule":{"conditions":["Diabetic Foot","Diabetic Neuropathies"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Foot Sole Sensation Evaluation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01270763","briefTitle":"Gene x Behavior Interaction in the Look AHEAD Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Miriam Hospital"},"collaborators":[{"name":"Tufts Medical Center"},{"name":"Brown University"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intensive lifestyle intervention"},{"name":"Diabetes support and education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00321256","briefTitle":"Human Islet Transplantation in Brittle Type 1 Diabetes Mellitus. The GRAGIL 2 Study."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Grenoble"},"collaborators":[{"name":"Alfediam"}]},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"human pancreatic islet transplantation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03733743","briefTitle":"Day-night Rhythm in Muscle Metabolism of Prediabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University"},"collaborators":[{"name":"Maastricht University Medical Center"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Standardized living protocol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03806920","briefTitle":"Isomaltulose VS Sucrose - Postprandial Effect on Incretin Profile and Second Meal Effect"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"German Institute of Human Nutrition"},"collaborators":[{"name":"Beneo GmbH"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intervention A"},{"name":"Intervention B"},{"name":"Intervention C"},{"name":"Intervention D"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01199692","briefTitle":"Characterization of Metabolic Biomarkers in Varying Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"CPL Associates"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00221208","briefTitle":"Home Based Resistance Training For Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alberta"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Resistance Training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01961466","briefTitle":"Diabetes and Psychological Profile"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire Dijon"}},"conditionsModule":{"conditions":["Type 1 or 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"psychological and social self-administered questionnaires"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02012465","briefTitle":"Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Washington University School of Medicine"}},"conditionsModule":{"conditions":["Lymphoma","Diabetes Mellitus, Type 2","Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin protocol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01847092","briefTitle":"A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ardelyx"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Chronic Kidney Disease","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD1722"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05164523","briefTitle":"The Effect of SGLT2 Inhibitors on Heart Rate Variability and BDNF Levels in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Goztepe Training and Research Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Heart Rate Variability"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"24-hour rhythm Holter"},{"name":"36 item Short Form Survey (SF-36)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01115088","briefTitle":"Effects of Stevia on Satiety and Eating Attitudes in Healthy, Overweight and Obese Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pennington Biomedical Research Center"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aspartame"},{"name":"Sucrose"},{"name":"Stevia"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04005261","briefTitle":"C-peptide Concentrations in Type 2 Diabetes Treated With Insulin; is it Time to Revise the Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Goztepe Training and Research Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Treated With Insulin"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"C-peptide concentrations"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04830462","briefTitle":"Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Herlev and Gentofte Hospital"}},"conditionsModule":{"conditions":["Latent Tuberculosis","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rifampicin 300 Mg Oral Capsule"},{"name":"Isoniazid 300 Mg ORAL TABLET"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00715663","briefTitle":"Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Delivery Systems"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06385899","briefTitle":"Effect of Intensive Monitoring of Patients With Poorly Controlled Type 2 Diabetes With Different Glycemic Background"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Goztepe Prof Dr Suleyman Yalcın City Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Poor Glycemic Control"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03764410","briefTitle":"Evaluation of Non - Surgical Periodontal Therapy in Diabetic Patients."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidade Metropolitana de Santos"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Periodontal Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Non-surgical periodontal treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01828229","briefTitle":"Consequences of Human Inactivity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rigshospitalet, Denmark"}},"conditionsModule":{"conditions":["Inactivity","Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"female inactivity and hypercaloric diet"},{"name":"inactivity"},{"name":"inactivity and hypercaloric diet"},{"name":"normal activity and hypercaloric diet"},{"name":"inactivity and iso-caloric diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03404700","briefTitle":"Determining Dietary Pattern Accompanying Egg Intake Using Remote Food Photography Method"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Texas Tech University"},"collaborators":[{"name":"Pennington Biomedical Research Center"},{"name":"American Egg Board"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Egg breakfast"},{"name":"Egg breakfast with high saturated fat"},{"name":"Cereal breakfast"},{"name":"Cereal breakfast with high saturated fat"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03495089","briefTitle":"DECODING Study (Dermal Electrochemical Conductance in Diabetic Neuropathy)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina"},"collaborators":[{"name":"Hospital Mutua de Terrassa"},{"name":"Hospital Universitari Sant Joan de Reus"}]},"conditionsModule":{"conditions":["Neuropathy, Diabetic","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"dermal electrochemical conductance (DEC)"},{"name":"Monofilament testing"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06060743","briefTitle":"Examining the Effect of Mobile Application on Insulin Use Perception and Self-Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ege University"},"collaborators":[{"name":"The Scientific and Technological Research Council of Turkey"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Treated With Insulin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INS-MOBILE: Mobile Application Developed for Insulin Use"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00885638","briefTitle":"Effects of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Hormonal Responses to Macronutrient Ingestion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lund University"}},"conditionsModule":{"conditions":["Healthy","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02791295","briefTitle":"Lifestyle Intervention in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Icadom"},"collaborators":[{"name":"AGIR à Dom"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Treated With Insulin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diet and physical activity program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03244449","briefTitle":"New IR Biomarkers (Myokines) in Colombian People"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Los Andes, Columbia"},"collaborators":[{"name":"The Administrative Department of Science, Technology and Innovation, Colciencias"},{"name":"Universidad Militar Nueva Granada"}]},"conditionsModule":{"conditions":["Insulin Resistance","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No apply"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02202876","briefTitle":"Redox Imbalance and the Development of Cystic Fibrosis Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"},"collaborators":[{"name":"Cystic Fibrosis Foundation"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Cystic Fibrosis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral Glucose Tolerance Test"},{"name":"High Glycemic Index Meal"},{"name":"Low Glycemic Index Meal"},{"name":"Test Soda"},{"name":"Fruit juice"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02547935","briefTitle":"A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus, CKD and Albuminuria"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin 10 mg"},{"name":"Saxagliptin 2.5 mg"},{"name":"Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01228240","briefTitle":"The Efficacy of Metformin Produced by Pars Mino Co in Comparison With Canadian Apotex Co."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Zanjan University of Medical Sciences"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2 AND Metformin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00425269","briefTitle":"Lifestyle Intervention for Pakistani Women in Oslo"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Oslo"},"collaborators":[{"name":"European Commission"},{"name":"The Research Council of Norway"}]},"conditionsModule":{"conditions":["Metabolic Syndrome","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"lifestyle intervention (diet and physical activity)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03597412","briefTitle":"Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yuhan Corporation"}},"conditionsModule":{"conditions":["Atherosclerotic Cardiovascular Disease","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosuvamibe"},{"name":"Monorova"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06384118","briefTitle":"Effects of a Health Intervention on Hypoglycemic Coping : a Pilot Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yating Liu"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Hypoglycemia","Health Education"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Impact of an IMB theory-based health education intervention on hypoglycemic coping in patients with type 2 diabetes: a pilot study"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00638560","briefTitle":"Changes of Biomarkers in Response to Training and Antioxidant Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Leipzig"},"collaborators":[{"name":"University of Jena"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin C, Vitamin E"},{"name":"Antioxidant treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03192228","briefTitle":"Impact of a Multidisciplinary Therapeutic Education Program Being Set up for Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Groupe Hospitalier Pitie-Salpetriere"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Patient Education as Topic"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Treatment adequacy score"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00602953","briefTitle":"Role of Pancreatic Triglyceride Content in Beta-cell Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Texas Southwestern Medical Center"},"collaborators":[{"name":"National Institutes of Health (NIH)"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No intervention planned."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04241575","briefTitle":"Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder Messages"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chinese University of Hong Kong"}},"conditionsModule":{"conditions":["Fatty Liver, Nonalcoholic","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Simple fibrosis scores and electronic reminder messages"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00545727","briefTitle":"Blood Glucose Response to Meals of Varying Glycemic Index in Youth With Type 1 & 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Type 2 Diabetes","Impaired Glucose Metabolism"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diet"},{"name":"Standard diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00174993","briefTitle":"Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04988594","briefTitle":"Effects of Yogurt With Probiotics in Adults With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Faculty of Medical Sciences, Clinical Hospital"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lactobacillus acidophilus 207, Bifidobacterium lactis B420/205"},{"name":"Lactobacillus bulgaricus and Streptococcus thermophillus"},{"name":"No culture"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05995756","briefTitle":"Evaluate the Safety and Efficacy of Sinocare CGM System Regarding Real Time Glucose Level Monitoring"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sinocare"}},"conditionsModule":{"conditions":["Type 1 or Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02325466","briefTitle":"Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Icahn School of Medicine at Mount Sinai"}},"conditionsModule":{"conditions":["Peripheral Artery Disease","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aspirin"},{"name":"Ticagrelor"},{"name":"Aspirin Placebo"},{"name":"Ticagrelor Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01145742","briefTitle":"Controlling Hypertension in Diabetes- Feasibility Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Albert Einstein College of Medicine"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Hypertension","Hyperlipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"home health/primary care collaboration"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00771693","briefTitle":"Effects of Insulin Treatment on Postprandial Platelet Activation in Patients With Non-insulin-dependent Diabetes Mellitus (NIDDM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Karolinska Institutet"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Postprandial Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin aspart (Novorapid®)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03049228","briefTitle":"In and ex Vivo Mitochondrial Function of the Heart"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"},"collaborators":[{"name":"Diabetes Fonds"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetic Cardiomyopathies"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"31P-MRS scan and cardiac MRI scan"},{"name":"Atrial biopsy for high-resolution respirometry"},{"name":"Blood analysis"},{"name":"Body composition"},{"name":"Indirect Calorimetry"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05094505","briefTitle":"Isolated and Combined Effect of a Low Carbohydrate Diet and Exercise in Hypoxia in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidade do Porto"},"collaborators":[{"name":"Fundação para a Ciência e a Tecnologia"},{"name":"University Institute of Maia"}]},"conditionsModule":{"conditions":["Carbohydrate","Hypoxia","Exercise","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise in normoxia"},{"name":"Control diet"},{"name":"Exercise in hypoxia"},{"name":"Low carbohydrate diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00412906","briefTitle":"Study of Gene Activity in Fat and Muscle in Diabetics and Healthy Controls"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rigshospitalet, Denmark"}},"conditionsModule":{"conditions":["Healthy","Type 2 Diabetes","Endotoxemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Escherichia Coli Endotoxin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00985712","briefTitle":"A Study on the Effect of 2 Pen Devices on HbA1c"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Lispro"},{"name":"Huminsulin Regular"},{"name":"HumaPen Memoir"},{"name":"HumaPen Luxura"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00655863","briefTitle":"Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin and Pioglitazone"},{"name":"Alogliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04377399","briefTitle":"High vs Low Dose Vitamin D in Patients With Diabetic Peripheral Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health"},"collaborators":[{"name":"Tameside Hospital NHS Foundation Trust"}]},"conditionsModule":{"conditions":["Diabetes Type 2","Diabetic Neuropathies","Vitamin D Deficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin D"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02629705","briefTitle":"Study of Carrageenan's Effect on Insulin Resistance in Humans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital Tuebingen"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Carrageenan"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03011177","briefTitle":"Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Handok Inc."}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Teneligliptin"},{"name":"Linagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01671345","briefTitle":"An Educational Intervention for Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VA Office of Research and Development"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intervention Video"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02115347","briefTitle":"Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Hepatic Impairment"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ertugliflozin 15 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03909269","briefTitle":"Glycaemic Markers in Persons With Type 2 Diabetes on Haemodialysis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rigshospitalet, Denmark"},"collaborators":[{"name":"Steno Diabetes Center Copenhagen"}]},"conditionsModule":{"conditions":["Diabetic Nephropathy Type 2","Type2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous glucose monitoring"},{"name":"Glycaemic markers"},{"name":"Erythrocyte life span"},{"name":"Carbon monoxide (CO)-rebreathing method"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01142297","briefTitle":"Comparative Study of Implant Surfaces to Enhance Stabilization in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"},"collaborators":[{"name":"Institut Straumann AG"}]},"conditionsModule":{"conditions":["Partially Edentulous Mandible","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"dental implant and modified dental implant"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01667900","briefTitle":"A Study of Dulaglutide in Chinese Participants"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Healthy Volunteers"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dulaglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02956811","briefTitle":"Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Dundee"},"collaborators":[{"name":"NHS Tayside"},{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Left Ventricular Hypertrophy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04653207","briefTitle":"The Dose Effects of Isomaltulose and Sucrose on Glycaemic and Insulinemic Response"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Singapore Institute of Food and Biotechnology Innovation"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity","Pre Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glucose Solution 1"},{"name":"Glucose Solution 2"},{"name":"Glucose Solution 3"},{"name":"Sucrose/Isomaltulose 100:0"},{"name":"Sucrose/Isomaltulose 0:100"},{"name":"Sucrose/Isomaltulose 50:50"},{"name":"Sucrose/Isomaltulose 60:40"},{"name":"Sucrose/Isomaltulose 70:30"},{"name":"Sucrose/Isomaltulose 80:20"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01354977","briefTitle":"Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Albert Einstein College of Medicine"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Resveratrol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04331444","briefTitle":"Steno2tech - Continuous Glucose Monitoring and Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Steno Diabetes Center Copenhagen"}},"conditionsModule":{"conditions":["Type 2 Diabetes Treated With Insulin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CGM"},{"name":"training course"},{"name":"Peer-support"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03231839","briefTitle":"Nutritional Prevention of Diabetes Mellitus Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital Tuebingen"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Nutritional and Metabolic Diseases","Liver Fat","Insulin Sensitivity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Caloric restriction"},{"name":"no red meat"},{"name":"Increased fiber intake"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01586780","briefTitle":"Metabolic Effects of a Pre-meal Protein Drink With or Without Added Amino Acids at a Subsequent Composite Meal"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lund University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Satiety Response"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Protein drink"},{"name":"Reference meal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01289587","briefTitle":"Promoting Physical Activity in Patients With Type 2 Diabetes (DIAfit)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Lausanne Hospitals"},"collaborators":[{"name":"University Hospital, Geneva"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physical activity intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03682445","briefTitle":"Metabolic, Physical Responses To Exercise In Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pamukkale University"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus","Exercise"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00248352","briefTitle":"A Study Comparing Standard Care for Diabetes to Case-Managed Care for Diabetes in Patients With Coronary Artery Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ottawa Heart Institute Research Corporation"},"collaborators":[{"name":"Sanofi"},{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Coronary Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Consultation with Endocrinologist"},{"name":"Counseling from Dietician"},{"name":"Counseling from Diabetes Educator"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04931836","briefTitle":"The Influence of Physical Activity on the Gut Microbiome of Pre-Diabetic Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Minnesota"}},"conditionsModule":{"conditions":["Obesity","Overweight","Overweight and Obesity","PreDiabetes","Type 2 Diabetes","Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus in Obese"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physical Activity Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03198832","briefTitle":"oxLDL in Diabetes Mellitus Patients and Disease Periodontal"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidade Estadual Paulista Júlio de Mesquita Filho"},"collaborators":[{"name":"LabviVale"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus With Periodontal Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Non-surgical periodontal treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04216654","briefTitle":"Role of Helicobacter Pylori in Microalbuminuria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Minia University"}},"conditionsModule":{"conditions":["Microalbuminuria Due to Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ELISA (enzyme-linked immunosorbent assay)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01294423","briefTitle":"Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","High Blood Sugar"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Dapagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01468519","briefTitle":"Exploratory CSII Trial on Erectile Dysfunction in T2DM Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jothydev's Diabetes and Research Centre"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Erectile Dysfunction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02261168","briefTitle":"Day-Night Rhythm in Human Skeletal Muscle"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Standardized living protocol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01454024","briefTitle":"Evaluating Safety of NovoPen® 3 and/or FlexPen® Devices in Routine Clinical Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Delivery Systems"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FlexPen®"},{"name":"NovoPen® 3"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01935804","briefTitle":"Effect of Pioglitazone Versus Metformin on Bone Health in Postmenopausal Women With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"King Abdulaziz University"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 2","Glucose Metabolism Disorders"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02578563","briefTitle":"Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy in Singapore"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02756832","briefTitle":"An Observational Study of Alogliptin Benzoate in Participants With Diabetes Mellitus Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin Benzoate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00770640","briefTitle":"Efficacy of Pioglitazone and Insulin in Treating Subjects With Type 2 Diabetes Mellitus and Renal Failure."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone and insulin"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01872299","briefTitle":"Studies Investigating Co-morbidities Aggravating Heart Failure"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Charite University, Berlin, Germany"},"collaborators":[{"name":"University of Hull"},{"name":"Wroclaw Medical University"},{"name":"IRCCS San Raffaele"},{"name":"Hannover Medical School"},{"name":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health"},{"name":"Moscow State University of Medicine and Dentistry"},{"name":"Siberian Branch of the Russian Academy of Medical Sciences"},{"name":"Russian Cardiology Research and Production Center"},{"name":"The University Clinic of Pulmonary and Allergic Diseases Golnik"},{"name":"Silesian Centre for Heart Diseases"}]},"conditionsModule":{"conditions":["Heart Failure","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00102297","briefTitle":"Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"FibroGen"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FG-3019"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00146484","briefTitle":"A Study of Two Versus Three Daily Injections in Children and Adolescents With Newly Diagnosed Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Children's Hospital of Eastern Ontario"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Twice Daily versus Three Times Daily Insulin Injections"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06236672","briefTitle":"Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LMC Diabetes & Endocrinology Ltd."},"collaborators":[{"name":"Novo Nordisk Canada Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Chronic Kidney Diseases"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLP-1 receptor agonist"},{"name":"basal insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02580513","briefTitle":"Circadian Misalignment and Insulin Sensitivity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Circadian Misalignment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00951119","briefTitle":"Device-guided Breathing Exercises on Blood Pressure in Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical Research Foundation, The Netherlands"}},"conditionsModule":{"conditions":["Hypertension in Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Resperate"},{"name":"Resperate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03260673","briefTitle":"Corneal Endothelial Cell Changes After Phacoemulsification in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Beijing Tsinghua Chang Gung Hospital"}},"conditionsModule":{"conditions":["Cataract","Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"specular microscope"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01447147","briefTitle":"A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"ChemoCentryx"}},"conditionsModule":{"conditions":["Diabetic Nephropathy","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"CCX140-B"},{"name":"CCX140-B"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05290207","briefTitle":"The Different Response of Endocrine Hormones to Hypoglycemia in Patients With Type 1 or Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nanjing First Hospital, Nanjing Medical University"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"The hyperinsulinaemic hypoglycaemic clamp"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05526157","briefTitle":"An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Chronic Kidney Disease","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Finerenone (Kerendia, BAY 948862)"},{"name":"Sodium-glucose cotransporter 2 inhibitors (SGLT2i)"},{"name":"Glucagon-like peptide-1 receptor agonists (GLP 1 RA)"},{"name":"Steroidal mineral corticoid receptor antagonists (sMRA)"},{"name":"Non-steroidal mineral corticoid receptor antagonists (nsMRA)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03864510","briefTitle":"NAFLD in Diabetes Type 2 in Primary Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Linkoeping University"}},"conditionsModule":{"conditions":["NAFLD"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00798915","briefTitle":"Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Washington University School of Medicine"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Glucose-dependent Insulinotropic Polypeptide (GIP)"},{"name":"Xenin-25"},{"name":"Glucose-dependent Insulinotropic Polypeptide plus Xenin-25"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03609463","briefTitle":"Promoting Weight Loss and Stress Reduction in Overweight and Obese Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chiara Rafanelli"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Overweight and Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Small change intervention"},{"name":"Well-being intervention"},{"name":"Treatment as usual"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00574639","briefTitle":"Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Maryland, Baltimore"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alprazolam"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01693406","briefTitle":"Breast Milk and Infant Growth Among Lean, Overweight and Diabetic Mothers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Denver"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"Thrasher Research Fund"},{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes","Gestational Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04390711","briefTitle":"Association of Carbamylated HDL and CAD in T2DM Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"RenJi Hospital"},"collaborators":[{"name":"Ruijin Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus With Circulatory Complciation"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High density lipoprotein isolation, detection and in-vitro study."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02070926","briefTitle":"The CRONOS-ADM Registry"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul St. Mary's Hospital"}},"conditionsModule":{"conditions":["Asymptomatic Patients With Type 2 Diabetes Mellitus","Atherosclerosis","Coronary Artery Disease","Cardiovascular Disease"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00358254","briefTitle":"Noninvasive Skin Spectroscopy for Diabetes Screening"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"InLight Solutions"},"collaborators":[{"name":"VeraLight, Inc."}]},"conditionsModule":{"conditions":["Prediabetic State","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01049737","briefTitle":"Cardiovascular Risk Factors in Patients With Diabetes -a Prospective Study in Primary Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Linkoeping University"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Cardiovascular Diseases"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01221519","briefTitle":"A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","High Blood Sugar"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD1656"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01313156","briefTitle":"LUPS-Lipids and Glucose Under Prospective Surveillance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Asklepios proresearch"},"collaborators":[{"name":"City of Hamburg"},{"name":"Universitätsklinikum Hamburg-Eppendorf"}]},"conditionsModule":{"conditions":["Metabolic Syndrome","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00638573","briefTitle":"The Incretin Effect in Patients With Chronic Pancreatitis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"},"collaborators":[{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Chronic Pancreatitis","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03176524","briefTitle":"A Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With T1DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Adocia"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BioChaperone® glucagon formulation 1"},{"name":"BioChaperone® glucagon formulation 2"},{"name":"GlucaGen® HypoKit®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00786721","briefTitle":"Mitochondria and Metabolic Syndrome in a Southern California Chinese Cohort"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, Irvine"},"collaborators":[{"name":"Beckman Laser Institute University of California Irvine"}]},"conditionsModule":{"conditions":["Metabolic Syndrome","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diffuse Optical Spectroscopy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01296308","briefTitle":"Complementary and Integrative Therapy for Diabetic Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universität Duisburg-Essen"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetic Neuropathy"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"inpatient integrative treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03979768","briefTitle":"Risk Assessment of Type 2 Diabetes in Pharmacies"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Bergen"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes risk assessment service in Norwegian community pharmacies"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00696722","briefTitle":"Effects of Atazanavir Treatment on Type 2 Diabetes Mellitus Related Endothelial Dysfunction"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Radboud University Medical Center"},"collaborators":[{"name":"Dutch Diabetes Research Foundation"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus Related Endothelial Dysfunction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo + atazanavir"},{"name":"atazanavir + placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01715818","briefTitle":"A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Cardiovascular Disease, Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"aleglitazar"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01586897","briefTitle":"The Medication Metronome Project - Study to Facilitate Follow-up Testing Resulting From Prescribed Medications to Improve Patient Safety and Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Massachusetts General Hospital"},"collaborators":[{"name":"Agency for Healthcare Research and Quality (AHRQ)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension","Hyperlipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Medication Metronome"},{"name":"Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00440375","briefTitle":"Effects of Rosiglitazone on Bone in Postmenopausal Diabetic Women"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baskent University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity","Menopause"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00933530","briefTitle":"A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sirtris, a GSK Company"},"collaborators":[{"name":"GlaxoSmithKline"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Healthy Volunteer"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SRT2104"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00006162","briefTitle":"Lifestyle Interventions to Reduce Diabetes Risk"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Glucose Intolerance","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exercise and diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03380338","briefTitle":"The Effect of Exercise on Gut Microbiota in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Amsterdam UMC, location VUmc"},"collaborators":[{"name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Insulin Sensitivity/Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Combined aerobic and strength exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00755846","briefTitle":"Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin"},{"name":"Alogliptin"},{"name":"Alogliptin"},{"name":"Alogliptin"},{"name":"Alogliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00285909","briefTitle":"Moderate Alcohol Consumption, Risk of Cardiovascular Disease and Type 2 Diabetes: Influence of Alcohol Oxidation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"TNO"}},"conditionsModule":{"conditions":["Cardiovascular Disease","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alcohol: 25 gday (white wine)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01845857","briefTitle":"A National Study of the Chronic Disease Self-Management Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Stanford University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Chronic Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Chronic Disease Self-Management Workshop"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01602913","briefTitle":"Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Depression, Postpartum"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pravastatin alone"},{"name":"Paroxetine alone"},{"name":"Pravastatin and paroxetine combined"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02475421","briefTitle":"Hyperglucagonaemia in Patients With Type 2 Diabetes - Role of Glucagon Clearance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"},"collaborators":[{"name":"University of Copenhagen"},{"name":"European Foundation for the Study of Diabetes"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glucagon"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01763346","briefTitle":"Beta Cell Restoration Through Fat Mitigation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Southern California"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Prediabetes","Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"gastric banding"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00277732","briefTitle":"Pharmaceutical Care for Diabetes Type 2 Patients: a Randomised Controlled Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Ghent"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pharmaceutical care at baseline and follow-up visits over 6 months"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02060916","briefTitle":"Study to Evaluate the Safety and Efficacy of PAZ320 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boston Therapeutics"}},"conditionsModule":{"conditions":["Type 2 Diabetes Treated With Insulin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PAZ320"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03362112","briefTitle":"Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nanjing First Hospital, Nanjing Medical University"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01803828","briefTitle":"REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Roma La Sapienza"}},"conditionsModule":{"conditions":["Diabetic Cardiomyopathy","Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tadalafil"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00812578","briefTitle":"Metabolic Effects of Vitamin D in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"Aarhus University Hospital"},{"name":"Regionshospitalet Silkeborg"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Vitamin D Insufficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cholecalciferol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06074965","briefTitle":"Impact of Two Medtronic Infusion Sets on Lipohypertrophy in Type 1 Diabetes (T1DM) Patients Thought to Have LH"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Azienda Ospedaliera San Camillo Forlanini"},"collaborators":[{"name":"Medtronic"}]},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Lipohypertrophy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Medtronic Extended Infusion Set"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04417725","briefTitle":"Burden of Chronic Kidney Disease (CKD), Type 2 Diabetes Mellitus (T2DM), and Comorbid T2DM/CKD in Alberta, Canada"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medlior Health Outcomes Research Ltd"}},"conditionsModule":{"conditions":["Chronic Kidney Diseases","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Not applicable - this is a non-interventional, observational study."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04636411","briefTitle":"Effects of Oral Magnesium Supplementation on Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Samar Fares, MD"},"collaborators":[{"name":"Walaa Reda Abdel Fattah Mohamed Badr"},{"name":"Marwa Mostafa Ahmed"},{"name":"Moushira Hosny Ezzelarab Sayed"},{"name":"Nagwa Eid Sobhy Saad"}]},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral Magnesium Supplementation"},{"name":"Standard Care for diabetic patients"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01078103","briefTitle":"Corneal Endothelial Changes Associated With Phacoemulsification in Diabetes Mellitus Type II"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Frederiksberg University Hospital"}},"conditionsModule":{"conditions":["Diabetes","Cataract"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00762736","briefTitle":"Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone and azilsartan"},{"name":"Pioglitazone and azilsartan"},{"name":"Pioglitazone"},{"name":"Pioglitazone and azilsartan"},{"name":"Pioglitazone and azilsartan"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00754403","briefTitle":"Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone and metformin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01271062","briefTitle":"Restoration of Beta Cell Function and Cardiovascular Parameters in Relation to Adipoinsular and Enteroinsular Axes After Gastric Bypass Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cantonal Hospital of St. Gallen"},"collaborators":[{"name":"European Foundation for the Study of Diabetes"},{"name":"Medical University of Graz"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Bariatric Surgery Candidate"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"gastric bypass surgery"},{"name":"abdominal surgery"},{"name":"very low caloric diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04023734","briefTitle":"A Targeted and Tailored Pharmacist Intervention to Improve Adherence to Antihypertensive Drugs Among Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Groningen"},"collaborators":[{"name":"Universitas Padjadjaran"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension","Medication Nonadherence"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Reminders, habit-based strategies and/or involvement of family member"},{"name":"Counselling to increase knowledge"},{"name":"Counselling to increase motivation"},{"name":"Explore/address other drug related problems"},{"name":"Usual care based on the Indonesian guideline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00773279","briefTitle":"Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Delivery Systems"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FlexTouch®"},{"name":"FlexPen®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01805414","briefTitle":"Breakfast Nutrition and Inpatient Glycemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Duke University"}},"conditionsModule":{"conditions":["Diabetes, Type 1","Diabetes, Type 2","Cardiovascular Disease","Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Modified Carbohydrate Breakfast"},{"name":"Control Breakfast"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04741685","briefTitle":"Clinical Efectivity of Two Different Sensor-augmented Pumps With Low Predictive Suspension Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Castilla-La Mancha Health Service"}},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TTSX2"},{"name":"MM640G"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00072891","briefTitle":"Improving Medication Adherence in Comorbid Conditions"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension","Hyperlipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"telephone counseling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02721602","briefTitle":"Families Preventing Diabetes Together"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Minnesota"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Pediatric Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Families Preventing Diabetes Together"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04429503","briefTitle":"Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Regeneron Pharmaceuticals"},"collaborators":[{"name":"Bayer"}]},"conditionsModule":{"conditions":["Diabetic Macular Edema","Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"aflibercept"},{"name":"High-dose aflibercept"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05683392","briefTitle":"Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tandem Diabetes Care, Inc."}},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"t:slim X2 insulin pump with Control-IQ technology 2.0"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00119041","briefTitle":"Diabetes Telemedicine Consultation: A Systems Improvement Intervention"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"US Department of Veterans Affairs"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Diabetes Mellitus, Type 1","Primary Care Provider"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"The Diabetes Treatment Satisfaction Questionnaire"},{"name":"Diabetes Empowerment Scale"},{"name":"CBOC's undergo half-day joint-clinics via teleconference"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03460899","briefTitle":"Impact of Hypoglycaemia in Patients With Diabetes Mellitus Type 2 on Platelet Activation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Graz"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Diabetes Mellitus With Hypoglycemia","Diabetes Mellitus, Type 2","Hypoglycemia","Hypoglycemic Episode"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Euglycaemic Clamp"},{"name":"Hyperinsulinaemic/Hypoglycaemic Clamp"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04484259","briefTitle":"Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Florida"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ticagrelor monotherapy"},{"name":"Ticagrelor plus aspirin"},{"name":"Clopidogrel with aspirin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02145611","briefTitle":"Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dr. José Fernando Vilela-Martin MD PhD"},"collaborators":[{"name":"Novartis"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Hypertension","Endothelial Dysfunction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glibenclamide"},{"name":"Vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00846300","briefTitle":"A Brief Intervention to Improve Medication Knowledge and Adherence Among Family Medicine Patients in South Texas"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hyperlipidemia","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physician counseling for health behavior change"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05806723","briefTitle":"Effects of High Intensity Statin Therapy on Steroid Hormones and Vitamin D in Type 2 Diabetic Men"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hopital La Rabta"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Dyslipidemia Associated With Type II Diabetes Mellitus","Statin Adverse Reaction","Hypogonadism, Male","Adrenal Insufficiency","Vitamin D Deficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Atorvastatin 40 Mg Oral Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04522882","briefTitle":"Clinical Data Collection for the Closed Loop Development for the Type 2 Diabetes Treatment - DT2_1"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diabeloop"},"collaborators":[{"name":"Icadom"},{"name":"AGIR à Dom"},{"name":"CHU Grenoble Alpes"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Treated With Insulin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Actimetry"},{"name":"Questionnaires"},{"name":"Glucose level and insulin administration"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01755572","briefTitle":"Blood Pressure Outcomes With Liraglutide Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mount Sinai Hospital, Canada"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Systolic Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01714505","briefTitle":"Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Virginia"},"collaborators":[{"name":"Juvenile Diabetes Research Foundation"},{"name":"Sansum Diabetes Research Institute"},{"name":"University of Padova"},{"name":"University Hospital, Montpellier"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Assistant (DiAs)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00943059","briefTitle":"Cross-over Study on Effect of Lipid Lowering by Acipimox on Cardiac and Skeletal Muscle Mitochondrial Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"},"collaborators":[{"name":"Center for Translational Molecular Medicine"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Cardiomyopathy, Dilated"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acipimox"},{"name":"Cellulosum Mycrocryst"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04560998","briefTitle":"A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Peripheral Arterial Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"},{"name":"Placebo (semaglutide)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01425580","briefTitle":"Liraglutide and Heart Failure in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Thomas Nystrom"},"collaborators":[{"name":"Örebro University, Sweden"}]},"conditionsModule":{"conditions":["Congestive Heart Failure","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"glimepiride"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00865124","briefTitle":"Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Brigham and Women's Hospital"},"collaborators":[{"name":"National Institutes of Health (NIH)"},{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Vascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Spironolactone"},{"name":"Hydrochlorothiazide + potassium"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00253786","briefTitle":"Study for the Effectiveness of Intensive Therapy Aiming at a Remission of Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Okayama University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intensive multifactorial therapy"},{"name":"Standard therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00191282","briefTitle":"Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Acute Myocardial Infarction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin lispro"},{"name":"Human insulin isophane suspension (NPH)"},{"name":"Insulin glargine"},{"name":"Human insulin isophane suspension"},{"name":"Human insulin 30/70"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00843479","briefTitle":"The Aging Endocrine Pancreas: Characterization of the Entero-insular Axis Physiology in the Elderly"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Campinas, Brazil"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Insulin Resistance"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02423434","briefTitle":"Evaluation of Corneal Confocal Microscopy for the Identification and Prediction of Neuropathy in Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"University of Calgary"},{"name":"Queensland University of Technology"},{"name":"University of Michigan"},{"name":"University of Manchester"}]},"conditionsModule":{"conditions":["Diabetic Polyneuropathy","Diabetes Mellitus","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Diabetes Complications"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exposure: Corneal nerve fibre morphology by the CCM Procedure"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04299763","briefTitle":"Oat Beta-glucan as a Supplement in Chilean Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centro de Estudios en Alimentación y Nutrición, Chile"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oat Beta-glucan as a Supplement in Type 2 Diabetics"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01068860","briefTitle":"To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Impaired Glucose Tolerance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canakinumab 150 mg"},{"name":"Placebo to Canakinumab"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01025856","briefTitle":"Combined Nutritional and Exercise Strategies to Reduce Liver Fat Content in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Federico II University"}},"conditionsModule":{"conditions":["Postprandial Lipids Metabolism","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rich in MUFA diet -PA"},{"name":"high fiber/low glycemic index diet + pa"},{"name":"Rich in MUFA diet+PA"},{"name":"High fibre/low glycemic index diet-PA"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01801254","briefTitle":"Using EEG Operant Conditioning to Improve Trait Self-Control and Promote Healthy Behavior"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Rochester"}},"conditionsModule":{"conditions":["Obesity","Type II Diabetes","Cardiovascular Disease","Health Behavior"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"STRIDES"},{"name":"Sham Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00968708","briefTitle":"Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Acute Coronary Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03362762","briefTitle":"Characteristics of Type 2 Diabetes Patients, Treated With Insulin and Their Follow up Care in Guadeloupe"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire de Pointe-a-Pitre"}},"conditionsModule":{"conditions":["Type 2 Diabetes Treated With Insulin"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Description of plans insuliniques used in Guadeloupe in the type 2 diabetes and the characteristics of the handled patients:"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01954771","briefTitle":"SMBG Protocols Predicting Glucose Levels in Senior Diabetes Mellitus With CAD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Beijing Anzhen Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SMBG"},{"name":"CGMS"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03352674","briefTitle":"Immunogenicity Study of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Indonesia University"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine Ezelin"},{"name":"Insulin Glargine Pen Injector [Lantus]"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00225277","briefTitle":"Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05887999","briefTitle":"A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3532226"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05232071","briefTitle":"Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Inventiva Pharma"}},"conditionsModule":{"conditions":["NASH - Nonalcoholic Steatohepatitis","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IVA337"},{"name":"Placebo"},{"name":"Empagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03526289","briefTitle":"GIP/GLP-1 Co-Activity in Subjects With Overweight and Type 2 Diabetes: Lowering of Food Intake"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"},"collaborators":[{"name":"Zealand Pharma"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Overweight and Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GIP1-42 infusion"},{"name":"Saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03369626","briefTitle":"Effectiveness of a Digital Therapeutic on Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"FareWell"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FareWell Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05725889","briefTitle":"Detection of Visual-Auditory Reaction Rates in Individuals With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baskent University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Cognitive Dysfunction","Nerve Damage"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"recation time test"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00379379","briefTitle":"Study of Improving Insulin Sensitivity by Electroacupuncture Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"China Medical University Hospital"},"collaborators":[{"name":"China Medical University, China"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"electroacupuncture"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04484480","briefTitle":"Balance and Motion Coordination Parameters Can be Improved in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Warsaw"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Gait Disorders, Neurologic"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Balance training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00509262","briefTitle":"Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Renal Insufficiency, Chronic"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Glipizide"},{"name":"Placebo for Sitagliptin"},{"name":"Placebo for Glipizide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00400036","briefTitle":"Dietary Fish Protein in Subjects With Insulin Resistance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Laval University"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Insulin Resistance","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cod protein NCEP-diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06329674","briefTitle":"Efficacy and Safety of AJU-A51 in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AJU Pharm Co., Ltd."}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AJU-A51"},{"name":"A51R2"},{"name":"A51R3"},{"name":"AJU-A51 Placebo"},{"name":"A51R2 Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01325987","briefTitle":"African American Children, Glycemic Control, and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alabama at Birmingham"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Vitamin D Deficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin D2"},{"name":"Sugar pill"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00236626","briefTitle":"A Study of the Safety and Effectiveness of Topiramate on Insulin Sensitivity in Overweight or Obese Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type 2","Diabetes Mellitus, Adult-Onset"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"topiramate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01850810","briefTitle":"Evaluation of a Nutritional Product for People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Nutrition"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Experimental Study Product"},{"name":"Control Study Product"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02769585","briefTitle":"Efficacy of Self-hypnosis for Weight Loss in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Levenson, David I., M.D."}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type 2","Weight Reduction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Self-hypnosis"},{"name":"CDE training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04183868","briefTitle":"Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Catanzaro"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Cardiovascular Risk Factor"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin 10 MG"},{"name":"Glimepiride 2 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01727817","briefTitle":"Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy (Italy)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Virginia"},"collaborators":[{"name":"Juvenile Diabetes Research Foundation"},{"name":"Sansum Diabetes Research Institute"},{"name":"University Hospital, Montpellier"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Assistant (DiAs)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02122874","briefTitle":"Percutaneous Electric Neurostimulation of Dermatome T7 Improves Glycemic Profile in Obese and Typo 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital General Universitario Elche"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2 in Obese","Type 2 Diabetes Mellitus With Features of Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Percutaneous Neurostimulation (PENS) of dermatome T7"},{"name":"1200 Kcal diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01770483","briefTitle":"The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Services Institute of Medical Sciences, Pakistan"},"collaborators":[{"name":"Getz Pharma"}]},"conditionsModule":{"conditions":["Hepatitis C, Chronic","DIABETES MELLITUS Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"nitazoxanide"},{"name":"conventional interferon alfa"},{"name":"Ribavirin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03921242","briefTitle":"Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Weill Medical College of Cornell University"},"collaborators":[{"name":"Patient-Centered Outcomes Research Institute"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Renal Insufficiency, Chronic"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Sulfonylurea"},{"name":"DPP-4 inhibitor"},{"name":"SGLT2 inhibitor"},{"name":"GLP1 receptor agonist"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02210871","briefTitle":"Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Hepatic Impaired"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05232812","briefTitle":"Validation of 3-[11C]-OHB"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Heart Failure","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"3-[11C]-OHB"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03814694","briefTitle":"Cut Down on Carbohydrate Usage in the Diet of Type 2 Diabetes. The Hypo-energetic Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bispebjerg Hospital"},"collaborators":[{"name":"University of Copenhagen"},{"name":"University of Aarhus"},{"name":"The Danish Dairy Research Foundation, Denmark"},{"name":"Arla Foods"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Overweight and Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CRHP Diet"},{"name":"CD Diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01742741","briefTitle":"Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy (France)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Virginia"},"collaborators":[{"name":"Juvenile Diabetes Research Foundation"},{"name":"University of Padova"},{"name":"University of California, Santa Barbara"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Assistant (DiAs)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00879801","briefTitle":"Genetic Physiopathology and Evolution of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pisa"},"collaborators":[{"name":"Italian Society of Diabetology"},{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Pre-Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02966626","briefTitle":"A Real World Experience of Dapagliflozin in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Malaya"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04304963","briefTitle":"Hypo-METRICS: Hypoglycaemia - Measurement, ThResholds and ImpaCtS"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"King's College London"},"collaborators":[{"name":"University of Southern Denmark"},{"name":"Sheffield Teaching Hospitals NHS Foundation Trust"},{"name":"Cambridge University Hospitals NHS Foundation Trust"},{"name":"Ninewells Hospital"},{"name":"Radboud University Medical Center"},{"name":"Nordsjaellands Hospital"},{"name":"Medical University of Graz"},{"name":"University Hospital, Montpellier"},{"name":"Innovative Medicines Initiative"},{"name":"The Leona M. and Harry B. Helmsley Charitable Trust"},{"name":"Juvenile Diabetes Research Foundation"},{"name":"International Diabetes Federation"},{"name":"Novo Nordisk A/S"},{"name":"Abbott Diabetes Care"},{"name":"Medtronic Diabetes"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Hypoglycemia","Hypoglycemia Unawareness"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NO intervention - observational study"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03077360","briefTitle":"Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Denver"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Pre-diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01951547","briefTitle":"The Periodontal Disease and Diabetes Mellitus Interrelationship Among Adult Malaysians"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Malaya"}},"conditionsModule":{"conditions":["Chronic Periodontitis","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nonsurgical periodontal therapy"},{"name":"Oral hygiene instructions"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05662475","briefTitle":"Effect of Periodontal Treatment on Visfatin, fetuin-a and Sirtuin 1 of Patients With Periodontitis and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ondokuz Mayıs University"}},"conditionsModule":{"conditions":["Periodontal Diseases","Type 2 Diabetes","Periodontitis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GCF (gingival crevicular fluid) collection"},{"name":"Non-surgical periodontal treatment completed in 24 hours"},{"name":"HbA1c level determination in blood serum"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03248206","briefTitle":"Home-based Proprioceptive Neuromuscular Facilitation for Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Cheng-Kung University Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Exercise"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"lifestyle changes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00364767","briefTitle":"Moderate Alcohol Consumption, Fat and Carbohydrate Metabolism and Insulin Sensitivity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"TNO"},"collaborators":[{"name":"Dutch Foundation for alcohol research"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"A"},{"name":"B"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05287906","briefTitle":"A Trial to Assess Steviol Glycosides on Acute Appetite Hormone Release"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Midwest Center for Metabolic and Cardiovascular Research"},"collaborators":[{"name":"Cargill"}]},"conditionsModule":{"conditions":["Overweight and Obesity","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Water"},{"name":"Glucose"},{"name":"Steviol Glycosides"},{"name":"Steviol Glycosides plus glucose"},{"name":"Rebaudioside A"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00568620","briefTitle":"The Role of the Duodenum in the Pathogenesis of Insulin Resistance and Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Insulin Resistance and Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placement of nasogastric feeding tube"},{"name":"Nasojejunal feeding tube"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03650088","briefTitle":"Adaptation of a Digital Weight Loss Intervention Promoting Self-regulation for Use in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of North Carolina, Chapel Hill"},"collaborators":[{"name":"Michigan Center for Diabetes Translational Research"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Overweight and Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Behavioral weight loss with digital tools"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03380325","briefTitle":"The Effect of Iloprost on Capillary Recruitment and Insulin Sensitivity in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Amsterdam UMC, location VUmc"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Insulin Sensitivity/Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Iloprost infusion"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00569998","briefTitle":"Comparison of Two Pen Systems in Patients With Diabetes Treated With Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Delivery Systems"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NovoPen™ 4"},{"name":"NovoPen® 3"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00118560","briefTitle":"Exercise Training for Patients With Poor Leg Circulation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"US Department of Veterans Affairs"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Intermittent Claudication"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physical exercise"},{"name":"Physical walking"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00231530","briefTitle":"A Study of the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetes Patients on a Controlled Diet"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type 2","Diabetes Mellitus, Adult-Onset"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"topiramate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01283113","briefTitle":"Evaluation of Intra-Abdominal Fat in Patients With Type 2 Diabetes Using a Non-Invasive Method"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Joslin Diabetes Center"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes","Metabolic Syndrome"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00286442","briefTitle":"Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin and metformin"},{"name":"Alogliptin and metformin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00672919","briefTitle":"Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05481034","briefTitle":"Simplified Meal Approach Using Hybrid Closed-loop Insulin Delivery in Youth and Young Adults With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lia Bally"},"collaborators":[{"name":"University of Zurich"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SMA bolus option"},{"name":"Exactly estimated carbohydrate content bolus option"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00707447","briefTitle":"Evaluation of a Primary Type 2 Diabetes Prevention Programme"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Forschungsinstitut der Diabetes Akademie Mergentheim"},"collaborators":[{"name":"Technische Universität Dresden"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PREDIAS"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04126551","briefTitle":"Mitochondrial Methylation in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Arizona"}},"conditionsModule":{"conditions":["Overweight","Obesity","Diabetes Mellitus, Type 2","Insulin Resistance"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Methylation status"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03726762","briefTitle":"Effects of Replacing Diet Beverages With Water on Weight Maintenance of Type 2 Diabetic Obese Women: 18 Months Follow up"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novindiet Clinic"},"collaborators":[{"name":"University of Nottingham"},{"name":"Tehran University of Medical Sciences"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Overweight","Obese"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DBs at the end of the main meal + weight control program"},{"name":"Water at the end of the main meal+ weight control program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04141241","briefTitle":"Phase 2a Study to Evaluate the Safety and Efficacy of PH100 Tablet in T2DM Patients With Recent Cardiovascular"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bota Bio Co., Ltd."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus With Circulatory Complciation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ecklonia cava Phlorotannin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06167616","briefTitle":"Infections and Latent Autoimmune Diabetes in Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Karolinska Institutet"},"collaborators":[{"name":"The Swedish Research Council"},{"name":"Swedish Council for Working Life and Social Research"},{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Latent Autoimmune Diabetes in Adults","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03561571","briefTitle":"Triglyceride Rich Lipoproteins and Platelet Activation in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospices Civils de Lyon"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"butter based breakfast"},{"name":"Chocolate spread based breakfast"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00693537","briefTitle":"Exercise Training Improves Coronary Endothelial Dysfunction in Diabetes Mellitus Type 2 and Coronary Artery Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Paracelsus Medical University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01806727","briefTitle":"Lifestyle Intervention for Treatment of Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Wake Forest University"},"collaborators":[{"name":"National Institute on Minority Health and Health Disparities (NIMHD)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Overweight","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Community Lifestyle Weight Loss (LWL)"},{"name":"Diabetes Self Management (DSM)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04838405","briefTitle":"A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Carmot Therapeutics, Inc."},"collaborators":[{"name":"Carmot Australia First Pty Ltd"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CT-388"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04112875","briefTitle":"Effect of L-arginine on Microcirculation, Myogenesis and Angiogenesis Associated With Aging, Sarcopenia and Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rio de Janeiro State University"},"collaborators":[{"name":"Laboratory for Clinical and Experimental Research on Vascular Biology"}]},"conditionsModule":{"conditions":["Aging","Sarcopenia","Type 2 Diabetes","Microcirculation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"L-arginine"},{"name":"Maltodextrin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04159922","briefTitle":"Study of the Psychological Profile of Type 2 Diabetic Patients With Foot Wounds, Compared to Diabetic Patients Without Foot Wounds"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire Dijon"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Foot Wound"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"questionnaire"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03770052","briefTitle":"Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pusan National University Hospital"},"collaborators":[{"name":"Chong Kun Dang Pharmaceutical Corp."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Inadequate Glucose Control"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"duvie"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03039075","briefTitle":"Metformin SR Tablet (DuLeNing) and Glucophage in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chongqing Medical University"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin SR Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02707380","briefTitle":"The Effectiveness of Resistance Training on Glycemic Control for Patients With Type 2 Diabetes in Cardiac Rehabilitation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NYU Langone Health"}},"conditionsModule":{"conditions":["Type 2 Diabetes (T2DM)","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Resistance Training"},{"name":"Standard of Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05979519","briefTitle":"Fresh Carts for Mom's to Improve Food Security and Glucose Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Alison Gustafson"},"collaborators":[{"name":"Instacart Health"},{"name":"Kentucky Association of Health Plans"}]},"conditionsModule":{"conditions":["Gestational Diabetes Mellitus in Pregnancy","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fresh Funds for Mom's"},{"name":"Standard Medical care"},{"name":"Medically Tailored Frozen Meals"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03792321","briefTitle":"Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Diabetic Patients\" (SETH2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Medical Centre Ljubljana"}},"conditionsModule":{"conditions":["Hypogonadism, Male","Diabetes Mellitus, Type 2","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Testosterone Undecanoate"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06553248","briefTitle":"A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gan and Lee Pharmaceuticals, USA"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GZR4"},{"name":"Insulin Degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02690766","briefTitle":"Translating Healthy Lifestyle Interventions for Cancer Survivors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of North Carolina, Chapel Hill"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent","Breast Cancer","Endometrial Cancer"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Standard Behavioral Weight Change Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03259321","briefTitle":"Fish, Polyunsaturated Fatty Acids Intake and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Zhejiang University"},"collaborators":[{"name":"National Institute of Health and Nutrition"}]},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01049412","briefTitle":"A Study for Patients With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2605541"},{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04238702","briefTitle":"Renohemodynamic Effects of Combined empagliflOzin and LosARtan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Amsterdam UMC, location VUmc"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetic Kidney Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin 10 MG"},{"name":"Losartan 50Mg Tab"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00612040","briefTitle":"Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"insulin degludec"},{"name":"insulin glargine"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02836574","briefTitle":"A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Prokidney"},"collaborators":[{"name":"CTI Clinical Trial and Consulting Services"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Chronic Kidney Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Renal Autologous Cell Therapy (REACT)"},{"name":"Renal Biopsy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02370537","briefTitle":"A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Exocrine Pancreatic Insufficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Epanova® (omega-3 carboxylic acids)"},{"name":"Omacor® (omega-3-acid ethyl esters)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03973515","briefTitle":"Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"PegBio Co., Ltd."}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"glucokinase activator"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01759953","briefTitle":"Educational Efficacy Assessment of a Serious Game to Teach Insulin Therapy to Primary Care Physicians"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidade Estadual de Londrina"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Knowledge, Attitudes, Practice"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Game"},{"name":"Traditional CME"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02105324","briefTitle":"The Summer Camp Study 2: Blood Glucose Control With a Bi-Hormonal Endocrine Pancreas"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Massachusetts General Hospital"},"collaborators":[{"name":"Boston University"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bionic Pancreas"},{"name":"Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04209075","briefTitle":"Prebiotics and Metformin Improve Gut and Hormones in Type 2 Diabetes in Youth (MIGHTY-fiber)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Biomebliss"},{"name":"Metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01053936","briefTitle":"Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Reata, a wholly owned subsidiary of Biogen"}},"conditionsModule":{"conditions":["Renal Insufficiency, Chronic","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bardoxolone methyl (amorphous dispersion)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02302599","briefTitle":"Mesenchymal Stem Cells to Treat Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chinese PLA General Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Mesenchymal Stem Cells"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Umbilical cord mesenchymal stem cells"},{"name":"Controlled suspension liquid"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01907399","briefTitle":"Study of Immune Response in Obesity and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire Dijon"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes","Healthy Volunteers"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Blood samples"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02924207","briefTitle":"Electronic Decision Support for Intervention in Poorly Controlled Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"St Elizabeth Healthcare"},"collaborators":[{"name":"PATH Decision Support Software, LLC"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PATH electronic decision support tool"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02150707","briefTitle":"The Differential Effects of Diabetes Therapy on Inflammation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University College Dublin"},"collaborators":[{"name":"Irish Endocrine Society"},{"name":"Royal College of Physicians"},{"name":"Merck Sharp & Dohme LLC"},{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetic Nephropathy","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dipeptidyl-Peptidase IV Inhibitors"},{"name":"Glucagon-Like Peptide 1"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03702660","briefTitle":"Effect of GIP After a Meal in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GIP(3-30)NH2"},{"name":"Peripheral venous cannulation"},{"name":"GLP-1"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01870557","briefTitle":"Markers of Bone Status in Diabetes Mellitus (Type 1 and Type 2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jakob Starup Linde"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Osteoporosis","Osteopenia"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03981627","briefTitle":"A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Adocia"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ADO09 formulation"},{"name":"NovoRapid®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06660134","briefTitle":"Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Chest Hospital"},"collaborators":[{"name":"The Third Affiliated Hospital of Anhui Medical University"},{"name":"The Second People's Hospital of Anhui Province"},{"name":"Hefei Second People's Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2DM)","Atrial Fibrillation (AF)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glucagon-like peptide-1 receptor agonists (GLP 1 RA)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02050399","briefTitle":"Cardiovascular Oscillations in Coronary Patients With and Without Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidade Federal de Sao Carlos"}},"conditionsModule":{"conditions":["Coronary Artery Disease","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Isometric exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02834715","briefTitle":"Metabolic Effects of Stevia in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yaounde Central Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Stevia rebaudiana liquid extract"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01487109","briefTitle":"A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Concert Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Chronic Kidney Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CTP-499"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01526733","briefTitle":"Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Halozyme Therapeutics"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sham Injection"},{"name":"Recombinant human hyaluronidase PH20"},{"name":"Insulin aspart"},{"name":"Insulin lispro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02982408","briefTitle":"Impact of Overfeeding and Following Exercise Training in Individuals With and Without Increased Risk of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rigshospitalet, Denmark"},"collaborators":[{"name":"Novo Nordisk A/S"},{"name":"Augustinus Fonden"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Insulin Resistance","Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High carbohydrate overfeeding"},{"name":"Exercise"},{"name":"Normal physical activity"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00231660","briefTitle":"A Study of the Efficacy and Safety of Topiramate in the Treatment fo Obese, Type 2 Diabetic Patients Treated With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type 2","Diabetes Mellitus, Adult-Onset"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"topiramate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02739984","briefTitle":"Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Amgen"}},"conditionsModule":{"conditions":["Hypercholesterolemia","Mixed Dyslipidemia","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Evolocumab"},{"name":"Placebo to Evolocumab"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01854463","briefTitle":"The Effect of Vitamin D Supplementation in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chuncheon Sacred Heart Hospital"},"collaborators":[{"name":"Korean Diabetes Association"}]},"conditionsModule":{"conditions":["DIABETES MELLITUS"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin D3"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00231647","briefTitle":"A Study on Efficacy and Safety of Topiramate OROS Controlled-Release in Obese, Type 2 Diabetic Subjects Managed With Diet or Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type 2","Diabetes Mellitus, Adult-Onset"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"topiramate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00950040","briefTitle":"Brief Alcohol Intervention to Reduce At-Risk Drinking Among Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rhode Island Hospital"}},"conditionsModule":{"conditions":["At-risk Drinking","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Brief alcohol intervention"},{"name":"General health education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05227196","briefTitle":"A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Healthy Volunteers","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide D Dose 1"},{"name":"Semaglutide D Dose 2"},{"name":"Semaglutide D Dose 3"},{"name":"Semaglutide Dose 4"},{"name":"Semaglutide Dose 5"},{"name":"Semaglutide Dose 6"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00521742","briefTitle":"Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"},"collaborators":[{"name":"Takeda Pharmaceuticals North America, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"Glyburide"},{"name":"Pioglitazone"},{"name":"Glyburide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00494715","briefTitle":"Preventing ESRD in Overt Nephropathy of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mario Negri Institute for Pharmacological Research"},"collaborators":[{"name":"Agenzia Italiana del Farmaco"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Benazepril"},{"name":"Valsartan"},{"name":"Benazepril/Valsartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02127762","briefTitle":"The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ottawa Hospital Research Institute"},"collaborators":[{"name":"Canadian Diabetes Association"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Type I Diabetes","Type II Diabetes","Diabetic Peripheral Neuropathy","Chronic Pain"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mindfulness Based Stress Reduction"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03164785","briefTitle":"Efficacy and Safety of Jinshuibao Capsule on Diabetic Kidney Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Second Xiangya Hospital of Central South University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Diabetic Kidney Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Jinshuibao Capsule"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04816890","briefTitle":"A Trial to Assess the Efficacy and Safety of M1 Pram P037 Prandial Insulin in Subjects With Type 1 Diabetes (T1DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Adocia"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"M1 Pram P037"},{"name":"Insulin lispro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00662857","briefTitle":"A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mannkind Corporation"}},"conditionsModule":{"conditions":["Diabetes Mellitus: Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Technosphere® Insulin Inhalation Powder"},{"name":"Technosphere Insulin® Inhalation Powder"},{"name":"RAA Population"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05640180","briefTitle":"An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Chronic Kidney Disease","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Finerenone (Kerendia, BAY94-8862)"},{"name":"Sodium-glucose cotransporter-2 inhibitors (SGLT2i)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01801631","briefTitle":"Tailored Support for Type 2 Diabetes Patients With an Acute Coronary Event After Discharge From Hospital"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"UMC Utrecht"},"collaborators":[{"name":"Dutch Diabetes Research Foundation"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Acute Coronary Event"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Home visits"},{"name":"Consultation by telephone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05703152","briefTitle":"Effect of a Combined Exercise Program on Neuropathic Pain and Perceived Quality of Life in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maria Gabriela Aké Palomo"},"collaborators":[{"name":"Universidad Autónoma de Yucatán"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Neuropathic Pain","Neuropathy, Diabetic"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Combined Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02545140","briefTitle":"Prevention Strategies for Adolescents at Risk of Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospitals, Leicester"},"collaborators":[{"name":"University of Leicester"},{"name":"Associacao Protectora dos Diabeticos de Portugal"},{"name":"The Algarve Regional Health Administration"},{"name":"University of Leipzig"},{"name":"Technische Universität Dresden"},{"name":"Alexander Technological Educational Institute, Thessaloniki, Greece"},{"name":"Diabetes Centre of Paediatrics P&A"},{"name":"Athens General Children's Hospital \"Pan. & Aglaia Kyriakou\""},{"name":"Primary Care Centre Egia, San Sebastian, Spain"},{"name":"Basque Government Department of Public Health"},{"name":"Health Department of the Alto/Bajo Deba"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Chronic Disease"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02790892","briefTitle":"Creative Arts Diabetes Initiative for Youth/Young Adults Transitioning to Adult Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Manitoba"}},"conditionsModule":{"conditions":["Coping Behavior","Emotional Distress","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Art therapy - pre and post test measures"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00801892","briefTitle":"Obstructive Sleep Apnea (OSA), Sleepiness, and Activity in Diabetes Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eileen R. Chasens"}},"conditionsModule":{"conditions":["Sleep Apnea, Obstructive","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous Positive Airway Pressure (CPAP)"},{"name":"Sham- Continuous Positive Airway Pressure (Sham-CPAP)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00845130","briefTitle":"Quantitative in Vivo Biomarkers of Oxidative Stress in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"In-Young Choi, Ph.D."}},"conditionsModule":{"conditions":["Type 2 Diabetes","Oxidative Stress"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ascorbic acid (Vitamin C)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05043467","briefTitle":"Retrospective Study to Evaluate the Safety of Duvie in Korean Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Duvie(Lobeglitazone) tab 0.5mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04758364","briefTitle":"Factors That Effect the Gait Speed in Diabetic Individuals Without Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GULIN FINDIKOGLU"}},"conditionsModule":{"conditions":["Gait Disorder, Sensorimotor","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"measurement of gait speed"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01572402","briefTitle":"Postprandial Insulin Secretion, Oxidative Stress and Gastrointestinal Peptides in Patients With Type 2 Diabetes Versus Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institute for Clinical and Experimental Medicine"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Postprandial Oxidative Stress"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bagueutte Cheese Gourmet (Crocodille)"},{"name":"Cous-cous sandwich"},{"name":"McCountry sandwich (McDonald's)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03581968","briefTitle":"Efficacy of Closed-Loop Strategy With and Without a Learning Component in Children and Adolescents With Type 1 Diabetes at a Diabetes Camp"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"McGill University"}},"conditionsModule":{"conditions":["Diabetes","Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Artificial Pancreas"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00676260","briefTitle":"Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00901472","briefTitle":"Sleep Disordered Breathing and Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Chicago"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obstructive Sleep Apnea"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00833716","briefTitle":"Effect of Renal Impairment on the Pharmacokinetics of NN9535"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2","Renal Impairment"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04736225","briefTitle":"Effects of the Insulin Self Titration Education for Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Taipei University of Nursing and Health Sciences"},"collaborators":[{"name":"Chiayi Christian Hospital"}]},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Self-Titration Education Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01246687","briefTitle":"Web-based Dietary Intervention for Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Monash University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Intervention Studies","Behavior"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"e-Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05667051","briefTitle":"Endocan Biomarker Level in Gingival Crevicular Fluid in Periodontitis Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Alexandria University"}},"conditionsModule":{"conditions":["Periodontitis","Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02762370","briefTitle":"Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pacira Pharmaceuticals, Inc"}},"conditionsModule":{"conditions":["Osteoarthritis of the Knee","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FX006 32 mg"},{"name":"TCA IR 40 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03263728","briefTitle":"Cardiac Magnetic Resonance for Asymptomatic Type 2 Diabetics With Cardiovascular High Risk (CATCH) - Pilot Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Hong Kong"},"collaborators":[{"name":"Radiological Society of North America"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cardiac Magnetic Resonance"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01680328","briefTitle":"Investigation of Pain During Subcutaneous Injections With Different Injection Speed and Volume Combinations"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Delivery Systems"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"19 injections"},{"name":"sodium chloride 0.9% solution"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04006028","briefTitle":"Kidney Biopsy Indications in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rennes University Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes, Chronic Kidney Disease"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02316483","briefTitle":"Genetic Contribution to the Pathophysiology of the Charcot Foot in Qatari Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Weill Medical College of Cornell University"},"collaborators":[{"name":"Hamad Medical Corporation"},{"name":"Weill Cornell Medical College in Qatar"}]},"conditionsModule":{"conditions":["Charcot Arthropathy","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05806190","briefTitle":"Hypoglycaemia (Low Blood Sugar) in Adults With Diabetes and Adrenal Failure"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Imperial College Healthcare NHS Trust"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Adrenal Insufficiency","Diabetes Mellitus Type 2 - Insulin-Treated"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous Glucose Monitoring"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02214056","briefTitle":"Mobile Unit Screening of Pathologies Associated With Chronic Diseases - Feasibility"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire de Nīmes"}},"conditionsModule":{"conditions":["Chronic Obstructive Pulmonary Disease","Type II Diabetes","Atherosclerosis"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Patient recruitment"},{"name":"Mobile team exam"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00681850","briefTitle":"OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05147116","briefTitle":"The Effect of Hypoxia on Type 2 Diabetes and Weight Loss"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Portsmouth"},"collaborators":[{"name":"Bournemouth University"},{"name":"University College, London"},{"name":"University of Cambridge"},{"name":"Portsmouth Hospitals NHS Trust"}]},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sleeping in a tent"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04743453","briefTitle":"EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Sao Paulo General Hospital"},"collaborators":[{"name":"Federal University of São Paulo"}]},"conditionsModule":{"conditions":["Kidney Transplantation","Diabetes Mellitus, Type 2","Diabetes Complications"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04055480","briefTitle":"Closing the Loop in Adults With Type 1 Diabetes Under Free Living Conditions"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Cambridge"},"collaborators":[{"name":"Manchester University NHS Foundation Trust"},{"name":"Insel Gruppe AG, University Hospital Bern"},{"name":"Medical University of Graz"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Closed-loop using standard rapid-acting insulin"},{"name":"Closed-loop using faster insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01494298","briefTitle":"Study of Cholesterol Levels and Types in African Americans With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mercer University"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"},{"name":"Emory University"},{"name":"Celera Genomics"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","African American","Cholesterol","Lipoprotein","Apolipoprotein"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05019274","briefTitle":"Culinary Medicine vs. Nutrition Education in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Texas Southwestern Medical Center"}},"conditionsModule":{"conditions":["Primary Disease: 1. Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Culinary Medicine Intervention"},{"name":"Standard of Care Nutrition Visits"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00476710","briefTitle":"Effects of Colesevelam HCl On Bile Acid Kinetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"KineMed"},"collaborators":[{"name":"Daiichi Sankyo"},{"name":"University Medical Center Groningen"},{"name":"Diabetes & Glandular Disease Research Associates"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Impaired Glucose Tolerance"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Colesevelam HCl"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01516242","briefTitle":"Evaluation of Safety and Parameters of Application Technique"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Delivery Systems"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00928005","briefTitle":"Evaluating the Effects of a Diet and Exercise Program in People With Type 2 Diabetes or Prediabetes: (The SHAPE3 Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johns Hopkins University"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Overweight","Obesity","Type 2 Diabetes","Prediabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Weight loss diet"},{"name":"Weight loss diet plus exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00354237","briefTitle":"DARE: Diabetes in cArdiac REhabilitation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire Dijon"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Conventional antidiabetic treatment"},{"name":"Intensive insulin treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00763074","briefTitle":"Exercise and Diet in Type 2 Diabetic Women"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eulji University Hospital"}},"conditionsModule":{"conditions":["Insulin Sensitivity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Standard life style modification for type 2 diabetes"},{"name":"Diet restriction"},{"name":"Exercise"},{"name":"Diet and exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06080451","briefTitle":"Implementing HEARTS in Guatemala"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"},{"name":"Institute of Nutrition of Central America and Panama"},{"name":"Ministry of Health of Guatemala"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension","Cardiovascular Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Integrated Diabetes and Hypertension Primary Care Model"},{"name":"Integrated Diabetes and Hypertension Primary Care Model - Providers"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01194479","briefTitle":"Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yale University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Formoterol"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00848315","briefTitle":"Diabetes Management in Low-Income Hispanic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Massachusetts, Worcester"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Glycemic Control"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cognitive Behavioral Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00315991","briefTitle":"Blood Glucose Awareness Training for Parents"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Virginia"},"collaborators":[{"name":"Joslin Diabetes Center"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Blood Glucose Awareness Training for Parents"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00343343","briefTitle":"Comparison of NovoFine® Needles (4 mm vs. 6 mm)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Delivery Systems"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NovoFine® needle 6 mm"},{"name":"NovoFine® needle 4 mm"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00853801","briefTitle":"Integrating Lifestyle Therapy for Diabetes Prevention Into Primary Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cook County Health"}},"conditionsModule":{"conditions":["Pre-Diabetes","Metabolic Syndrome","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle intervention and provider feedback"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05343767","briefTitle":"Investigate the Efficacy and Safety of Low-Glu in Patients Newly Diagnosed With Type II Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Natural Wellness Egypt"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Natural Wellness Low-Glu low dose"},{"name":"Natural Wellness Low-Glu high dose"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01877603","briefTitle":"The Relation Between Plasma Irisin Level and Endothelial Dysfunction in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Wuhan General Hospital of Guangzhou Military Command"}},"conditionsModule":{"conditions":["Irisin","Endothelial Dysfunction","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01136785","briefTitle":"Effects of Continuous Positive Airway Pressure (CPAP) Treatment on Glucose Control in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Chicago"}},"conditionsModule":{"conditions":["Obstructive Sleep Apnea","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"active CPAP Therapy"},{"name":"sham CPAP therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03893526","briefTitle":"Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Copenhagen"},"collaborators":[{"name":"Hvidovre University Hospital"}]},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Entresto"},{"name":"Sitagliptin"},{"name":"Valsartan"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04350879","briefTitle":"Diabetes Mellitus and Pregnancy : Knowledge Assessment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"CHU de Reims"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Data record"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03217591","briefTitle":"A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Akebia Therapeutics"},"collaborators":[{"name":"Cyclerion Therapeutics"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus With Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IW-1973"},{"name":"IW-1973"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05266261","briefTitle":"Use of Ibandronate in Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yeouido St. Mary's Hospital"},"collaborators":[{"name":"Samsung Medical Center"},{"name":"Seoul National University Bundang Hospital"}]},"conditionsModule":{"conditions":["Osteoporosis, Postmenopausal","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ibandronate Oral Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00818935","briefTitle":"Low-Intermediate-Glycemic Index Caribbean Foods Versus High Glycemic Index Foods in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital of the West Indies"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Inflammation","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low-Intermediate-Glycemic Index diets"},{"name":"High GI diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03214107","briefTitle":"Carbohydrate-based Strategies to Prevent Exercise-induced Hypoglycemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institut de Recherches Cliniques de Montreal"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise"},{"name":"Snack"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05483140","briefTitle":"Digitally-Enabled Weight Management Program on T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Nutrition"},"collaborators":[{"name":"Changing Health"},{"name":"National Health Service, United Kingdom"}]},"conditionsModule":{"conditions":["Weight Change, Body","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Option 1"},{"name":"Option 2"},{"name":"Option 3"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01845870","briefTitle":"Serum 1,25-dihydroxyvitamin D Levels in Type 2 Diabetes Mellitus Patients With Different Levels of Albuminuria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tianjin Medical University General Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus With Diabetic Nephropathy"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03931434","briefTitle":"Effect of Aged Garlic Extract (AGE) on Improving Coronary Atherosclerosis in People With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center"}},"conditionsModule":{"conditions":["Coronary Arteriosclerosis","Endothelial Dysfunction","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aged Garlic Extract (AGE)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00871416","briefTitle":"Localisation of Potential Insulin Deposits in Normal Weight and Obese Diabetics Using 6 mm and 12 mm Long Needles"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Delivery Systems"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NovoFine® needle 6 mm"},{"name":"NovoFine® needle 12 mm"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02358096","briefTitle":"A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Europe B.V."}},"conditionsModule":{"conditions":["Chronic Kidney Disease","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ASP8232"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00315952","briefTitle":"Study to Estimate the Effects of Inhaled Versus Intravenous (IV) Infusion of Human Insulin in Subjects With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pittsburgh"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exubera"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02316821","briefTitle":"The Phase II Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kyowa Kirin Co., Ltd."}},"conditionsModule":{"conditions":["Chronic Kidney Disease","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"RTA 402"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01373346","briefTitle":"Safety and Efficacy of Long Limb Roux-en Y Reconstruction"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gangnam Severance Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2 in Nonobese","Gastric Cancer"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Long limb Roux-en Y reconstruction"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04304261","briefTitle":"Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Third Military Medical University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Cognitive Functions Confusion"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00157729","briefTitle":"MATCHED (MC-1 and ACE Therapeutic Combination for Hypertensive Diabetics)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medicure"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Hypertension","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pyridoxal-5'-phosphate with and without ACE inhibitor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00548639","briefTitle":"The STATIN CHOICE Decision Aid for Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Icahn School of Medicine at Mount Sinai"},"collaborators":[{"name":"Mayo Clinic"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Statin Choice Decision Aid"},{"name":"Control Pamphlet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02437084","briefTitle":"Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Stanford University"},"collaborators":[{"name":"Doris Duke Charitable Foundation"}]},"conditionsModule":{"conditions":["Hyperlipidemia","Insulin Resistance","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Atorvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01726777","briefTitle":"Effect of Vitamin D Supplementation on Glucose Tolerance in Subjects at Risk for Diabetes With Low Vitamin D."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Toronto"},"collaborators":[{"name":"Dairy Farmers of Canada"},{"name":"Public Health Agency of Canada (PHAC)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Vitamin D Deficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Control"},{"name":"Vitamin D"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06579898","briefTitle":"The Effect of Progressive Resistance Exercise Training (PRET) on CVRF in Adults With ID."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Erasmus Medical Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension","Hypercholesterolemia","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Progressive resistance exercise training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05013294","briefTitle":"Using mHealth (Mobile Health) to Optimize Glycemic Control in Adults With Type 2 Diabetes: Proof of Concept Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"KU Leuven"},"collaborators":[{"name":"Jomo Kenyatta University of Agriculture and Technology"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06535295","briefTitle":"Physical Activity, Functional Capacity and Quality of Life in Older Patients With Chronic Comorbidities"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Biruni University"}},"conditionsModule":{"conditions":["Obesity","Hypertension","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00675220","briefTitle":"Observational Study to Assess the Efficacy and Safety of NovoRapid™ Flexpen™"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Delivery Systems"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03256747","briefTitle":"Effects of Neuromuscular Electrical Stimulation on Glucose Variability in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital de Clinicas de Porto Alegre"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NMES"},{"name":"NMES-placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00766857","briefTitle":"Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Amsterdam UMC, location VUmc"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Congestive Heart Failure"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01503112","briefTitle":"Predicting Response to Incretin Based Agents in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Royal Devon and Exeter NHS Foundation Trust"},"collaborators":[{"name":"National Institute for Health Research, United Kingdom"},{"name":"University of Exeter"}]},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No intervention, observational study"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03717233","briefTitle":"Assistive ExoSkeletons to Enable Wearable Rehabilitation Robotics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Results Group LLC"},"collaborators":[{"name":"Southern Connecticut State University"}]},"conditionsModule":{"conditions":["Diabetic Foot Ulcer","Diabetic Foot Ulcer Associated With Type II Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exoskeleton"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00364988","briefTitle":"Pioglitazone and Losartan Provides Additional Renoprotection"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Jiao Tong University School of Medicine"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pioglitazone+losartan"},{"name":"losartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04450407","briefTitle":"A Study of LY3209590 in Participants With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY3209590"},{"name":"Insulin Degludec"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03270956","briefTitle":"A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Prokidney"},"collaborators":[{"name":"CTI Clinical Trial and Consulting Services"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Chronic Kidney Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Renal Autologous Cell Therapy (REACT)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02713841","briefTitle":"Pharmacologic Response and Safety of Inhaled Insulin in Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dance Biopharm Inc."}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"inhaled human insulin (INH)"},{"name":"sc insulin lispro (LIS)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01621178","briefTitle":"A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Chronic Kidney Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dulaglutide"},{"name":"Insulin glargine"},{"name":"Insulin lispro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01021865","briefTitle":"Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"},"collaborators":[{"name":"University of Nebraska"},{"name":"Astellas Pharma US, Inc."},{"name":"Lantheus Medical Imaging"}]},"conditionsModule":{"conditions":["Coronary Artery Disease","Diabetes Mellitus Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04509245","briefTitle":"The Effects of a Novel Lifestyle Intervention Program on Insulin Sensitivity in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"German Diabetes Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Fatty Liver, Nonalcoholic"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low-calorie diet supported by an app-guided digital education program, nutritional coaching calls via phone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00423488","briefTitle":"Ezetimibe and Simvastatin in Primary Hypercholesterolemia, Diabetes Mellitus Type 2, and Coronary Heart Disease (COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Organon and Co"},"collaborators":[{"name":"Schering-Plough"}]},"conditionsModule":{"conditions":["Hypercholesterolemia","Diabetes Mellitus, Type 2","Coronary Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ezetimibe 10 mg"},{"name":"Simvastatin 20 mg"},{"name":"Ezetimibe Placebo"},{"name":"Simvastatin 20 mg"},{"name":"Simvastatin Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03437044","briefTitle":"Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Florida"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ticagrelor"},{"name":"Clopidogrel"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06182891","briefTitle":"Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Affiliated Hospital of Xuzhou Medical University"}},"conditionsModule":{"conditions":["Type 2 Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dulaglutide Injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01726491","briefTitle":"Epigenetics and the Origin of Muscle Insulin Resistance in Humans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2 in Obese","Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00727857","briefTitle":"Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone and metformin"},{"name":"Pioglitazone"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01307566","briefTitle":"Evolution With CPAP Treatment of a Cohort of Type 2 Diabetic Patients With Apnea-hypopnea Syndrome"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital de Granollers"},"collaborators":[{"name":"EsteveTeijin Healthcare"}]},"conditionsModule":{"conditions":["Sleep Apnea","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous Positive Airway Pressure CPAP"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01349855","briefTitle":"Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine HOE901"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02460978","briefTitle":"Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo for dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03157960","briefTitle":"Effect of Acute Fructose Load in Human"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Karolinska University Hospital"}},"conditionsModule":{"conditions":["Chronic Kidney Diseases","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Blueberry drink"},{"name":"Blueberry and pizza"},{"name":"Soft beverage"},{"name":"Soft beverage and pizza"},{"name":"Fructose"},{"name":"Fructose and pizza"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02748330","briefTitle":"Platelet Inhibition of Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients After Elective Percutaneous Coronary Intervention"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Peking Union Medical College Hospital"}},"conditionsModule":{"conditions":["Coronary Artery Disease","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ticagrelor"},{"name":"Clopidogrel"},{"name":"Aspirin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06374043","briefTitle":"Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Medical Center Groningen"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes Mellitus Type 2 With Proteinuria","Diabetes Mellitus","Diabetes","Diabetes Complications","Albuminuria","Chronic Kidney Diseases","Chronic Kidney Disease Due to Type 2 Diabetes Mellitus","CKD","Proteinuria"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin 10mg Tab"},{"name":"Placebo"},{"name":"Withings BPM Connect"},{"name":"Withings Body+"},{"name":"Hem-Col Capillary Blood Collection Device"},{"name":"MEMS (Medication Electronic Monitoring System) Cap"},{"name":"Questionnaire: participants' perspectives toward remote data collection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01544309","briefTitle":"LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Listen Trial Group"}},"conditionsModule":{"conditions":["Hypercholesterolemia With Concomitant Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Atorvastatin"},{"name":"Rosuvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05349903","briefTitle":"Impact of Slowly Digestible Carbohydrates on the Gut-brain Axis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Purdue University"},"collaborators":[{"name":"Société des Produits Nestlé (SPN)"}]},"conditionsModule":{"conditions":["Appetitive Behavior","Obesity","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rice flour"},{"name":"Alternanoligosaccharide 15"},{"name":"Inulin"},{"name":"Waxy potato starch"},{"name":"Waxy potato starch + epigallocatechin gallate (EGCG)"},{"name":"Chickpea flour + epigallocatechin gallate (EGCG)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00960765","briefTitle":"Endotoxin and Intestinal Flora Before and After Gastric Bypass or Banding in Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"CPL Associates"},"collaborators":[{"name":"Synergy Bariatrics"},{"name":"Sisters of Charity Hospital"},{"name":"The New York State Center of Excellence in Bioinformatics & Life Sciences"}]},"conditionsModule":{"conditions":["Obesity, Morbid","Diabetes Mellitus, Type 2","Gastric Bypass"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01008163","briefTitle":"A Dose-Finding, Efficacy and Safety Study of YY-351 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yuyu Pharma, Inc."}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"YY-351/Placebo"},{"name":"YY-351/Placebo"},{"name":"YY-351"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06046976","briefTitle":"Piezosurgical vs Conventional Exodontia Surgery in Healthy and Patients With Diabetes Mellitus Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Belgrade"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Surgery","Tooth Extraction Status Nos"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"piesosurgical extraction"},{"name":"conventional extraction"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05563987","briefTitle":"ACT-DE for Diabetes Distress in Adults With Type 2 Diabetes: A Pilot RCT"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chinese University of Hong Kong"}},"conditionsModule":{"conditions":["Acceptance and Commitment Therapy","Type 2 Diabetes","Diabetes Distress"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ACT-DE"},{"name":"DE"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01058733","briefTitle":"Semi-automatic Response System(SARS)in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Catholic University of Korea"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Internet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04618744","briefTitle":"A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oramed, Ltd."},"collaborators":[{"name":"Integrium"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","NASH - Nonalcoholic Steatohepatitis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ORMD-0801 (Insulin) capsule 8 mg BD"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00728156","briefTitle":"Platelet-dependent Thrombosis: a Placebo-controlled Trial of Antiplatelet Therapy (Clopidogrel)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Newcastle-upon-Tyne Hospitals NHS Trust"},"collaborators":[{"name":"British Heart Foundation"},{"name":"University of Newcastle Upon-Tyne"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"clopidogrel"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00005760","briefTitle":"Health Effects of Liposuction in Overweight Women With Elevated Insulin Levels, Impaired Glucose Tolerance and/or Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)"}},"conditionsModule":{"conditions":["Glucose Intolerance","Hyperinsulinemia","Diabetes Mellitus, Non Insulin Dependent","Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05353686","briefTitle":"A Trial Investigating the Effect of 4 Weeks Dosing of XEN-D0501 on Blood Glucose Reduction in Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pila Pharma"},"collaborators":[{"name":"Biomapas"}]},"conditionsModule":{"conditions":["Efficacy","Safety","Pharmacokinetics","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"XEN-D0501"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01219400","briefTitle":"Vildagliptin and the Glucagon Response to Hypoglycemia in Insulin-Treated Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lund University"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03001999","briefTitle":"Boosting Emotions & Happiness in Outpatients Living With Diabetes: Phase I"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Massachusetts General Hospital"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Emotions","Patient Compliance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PP-MI health behavior intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03901248","briefTitle":"Study of Association of Salivary Adipokines With Prediabetes and Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01868529","briefTitle":"Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04809220","briefTitle":"A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 2","Glucose Metabolism Disorders","Metabolic Disease","Endocrine System Diseases","Hypoglycemic Agents","Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dulaglutide"},{"name":"Oral antihyperglycemics"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01614262","briefTitle":"Examining The Role of CGM in T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of North Carolina, Chapel Hill"},"collaborators":[{"name":"Medtronic"},{"name":"Atlanta Diabetes Associates"},{"name":"UNC Coordinating Center"}]},"conditionsModule":{"conditions":["DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (Disorder)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous Glucose Monitoring with treatment algorithm"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04190251","briefTitle":"PANDIA IRIS: Patients With Diabetes and Kidney Failure, an Interdisciplinary Medication Adherence Support Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland"},"collaborators":[{"name":"pharmaSuisse"},{"name":"santésuisse"},{"name":"Curafutura"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Renal Insufficiency, Chronic"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Inteprofessional medication adherence support program (IMAP)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00399347","briefTitle":"Prevalence of Type 2 Diabetes Mellitus in Ethiopian Community in Israel: an Update"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HaEmek Medical Center, Israel"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02027740","briefTitle":"Almond Intervention in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diabetes Foundation, India"}},"conditionsModule":{"conditions":["Cardiovascular Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"almond"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01005498","briefTitle":"Comparison Between Low Carbohydrate Diet and Traditionally Recommended Diabetic Diet in the Treatment of Diabetes Mellitus Type 2."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vårdcentralen Lyckorna"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low carbohydrate - high fat diet"},{"name":"High carbohydrate - low fat diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03895996","briefTitle":"Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Avotres Inc."}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AVT001"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02964572","briefTitle":"Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yonsei University"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glimepiride"},{"name":"Empagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03534921","briefTitle":"Improving Diabetes Outcomes for People With Severe Mental Illness (SMI)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of York"},"collaborators":[{"name":"University of Leeds"},{"name":"University of Southampton"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Severe Mental Disorder"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01201785","briefTitle":"Aspirin Dosing in Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Florida"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aspirin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04041492","briefTitle":"Effect of Vitamins D3 and K2 in uOc and Insulin Serum Levels in Patients With Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Guadalajara"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Bone Loss","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Supplementation with Vitamin D3 y K2"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00185159","briefTitle":"Olmesartan Medoxomil in Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sankyo Pharma Gmbh"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Cardiovascular Disease","Kidney Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Olmesartan medoxomil"},{"name":"Placebo Tablets"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02212665","briefTitle":"Life Without Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"}},"conditionsModule":{"conditions":["Prevention of Developing Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High intense interval training"},{"name":"Increased daily activity detected by the pedometer"},{"name":"Increased daily activity detected by the pedometer+HIIT"},{"name":"Increased daily activity detected by the pedometer+group intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04820348","briefTitle":"Assessing Adherence to Digital Health Technologies Among Hispanic/Latino Adults With or At Risk of Type 2 Diabetes:"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sansum Diabetes Research Institute"},"collaborators":[{"name":"William Marsh Rice University"},{"name":"Carnegie Mellon University"},{"name":"Baylor College of Medicine"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Depression","Anxiety","Diet Habit"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04254029","briefTitle":"The Cardiovascular and Renal Effects of Moringa Oleifera Extracts and Stevia Rebaudiana Bertoni in Patients With Type II Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yaounde Central Hospital"}},"conditionsModule":{"conditions":["Benefits of a Capsules of Moringa Oleifera and Stevia Rebaudiana Bertoni in Patients With Type 2 Diabetes Mellitus Before and After 45 Days of add-on Therapy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MOROLSTEVER1"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00279240","briefTitle":"Life Style Modifications Prevents Type 2 Diabetes in Asian Indians"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"M.V. Hospital for Diabetes"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03147677","briefTitle":"Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and Irbesartan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Third Xiangya Hospital of Central South University"}},"conditionsModule":{"conditions":["Type 2 Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alfacalcidol"},{"name":"Irbesartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04269668","briefTitle":"An Open-label, Two-center, Randomized, Cross-over Study to Evaluate the Safety and Efficacy of Glycemic Control Using Hybrid-closed Loop vs. Advanced Hybrid Closed-loop in Young Subjects With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rabin Medical Center"},"collaborators":[{"name":"GIF"},{"name":"Medtronic"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Medtronic Minimed 670G 3.0 HCL"},{"name":"Medtronic Minimed 670G 4.0 AHCL"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06326034","briefTitle":"Impact of Dapagliflozin as Add-on Therapy on Glycemic Status and Quality of Life in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mohammed Mahmood Mohammed"}},"conditionsModule":{"conditions":["Diabetic Nephropathy Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01281098","briefTitle":"Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Association for Innovation and Biomedical Research on Light and Image"}},"conditionsModule":{"conditions":["High Risk Proliferative Diabetic Retinopathy","Diabetes Mellitus Type I","Diabetes Mellitus Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Panretinal Photocoagulation (PRP)"},{"name":"Intravitreous injection of pegaptanib"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05521256","briefTitle":"A Research Study of a New Medicine NNC0113-6856 in Healthy Males"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Healthy Volunteers","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NNC0113-6856"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00389350","briefTitle":"Effect of an Extract of Green Tea on Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dartmouth-Hitchcock Medical Center"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Extract of Green and Black Tea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00927524","briefTitle":"Insulin Exposure and Glucose Response to Meals in Type 1 Diabetic Subjects Administered Two Different Insulin Regimens Compared to the Endogenous Insulin Exposure and Glucose Response to Meals In Healthy Adult Controls"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glulisine"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04190212","briefTitle":"The Effect of High-Intensity Interval Training on Glucose Variability and Atrial Fibrillation Symptoms"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ottawa Heart Institute Research Corporation"}},"conditionsModule":{"conditions":["Atrial Fibrillation","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High-intensity interval training + standard care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04767750","briefTitle":"Role of LncRNA H19 in The Regulation of IGF-1R Expression"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mansoura University"}},"conditionsModule":{"conditions":["Hepatocellular Carcinoma","Type 2 Diabetes","Cancer"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Blood sample collection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02467478","briefTitle":"Linagliptin's Effect on CD34+ Stem Cells"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"George Washington University"},"collaborators":[{"name":"Boehringer Ingelheim"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Impaired Renal Function"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Linagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03031886","briefTitle":"Energy Flux and Fat Oxidation Using Low and High Glycaemic Index Foods"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Singapore Institute of Food and Biotechnology Innovation"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity","PreDiabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"low glycaemic index intervention"},{"name":"high glycaemic index intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04056208","briefTitle":"Pistachios Blood Sugar Control, Heart and Gut Health"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Penn State University"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Cardiovascular Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pistachio"},{"name":"Usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03344692","briefTitle":"Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nantes University Hospital"},"collaborators":[{"name":"Regeneron Pharmaceuticals"}]},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alirocumab"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02029924","briefTitle":"A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Adocia"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BioChaperone insulin lispro"},{"name":"Humalog®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01136798","briefTitle":"Impact of Exenatide on Sleep in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Chicago"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Sleep Disordered Breathing"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05654285","briefTitle":"Enteroendocrine Hormonal Response After the Ingestion of Cola Beverages With Sucrose and Non-nutritive Sweeteners"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital Infantil de Mexico Federico Gomez"}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type 2","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cola beverage with aspartame and acesulfame K"},{"name":"Cola beverage with sucrose and stevia"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05409027","briefTitle":"A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sparrow Pharmaceuticals"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus in Obese","Obesity","Type2Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SPI-62"},{"name":"Cortisone-d8"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03623139","briefTitle":"Effects of Basic Carbohydrate Counting Versus Standard Outpatient Nutritional Education in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Steno Diabetes Center Copenhagen"},"collaborators":[{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Type2 Diabetes","Diabetes Mellitus, Type 2","Glucose Metabolism Disorders"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Standard nutritional education"},{"name":"Basic carbohydrate counting"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00964964","briefTitle":"A Trial Assessing Changes in Blood Sugar and the Number of Periods Where Supplementation of Carbohydrate is Needed to Treat Low Blood Sugar, During Two Different Treatment Regimens of NN1250 in Type 1 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"insulin degludec"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00226902","briefTitle":"Vascular Reactivity in Kidney Disease Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Melbourne Health"}},"conditionsModule":{"conditions":["Kidney Failure, Chronic","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Changing hemoglobin concentration"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02444156","briefTitle":"Rowing Away From Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Leicester"},"collaborators":[{"name":"Medtronic"},{"name":"Wellcome Trust"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Glucose Intolerance","Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Indoor rowing"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04389775","briefTitle":"To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sciwind Biosciences APAC CO Pty. Ltd."},"collaborators":[{"name":"Hangzhou Sciwind Biosciences Co., Ltd."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity","Nonalcoholic Steatohepatitis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cohort A"},{"name":"Placebo A"},{"name":"Cohort B"},{"name":"Placebo B"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00141453","briefTitle":"ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo Co., Ltd."}},"conditionsModule":{"conditions":["Diabetic Nephropathy","Type 2 Diabetes Mellitus","Proteinuria"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"olmesartan medoxomil"},{"name":"Placebo Tablets"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01277913","briefTitle":"The Effect of Supplementation With Two Different Doses of Vitamin D on Bone Mineral Density, Vitamin D Levels and Hand Grip Strength in Children With Diabetes Mellitus Type 1"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Warsaw"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin D3"},{"name":"Vitamin D3"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04017221","briefTitle":"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Canadian Network for Observational Drug Effect Studies, CNODES"},"collaborators":[{"name":"Drug Safety and Effectiveness Network, Canada"},{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Urosepsis","Diabetic Ketoacidosis","Lower Extremity Amputation"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors"},{"name":"Dipeptidyl peptidase-4 (DPP-4) inhibitors"},{"name":"Other treatment combinations"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01595789","briefTitle":"The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Haugaard, Steen Bendix, M.D., DMSc"}},"conditionsModule":{"conditions":["Coronary Artery Disease","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03753087","briefTitle":"Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation"},"collaborators":[{"name":"Ministry of Health of the Russian Federation"}]},"conditionsModule":{"conditions":["Heart Failure, Diastolic","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Standard care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04268212","briefTitle":"An Alternative Approach to Improve Hyperglycemia Among Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Arizona State University"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bitter melon juice (100 ml)"},{"name":"Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00837408","briefTitle":"Genetics of Type 2 Diabetes Among Han Chinese"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Human Genome Research Institute (NHGRI)"}},"conditionsModule":{"conditions":["Diabetes","Hypertension"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01168076","briefTitle":"Noninvasive Transcutaneous Glucometer Development"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"InLight Solutions"}},"conditionsModule":{"conditions":["Healthy","Prediabetic State (IGT)","Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05691452","briefTitle":"Technology Based Sedentary Reduction Intervention in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Sedentary Behavior","Physical Activity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sit Less Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05239572","briefTitle":"Scaling Up NCD Interventions in South East Asia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Medical Center Groningen"},"collaborators":[{"name":"University of Groningen"},{"name":"University of Passau"},{"name":"Universitas Sebelas Maret"},{"name":"Health Strategy and Policy Institute"},{"name":"Trnavska Universita v Trnava"},{"name":"HelpAge International"},{"name":"Thai Nguyễn University of Medicine and Pharmacy"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension","Cardiovascular Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"screening, prevention and counselling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06469658","briefTitle":"Personalized Management of Type 2 Diabetes Using AI-Guided (GenAIS TM) Dietary Supplementation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"S.LAB (SOLOWAYS)"},"collaborators":[{"name":"Triangel Scientific"},{"name":"Center of New Medical Technologies"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"The standard practice dietary supplements intervention"},{"name":"The AI-guided practice dietary supplements group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02027571","briefTitle":"Pathobiology and Reversibility of Prediabetes in a Biracial Cohort"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Tennessee"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Prediabetes","Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intensive Lifestyle Intervention (ILI)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00770445","briefTitle":"Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With Insulin-Treated Type 2 Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone and insulin"},{"name":"Pioglitazone and metformin and insulin"},{"name":"Metformin and insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06228898","briefTitle":"Changes in Hematological Parameters With Glycemia Control in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Goztepe Prof Dr Suleyman Yalcın City Hospital"}},"conditionsModule":{"conditions":["Poorly Controlled Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02603510","briefTitle":"Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SAR342434"},{"name":"insulin lispro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02996539","briefTitle":"Heart Rate Variability and Diabetic Kidney Disease in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shi wei, MM"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Clinical examination and laboratory measurements"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00818779","briefTitle":"Direct Renin Inhibition Effects on Atherosclerotic Biomarkers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Texas Tech University Health Sciences Center"}},"conditionsModule":{"conditions":["Coronary Artery Disease","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aliskiren"},{"name":"Amlodipine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02631083","briefTitle":"The Influence of Glucose Flux on Fat Synthesis in a Whole Body Calorimeter"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Singapore Institute of Food and Biotechnology Innovation"}},"conditionsModule":{"conditions":["Type 2 Diabetes, Obesity, Prediabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Breakfast, lunch, snack and dinner"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01891786","briefTitle":"Coronary Heart Disease Risk in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"City, University of London"},"collaborators":[{"name":"University College, London"}]},"conditionsModule":{"conditions":["Coronary Heart Disease","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Self-Management Intervention"},{"name":"Risk Result"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01220349","briefTitle":"Alteration of Myocardial Deformations in Diabetes: Relationship to Micro-angiopathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Bordeaux"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Echocardiographic 2D strain analysis"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02201199","briefTitle":"Single Dose Clamp Study To Compare Concentration/Time Profile And Metabolic Activity Profile Of 2 New Formulations Of Insulin Glargine With Lantus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glargine U200 HOE901"},{"name":"insulin glargine U500 HOE901"},{"name":"insulin glargine U100 HOE901"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01452451","briefTitle":"Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hanmi Pharmaceutical Company Limited"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HM11260C"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02863523","briefTitle":"COMRADE: Collaborative Care Management for Distress and Depression in Rural Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"East Carolina University"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Diabetes-related Distress","Depression"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Integrated Behavioral Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00770835","briefTitle":"Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone and Metformin"},{"name":"Glibenclamide and Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04878406","briefTitle":"A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Healthy Volunteers Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NNC0480-0389"},{"name":"Placebo (NNC0480-0389)"},{"name":"Semaglutide"},{"name":"Placebo (Semaglutide)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04115592","briefTitle":"The Effect of Different States of Lipid in Food on Glycaemia, Lipaemia and Insulinaemia."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Singapore Institute of Food and Biotechnology Innovation"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Cardiovascular Risk Factor"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cocoa butter"},{"name":"Cocoa butter oleogel"},{"name":"Sal seed oil"},{"name":"Sal seed oleogel"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04568382","briefTitle":"Diabetes Communication and Treatment Burden"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, Davis"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Multiple Chronic Conditions"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CI-PVP (context-informed pre-visit planning)"},{"name":"Standard PVP (pre-visit planning)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05865717","briefTitle":"Lifestyle Practices With Chronic Diseases Among Different Professionals"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Health Services Academy, Islamabad, Pakistan"}},"conditionsModule":{"conditions":["Chronic Diseases in Adolescence","Cardio Vascular Disease","Diabetes Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Quantitative sampling"},{"name":"Qualitative interviews"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02128854","briefTitle":"Tablet-Aided BehavioraL Intervention EffecT on Self-management Skills"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of South Carolina"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes Mellitus, Adult-Onset","Diabetes Mellitus, Non-Insulin-Dependent","Diabetes Mellitus, Noninsulin Dependent","Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tablets Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00482183","briefTitle":"Comparison Between Pioglitazone and SES With type2 DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Showa University"}},"conditionsModule":{"conditions":["Coronary Artery Disease","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04298970","briefTitle":"Novel Organic Kale Products for Prevention of Obesity/Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"Future Food Innovation"}]},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intervention"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01826409","briefTitle":"Hypoglycemic Effects of Fermented Red Ginseng in Subject With Impaired Fasting Glucose or Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chonbuk National University Hospital"}},"conditionsModule":{"conditions":["Impaired Glucose or Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fermented Red Ginseng"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00814294","briefTitle":"Study of Two Doses of Oral HDV-Insulin and Placebo With Background Metformin Treatment in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diasome Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo"},{"name":"Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15)"},{"name":"Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03868813","briefTitle":"An Artificial Intelligence Assisted Telehealth Intervention to Promote Self-Management in Patients With Type 2 Diabetes Mellitus (Qualitative Interview)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alabama at Birmingham"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semi-structured Interview"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02506647","briefTitle":"PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gan and Lee Pharmaceuticals, USA"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gan & Lee insulin glargine followed by Lantus"},{"name":"Lantus followed by Gan & Lee insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02920918","briefTitle":"Treatment of Diabetes in Patients With Systolic Heart Failure"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Virginia Commonwealth University"},"collaborators":[{"name":"Janssen Scientific Affairs, LLC"}]},"conditionsModule":{"conditions":["Heart Failure, Systolic","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01857167","briefTitle":"Effect of Omega-3 Fatty Acids on Insulin Sensitivity in Chinese Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Zhejiang University"},"collaborators":[{"name":"National Natural Science Foundation of China"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fish Oil Supplementation"},{"name":"Flaxseed Oil Supplementation"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02340507","briefTitle":"The Impact of the Glycaemic Index (GI) on Daily Blood Glucose Profiles and Food Intake in Young Chinese Adult Males"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Singapore Institute of Food and Biotechnology Innovation"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity","Prediabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rice and bread (high GI)"},{"name":"Rice and bread (low GI)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03010683","briefTitle":"Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Athens"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04676906","briefTitle":"A Study Investigating the Distribution and Metabolism of Three 14C-labeled Radioactive Study Compounds"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Healthy Volunteers","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NNC0113-6861"},{"name":"NNC0113-6860"},{"name":"NNC0113-6891"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00057304","briefTitle":"Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"RO 205-2349"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02610088","briefTitle":"Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Bundang Hospital"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Gliclazide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02851745","briefTitle":"Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Heart Care Foundation"},"collaborators":[{"name":"Fondazione dell'Associazione Medici Diabetologi"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Left Ventricular Systolic Dysfunction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Linagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02139943","briefTitle":"A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin 100 mg"},{"name":"Canagliflozin 300 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02798250","briefTitle":"Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation - Part 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institut de Recherches Cliniques de Montreal"}},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dual-hormone closed-loop"},{"name":"Insulin"},{"name":"Glucagon"},{"name":"Dexcom G4 Platinum glucose sensor"},{"name":"Accu Chek Combo insulin pump"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02218138","briefTitle":"Learning to BREATHE: A Randomized Controlled Trial to Lower Diabetes Risk in Adolescent Girls"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Colorado State University"},"collaborators":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Depression","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Learning 2 BREATHE"},{"name":"Colorado Blues"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04534439","briefTitle":"Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aptabio Therapeutics, Inc."}},"conditionsModule":{"conditions":["Diabetic Nephropathies","Diabetes Mellitus, Type 2","Nephropathy, Diabetic"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"APX-115"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02535169","briefTitle":"Lifestyle-Related Health Outcomes in Prediabetes and Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Indiana University"},"collaborators":[{"name":"Purdue University"}]},"conditionsModule":{"conditions":["Obesity","Prediabetic State","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Health Education and Coaching Strategy"},{"name":"Dietary consult"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02588898","briefTitle":"B-Vitamins and Polyneuropathy in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universität des Saarlandes"}},"conditionsModule":{"conditions":["Diabetes Complications"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Blood collection and electrophysiological tests"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04513704","briefTitle":"A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Healthy Volunteers Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral Semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03487029","briefTitle":"High-intensity Interval Training Training Protocols on Cardiorespiratory Parameters in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hacettepe University"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Short duration"},{"name":"Long duration"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02383940","briefTitle":"Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lexicon Pharmaceuticals"},"collaborators":[{"name":"Juvenile Diabetes Research Foundation"},{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sotagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05597605","briefTitle":"The SHINE Study: Safety of Implant and Preliminary Performance of the SHINE SYSTEM in Diabetic Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Indigo Diabetes NV"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Ketoacidosis, Diabetic","Hyperglycaemia (Diabetic)","Hypoglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"The SHINE SYSTEM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03630458","briefTitle":"Digestive Properties of Carbohydrate-based Foods"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Purdue University"}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type 2","Appetitive Behavior"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pearl millet couscous - made in Senegal"},{"name":"Pearl millet couscous - made in USA"},{"name":"Pearl millet thick porridge"},{"name":"Wheat couscous"},{"name":"White rice"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03630445","briefTitle":"Slowly Digestible Carbohydrates and the Ileal Brake"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Purdue University"},"collaborators":[{"name":"General Mills"}]},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type 2","Appetitive Behavior"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Isomaltooligosaccharides (IMOs)"},{"name":"Xtend® sucromalt"},{"name":"Combination of IMOs and Xtend® sucromalt"},{"name":"Raw corn starch"},{"name":"Maltodextrin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03630263","briefTitle":"This Study Assessed the Impact of Diet on Gastric Emptying Time and Metabolic Flexibility"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Purdue University"}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type 2","Appetitive Behavior"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Raw Corn Starch"},{"name":"No Raw Corn Starch"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02500979","briefTitle":"Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Juvenile Diabetes Research Foundation"}]},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pramlintide acetate"},{"name":"Placebo"},{"name":"Lispro insulin U-100"},{"name":"Regular insulin U-100"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05703880","briefTitle":"An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Chronic Kidney Disease","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Finerenone (Kerendia, BAY948862)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00135941","briefTitle":"Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glargine"},{"name":"insulin glulisine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02045563","briefTitle":"Genetic Polymorphisms, Steatosis and Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire Dijon"}},"conditionsModule":{"conditions":["Type 1 and 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"prise de sang"},{"name":"magnetic resonance imaging and magnetic resonance spectroscopy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04123054","briefTitle":"A Novel mHealth Application Guided by an Optimization Algorithm for T1D Sensor-Augmented Insulin Injection Users"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"McGill University"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mobile App"},{"name":"Mobile App + Basal-Bolus Optimization Algorithm"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01891474","briefTitle":"Efficacy and Safety of Voice Inception Technique Based U-healthcare Service in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Bundang Hospital"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"U-health care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03152994","briefTitle":"The Early Predictors for Developing Type 2 Diabetes Mellitus in Patients With Chronic Obstructive Pulmonary Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Zhujiang Hospital"}},"conditionsModule":{"conditions":["Chronic Obstructive Pulmonary Disease","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Checking fasting blood glucose(FBG)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01379690","briefTitle":"Retrospective Study: Hip Fractures in Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Changi General Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Hip Fractures"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HBA1C"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03501511","briefTitle":"Health Education During Ramadan Fasting in Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ain Shams University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Fasting"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IDF modules"},{"name":"Conversational Maps"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00721084","briefTitle":"Fitness and Sleep in People With Family History of Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Chicago"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Sleep","Physical Fitness","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02528396","briefTitle":"To Investigate the Efficacy and Safety of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 1 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Adocia"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BioChaperone insulin lispro"},{"name":"Humalog®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01742208","briefTitle":"Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lexicon Pharmaceuticals"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sotagliflozin"},{"name":"Placebo"},{"name":"Sotagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03467659","briefTitle":"Whole Grains, Gastric Emptying and Glycemic Response"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Purdue University"}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type 2","Appetitive Behavior"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cracked whole wheat porridge"},{"name":"Semolina wheat porridge"},{"name":"Whole wheat flour porridge"},{"name":"Refined wheat flour porridge"},{"name":"Refined wheat flour porridge,fine bran"},{"name":"Refined wheat flour porridge,coarse bran"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00184665","briefTitle":"Comparison of Insulin Detemir With NPH Insulin in Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin NPH"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03376789","briefTitle":"Mylan Insulin Glargine Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mylan Inc."},"collaborators":[{"name":"Mylan GmbH"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MYL-1501D product using manufacture process V"},{"name":"MYL-1501D product using manufacture process VI"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01839448","briefTitle":"Abnormal Post-partum Glucose Metabolism After Gestational Diabetes Diagnosed Before or After 24 Weeks of Gestation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire de Nīmes"}},"conditionsModule":{"conditions":["Gestational Diabetes","Type 2 Diabetes","Glucose Intolerance"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Post-partum oral glucose tolerance test"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02862067","briefTitle":"SGLT2 Inhibition in Diabetes and Heart Failure"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Virginia Commonwealth University"},"collaborators":[{"name":"American Heart Association"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Heart Failure, Systolic"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Assessment of cardiorespiratory fitness"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03445702","briefTitle":"Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"St. Louis University"},"collaborators":[{"name":"Washington University School of Medicine"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Metformin Adverse Reaction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00810589","briefTitle":"A Randomised, Single Centre, Double-Blind, Two-Period Crossover, Glucose Clamp Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Graz"}},"conditionsModule":{"conditions":["Diabetes, Type I"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Levemir"},{"name":"Humalog NPL Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03033433","briefTitle":"DCB-DM101 in Healthy Volunteers and for Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VitNovo, Inc."}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DCB-DM101"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00707616","briefTitle":"Common Genetic Variation and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"},"collaborators":[{"name":"University of Padova"}]},"conditionsModule":{"conditions":["Pre-diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral glucose tolerance test"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03903965","briefTitle":"Comparison of Retinal Perfusion Between Diabetic and Non-diabetic Patients With OCT Angiography After Cataract Surgery."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Peking University Third Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Age Related Cataracts"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02893891","briefTitle":"Metabolic Changes After Bariatric Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital Ostrava"},"collaborators":[{"name":"University of Ostrava"},{"name":"Vitkovice Hospital, Ostrava, Czech Republic"}]},"conditionsModule":{"conditions":["Grade III Obesity","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Laparoscopic sleeve gastrectomy"},{"name":"Laparoscopic gastric plication"},{"name":"Intragastric balloon"},{"name":"Intragastric balloon implantation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03708419","briefTitle":"Personalized Glucose Optimization Through Nutritional Intervention"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"},"collaborators":[{"name":"Wageningen University and Research"},{"name":"Top Institute Food and Nutrition"},{"name":"Netherlands Organisation for Scientific Research"}]},"conditionsModule":{"conditions":["Obesity","Pre-diabetic","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Optimal diet"},{"name":"Suboptimal diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04109508","briefTitle":"A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Healthy Volunteers","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04097600","briefTitle":"A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Healthy Volunteers","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral semaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01296100","briefTitle":"DEMOJUAN- DEMOnstration Area for Primary Prevention of Type 2 Diabetes, JUAN Mina and Barranquilla, Colombia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centro de Investigacion Sanitaria"},"collaborators":[{"name":"International Diabetes Federation"},{"name":"University of Helsinki"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Glucose Metabolism Disorders"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle intervention (nutrition)"},{"name":"Lifestyle intervention (physical activity)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03361878","briefTitle":"Pharmacokinetics of Metformin Intolerance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NHS Tayside"},"collaborators":[{"name":"University of Southern Denmark"},{"name":"University of Dundee"},{"name":"Helmholtz Zentrum München"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Metformin Adverse Reaction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin Hydrochloride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00754143","briefTitle":"Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"FibroGen"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FG-3019"},{"name":"FG-3019"},{"name":"FG-3019"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00286429","briefTitle":"Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin and insulin"},{"name":"Alogliptin and insulin"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02001532","briefTitle":"Arterial Stiffness and Complication Risk in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aarhus University Hospital"},"collaborators":[{"name":"University of Aarhus"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes Complications","Diabetic Angiopathies","Diabetic Nephropathies"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01542450","briefTitle":"Pharmacokinetics of Insulin Detemir in Subjects With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin NPH"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05439473","briefTitle":"Evaluation of the Efficacy and Safety of Curalin as Add-On Therapy in Adults With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"CuraLife"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Curalin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01821508","briefTitle":"Clinical Study on Metabolic Surgery Compared to the Best Clinical Treatment in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital Alemão Oswaldo Cruz"},"collaborators":[{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."}]},"conditionsModule":{"conditions":["Complications of Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Clinical Treatment"},{"name":"Roux-En-Y gastric bypass surgery"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03252964","briefTitle":"Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Savvysherpa, Inc."}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous Glucose Monitor (CGM)"},{"name":"Activity Tracker"},{"name":"Coaching"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01785043","briefTitle":"Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Anna Cruceta"}},"conditionsModule":{"conditions":["DIABETES Mellitus Type 2 Not Well Controlled"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01610778","briefTitle":"Effects of 5-Aminolevulinic Acid on Glucose Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hiroshima University"},"collaborators":[{"name":"SBI Pharmaceuticals Co, Ltd."}]},"conditionsModule":{"conditions":["Type 2 Diabetes on Medication"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"5-aminolevulinic acid phosphate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00707460","briefTitle":"The Effect of a Traditional Dietary Intervention on Diabetes Mellitus and Cardiovascular Disease Risk Factors in a First Nation Community: A Pilot Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Toronto"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Cardiovascular Disease","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dietary Intervention (Macronutrient composition)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03283774","briefTitle":"Multifactorial Control of Type 2 Diabetes and Treatment Intensity in Primary Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"current clinical practice"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04495972","briefTitle":"Intestinimonas for Prevention of Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Caelus Pharmaceuticals BV"}},"conditionsModule":{"conditions":["PreDiabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intestinimonas-capsules"},{"name":"Placebo-capsules"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04051008","briefTitle":"CTSI Pilot: Improving Adherence to Diabetic Diet"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"State University of New York at Buffalo"},"collaborators":[{"name":"National Center for Advancing Translational Sciences (NCATS)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diet, Healthy","Pre-diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Online - use of online grocery shopping platform"},{"name":"Default - use of online grocery shopping platform with default shopping carts"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03064906","briefTitle":"Insulet Artificial Pancreas Evaluating Meal Performance and Moderate Exercise (IDE2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Insulet Corporation"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulet AP (artificial pancreas) System"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02408705","briefTitle":"Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Graz"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Placebo"},{"name":"Mixed Meal Tolerance Test with paracetamol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02079805","briefTitle":"A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Essential Hypertension Complicated by Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Azilsartan"},{"name":"Telmisartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00855439","briefTitle":"Evaluation of Exenatide in Patients With Diabetic Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"},"collaborators":[{"name":"Amylin Pharmaceuticals, LLC."},{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Diabetic Peripheral Neuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide"},{"name":"Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03103867","briefTitle":"QUality of Control and slEep in Children With diabeteS, Using New Technology"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier du Luxembourg"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CGM augmented pump with PLGS ,"},{"name":"Insulin pump with CGM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02536859","briefTitle":"Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02174562","briefTitle":"Improving Medication Adherence in Older African Americans With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Thomas Jefferson University"},"collaborators":[{"name":"Johns Hopkins University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Mild Cognitive Impairment"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Primary Care-Occupational Therapy"},{"name":"Enhanced Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00609856","briefTitle":"Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Skane University Hospital"},"collaborators":[{"name":"Medical Research Council"},{"name":"Skane County Council Research & Development Foundation"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Secondary Drug Failure"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pioglitazone"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01213784","briefTitle":"Optimized Glycemic Control in Heart Failure Patients With DM2:\"Effect on Left Ventricular Function and Skeletal Muscle\""},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"The Danish Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Heart Failure"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"all antidiabetic drugs will be appliable"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04012983","briefTitle":"Possible Role of Gingival Crevicular Fluid Levels of Chemerin and Fibroblast Growth Factor 21 as Biomarkers of Periodontal Disease in Diabetic and Non-diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cairo University"}},"conditionsModule":{"conditions":["Periodontal Disease (Diagnosis)","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"gingival crevicular fluid level"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03150199","briefTitle":"A Psychological-behavioral Intervention for Physical Activity in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Massachusetts General Hospital"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Positive Psychology + Motivational Interviewing"},{"name":"MI-based Health Education Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01194245","briefTitle":"Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Halozyme Therapeutics"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin lispro"},{"name":"recombinant human hyaluronidase PH20"},{"name":"Insulin aspart"},{"name":"Insulin glulisine"},{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05013008","briefTitle":"An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Chronic Kidney Disease","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Finerenone (Kerendia, BAY94-8862)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04605900","briefTitle":"Impact of Therapeutic Footwear and Plantar Orthoses on Diabetic Neuropathic Foot in Quality of Life and Functionality"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidade do Algarve"},"collaborators":[{"name":"University of Huelva"},{"name":"OKM Química Ortopédica S.L."},{"name":"Lola - J. Andrade Ferreira Neves Lda"},{"name":"Instituto São João de Deus (ISJD)"},{"name":"Ortobalance - Ortopedia Técnica e Desportiva"},{"name":"Sensor Médica"},{"name":"Pierre Fabre Portugal"},{"name":"Associação para o Estudo da Diabetes Mellitus e de Apoio ao Diabético do Algarve (AEDMADA)"},{"name":"Unidade Funcional de Faro - Agrupamento de Centros de Saúde do Central"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetic Peripheral Neuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Orthopedic Footwear"},{"name":"Standard Footwear"},{"name":"Plantar Orthoses"},{"name":"Education on foot self-care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04468152","briefTitle":"Advanced Glycation End Products Are Associated With Diabetic Macular Edema"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hacettepe University"}},"conditionsModule":{"conditions":["Diabetic Macular Edema","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dietary habits and intake"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01390610","briefTitle":"Continuous Glucose Monitoring Self-Monitored Blood Glucose Type 2 Therapy Matrix Definition"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HealthPartners Institute"},"collaborators":[{"name":"Abbott Diabetes Care"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetic Blood Glucose Monitoring"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01480895","briefTitle":"Prevention of Diabetes Mellitus Type 2 in Women Post Gestational Diabetes Mellitus Diagnosis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Soroka University Medical Center"}},"conditionsModule":{"conditions":["Gestational Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle instruction for Jews and Bedouin GDM women."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03576300","briefTitle":"Comparison of Ocular Surface Features in Patients With Diabetes and Dry Eye Syndrome"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Peking University Third Hospital"}},"conditionsModule":{"conditions":["Dry Eye Syndrome","Diabetes Mellitus Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02034266","briefTitle":"The Effect of Omega-3 Supplementation on Nerve Structure and Function in Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eduardo Ng"},"collaborators":[{"name":"Canadian Diabetes Association"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omega-3 supplementation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00797823","briefTitle":"Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Legacy Health System"},"collaborators":[{"name":"Juvenile Diabetes Research Foundation"},{"name":"Oregon Health and Science University"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin, Asp(B28)-"},{"name":"Glucagon"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01617824","briefTitle":"Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Padova"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Chronic Renal Failure"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Linagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00916513","briefTitle":"Quality of Life and Treatment Satisfaction of People With Type 2 Diabetes: A European Survey"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04618354","briefTitle":"Comparing the Clinical Characteristics of Male LADA, T1DM and T2DM Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai 10th People's Hospital"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No interventions"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05436041","briefTitle":"Nutri Diet Goal Setting Software Pilot Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Texas at Austin"},"collaborators":[{"name":"Lone Star Circle of Care"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Pre-diabetes","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Collaborative Diet Goal Setting Clinical Decision Support"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02794506","briefTitle":"Propolis Improves Glycemic Control in Subjects With Type 2 Diabetes and Chronic Periodontitis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mohamed Anees"},"collaborators":[{"name":"Mansoura University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Periodontitis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Propolis"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01688778","briefTitle":"Telemedicine as a Means to Achieving Good Diabetes Control Among Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bispebjerg Hospital"},"collaborators":[{"name":"The Health and Care Committee, Copenhagen City Council"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Poor Glycemic Control","Medication Adherence"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Telemedicine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00639964","briefTitle":"Exploration of the Lipid Metabolism During the Diabetic Pregnancies"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Lille"},"collaborators":[{"name":"Ministry of Health, France"}]},"conditionsModule":{"conditions":["Pregnancy","Pregnancy in Diabetes","Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"blood tests"},{"name":"diet questionnaire"},{"name":"umbilical cord blood collect"},{"name":"placenta collect"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02199769","briefTitle":"Reducing Type 2 Diabetes Diagnostic Delays Using Decision Support"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Texas Southwestern Medical Center"}},"conditionsModule":{"conditions":["Diabetes","Prediabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Clinical Decision Support"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05257460","briefTitle":"Closing the Loop in Adults With Type 1 Diabetes Under Free Living Conditions (AP@Home04_Phase 4)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Cambridge"}},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hybrid closed-loop using ultra-rapid insulin lispro"},{"name":"Hybrid closed-loop using standard insulin lispro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01766778","briefTitle":"Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Type-2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LAF237 (vildagliptin)"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00883558","briefTitle":"Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Halozyme Therapeutics"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Lispro"},{"name":"regular human insulin"},{"name":"recombinant human hyaluronidase PH20"},{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01973400","briefTitle":"Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universiti Sains Malaysia"},"collaborators":[{"name":"Clinical Research Centre, Malaysia"},{"name":"Malaysia Palm Oil Board"}]},"conditionsModule":{"conditions":["Diabetic Neuropathy","Cognitive Impairment"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tocotrienol"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03916601","briefTitle":"Comparison of Exposure and Activity of SAR341402 Mix 70/30 to NovoLog Mix 70/30, NovoMix 30 and SAR341402 Rapid-acting Solution in Patients With Type 1 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SAR341402"},{"name":"Insulin Aspart"},{"name":"Insulin Aspart"},{"name":"SAR341402"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02219646","briefTitle":"Diabetes & Vardenafil"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Azienda USL Modena"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2DM)","Endothelial Dysfunction","Erectile Dysfunction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vardenafil"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01606904","briefTitle":"The Effect of CBT- Based Weight Loss Program on Obesity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Oulu"},"collaborators":[{"name":"Juho Vainio Foundation"},{"name":"Yrjo Jahnsson Foundation"},{"name":"Oulu University Hospital"}]},"conditionsModule":{"conditions":["Obesity","Hypercholesterolemia","Diabetes Mellitus, Type 2","Anhedonia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cognitive behavioral therapy -based weight loss program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04622371","briefTitle":"Physical Therapy for Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cairo University"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Moderate exercises"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01784289","briefTitle":"Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Lille"}},"conditionsModule":{"conditions":["Lipodystrophy","Obesity","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01102673","briefTitle":"Single Dose Study of PF-04991532 in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 2","Glucose Metabolism Disorders"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-04991532"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05174078","briefTitle":"Food as Medicine: A Quasi-Randomized Control Trial of Healthy Foods for Chronic Disease Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cleveland Clinic Akron General"},"collaborators":[{"name":"The Cleveland Clinic"},{"name":"The University of Akron"}]},"conditionsModule":{"conditions":["Obesity","Hypertension","Pre-diabetes","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Medically-tailored meals"},{"name":"Produce box and recipes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00441844","briefTitle":"Monocyte Function and Inflammation in Type 1 Diabetes and Its Modulation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, Davis"},"collaborators":[{"name":"Juvenile Diabetes Research Foundation"},{"name":"National Institutes of Health (NIH)"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Simvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02513277","briefTitle":"Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Leicester"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Prediabetic State","Intellectual Disability"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00929838","briefTitle":"Telephone Delivered Behavioral Skills Intervention for Blacks With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"State University of New York at Buffalo"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes Mellitus, Adult-Onset","Diabetes Mellitus, Non-Insulin-Dependent","Diabetes Mellitus, Noninsulin Dependent","Diabetes Mellitus, Type II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Knowledge/Information"},{"name":"Motivation/Behavioral Skills"},{"name":"Combined Intervention"},{"name":"Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04040595","briefTitle":"The Genetics of Adipose Tissue Function and Its Link to Type 2 Diabetes and Heart Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Royal Devon and Exeter NHS Foundation Trust"},"collaborators":[{"name":"University of Exeter"},{"name":"NIHR Exeter Clinical Research Facility"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Abdominal fat biopsy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06249399","briefTitle":"The Effect of Aerobic Exercise on Lower Urinary System Symptoms in Women With Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gaziantep Islam Science and Technology University"},"collaborators":[{"name":"University of Gaziantep"},{"name":"Hasan Kalyoncu University"}]},"conditionsModule":{"conditions":["Lower Urinary Tract Symptoms","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aerobic Exercise"},{"name":"Behavioral Treatment Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02131701","briefTitle":"PPP-Botnia Exercise Intervention Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Folkhälsan Researech Center"},"collaborators":[{"name":"Närpes Health Care Center, Närpes, Finland"},{"name":"Department of Social Services and Health Care, Jakobstad, Finland"},{"name":"Department of Clinical Sciences, Lund University Diabetes Center, CRC, Lund University, Malmö, Sweden"}]},"conditionsModule":{"conditions":["Family History of Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physical activity"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03329651","briefTitle":"The Interaction Between Metformin and Acute Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kristian Karstoft"},"collaborators":[{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Impaired Glucose Tolerance","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin treatment"},{"name":"Placebo treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03316690","briefTitle":"The Interaction Between Metformin and Physical Training"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kristian Karstoft"},"collaborators":[{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Impaired Glucose Tolerance","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin treatment"},{"name":"Placebo treatment"},{"name":"Physical training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00720889","briefTitle":"Glucose Metabolism and Sleep in People With Family History of Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Chicago"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Sleep","Insulin Resistance","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03118739","briefTitle":"Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Hyperuricemia","Albuminuria","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Verinurad 9 mg+Febuxostat 80 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03092063","briefTitle":"Using Multifamily Groups to Improve Self-Management of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, Los Angeles"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tomando Control-Nurse"},{"name":"Tomando Control-Promotora"},{"name":"Enhanced engagement"},{"name":"Multifamily Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03193125","briefTitle":"Carnitine and Liver Mitochondria Fatty Acid Processing"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pennington Biomedical Research Center"},"collaborators":[{"name":"University of Tennessee"},{"name":"Touro University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Insulin Resistance","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"L-Carnitine"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02360774","briefTitle":"Mechanisms of Weight Loss With SGLT2 Inhibition"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Beth Israel Deaconess Medical Center"},"collaborators":[{"name":"Janssen Scientific Affairs, LLC"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Overweight","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01136512","briefTitle":"Metformin Use and Vitamin B12 Deficiency"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Northwell Health"}},"conditionsModule":{"conditions":["Vitamin B12 Deficiency","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02159638","briefTitle":"Accuracy of Two CGM Systems Tested Simultaneously in Ambulatory Patients With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vastra Gotaland Region"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Blood Glucose"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Guardian Enlite sensor"},{"name":"Dexcom G4 platinum sensor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01231178","briefTitle":"The Effect of an Alginate Based Beverage on Weight Loss"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Copenhagen"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alginate beverage"},{"name":"Control beverage"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00789295","briefTitle":"Mediterranean Diet and Postprandial Lipemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Federico II University"}},"conditionsModule":{"conditions":["Postprandial Lipemia","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mediterranean diet and Low-Carbohydrates diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01646047","briefTitle":"Diabetes Visual Function Supplement Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"ZeaVision, LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus - Type 1","Diabetes Mellitus - Type 2","Non-proliferative Diabetic Retinopathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"multi-component nutritional supplement capsules"},{"name":"multi-component dietary supplement"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00348374","briefTitle":"Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Lispro"},{"name":"Exubera"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00296296","briefTitle":"Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Stanford University"}},"conditionsModule":{"conditions":["Kidney Transplant","Diabetes Mellitus, Type 2","Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cyclosporin"},{"name":"Tacrolimus"},{"name":"'Diabetes Education / Management'"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01170208","briefTitle":"Insulin Dosage Software Program for People With Type 1 and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HealthPartners Institute"},"collaborators":[{"name":"National Institutes of Health (NIH)"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"Hygieia, Inc"},{"name":"International Diabetes Center at Park Nicollet"}]},"conditionsModule":{"conditions":["Diabetes","Insulin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin dose software"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01671514","briefTitle":"Effects of Dark Chocolate on Exercise Capacity, and Mitochondrial Structure and Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Diego"},"collaborators":[{"name":"The Hershey Company"}]},"conditionsModule":{"conditions":["Heart Failure","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Epicatechin-enriched dark chocolate"},{"name":"Low-epicatechin dark chocolate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00074633","briefTitle":"Evaluating \"Health at Every Size\"(HAES) as an Alternative Obesity Treatment Model"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},"collaborators":[{"name":"University of California, Davis"},{"name":"United States Department of Agriculture (USDA)"}]},"conditionsModule":{"conditions":["Hypercholesterolemia","Hypertension","Depression","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Health at Every Size (HAES)"},{"name":"Diet (Traditional, moderate energy restriction)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01526941","briefTitle":"Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"},{"name":"biphasic insulin aspart 70"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01032629","briefTitle":"CANVAS - CANagliflozin cardioVascular Assessment Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"},"collaborators":[{"name":"The George Institute for Global Health, Australia"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Cardiovascular Diseases","Risk Factors"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Canagliflozin (JNJ-28431754) 100 mg"},{"name":"Canagliflozin (JNJ-28431754) 300 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00110448","briefTitle":"Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kumamoto University"}},"conditionsModule":{"conditions":["Coronary Disease","Arteriosclerosis","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aspirin"},{"name":"No aspirin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03121755","briefTitle":"CCK1R Function in Patient Leukocytes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type 2","Metabolic Syndrome"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00911482","briefTitle":"Production of Free Fatty Acids From Blood Triglycerides"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Insulin Resistance","Dyslipidemias"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02821104","briefTitle":"Complement and Cardiovascular Risk in Adolescents"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ohio State University"},"collaborators":[{"name":"American Heart Association"}]},"conditionsModule":{"conditions":["Cardiovascular Disease","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02628301","briefTitle":"Microvascular Dysfunction and the Development of Whole-body Insulin Resistance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Amsterdam UMC, location VUmc"},"collaborators":[{"name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)"}]},"conditionsModule":{"conditions":["Insulin Resistance","Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hypercaloric diet"},{"name":"Normocaloric diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01495052","briefTitle":"Effect of Organic Naked Oat With Whole Germ on Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yong Li"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"organic naked oat with whole germ (ONOG)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04082351","briefTitle":"Using Nanotechnology Structured Water to Control Blood Glucose in Type 2 Diabetic Patients."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"ALI KAMAL M. SAMI"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nanotechnology structured water ( Magnalife)"},{"name":"ordinary water"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01629862","briefTitle":"Vascular Impairment in Type II Diabetes Mellitus With Co-morbid Obstructive Sleep Apnea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanjay R Patel"},"collaborators":[{"name":"Beth Israel Deaconess Medical Center"},{"name":"Brigham and Women's Hospital"},{"name":"National Institutes of Health (NIH)"}]},"conditionsModule":{"conditions":["Sleep Apnea, Obstructive","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous positive airway pressure"},{"name":"Sham continuous positive airway pressure"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01283425","briefTitle":"Evaluation of the Safety Use of the InsuPatch Device in Daily Life Conditions"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Insuline Medical Ltd."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"InsuPatch"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02586155","briefTitle":"Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Resverlogix Corp"},"collaborators":[{"name":"PPD DEVELOPMENT, LP"},{"name":"ICON plc"},{"name":"Medidata Solutions"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Apabetalone"},{"name":"Placebo"},{"name":"Atorvastatin"},{"name":"Rosuvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04977908","briefTitle":"Closing the Loop in Adults With Type 1 Diabetes (CLEAR)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Cambridge"},"collaborators":[{"name":"Cambridge University Hospitals NHS Foundation Trust"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CamAPS HX"},{"name":"Standard insulin pump therapy with CGM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04123587","briefTitle":"Genetic Variants Replication Study Associated With Dependence on Sulfonylurea in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"discontinuation of Sulfonylureas"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01278121","briefTitle":"Study of the Potential of a Macronutrient Balanced Normocaloric Diet to Treat Lifestyle Diseases"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Norwegian University of Science and Technology"},"collaborators":[{"name":"St. Olavs Hospital"}]},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type 2","Cardiovascular Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diet A"},{"name":"Diet B"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03224234","briefTitle":"A Randomized Study to Evaluate the Efficacy of Insulclock® in Patients With Uncontrolled Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"},"collaborators":[{"name":"Insulcoud S.L."}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulclock with feedback"},{"name":"Insulclock without feedback"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01100125","briefTitle":"Sitagliptin Versus Insulin Dose Increase in Type 2 Diabetes on Insulin Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Bundang Hospital"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin"},{"name":"insulin dose increase"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02633722","briefTitle":"Intermittent Fasting for Metabolic Health, Does Meal Timing Matter?"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Adelaide"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle intervention B"},{"name":"Lifestyle Intervention D"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02598791","briefTitle":"GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"}},"conditionsModule":{"conditions":["Obesity","Adiposity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IIGI+GIP"},{"name":"IIGI+GLP-1"},{"name":"IIGI+NaCl (placebo)"},{"name":"OGTT"},{"name":"IIGI+GIP+GLP-1"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02724566","briefTitle":"Effect of Apelin on Insulin Sensitivity in Type 2 Diabetic Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Toulouse"},"collaborators":[{"name":"Société Francophone du Diabète"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"apelin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02519309","briefTitle":"Dietary Intervention in Type-2 Diabetes and Pre-Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Virta Health"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Pre-diabetes","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Virta Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00922376","briefTitle":"Assessment of the Clinical Efficacy and Acceptability of Think Positive (T+) in Diabetes Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University College London Hospitals"},"collaborators":[{"name":"University College, London"},{"name":"Department of Health, United Kingdom"}]},"conditionsModule":{"conditions":["Diabetes (Insulin-requiring, Type 1 or Type 2)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mobile phone telehealth application: Think Positive (T+)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04711083","briefTitle":"Correlation Between Nocturnal Oxygen Desaturation and Glycemic Control in Diabetic Patients With Obstructive Sleep Apnea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ain Shams University"}},"conditionsModule":{"conditions":["Obstructive Sleep Apnea","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"overnight pulse oximetry"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04498819","briefTitle":"Wearable Technology and a Virtual Lifestyle Program for Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Western University, Canada"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Comorbidities and Coexisting Conditions"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Wearable Activity Trackers, Exercise Prescription and Virtual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05258630","briefTitle":"Diabetes Homeless Medication Support"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hennepin Healthcare Research Institute"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Housing Problems","Psychological Distress"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Homeless Medication Support (D-Homes)"},{"name":"Enhanced usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02371759","briefTitle":"Lidocaine + Clonidine for Intraoral Anesthesia in Patients With Diabetes Mellitus Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Belgrade"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Local Anesthesia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"L+C maxillary anesthesia"},{"name":"L+C mandibular anesthesia"},{"name":"L+E maxillary anesthesia"},{"name":"L+E mandibular anesthesia"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01966432","briefTitle":"Screening, Brief Intervention, and Referral to Treatment in Primary Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Duke University"},"collaborators":[{"name":"National Institute on Drug Abuse (NIDA)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Substance-related Disorders"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Referral to Treatment"},{"name":"Brief Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01853332","briefTitle":"Physical Health in Midlife: Influences of Adversity and Relationships Over Time"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Beth Israel Deaconess Medical Center"},"collaborators":[{"name":"Judge Baker Children's Center"},{"name":"National Institute on Aging (NIA)"}]},"conditionsModule":{"conditions":["Cardiovascular Disease","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02929901","briefTitle":"The Effects of Coffee Main Constituents (Caffeine and Chlorogenic Acid) Supplementation on Inflammatory, Metabolic Factors, Hepatic Steatosis and Fibrosis in None- Alcoholic Fatty Liver Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Nutrition and Food Technology Institute"}},"conditionsModule":{"conditions":["Type 2 Diabetes Nonalcoholic Fatty Liver"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"caffeine and chlorogenic acid"},{"name":"caffeine"},{"name":"chlorogenic acid"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01099137","briefTitle":"Effect of Vildagliptin in Type 2 Diabetes Treated With Sulphonylurea and Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Bundang Hospital"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"Sulphonylurea dose-up"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00944619","briefTitle":"Closing the Loop in Adults With Type 1 Diabetes - Alcohol Consumption"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Cambridge"},"collaborators":[{"name":"Cambridge University Hospitals NHS Foundation Trust"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Closed loop"},{"name":"Conventional insulin pump delivery"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01679899","briefTitle":"Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centro de Diabetes Curitiba Ltda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Menopause","Osteoporosis","Osteopenia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"Gliclazide MR"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03044860","briefTitle":"Anatomical and Physiological Characterisation of the Gut Endocrine Cells in Healthy and in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Double-balloon enteroscopy (DBE) with biopsy retrieval"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00436475","briefTitle":"Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tufts Medical Center"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Glucose Intolerance","Type 2 Diabetes Mellitus","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin D3 2,000 IU orally once daily"},{"name":"Calcium Carbonate 400 mg orally twice daily"},{"name":"Vitamin D3-Placebo"},{"name":"Calcium-Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04054284","briefTitle":"Safety and Efficacy of Herbal Tea in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Josip Juraj Strossmayer University of Osijek"},"collaborators":[{"name":"Dom zdravlja Osijek (Health Centre Osijek)"},{"name":"Osijek University Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Herbal Medicine Adverse Reaction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Antidiabetic Herbal Tea"},{"name":"Herbal Tea"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00324675","briefTitle":"Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Technische Universität Dresden"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Overt Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04150107","briefTitle":"A Study to Compare ORMD-0801 Once Daily to ORMD-0801 Three Times Daily in Subjects With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oramed, Ltd."},"collaborators":[{"name":"Integrium"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ORMD-0801 Treatment A"},{"name":"ORMD-0801 Treatment B"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00566189","briefTitle":"New Frontiers on Bariatric Surgical Procedures: Classical Bypass for Type-2 Diabetic Patients With Obesity Grade I"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Campinas, Brazil"},"collaborators":[{"name":"Ethicon Endo-Surgery"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Insulin Resistance","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Roux-en-Y Bypass Gastroplasty"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00772174","briefTitle":"Efficacy and Safety Study of Pioglitazone Combined With Metformin on Metabolic Syndrome in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone and Metformin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01801150","briefTitle":"CPAP in Diabetes Type 2 Patients With Sleep Apnea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital Universitario La Paz"}},"conditionsModule":{"conditions":["Diabetes","Sleep Apnea"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CPAP nasal treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03805802","briefTitle":"Influence of a Liquid Oat Bran Product on Blood Glucose in Patients With Poorly Controlled Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Stoffwechselzentrum Rhein - Pfalz"},"collaborators":[{"name":"Glucanova AB"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity","Overweight","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"active product"},{"name":"reference product"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05844137","briefTitle":"Improving Detection and Evidence-based Care of NAFLD in Latinx and Black Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Duke University"}},"conditionsModule":{"conditions":["NAFLD","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NAFLD Education"},{"name":"diet/lifestyle support"},{"name":"T2D medication management"},{"name":"clinically-indicated liver testing and care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02204670","briefTitle":"EXIT: Prospective Study of the Response to Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Manitoba"}},"conditionsModule":{"conditions":["Liver Fat","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acute release of irisin after a single exercise session."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02159417","briefTitle":"Therapeutic Education of the Patients Diabetics Imprisoned at the Paris Jail"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Assistance Publique - Hôpitaux de Paris"}},"conditionsModule":{"conditions":["Type 1 or 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Therapeutic Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03371355","briefTitle":"Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Akcea Therapeutics"},"collaborators":[{"name":"Ionis Pharmaceuticals, Inc."}]},"conditionsModule":{"conditions":["NAFLD","Diabetes Mellitus, Type 2","Hypertriglyceridemia","Fatty Liver, Nonalcoholic"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"ISIS 703802 40 mg"},{"name":"ISIS 703802 80 mg"},{"name":"ISIS 703802 20 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00552227","briefTitle":"Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chromaderm, Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ruboxistaurin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01645995","briefTitle":"The Impact of Reformulated Foods on Cardiovascular Risk Factors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Reading"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Cardiovascular Disease","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Reformulated products"},{"name":"Conventional products"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02020343","briefTitle":"Insulin Resistance in the Control of Intestinal Lipid Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Missouri-Columbia"}},"conditionsModule":{"conditions":["Insulin Resistance","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"taste tests"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02185963","briefTitle":"Effect of Rosuvastatin on Function of High Density Lipoprotein Cholesterol in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Bundang Hospital"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosuvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03018444","briefTitle":"The Effect of HMG-CoA Reductase Inhibition on Postprandial GLP-1 Secretion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hydroxymethylglutaryl-CoA Reductase Inhibitors"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Atorvastatin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00982358","briefTitle":"Anti-Inflammatory Actions of Valsartan in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Charite University, Berlin, Germany"},"collaborators":[{"name":"University of Ulm"}]},"conditionsModule":{"conditions":["Hypertension","Type 2 Diabetes Mellitus","Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Valsartan"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04032561","briefTitle":"Relationship Between HbA1c Level, Sleep Quality and Sleep Duration"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Hertfordshire"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Pre Diabetes","Sleep Disorder"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01211717","briefTitle":"The Effects of Orally Ingesting Branched Chained Amino Acids on Delayed Onset Muscle Soreness in Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Loma Linda University"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Healthy Individuals"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Branched Chained Amino Acids"},{"name":"Cellulose Placebo mix"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03997773","briefTitle":"Face-it: Health Promotion for Women With Prior Gestational Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Steno Diabetes Center Copenhagen"},"collaborators":[{"name":"Steno Diabetes Center Odense"},{"name":"Aarhus University Hospital"},{"name":"Rigshospitalet, Denmark"},{"name":"Odense University Hospital"},{"name":"Aarhus Municipality"},{"name":"Odense Municipality"},{"name":"Copenhagen Municipality, Denmark"},{"name":"Liva Healthcare A/S"}]},"conditionsModule":{"conditions":["Gestational Diabetes","Type 2 Diabetes Mellitus","Quality of Life"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Face-it Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01788033","briefTitle":"Effects of XOMA 052 on Insulin Production in Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Zurich"},"collaborators":[{"name":"XOMA (US) LLC"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"XOMA 052"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03693521","briefTitle":"Effects of Measurement of Handgrip Strength on Physical Activity Level for Patients With Diabetes Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Göteborg University"},"collaborators":[{"name":"Vastra Gotaland Region"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Physical Activity","Muscular Weakness"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Handgrip strength measurement"},{"name":"Standard care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01831102","briefTitle":"Adiponectin and Ethnic Differences in Insulin Resistance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Denver"}},"conditionsModule":{"conditions":["Insulin Resistance","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"none- observational study"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02156037","briefTitle":"An RCT Evaluation of a Diabetes Dashboard Team Model in Primary Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baystate Medical Center"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Dashboard Intervention"},{"name":"Usual Diabetes Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02423850","briefTitle":"Three-dimensional Measurements of Diabetic Foot Ulcers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Odense University Hospital"},"collaborators":[{"name":"University of Southern Denmark"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Diabetes Complications","Diabetic Foot"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"3D Wound Assessment Monitor (WAM) camera"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01787617","briefTitle":"Aerobic Plus Resistance Training and Insulin Sensitivity in African American Men"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pennington Biomedical Research Center"}},"conditionsModule":{"conditions":["Insulin Resistance","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aerobic Plus Resistance Training Group"},{"name":"Control Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04406402","briefTitle":"L-arginine and Asymmetric Dimethylarginine (ADMA) and Lifestyle Protocols"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tel-Aviv Sourasky Medical Center"},"collaborators":[{"name":"Wolfson Medical Center"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity","Arginine","Asymmetric Dimethylarginine"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acute dietary protocols and lifestyle modification"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00461617","briefTitle":"Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kissei Pharmaceutical Co., Ltd."}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mitiglinide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00728286","briefTitle":"Assessment of Thrombogenicity in Acute Coronary Syndrome"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Newcastle-upon-Tyne Hospitals NHS Trust"},"collaborators":[{"name":"British Heart Foundation"},{"name":"University of Newcastle Upon-Tyne"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Acute Coronary Syndrome"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00685594","briefTitle":"Vitamin D for the Prevention of Diabetes Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Tromso"},"collaborators":[{"name":"University Hospital of North Norway"}]},"conditionsModule":{"conditions":["Impaired Glucose Tolerance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"cholecalciferol"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03461510","briefTitle":"Type 2 Diabetes and the Brain in Adolescents"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nemours Children's Clinic"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity","Pediatric Obesity","Insulin Resistance","Dysglycemia","Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hyperglycemic clamp"},{"name":"Hyperinsulinemic Euglycemic clamp"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01302639","briefTitle":"Dietary Polyphenols and Lipid Oxidation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"},"collaborators":[{"name":"Alpro Foundation"}]},"conditionsModule":{"conditions":["Obesity, Insulin Sensitivity, Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Comparison of different combinations of polyphenols with respect to effects on fat oxidation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03002155","briefTitle":"Effects of a Exercise Program on Health Outcomes in People With Diabetic Foot Ulcers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Washington"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetic Foot Ulcer","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EnhanceFitness community exercise program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00220961","briefTitle":"Actos Now for Prevention of Diabetes (ACT NOW)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"},"collaborators":[{"name":"University of Texas"},{"name":"Takeda Pharmaceuticals North America, Inc."}]},"conditionsModule":{"conditions":["Impaired Glucose Tolerance","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03693560","briefTitle":"Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Damanhour University"},"collaborators":[{"name":"Tanta University"}]},"conditionsModule":{"conditions":["Coronary Artery Disease","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin 50 mg Oral Tablet"},{"name":"Metformin 1000 mg Oral Tablet"},{"name":"Glimepiride upto 4 mg Oral Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05053828","briefTitle":"Type 2 Diabetes With Antiplatelet Drugs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tabula Rasa HealthCare"}},"conditionsModule":{"conditions":["Type2 Diabetes","Antiplatelet Drugs","Myocardial Infarction","Heart Failure"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Antiplatelet Drug"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00469287","briefTitle":"Early Diagnosis of Diabetes Mellitus Type 2 (DM2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"TNO"},"collaborators":[{"name":"Netherlands: Ministry of Health, Welfare and Sports"}]},"conditionsModule":{"conditions":["Impaired Blood Glucose Level","Overweight","Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01474161","briefTitle":"Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Genfit"},"collaborators":[{"name":"SGS Aster S.A.S."},{"name":"Naturalpha"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Diabetes Mellitus, Type 2","Metabolic Diseases","Cardiovascular Diseases","Obese","Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GFT505 120mg - old formulation"},{"name":"GFT505 120mg - new formulation"},{"name":"GFT505 180mg - new formulation"},{"name":"GFT505 240mg - new formulation"},{"name":"GFT505 300mg - new formulation"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03404037","briefTitle":"Serum Endostatin Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Zagazig University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Coronary Artery Disease","Coronary Arteriosclerosis"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"serum endostatin level"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03408678","briefTitle":"Determinants of Type 2 Diabetes Risk in Middle-aged Black South African Men and Women"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Witwatersrand, South Africa"},"collaborators":[{"name":"Medical Research Council, South Africa"},{"name":"GlaxoSmithKline"},{"name":"University of Oxford"},{"name":"University Hospital, Umeå"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Insulin Resistance","Menopause","Hiv"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02473926","briefTitle":"Targeting Physical Activity to Improve Cardiovascular Health in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Denver"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Motor Activity","Health Behavior","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physical Activity"},{"name":"Questionnaires"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02846831","briefTitle":"Closed-loop Control of Glucose Levels (Artificial Pancreas) for 12 Days in Adults With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institut de Recherches Cliniques de Montreal"}},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"12-day intervention with sensor-augmented pump therapy"},{"name":"12-day intervention with single-hormone closed-loop strategy"},{"name":"Insulin pump"},{"name":"Continuous glucose monitoring system"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00996645","briefTitle":"Optimizing Audit and Feedback for Primary Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sunnybrook Health Sciences Centre"},"collaborators":[{"name":"Institute for Clinical Evaluative Sciences"},{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Worksheet to facilitate goal-setting and action plans"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03430856","briefTitle":"Comparison of Insulin Tregopil (IN-105) With Insulin Aspart in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Biocon Limited"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Tregopil"},{"name":"Insulin Aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01676233","briefTitle":"Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glargine (HOE901)"},{"name":"insulin glargine- new formulation (HOE901)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01524809","briefTitle":"Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biphasic insulin aspart 30"},{"name":"biphasic insulin aspart 70"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00592332","briefTitle":"Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vanderbilt University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alprazolam"},{"name":"control group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04981808","briefTitle":"Diabetes teleMonitoring of Patients in Insulin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aalborg University Hospital"},"collaborators":[{"name":"Steno Diabetes Center Sjaelland"},{"name":"Novo Nordisk A/S"},{"name":"Glooko"},{"name":"DexCom, Inc."}]},"conditionsModule":{"conditions":["Type 2 Diabetes Treated With Insulin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Telemonitoring"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04660305","briefTitle":"AT278 and NovoRapid® in Glucose Clamp Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Arecor Limited"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AT278"},{"name":"NovoRapid"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01407640","briefTitle":"Diagnosis and Physiopathology of Insulin Allergy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Assistance Publique - Hôpitaux de Paris"},"collaborators":[{"name":"Institut National de la Santé Et de la Recherche Médicale, France"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Hypersensitivity","Immediate Hypersensitivity","Allergy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Allergy tests"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00221715","briefTitle":"Comparison of Two Lower Limb Bypass Types : Prosthesis Versus Autologous Vein"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Bordeaux"},"collaborators":[{"name":"Ministry of Health, France"}]},"conditionsModule":{"conditions":["Arteritis","Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"femoropopliteal artery bypass"},{"name":"femoropopliteal artery bypass"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01467141","briefTitle":"Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin aspart"},{"name":"human insulin"},{"name":"isophane human insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03557541","briefTitle":"Sardine-enriched Diet for Prevention Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institut d'Investigacions Biomèdiques August Pi i Sunyer"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","PreDiabetes","Diet Habit","Diabetes","Nutritional and Metabolic Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sardine"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00995930","briefTitle":"Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Atherosclerosis","Prediabetic State"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ACZ885"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01215903","briefTitle":"Fish Gelatin Supplement and Omega-3 Supplement in Obese or Overweight Subjects With Insulin Resistance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Laval University"},"collaborators":[{"name":"Advance Foods and Materials Network"},{"name":"Institut des Nutraceutiques et Aliments fonctionnels, Quebec (Clinical nutrition facilities)"},{"name":"University of Guelph"},{"name":"Ocean Nutrition Canada, Halifax (in-kind support: omega-3 supplements)"},{"name":"Kenney & Ross"}]},"conditionsModule":{"conditions":["Insulin Resistance","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fish gelatin and omega-3 polyunsaturated fatty acid"},{"name":"Omega-3 polyunsaturated fatty acid"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01145534","briefTitle":"Evaluation of Cissus Verticillata L. Infusion in Controlling Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Federal University of Paraíba"},"collaborators":[{"name":"Conselho Nacional de Desenvolvimento Científico e Tecnológico"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"glibenclamide"},{"name":"medicinal plant infusion"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01407276","briefTitle":"A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Chronic Renal Insufficiency","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omarigliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03178591","briefTitle":"Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chiang Mai University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Ischemic Heart Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vildagliptin"},{"name":"Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00989898","briefTitle":"Automated Overnight Closed-loop Glucose Control in Young People With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Cambridge"},"collaborators":[{"name":"Cambridge University Hospitals NHS Foundation Trust"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Automated closed-loop insulin delivery"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02451917","briefTitle":"Glargine Versus NPH in Patients With Chronic Kidney Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Sao Paulo General Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Chronic Kidney Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glargine insulin"},{"name":"NPH insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00998699","briefTitle":"Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"XOMA (US) LLC"},"collaborators":[{"name":"Juvenile Diabetes Research Foundation"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Xoma 052"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01071772","briefTitle":"The Effect of Hyperglycemia on LV Function and Exercise Capacity in Diabetics With and Without Heart Failure."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"Danish Heart Foundation"},{"name":"Region midtjyllands sundhedsvidenskabelige forskningsfond"}]},"conditionsModule":{"conditions":["Heart Failure","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02485327","briefTitle":"PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mannkind Corporation"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Technosphere Insulin SAR439065 Afrezza®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00163683","briefTitle":"Effects of a Mediterranean Style Diet on Vascular Health in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayside Health"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Coronary Heart Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dietary Therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01498185","briefTitle":"BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Astra Zeneca, Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo matching Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01326442","briefTitle":"Vitamin D and Omega-3 Inhibit Metabolic Syndrome"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Guelph"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Hypertension","Hyperlipidemia","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"low glycemic diet"},{"name":"vitamin D omega-3"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03676309","briefTitle":"Efficacy and Safety of Nutraceuticals in Patients With Diabetes Mellitus Type II and Dyslipidemia."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Villa dei Gerani"},"collaborators":[{"name":"University Magna Graecia"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Nutritional and Metabolic Diseases","Vascular System Injury","Therapy-Related Morphologic Change"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nutriceutical Oral Capsule,"},{"name":"Placebo Oral Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03010956","briefTitle":"Changes in Arterial Stiffness and Endothelial Glycocalyx in Patients With Poorly Controlled Diabetes Mellitus Type 1 or Type 2 After Optimization of Antidiabetic Medication."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Athens"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01259206","briefTitle":"Plantar Faciitis and Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gulhane School of Medicine"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03047447","briefTitle":"Induced and Controlled Dietary Ketosis as a Regulator of Obesity and Metabolic Syndrome Pathologies"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristlecone Behavioral Health, Inc."},"collaborators":[{"name":"University of Minnesota"}]},"conditionsModule":{"conditions":["Metabolic Syndrome","Diabetes Mellitus, Type 2","Pre Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dietary Ketosis: Regulator of Obesity and Metabolic Syndrome"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01121172","briefTitle":"Apelin Levels and G212A Polymorphism of Apelin Receptor (APJ)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aristotle University Of Thessaloniki"}},"conditionsModule":{"conditions":["Obesity","Insulin Resistance","Diabetes Mellitus Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01604213","briefTitle":"Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sheba Medical Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Ischemic Heart Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin plus vildagliptin"},{"name":"Metformin only"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02245399","briefTitle":"Canola-Mediterranean Diet Study in T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Unity Health Toronto"},"collaborators":[{"name":"University of Toronto"},{"name":"Laval University"},{"name":"University of Manitoba"},{"name":"Canola Council of Canada"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity","Overweight","Cardiovascular Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"A canola oil enriched mediterranean diet"},{"name":"A high wheat fiber diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02509858","briefTitle":"The Effect of Administration of Small Doses of Thyroxine on Glucose and Lipid Metabolism, in Type 2 Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Attikon Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"thyroxine"},{"name":"Placebo"},{"name":"A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01179555","briefTitle":"Confronting Unequal Eye Care in Pennsylvania"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Wills Eye"},"collaborators":[{"name":"Thomas Jefferson University"},{"name":"Temple University"}]},"conditionsModule":{"conditions":["Diabetic Retinopathy","Diabetes Mellitus, Type 2","Glaucoma"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Behavioral Activation"},{"name":"Supportive Therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00854503","briefTitle":"Metabolic and Vascular Effects of Statins in Untreated Dyslipidemic Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Rome Tor Vergata"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Diabetic Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Simvastatin"},{"name":"Rosuvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00842972","briefTitle":"Is Carotid Intima-media Thickness Affected by A1C Variability?"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yonsei University"}},"conditionsModule":{"conditions":["Type 2 Diabetes","A1C Variability"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00509236","briefTitle":"Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","End-Stage Kidney Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Glipizide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00349362","briefTitle":"Testosterone for Men With Insulin Treated Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Barnsley Hospital"}},"conditionsModule":{"conditions":["Hypogonadism","Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Testosterone"},{"name":"0.9% saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00817622","briefTitle":"Effects of EPA and Vitamin E on Leptin, Adiponectin and Enzymatic Antioxidants in Type 2 DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tehran University of Medical Sciences"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EPA, Vitamin E"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04453605","briefTitle":"Phenotyping Individuals With Neo-diagnosed Type 2 Diabetes at Risk for All-cause Mortality"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pisa"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Vascular Diseases","Cardiac Disease"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"standard treatments"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01232608","briefTitle":"Exercise Training in Patients With Coronary Heart Disease and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oslo University Hospital"}},"conditionsModule":{"conditions":["Coronary Artery Disease","Diabetes Mellitus, Type 2","Atherosclerosis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00381186","briefTitle":"Impact of 3-year Lifestyle Intervention on Postprandial Glucose Metabolism: the SLIM Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"}},"conditionsModule":{"conditions":["Impaired Glucose Tolerance","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"diet- and exercise intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01430143","briefTitle":"Physical Activity for a Long and Healthy Life"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Copenhagen"},"collaborators":[{"name":"Universitetssenteret på Kjeller"},{"name":"Center for Healthy Aging"},{"name":"The Novo Nordic Foundation"},{"name":"Copenhagen University Hospital, Denmark"},{"name":"Glostrup University Hospital, Copenhagen"}]},"conditionsModule":{"conditions":["Overweight","Insulin Resistance","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00657943","briefTitle":"The Copenhagen Insulin and Metformin Therapy Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Steno Diabetes Center Copenhagen"},"collaborators":[{"name":"Hvidovre University Hospital"},{"name":"Hillerod Hospital, Denmark"},{"name":"Frederiksberg University Hospital"},{"name":"University Hospital, Gentofte, Copenhagen"},{"name":"Rigshospitalet, Denmark"},{"name":"Bispebjerg Hospital"},{"name":"Herlev Hospital"},{"name":"Zealand University Hospital"},{"name":"Copenhagen Trial Unit, Center for Clinical Intervention Research"},{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Atherosclerosis","Arteriosclerosis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"metformin"},{"name":"insulin detemir"},{"name":"insulin aspart + insulin aspart protamin"},{"name":"Insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01399346","briefTitle":"Investigation of the Impact of Different Application Volumes of Insulin Aspart in Subjects With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Graz"},"collaborators":[{"name":"European Commission"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin aspart"},{"name":"Insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01757756","briefTitle":"Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 2","Glucose Metabolism Disorders"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pf-05175157"},{"name":"placebo"},{"name":"midazolam"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02219750","briefTitle":"Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mackay Memorial Hospital"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"switch twice-daily insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02735044","briefTitle":"Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine,300 U/mL"},{"name":"Insulin glargine (100 units /mL)"},{"name":"Background therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00542620","briefTitle":"Comparison of Insulin Detemir and Insulin Aspart in 2 Separate Injections Twice Daily to Extemporaneous Mixing Injection Regimen Twice Daily - The Paediatric Mixing Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin detemir"},{"name":"insulin aspart"},{"name":"insulin detemir"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05487755","briefTitle":"Investigational and Comparative Study in the Management of Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tanta University"}},"conditionsModule":{"conditions":["Diabetic Nephropathy Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tadalafil 20Mg Oral Tablet"},{"name":"Pentoxifylline 400 MG Oral Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03895697","briefTitle":"A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Zealand Pharma"}},"conditionsModule":{"conditions":["Hypoglycemia","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"dasiglucagon"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03658655","briefTitle":"Stem Cells From Human Exfoliated Teeth in Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"CAR-T (Shanghai) Biotechnology Co., Ltd."}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Stem Cells From Human Exfoliated Teeth"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01730534","briefTitle":"Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"},{"name":"The TIMI Study Group"},{"name":"Hadassah Medical Organization"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent","High Risk for Cardiovascular Event"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin 10 mg"},{"name":"Placebo tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01109797","briefTitle":"Transition of Adolescents and Young Adults With Diabetes From Pediatric to Adult Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Kansas"}},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Transition Social Behavioral Intervention"},{"name":"Diabetes Transition Clinic"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02465515","briefTitle":"Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"},"collaborators":[{"name":"Duke Clinical Research Institute"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Albiglutide 30 mg"},{"name":"Albiglutide 50 mg"},{"name":"Albiglutide matching placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01729130","briefTitle":"Adipose Tissue Function After Pancreas Transplantation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Medical Branch, Galveston"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1","End Stage Renal Disease"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Adipose tissue biopsy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00627484","briefTitle":"Changes in Insulin Sensitivity After Weight Loss"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Columbia University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes Mellitus","Insulin Resistance"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gastric bypass"},{"name":"Gastric banding"},{"name":"Sleeve gastrectomy"},{"name":"Very low calorie diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02009527","briefTitle":"Arginase Inhibition in Ischemia-reperfusion Injury"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Karolinska Institutet"}},"conditionsModule":{"conditions":["Coronary Artery Disease","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"N-hydroxy-nor-arginine"},{"name":"NaCl"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01369277","briefTitle":"A Single Dose Study In Japanese And Western Healthy Subjects To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-04991532"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 2","Glucose Metabolism Disorders"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-04991532"},{"name":"Placebo"},{"name":"PF-04991532"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05173675","briefTitle":"Empathy in Action: Sunshine Calls for Life With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Texas at Austin"},"collaborators":[{"name":"Lone Star Circle of Care"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes","Mental Health","Health Behavior"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empathy in Action for life with diabetes."},{"name":"Control Phase 2 Materials Only"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01277432","briefTitle":"Prevalence Study of Depression in Chinese Patients With Type 2 Diabetes (HK13)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chinese University of Hong Kong"},"collaborators":[{"name":"Asia Diabetes Foundation"}]},"conditionsModule":{"conditions":["Diabetes","Depression"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Psychiatrist Interview"},{"name":"Depression screening - control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04602650","briefTitle":"Microbial Determinants of Dementia Risk in Type 2 Diabetics of Mexican Descent"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Medical Branch, Galveston"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02697201","briefTitle":"Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pennington Biomedical Research Center"}},"conditionsModule":{"conditions":["Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intralipid"},{"name":"Saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02505308","briefTitle":"Defining the Molecular and Physiological Mechanisms of Pancreatic Islet Cell Dysfunction Which Lead to Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Royal Devon and Exeter NHS Foundation Trust"},"collaborators":[{"name":"University of Exeter"},{"name":"University of Oxford"},{"name":"Oxford University Hospitals NHS Trust"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glucose-Potentiated Arginine-Induced Insulin Secretion"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02999867","briefTitle":"Effect of Triticale, Mung Bean and Adzuki Bean Intervention on Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Peking Union Medical College Hospital"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"triticale and mung bean"},{"name":"adzuki bean"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01904422","briefTitle":"Periodontal Treatment in Non-controlled Type 2 Diabetes Mellitus Patients. Clinical Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidad de los Andes, Chile"}},"conditionsModule":{"conditions":["Diabetes Mellitus.","Chronic Periodontitis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"conventional periodontal treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02626936","briefTitle":"Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institut de Recherches Cliniques de Montreal"}},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dual-hormone closed-loop"},{"name":"Insulin"},{"name":"Glucagon"},{"name":"Dexcom G4 Platinum glucose sensor"},{"name":"Accu Chek Combo insulin pump"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01838083","briefTitle":"Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine new formulation HOE901"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00770653","briefTitle":"Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Dyslipidemias"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone and Metformin"},{"name":"Glimepiride and Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00966407","briefTitle":"Assessing Inherited Markers of Metabolic Syndrome in the Young"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eric Hoffman"},"collaborators":[{"name":"National Institute on Minority Health and Health Disparities (NIMHD)"},{"name":"Howard University"},{"name":"University of Massachusetts, Worcester"},{"name":"East Carolina University"}]},"conditionsModule":{"conditions":["Metabolic Syndrome","Diabetes Mellitus, Type 2","Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03260452","briefTitle":"Comparison of Hematopoietic Stem Cell Activity in Adipose Tissue From Type 2 Diabetic Patients and Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Toulouse"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Abdominal subcutaneous biopsies and Blood test"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05713058","briefTitle":"Metabolic Effects of Early Time-restricted Carbohydrate Consumption"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Azienda Ospedaliero, Universitaria Pisana"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity","Nutrition, Healthy","Weight Loss"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"eTRC diet"},{"name":"Control diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01552018","briefTitle":"Saxagliptin and Atherosclerosis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oslo University Hospital"}},"conditionsModule":{"conditions":["Coronary Artery Disease","Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00974272","briefTitle":"Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Carl T. Hayden VA Medical Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Impaired Glucose Tolerance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide"},{"name":"Normal Saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04025775","briefTitle":"Closed-loop in Adults With T2D Requiring Dialysis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Cambridge"},"collaborators":[{"name":"Insel Gruppe AG, University Hospital Bern"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","End Stage Renal Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CamAPS HX Closed-loop"},{"name":"Multiple Daily Insulin Injections (Control)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04068285","briefTitle":"Neuromuscular Adaptations to Exercise In Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pamukkale University"}},"conditionsModule":{"conditions":["Gait, Unsteady","Aerobic Exercise"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aerobic Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00513630","briefTitle":"Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Jiao Tong University School of Medicine"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glipizide"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00556465","briefTitle":"Efficacy of N-Acetylcysteine in Treatment of Overt Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shiraz University of Medical Sciences"}},"conditionsModule":{"conditions":["Diabetic Nephropathy","Chronic Kidney Disease","Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"N-acetylcysteine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02006836","briefTitle":"Glycemic Responses to Majia Pomelos in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Huazhong University of Science and Technology"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pomelo"},{"name":"Glucose"},{"name":"Blank"},{"name":"Insulin"},{"name":"met or diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03519529","briefTitle":"Sex Hormone Binding Globulin, Testosterone and Glycemic Control in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nanjing First Hospital, Nanjing Medical University"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00467376","briefTitle":"Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glulisine"},{"name":"Lispro"},{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04364685","briefTitle":"Effect of Walking on Sand With Dietary Intervention in Overweight Type 2 Diabetes Mellitus Patients."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Majmaah University"}},"conditionsModule":{"conditions":["Walking, Difficulty","Diabetes Mellitus, Type 2","Hemoglobin; Hb-SC"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Walking on soft-sand"},{"name":"Walking on Levelled Surface"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00949221","briefTitle":"Study of Insulin Therapy Augmented by Real Time Sensor IN Type 1 Children and Adolescents (START-IN!)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Assistance Publique - Hôpitaux de Paris"}},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03464812","briefTitle":"Evaluating Outcomes for Ethnically Diverse Patients With Type 2 Diabetes Participating in a Diabetes Education Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoag Memorial Hospital Presbyterian"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DSMES"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03324776","briefTitle":"Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Model Clinical Research LLC"},"collaborators":[{"name":"Mannkind Corporation"}]},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Afrezza Inhalant Product"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00143104","briefTitle":"To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Inhaled insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01121471","briefTitle":"Supplementation With Conjugated Linoleic Acid (CLA) as Complementary Therapy in the Management of Type 2 Diabetes Mellitus (Women's Diabetes Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ohio State University"},"collaborators":[{"name":"Cognis"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Conjugated Linoleic Acid (CLA)"},{"name":"Safflower OIl"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04857346","briefTitle":"Antimicrobial Photodynamic Therapy in Chronic Periodontitis and Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"King Saud University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Prediabetic State","Chronic Periodontitis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Indocyanine green"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03437525","briefTitle":"Peer Support in Diabetes Management - Insulin Peer Support"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai 6th People's Hospital"},"collaborators":[{"name":"University of North Carolina, Chapel Hill"},{"name":"Asian Center for Health Education"},{"name":"Shanghai Municipal Commission of Health and Family Planning"},{"name":"Sanofi China"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Treated With Insulin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Peer Support"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00231673","briefTitle":"A Study To Evaluate The Effect Of Topiramate On Clinical And Electrophysiological Parameters In Subjects With Diabetic Peripheral Polyneuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."}},"conditionsModule":{"conditions":["Diabetic Neuropathies","Diabetes Mellitus, Type 2","Polyneuropathies"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Topiramate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03338855","briefTitle":"Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Skeletal Muscle Insulin Sensitivity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03290768","briefTitle":"Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Savvysherpa, Inc."}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous Glucose Monitor (CGM)"},{"name":"Activity Tracker"},{"name":"Coaching"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01890122","briefTitle":"Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin"},{"name":"Metformin HCl"},{"name":"Alogliptin and Metformin Fixed-Dose Combination (FDC)"},{"name":"Alogliptin Placebo"},{"name":"Metformin Placebo"},{"name":"Alogliptin and Metformin FDC Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01145599","briefTitle":"Identifying Progression of Retinal Disease in Eyes With NPDR in Diabetes Type 2 Using Non-invasive Procedures"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"European Vision Institute Clinical Research Network"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Non Proliferative Diabetic Retinopathy"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02265809","briefTitle":"Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cambridge University Hospitals NHS Foundation Trust"},"collaborators":[{"name":"University of Cambridge"},{"name":"Sir Jules Thorn Charitable Trust"},{"name":"Juvenile Diabetes Research Foundation"},{"name":"Wellcome Trust"},{"name":"National Institute for Health Research, United Kingdom"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aldesleukin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05216172","briefTitle":"AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Queen Mary University of London"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Diabetes Mellitus, Type 2","Renal Transplant","Kidney Transplant; Complications","End Stage Renal Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD1656"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01827735","briefTitle":"Regulatory T Cells in Type 1 Diabetes Patients Treated With IL-2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cambridge University Hospitals NHS Foundation Trust"},"collaborators":[{"name":"University of Cambridge"},{"name":"Juvenile Diabetes Research Foundation"},{"name":"National Institute for Health Research, United Kingdom"},{"name":"Wellcome Trust"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aldesleukin (Proleukin)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00256256","briefTitle":"The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Stroke","Myocardial Infarction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"glucagon-like-peptide-1"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04688359","briefTitle":"Effectiveness of Nurse-coordinated Follow-up Program in Primary Care for People at Risk for T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Akureyri"},"collaborators":[{"name":"Western Norway University of Applied Sciences"}]},"conditionsModule":{"conditions":["Pre-diabetes","Cardiovascular Risk Factor","T2DM (Type 2 Diabetes Mellitus)","Primary Health Care"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Guided Self Determination"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00910767","briefTitle":"Closing the Loop in Adults With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Cambridge"},"collaborators":[{"name":"Cambridge University Hospitals NHS Foundation Trust"},{"name":"Diabetes UK"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Conventional insulin pump delivery"},{"name":"Closed loop"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02982330","briefTitle":"Impact of a Low Carbohydrate Breakfast on Glucose Control in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of British Columbia"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low Carbohydrate Breakfast"},{"name":"Guidelines Breakfast"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02290860","briefTitle":"Screening Type 2 Diabetes Mellitus on the 2nd Day After Delivery in Women With Gestational Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Université de Sherbrooke"},"collaborators":[{"name":"University of Toronto"},{"name":"University of Manitoba"}]},"conditionsModule":{"conditions":["Diabetes, Gestational"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Type 2 diabetes diagnosis test"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05518448","briefTitle":"The Effect of a Ketone Drink on Liver Glucose Production in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Exeter"},"collaborators":[{"name":"University of British Columbia"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Ketosis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ketone - beta-hydroxybutyrate (β-OHB)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04445181","briefTitle":"A Study Using the LMC Diabetes Registry to Learn More About Chronic Kidney Disease (CKD) in Canadian Patients With Type 2 Diabetes (T2D)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Chronic Kidney Disease in Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"The physician's prescription in routine clinical practice"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04105608","briefTitle":"GLP-1 and Oxyntomodulin Release in Relation to Diet in Type 2 Diabetes Patients."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Antonio Di Mauro"}},"conditionsModule":{"conditions":["Type-2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High-fiber vegetarian meal"},{"name":"Mediterranean-like meal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03579615","briefTitle":"Comparison of Day and Night Closed-loop With Faster-acting Insulin Aspart With Insulin Aspart"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Manchester University NHS Foundation Trust"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FIASP + closed loop device"},{"name":"Insulin aspart (standard of care insulin) + closed loop device"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02985099","briefTitle":"1.2% Rosuvastatin Subgingivally Delivered In Chronic Periodontitis With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Government Dental College and Research Institute, Bangalore"}},"conditionsModule":{"conditions":["Chronic Periodontitis","Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SRP plus Rosuvastatin gel"},{"name":"SRP plus placebo gel"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01006889","briefTitle":"Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Florida"},"collaborators":[{"name":"Amylin Pharmaceuticals, LLC."}]},"conditionsModule":{"conditions":["Nonalcoholic Fatty Liver Disease","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04894344","briefTitle":"Education to Decrease in Sodium Intake Evaluated With 24 Hour Urinary Sodium Excretion (RCT)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidad Autonoma de Baja California"}},"conditionsModule":{"conditions":["Hypertension","Overweight or Obesity","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Education group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01814748","briefTitle":"A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omarigliptin"},{"name":"Placebo to omarigliptin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03269058","briefTitle":"Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire Dijon"}},"conditionsModule":{"conditions":["Type-2 Diabetes","Oral Antidiabetics"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebos"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01394341","briefTitle":"Liraglutide Treatment to Patients With Severe Renal Insufficiency"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bo Feldt-Rasmussen"},"collaborators":[{"name":"Novo Nordisk A/S"},{"name":"The GCP unit at Copenhagen University Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","End-stage Renal Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03371940","briefTitle":"Program ACTIVE II: Behavioral Depression Treatment for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Indiana University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"West Virginia University"},{"name":"Ohio University"},{"name":"University of Michigan"}]},"conditionsModule":{"conditions":["Type2 Diabetes","Depression"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Program ACTIVE Exercise"},{"name":"Program ACTIVE CBT"},{"name":"Program ACTIVE"},{"name":"Usual Care - No intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03938740","briefTitle":"Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diasome Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HDV-Insulin Lispro and Insulin Degludec (-40%)"},{"name":"HDV-Insulin Lispro and Insulin Degludec (-10%)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01982630","briefTitle":"Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK-8521"},{"name":"Liraglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00418288","briefTitle":"The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men During Hypoglycemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Stroke","Myocardial Infarction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"glucagon-like-peptide-1"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03818581","briefTitle":"Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Massachusetts General Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Insomnia","Sleep Disorder","Inflammation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Suvorexant"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01074801","briefTitle":"Closing the Loop for 36 Hours in Adolescents With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Cambridge"},"collaborators":[{"name":"Cambridge University Hospitals NHS Foundation Trust"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Closed-loop insulin delivery"},{"name":"Standard insulin pump treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03644004","briefTitle":"Oral Glucose Tolerance Test and Post Partum Diagnosis of Diabetes Mellitus, Type 2 (DT2 Post-Partum)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospices Civils de Lyon"}},"conditionsModule":{"conditions":["Gestational Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"frequency of diabetes mellitus, type 2, diagnosis in patients with medical history of gestational diabetes."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00417729","briefTitle":"Effects of Acarbose Versus Glibenclamide on MAGE and Oxidative Stress in Patients With Type 2 DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Taichung Veterans General Hospital"},"collaborators":[{"name":"Taipei Veterans General Hospital, Taiwan"},{"name":"Changhua Christian Hospital"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acarbose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02216552","briefTitle":"Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Manitoba"},"collaborators":[{"name":"DSM Nutritional Products, Inc."}]},"conditionsModule":{"conditions":["NAFLD","TYPE 2 DIABETES","METABOLIC SYNDROME"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Resveratrol"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05691712","briefTitle":"A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetes Type 2","Diabetes Mellitus","Glucose Metabolism Disorders","Metabolic Disease","Endocrine System Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04392570","briefTitle":"The Effect of Fasting on Serum Osmolarity in Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Istanbul Medeniyet University"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fasting"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01153438","briefTitle":"Relationship Between Changes in Gut Hormones After Gastric Bypass and Gastric Banding and Improvements in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pennsylvania"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity","Bariatric Surgery"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06288269","briefTitle":"Factors of Control Hypertension or Type 2 Diabetes on the Severity of Stroke and Survival Rates Within 1 Year in Trat"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Phrapokklao Hospital,Thailand"}},"conditionsModule":{"conditions":["Stroke","Hypertension","Type2diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Severity of Stroke and 1 year survival"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00539396","briefTitle":"A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mannkind Corporation"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Technosphere Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04440449","briefTitle":"Effect of Behavioral Lifestyle Intervention on Frailty in Older Adults With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"},"collaborators":[{"name":"The Claude D. Pepper Older Americans Independence Centers"},{"name":"National Institute on Aging (NIA)"}]},"conditionsModule":{"conditions":["Frailty","Weight, Body","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle App"},{"name":"Look AHEAD behavior lifestyle intervention"},{"name":"Abbreviated Look AHEAD behavior lifestyle intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05266404","briefTitle":"Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Parexel"}]},"conditionsModule":{"conditions":["Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin/sitagliptin FDC"},{"name":"Sitagliptin"},{"name":"Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03581266","briefTitle":"Glucose Kinetics After Wheat and Rye Breads"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Swedish University of Agricultural Sciences"},"collaborators":[{"name":"Uppsala University"},{"name":"CTC Clinical Trial Consultants AB"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2. Physiology of Glucose Kinetics"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rye/Wheat"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06688708","briefTitle":"Long-term Effects of Using a Novel Orthotic Insole for Tactile Stimulation in Diabetic Peripheral Neuropathy and Follow-up"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Srinakharinwirot University"}},"conditionsModule":{"conditions":["Diabetic Peripheral Neuropathy Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Using vibrating foot orthosis with tactile stimulation"},{"name":"Using vibrating foot orthosis without tactile stimulation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04994288","briefTitle":"A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients(SUPER-1)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd."}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Supaglutide injection"},{"name":"placebo injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03826472","briefTitle":"Almond Butter and Fasting Glucose"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Penn State University"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Almond Butter"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05854875","briefTitle":"Diabetes Remission After RYGBP and RYGBP With Fundus Resection"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Patras"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Morbid Obesity","Bariatric Surgery"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Laparoscopic Roux en Y gastric bypass"},{"name":"Laparoscopic Roux en Y gastric bypass with fundus resection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05027334","briefTitle":"Self-Management of Type-2 Diabetes Using a Mobile Application"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Mauritius"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DiaMon - Mobile Application for Type 2 Diabetes mellitus and pre-diabetes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05306990","briefTitle":"Statins in Patients With Type 2 Diabetes Mellitus and Previous History of Acute Coronary Syndrome"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Helwan University"}},"conditionsModule":{"conditions":["Hydroxymethylglutaryl-CoA Reductase Inhibitors","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Atorvastatin 40 Mg Oral Tablet"},{"name":"Rosuvastatin 20 Mg Oral Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01654172","briefTitle":"Effect of Flavanol-rich Cocoa on Peripheral and Cerebral Blood Flow in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Nottingham"},"collaborators":[{"name":"Mars, Inc."}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High Flavanol Cocoa"},{"name":"Low Flavanol Cocoa"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01390480","briefTitle":"Effects of Vitamin D Supplementation in Subjects With New Onset of Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Graz"},"collaborators":[{"name":"Medical University of Vienna"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cholecalciferol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00369148","briefTitle":"Combination of Glinides With Premixed Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Keio University"}},"conditionsModule":{"conditions":["Type 2 Diabets Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"nateglinide(drug) mitiglinide(drug)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02312375","briefTitle":"Effects of Fimasartan on Insulin Secretion in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fimasartan"},{"name":"Amlodipine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05926388","briefTitle":"Video-Assisted Instruction in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Izmir Bakircay University"}},"conditionsModule":{"conditions":["Education, Patient"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Video-assisted training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01403961","briefTitle":"Hemoglobin A1c and Immediate Postsurgical Complications Diabetes Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital Italiano de Buenos Aires"}},"conditionsModule":{"conditions":["Postoperative Complications"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02129595","briefTitle":"Resveratrol and First-degree Relatives of Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"},"collaborators":[{"name":"DSM Nutritional Products, Inc."},{"name":"Diabetes Fonds"}]},"conditionsModule":{"conditions":["Pre-diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo"},{"name":"resveratrol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04074317","briefTitle":"Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Xeris Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Insulin-dependent Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PRAM9"},{"name":"Regular Insulin + Pramlintide"},{"name":"Regular Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01679210","briefTitle":"Study of a Postpartum Diabetes Prevention Program for Hispanic Women"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Massachusetts, Amherst"},"collaborators":[{"name":"University of California, San Diego"},{"name":"Northeastern University"},{"name":"Baystate Medical Center"},{"name":"University of Massachusetts, Worcester"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01666028","briefTitle":"Short Term Closed-loop Glucose Control in Adults With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Cambridge"},"collaborators":[{"name":"Cambridge University Hospitals NHS Foundation Trust"},{"name":"Profil Institut für Stoffwechselforschung GmbH"},{"name":"Medical University of Graz"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FlorenceD or similar closed loop glucose control system"},{"name":"CSII with real-time CGM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05988346","briefTitle":"Ghrelin and Diastolic Heart Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Campania \"Luigi Vanvitelli\""}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity, Abdominal","Diastolic Dysfunction"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"abdominal plastic intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01172093","briefTitle":"A Study on the Prevalence of Obstructive Sleep Apnea in Patients With Type II Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Hong Kong"}},"conditionsModule":{"conditions":["Obstructive Sleep Apnea","Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05456347","briefTitle":"Effect of a Low-calorie and High-protein Diet Specially Rich in Animal Protein Compared to a Low-calorie and High-protein Diet Specially Rich in Plant Protein on Glucose Metabolism in Subjects With Prediabetes or Type 2 Diabetes and Overweight or Obesity."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidad de Zaragoza"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Overweight and Obesity","PreDiabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low-calorie and high-protein diet with the majority of protein coming from animal sources."},{"name":"Low-calorie and high-protein diet with the majority of protein coming from plant sources."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00660075","briefTitle":"Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Laval University"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Postprandial Lipemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00006305","briefTitle":"Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pittsburgh"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Coronary Disease","Cardiovascular Diseases","Heart Diseases","Insulin Resistance","Diabetes Mellitus","Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions"},{"name":"Coronary Artery Bypass"},{"name":"Biguanides, thiazolidinediones"},{"name":"Insulin, sulfonylurea"},{"name":"ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01636349","briefTitle":"Health Effects of Recreational Soccer in Type 2 Diabetic Men"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Copenhagen"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Hypertension","Obesity","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"soccer exercise or continued daily lifestyle"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03681704","briefTitle":"the Integrated Traditional Chinese and Western Medicine Treat Early Stage DKD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai University of Traditional Chinese Medicine"},"collaborators":[{"name":"Shanghai Jiao Tong University Affiliated Sixth People's Hospital"}]},"conditionsModule":{"conditions":["Diabetic Nephropathy Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HuangQi Decoction"},{"name":"HuangQi Decoction placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03681249","briefTitle":"the Integrated Traditional Chinese and Western Medicine Treat Middle Stage DKD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai University of Traditional Chinese Medicine"},"collaborators":[{"name":"Shanghai Jiao Tong University Affiliated Sixth People's Hospital"}]},"conditionsModule":{"conditions":["Diabetic Nephropathy Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ShenqiDihuang Decoction"},{"name":"ShenqiDihuang Decoction placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00214786","briefTitle":"Pancreatic Islet Cell Transplantation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baylor Research Institute"},"collaborators":[{"name":"Baylor Health Care System"},{"name":"University of Miami"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Islet cell transplantation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04180332","briefTitle":"Anti Oxidant Enzymes and Total Antioxidant Levels in Diabetes Mellitus Type II Patients and Healthy Individuals With Periodontitis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ajman University"}},"conditionsModule":{"conditions":["Periodontal Diseases","Diabetes Mellitus","Enzyme Disorder"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Blood sample"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01326533","briefTitle":"Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pittsburgh"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Pre-diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"hydroxychloroquine"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00031239","briefTitle":"Sleep Apnea in Look AHEAD Participants - Ancillary to Look AHEAD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}},"conditionsModule":{"conditions":["Sleep Apnea Syndromes","Diabetes Mellitus, Non-insulin Dependent","Obesity","Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02386020","briefTitle":"Aloe Vera in Chronic Periodontitis With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Government Dental College and Research Institute, Bangalore"}},"conditionsModule":{"conditions":["Chronic Periodontitis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"aloe vera"},{"name":"placebo gel"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04181853","briefTitle":"The Effect of Aerobic Exercise on Genetic Molecules"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pamukkale University"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Aerobic Exercise","Genetic Response"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00005146","briefTitle":"Diabetes and Cardiovascular Risk In Mexico City (San Antonio Heart Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Heart Diseases","Diabetes Mellitus, Non-insulin Dependent","Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00941954","briefTitle":"Walking Away: Structured Education Versus Written Information for Individuals With High Risk of Developing Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospitals, Leicester"},"collaborators":[{"name":"University of Leicester"},{"name":"National Institute for Health Research, United Kingdom"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Structured Education"},{"name":"Written Information"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00672386","briefTitle":"A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes Mellitus","Endocrine System Diseases","Nutritional and Metabolic Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"JNJ16269110"},{"name":"JNJ16269110"},{"name":"JNJ16269110"},{"name":"Placebo"},{"name":"Metformin"},{"name":"Dietary Counseling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00385697","briefTitle":"The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"MacroGenics"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Teplizumab"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00005193","briefTitle":"Prospective Study of Diabetes-related Vascular Disease in Oklahoma Indians"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}},"conditionsModule":{"conditions":["Cardiovascular Diseases","Heart Diseases","Diabetes Mellitus, Non-insulin Dependent","Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04259801","briefTitle":"First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Healthy Volunteers","Overweight","Obesity","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NNC0480-0389"},{"name":"Semaglutide"},{"name":"Placebo (NNC0480-0389)"},{"name":"Placebo (semaglutide)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02009514","briefTitle":"Glucose Containing and Glucose Free Hemodialysate in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tampere University Hospital"}},"conditionsModule":{"conditions":["End-Stage Kidney Disease","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glucose-containing compared to glucose-free hemodialysate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01802541","briefTitle":"Effect of Diacylglycerol Oil on Risk Factors of Type 2 Diabetes and Complicating Disease, and Mechanism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Zhejiang University"}},"conditionsModule":{"conditions":["Insulin Sensitivity","Type 2 Diabetes","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"diacylglycerol oil"},{"name":"triacylglycerol oil"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00005137","briefTitle":"Heritage Study--Genetics, Exercise and Risk Factors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Washington University School of Medicine"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Heart Diseases","Diabetes Mellitus, Non-insulin Dependent","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exercise program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00417989","briefTitle":"Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medtronic Diabetes"}},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MiniMed Paradigm REAL-Time System"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00978263","briefTitle":"Comparison of Glargine and Oral Antidiabetic Drugs (OADs) in Newly Diagnosed Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chongqing Medical University"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"metformin-based Oral Antidiabetic Drugs"},{"name":"Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03470454","briefTitle":"Contrast Nephropathy in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fayoum University"},"collaborators":[{"name":"Boehringer Ingelheim"}]},"conditionsModule":{"conditions":["Kidney Function Affection Upon Exposure to Radiocontrast","Diabetes","Microalbuminuria"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Linagliptin Oral Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00036192","briefTitle":"Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a Sulfonylurea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Inc"},"collaborators":[{"name":"Astellas Pharma US, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FK614"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00044408","briefTitle":"Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chromaderm, Inc."}},"conditionsModule":{"conditions":["Diabetic Neuropathies","Diabetes Mellitus, Insulin-Dependent","Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ruboxistaurin mesylate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00044395","briefTitle":"Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Diabetic Neuropathies","Diabetes Mellitus, Insulin-Dependent","Diabetes Mellitus, Non-Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ruboxistaurin mesylate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05145998","briefTitle":"Metabolic Effects of Pulse Consumption on Biomarkers in Adults With Type 2 Diabetes or Met Syn"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Iowa State University"},"collaborators":[{"name":"USA Dry Pea & Lentil Council"}]},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glucola"},{"name":"Whole pea meal"},{"name":"Pea flour meal"},{"name":"Whole lentils"},{"name":"Lentil flour"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04764968","briefTitle":"Pen-Administered Low-Dose Dasiglucagon for Prevention and Treatment of Hypoglycemia in People With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Steno Diabetes Center Copenhagen"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Hypoglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dasiglucagon"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02229110","briefTitle":"Effectiveness of a Computerised Prompt for Primary and Secondary Care Physicians to Refer or Refer Back Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"UMC Utrecht"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Signal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03686722","briefTitle":"Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mohamed Raslan"},"collaborators":[{"name":"Ain Shams University"},{"name":"Drug Research Centre, Cairo, Egypt"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hepatitis C","Drug Interactions"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Daclatasvir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00537251","briefTitle":"32 Week, Open, Randomized, 2 Way Cross Over Multicentre Trial to Compare Safety & Efficacy of Combination of HOE901 Insulin Analogue Once Daily at Bedtime + Lispro Insulin Before Meals vs NPH Insulin (Twice a Day) + Regular in Type 1 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01805245","briefTitle":"Mindfulness: a Novel Approach for the Management of Diabetes-related Distress"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of North Carolina, Chapel Hill"}},"conditionsModule":{"conditions":["Emotional Distress","Type 2 Diabetes","Stress"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mindfulness Based Stress Reduction"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02208921","briefTitle":"An Observational, Cross Sectional Study to Assess the Prevalence of Chronic Kidney Disease (CKD) in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01497132","briefTitle":"Effects of Vitamin D on Beta Cell Function and Insulin Sensitivity in Pre-diabetes and Diabetes Mellitus Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Karolinska Institutet"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Glucose Intolerance","Vitamin D Deficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin D3"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04863755","briefTitle":"Change of Lifestyle in Elderly Patients With Type 2 Diabetes and Systemic Arterial Hypertension"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital de Clinicas de Porto Alegre"},"collaborators":[{"name":"Federal University of Health Science of Porto Alegre"}]},"conditionsModule":{"conditions":["Diabetes","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DASH"},{"name":"DASHPED"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05786703","briefTitle":"Integrated Hypertension and Diabetes Mellitus Type II Treatment and Care Among People Living With HIV/AIDS"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Muhimbili University of Health and Allied Sciences"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Hypertension","HIV Infections"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Biochemical, weight measurements, Blood pressure and blood sugar level"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04379427","briefTitle":"Measurement Algorithm Control and Optimization With Subsequent Performance Evaluation of Sanmina Non-invasive Biosensors During a Standardized Meal Test in Patients With Diabetes Mellitus Type 1 and Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sciema UG"},"collaborators":[{"name":"Sanmina"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sanmina Biosensor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04042207","briefTitle":"Diabeloop for Highly Unstable Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Brittle","Closed-Loop"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low Glucose Predictive Suspend system"},{"name":"DBLHU System"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00394407","briefTitle":"Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"},"collaborators":[{"name":"Sanofi"},{"name":"University of Miami"}]},"conditionsModule":{"conditions":["Diabetes","Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sliding scale regular insulin"},{"name":"glargine basal insulin and glulisine prandial insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01440140","briefTitle":"Closing the Loop in Adults With Type 1 Diabetes in the Home Setting"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Cambridge"},"collaborators":[{"name":"Diabetes UK"}]},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Closed-loop"},{"name":"Conventional insulin pump delivery"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01425359","briefTitle":"Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gilead Sciences"}},"conditionsModule":{"conditions":["Angina Pectoris","Coronary Artery Disease","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ranolazine"},{"name":"Ranolazine placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04515992","briefTitle":"High Intensity Body-weight Circuit Training in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kennesaw State University"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High Intensity Body-weight Circuit Training (HIBC)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01328639","briefTitle":"TeamCare PCN: Collaborative Care for Diabetes and Depression"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Alliance for Canadian Health Outcomes Research in Diabetes"},"collaborators":[{"name":"Alberta Health & Wellness"},{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Depression","Depressive Symptoms","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TeamCare Depression Intervention"},{"name":"Usual diabetes and depression care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05631119","briefTitle":"Biorepository of Biospecimen Samples in Matched Healthy Control Participants and Participants Diagnosed With Diabetic Kidney Disease, Chronic Kidney Disease, or Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanguine Biosciences"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Diabetic Kidney Disease","Diabetes Type 2","Chronic Kidney Diseases","Healthy"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01345500","briefTitle":"UCSD Take Charge Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Diego"},"collaborators":[{"name":"HealthPartners Institute"},{"name":"University of Minnesota"}]},"conditionsModule":{"conditions":["Overweight","Obese","Obesity","Diabetic","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Higher Carbohydrate, Lower Fat Diet"},{"name":"Lower carbohydrate, Higher fat diet"},{"name":"Individualized Counseling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03101865","briefTitle":"The Artificial Pancreas in Very Young Children With T1D - Pilot (KidsAP01)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Cambridge"},"collaborators":[{"name":"European Commission"},{"name":"Medtronic"},{"name":"Cambridge University Hospitals NHS Foundation Trust"},{"name":"The Leeds Teaching Hospitals NHS Trust"},{"name":"University of Luxembourg"},{"name":"University of Leipzig"},{"name":"Medical University of Graz"},{"name":"Medical University Innsbruck"},{"name":"Medical University of Vienna"},{"name":"Jaeb Center for Health Research"}]},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FlorenceM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04847856","briefTitle":"Diabetic Self-care Education at Primary Health Care in Saudi Arabia: A Pragmatic Randomized Trial in Tabuk"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Tabuk"}},"conditionsModule":{"conditions":["Self-care","Preventive Care","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetic care Information, education, and communication intervention will be delivered by relevant and trained health animators working in chronic care clinic."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03926598","briefTitle":"Guide To Goals: A Novel Care Coordination Tool for Children With Type Two Diabetes (T2D)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Georgia Institute of Technology"},"collaborators":[{"name":"Emory University"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Patient and/or Family Member Intervention"},{"name":"Certified Diabetes Educator Intervention"},{"name":"Physician Intervention"},{"name":"Front Desk Staff Intervention"},{"name":"Nurse Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04201496","briefTitle":"SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ananda Basu, MD"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"Tandem Diabetes Care, Inc."},{"name":"DexCom, Inc."}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks"},{"name":"Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks"},{"name":"No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks"},{"name":"No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00409240","briefTitle":"Multi-Targeted Cardiac Risk Intervention in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Providence VA Medical Center"},"collaborators":[{"name":"Sandra A. Daugherty Foundation"}]},"conditionsModule":{"conditions":["Diabetes","Hypertension","Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MEDIC"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04228484","briefTitle":"The Insulin Response to the Gut Hormone GIP After Near-normalisation of Plasma Glucose in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"GIP receptor antagonization"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00306072","briefTitle":"Effect of Different Doses of Salacinol Extract on Glycemic and Insulinemic Response in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ross Products"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"nutritional herbal extract from Salacia oblonga"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03835923","briefTitle":"Lifestyle Intervention in Chronic Ischemic Heart Disease and Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Techniker Krankenkasse"},"collaborators":[{"name":"Technical University of Munich"},{"name":"privates Institut für angewandte Versorgungsforschung GmbH"},{"name":"IDS Diagnostic Systems AG"},{"name":"Federal Joint Committee"}]},"conditionsModule":{"conditions":["Ischemic Heart Disease Chronic","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"lifestyle intervention"},{"name":"usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00810173","briefTitle":"Phone Call in Type 2 Diabetes Patient"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Sao Paulo"}},"conditionsModule":{"conditions":["Behavior Change"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"phone call support"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03242252","briefTitle":"Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lexicon Pharmaceuticals"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Chronic Kidney Disease Stage 3"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Sotagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06548997","briefTitle":"A Phase I Study of GZR18 Injection in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gan and Lee Pharmaceuticals, USA"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Overweight and Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GZR18"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03655535","briefTitle":"Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boston Therapeutics"},"collaborators":[{"name":"Sugardown Company Limited"}]},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BTI320"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03417466","briefTitle":"A Pivotal Study to Evaluate Enlite™ Sensor Performance With iPro™2 in China"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medtronic Diabetes"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Enlite 1 connected to iPro2 recorder"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02967354","briefTitle":"[11C]5-Hydroxy-tryptophan PET for Assessment of Islet Mass in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Per-Ola Carlsson"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01859793","briefTitle":"Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical College of Wisconsin"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Diabetes","Atherosclerosis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04848480","briefTitle":"A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin icodec"},{"name":"insulin degludec"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01370707","briefTitle":"A Study to Evaluate the Efficacy and Safety of CJ-30001 and CJ-30002 in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HK inno.N Corporation"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"CJ-30001/CJ-30002"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04931030","briefTitle":"Low Carbohydrate Diet in Diabetic Kidney Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universiti Teknologi Mara"},"collaborators":[{"name":"International Medical University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Diabetic Kidney Disease","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dietary advice"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00790517","briefTitle":"Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kaiser Permanente"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"LifeWorks Northwest"},{"name":"Cascadia Behavioral Healthcare"}]},"conditionsModule":{"conditions":["Weight Loss","Diabetes Mellitus, Type 2","Psychotic Disorders"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Premier Lifestyle Intervention with DASH Diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04853030","briefTitle":"Fast Advanced Closed-Loop Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Ljubljana, Faculty of Medicine"},"collaborators":[{"name":"Medical University of Graz Department of Pediatrics and Adolescent Medicine, Graz, Austria"},{"name":"UMC Ljubljana University Children's Hospital Ljubljana"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fiasp"},{"name":"Novorapid"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01146314","briefTitle":"A Family Based Intervention to Reduce the Risk of Type 2 Diabetes in Children"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nemours Children's Clinic"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Pediatric Obesity","Type 2 Diabetes","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Family Focused Lifestyle Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03985384","briefTitle":"Semaglutide Treatment On Coronary Progression"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide 2 MG/1.5 ML Subcutaneous Solution"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01667614","briefTitle":"Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tehran University of Medical Sciences"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Diabetic Nephropathy","Essential Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"spironolacone 25 mg tablets added to losartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05202067","briefTitle":"Impact of Pharmaceutical Education on Medication Adherence"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital Civil Juan I. Menchaca"},"collaborators":[{"name":"Drake University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Systemic Arterial Hypertension","Medication Adherence"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pharmaceutical education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01297946","briefTitle":"Closed-loop Control of Glucose Levels in the Context of Exercise in Adults With Type-1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institut de Recherches Cliniques de Montreal"},"collaborators":[{"name":"McGill University"},{"name":"Montreal Children's Hospital of the MUHC"},{"name":"Diabetes Québec"},{"name":"Medtronic Minimed"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Conventional continuous subcutaneous insulin infusion therapy"},{"name":"Dual-hormone closed-loop"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02033499","briefTitle":"Three Approaches to Glucose Monitoring in Non-insulin Treated Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of North Carolina, Chapel Hill"},"collaborators":[{"name":"Patient-Centered Outcomes Research Institute"}]},"conditionsModule":{"conditions":["DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (Disorder)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SMBG"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00939250","briefTitle":"A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Texas Southwestern Medical Center"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Major Depressive Disorder"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes and depression intervention"},{"name":"Diabetes intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03242018","briefTitle":"A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lexicon Pharmaceuticals"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Chronic Kidney Disease Stage 4"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Sotagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00970593","briefTitle":"Study Evaluating Safety, Tolerability, And Action Of OAP-189 In Subjects With Type 2 Diabetes On Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"OAP-189"},{"name":"placebo comparator"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05167513","briefTitle":"Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Getz Pharma"}},"conditionsModule":{"conditions":["Quality of Life","Type 2 Diabetes","Metformin+Sitagliptin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin / Sitagliptin Oral Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03782259","briefTitle":"Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Washington"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Myocardial Fibrosis","Myocardial Inflammation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"dapagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02612675","briefTitle":"Glycemic Response to Oral Nutrition Supplements"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Société des Produits Nestlé (SPN)"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ONS"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03787836","briefTitle":"Improving Individual Glycemic Response With Exercise Intensity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of New Brunswick"},"collaborators":[{"name":"Heart and Stroke Foundation of Canada"},{"name":"New Brunswick Health Research Foundation"}]},"conditionsModule":{"conditions":["PreDiabetes","Diabetes Mellitus, Type 2","Exercise","Physical Activity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Maintained Exercise"},{"name":"Increased Intensity"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00526513","briefTitle":"Study of Safety and Effectiveness of Apidra® in Combination With Basal Insulin in Patients With Type 1 & 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glulisine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00563004","briefTitle":"The Effect of DBcare, a Food Supplement on Diabetes Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Meir Medical Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-insulin Dependant","Diabetes Mellitus Type 2","Diabetes Mellitus, on Oral Hypoglycemic Treatment","Adult Type Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DBCARE"},{"name":"DBCARE"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03713996","briefTitle":"The Effect of Cognitive Behavioral Therapy for Insomnia on Type 2 Diabetes Health Outcomes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Kansas Medical Center"}},"conditionsModule":{"conditions":["Type2 Diabetes","Insomnia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cognitive behavioral therapy for insomnia"},{"name":"Health Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00114998","briefTitle":"CV Disease in Adolescents With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Children's Hospital Medical Center, Cincinnati"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Diabetes Mellitus","Heart Diseases","Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00233649","briefTitle":"DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Crestor, Rosuvastatin","LDL Cholesterol","Observational"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04189848","briefTitle":"Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Healthy Volunteers","Diabetes Mellitus, Type 2","Overweight","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"},{"name":"Dulaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03739125","briefTitle":"Efficacy and Safety of CKD-501 Added to D150 Plus D745 10mg Therapy in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-501 0.5mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01607190","briefTitle":"Biomarkers of Diabetic Retinopathy Progression"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Association for Innovation and Biomedical Research on Light and Image"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Mild Nonproliferative Diabetic Retinopathy"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01065909","briefTitle":"Observatory on Elderly Patients \"Les S.AGES\""},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Chronic Pain","Atrial Fibrillation"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05369793","briefTitle":"Clinical Study Evaluating the Safety and Efficacy of Roflumilast in Type 2 Diabetic Patients With Diabetic Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tanta University"}},"conditionsModule":{"conditions":["Type 2 Diabetes (Adult Onset)","Diabetic Neuropathies"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alpha lipoic acid"},{"name":"Roflumilast"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04504305","briefTitle":"To Assess the Efficacy of Investigational Product on the Neuropathic Pain in Individuals Suffering From Type II Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vedic Lifesciences Pvt. Ltd."}},"conditionsModule":{"conditions":["Diabetic Neuropathies","Insomnia Due to Medical Condition"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NeuropAWAY"},{"name":"Microcystalline cellulose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02987751","briefTitle":"A Study on Comparison of Glargine Plus Glulisine With Premixed Insulin in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glargine + Glulisine"},{"name":"Premixed analogue insulin (70/30)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04136730","briefTitle":"Effects of Home-based Resistance Exercise on Body Composition, Muscle Strength and Glycemic Control in People With Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dasman Diabetes Institute"},"collaborators":[{"name":"University of Glasgow"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Home-based"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03925519","briefTitle":"Exercise as Cardio Protective Modulates in Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"King Saud University"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Exercise"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Supervised aerobic exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03936010","briefTitle":"Replication of the CANVAS Diabetes Trial in Healthcare Claims"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Brigham and Women's Hospital"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin"},{"name":"DPP-4 inhibitor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04332354","briefTitle":"Glycemic Profile by CGMS in Diabetic Patients After Bariatric Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Caen"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus in Obese","Bariatric Surgery Candidate"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"routine care. No intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01961622","briefTitle":"Closing the Loop in Adults With Sub-optimally Controlled Type 1 Diabetes Under Free Living Conditions"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Cambridge"},"collaborators":[{"name":"Profil Institut für Stoffwechselforschung GmbH"},{"name":"Medical University of Graz"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Florence D2A or similar closed loop glucose control system"},{"name":"CSII with real-time CGM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01241474","briefTitle":"Effect of Fish Oil on Insulin Sensitivity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aberdeen"}},"conditionsModule":{"conditions":["Metabolic Syndrome X","Type 2 Diabetes Mellitus","Sarcopenia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EPAX 6000 (marine omega 3 EPA/DHA fatty acid concentrates"},{"name":"Maize (corn) oil"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02411253","briefTitle":"Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Assistance Publique - Hôpitaux de Paris"},"collaborators":[{"name":"Iltoo Pharma"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rhIL-2"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00390728","briefTitle":"Insulin Glargine in Type I Diabetes Mellitus> Main Study \"AT.LANTUS\": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: \"HALT\"(Hypoglycaemia Avoidance With Lantus Trial)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03130894","briefTitle":"Association Between TMAO and Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Liegang Liu"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Plasma TMAO concentration"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00872560","briefTitle":"Comparison of 2 NovoFine® Needles on the Reflux of Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Delivery Systems"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NovoFine® needle 6 mm"},{"name":"NovoFine® needle 8 mm"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02250066","briefTitle":"Prevention of Type 2 Diabetes Mellitus by Changes in Diet"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ilam University of Medical Sciences"}},"conditionsModule":{"conditions":["Prediabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00021944","briefTitle":"Non-Traditional Cardiovascular Risk Factors in Type 2 Diabetes Mellitus - Ancillary to VA Study of Glycemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}},"conditionsModule":{"conditions":["Atherosclerosis","Cardiovascular Diseases","Diabetes Mellitus","Diabetes Mellitus, Non-insulin Dependent","Heart Diseases"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04131049","briefTitle":"Comparison of Two Different Insulin Dose Calculation Algorithms in Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"TC Erciyes University"}},"conditionsModule":{"conditions":["Insulin-Dependent Diabetes Mellitus 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High GI calculated by CC (CHGI)"},{"name":"Low GI calculated by CC (CLGI)"},{"name":"High GI calculated by FII (FHGI)"},{"name":"Low GI calculated by FII (FLGI)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05395442","briefTitle":"Web-based Diabetic Foot Care Training Prepared With the Health Belief Model for Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yuzuncu Yıl University"},"collaborators":[{"name":"Ataturk University"}]},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Training on web-based diabetic foot care based on the Health Belief Model"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01642394","briefTitle":"Impact of Self-care Education Program in Patients With Type 2 Diabetes in Primary Care in the Basque Country"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Osakidetza"},"collaborators":[{"name":"Kronikgune-- Association Centre of International Excellence in Research on Chronicity"},{"name":"Department of Health Basque Government"},{"name":"Fondo de Investigacion Sanitaria"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Self-Management Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01761318","briefTitle":"Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Leiden University Medical Center"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Metabolic Syndrome","Cardiovascular Disease","Diastolic Dysfunction","Fatty Liver"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Liraglutide - Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01629277","briefTitle":"Closing the Loop in Adolescents During Non-compliance Behaviours"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Cambridge"},"collaborators":[{"name":"Cambridge University Hospitals NHS Foundation Trust"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Closed-loop"},{"name":"standard insulin pump"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03544645","briefTitle":"Are Audiovisual Materials Superior to Printed Materials in Improving Awareness Among Type 2 Diabetic Patients?"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"King Abdullah International Medical Research Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Audiovisual material \"video\""},{"name":"Printed material \"brochure\""}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03784027","briefTitle":"The Artificial Pancreas in Very Young Children With T1D"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Cambridge"},"collaborators":[{"name":"European Commission"},{"name":"Cambridge University Hospitals NHS Foundation Trust"},{"name":"The Leeds Teaching Hospitals NHS Trust"},{"name":"University of Luxembourg"},{"name":"University of Leipzig"},{"name":"Medical University of Graz"},{"name":"Medical University Innsbruck"},{"name":"Medical University of Vienna"},{"name":"Jaeb Center for Health Research"},{"name":"University of Edinburgh"},{"name":"Stanford University"},{"name":"Glooko"}]},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CamAPS FX"},{"name":"Sensor augmented therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00726713","briefTitle":"Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pamlab, Inc."},"collaborators":[{"name":"Tulane University Health Sciences Center"},{"name":"VA Nebraska Western Iowa Health Care System"},{"name":"Scott and White Hospital & Clinic"},{"name":"Dallas Diabetes and Endocrine Center"},{"name":"University of Alabama at Birmingham"},{"name":"dgd Research, Inc."},{"name":"Baylor Health Care System"}]},"conditionsModule":{"conditions":["Type 2 Diabetic Peripheral Neuropathy (DPN)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metanx (a medical food)"},{"name":"Metanx placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05166200","briefTitle":"Glycemic Response in Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Nutrition"}},"conditionsModule":{"conditions":["Glycemic Control"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Experimental Formula"},{"name":"Test Meal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03917576","briefTitle":"Heart Rate During Exercise in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidad de Los Lagos"},"collaborators":[{"name":"Universidad de La Frontera"}]},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus","Hyperglycemia","Heart Rate","Exercise Training"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Behavioral"},{"name":"Exercise training intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00504712","briefTitle":"Testosterone for Peripheral Vascular Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Barnsley Hospital"}},"conditionsModule":{"conditions":["Hypogonadism","Peripheral Vascular Disease","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Testosterone"},{"name":"saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01768546","briefTitle":"Evaluation of Video On-Demand Programming to Prevent Type 2 Diabetes in Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"UnitedHealth Group"},"collaborators":[{"name":"Comcast Corporation"},{"name":"Dr. Ron Ackermann"}]},"conditionsModule":{"conditions":["Pre-diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Virtual Diabetes Prevention Program"},{"name":"Interactive tracking and problem solving web portal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03552315","briefTitle":"Effects of a Carbonated Water Enriched With Amino Acids and Chromium Picolinate (Good Idea®) on Glucose Homeostasis."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"DoubleGood AB"},"collaborators":[{"name":"Lund University"}]},"conditionsModule":{"conditions":["Postprandial Hyperglycemia","Metabolic Syndrome","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Carbonated water with amino acids and chromium"},{"name":"Placebo Carbonated Water"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01042977","briefTitle":"Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Cardiovascular Disease","Inadequate Glycaemic Control"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03447275","briefTitle":"The Vitamin B Status in Type 2 Diabetes (VITA) Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rima Obeid"},"collaborators":[{"name":"Merck KGaA, Darmstadt, Germany"},{"name":"Syneed Medidata GmbH"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Vitamin B 12 Deficiency","Vitamin B 6 Deficiency"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Type 2 diabetes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03037918","briefTitle":"Effect of Yakult Ingestion on Diet-induced Insulin Resistance in Humans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Loughborough University"},"collaborators":[{"name":"Yakult Honsha Co., LTD"}]},"conditionsModule":{"conditions":["Insulin Sensitivity","Insulin Resistance","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Yakult light"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00803296","briefTitle":"Incretin Effect in Lean and Obese Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"}},"conditionsModule":{"conditions":["Incretin Effect","Insulin Resistance","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral glucose tolerance test (OGTT)"},{"name":"Isoglycemic intravenous glucose infusion"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01823510","briefTitle":"Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Juan J Badimon"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Type-2 Diabetes Mellitus","Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ticagrelor + Aspirin"},{"name":"Clopidogrel + Aspirin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05550688","briefTitle":"Weight Gain After Smoking Cessation and NAFLD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ningbo No. 1 Hospital"}},"conditionsModule":{"conditions":["Nonalcoholic Fatty Liver Disease","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04183257","briefTitle":"Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"King Edward Medical University"}},"conditionsModule":{"conditions":["Vitamin D Deficiency","Insulin Resistance","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"oral vitamin D"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00722631","briefTitle":"Anti-Inflammatory Effects of Pioglitazone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kurume University"}},"conditionsModule":{"conditions":["Impaired Glucose Tolerance","Type 2 Diabetes Mellitus","Atherosclerosis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01221467","briefTitle":"Closing the Loop in Youth With Type 1 Diabetes in the Home Setting"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Cambridge"},"collaborators":[{"name":"Cambridge University Hospitals NHS Foundation Trust"}]},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Overnight closed-loop"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01586442","briefTitle":"Comparison of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Montreal Heart Institute"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Heart Failure","Type 2 Diabetes","Glucose Intolerance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Eplerenone"},{"name":"Spironolactone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01240980","briefTitle":"Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristol-Myers Squibb"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BMS-903452"},{"name":"BMS-903452"},{"name":"BMS-903452"},{"name":"BMS-903452"},{"name":"BMS-903452"},{"name":"BMS-903452"},{"name":"BMS-903452"},{"name":"Placebo"},{"name":"Placebo"},{"name":"BMS-903452"},{"name":"BMS-903452"},{"name":"Placebo"},{"name":"BMS-903452"},{"name":"BMS-903452"},{"name":"BMS-903452"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02735837","briefTitle":"The Effect of Topical Doxycycline Gel on HbA1c in Patients With Type 2 Diabetes Mellitus(DM) ®"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Amirhossein Farahmand"}},"conditionsModule":{"conditions":["Diabetes Mellitus With Periodontal Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Doxycycline Group"},{"name":"placebo topical gel"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00212914","briefTitle":"Increasing Screening for Type 2 Diabetes in Women With Previous Gestational Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ottawa Hospital Research Institute"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Gestational Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Reminder letter"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03651622","briefTitle":"ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of North Carolina, Chapel Hill"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Overweight and Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hypocaloric, low carbohydrate diet"},{"name":"Hypocaloric, moderate low fat diet"},{"name":"Mediterranean diet, no caloric restriction"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02625649","briefTitle":"Effect of Gastric Bypass Surgery on Diabetes Status and Microvascular Complications in Obese Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity","Diabetic Retinopathy","Diabetic Nephropathy"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02436369","briefTitle":"The Effect of Yogurt Enriched With Flaxseed on Cardiovascular Risk Factors in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Urmia University of Medical Sciences"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"low fat yogurt enriched with flaxseed"},{"name":"low fat yogurt"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00862602","briefTitle":"Pedometers for Gestational Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Gestational Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Stepping Up to Health"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05919706","briefTitle":"Mobile Technology and Motivational Interviewing in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Inonu University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Gaming","Motivational Interviewing","Self-Management","Quality of Life","Mobile Technology"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Patient Education with Game-Based Mobile Technology and Motivational Interviewing"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03829982","briefTitle":"The Effects of Light on Glucose Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University"},"collaborators":[{"name":"Maastricht University Medical Center"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Glucose Intolerance","Prediabetic State"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exposure to bright light during the day"},{"name":"Exposure to dim light during the day"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02506582","briefTitle":"The Effects of Jerusalem Artichoke and Fermented Soybean Powder Mixture Supplementation on Glucose Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yonsei University"}},"conditionsModule":{"conditions":["Prediabetes","Newly Diagnosed Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"jerusalem artichoke and fermented soybeans powder mixture"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05104047","briefTitle":"Distal Peripheral Neuropathy in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"New York University"}},"conditionsModule":{"conditions":["Peripheral Neuropathy","Pain, Neuropathic","Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Moxibustion - Traditional (Active)"},{"name":"Moxibustion - Smokeless - (Active)"},{"name":"Placebo Moxibustion"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04178603","briefTitle":"Copenhagen, Boston, Sydney"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Copenhagen"},"collaborators":[{"name":"Pfizer"},{"name":"University of Sydney"}]},"conditionsModule":{"conditions":["Insulin Resistance","Insulin Sensitivity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise, insulin infusion"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05136287","briefTitle":"SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jose Seijas Amigo"}},"conditionsModule":{"conditions":["Weight Loss","Diabetes Mellitus, Type 2","Quality of Life","Safety Issues"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLP-1 receptor agonist"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01971125","briefTitle":"Left Ventricular DYsfunction in DiAbetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Heart Care Foundation"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Heart Diseases","Left Ventricular Dysfunction"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00313313","briefTitle":"A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Saxagliptin"},{"name":"Glyburide"},{"name":"Placebo"},{"name":"Glyburide"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00474838","briefTitle":"Study To Evaluate Beta Cell Function and Glycemic Outcome by Intensive Insulin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kyunghee University Medical Center"},"collaborators":[{"name":"Korea University Guro Hospital"},{"name":"Hanyang University"},{"name":"Inha University Hospital"},{"name":"Ajou University"},{"name":"Sanofi"},{"name":"East West Neo Medical Center"},{"name":"The Catholic University of Korea"},{"name":"Jeju National University Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Pancreatic Beta Cell Function","Glucotoxicity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"intensive insulin group"},{"name":"Oral AntiDiabetic Drug (glimepiride and metformin)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04971317","briefTitle":"The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NYU Langone Health"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes","Dental Caries"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sugar-Sweetened Beverage (SSB) Video"},{"name":"Water Video"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01447251","briefTitle":"Assessing the Risk of Developing Type II Diabetes Using Serum Biomarkers in Patients Diagnosed With Obstructive Sleep Apnea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mike O'Callaghan Military Hospital"}},"conditionsModule":{"conditions":["Obstructive Sleep Apnea","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PreDx Diabetes Risk Score"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02432924","briefTitle":"Using Combined Instantaneous and Multidimensional Feedback to Support a Change in Physical Activity Behaviour"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Bath"}},"conditionsModule":{"conditions":["Motor Activity","Cardiovascular Diseases","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Instant + Multidimensional Physical Activity Feedback"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03125772","briefTitle":"Trial on Safety & Performance of TAXUS Element vs. XIENCE Prime Stent in Treatment of Coronary Lesion in Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fortis Escorts Heart Institute"},"collaborators":[{"name":"Boston Scientific Corporation"},{"name":"Max Neeman Medical International Ltd."}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Coronary Heart Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TAXUS Element™ Paclitaxel-Eluting Stent System"},{"name":"Xience PRIME Everolimus-Eluting Stent System"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03178019","briefTitle":"DPP4 Activity, Microvascular Reactivity and Inflammation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rio de Janeiro State University"}},"conditionsModule":{"conditions":["Overweight","Pre Diabetes","Diabetes Mellitus Type 2 Without Complication"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Laser-Doppler methods"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00237640","briefTitle":"Effect of Cinnamon on Glucose and Lipid Levels in Non-Insulin Dependent Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Oklahoma"},"collaborators":[{"name":"National Center for Research Resources (NCRR)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Adult Onset"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cinnamon or placebo 500 mg capsule twice daily"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03030300","briefTitle":"Remission Rate of Newly Diagnosed Type 2 Diabetes Outpatients Treated With Short-term Intensive Insulin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Qianfoshan Hospital"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Novolin 30R;Pioglitazone;Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02266576","briefTitle":"A Patient-Centered Strategy for Improving Diabetes Prevention in Urban American Indians"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Stanford University"},"collaborators":[{"name":"San Jose State University"},{"name":"Patient-Centered Outcomes Research Institute"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Metabolic Syndrome","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Standard DPP"},{"name":"Enhanced DPP"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03913793","briefTitle":"Aerobic Training in Post-MI Patients With DPN"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yousra Hisham Abdel Fattah"},"collaborators":[{"name":"Diaa Mohamed Mohasseb"},{"name":"Mahmoud Mohamed Hassanein"},{"name":"Gihan Younis El-tantawi"},{"name":"Aya Hanafy Ibrahiem"}]},"conditionsModule":{"conditions":["Myocardial Infarction","Diabetes Mellitus, Type 2","Diabetic Peripheral Neuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise based-cardiac rehabilitation (EB-CR) program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02329366","briefTitle":"Development of a Cellular Biomarker for the Diagnosis and Treatment of Diabetic Foot Ulcers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Winthrop University Hospital"}},"conditionsModule":{"conditions":["Diabetic Foot Ulcer","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Specimen Collection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00624767","briefTitle":"A Study to Evaluate the Effect of Nasal Insulin on Postprandial Glycemic Control in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nastech Pharmaceutical Company, Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin (recombinant human insulin)"},{"name":"NovoLog"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00419484","briefTitle":"Effect of Pioglitazone on Cardiovascular Outcome on Higashi-Saitama Trial in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dokkyo Medical University"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Hypertension","Dyslipidemia","Diabetic Nephropathy"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01637935","briefTitle":"Cohort Study of Pioglitazone and Bladder Cancer in Patients With Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"},"collaborators":[{"name":"Kaiser Permanente"},{"name":"Department of Epidemiology at University of Pennsylvania"}]},"conditionsModule":{"conditions":["Diabetes","Bladder Cancer"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03593135","briefTitle":"Effect of Apple Cider Vinegar in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sheikh Zayed Federal Postgraduate Medical Institute"}},"conditionsModule":{"conditions":["Randomized Controlled Trial","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Apple Cider Vinegar and tablet Tagipmet (Metformin + Sitagliptin group)"},{"name":"Water with Apple Cider vinegar flavor and tablet Tagipmet (Metformin + Sitagliptin group)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03060538","briefTitle":"A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Genentech, Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Non-Alcoholic Fatty Liver Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BFKB8488A"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04416503","briefTitle":"Effect of Reflexology on Diabetic Foot and Glycemic Control in Elderly Diabetic Individuals"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abant Izzet Baysal University"},"collaborators":[{"name":"The Scientific and Technological Research Council of Turkey"}]},"conditionsModule":{"conditions":["Reflexology","Type 2 Diabetes","Older People"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Foot reflexology"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04998032","briefTitle":"A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients On Metformin Treatment(SUPER-2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd."}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"supaglutide injection+metformin"},{"name":"placebo+metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02845791","briefTitle":"PRE-STARt Intervention - Trial of an Interactive Family Based Lifestyle Programme"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospitals, Leicester"},"collaborators":[{"name":"University of Leicester"},{"name":"Associacao Protectora dos Diabeticos de Portugal"},{"name":"The Algarve Regional Health Administration"},{"name":"University of Leipzig"},{"name":"Technische Universität Dresden"},{"name":"Alexander Technological Educational Institute, Thessaloniki, Greece"},{"name":"Diabetes Centre of Paediatrics P&A"},{"name":"Primary Care Centre Egia, San Sebastian, Spain"},{"name":"Basque Government Department of Public Health"},{"name":"Health Department of the Alto/Bajo Deba"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Chronic Disease","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Interactive Lifestyle programme workshop"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02974504","briefTitle":"Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dong-A ST Co., Ltd."}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"evogliptin"},{"name":"Linagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03419195","briefTitle":"Cardiovascular Mechanisms of Exercise Intolerance in Diabetes and the Role of Sex"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Denver"},"collaborators":[{"name":"VA Eastern Colorado Health Care System"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Healthy","Overweight","Cardiovascular Risk Factor"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cardiovascular exercise training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03703869","briefTitle":"Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glargine (U300)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04858321","briefTitle":"Chronic Passive Heating in Individuals With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Portsmouth"},"collaborators":[{"name":"Portsmouth Hospitals NHS Trust"}]},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Passive heating"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03317028","briefTitle":"CS02 vs Placebo With Metformin in Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Center Laboratories, Inc."}},"conditionsModule":{"conditions":["T2DM With Inadequate Glycemic Control"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CS02 tablet and placebo tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00978627","briefTitle":"Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin degludec/insulin aspart"},{"name":"insulin detemir"},{"name":"insulin aspart"},{"name":"insulin aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04066400","briefTitle":"Role of a Wheat Containing Diet on Non-alcoholic Steatohepatitis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johannes Gutenberg University Mainz"},"collaborators":[{"name":"Goethe University"}]},"conditionsModule":{"conditions":["NASH - Nonalcoholic Steatohepatitis","Diabetes Mellitus, Type 2","Hyperlipidemias"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nutritional Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05335629","briefTitle":"Evaluation of the Effect of SGLT-2 Inhibitors on Cardiac Remodeling in Post Myocardial Infarction Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ain Shams University"}},"conditionsModule":{"conditions":["Myocardial Infarction","Diabetes Mellitus, Type 2","Myocardial Remodeling, Ventricular"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin 10Mg Tab"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02001480","briefTitle":"Surrogate Markers for Sudden Cardiac Death in Patients With Diabetes Mellitus and End Stage Renal Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"RWTH Aachen University"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","End Stage Renal Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"12 lead Holter"},{"name":"CGM Continuous Glucose Monitoring"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01577095","briefTitle":"Evaluating the Effects of Electroacupuncture and Rosiglitazone Combined Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"China Medical University Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus With Features of Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EA + Rosiglitazone"},{"name":"TZD"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00320502","briefTitle":"A Phase 2 Study to Determine the Effects of BXT-51072 in Diabetic Patients Undergoing Angioplasty (PCI)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Synvista Therapeutics, Inc"}},"conditionsModule":{"conditions":["Acute Coronary Syndrome","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BXT-51072"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02350478","briefTitle":"Effects of Linagliptin on Endothelial Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Graz"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Linagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00845182","briefTitle":"Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Healthy","Impaired Glucose Tolerance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"Exenatide"},{"name":"Pioglitazone and Exenatide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01208558","briefTitle":"Grain Exercise Trial - Whole Grain Versus no Grain With or Without Physiotherapy-promoted Exercise for Waist Loss"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lund University"},"collaborators":[{"name":"Region Skane"}]},"conditionsModule":{"conditions":["Abdominal Obesity","Cardiovascular Diseases","Diabetes Type 2","Hypertension","Overweight"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diet A"},{"name":"Diet B"},{"name":"Physiotherapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05189015","briefTitle":"Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Bundang Hospital"}},"conditionsModule":{"conditions":["Angiotensin/Renin/Aldosterone Hypertension","Hypertension","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Olmesartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01313949","briefTitle":"PLATINUM Program: A Feasibility Study on a Train-the-trainer Course on Peer Support for People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Asia Diabetes Foundation"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Training program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02738086","briefTitle":"Physical Activity Behavior Change for Older Adults After Dysvascular Amputation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VA Office of Research and Development"}},"conditionsModule":{"conditions":["Amputation","Diabetes Mellitus, Type 2","Peripheral Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physical Activity Behavior Change (PABC)"},{"name":"Physical Activity Behavior Change (PABC)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03259789","briefTitle":"Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Theracos"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bexagliflozin tablets, 20 mg"},{"name":"Bexagliflozin tablets, placebo"},{"name":"Bexagliflozin tablets, 20 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00985179","briefTitle":"Increasing Vitamin Intake and Physical Activity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Freie Universität Berlin"},"collaborators":[{"name":"Boehringer Ingelheim"}]},"conditionsModule":{"conditions":["Heart Diseases","Diabetes Mellitus, Type 2","Behavior","Motivation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intervention Group (IG)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06434922","briefTitle":"Prevention and Early Detection of Ulcer Recurrence in Patients With Type II Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institute Technology and Health Muhammadiyah West Kalimantan"}},"conditionsModule":{"conditions":["Recurrence","Diabetic Foot","Thermography","Quality of Life"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Prevention Strategies"},{"name":"Standard Strategiies"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00060918","briefTitle":"Glycemic Control Of Carvedilol Versus Metoprolol In Patients With Type II Diabetes Mellitus And Hypertension"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"carvedilol"},{"name":"metoprolol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00413335","briefTitle":"Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yale University"}},"conditionsModule":{"conditions":["Obesity","Impaired Glucose Tolerance","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03383627","briefTitle":"Assessment of Glycemic Control in Patients With Type 2 Diabetes Mellitus and Late Stage Chronic Kidney Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Northwell Health"}},"conditionsModule":{"conditions":["Diabetes","Kidney Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous Glucose Monitoring"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01429506","briefTitle":"Efficacy of Laparoscopic Sleeve Gastrectomy and Intensive Medical Management in Obese Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Post Graduate Institute of Medical Education and Research, Chandigarh"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sleeve gastrectomy"},{"name":"Intensive medical management"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01904032","briefTitle":"Sunshine 2 Study for Women With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Loyola University"},"collaborators":[{"name":"National Institutes of Health (NIH)"},{"name":"National Institute of Nursing Research (NINR)"}]},"conditionsModule":{"conditions":["Diabetes","Depression","Quality of Life"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin D3"},{"name":"Vitamin D3 comparator"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03243136","briefTitle":"The Association Between Food Insecurity and Incident Type 2 Diabetes in Canada: A Population-based Cohort Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Christopher Tait"},"collaborators":[{"name":"Ontario Agency for Health Protection and Promotion"}]},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exposure of interest is food insecurity"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04256304","briefTitle":"The Effect of The Personalized Patient Engagement Plan on Diabetes Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hacettepe University"},"collaborators":[{"name":"The Scientific and Technological Research Council of Turkey"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Patient Engagement","Self Efficacy","Adherence, Patient"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PHEinAction-Personalized Patient Engagement Plan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01884363","briefTitle":"Walnut Consumption, Endothelial Function, and Biomarkers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Brigham and Women's Hospital"}},"conditionsModule":{"conditions":["Coronary Heart Disease","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Once ounce per day of walnuts"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04633941","briefTitle":"Impact of Social Distancing on Bariatric Versus Non-Surgical Obese Patients During COVID-19 Pandemic"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Singapore General Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity, Morbid","Bariatric Surgery Candidate"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Standard Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01074762","briefTitle":"Randomised Controlled Trial of Structured Personal Care of Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Research Unit Of General Practice, Copenhagen"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Quality of Health Care","Health Services Research"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Structured personal care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04433598","briefTitle":"Effectiveness of Nutrition Education Intervention on Glycemic Control (HbA1c)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universiti Putra Malaysia"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Diet, Healthy","Health Knowledge, Attitudes, Practice"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nutrition Education Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05165693","briefTitle":"Evaluation of Glycemic Response in Individuals With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Nutrition"}},"conditionsModule":{"conditions":["Glycemic Control"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Experimental Formula"},{"name":"Test Meal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03719911","briefTitle":"Evaluating the Impact of a Technologically-Enhanced Personal Coaching Program on Hemoglobin A1c in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Welkin Health"},"collaborators":[{"name":"LifeScan"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Live diabetes coaching program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03289494","briefTitle":"Evaluation of 2 Diets With Different Starch Digestibility Profiles on Daily Glycemic Profile, in T2D Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mondelēz International, Inc."},"collaborators":[{"name":"Centre de Recherche en Nutrition Humaine Rhone-Alpe"},{"name":"Biofortis Mérieux NutriSciences"}]},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Balanced diet high in Slowly Digestible Starch"},{"name":"Balanced diet low in Slowly Digestible Starch"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01645332","briefTitle":"Efficacy and Safety of DLBS3233 in Subjects With New Onset of Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dexa Medica Group"}},"conditionsModule":{"conditions":["Type-2-diabetes Mellitus","New Onset"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo of DLBS3233"},{"name":"DLBS3233"},{"name":"Lifestyle modification"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00697580","briefTitle":"Strength and Nutrition Outcomes for Latino Adolescents"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Southern California"},"collaborators":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes","Cardiovascular Risk","Cancer"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nutrition"},{"name":"Strength Training & Nutrition"},{"name":"Circuit Training & Nutrition"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02303730","briefTitle":"Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fudan University"},"collaborators":[{"name":"Huadong Hospital"},{"name":"Shanghai Minhang Central Hospital"},{"name":"Shanghai 6th People's Hospital"},{"name":"Shanghai Changzheng Hospital"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Non-alcoholic Fatty Liver Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02973477","briefTitle":"Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Type2 Diabetes","Cardiovascular Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02175537","briefTitle":"Microclinic Social Induction Pilot Intervention for Diabetes and Obesity Management in Qatar"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Microclinic International"},"collaborators":[{"name":"Qatar University"},{"name":"Qatar Foundation"},{"name":"Qatar Diabetes Association"},{"name":"Qatar Supreme Council of Health"},{"name":"Harvard School of Public Health (HSPH)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type II","Overweight and Obesity","Hypertension","Behavioral Lifestyle Change","Social Change"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Microclinic Social Induction Diabetes and Obesity Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03889977","briefTitle":"Resistance Exercise on Postprandial Hyperglycemia in Patients With B-thalassemia Exhibiting Resistance to Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Thessaly"}},"conditionsModule":{"conditions":["Beta-Thalassemia","Insulin Resistance","PreDiabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Resistance exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00701051","briefTitle":"Exercise Training and Glucose Metabolism in Aging"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"US Department of Veterans Affairs"},"collaborators":[{"name":"University of Maryland"},{"name":"National Institutes of Health (NIH)"},{"name":"National Institute on Aging (NIA)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Impaired Glucose Tolerance (Prediabetes)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aerobic exercise training"},{"name":"Detraining (cessation of exercise)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03966911","briefTitle":"Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medtronic Diabetes"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus","Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06180109","briefTitle":"Bioequivalence Study of Empagliflozin 25 mg Film Coated Tablets of Humanis, Turkey and Jardiance (Empagliflozin) 25 mg Film-coated Tablets of Boehringer Ingelheim International GmbH, Germany in Normal, Healthy, Adult, Human Subjects Under Fasting Condition"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Humanis Saglık Anonim Sirketi"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin film coated tablets"},{"name":"Jardiance film-coated tablets"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01441323","briefTitle":"Strength Training and Nutrition Development for African American Youth"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Southern California"},"collaborators":[{"name":"National Cancer Institute (NCI)"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes","Cardiovascular Risk","Cancer"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nutrition"},{"name":"Strength Training & Nutrition"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03003793","briefTitle":"Insulin Sensitivity in Patients With Atopic Dermatitis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"}},"conditionsModule":{"conditions":["Atopic Dermatitis/Eczema","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hyperinsulinemic euglycemic clamp"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02148250","briefTitle":"PK/PD Study of U-500 Regular Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Minnesota"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Insulin Resistance","High Insulin Requirements"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"U-500 insulin, 100 syringe units"},{"name":"U-500 insulin, 200 syringe units"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05118945","briefTitle":"Study on the Use of the Insulin Pump Tandem X:2 With Control IQ Algorithm - Update"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kinderkrankenhaus auf der Bult"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Insulin Therapy"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin pump Tandem: t:slim X2"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02963662","briefTitle":"Impact of Gut Hormones and Inflammatory Adipokines in Obese Patients Underwent Bariatric Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gao Zhiguang"}},"conditionsModule":{"conditions":["Obesity","Chronic Inflammation","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"laparoscopic Roux-en-Y gastric bypass"},{"name":"laparoscopic sleeve gastrectomy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05762471","briefTitle":"Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics"}},"conditionsModule":{"conditions":["Overweight or Obesity","Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSBR-1290"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02908152","briefTitle":"Curcumin Supplement in Nonalcoholic Fatty Liver Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Nutrition and Food Technology Institute"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Nonalcoholic Fatty Liver"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"curcumin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01795248","briefTitle":"The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tina Vilsboll"},"collaborators":[{"name":"Novo Nordisk A/S"},{"name":"Rigshospitalet, Denmark"},{"name":"Hvidovre University Hospital"},{"name":"Herlev Hospital"},{"name":"Hillerod Hospital, Denmark"},{"name":"University of Copenhagen"},{"name":"The Novo Nordisk Foundation Center for Basic Metabolic Research"},{"name":"Aarhus University Hospital"}]},"conditionsModule":{"conditions":["Gestational Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05892861","briefTitle":"The Effect of Multidomain Dietary Education in Type 2 Diabetic Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Kaohsiung Normal University"},"collaborators":[{"name":"National Cheng-Kung University Hospital"}]},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus","Cognitive Impairment, Mild"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"cognitive stimulation"},{"name":"as usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02324010","briefTitle":"Effects of Sitagliptin on Gastric Emptying, Glycaemia and Blood Pressure in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Royal Adelaide Hospital"}},"conditionsModule":{"conditions":["Gastroparesis","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04558827","briefTitle":"Low-Carb/Time-restricted Feeding Protocol in Insulin-Using Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Wisconsin, Madison"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low Carbohydrate Diet"},{"name":"Time Restricted Feeding"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00233259","briefTitle":"Lifestyle Modification Program to Reduce Risk of Coronary Heart Disease in Latina Women With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oregon Research Institute"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Heart Diseases","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mediterranean Diet"},{"name":"Physical Activity"},{"name":"Stress Management"},{"name":"Social Support"},{"name":"Smoking Cessation"},{"name":"Control group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01403571","briefTitle":"Effectiveness and Safety of Salba on Weight Loss in Overweight Individuals With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Unity Health Toronto"},"collaborators":[{"name":"Canadian Diabetes Association"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Overweight","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Salba (Salvia hispanica L.)"},{"name":"Oat-based Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02062034","briefTitle":"Efficacy of Ubiquinone and Combined Antioxidant Therapy in Non-proliferative Diabetic Retinopathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Guadalajara"},"collaborators":[{"name":"Instituto Mexicano del Seguro Social"}]},"conditionsModule":{"conditions":["Non-proliferative Diabetic Retinopathy","Diabetes Mellitus Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ubiquinone"},{"name":"Combined antioxidant therapy"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00078052","briefTitle":"Genetic Markers of Coronary Heart Disease in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Harvard School of Public Health (HSPH)"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Coronary Disease","Diabetes Mellitus, Non-insulin Dependent","Diabetes Mellitus","Heart Diseases"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02739971","briefTitle":"Dietary Reduction of AGEs to Prevent Cognitive Decline in Elderly Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sheba Medical Center"},"collaborators":[{"name":"Hebrew University of Jerusalem"}]},"conditionsModule":{"conditions":["Cognitive Decline","Aging","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low AGEs diet"},{"name":"Standard of care dietary guidance for Type 2 diabetes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01751399","briefTitle":"A Single Dose Study of LY2605541 in Participants With Liver Impairment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Healthy Volunteers","Hepatic Insufficiency","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2605541"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06241638","briefTitle":"Improving HbA1c Levels by Methylcobalamin Vitamin in Diabetic Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Al-Balqa Applied University"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin B12 0.5 MG/ACTUAT"},{"name":"Dapagliflozin 10mg Tab"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04858854","briefTitle":"Effect of Broccoli Sprout Extract in Patients With Chronic Kidney Disease With Diabetes Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Karolinska Institutet"},"collaborators":[{"name":"Lantmännen"}]},"conditionsModule":{"conditions":["Chronic Kidney Disease Stage 3B","Chronic Kidney Disease stage4","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sulforaphane, administered as Broccoli sprout extract"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02608177","briefTitle":"Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Washington"},"collaborators":[{"name":"American Diabetes Association"},{"name":"Medtronic"},{"name":"Abbott"}]},"conditionsModule":{"conditions":["Chronic Kidney Diseases","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Linagliptin"},{"name":"Glipizide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04217759","briefTitle":"Healthy Lifestyle Intervention on Diabetes Risk Reduction Among Bruneian Young Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universiti Brunei Darussalam"}},"conditionsModule":{"conditions":["Overweight and Obesity","Risk Reduction","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Healthy lifestyle intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02655770","briefTitle":"Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rigshospitalet, Denmark"},"collaborators":[{"name":"Slagelse Hospital"},{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Diastolic Dysfunction","Cardiac MRI","Myocardial Perfusion"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05925829","briefTitle":"Stromal Vascular Fraction and Autologous Activated Platelet-Rich Plasma Combination in Treating Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hayandra Peduli Foundation"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Platelet-rich Plasma","Stromal Vascular Fraction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SVF and aaPRP"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01777282","briefTitle":"A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Albiglutide"},{"name":"Sulfonylurea"},{"name":"Biguanide"},{"name":"Glinide"},{"name":"Thiazolidinedione"},{"name":"Alpha-glucosidase inhibitor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00295256","briefTitle":"Randomized Trial to Evaluate the Effectiveness of Nurse Case Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johns Hopkins University"},"collaborators":[{"name":"Robert Wood Johnson Foundation"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Gestational Diabetes","Hypertension","Preterm Delivery"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"nurse case manager"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03297879","briefTitle":"Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients With Newly Diagnosed Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Beijing Chao Yang Hospital"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide or metformin hydrochloride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02474823","briefTitle":"Neck Grasp as a Predictor of Sleep Apnea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bassett Healthcare"}},"conditionsModule":{"conditions":["Obstructive Sleep Apnea","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"polysomnogram"},{"name":"home sleep test"},{"name":"Easy Sleep Apnea Predictor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01083043","briefTitle":"Continuous Glucose Monitoring in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NYU Langone Health"}},"conditionsModule":{"conditions":["Diabetic Vascular Complications"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03098654","briefTitle":"Impact of Integrated HIV/NCD Screening on HIV Testing Uptake and Engagement in HIV Care in Kisarawe, Tanzania"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of South Carolina"},"collaborators":[{"name":"National Institute of Mental Health (NIMH)"},{"name":"Muhimbili University of Health and Allied Sciences"}]},"conditionsModule":{"conditions":["Human Immunodeficiency Virus","Diabetes Mellitus, Type 2","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Blood glucose and blood pressure testing"},{"name":"Diet and lifestyle counseling"},{"name":"DM/HTN medications as needed"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05231031","briefTitle":"Effect of Breathing and Relaxation Exercises on Serum Cortisol Levels in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cairo University"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Stress"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aerobic exercise"},{"name":"breathing exercise"},{"name":"Relaxation training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00562133","briefTitle":"Effect of Insulin Glulisine vs Regular Human Insulin on Postprandial Endothelial Function in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"IKFE Institute for Clinical Research and Development"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glulisine"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00707993","briefTitle":"Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin"},{"name":"Glipizide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06145360","briefTitle":"Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"SINA Health Education and Welfare Trust"},"collaborators":[{"name":"Horizon Pharmaceutical Pvt Ltd"}]},"conditionsModule":{"conditions":["Glucose Metabolism Disorders","Diabetes Mellitus, Type 2","Hypoglycemic Agents","Empagliflozin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin 10 MG"},{"name":"Insulin+Metformin+DPP4 inhibitor (DPP4I)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01034618","briefTitle":"Protein Hydrolyzation and Glycemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Protein hydrolyzation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02242149","briefTitle":"Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidade Federal do Rio de Janeiro"},"collaborators":[{"name":"Rio de Janeiro State Research Supporting Foundation (FAPERJ)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Non-alcoholic Fatty Liver Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diacerein"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01117311","briefTitle":"Vagal Nerve Stimulation and Glucose Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"National Center for Research Resources (NCRR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity","Gastric Emptying"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"VNB on"},{"name":"VNB off"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00854984","briefTitle":"Pilot Study of a Self-help Intervention for Depression in Patients With a Chronic Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Edinburgh"},"collaborators":[{"name":"University of Stirling"},{"name":"Robert Gordon University"},{"name":"University of Glasgow"},{"name":"Chief Scientist Office of the Scottish Government"}]},"conditionsModule":{"conditions":["Depression","Diabetes Mellitus Type 2","Coronary Heart Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Living Life to the Full"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00414986","briefTitle":"Using Learning Teams for Reflective Adaptation for Diabetes and Depression"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Denver"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"National Institute of Mental Health (NIMH)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Hyperlipidemia","Hypertension","Depression"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Standard CQI intervention"},{"name":"Chronic Care Improvement (CCI) Intervention"},{"name":"Self-directed practice comparison"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05093517","briefTitle":"Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Glucose Tolerance Impaired","Insulin Sensitivity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"REMD-477"},{"name":"Placebo Subcutaneous injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04861324","briefTitle":"Effects of a Lifestyle Intervention on Gestational Diabetes Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Nevada, Las Vegas"}},"conditionsModule":{"conditions":["Gestational Diabetes","Type 2 Diabetes","Nutritional and Metabolic Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dietary Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05896319","briefTitle":"Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Turin, Italy"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Delayed Wound Healing","Tooth Extraction Status Nos"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hyaluronic acid gel"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00374361","briefTitle":"Study of the Relationship Between Blood Vessels and Insulin Response in Adolescents"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ohio State University"},"collaborators":[{"name":"Nationwide Children's Hospital"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension","Heart Disease","Stroke"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03657537","briefTitle":"Effects of Ketone Bodies on Cognition in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bispebjerg Hospital"},"collaborators":[{"name":"Psychiatric Centre Rigshospitalet"}]},"conditionsModule":{"conditions":["Type2 Diabetes","Ketonemia","Cognitive Change"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ketone infusion"},{"name":"Saline infusion"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02056366","briefTitle":"The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Catholic University of Korea"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Cardiac Autonomic Neuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"α-lipoic acid"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00596427","briefTitle":"Mechanisms of Glucose Lowering Effect of Colesevelam HCl"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Carine Beysen"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Colesevelam HCL"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02048839","briefTitle":"Long-term Effects of Lifestyle Intervention During Pregnancy in High Risk Women and in Their Offspring - Role of Environmental, Genetic and Epigenetic Factors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Helsinki University Central Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Obesity","Metabolic Syndrome"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05154045","briefTitle":"Postprandial Glycemic Response in Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Nutrition"}},"conditionsModule":{"conditions":["Glycemic Control"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Experimental Formula"},{"name":"Test Meal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04126291","briefTitle":"Type 2 Diabetes Prevention Toolkit for Health-Care Professionals"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Hospital for Sick Children"},"collaborators":[{"name":"University of Ottawa"}]},"conditionsModule":{"conditions":["Childhood Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Evaluation of whiteboard videos"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05866497","briefTitle":"Arterial Stiffness in Type 2 Diabetic Patients With Severe Periodontitis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pamukkale University"}},"conditionsModule":{"conditions":["Coronary Heart Disease","Diabetes Mellitus, Type 2","Periodontitis","Arterial Stiffness"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"clinical periodontal measurements"},{"name":"CAVI measurements"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00820573","briefTitle":"Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Metformin"},{"name":"Sitagliptin + Metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01456130","briefTitle":"Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin"},{"name":"Rapid-acting insulin secretagogue"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03281486","briefTitle":"\"Hyaluronan\" Formulation for Type 2 Diabetic Patients With Dry Mouth"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"You First Services"}},"conditionsModule":{"conditions":["Dry Mouth","Xerostomia","Type 2 Diabetics"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HA formulation Oral Spray"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03559621","briefTitle":"Mobile-based Lifestyle Intervention in Women With Glucose Intolerance After Gestational Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universitaire Ziekenhuizen KU Leuven"}},"conditionsModule":{"conditions":["Gestational Diabetes","Type 2 Diabetes Mellitus","Glucose Intolerance","Healthy Lifestyle"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"mobile-based lifestyle intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00732602","briefTitle":"The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"},"collaborators":[{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GIP-infusion"},{"name":"Sodium-chloride"},{"name":"GLP-2 infusion"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01507038","briefTitle":"Safety and Efficacy of YH14617 in Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yuhan Corporation"},"collaborators":[{"name":"Peptron, Inc."}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"YH14617"},{"name":"YH14617"},{"name":"YH14617"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01436916","briefTitle":"Oral Cholecalciferol in Prevention of Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Post Graduate Institute of Medical Education and Research, Chandigarh"}},"conditionsModule":{"conditions":["Prediabetes","Vitamin D Deficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"oral cholecalciferol + life style counselling"},{"name":"placebo + life style counselling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00515723","briefTitle":"Glucose and Lipid Metabolism on Antipsychotic Medication"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Washington University School of Medicine"},"collaborators":[{"name":"National Institute of Mental Health (NIMH)"}]},"conditionsModule":{"conditions":["Schizophrenia","Schizoaffective Disorder","Type 2 Diabetes Mellitus","Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"risperidone"},{"name":"olanzapine"},{"name":"quetiapine"},{"name":"ziprasidone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01418716","briefTitle":"TRANSforming InTerprofessional Cardiovascular Prevention in Primary Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fonds de la Recherche en Santé du Québec"},"collaborators":[{"name":"Université de Montréal"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hypertension","Dyslipidemias","Cholesterol, LDL","Comorbitdity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Facilitation"},{"name":"Passive diffusion"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02845024","briefTitle":"The Effect of Non-surgical Periodontal Therapy Plus Doxycycline on HbA1c in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Islamic Azad University, Tehran"}},"conditionsModule":{"conditions":["Diabetes Mellitus With Periodontal Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Doxycycline Group"},{"name":"placebo Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00456352","briefTitle":"Duodenal Exclusion for the Treatment of T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medtronic - MITG"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"duodenal exclusion"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01785134","briefTitle":"Effects of Different Surgical Methods to Treat Obesity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Karolinska Institutet"},"collaborators":[{"name":"Region Stockholm"},{"name":"The Swedish Research Council"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes","Insulin Sensitivity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omentectomy"},{"name":"Gastric bypass operation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03792685","briefTitle":"Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Bialystok"},"collaborators":[{"name":"Ministry of Science and Higher Education, Poland"}]},"conditionsModule":{"conditions":["Overweight and Obesity","Diabetes Mellitus, Type 2","Metabolic Syndrome","Genetic Predisposition","Diet Modification"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Normo-carbohydrate meal intake"},{"name":"High-carbohydrate meal intake"},{"name":"High-fat meal intake"},{"name":"High-protein meal intake"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02302443","briefTitle":"A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12470"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hanmi Pharmaceutical Company Limited"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HM12470"},{"name":"Active comparator"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00469833","briefTitle":"Insulin Secretion in Diabetes Before and After Glycemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"US Department of Veterans Affairs"}},"conditionsModule":{"conditions":["Diabetes","Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03955952","briefTitle":"Cardiovascular Outcomes in Bariatric Surgery Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Cleveland Clinic"}},"conditionsModule":{"conditions":["Obesity","Type2 Diabetes","Bariatric Surgery Candidate"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bariatric Surgery"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05437848","briefTitle":"Chinese Multiple Dose Escalation (MDE) High Dose Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Experimental: Cotadutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00600067","briefTitle":"A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VIVUS LLC"},"collaborators":[{"name":"Synteract, Inc."},{"name":"Sentrx"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Phentermine/Topiramate"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03667300","briefTitle":"Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Samsung Medical Center"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus","Albuminuria","Renal Insufficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Evogliptin"},{"name":"Linagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01631084","briefTitle":"Comparing the Effect of Structured Care Versus Usual Care in Type 2 Diabetes Patients Across the Asia Pacific Region"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Asia Diabetes Foundation"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"JADE"},{"name":"DIAMOND"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03826381","briefTitle":"NAFLD Among Patients With Type 2 Diabetes and CKD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rigshospitalet, Denmark"}},"conditionsModule":{"conditions":["Non-Alcoholic Fatty Liver Disease","Chronic Kidney Diseases","Type2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Magnetic resonance (MR) spectroscopy of the liver"},{"name":"Fibroscan"},{"name":"Continuous glucose monitoring (CGM) for four days."},{"name":"Dual Energy X-ray Absorptiometry (DEXA) scan"},{"name":"Blood samples"},{"name":"Clinical and demographic data"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04254016","briefTitle":"Short Term Effects of a Hibiscus Sabdariffa and Stevia Rebaudiana Drink on Cardiac Relaxation and Urinary Albumin Excretion in a Group of Diabetic Type 2 Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yaounde Central Hospital"}},"conditionsModule":{"conditions":["Benefits of a Hibiscus Sabdariffa and Stevia Rebaudiana Drink in Patients With Type 2 Diabetes Mellitus Before and After 8 Weeks of add-on Therapy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HIBISTEVER1"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01429818","briefTitle":"Endothelial Disfunction Treatment With Glimepiride/Metformin Combination (Glimetal) in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Laboratorios Silanes S.A. de C.V."}},"conditionsModule":{"conditions":["Endothelial Dysfunction","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glimepiride/metformin"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00678080","briefTitle":"Metformin Versus Insulin in Pregnant Women With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center, Houston"}},"conditionsModule":{"conditions":["Pregnancy Complications"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Insulin (NPH and Regular)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03196024","briefTitle":"Corazon de la Familia (Heart of the Family)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gia Mudd"},"collaborators":[{"name":"National Institute of Nursing Research (NINR)"},{"name":"National Institutes of Health (NIH)"}]},"conditionsModule":{"conditions":["Risk Reduction Behavior","Diabetes Mellitus, Type 2","Cardiovascular Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Family-focused intervention arm"},{"name":"Individual-focused intervention arm"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00651105","briefTitle":"Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Type-2 Diabetes","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00677599","briefTitle":"The FLAVO Trial: Dietary Flavonoids and Cardiovascular Disease Risk Reduction in Postmenopausal Women With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of East Anglia"},"collaborators":[{"name":"Quadram Institute Bioscience"},{"name":"The Bertram Diabetes Centre & Radiology department (Norfolk & Norwich University Hospital, UK)"},{"name":"Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)"},{"name":"Diabetes UK"},{"name":"Frutarom Netherlands B.V. - Soy producer"},{"name":"Barry Callebaut - chocolate manufacturer contracted to produce intervention foods"}]},"conditionsModule":{"conditions":["Cardiovascular Disease","Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Flavonoid enrichment (cocoa / soy compounds)"},{"name":"Flavonoid enrichment (cocoa / soy compounds)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00724087","briefTitle":"Sleep Loss and Energy Metabolism in People With Family History of Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Chicago"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Sleep","Sleep Deprivation","Insulin Resistance","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"5.5-hour bedtime"},{"name":"8.5-hour bedtime"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00721019","briefTitle":"Sleep Loss and Glucose Metabolism in People With Family History of Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Chicago"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Sleep","Sleep Deprivation","Insulin Resistance","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"5-hour bedtime"},{"name":"8.5-hour bedtimes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00834626","briefTitle":"Ileal Interposition With Sleeve Gastrectomy for Control of Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kirloskar Hospital"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ileal Interposition with Sleeve Gastrectomy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00994513","briefTitle":"Effect of Alpha Lipoic Acid on Obesity Related Comorbidities"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Augusta University"},"collaborators":[{"name":"Xinjiang Medical University"}]},"conditionsModule":{"conditions":["Obesity","Cardiovascular Disease","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alpha Lipoic Acid"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06032429","briefTitle":"Effects of Shared Medical Appointments for Diabetic Patients in Taiwan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dalin Tzu Chi General Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Shared Medical Appointments"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03197324","briefTitle":"Bexagliflozin Drug/Drug Interaction Study With Digoxin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Theracos"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bexagliflozin"},{"name":"Digoxin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02723019","briefTitle":"Mi Puente: My Bridge to Better Cardiometabolic Health and Well-Being"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Scripps Whittier Diabetes Institute"},"collaborators":[{"name":"San Diego State University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Cardiometabolic Conditions","Behavioral Health Concerns"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Volunteer Peer Mentor+Behavioral Health Nurse"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02919397","briefTitle":"Motivational Instant Messaging and E-diabetes Prevention Programme for High Risk of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"King's College London"}},"conditionsModule":{"conditions":["Pre-diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Wearable technology"},{"name":"Diabetes Prevention Programme educational material"},{"name":"Motivational messaging"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01035879","briefTitle":"Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gilead Sciences"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MBX-2982"},{"name":"MBX-2982"},{"name":"MBX-2982"},{"name":"Sitagliptin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00037297","briefTitle":"Epidemiology of Cardiovascular Disease in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}},"conditionsModule":{"conditions":["Cardiovascular Diseases","Diabetes Mellitus, Non-insulin Dependent","Heart Diseases","Atherosclerosis","Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00818077","briefTitle":"Using Continuous Glucose Monitoring to Understand the Glycemic Impact of Food"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HealthPartners Institute"},"collaborators":[{"name":"International Diabetes Center at Park Nicollet"},{"name":"Abbott Diabetes Care"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Currently Taking Metformin"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous Glucose Monitoring of Carbohydrate Intake"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00795860","briefTitle":"Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"},"collaborators":[{"name":"American Diabetes Association"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Insulin Resistance and Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Weight loss - diet only"},{"name":"Weight loss plus exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01507116","briefTitle":"Diabetes Attitudes Wishes and Needs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Relatives to/Carers of Patients","Healthcare Professionals"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05816941","briefTitle":"Antimicrobial Photodynamic Therapy in Patients With Periodontal Disease and Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Ljubljana"},"collaborators":[{"name":"University Medical Centre Ljubljana"}]},"conditionsModule":{"conditions":["Periodontal Diseases","Diabetes Mellitus, Type 2","Periodontitis","Periodontal Pocket","Periodontal Attachment Loss","Periodontal Inflammation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Conventional Periodontal Treatment (Complete Oral Disinfection)"},{"name":"Adjunctive Photodynamic Therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02229383","briefTitle":"Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide"},{"name":"Exenatide matching placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03962686","briefTitle":"Molecular Mechanisms and Carotid Atherosclerosis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Campania \"Luigi Vanvitelli\""}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Atherosclerosis of Artery","Atherosclerotic Plaque"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"statin Oral Tablet plus PCSK9i"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00037258","briefTitle":"Dyslipidemia and Risk of Cardiovascular Disease in Diabetic Men and Women"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Brigham and Women's Hospital"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Diabetes Mellitus, Non-insulin Dependent","Heart Diseases","Atherosclerosis","Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02021890","briefTitle":"Efficacy Study of Standard Ballroom and Latin Dance Program in Type 2 Diabetes and Obesity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Bologna"},"collaborators":[{"name":"General Hospital, Gavardo"},{"name":"Villa Garda Hospital"}]},"conditionsModule":{"conditions":["Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dance program"},{"name":"Self-selected physical activity"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03193229","briefTitle":"MapTrek to Increase Activity Among Patients at Risk for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Philip Polgreen"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Pre Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MapTrek"},{"name":"Fitbit"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00136773","briefTitle":"Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Albuminuria"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"amlodipine/benazepril"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04885712","briefTitle":"A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boryung Pharmaceutical Co., Ltd"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin≥1000mg"},{"name":"Pioglitazone 15mg"},{"name":"Pioglitazone 30 mg"},{"name":"Pioglitazone 15mg Placebo"},{"name":"Pioglitazone 30mg Placebo"},{"name":"Dapagliflozin 10mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04722289","briefTitle":"The Together on Diabetes Intervention - a Realist Evaluation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Center for Diabetes, Copenhagen Municipality"},"collaborators":[{"name":"Novo Nordisk A/S"},{"name":"Innovation Fund Denmark"},{"name":"University of Copenhagen"},{"name":"The Danish Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Health Behavior","Delivery of Health Care"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Together on Diabetes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00486941","briefTitle":"Lifestyle Intervention in Primary Health Care - the Björknäs Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Umeå University"},"collaborators":[{"name":"County Council of Norrbotten, Sweden"}]},"conditionsModule":{"conditions":["Hypertension","Type 2 Diabetes","Obesity","Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise and diet - based on DPS and DPP"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04573296","briefTitle":"Impact of Digital Therapeutic on Metabolic Parameters"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vitadio s.r.o."},"collaborators":[{"name":"University Hospital Olomouc"}]},"conditionsModule":{"conditions":["Insulin Resistance","Prediabetic State","Diabetes Mellitus, Type 2","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitadio"},{"name":"Conventional high-intensity lifestyle intervention program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05633784","briefTitle":"Telemedicine Home-based Management in Patients With CHF and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Istituti Clinici Scientifici Maugeri SpA"},"collaborators":[{"name":"Azienda Ospedaliera Bolognini di Seriate Bergamo"},{"name":"Papa Giovanni XXIII Hospital"}]},"conditionsModule":{"conditions":["Chronic Heart Failure","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Teleassistance"},{"name":"Teleconsultation"},{"name":"Telerehabilitation"},{"name":"Telemonitoring"},{"name":"mHealth"},{"name":"telepsycology"},{"name":"Quality of life"},{"name":"Biochemistry evaluation"},{"name":"Clinical evaluation"},{"name":"State of health of the patient"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01991054","briefTitle":"The Effects of Vitamin D Supplementation on Patients With Type 2 Diabetes and Vitamin D Deficiency"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HaEmek Medical Center, Israel"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Vitamin D Deficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vitamin D3"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03196336","briefTitle":"Effectiveness of Pharmacotherapy Follow-up Care in Outpatients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Sorocaba"},"collaborators":[{"name":"Cristiane de Cássia Bergamaschi"}]},"conditionsModule":{"conditions":["Pharmaceutical Services"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pharmacotherapy follow-up care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02771821","briefTitle":"Promoting Healthy Habits With Elderlies Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidade Federal de Pernambuco"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Aged","Health Behavior","Group Processes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Operative groups based on methodology of problematization"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00422253","briefTitle":"Dietary Advanced Glycation End-products and Insulin Resistance in Overweight and Obese Humans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayside Health"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Insulin Resistance","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"dietary intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04076007","briefTitle":"The Effect of Dietary Nitrate on Blood Pressure, Insulin Sensitivity, and Vascular Function in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Exeter"}},"conditionsModule":{"conditions":["Diabetes","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Beetroot juice"},{"name":"Nitrate depleted beetroot juice"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00230087","briefTitle":"Iron Depletion Therapy for Type 2 DM and NAFLD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Non-Alcoholic Fatty Liver Disease","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"blood donation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05110625","briefTitle":"mHealth Intervention to Prevent Type 2 Diabetes Mellitus (Phase II Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fundació d'investigació Sanitària de les Illes Balears"}},"conditionsModule":{"conditions":["Prediabetic State"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"preDIABE-TEXT"},{"name":"Online Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05628259","briefTitle":"The Effect of Tele-Nursing Based Motivational Interviewing in Individuals With Type 2 Diabetes:RCT"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pamukkale University"},"collaborators":[{"name":"Bakirkoy Dr. Sadi Konuk Research and Training Hospital"}]},"conditionsModule":{"conditions":["Type2 Diabetes","Self Efficacy","Self Management","Tele-nursing","Motivational Interview","LDL - Low Density Lipoprotein Receptor Disorder","High Density Lipoprotein Deficiency","Cholesterol; Lipidosis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tele-Nursing based Motivational Interviewing"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04708574","briefTitle":"Lifestyle Changes Reducing Type 2 Diabetes Risk Among Arab Canadian Muslim Women."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Western University, Canada"}},"conditionsModule":{"conditions":["Lifestyle Risk Reduction","Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle intervention"},{"name":"Placebo - Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05310526","briefTitle":"BALANCE Diet Implementation in Primary Health Care: a Cluster Randomized Type II Hybrid Implementation Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital do Coracao"}},"conditionsModule":{"conditions":["Obesity","Hypertension","Diabetes","Dyslipidemias"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Training Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04804774","briefTitle":"Virtual Weight Control Program Tailored for Adults With Type 2 Diabetes (VITAL)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pennington Biomedical Research Center"},"collaborators":[{"name":"WW International Inc"}]},"conditionsModule":{"conditions":["Type2 Diabetes","Overweight and Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"WW program modified for people with Type 2 diabetes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05106231","briefTitle":"Effectiveness of PICC Improving HBA1C and Knowledge in Diabetes Mellitus Education"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Clinical Research Centre, Malaysia"},"collaborators":[{"name":"Ministry of Health, Malaysia"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PICC Program"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00054925","briefTitle":"Weight Loss Maintenance (WLM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Duke University"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Heart Diseases","Obesity","Diabetes Mellitus, Non-insulin Dependent","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Personal contact (PC)"},{"name":"Interactive technology (IT)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02637973","briefTitle":"Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Deutsche Diabetes Forschungsgesellschaft e.V."},"collaborators":[{"name":"Boehringer Ingelheim"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Non-alcoholic Fatty Liver Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01392027","briefTitle":"Biospecimens for Identification of Diseases of the Pancreas."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"}},"conditionsModule":{"conditions":["Pancreatic Cancer","Chronic Pancreatitis","Type II Diabetes","Pancreatic Cysts","Healthy Control"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Blood Draw"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01213212","briefTitle":"Preventing Renal Functional Abnormalities With Calorie Restriction in Subjects With Abdominal Obesity and Type 2 Diabetes at Increased Renal and Cardiovascular Risk"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mario Negri Institute for Pharmacological Research"},"collaborators":[{"name":"Istituto Superiore di Sanità"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Caloric restriction"},{"name":"No intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04991142","briefTitle":"Models of Nutrition From Continuous Glucose Monitors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Texas A&M University"},"collaborators":[{"name":"Sansum Diabetes Research Institute"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Pre-diabetes","Diet Habit","Diet, Healthy"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05538819","briefTitle":"The Effects of Glimepiride in Patients With Type 2 Diabetes and Chronic Heart Failure"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dao Wen Wang"},"collaborators":[{"name":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences"}]},"conditionsModule":{"conditions":["Chronic Heart Failure","Type 2 Diabetes","Cardiovascular Mortality","Cohort Study"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04009642","briefTitle":"Cardiac Rest and Stress Metabolism in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Leicester"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Metabolic Cardiomyopathy","Metabolic Disturbance","Fatty Acid Oxidation Disorder"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Surely observational based on disease state"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02360527","briefTitle":"Retinal Neurodegeneration in Type 2 Diabetes as Biomarker for Alzheimer´s Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital Universitari Vall d'Hebron Research Institute"}},"conditionsModule":{"conditions":["Retinal Neurodegeneration","Alzheimer´s Disease","Type 2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05337306","briefTitle":"Improving Diabetic Patient Health Through Assistive-Reading Technology"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GogyUp Inc"},"collaborators":[{"name":"University of Minnesota"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Health Knowledge, Attitudes, Practice","Literacy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GogyUp Reader"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04190160","briefTitle":"Quality of Life and Fixed-ratio Combination of Insulin Degludec and Liraglutide (iDegLira)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Stefano Rizza"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IDegLira"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02684929","briefTitle":"Effects of Chronic Dietary Exposure to Branched Chain Amino Acids"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Charles University, Czech Republic"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus With Features of Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"branched chain amino acids"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04694053","briefTitle":"Fournier's Gangrene in Patient With Uncontrolled Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Catania"}},"conditionsModule":{"conditions":["Fournier Gangrene"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"surgical debridement"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05161741","briefTitle":"Research on Human Insulin rDNA Safety and Efficacy in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Getz Pharma"}},"conditionsModule":{"conditions":["Adverse Drug Event","Effect of Drug","Type 2 Diabetes Treated With Insulin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01945216","briefTitle":"Alogliptin Tablets Special Drug Use Surveillance \"Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI\""},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus Who Have Been Examined at a Medical Institution"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00678522","briefTitle":"The Acute Effect of Atorvastain on Renal Function in Patients With Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Regional Hospital Holstebro"},"collaborators":[{"name":"Medical Research"}]},"conditionsModule":{"conditions":["Healthy Subjects"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Atorvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03167411","briefTitle":"Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Theracos"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bexagliflozin"},{"name":"Exenatide Injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03175315","briefTitle":"Evaluation of a Treatment and Education Program for Diabetic Patients Who Use Flash Glucose Monitoring"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Norbert Hermanns"},"collaborators":[{"name":"Abbott Diabetes Care"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Treatment and education program for patients with diabetes who use flash glucose monitoring (FLASH)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01251497","briefTitle":"¡Si, Yo Puedo Control Mi Diabetes!: A Diabetes Self-management Education Program for Hispanic/Latinos"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Texas AgriLife Extension Service"},"collaborators":[{"name":"Texas A&M University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes, Hispanic/Latinos, Diabetes Self-management Education"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"diabetes self-management education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00289237","briefTitle":"Lifestyle Intervention in a General Population for Prevention of Ischaemic Heart Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Glostrup University Hospital, Copenhagen"},"collaborators":[{"name":"Steno Diabetes Center Copenhagen"}]},"conditionsModule":{"conditions":["CHD","AMI","CVD","Type 2 Diabetes","COLD"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06396819","briefTitle":"Collagen-povidone for Diabetic Seniors' Tenosynovitis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Instituto Mexicano del Seguro Social"}},"conditionsModule":{"conditions":["Diabetes Complications"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"collagen-povidone solution"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05038176","briefTitle":"Improving the Diabetic Health of Black Men: MANUP Feasibility Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"North Carolina Central University"},"collaborators":[{"name":"University of North Carolina, Chapel Hill"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Coping Behavior","Self Efficacy","Masculinity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MANUP"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00738114","briefTitle":"Diabetes in the Perioperative Period"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"}},"conditionsModule":{"conditions":["Hyperglycemia","Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02916589","briefTitle":"Nutrition, Oral Health and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kristianstad University"}},"conditionsModule":{"conditions":["Inflammation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00063674","briefTitle":"Type 2 Diabetes Primary Prevention for At Risk Girls"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus","Prediabetic State"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nutrition Education"},{"name":"After-school dance class"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00316082","briefTitle":"Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Saxagliptin"},{"name":"Saxagliptin"},{"name":"Saxagliptin"},{"name":"Placebo"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01464437","briefTitle":"AMG 151 Amgen Protocol Number 20100761"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Amgen"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AMG 151"},{"name":"Placebo"},{"name":"Metformin"},{"name":"AMG 151"},{"name":"AMG 151"},{"name":"AMG 151"},{"name":"AMG 151"},{"name":"AMG 151"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03737240","briefTitle":"IDegLira HIGH Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IDegLira"},{"name":"Insulin Degludec (U-100)"},{"name":"Insulin Aspart"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03823664","briefTitle":"Cardiorespiratory Fitness in Prediabetic,Type 2 Diabetic and Healthy Individuals"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hacettepe University"}},"conditionsModule":{"conditions":["Prediabetic State","Diabetes Mellitus, Type 2","Cardiorespiratory Fitness","Inflammation","Exercise Test"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cardiorespiratory Fitness"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04340648","briefTitle":"Measurement Algorithm Control, Optimization, and Performance Evaluation of the Vital USA GlucoseDetect"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sciema UG"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vital GlucoseDetect"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00970294","briefTitle":"Pilot Project of Health Promotion for People With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Patricia Kluding, PhD"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Health Promotion Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00784433","briefTitle":"The CArdiovasCulAr Diabetes & Ethanol (CASCADE) Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ben-Gurion University of the Negev"}},"conditionsModule":{"conditions":["Diabetes","Prediabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"alcohol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03261362","briefTitle":"Impact of Branched-chain Amino Acids in the Development of Insulin Resistance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"German Diabetes Center"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Branched-chain amino acids reduced intake"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02106585","briefTitle":"Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Akros Pharma Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"JTT-251 or Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00217061","briefTitle":"Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Dyslipidemia","Hypercholesterolemia","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Decision Aid Statin Choice"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03748810","briefTitle":"Head-to-head Comparison of Empagliflozin and Dapagliflozin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chungbuk National University Hospital"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03796975","briefTitle":"Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Xijing Hospital"},"collaborators":[{"name":"Second Affiliated Hospital of Xi'an Jiaotong University"},{"name":"Shaanxi Aerospace Hospital"},{"name":"Genertec Universal Xi'an Aero-Engine hospital (Xi' an) Co., Ltd"},{"name":"Xi'an Gaoxin Hospital"},{"name":"Chang'An Hospital"},{"name":"Yan'an people's Hospital"},{"name":"Shangluo Central Hospital"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Non-alcoholic Fatty Liver Disease","Efficacy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Combination of Pioglitazone and Metformin Tablets"},{"name":"Metformin Hydrochloride Tablets"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00362518","briefTitle":"Vitamins C and Vitamin E and Cardiovascular Risk"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of New Mexico"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Study Arm A"},{"name":"Study Arm B"},{"name":"Study Arm C"},{"name":"Study Arm D"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02434315","briefTitle":"FreeStyle Libre Pro Use in Primary & Secondary Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Diabetes Care"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FreeStyle Libre Pro 4 sensor wears, 2 with reviews"},{"name":"FreeStyle Libre Pro 6 sensor wears, 4 with reviews"},{"name":"FreeStyle Libre Pro 3 sensor wears"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00264394","briefTitle":"Cardiovascular Risk Factor Management in HIV Infection"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Basel, Switzerland"},"collaborators":[{"name":"Swiss National Science Foundation"},{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Coronary Heart Disease","Dyslipidemia","Diabetes Mellitus, Non-Insulin-Dependent","HIV Infection"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Updated CHD risk profiles"},{"name":"Guidelines"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00491543","briefTitle":"Evaluation of ALT-2074 in Subjects With Type-2 Diabetes, Haptoglobin Type 2-2 Genotype and Coronary Artery Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Synvista Therapeutics, Inc"}},"conditionsModule":{"conditions":["Diabetes","Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ALT-2074"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01392677","briefTitle":"Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","High HbA1c Level","Inadequate Glycaemic Control"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"dapagliflozin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01617031","briefTitle":"Aspirin Twice Daily in Diabetic Patients With Coronary Artery Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hopital Lariboisière"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03459079","briefTitle":"Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Florida"},"collaborators":[{"name":"Inventiva Pharma"}]},"conditionsModule":{"conditions":["Nonalcoholic Fatty Liver Disease (NAFLD)","Type 2 Diabetes (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lanifibranor"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00676923","briefTitle":"Improving Diabetes After Bariatric Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pittsburgh"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Obesity","Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02540642","briefTitle":"Effect of Vitamin B12 Supplementation on Glycaemic Control in Uncontrolled Hyperhomocysteinemic Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Smt. Kashibai Navale Medical College and General Hospital"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Vitamin B12 Deficiency","Hyperhomocysteinemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"METHYLCOBALAMIN 500 micrograms"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02979860","briefTitle":"Experimental Changes in Children's Sleep Duration and Timing: Effect on Obesity and Type 2 Diabetes Risk"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Temple University"}},"conditionsModule":{"conditions":["Type2 Diabetes","Sleep"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sleep duration 90 min"},{"name":"Sleep duration 45 min"},{"name":"Sleep timing"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00395031","briefTitle":"Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Manhattan Psychiatric Center"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Schizophrenia","Schizoaffective Disorder"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ziprasidone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01863147","briefTitle":"Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Wuhan General Hospital of Guangzhou Military Command"}},"conditionsModule":{"conditions":["Newly Diagnosed Type 2 Diabetes","Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin and acarbose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03434860","briefTitle":"Effect of Probiotic on Insulin Resistance in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bogomolets National Medical University"}},"conditionsModule":{"conditions":["Type2 Diabetes","Insulin Resistance","Probiotic"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"probiotic"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01010100","briefTitle":"Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acarbose (Glucobay, BAYG5421)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01022645","briefTitle":"Postpartum Glucose Tolerance With Levonorgesterel IUD Use in Women With Recent Gestational Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Northwestern University"},"collaborators":[{"name":"Society of Family Planning"}]},"conditionsModule":{"conditions":["Gestational Diabetes","Glucose Intolerance","Type 2 Diabetes","Intrauterine Contraception"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mirena (Levonorgestrel IUD)"},{"name":"Paragard (Copper IUD ) or Tubal Ligation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00222781","briefTitle":"Multi-Tracer PET Quantitation of Skeletal Muscle Insulin Resistance in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pittsburgh"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes","Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05581043","briefTitle":"Pre-meals of 3-hydroxybutyrate in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"Steno Diabetes Center Aarhus, Aarhus University Hospital, Denmark"},{"name":"Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Denmark"}]},"conditionsModule":{"conditions":["Ketosis","Postprandial Hyperglycemia","Glucose Metabolism Disorders (Including Diabetes Mellitus)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"3-hydroxybutyrate (3-OHB)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02061969","briefTitle":"ADA Linagliptin in Long Term Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"linagliptin"},{"name":"insulin glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00575172","briefTitle":"Nippon Ultra-Rapid Insulin and Diabetic Complication Evaluation-Study (NICE-Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Osaka Saiseikai Nakatsu Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02910518","briefTitle":"A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Type1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin glulisine (U300)"},{"name":"Insulin glulisine"},{"name":"Insulin aspart"},{"name":"NPH insulin"},{"name":"Glucagon"},{"name":"Glucose"},{"name":"Heparin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03398590","briefTitle":"mHealth Intervention for Older Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boston College"},"collaborators":[{"name":"Joslin Diabetes Center"}]},"conditionsModule":{"conditions":["Type2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"self-regulation theory-based mHealth behavior intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01777893","briefTitle":"Effect of Diet and Physical Activity on Incidence of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Anne Birgitte Raben"},"collaborators":[{"name":"University of Helsinki"},{"name":"Maastricht University"},{"name":"University of Nottingham"},{"name":"University of Navarra"},{"name":"Clinical Center of Endocrinology, Medical University, Sofia, Bulgaria"},{"name":"University of Sydney"},{"name":"University of Auckland, New Zealand"},{"name":"University of Stuttgart"},{"name":"Swansea University"},{"name":"Cambridge Manufacturing Company Limited"},{"name":"European Union"},{"name":"Wageningen University"},{"name":"Meyers Madhus"},{"name":"NetUnion SARL"},{"name":"Terveyden Ja Hyvinvoinnin Laitos"},{"name":"Laval University"}]},"conditionsModule":{"conditions":["Pre-diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High protein/ high intensity physical activity (HP-HI)"},{"name":"High protein / moderate intensity physical activity (HP-MI)"},{"name":"Moderate protein/ high intensity physical activity (MP-HI)"},{"name":"Moderate protein/ moderate intensity physical activity (MP-MI)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00362960","briefTitle":"Olmesartan Medoxomil and Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sankyo Pharma Gmbh"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Diabetic Nephropathy","Proteinuria","Renal Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Olmesartan medoxomil"},{"name":"Losartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01107717","briefTitle":"Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"},"collaborators":[{"name":"American Diabetes Association"},{"name":"Amylin Pharmaceuticals, LLC."},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"metformin\\pioglitazone\\exenatide"},{"name":"metformin, glyburide and glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04779164","briefTitle":"The Relation Between Abdominal Obesity, Type 2 Diabetes Mellitus and Knee Osteoarthritis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eskisehir City Hospital"}},"conditionsModule":{"conditions":["Knee Osteoarthritis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"knee ultrasonography"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00065676","briefTitle":"Investigating the Use of Quercetin on Glucose Absorption in Obesity, and Obesity With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Obesity","Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Quercetin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01975935","briefTitle":"Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Non-alcoholic Fatty Liver Disease","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Amlexanox"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02011100","briefTitle":"Effect of Carnosine on Diabetes and Cardiovascular Risk Factors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jozef Ukropec"}},"conditionsModule":{"conditions":["Metabolic Diseases, Type 2 Diabetes, Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Carnosine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05719675","briefTitle":"Healthcare Intervention Program on Treatment Adherence in People With Newly Diagnosed Type 2 Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidad Nacional Autonoma de Mexico"}},"conditionsModule":{"conditions":["Treatment Adherence","Quality of Life","Glucose Metabolism Disorders (Including Diabetes Mellitus)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00200018","briefTitle":"Study of Weight Loss Using Gastric Stimulation in Obese Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"MedtronicNeuro"}},"conditionsModule":{"conditions":["Severe to Morbid Obesity and Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Enterra Therapy System (H9900014)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04117763","briefTitle":"Effect of Empagliflozin on Ventricular Repolarization."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Sao Paulo"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Coronary Heart Disease","Arrythmia, Cardiac"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin 25 MG"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06289933","briefTitle":"A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of \"BR3005\" and Co-administration of \"BR3005-1\" and \"BR3005-2\" Under Fed Conditions in Healthy Adult Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boryung Pharmaceutical Co., Ltd"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BR3005"},{"name":"BR3005-1"},{"name":"BR3005-2"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06061510","briefTitle":"Fish Oil-derived Omega-3 Fatty Acids on Gut Microbiota and Lipid Metabolome in Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Southeast University, China"},"collaborators":[{"name":"The First Affiliated Hospital with Nanjing Medical University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Lipid Metabolism Disorder","Fatty Acid Metabolism Disorder"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"omega-3 polyunsaturated fatty acids"},{"name":"corn oil"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05668325","briefTitle":"The Effect of Mini Trampoline Exercise Program on Diabetic Foot Care Behavior and Polyneuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Karadeniz Technical University"}},"conditionsModule":{"conditions":["Diabetic Polyneuropathy","Diabetic Foot","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mini trampoline exercise group"},{"name":"Control group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01786421","briefTitle":"Diurnal Triglyceridemia in Relation to Alcohol Intake"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sint Franciscus Gasthuis"}},"conditionsModule":{"conditions":["Healthy Subjects","Hyperlipidemias","Type 2 Diabetes Mellitus","Cardiovascular Diseases"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03964428","briefTitle":"Serum Ferritin and Hepicidin Concentration in Chronic Periodontitis Patients With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fayoum University"}},"conditionsModule":{"conditions":["Periodontitis","Type2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01655810","briefTitle":"Vitamin D, Cardiovascular Disease, and African Americans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Washington University School of Medicine"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Vitamin D Deficiency","Type 2 Diabetes Mellitus","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin D3"},{"name":"Vitamin D3"},{"name":"Calcium carbonate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00811889","briefTitle":"Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Reata, a wholly owned subsidiary of Biogen"}},"conditionsModule":{"conditions":["Chronic Kidney Disease","Type 2 Diabetes","Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Bardoxolone Methyl (RTA 402)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01947790","briefTitle":"Pioglitazone Regress Left Ventricular Mass in Type 2 Diabetes With Ischeamia Heart Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Xiang Guang-da"}},"conditionsModule":{"conditions":["LVM","Type 2 Diabetic Patients With IHD","Endothelial Function"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pioglitazone group"},{"name":"Metformin group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02656069","briefTitle":"Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Xeris Pharmaceuticals"}},"conditionsModule":{"conditions":["Hypoglycemia","Diabetes Mellitus, Type 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"G-Pen (glucagon injection)"},{"name":"Lilly Glucagon (glucagon injection [rDNA origin])"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03661684","briefTitle":"Effect of Short Course of Glucocorticoid in Patients With Diabetes Mellitus(DM) Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cook County Health"}},"conditionsModule":{"conditions":["Diabetes","Hyperglycemia Steroid-induced"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Prednisone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05407662","briefTitle":"A Study Using Surveys to Learn More About Treatment With Steroidal Mineralocorticoid Receptor Antagonists, How They Are Used, What Side Effects They Have, and How Satisfied People Who Receive Them Are in the US"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Chronic Kidney Disease","Type 2 Diabetes Mellitus","Heart Failure"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sMRA therapies"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01950806","briefTitle":"The Effect of Pecans on Biomarkers of Risk for Cardiovascular Disease and Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tufts University"},"collaborators":[{"name":"National Pecan Shellers Association"}]},"conditionsModule":{"conditions":["Cardiovascular Disease Risk","Type 2 Diabetes Risk"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pecan-containing diet"},{"name":"Nut-free diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03283657","briefTitle":"Diabetes Risk Education and Communication Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Northwestern University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["PreDiabetes","Diabetes Mellitus","Diabetes Mellitus, Type 2","Body Weight","Body Weight Changes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DiRECT"},{"name":"Usual care (UC)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04330911","briefTitle":"The Effects of Aerobic Exercises on Exercise Capacity in Type-2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emresenocak"}},"conditionsModule":{"conditions":["Type-2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aerobic Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01794143","briefTitle":"A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GRADE Study Group"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"National Heart, Lung, and Blood Institute (NHLBI)"},{"name":"Becton, Dickinson and Company"},{"name":"Bristol-Myers Squibb"},{"name":"Merck Sharp & Dohme LLC"},{"name":"Novo Nordisk A/S"},{"name":"Roche Diagnostics GmbH"},{"name":"Sanofi"},{"name":"Centers for Disease Control and Prevention"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Comparative Effectiveness of Glycemia-lowering Medications"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sulfonylurea (glimepiride)"},{"name":"DPP-4 inhibitor (sitagliptin)"},{"name":"GLP-1 receptor agonist (liraglutide)"},{"name":"Insulin (glargine)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02062047","briefTitle":"Full-mouth and Partial-mouth Scaling and Root Planing in Type 2 Diabetic Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Guarulhos"}},"conditionsModule":{"conditions":["Periodontitis","Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FMSRP"},{"name":"Chlorhexidine"},{"name":"PMSRP"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00468364","briefTitle":"Comparison of Insulin Glargine and NPH Insulin at Night and at Hypoglycemia in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Giessen"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"insulin glargine"},{"name":"NPH insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03704389","briefTitle":"Behavioral Economics Applications to Geriatrics Leveraging EHRs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Northwestern University"},"collaborators":[{"name":"University of California, Los Angeles"},{"name":"University of Southern California"}]},"conditionsModule":{"conditions":["Prostate Specific Antigen","Asymptomatic Bacteriuria","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Clinical decision support"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01031680","briefTitle":"Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Cardiovascular Disease","Hypertension","Inadequate Glycaemic Control"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01181882","briefTitle":"Fish Oil and Aspirin With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Rochester"},"collaborators":[{"name":"Cornell University"},{"name":"Albany College of Pharmacy and Health Sciences"}]},"conditionsModule":{"conditions":["Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fish Oil and Aspirin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03654313","briefTitle":"Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"MedImmune LLC"}},"conditionsModule":{"conditions":["Atherosclerosis","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MEDI6570"},{"name":"Placebo"},{"name":"Part B Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04927871","briefTitle":"Hybridized Three Steps Intervention to Prevent Diabetes in Venezuela"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Foundation for Public Health and Epidemiological Research of Venezuela"}},"conditionsModule":{"conditions":["Obesity","Overweight","PreDiabetes","Diabetes Mellitus, Type 2","Risk Factor, Cardiovascular"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Total Diet Replacement (TDR)"},{"name":"Medical Nutritional Therapy (MNT)"},{"name":"Diabetes Prevention Program 4 months"},{"name":"Diabetes Prevention Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05870358","briefTitle":"Melatonin Supports Non Surgical Periodontal Treatment in Patients With Type 2 Diabetes and Periodontitis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yağmur Saraç Gül"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Periodontitis","Melatonin","Matrix Metalloproteinases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Melatonin 3 MG"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02478190","briefTitle":"ED Management of Severe Hyperglycemia: A Clinical Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hennepin Healthcare Research Institute"}},"conditionsModule":{"conditions":["Hyperglycemia","Diabetes Mellitus","Complications of Diabetes Mellitus","Diabetes-Related Complications","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tight control: goal glucose 350 mg/dL or lower"},{"name":"Loose control: goal glucose 600 mg/dL or lower"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02058641","briefTitle":"Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Atherosclerosis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Darapladib"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01950676","briefTitle":"Feasibility of Using a Smart Phone Application for Self-titration of Insulin on Glycemic Control in Patients With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National University of Singapore"},"collaborators":[{"name":"Duke-NUS Graduate Medical School"},{"name":"Singapore General Hospital"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Smart phone application"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04617275","briefTitle":"A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-06882961"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05180604","briefTitle":"The Application and Evaluation of eHealth Literacy (eHL) Concept"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Yang Ming Chiao Tung University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Chronic Kidney Diseases","Cardiovascular Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"experience learning programs of eHealth care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03151343","briefTitle":"SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Caroline M Kistorp"},"collaborators":[{"name":"Danish Heart Foundation"},{"name":"Herlev and Gentofte Hospital"},{"name":"Rigshospitalet, Denmark"}]},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Placebo Oral Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05166525","briefTitle":"Kaiser Permanente Evaluation of Medically Tailored Meals in Adults With Medical Conditions at High Readmission Risk"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kaiser Permanente"}},"conditionsModule":{"conditions":["Heart Failure","Chronic Kidney Diseases","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Medically tailored meals"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03365349","briefTitle":"Two Narrative Medicine Interventions in Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Assistance Publique - Hôpitaux de Paris"}},"conditionsModule":{"conditions":["Type1diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"participating in a session of \"living theatre\""},{"name":"writing workshop"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02373059","briefTitle":"Shared Decision Making With Pharmaceutical Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Issue Cards Decision Aids"},{"name":"Usual Pharmaceutical Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05271695","briefTitle":"Effect of Dietary Inflammatory Index on Inflammatory Markers and Metabolic Parameters, in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Istanbul University"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Dietary Inflammatory Index (DII)","Inflammation","Medical Nutrition Therapy"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02551640","briefTitle":"Improving Physical Activity Through a mHealth Intervention in Cardio-metabolic Risk Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Massachusetts General Hospital"},"collaborators":[{"name":"Samsung Electronics"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Prediabetic State","Hypertension","Prehypertension","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"FeatForward App (on study smartphone)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03583593","briefTitle":"Evaluation of DIAMEL® Combined With Insulin in Diabetic Foot Ulcer"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Catalysis SL"}},"conditionsModule":{"conditions":["Diabetic Foot Ulcer","Diabetic Foot","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DIAMEL"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03249610","briefTitle":"Randomized Control Trial for Overweight Employees in Worksites"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diabetes Foundation, India"},"collaborators":[{"name":"Sprim Advanced Life Sciences"},{"name":"Abbott"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Metabolic Syndrome","Lifestyle Risk Reduction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00947726","briefTitle":"Ceramide Containing Multivesicular Emulsion Application . . ."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Foot Transepidermal Water Loss in Patients in NIDDM","Foot Dryness in Patients With NIDDM"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CeraVe"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04440319","briefTitle":"Diabetes Nutrition Education With Glycemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Andalas University"},"collaborators":[{"name":"Universiti Putra Malaysia"}]},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intervention group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02288585","briefTitle":"The Effect of Plant Sterols on the Blood Lipid Profile of Subjects With and at High Risk of Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Unilever R&D"},"collaborators":[{"name":"Commonwealth Scientific and Industrial Research Organisation, Australia"}]},"conditionsModule":{"conditions":["Vascular Diseases","Hypercholesterolemia","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Plant sterols"},{"name":"Placebo product"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03449199","briefTitle":"Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Teijin America, Inc."}},"conditionsModule":{"conditions":["Diabetic Kidney Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TMX-049"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03334643","briefTitle":"Fiber Mix and Glycemic Response"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rutgers, The State University of New Jersey"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fiber mix"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04891627","briefTitle":"Gingival Crevicular IL-34 and CSF-1 Levels in Patients With Periodontitis and Uncontrolled Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Uşak University"}},"conditionsModule":{"conditions":["Periodontitis","Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gingival crevicular fluid"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03047278","briefTitle":"Transporters for Organic Cations and Glycemic Control in Patients With Neuropathic Pain."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Natalia Valadares de Moraes"},"collaborators":[{"name":"University of Sao Paulo"}]},"conditionsModule":{"conditions":["Neuropathic Pain","Type 2 Diabetes Mellitus","Diabetic Neuropathy, Painful"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Serial Blood Samples"},{"name":"Serial Urine Samples"},{"name":"Gabapentin 300 mg"},{"name":"Cetirizine Hydrochloride 10 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01208701","briefTitle":"The Effects of Atorvastatin on the Nitrogen Oxide-system in Patients With Type 2 Diabetes and Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Erling Bjerregaard Pedersen"}},"conditionsModule":{"conditions":["Nephropathy","Cardiovascular Diseases","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Atorvastatin"},{"name":"Unikalk"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01895387","briefTitle":"Dietary Effects on Circulating Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity and Enzyme Activity in Peripheral Blood Mononuclear Cells (PBMCs) in Patients With Prediabetes or Newly Diagnosed Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yonsei University"}},"conditionsModule":{"conditions":["Impaired Fasting Glucose","Newly Diagnosed Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dietary intervention-whole grains and legumes"},{"name":"Dietary intervention-Refined rice"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00535925","briefTitle":"Nephropathy In Type 2 Diabetes and Cardio-renal Events"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Campania \"Luigi Vanvitelli\""}},"conditionsModule":{"conditions":["Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SoC therapy"},{"name":"irbesartan"},{"name":"ramipril"},{"name":"hydrochlorothiazide"},{"name":"furosemide"},{"name":"amlodipine"},{"name":"atenolol"},{"name":"doxazosin"},{"name":"clonidine"},{"name":"insulin"},{"name":"simvastatin"},{"name":"fibrate"},{"name":"erythropoietin"},{"name":"aspirin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01702311","briefTitle":"Point-of-Care Glucose Testing and Insulin Supplementation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bedtime insulin Aspart (Novolog)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00355537","briefTitle":"Testosterone Replacement in Diabetes With Vascular Disease (Version 2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Barnsley Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Peripheral Vascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Testosterone"},{"name":"0.9% saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02153190","briefTitle":"Hybrid Artificial Pancreas in Home Setting"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Montpellier"}},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus","Treatement by Insulin Pump"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HYBRID"},{"name":"OPEN"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03366337","briefTitle":"A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Reata, a wholly owned subsidiary of Biogen"}},"conditionsModule":{"conditions":["IgA Nephropathy","CKD Associated With Type 1 Diabetes","Focal Segmental Glomerulosclerosis","Autosomal Dominant Polycystic Kidney"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bardoxolone methyl capsules"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01294436","briefTitle":"Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Type2 Diabetes","High Blood Sugar"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06376305","briefTitle":"EndoBarrier in Obstructive Sleep Apnoea Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dr Bob Ryder"},"collaborators":[{"name":"Association of British Clinical Diabetologists"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Obstructive Sleep Apnoea","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EndoBarrier"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00610038","briefTitle":"Efficacy and Safety Study of Sulfonylureas in Neonatal Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Assistance Publique - Hôpitaux de Paris"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"glibenclamide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00606112","briefTitle":"A Single Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Genaera Corporation"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Trodusquemine (MSI-1436)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04810676","briefTitle":"A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CKD-501, D745, D150"},{"name":"CKD-383"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04090840","briefTitle":"Lifestyle Intervention Feasibility for Arrhythmia and Symptoms With Intermittent Fasting (LIFE AS IF)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Chicago"}},"conditionsModule":{"conditions":["Obesity","Morbid Obesity","Diabetes Mellitus, Type 2","Atrial Fibrillation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intermittent Fasting"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00327015","briefTitle":"A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Saxagliptin"},{"name":"Metformin"},{"name":"Placebo"},{"name":"pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01026688","briefTitle":"Evaluation of a Toolkit to Improve Cardiovascular Disease Screening and Treatment for People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sunnybrook Health Sciences Centre"},"collaborators":[{"name":"Institute for Clinical Evaluative Sciences"},{"name":"Unity Health Toronto"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Toolkit"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04336800","briefTitle":"Multi-Parametric MRI Assessment of the Liver in Diabetic Volunteers (Partners Registry)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Perspectum"}},"conditionsModule":{"conditions":["Non-Alcoholic Fatty Liver Disease","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LiverMultiscan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02137070","briefTitle":"The WISE (Weightloss Intervention Surgical Effects) Brain Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Florida"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Diabetes","Weightloss"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bariatric Surgery Candidates"},{"name":"Non surgical/Community volunteers"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04791787","briefTitle":"Effect of Ketogenic Diet on Glucose Metabolism and Energy Expenditure in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"}},"conditionsModule":{"conditions":["Glucose Metabolism Disorders (Including Diabetes Mellitus)","Energy Supply; Deficiency","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Standard weight maintaining diet"},{"name":"Weight maintaining isocaloric ketogenic diet"},{"name":"Beta-hydroxy butyrate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00824603","briefTitle":"Impact of Continuing Medical Education (CME) Insulin Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HealthPartners Institute"},"collaborators":[{"name":"International Diabetes Center at Park Nicollet"},{"name":"Eli Lilly and Company"},{"name":"Novo Nordisk A/S"},{"name":"United Health Care"},{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04025762","briefTitle":"24/7 Closed-loop in Older Subjects With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Cambridge"},"collaborators":[{"name":"Manchester University NHS Foundation Trust"},{"name":"University Hospital Birmingham NHS Foundation Trust"},{"name":"Medical University of Graz"}]},"conditionsModule":{"conditions":["Type 1 Diabetes Mellitus","Hypoglycemia","Arrythmia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hybrid closed-loop system (CamAPS FX)"},{"name":"Sensor augmented pump therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03624803","briefTitle":"DAPA - Egypt Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Type-2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02848547","briefTitle":"Post Trial Analysis of a Primary Prevention Study in Asian Indians"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Text Messaging via Short Message Service"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03222245","briefTitle":"The Effect of Injectable Therapies on Quality of Life in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Portsmouth Hospitals NHS Trust"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02621489","briefTitle":"Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Karolinska Institutet"}},"conditionsModule":{"conditions":["Atherosclerosis","Diabetes","Restenosis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bydureon"},{"name":"Humulin kwickpen"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03001336","briefTitle":"Thyroid Function and Diabetes Complications"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nanjing First Hospital, Nanjing Medical University"}},"conditionsModule":{"conditions":["Diabetes","Thyroid Disease"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"no intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05069727","briefTitle":"Simple Initiation of Advanced Hybrid Closed Loop System"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sidra Medicine"}},"conditionsModule":{"conditions":["Diabetes type1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Regular Protocol with advanced carbohydrate counting"},{"name":"Simplified Protocol with fixed carbohydrate content"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01152372","briefTitle":"Experimental Study to Validate the Modified Glucose Disposal Test"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristol-Myers Squibb"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin, glucose and staple isotopes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04016584","briefTitle":"Diabetes Pueblo Program - Application and Acceptability of Culturally Appropriate Latino Education for Insulin Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sansum Diabetes Research Institute"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Pueblo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03182712","briefTitle":"n-3 Fatty Acid Effects in T2DM After Acute High Intensity Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Federal University of Rio Grande do Sul"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"n-3 PUFA Group"},{"name":"Placebo Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00771004","briefTitle":"Efficacy of Pioglitazone on Myocardial Function in Patients Undergoing Coronary Stent Implantation."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Oxidative Stress","Coronary Artery Disease","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05770076","briefTitle":"Probiotic Lysate (Postbiotic and Metabiotic) Supplementation for Type 2 Diabetes Patients (DELI_Diab Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bogomolets National Medical University"},"collaborators":[{"name":"Taras Shevchenko National University of Kyiv"},{"name":"Danylo Halytsky Lviv National Medical University"},{"name":"Center for Innovative Medical Technologies of the National Academy of Sciences of Ukraine"},{"name":"Kyiv City Clinical Endocrinology Center"},{"name":"MirImmunoFarm"},{"name":"Stellar Biotics"}]},"conditionsModule":{"conditions":["Obesity","Obesity, Abdominal","Insulin Resistance","Insulin Sensitivity","Type2 Diabetes","Type 2 Diabetes Mellitus in Obese"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Probiotic lysate (postbiotic and metabiotic)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04473430","briefTitle":"Study to Determine the Efficacy of Real-time CGM in Preventing Hypoglycemia Among Insulin-treated Patients With DM2 on Hemodialysis, Compared to Standard of Care (POC BG)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["End-Stage Renal Disease","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dexcom real-time G6 Continuous Glucose Monitoring System (CGM)"},{"name":"POC BG"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03105011","briefTitle":"Utilizing Off-the-shelf Technology to Improve Diabetes Management in a Rural Population"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Missouri-Columbia"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EpxDiabetes software"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05765292","briefTitle":"Probiotic Supplementation and Pancreatic β-Cell Function in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bogomolets National Medical University"},"collaborators":[{"name":"Taras Shevchenko National University of Kyiv"},{"name":"Danylo Halytsky Lviv National Medical University"},{"name":"Kyiv City Clinical Endocrinology Center"}]},"conditionsModule":{"conditions":["Type2 Diabetes","Obesity","Insulin Resistance","Obesity, Abdominal"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Probiotic"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00225264","briefTitle":"Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05781334","briefTitle":"Optimizing In-hospital Use of Evidence-based Therapies for Patients With Cardio-Renal-Metabolic Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Duke University"},"collaborators":[{"name":"Boehringer Ingelheim"}]},"conditionsModule":{"conditions":["Heart Failure","Type 2 Diabetes","Chronic Kidney Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Virtual Consult Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02298803","briefTitle":"QT Interval Abnormalities in Sulfonylurea Treated Type 2 Diabetes: Relationship to Treatment Induced Hypoglycaemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Royal Prince Alfred Hospital, Sydney, Australia"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Diabetes Related Complications"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Holter and Glucose monitoring"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05928637","briefTitle":"A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of D745, D759, and D150"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Diabetes type2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"D745, D759, D150"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02451722","briefTitle":"Evaluation of Pressure Distribution of Kyboot Shoes in Comparison to Other Foot Wear"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sheba Medical Center"},"collaborators":[{"name":"Kybun AG"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Sensory Neuropathy","Foot Ulcer, Diabetic"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Kyboot shoes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01301456","briefTitle":"Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 2","Glucose Metabolism Disorders","Metabolic Diseases","Endocrine System Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"PF-04856883"},{"name":"PF-04856883"},{"name":"PF-04856883"},{"name":"Placebo"},{"name":"PF-04856883"},{"name":"PF-04856883"},{"name":"PF-04856883"},{"name":"Placebo"},{"name":"PF-04856883"},{"name":"PF-04856883"},{"name":"PF-04856883"},{"name":"PF-04856883"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04907110","briefTitle":"NR Supplementation and Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"}},"conditionsModule":{"conditions":["Overweight and Obesity","Aging","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Niagen"},{"name":"Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00489879","briefTitle":"Management of Patients With Type 2 Diabetes and Hypertension Using Mobile Health Care System"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Korea University"}},"conditionsModule":{"conditions":["Diabetes","Hypertension","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mobile Health Care System (DrUB)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04511325","briefTitle":"Effects of White Potato Consumption on Measures of Cardiometabolic Health in Individuals With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Florida State University"},"collaborators":[{"name":"Alliance for Potato Research and Education"}]},"conditionsModule":{"conditions":["Type2 Diabetes","Cardiometabolic Syndrome","Arterial Stiffness","Overweight and Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Potato Regimen"},{"name":"Refined Grain Regimen"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01374594","briefTitle":"Importance of Meal Fat Content and Gall Bladder Emptying for Postprandial GLP-1 Secretion in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05628597","briefTitle":"Effects of Fos Biomedical Device on Diabetes Risk Factors and Sleep Quality in Adults at Risk for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Griffin Hospital"},"collaborators":[{"name":"Fos Biomedical"}]},"conditionsModule":{"conditions":["Pre Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fos Biomedical patch product"},{"name":"Fos Biomedical patch product:placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00816608","briefTitle":"The Effect of Maximum Body Weight in Lifetime on the Development of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Bundang Hospital"}},"conditionsModule":{"conditions":["Diabetes","Prediabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05259735","briefTitle":"A Clinical Guideline-based Management of Type-2 Diabetes by Ayurvedic Practitioners in Nepal"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nepal Health Research Council"},"collaborators":[{"name":"University of Nottingham"}]},"conditionsModule":{"conditions":["Diabetes","Type2Diabetes","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Clinical Guideline based Management"},{"name":"Comparator"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00522158","briefTitle":"Effects of Achieving Very Low LDL-Cholesterol After Treatment With Statins on Steroidogenesis and Cognition"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baskent University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Cardiovascular Disease","LDL Cholesterol","Cognition"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"simvastatin"},{"name":"atorvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01027585","briefTitle":"The Effects of Cinnamon on Postprandial Blood Glucose, and Insulin in Subjects With Impaired Glucose Tolerance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Skane University Hospital"},"collaborators":[{"name":"Lund University"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00172536","briefTitle":"Effects of Exercise Training on Left Ventricular Function in Type 2 Diabetic Patients Post Coronary Artery Bypass Graft"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Taiwan University Hospital"},"collaborators":[{"name":"National Science Council, Taiwan"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-Insulin-Dependent","Coronary Arteriosclerosis","Post Coronary Artery Bypass Grafting"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise training"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05902546","briefTitle":"Effect of HIIT Vs Moderate Intensity Aerobic Exercise on Insulin Resistance in Type 2 DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Badr University"},"collaborators":[{"name":"Ahmed Maher Teaching Hospital"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High intensity interval training"},{"name":"moderate intensity aerobic exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00925717","briefTitle":"of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol)."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Low Density Lipoprotein Cholesterol Goal Achievement"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03475069","briefTitle":"Which Exercises Should Diabetic Patients do?"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Biruni University"},"collaborators":[{"name":"Hacettepe University"}]},"conditionsModule":{"conditions":["Type2 Diabetes","Physical Activity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Custom Designed Exercises"},{"name":"Plates Exercises"},{"name":"Calisthenics Exercises"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04653805","briefTitle":"Therapeutic Approach of Cardiovascular Risk Factors in T2DM by Gender"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Cardiovascular Risk Factor","Gender"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Current clinical practice in primary care of patients with type 2 diabetes mellitus"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02500628","briefTitle":"Heart Rate Variability in Response to Metformin Challenge"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Woodinville Psychiatric Associates"}},"conditionsModule":{"conditions":["Fibromyalgia","Mitochondrial Diseases","Movement Disorders","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01892124","briefTitle":"Motivational Interviewing and Cognitive Behavioral Therapy-based Intervention for Cardiovascular Disease Prevention Amongst American Indians With Diabetic and Depressive Symptoms"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Washington"},"collaborators":[{"name":"National Institute on Minority Health and Health Disparities (NIMHD)"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Diabetes Mellitus, Type 2","Depression","Dysthymic Disorder"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Motivational Interviewing/Cognitive Behavioral-based Therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02983214","briefTitle":"Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Ioannina"},"collaborators":[{"name":"LIBYTEC Pharmaceutical S.A."}]},"conditionsModule":{"conditions":["Ischemic Stroke","Peripheral Artery Disease","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Clopidogrel"},{"name":"Cilostazol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01053234","briefTitle":"Different Insulin Regimens and Postprandial Coagulation Activation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Esbjerg Hospital - University Hospital of Southern Denmark"},"collaborators":[{"name":"Ribe County Hospital"},{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Cardiovascular Risk","Hemostasis","Inflammation","Endothelial Function"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Standardised meals"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04473209","briefTitle":"Serum Resistin Level Following Non-surgical Periodontal Therapy in Diabetic Patients With Chronic Periodontitis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cairo University"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"non-surgical periodontal therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02513875","briefTitle":"Prevention of Type 2 Diabetes With Vitamin D"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diabetes Foundation, India"},"collaborators":[{"name":"Ministry of Science and Technology, India"}]},"conditionsModule":{"conditions":["Prediabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vitamin D"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05695170","briefTitle":"Couple-Based Lifestyle Intervention to Prevent Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Utah"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["PreDiabetes","Prediabetic State","Overweight and Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PreventT2 (Individual intervention)"},{"name":"PreventT2 Together (Couple-based intervention)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03033407","briefTitle":"A Study to Evaluate the Efficacy of Diabetes Management Based on Ubiquitous Healthcare System"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kangbuk Samsung Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tailored mobile coaching messages"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02622672","briefTitle":"Water-soluble Ubiquinol Supplementation on Blood Glucose, Lipids, Oxidative Stress, and Inflammation in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yeh"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"water-soluble ubiquinol"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03714594","briefTitle":"Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pisa"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin 10mg"},{"name":"Saxagliptin 5mg"},{"name":"Saxagliptin 5mg + Dapagliflozin 10 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05526131","briefTitle":"BDNF Level and val66met Polymorphism of Brain Derived Neurotropic Factor Gene in Patients With T2DM and Depression"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kasr El Aini Hospital"}},"conditionsModule":{"conditions":["Depression","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Questionare"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03670043","briefTitle":"Tolerance & Responsiveness Improvement for Metformin (TRIM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"West Side Institute for Science and Education"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Psyllium powder"},{"name":"Metformin Extended Release Oral Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04782999","briefTitle":"Effect of RYGB on Alpha- and Beta Cell Function and Sensitivity to Incretins in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hvidovre University Hospital"},"collaborators":[{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Type2 Diabetes","Obesity, Morbid"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral Glucose Tolerance Test"},{"name":"Hyperglycemic clamp with infusion of saline, GLP-1 or GIP"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02814838","briefTitle":"A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dompé Farmaceutici S.p.A"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Insulin-Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ladarixin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01348867","briefTitle":"Effectiveness of a Treat-to-target Clinic Led by a Nurse Consultants"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Asia Diabetes Foundation"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Structured care led by a nurse consultant"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03557658","briefTitle":"Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Theracos"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bexagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00316667","briefTitle":"Health2006 - an Observational Study of Cardiovascular Disease, Diabetes, Asthma and Allergy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Glostrup University Hospital, Copenhagen"},"collaborators":[{"name":"Steno Diabetes Center Copenhagen"}]},"conditionsModule":{"conditions":["Cardiovascular Disease","Type 2 Diabetes","Asthma","Hypersensitivity","Osteoporosis"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04170998","briefTitle":"Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dong-A ST Co., Ltd."}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Evogliptin 5mg"},{"name":"Evogliptin Placebo"},{"name":"Dapagliflozin 10mg"},{"name":"Metformin ≥ 1000mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02589028","briefTitle":"The Effects of Premeal Consumption of Protein-enriched Bar on Blood Glucose Level and Secretion of Hormones"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"premeal protein-enriched bar intake"},{"name":"breakfast follows by protein bar"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00699686","briefTitle":"Endothelial Effects of Basal Insulin: Detemir Versus Glargine"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Padova"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Endothelial Dysfunction","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glargine"},{"name":"Detemir"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00021918","briefTitle":"Serum Total Homocysteine and C-Reactive Protein - Ancillary to IDNT"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}},"conditionsModule":{"conditions":["Cardiovascular Diseases","Atherosclerosis","Heart Diseases","Diabetes Mellitus, Non-insulin Dependent","Hypertension","Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00005462","briefTitle":"Genetics of Atherosclerosis in Mexican Americans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}},"conditionsModule":{"conditions":["Cardiovascular Diseases","Coronary Disease","Obesity","Atherosclerosis","Diabetes Mellitus, Non-insulin Dependent","Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05326958","briefTitle":"Repeatability of Static & Dynamic Composite Confocal Microscopy for Assessment of the Corneal Nerve Fiber Plexus in Early Diabetic Polyneuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Heidelberg Engineering GmbH"}},"conditionsModule":{"conditions":["Normal Eyes of Subjects Without Diabetes Mellitus","Subjects With Diabetes Mellitus Type 2 Without Coexisting DPN","Subjects With Diabetes Mellitus Type 2 With Coexisting Early to Moderate DPN"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HRT RCM"},{"name":"HRT RCM-E"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02505451","briefTitle":"Myocardial Regional Function by Dobutamine Stress Echocardiography in the Metabolic Syndrome and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Avignon"}},"conditionsModule":{"conditions":["Diabetes-related Complications"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"dobutamine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02466880","briefTitle":"Intervention for Diabetes With Education, Advancement and Support"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Monash University"},"collaborators":[{"name":"MOSTI Malaysia"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Telemedicine"},{"name":"Usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02807974","briefTitle":"Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo Co., Ltd."}},"conditionsModule":{"conditions":["Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CS-3150"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00875108","briefTitle":"An Open Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin VIAject™ in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Biodel"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"VIAject™"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03881540","briefTitle":"Efficacy of tDNA Care on Weight Loss and Metabolic Outcomes in Patients With Overweight, Obesity and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"International Medical University"}},"conditionsModule":{"conditions":["Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"tDNA-MI group"},{"name":"tDNA-CC group"},{"name":"UC group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04438018","briefTitle":"Towards a Better Understanding of Diabetes Distress, Depression and Poor Glycaemic Control in T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Norbert Hermanns"},"collaborators":[{"name":"German Center for Diabetes Research"},{"name":"University of Giessen"},{"name":"Helmholtz Zentrum München"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Depressive Symptoms","Stress, Psychological","Glucose, High Blood"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03104738","briefTitle":"Basal Insulin Strategies Before Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ohio State University"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"25% reduction of basal insulin dose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00085800","briefTitle":"Dietary Fiber and Cardiovascular Inflammatory Markers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of South Carolina"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Heart Diseases","Diabetes Mellitus, Non-insulin Dependent","Hypertension","Obesity","Inflammation"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02544347","briefTitle":"Gingival Crevicular Fluid Vaspin and Omentin Levels in Type 2 Diabetic Patients With Chronic Periodontitis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bulent Ecevit University"}},"conditionsModule":{"conditions":["Chronic Periodontitis","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"gingival crevicular fluid"},{"name":"non-surgical periodontal treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03072407","briefTitle":"MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"PegBio Co., Ltd."}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PB-119 injection"},{"name":"PB-119 injection placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03062774","briefTitle":"Continuous Multiple Dose PB-119 Injection in Health Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"PegBio Co., Ltd."}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PB-119 injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02956044","briefTitle":"Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Theracos"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bexagliflozin"},{"name":"Metformin"},{"name":"Glimepiride"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02285205","briefTitle":"A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yonsei University"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Non-alcoholic Fatty Liver Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral administration of Lobeglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00482976","briefTitle":"Effect of LY333531 on Vascular and Neural Functions"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chromaderm, Inc."},"collaborators":[{"name":"Joslin Diabetes Center"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ruboxistaurin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06501456","briefTitle":"Evaluation of the Relationship Between Missed Appointments and Adherence to Medical Indications"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital Italiano de Buenos Aires"}},"conditionsModule":{"conditions":["No-Show Patients","Therapeutic Adherence and Compliance","Type 2 Diabetes Mellitus","COVID-19"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03544411","briefTitle":"Effects of Olive Oil and Bran Oil on Antioxidant Levels, Glycemic Control, and Lipid Profile in Patient Type 2 DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Indonesia University"},"collaborators":[{"name":"Fakultas Kedokteran Universitas Indonesia"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Oxidative Stress","Glucose, High Blood","Lipid Disorder"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"olive oil"},{"name":"bran oil"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04698486","briefTitle":"Hepatic and Cardiac Metabolic Flexibility in Subjects With T2DM With and Without NAFLD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"Danish Diabetes Academy"}]},"conditionsModule":{"conditions":["NAFLD - Non-Alcoholic Fatty Liver Disease","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hyperinsulinemic euglycaemic clamp"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00046501","briefTitle":"Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lantus (insulin glargine [rDNA origin] injection)"},{"name":"Humulin N"},{"name":"Humulin L"},{"name":"Lispro"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04356898","briefTitle":"Ramadan Flash Glucose Monitoring Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Imperial College London Diabetes Centre"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04990427","briefTitle":"CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lisata Therapeutics, Inc."}},"conditionsModule":{"conditions":["Chronic Kidney Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CLBS201"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04572802","briefTitle":"Changes of Serum Orphanin FQ in Patients With Coronary Heart Disease in Different Courses of Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Second Hospital of Shanxi Medical University"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Coronary angiography"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00658463","briefTitle":"Effects of Rosuvastatin on the, in Vivo, Kinetic of apoB and apoA1, Using Stable Isotopes, in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire Dijon"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosuvastatin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03590158","briefTitle":"Time RestrIcted Feeding For Improving Diabetes Risk (TRIFFID)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Adelaide"},"collaborators":[{"name":"University of South Australia"},{"name":"Salk Institute for Biological Studies"}]},"conditionsModule":{"conditions":["Type2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TRF"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00729040","briefTitle":"Enhancing Adherence by Building Online Communities"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Robert Wood Johnson Foundation"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Coronary Artery Disease","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Stepping Up to Health"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00642434","briefTitle":"Comparison of Blood Pressure Medications on Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of New Mexico"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"carvedilol"},{"name":"metoprolol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03696810","briefTitle":"Characterization of Retinal Vascular Disease in Eyes With Mild to Moderate NPDR in Diabetes Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Association for Innovation and Biomedical Research on Light and Image"},"collaborators":[{"name":"Fundação para a Ciência e a Tecnologia"}]},"conditionsModule":{"conditions":["NPDR - Non Proliferative Diabetic Retinopathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Laboratory tests"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00550095","briefTitle":"To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Microalbuminuria","Proteinuria"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"valsartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05071950","briefTitle":"The Effect of D-allulose on the Glycemic Changes in Patients With Type 2 Diabetes Mellitus During Ramadan Fasting"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universiti Putra Malaysia"},"collaborators":[{"name":"Matsutani Chemical Industry Co., Ltd."},{"name":"Kagawa University"}]},"conditionsModule":{"conditions":["Glucose, High Blood"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Control period"},{"name":"D-allulose period"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02565706","briefTitle":"Online WIC Nutrition Education to Promote Farmers' Market Fruit and Vegetable Purchases and Consumption"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"William Paterson University of New Jersey"},"collaborators":[{"name":"USDA Food and Nutrition Service"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Cancer","Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"WIC Fresh Start Program"},{"name":"Existing Online Health Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04786340","briefTitle":"A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"WinSanTor, Inc"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"Eastern Virginia Medical School"}]},"conditionsModule":{"conditions":["Painful Diabetic Neuropathy","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution"},{"name":"Placebo: WST-057 4mL topical solution"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02053077","briefTitle":"Risk Identification of the GlucoTab System in Routine Use"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Graz"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03500016","briefTitle":"Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Odense University Hospital"},"collaborators":[{"name":"Department of Sports Science and Clinical Biomechanics, University of Southern Denmark"}]},"conditionsModule":{"conditions":["Type2 Diabetes","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High intensity interval training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04786054","briefTitle":"Genetic Association of Glucocorticoid Receptor Gene Polymorphisms With Binge Eating"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Corporacion Parc Tauli"}},"conditionsModule":{"conditions":["Binge-Eating Disorder","Eating Disorders","Obesity","Diabetes Type 2","Adolescent Behavior"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BED Questionnaire"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00829296","briefTitle":"Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Chicago"},"collaborators":[{"name":"Forest Laboratories"}]},"conditionsModule":{"conditions":["Hypertension","Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"nebivolol"},{"name":"Metoprolol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00506961","briefTitle":"Evaluate the Efficacy and Safety of Rosuvastatin Versus Simvastatin in Type 2 Diabetic Patients With Dyslipidemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Taipei Veterans General Hospital, Taiwan"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosuvastatin"},{"name":"Simvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00969566","briefTitle":"Predictive Parameters for Efficacy of Sitagliptin and Metformin Combination"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Bundang Hospital"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin, metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02330549","briefTitle":"ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tobira Therapeutics, Inc."}},"conditionsModule":{"conditions":["Prediabetic State","Non-alcoholic Fatty Liver Disease","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cenicriviroc 150 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03305939","briefTitle":"Lifestyle Intervention IN Gestational Diabetes (LIVING)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The George Institute"},"collaborators":[{"name":"National Health and Medical Research Council, Australia"},{"name":"All India Institute of Medical Sciences, New Delhi"}]},"conditionsModule":{"conditions":["Gestational Diabetes Mellitus in Pregnancy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Life style Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04824586","briefTitle":"Intraoperative Insulin Administration at Cardiac Surgery for Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Hashemite University"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Cardiac Event"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fast-acting human insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02134860","briefTitle":"Bed Rest, Alternate Daily Fasting and Incretin Effect"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rigshospitalet, Denmark"}},"conditionsModule":{"conditions":["Metabolic Syndrome","Type 2 Diabetes","Critical Illness"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bed rest"},{"name":"OGTT"},{"name":"IVGTT"},{"name":"Cognitive testing"},{"name":"Muscle and fat biopsies"},{"name":"Dual-energy X-ray Absorptiometry (DXA) scan"},{"name":"MRI"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01991093","briefTitle":"Multiple Electrode Aggregometry & Clopidogrel Resistance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Elpen Pharmaceutical Co. Inc."}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus (T2DM)","Coronary Artery Disease (CAD)","Myocardial Infraction"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02024399","briefTitle":"Cardiovascular Risk Factors, Body Composition, Fitness Levels And Quality Of Life In Overweight And Obese 8-17 Year Olds"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Stony Brook University"}},"conditionsModule":{"conditions":["Childhood Obesity","Type 2 Diabetes","Hypercholesterolemia","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05236335","briefTitle":"Modulation of Circulating Levels of the Ketone Body 3-hydroxybutyrate in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction: Cardiovascular Effects."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"}},"conditionsModule":{"conditions":["Heart Failure With Preserved Ejection Fraction","Diabetes Mellitus, Type 2","Ketonemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ketone ester"},{"name":"Placebo drink"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02817152","briefTitle":"Low-level Laser Therapy in the Treatment of Chronic Periodontitis in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidade Estadual Paulista Júlio de Mesquita Filho"},"collaborators":[{"name":"Coordenação de Aperfeiçoamento de Pessoal de Nível Superior."}]},"conditionsModule":{"conditions":["Chronic Periodontitis","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Periodontal ultrasonic debridement"},{"name":"Debridement plus low-level laser therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01867970","briefTitle":"Interactive Tool to Support Self-management Through Lifestyle Feedback, Aimed at Physical Activity of COPD/DM Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"},"collaborators":[{"name":"ZonMw: The Netherlands Organisation for Health Research and Development"}]},"conditionsModule":{"conditions":["Chronic Obstructive Pulmonary Disease","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tool"},{"name":"Self-management Support Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03120871","briefTitle":"Microbiome Insulin Sensitivity Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Denver"},"collaborators":[{"name":"National Institutes of Health (NIH)"},{"name":"Children's Hospital Colorado"}]},"conditionsModule":{"conditions":["Obesity","Insulin Resistance","Type2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00703417","briefTitle":"Does Bone Structure Explain the Increased Fracture Risk in Type II Diabetes Patients? A Pilot Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Francisco"}},"conditionsModule":{"conditions":["Osteoporosis"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"magnetic Resonance Imaging"},{"name":"Computed Tomography"},{"name":"High resolution peripheral quantitative computed tomography"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05747872","briefTitle":"Effectiveness of Buerger Allen Exercise Among Type 2 Diabetes Mellitus Patients With Foot Ulcer"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gazi University"}},"conditionsModule":{"conditions":["Diabetic Foot Ulcers"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Buerger Allen Exercises"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01754792","briefTitle":"Effects of Pinitol on Hidrocarbonated Metabolism Parameters in Diabetic, Impaired and Normal Fasting Glucose Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Valencia"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Impaired Glucose Tolerance","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pinitol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00815178","briefTitle":"Effects of Inspiratory Muscle Training on Type 2 Diabetes Mellitus Patients With Inspiratory Muscle Weakness"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital de Clinicas de Porto Alegre"},"collaborators":[{"name":"Coordenação de Aperfeiçoamento de Pessoal de Nível Superior."}]},"conditionsModule":{"conditions":["Diabetes Complications","Inspiratory Muscle Weakness"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Inspiratory muscle training"},{"name":"Inpiratory muscle training placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03527641","briefTitle":"United for Health: Type 2 Diabetes Prevention in Latino Teens"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Colorado State University"}},"conditionsModule":{"conditions":["Prediabetic State","Insulin Resistance","Type2 Diabetes","Stress","Adolescent Development","Family Research"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CookingMatters"},{"name":"Parent Education"},{"name":"Physical Activity"},{"name":"Health Education"},{"name":"Mindfulness-based Stress Reduction"},{"name":"Brief Mindfulness Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01705210","briefTitle":"Functional MRI Biomarkers of Cognitive Decrements in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"},"collaborators":[{"name":"ZonMw: The Netherlands Organisation for Health Research and Development"},{"name":"Netherlands Organisation for Scientific Research"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Metabolic Syndrome X","Mild Cognitive Impairment"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02161276","briefTitle":"Clinical Trials for the Optimal Dosage of Tang Ning Tongluo Capsule"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Guizhou Bailing Group Pharmaceutical Co Ltd"},"collaborators":[{"name":"China-Japan Friendship Hospital"}]},"conditionsModule":{"conditions":["Accidental Exposure While Preparing Drug for Administration"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TNTL capsule"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03730727","briefTitle":"Exercise-meal Timing and Postprandial Glucose Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Birmingham"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Hyperglycemia, Postprandial","Physical Activity","Glucose Intolerance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physical activity"},{"name":"Meal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03847779","briefTitle":"Microcirculatory Vasomotor Changes in Type 2 Diabetes With Peripheral Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Avignon"}},"conditionsModule":{"conditions":["Diabetic Neuropathy Peripheral","Small Vessel Disease of Diabetes Mellitus","Vasodilation","Vasoconstriction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"\"Rest\""},{"name":"\"Exercise\""},{"name":"\"Foot lowering\""},{"name":"\"Hyperthermia\""}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01972542","briefTitle":"The Usefulness of Postprandial Triglyceride for Assessment of Cardiovascular Risk"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Bundang Hospital"}},"conditionsModule":{"conditions":["Diabetes","Prediabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral fat tolerance test"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01955746","briefTitle":"PST Linkage Based Analysis in the Family of More Than Two Members With Type 1 Diabetes in Taiwan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chang Gung Memorial Hospital"}},"conditionsModule":{"conditions":["The Genetic Variation of Type 1 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01422421","briefTitle":"Intensive Blood Pressure and LDL Lowering in Diabetic Patients With Coronary Artery Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeshi Morimoto"},"collaborators":[{"name":"University of the Ryukyus"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Coronary Artery Disease","Hypertension","Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"intensive control"},{"name":"standard control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02660047","briefTitle":"Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Leiden University Medical Center"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Type 2","Metabolic Syndrome","Cardiovascular Disease","Diastolic Dysfunction","Fatty Liver"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Liraglutide - Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05159570","briefTitle":"Modulation of Circulating Levels of the Ketone Body 3-hydroxybutyrate in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction: Metabolic Effects. (KETO-HFpEF-Metabolic)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"}},"conditionsModule":{"conditions":["Heart Failure With Preserved Ejection Fraction","Diabetes Mellitus, Type 2","Ketonemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ketone ester"},{"name":"Placebo drink"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00891124","briefTitle":"Effect of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol)."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Glycemia","Hypertension","Hyperlipidemia"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03314467","briefTitle":"Role of Obstructive Sleep Apnea Syndrome in the Occurrence of Diabetic Retinopathy in Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire Saint Pierre"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Obstructive Sleep Apnea"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"polysomnography"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01463449","briefTitle":"\"Can Soluble-CD163 Discriminate Between Healthy and Unhealthy Obese Individuals?\""},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"Novo Nordisk A/S"},{"name":"The Danish Medical Research Council"}]},"conditionsModule":{"conditions":["Obesity","Insulin Resistance","Type 2-diabetes","Inflammation"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"gastric bypass"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01875341","briefTitle":"Role of Sleep Apnea and Sympathetic Activity in Resistant Hypertensive Patients."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ottawa Hospital Research Institute"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Diabetic Nephropathy","Hypertension","Sleep Apnea"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NCPAP; Nasal continuous positive airway pressure."},{"name":"NCPAP Nasal Continuous Positive Airway Pressure-sub-therapeutic treatment group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04952948","briefTitle":"Pilates Method on Functional Capacity and Blood Pressure of Elderly Women With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidade Federal do vale do São Francisco"}},"conditionsModule":{"conditions":["Type-2 Diabetes","Physical Disability","Blood Pressure"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PILATES Training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02244879","briefTitle":"Effects of Resveratrol on Inflammation in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Turin, Italy"},"collaborators":[{"name":"Ministry of Health, Italy"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Inflammation","Insulin Resistance","Other Disorders of Bone Density and Structure"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"resveratrol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03832907","briefTitle":"Dexcom G6 Observational Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dexcom G6 CGM - Continues Glucose Monitoring sensor system"},{"name":"POC BG - Point-of-Care Blood Glucose monitoring"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03634098","briefTitle":"Identification and Validation of Noninvasive Biomarkers of the Diagnosis and Severity of NASH in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Assistance Publique - Hôpitaux de Paris"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"new quantitative imaging techniques with contast products"},{"name":"blood sample"},{"name":"second generation tests"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00806338","briefTitle":"An Ascending Multi-Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Genaera Corporation"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Trodusquemine (MSI-1436)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01357603","briefTitle":"Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Wockhardt"}},"conditionsModule":{"conditions":["Type1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02304081","briefTitle":"Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Prof. Dr. Thomas Forst"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Placebo for Saxagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00649246","briefTitle":"Prospective Assessment in Newborns for Diabetes Autoimmunity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Augusta University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"University of Florida"},{"name":"Emory University"},{"name":"Medical University of South Carolina"},{"name":"University of South Carolina"}]},"conditionsModule":{"conditions":["Type 1 Diabetes","Autoimmunity"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01855243","briefTitle":"Comparison on Efficacy and Safety of Three Inpatient Insulin Therapy in Type2 DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cairo University"}},"conditionsModule":{"conditions":["Diabetes Mellitus (DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"regular insulin"},{"name":"70/30 insulin"},{"name":"Glargine"},{"name":"glulisine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01123187","briefTitle":"Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Lille"},"collaborators":[{"name":"Institut National de la Santé Et de la Recherche Médicale, France"}]},"conditionsModule":{"conditions":["Type 1 Diabetes","Organ Transplantation","Immunosuppression"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"islet transplantation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03920683","briefTitle":"Toe-brachial Index and Coronary Calcification in Type 1 and 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Assistance Publique - Hôpitaux de Paris"}},"conditionsModule":{"conditions":["Coronary Artery Calcification"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Data collection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04235829","briefTitle":"Does Early Weight Loss Following Laparoscopic Sleeve Gastrectomy Affect Long-term Outcomes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shaare Zedek Medical Center"}},"conditionsModule":{"conditions":["Hypertension","Diabetes Mellitus, Type 2","Gastrostomy","Morbid Obesity","Weight Loss"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Laparoscopic sleeve gastrectomy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06592950","briefTitle":"Patient Preference Study in Type-2 Diabetes Mellitus: Discrete Choice Experiment (DCE) to Support Novo Nordisk's Long-Acting Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Type-2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No treatment given"},{"name":"No treatment given"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00000620","briefTitle":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Heart, Lung, and Blood Institute (NHLBI)"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"National Institute on Aging (NIA)"},{"name":"National Eye Institute (NEI)"},{"name":"Centers for Disease Control and Prevention"}]},"conditionsModule":{"conditions":["Atherosclerosis","Cardiovascular Diseases","Hypercholesterolemia","Hypertension","Diabetes Mellitus, Type 2","Diabetes Mellitus","Coronary Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Anti-hyperglycemic Agents"},{"name":"Anti-hypertensive Agents"},{"name":"Blinded fenofibrate or placebo plus simvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01399645","briefTitle":"Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre hospitalier de l'Université de Montréal (CHUM)"},"collaborators":[{"name":"Centre de Recherche du Centre Hospitalier de l'Université de Montréal"},{"name":"Diabetes Québec"},{"name":"Radiological Society of North America"},{"name":"Canadian Heads of Academic Radiology-GE Healthcare Development Award"}]},"conditionsModule":{"conditions":["Nonalcoholic Fatty Liver Disease","Nonalcoholic Steatohepatitis","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide-metformin vs insulin-metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00970099","briefTitle":"Mechanism of Insulin-Resistant in Lean Non-Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Francisco"}},"conditionsModule":{"conditions":["Insulin Resistance","Insulin Sensitivity","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exercise"},{"name":"Non exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00240383","briefTitle":"Dose Ranging Study With LT, Monotherapy, PPAR"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristol-Myers Squibb"}},"conditionsModule":{"conditions":["Diabetes Mellitus II"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Muraglitazar"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00886340","briefTitle":"A Lifestyle Change Program to Prevent Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Prediabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Enhanced standard care"},{"name":"Lifestyle counseling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01396330","briefTitle":"Effect of Mental Stress on Glucose Control in Patients With Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Basel, Switzerland"},"collaborators":[{"name":"Kantonsspital Frauenfeld"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Mental Stress"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"stress"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04446754","briefTitle":"The Genetic Effects of rs7903146 and Dietary Intake on Type 2 Diabetes Mellitus Risk in a Healthy Population"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"St Mary's University College"}},"conditionsModule":{"conditions":["Health Behavior","Blood Glucose, High","Diet Habit","Genetic Predisposition"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02204384","briefTitle":"Glycemic and Insulinemic Response With Different Sources of Soluble Fiber in Patients Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital de Clinicas de Porto Alegre"},"collaborators":[{"name":"Federal University of Rio Grande do Sul"},{"name":"Coordenação de Aperfeiçoamento de Pessoal de Nível Superior."}]},"conditionsModule":{"conditions":["Dietary Modification","Diabetes Mellitus Type 2","Insulin Tolerance","Diabetic Blood Glucose Monitoring"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HFD Meal: High fiber from food"},{"name":"HFS Meal: High fiber from supplement"},{"name":"UF Meal: usual amount of fiber"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01477034","briefTitle":"Vitamin D and Adipose Tissue Inflammation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fred Hutchinson Cancer Center"},"collaborators":[{"name":"University of Washington"}]},"conditionsModule":{"conditions":["Vitamin D Deficiency","Obesity","Type 2 Diabetes Mellitus","Intestinal Permeability"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin D3"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03463941","briefTitle":"Peer Support Dyads in Churches"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Duke University"},"collaborators":[{"name":"National Institute of Nursing Research (NINR)"}]},"conditionsModule":{"conditions":["Peer Support and Chronic Disease","Obesity","Type II Diabetes","Cardiovascular Disease","Cancer"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Peer Support Dyad Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02125682","briefTitle":"The HDL Particle Protection Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hotel Dieu de France Hospital"},"collaborators":[{"name":"Nouvelle Société Française d'Athérosclérose"},{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Dyslipidemia in Patients With Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"atovastatin 10 mg/day"},{"name":"Atorvastatin 80 mg/day"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00525629","briefTitle":"The Metabolic Effects of Short-term Walnut Consumption in Subjects With the Metabolic Syndrome"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Christos Mantzoros"},"collaborators":[{"name":"California Walnut Commission"}]},"conditionsModule":{"conditions":["Metabolic Syndrome","Type 2 Diabetes","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Walnuts"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05284071","briefTitle":"Actiste® Diabetes Management as a Service (ADMS) Clinical Investigation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Northern Care Alliance NHS Foundation Trust"},"collaborators":[{"name":"Brighter AB"}]},"conditionsModule":{"conditions":["Diabetes type1","Diabetes type2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Device: Actiste 1.0 and the Companion app with TBL Backend"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00443755","briefTitle":"Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"Takeda Pharmaceuticals North America, Inc."},{"name":"National Center for Research Resources (NCRR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Insulin Resistance","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"metformin"},{"name":"pioglitazone"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00832390","briefTitle":"Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Merck Sharp & Dohme LLC"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin phosphate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01521962","briefTitle":"Study of Combination Therapy With SYR-322"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alogliptin"},{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00564551","briefTitle":"Effect of Increased Intake of Low Fat Dairy Products on Weight Loss and Insulin Resistance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Calgary"}},"conditionsModule":{"conditions":["Impaired Glucose Tolerance","Type 2 Diabetes","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High dairy and calcium intake"},{"name":"Usual intake"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02627534","briefTitle":"Effects of Adjunct Photodynamic Therapy in the Treatment of Type 2 Diabetic Patients With Chronic Periodontitis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidade Estadual Paulista Júlio de Mesquita Filho"}},"conditionsModule":{"conditions":["Chronic Periodontitis","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ultrasonic debridement"},{"name":"Antimicrobial photodynamic therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01852214","briefTitle":"Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Florida"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Prasugrel"},{"name":"Ticagrelor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00145392","briefTitle":"Body Composition, Glucose Metabolism, Insulin Resistance and Gene Expression in Muscle Cells in Healthy Overweight Women"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Odense University Hospital"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes","Polycystic Ovary Syndrome"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00994682","briefTitle":"University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Florida"},"collaborators":[{"name":"The University of Texas at San Antonio"}]},"conditionsModule":{"conditions":["Nonalcoholic Steatohepatitis","Nonalcoholic Fatty Liver Disease","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone study drug"},{"name":"Placebo"},{"name":"Pioglitazone Open Label"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03847116","briefTitle":"Alcohol Consumption and Type 2 Diabetes Mellitus Risk in Nonalcoholic Fatty Liver Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ningbo No. 1 Hospital"}},"conditionsModule":{"conditions":["Nonalcoholic Fatty Liver Disease","Light-to-moderate Alcohol Consumption","Type2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02450500","briefTitle":"Prohealth@Home: A Feasibility Study Investigating the Use of a Lifestyle App in People at Risk of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Plymouth"}},"conditionsModule":{"conditions":["Pre-diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle counselling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04004273","briefTitle":"Diabetes, Exercise and Liver Fat (DELIVER)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"James King"},"collaborators":[{"name":"University Hospitals, Leicester"},{"name":"Nottingham University Hospitals NHS Trust"},{"name":"University of Nottingham"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Non-Alcoholic Fatty Liver Disease","Obesity","Insulin Resistance","Liver Diseases","Fatty Liver","Diabetes Mellitus","Glucose Metabolism Disorders","Glucose Intolerance","Metabolic Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01935466","briefTitle":"Risk of Bladder Cancer in Type 2 Diabetes Patients With Pioglitazone Therapy \"PROBE\""},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Post Graduate Institute of Medical Education and Research, Chandigarh"}},"conditionsModule":{"conditions":["Bladder Cancer"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03206827","briefTitle":"Effect of Plant and Animal Proteins on Biomarkers of Colorectal Cancer and Type 2 Diabetes in Healthy Adults (ScenoProt)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Helsinki"},"collaborators":[{"name":"Natural Resources Institute Finland"},{"name":"Makery Ltd, Finland"}]},"conditionsModule":{"conditions":["Colorectal Cancer","Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"70% animal, 30% plant proteins in diet"},{"name":"50% animal, 50% plant proteins in diet"},{"name":"30% animal, 70% plant proteins in diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04880291","briefTitle":"First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Goldfinch Bio, Inc."}},"conditionsModule":{"conditions":["Kidney Diseases","Diabetic Nephropathies","Diabetes Complications","Diabetes Mellitus","Endocrine System Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GFB-024"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03378271","briefTitle":"Accuracy and Treatment Experience of Two Glucose Monitoring Systems Tested in Patients With Type 1 Diabetes and Renal Impairment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vastra Gotaland Region"}},"conditionsModule":{"conditions":["Diabetes Mellitus Complication","Renal Impairment"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Simultanious CGM/FGM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05581264","briefTitle":"Diabetes Self-Management Educational Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mutah University"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Self-Management Education Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05140551","briefTitle":"Emotional Wellbeing in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"King's College London"},"collaborators":[{"name":"South London and Maudsley NHS Foundation Trust"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1","Diabetes","Depression","Anxiety","Distress, Emotional","Diabetes Distress","Loneliness","Social Functioning","Quality of Life"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"COMPASS: digital CBT"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00976729","briefTitle":"NOX-E36 First-in-Human (FIH) Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"TME Pharma AG"}},"conditionsModule":{"conditions":["Chronic Inflammatory Diseases","Type 2 Diabetes Mellitus","Systemic Lupus Erythematosus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NOX-E36"},{"name":"NOX-E36"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01807351","briefTitle":"Progression From Impaired Fasting Glucose to Type 2 Diabetes Mellitus Among Subjects With and Without Hypertension in Primary Care Setting"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kowloon Hospital, Hong Kong"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Hypertension","Impaired Fasting Glucose"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02513888","briefTitle":"Prevention of Type 2 Diabetes With Vitamin D Supplementation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diabetes Foundation, India"},"collaborators":[{"name":"Ministry of Science and Technology, India"}]},"conditionsModule":{"conditions":["Prediabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"vitamin D + diet and lifestyle"},{"name":"Placebo + diet and lifestyle"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02082028","briefTitle":"Efficacy of a Chronic Care Model Supported by Self Monitoring of Blood Glucose With BGStar Over Usual Care in Improving Glycemic Control in Patients With Type 2 Diabetes Not Treated With Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BGStar"},{"name":"glucose meter"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01926925","briefTitle":"Endothelial Function in Hispanic Children/Adolescents at Risk for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Joslin Diabetes Center"}},"conditionsModule":{"conditions":["Obesity","Insulin Resistance"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00704314","briefTitle":"Does Simvastatin Affect Insulin Sensitivity in Dyslipidemic Type 2 Diabetic Patients?"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Vienna"},"collaborators":[{"name":"Austrian Science Fund (FWF)"},{"name":"European Foundation for the Study of Diabetes"},{"name":"EU grant"},{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Hypercholesterolemia","Diabetes","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Simvastatin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01049750","briefTitle":"Prevalence and Risk Factors of Erectile Dysfunction in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pavia"}},"conditionsModule":{"conditions":["Type 2 Diabetic Patients","Erectile Dysfunction"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"type 2 diabetic patients"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01911663","briefTitle":"The Effect of Korean Red Ginseng Supplementation on Glucose Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yonsei University"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"KRG"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00771069","briefTitle":"Hypertensive Treatment Pattern Survey for Type II Diabetes Mellitus Patients With Complication and Hypertension"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Hypertension"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03599401","briefTitle":"Effect of Aspirin Vs Omega 3 Fatty Acid After Scaling and Root Planing in Type II Diabetic Patients With Chronic Periodontitis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre"}},"conditionsModule":{"conditions":["Periodontitis","Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Scaling and root planing"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03438162","briefTitle":"Impact of Pharmacotherapeutic Education on Medication Adherence and Adverse Outcomes in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital Dubrava"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Education","Drug-Related Side Effects and Adverse Reactions"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02956577","briefTitle":"Cardiac Function and Microcirculation: Type 2 DIABetes and ECHOcardiographic Changes Over Time"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Svendborg Hospital"}},"conditionsModule":{"conditions":["Left Ventricular Dysfunction"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01559896","briefTitle":"Egg Protein Hydrolysate and Vascular Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"}},"conditionsModule":{"conditions":["Arterial Stiffness","Dietary Modification","Impaired Glucose Tolerance","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"protein hydrolysate capsules and placebo capsules"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01873066","briefTitle":"Closing the Loop 24/7 in Adolescents With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Cambridge"},"collaborators":[{"name":"Cambridge University Hospitals NHS Foundation Trust"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 1","Glucose Metabolism Disorders","Endocrine System Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Closed-loop system"},{"name":"real-time CGM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02168348","briefTitle":"Impact of Malnutrition on the Healing of Foot Lesions in Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire Dijon"}},"conditionsModule":{"conditions":["Patients With Type 1 or 2 Diabetes","Lesion Situated on a Toe or on the Plantar or Dorsal Side of the Foot"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"biological examination at consultations at 3 and 6 months"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00340132","briefTitle":"Cross-Sectional and Longitudinal Studies of \"Pre-Diabetes\" in the Pima Indians"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Weight Gain","Overweight","Insulin Resistance","Obesity","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03353376","briefTitle":"Group Versus Individual Care in Diabetes Clinic"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rabin Medical Center"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Group Meetings"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"group care with Empowerment model"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04643873","briefTitle":"Effects of Physical Activity in Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Istanbul University - Cerrahpasa (IUC)"}},"conditionsModule":{"conditions":["Diabetes Mellitus","PreDiabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"physical activity counseiling +pilates exercise group"},{"name":"physical activity counseiling group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01069926","briefTitle":"To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Glucose Lowering"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD1656"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02278913","briefTitle":"Basal Bolus Versus Human Insulin in Hospitalized Patients With Diabetes in Paraguay"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidad Nacional de Asunción"}},"conditionsModule":{"conditions":["Hyperglycemia","Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Basal Bolus (Glargine and Glulisine)"},{"name":"Human Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03774394","briefTitle":"Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Florida"},"collaborators":[{"name":"Scott R. MacKenzie Foundation"}]},"conditionsModule":{"conditions":["Chronic Kidney Disease (CKD)","Type 2 Diabetes Mellitus (T2DM)","Coronary Artery Disease (CAD)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Clopidogrel"},{"name":"Clopidogrel active metabolite"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01472614","briefTitle":"Efficacy and Safety of Add-on Therapy With DLBS3233 in Patients With Type-2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dexa Medica Group"}},"conditionsModule":{"conditions":["Type-2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DLBS3233"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04375943","briefTitle":"Clinical and Echocardiographic Management of Patients With Heart Failure and Diabetes: SCODIAC Follow up Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Federico II University"}},"conditionsModule":{"conditions":["Diabetes","Heart Failure"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Antidiabetic"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01485913","briefTitle":"A Randomized Trial of an Intensive Education Intervention Using a Network of Involved Diabetic Patients (Peer Educators) to Improve Glycemic Control of Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sante Diabete Mali"},"collaborators":[{"name":"Bridges program, International Diabetes Federation"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"intensive education intervention using a network of involved diabetic patients (peer educators)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00931879","briefTitle":"Lovaza® and Microvascular Function in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eastern Virginia Medical School"},"collaborators":[{"name":"GlaxoSmithKline"}]},"conditionsModule":{"conditions":["Hypertriglyceridemia","Diabetic Neuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"omega-3-ethyl esters"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00565162","briefTitle":"Insulin Glargine, INITIATE Metabolic and Economic Outcomes of Lantus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02587936","briefTitle":"Improving Chronic Disease Management With Pieces"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Texas Southwestern Medical Center"},"collaborators":[{"name":"Parkland Center for Clinical Innovation"},{"name":"Parkland Health and Hospital System"},{"name":"Texas Health Resources"},{"name":"Connecticut Center for Primary Care"},{"name":"Dallas VA Research Corporation"},{"name":"G-Health Enterprises"},{"name":"National Institutes of Health (NIH)"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Chronic Kidney Disease","Diabetes","Hypertension","High BP","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Collaborative Model of Primary care and Subspecialty care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04283942","briefTitle":"Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Zhongshan Hospital"}},"conditionsModule":{"conditions":["Fatty Liver Disease","Type 2 Diabetes","Impaired Glucose Regulation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intermittent calorie restriction (ICR)"},{"name":"Continuous calorie restriction (CCR)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05076656","briefTitle":"Epigenetic and Microbiota Modifications"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud"}},"conditionsModule":{"conditions":["Diabetes type2","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lactobacillus fermentum D3"},{"name":"Fecal microbiota transplant (FMT)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04874415","briefTitle":"Behavioral Economics for Activity Motivation in Adolescents (BEAM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pittsburgh"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","PreDiabetes","Insulin Resistance","Polycystic Ovary Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"1RLD"},{"name":"1RLW"},{"name":"1RGD"},{"name":"1RGW"},{"name":"2RLD"},{"name":"2RLW"},{"name":"2RGD"},{"name":"2RGW"},{"name":"1FLD"},{"name":"1FLW"},{"name":"1FGD"},{"name":"1FGW"},{"name":"2FLD"},{"name":"2FLW"},{"name":"2FGD"},{"name":"2FGW"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03553680","briefTitle":"An Emotion-Focused Intervention for Glycemic Control in T2D"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Chicago"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Emotion-Focused CBT"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00060931","briefTitle":"Effect Of Carvedilol Versus Metoprolol On Glycemic Control In Patients With Type II Diabetes And Hypertension"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"carvedilol"},{"name":"metoprolol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01774942","briefTitle":"Taking Out All Teeth and Replacing Them With Dentures That Rest on Implants in People With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"},"collaborators":[{"name":"Rahman & Rahman Dental Surgeons, Lahore, Pakistan"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus With Periodontal Complication","Inflammation","Dental Implant Failed"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Procedure/Surgery"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02948673","briefTitle":"The Production of Reactive Oxygen Species in Response to Glutathione Supplementation and Acute Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Copenhagen"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Oxidative Stress","Mitochondrial Reactive Oxygen Species Production"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glutathione"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02217943","briefTitle":"Prospective Metabolic Surgery in T2DM Chinese Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ethicon Endo-Surgery"}},"conditionsModule":{"conditions":["Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Roux-en-Y gastric bypass"},{"name":"Sleeve gastrectomy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04007107","briefTitle":"A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Healthy Volunteers Diabetes Mellitus, Type 2","Healthy Volunteers Overweight","Healthy Volunteers Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide (administered by DV3396 pen)"},{"name":"Semaglutide (administered by PDS290 pen)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05329376","briefTitle":"Interactive Virtual Assistance for Self-Care Management and Mental Health Promotion in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pontificia Universidade Católica do Rio Grande do Sul"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Depression, Anxiety","Mental Health Disorder","Old Age; Debility"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Smart Speaker Echo Dot"},{"name":"Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01167231","briefTitle":"Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acarbose (Glucobay, BAYG5421)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03181165","briefTitle":"Pharmacist-led Therapeutic Nutritional Intervention in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of British Columbia"},"collaborators":[{"name":"Mitacs"},{"name":"Pharmasave"}]},"conditionsModule":{"conditions":["Diet Modification"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low-carbohydrate Therapeutic Nutrition"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06259318","briefTitle":"Feasibility of Kanasina Gulabi, a Pilot Peer Support Intervention for Young Adults With Type 2 Diabetes in Mysore District, South India"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Duke University"},"collaborators":[{"name":"Public Health Research Institute of India"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Quality of Life","Depression","Stigma, Social","Behavior, Health"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Kanasina Gulabi"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01394055","briefTitle":"Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Motus Therapeutics, Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus Type 1 and 2","Diabetes Mellitus Complications","Gastroparesis","Gastrointestinal Motility Disorder"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"RM-131"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02246400","briefTitle":"CardioMetabolic Program Meets eHealth: Redesign and Evaluation for Optimal Reach and Impact"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Palo Alto Medical Foundation"}},"conditionsModule":{"conditions":["Obesity","Metabolic Syndrome","Pre-diabetes","Type 2 Diabetes","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"eCMP"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01766362","briefTitle":"Incidence of Macular Edema After Panretinal Photocoagulation (PRPC) Performed in a Single Session Versus Four Sessions in Diabetic Patients."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire Dijon"}},"conditionsModule":{"conditions":["Diabetes Type 1 or 2 With Diabetic Retinopathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PRPC using Pascal laser"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02609815","briefTitle":"Initial Combination of Gemigliptin and Metformin on Microbiota Change"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Bundang Hospital"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"gemigliptin/metformin"},{"name":"glimepiride/metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01167959","briefTitle":"Hypothalamic Function Before and After Bariatric Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Leiden University Medical Center"}},"conditionsModule":{"conditions":["Obesity","Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Roux en Y gastric bypass and lap. gastric banding"},{"name":"Prodimed dietary intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04835194","briefTitle":"Phenotypes and Outcomes of Heart Failure With Preserved Ejection Fraction in Patients With Hypertension and Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Medicine and Pharmacy at Ho Chi Minh City"}},"conditionsModule":{"conditions":["Heart Failure With Preserved Ejection Fraction","Diabetes Mellitus, Type 2","Hypertension"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05963594","briefTitle":"To Evaluate the Post-Prandial Metabolic Effects of Oligomalt in Adults With T2D and in HAO"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Société des Produits Nestlé (SPN)"}},"conditionsModule":{"conditions":["Dietary Supplement"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oligomalt"},{"name":"maltodextrin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03814915","briefTitle":"Diabetes Research on Patient Stratification"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lund University"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03062592","briefTitle":"FFAR Agonist on Incretins, Insulin, Lipids and Inflammation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Odense University Hospital"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pine nut oil"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02317003","briefTitle":"Physical Exercise Prescription With PEdometeR in General Practice for Patients With Cardiovascular Risk Factors - PEPPER"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Angers"}},"conditionsModule":{"conditions":["Sedentary Lifestyle","Cardiovascular Diseases","Hypertension","Hypercholesterolemia","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intervention PPIL"},{"name":"Control OR"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00527254","briefTitle":"Telemedicine Influence in the Follow up of the Type 2 Diabetes Patient"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Province of Malaga Health Department"},"collaborators":[{"name":"Roche Diagnostics Spain (Diabetes Care)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Telemedicine","Self Monitoring Blood Glucose","Primary Care"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Telemedicine system"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05491850","briefTitle":"Effects of Moderate Physical Activity on Early Symptoms of Peripheral Diabetic Neuropathy in Type-II Diabetes: A Randomized Clinical Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Riphah International University"}},"conditionsModule":{"conditions":["Peripheral Diabetic Neuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Moderate Physical Activity for Peripheral Diabetic Neuropathy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05601310","briefTitle":"Metabolic Characteristics of Type 2 Diabetes Mellitus Combined With Acute Myocardial Infarction: A Untargeted Metabolomics Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Beijing Friendship Hospital"}},"conditionsModule":{"conditions":["STEMI"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liquid chromatography-mass spectrometry (LC/MS) analysis"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00917449","briefTitle":"Prevention of Type 2 Diabetes Mellitus by L-Arginine in Patients With Metabolic Syndrome"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"IRCCS San Raffaele"}},"conditionsModule":{"conditions":["Metabolic Syndrome","Impaired Glucose Tolerance","Insulin Resistance","Endothelial Dysfunction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"L-arginine"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00494312","briefTitle":"Safety Study of Pioglitazone Compared To Glyburide on Liver Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Liver"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"Glyburide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03563456","briefTitle":"Development of Structured Exercise Program for T2DM Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Indonesia University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","High-Intensity Interval Training","Resistance Training","Oxidative Stress","Physical Fitness"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"structured combined exercise"},{"name":"cardiorespiratory exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02745015","briefTitle":"Effect of Non Surgical Treatment of Periodontitis on Diabetes Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yaounde Central Hospital"}},"conditionsModule":{"conditions":["Periodontitis","Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"non-surgical periodontal treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02251431","briefTitle":"Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baylor Research Institute"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Chronic Kidney Disease","Left Ventricular Diastolic Dysfunction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BYDUREON"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02768935","briefTitle":"Macrophage Phenotype in Type 2 Diabetics After Myocardial Infarction and the Potential Role of miRNAs Secreted"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire de Nice"}},"conditionsModule":{"conditions":["DIABETES","MYOCARD INFARCTUS"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"blood sample"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04125160","briefTitle":"Glycaemic Markers in Persons With Type 2 Diabetes on Peritoneal Dialysis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rigshospitalet, Denmark"},"collaborators":[{"name":"Steno Diabetes Center Copenhagen"},{"name":"Zealand University Hospital"},{"name":"Herlev Hospital"},{"name":"Hillerod Hospital, Denmark"}]},"conditionsModule":{"conditions":["HbA1c","Peritoneal Diseases","Glycated Albumin","Fructosamine","Continuous Glucose Monitoring"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous glucose monitoring"},{"name":"Glycaemic markers"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00041405","briefTitle":"Mechanisms of Pro-Thrombosis in Diabetes Mellitus -- Ancillary to BARI 2D"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}},"conditionsModule":{"conditions":["Cardiovascular Diseases","Heart Diseases","Diabetes Mellitus, Non-insulin Dependent","Coronary Disease","Thrombosis","Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02875821","briefTitle":"Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yonsei University"}},"conditionsModule":{"conditions":["Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ipragliflozin"},{"name":"metformin with pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02012972","briefTitle":"Non-Communicable Diseases and Antiretroviral Therapy Outcomes in the RapIT Study Population"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boston University"},"collaborators":[{"name":"University of Witwatersrand, South Africa"},{"name":"National Institute of Allergy and Infectious Diseases (NIAID)"},{"name":"City of Johannesburg"}]},"conditionsModule":{"conditions":["Antiretroviral Therapy, Highly Active","Diabetes Mellitus, Type 2","Cardiovascular Diseases"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Referral for NCD care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05299918","briefTitle":"Diabetic Neuropathy Rapid Screening Test in Turkish Patients With Type 2 Diabetes: Sudoscan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Istanbul University"}},"conditionsModule":{"conditions":["Neuropathy Autonomic","Cardiac Autonomic Neuropathy","Type2Diabetes","Diabetic Neuropathy Peripheral","Diabetic Neuropathies"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03462069","briefTitle":"Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sotagliflozin (SAR439954)"},{"name":"Placebo"},{"name":"Empagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03007329","briefTitle":"Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Vienna"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Steatosis, Liver","Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide"},{"name":"Exenatide matching Placebo"},{"name":"Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05404711","briefTitle":"Continuous Glucose Monitors (CGM) for Type 2 Diabetes (T2D) Risk Evaluation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mary Ellen Vajravelu, MD"}},"conditionsModule":{"conditions":["Overweight and Obesity","PreDiabetes","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CGM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00529048","briefTitle":"Quantification of the Incretin Effect in Healthy Subjects and Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Herlev Hospital"},"collaborators":[{"name":"University of Copenhagen"},{"name":"Merck Sharp & Dohme LLC"},{"name":"Forskningsrådet"},{"name":"Diabetesforeningen"}]},"conditionsModule":{"conditions":["Incretin Effect"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral Glucose Tolerance Test"},{"name":"Isoglycemic clamp"},{"name":"Gastric emptying rate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02130505","briefTitle":"Inflammatory Aspects of Glucose in Hyperlipidemia and Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sint Franciscus Gasthuis"}},"conditionsModule":{"conditions":["Atherosclerosis","Leukocyte Activation Disorder","Type 2 Diabetes Mellitus","Familial Combined Hyperlipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"OGTT"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01317576","briefTitle":"Optimizing the Beneficial Health Effects of Exercise for Diabetes: Focus on the Liver!"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bram Brouwers"},"collaborators":[{"name":"Dutch Diabetes Research Foundation"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Non-alcoholic Fatty Liver Disease","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03481361","briefTitle":"Obstructive Sleep Apnoea in Patients With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Birmingham"},"collaborators":[{"name":"Heart of England NHS Trust"}]},"conditionsModule":{"conditions":["Type 1 Diabetes","Obstructive Sleep Apnoea"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03531177","briefTitle":"Healthy Eating & Active Lifestyles for Diabetes: Feasibility Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"King's College London"},"collaborators":[{"name":"University College, London"}]},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HEAL-D"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02635646","briefTitle":"Interdisciplinary and Family Intervention to Prevent Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidad de Guanajuato"},"collaborators":[{"name":"University of Texas"},{"name":"National Council of Science and Technology, Mexico"}]},"conditionsModule":{"conditions":["Prediabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Family and interdisciplinary approach"},{"name":"individual approach"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00005441","briefTitle":"Lifestyle Management for Women With CHD and NIDDM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oregon Research Institute"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Coronary Disease","Heart Diseases","Diabetes Mellitus, Non-insulin Dependent","Postmenopause","Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01828242","briefTitle":"The Empowerment Model Towards Type 2 Diabetic Adults To Enhance Vegetable Intake in Achieving Glycemic Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"SEAMEO Regional Centre for Food and Nutrition"}},"conditionsModule":{"conditions":["Glycemic Control for Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empowerment model to improve dietary intake"},{"name":"Control group following conventional approach"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03782805","briefTitle":"Effect of Vitamin D Supplementation on Inflammatory Markers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Université d'Auvergne"}},"conditionsModule":{"conditions":["Vitamin D Deficiency","Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"cholecalciferol (Euro-Pharm International, Canada)"},{"name":"Placebo tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00005419","briefTitle":"Physical Activity, Hypertension, Diabetes, and Coronary Heart Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Stanford University"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Heart Diseases","Diabetes Mellitus","Coronary Disease","Hypertension","Diabetes Mellitus, Non-insulin Dependent"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03334214","briefTitle":"Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ionis Pharmaceuticals, Inc."}},"conditionsModule":{"conditions":["Hepatic Steatosis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IONIS DGAT2Rx"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04915066","briefTitle":"Study of Insulin Pump Discontinuation in Adults With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Sud Francilien"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Medical data collection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00031226","briefTitle":"Biomarkers of Oxidative Stress in LOOK AHEAD - Ancillary to LOOK AHEAD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Arizona State University"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Heart Diseases","Myocardial Infarction","Obesity","Diabetes Mellitus, Non-insulin Dependent","Cardiovascular Diseases","Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06066021","briefTitle":"Evaluation of a Health Education Program for Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Association for Innovation and Biomedical Research on Light and Image"}},"conditionsModule":{"conditions":["Retinopathy, Diabetic"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"health educational sessions in diabetic patients type 2."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00005530","briefTitle":"Diet, Insulin Resistance, and Cardiovascular Risk"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of South Carolina"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Heart Diseases","Insulin Resistance","Hyperinsulinism","Diabetes Mellitus, Non-insulin Dependent","Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02000024","briefTitle":"Assessing the Effectiveness of a Weight Watchers-based Lifestyle Intervention for the Primary Prevention of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Indiana University"},"collaborators":[{"name":"WW International Inc"},{"name":"Indiana Clinical and Translational Sciences Institute"},{"name":"National Diabetes Education Program"}]},"conditionsModule":{"conditions":["Prediabetes","Gestational Diabetes Mellitus","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Weight Watchers"},{"name":"National Diabetes Education Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03722199","briefTitle":"Effects of Flavanoids in Essential Hypertension, Type 2 Diabetes and Healthy Persons"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Ghent"}},"conditionsModule":{"conditions":["Vascular Complications, Diabetic"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00031213","briefTitle":"Heavy Metals, Obesity and Cardiovascular Risk - Ancillary to Look AHEAD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Non-insulin Dependent","Cardiovascular Diseases","Obesity","Myocardial Infarction","Heart Diseases","Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04621929","briefTitle":"Obesity and Uric Acid Stones Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Florida"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Obesity","Uric Acid Stones","Type 2 Diabetes Mellitus in Obese","Pre-Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Phentermine / Topiramate Oral Product"},{"name":"Citrate Salts, Allopurinol, Diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02882945","briefTitle":"Gene Polymorphism Associated With Macroangiopathy in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"First Affiliated Hospital of Harbin Medical University"}},"conditionsModule":{"conditions":["Diabetic Angiopathies"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Group A"},{"name":"Group B"},{"name":"Group C"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05222477","briefTitle":"Abdominal Muscle Exercises on Nocturia and Sleep Quality in Women With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cairo University"},"collaborators":[{"name":"Mansoura University"}]},"conditionsModule":{"conditions":["Nocturia","Sleep Deprivation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pelvic floor exercise"},{"name":"Abdominal muscles exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02868177","briefTitle":"Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Valbiotis"},"collaborators":[{"name":"Biofortis Mérieux NutriSciences"},{"name":"Institut Pasteur de Lille"}]},"conditionsModule":{"conditions":["Prediabetes","Type 2 Diabetes","Hypertriglyceridemia","Obesity","Disease","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Totum-63"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00134147","briefTitle":"A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Inhaled Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01648296","briefTitle":"Fatty Acid Radiotracer Comparison Study in Heart Failure Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Washington University School of Medicine"}},"conditionsModule":{"conditions":["Heart Failure","Obesity","Type 2 Diabetes Mellitus","Health Normal Volunteer Subjects"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"[18F]FluorbetaOx"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00065793","briefTitle":"VLDL and LDL Particle Types as Coronary Heart Disease Risk Factors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Brigham and Women's Hospital"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Heart Diseases","Coronary Disease","Myocardial Infarction","Diabetes Mellitus","Diabetes Mellitus, Non-insulin Dependent"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05229705","briefTitle":"Exercise in Older Adults at Risk for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Western University, Canada"}},"conditionsModule":{"conditions":["Cognitive Change"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Resistance exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02304497","briefTitle":"PRF Growth Factors Levels in Diabetic Patients With Chronic Periodontitis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bulent Ecevit University"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Chronic Periodontitis"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Platelet Rich Fibrin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02955238","briefTitle":"Latinos Understanding the Need for Adherence"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"San Diego State University"}},"conditionsModule":{"conditions":["Atherosclerosis","High Blood Pressure","Type 2 Diabetes Mellitus","Heart Disease","Hypercholesterolemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Special Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02919345","briefTitle":"Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Campinas, Brazil"},"collaborators":[{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Coronary Artery Disease","Carotid Artery Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin 10 mg"},{"name":"Glibenclamide 5 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03983499","briefTitle":"Latinos Understanding the Need for Adherence in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"San Diego State University"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Glycemic Control","Cardiovascular Risk Factors","Psychological Distress"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Special Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04938869","briefTitle":"Continuous Glucose Monitor Application After Hospital Discharge for the Improvement of Outcomes in Patients With Poorly Controlled Type 2 Diabetes and Active Cancer"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ohio State University Comprehensive Cancer Center"}},"conditionsModule":{"conditions":["Hematopoietic and Lymphoid System Neoplasm","Malignant Solid Neoplasm","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Educational Intervention"},{"name":"Medical Device Usage and Evaluation"},{"name":"Survey Administration"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03442595","briefTitle":"MedStar Diabetes Pathway Chart Reviews"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medstar Health Research Institute"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intensive diabetes education and medication management"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02866539","briefTitle":"Effect of Polyherbal Compound for Control of Blood Sugar in Impaired Glucose Tolerance and Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Composite Interceptive Med Science"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Polyherbal capsule coccinia, bougainvillea, catharanthus"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05034380","briefTitle":"Epigenetic Effects of a Single Bout of Exercise on Cardiovascular Risk Factors and the Metabolome"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"East Carolina University"},"collaborators":[{"name":"Purdue University"},{"name":"Louisiana State University Health Sciences Center Shreveport"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes","Cardiovascular Diseases","Acute Exercise"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acute exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03221205","briefTitle":"Effect of CPAP on Myocardial Dysfunction in Type 2 Diabetes Mellitus and Obstructive Sleep Apnea Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Instituto Nacional de Enfermedades Respiratorias"},"collaborators":[{"name":"Fundación Clínica Médica Sur"},{"name":"National Council of Science and Technology, Mexico"}]},"conditionsModule":{"conditions":["Sleep Apnea, Obstructive","Diabetes Mellitus, Type 2","Continuous Positive Airway Pressure","Myocardial Dysfunction","Echocardiography","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sham CPAP"},{"name":"Therapeutic CPAP"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04562467","briefTitle":"The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Canadian Medical and Surgical Knowledge Translation Research Group"},"collaborators":[{"name":"HLS Therapeutics, Inc"},{"name":"Unity Health Toronto"},{"name":"Western University, Canada"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Cardiovascular Risk Factor","Triglycerides High","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04916470","briefTitle":"Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide"},{"name":"Placebo (Semaglutide)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05585268","briefTitle":"Electronic Decision Support for Deprescribing in Patients on Hemodialysis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"McGill University Health Centre/Research Institute of the McGill University Health Centre"}},"conditionsModule":{"conditions":["End Stage Renal Disease","Hypertension","Diabete Type 2","Renal Failure Chronic","Anemia","Medication Interaction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Medication reconciliation supplemented with MedSafer and deprescribing brochures"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02076347","briefTitle":"Comparison of Two Pharmacist-led Population Management Approaches to Increase Monitoring of Vitamin B12 and Serum Creatinine Levels for Patients on Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ohio State University"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Vitamin B12 Deficiency","Neuropathy","Anemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Office visit intervention"},{"name":"Electronic Message Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03590626","briefTitle":"Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medanta, The Medicity, India"}},"conditionsModule":{"conditions":["Non Alcoholic Fatty Liver Disease","Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dulaglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00642174","briefTitle":"Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"},"collaborators":[{"name":"Daiichi Sankyo"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"prasugrel"},{"name":"Clopidogrel"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00633425","briefTitle":"Continuous Glucose Monitoring System (CGMS) in Type 2 Diabetic Patients Inadequately Controlled by Metformine Monotherapy; Analyze of Glycemic Profile Before and After Association of Glimepiride"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLIMEPIRIDE"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03815487","briefTitle":"Comparison of Two Management Systems in Patients With Type 1 Diabetes (Pediatric SmartHome)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kinderkrankenhaus auf der Bult"}},"conditionsModule":{"conditions":["Patient Care","Drug Therapy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Medtronic MiniMed 670G Insulin Pump in Auto Mode"},{"name":"Medtronic MiniMed 670G Insulin Pump without Auto Mode"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01910194","briefTitle":"Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Profil Institut für Stoffwechselforschung GmbH"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Luyxumia versus Lantus"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02596581","briefTitle":"Chemerin and IL-6 Levels in Diabetes and Periodontitis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bulent Ecevit University"}},"conditionsModule":{"conditions":["Chronic Periodontitis","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"non-surgical periodontal treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02112071","briefTitle":"Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Minnesota"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Focus Type 2 Diabetes Related Chronic Kidney Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04456192","briefTitle":"Effects of an Indoor Cycling Program on Cardio-Metabolic Factors in Women With Obesity and Normal Body Weight"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Poznan University of Physical Education"},"collaborators":[{"name":"Poznan University of Medical Sciences"}]},"conditionsModule":{"conditions":["Obesity","Dyslipidemias","Hypertension","Type 2 Diabetes","Endothelial Dysfunction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Indoor Cycling Interval Exercise Training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03291171","briefTitle":"Identifying the Effect and Working Mechanisms of MyPlan 2.0 in Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Ghent"}},"conditionsModule":{"conditions":["Chronic Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MyPlan 2.0"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02132442","briefTitle":"Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Massachusetts, Worcester"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Nonalcoholic Fatty Liver Disease","Vitamin D Deficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ergocalciferol, placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03950713","briefTitle":"Mindfulness Program for Older-Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fooyin University"}},"conditionsModule":{"conditions":["Mental Health Wellness 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mindfulness-based Stress Reduction Program - Taiwan (MBSR-T)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05125445","briefTitle":"Stability and Crestal Bone Changes Around Implants Placed at Crestal Versus Subcrestal Level in Controlled Type Two Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hams Hamed Abdelrahman"}},"conditionsModule":{"conditions":["Dental Implant","Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Implants placed at bone crest"},{"name":"Implants placed 1mm Subcrestally"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01241695","briefTitle":"Safety, Acceptability and Efficacy of a Long-term Intervention With a Diabetes-specific Low-carbohydrate, High-mono-unsaturated Fatty Acid Containing Oral Nutritional Supplement on Glycaemic Control in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fresenius Kabi"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral nutritional supplement, food for special medical purposes"},{"name":"Oral nutritional supplement, food for special medical purposes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01274364","briefTitle":"Establishing a Diabetes Registry Using the JADE-DIAMOND Electronic Portal (CN001)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Asia Diabetes Foundation"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"JADE"},{"name":"DIAMOND"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00387452","briefTitle":"Exercise and Cardiovascular Control During Upright Tilt in Older Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of British Columbia"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Cardiovascular","Diabetic"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aerobic Exercise and Strength Exercise"},{"name":"Strength training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01220856","briefTitle":"Reparixin in Pancreatic Islet Transplantation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dompé Farmaceutici S.p.A"}},"conditionsModule":{"conditions":["Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Reparixin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01771887","briefTitle":"Effects of Education Program for Lebanese Diabetic T2 in Their Behavior of Auto Managing, of Self-efficacy and Adhesion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Université de Montréal"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"education program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05294458","briefTitle":"A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Quotient Sciences"}]},"conditionsModule":{"conditions":["Non-alcoholic Steatohepatitis","Type 2 Diabetes Mellitus (T2DM)","Chronic Kidney Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"cotadutide solution for injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04733612","briefTitle":"The Effects of Short Message Notifications on Middle-Aged Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Istanbul University"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Informative messages"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00201110","briefTitle":"Problem Solving and Cardiovascular Disease Risk Management in Diabetic Blacks"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johns Hopkins University"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Heart Diseases","Diabetes Mellitus, Type 2","Coronary Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Problem Solving Skills"},{"name":"Problem Solving Skills"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03159494","briefTitle":"High-intensity Training, Self-monitoring and Diabetes 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University College of Northern Denmark"},"collaborators":[{"name":"Aalborg University"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","High-Intensity Interval Training","Self Care"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High-Intensity Training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03154398","briefTitle":"Thyroid Dysfunction in Patients With Type 2 Diabetes With Early Diabetic Nephropathy."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Assiut University"}},"conditionsModule":{"conditions":["Evaluation Thyroid Functions in Diabetic Patient"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04474795","briefTitle":"Clinic to Community Connections - Broader Distribution"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Washington University School of Medicine"},"collaborators":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)"},{"name":"Longer Life Foundation"}]},"conditionsModule":{"conditions":["Gestational Diabetes","Gestational Diabetes Mellitus in Pregnancy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Staff -Educational training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04550468","briefTitle":"Low-carbohydrate Versus Low-fat Breakfast in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of British Columbia"},"collaborators":[{"name":"University of Wollongong"}]},"conditionsModule":{"conditions":["Dietary Habits"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low-Carb High-Fat breakfast"},{"name":"Low fat \"standard care\" control breakfast"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02540993","briefTitle":"Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Chronic Kidney Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Finerenone (BAY94-8862)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04020445","briefTitle":"Simplification of Complex Insulin Regimens With Preserving Good Glycemic Control in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bekes County Central Hospital"},"collaborators":[{"name":"University of Debrecen"},{"name":"Szeged University"}]},"conditionsModule":{"conditions":["HBA1c","Body Weight","Hypoglycemia"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"de-escalation of complex insulin regimens"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04829903","briefTitle":"Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Corporacion Parc Tauli"}},"conditionsModule":{"conditions":["Type 2 Diabetes Treated With Insulin","Obesity","Adolescent Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dulaglutide"},{"name":"Liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02224365","briefTitle":"The Effects of Apple Consumption on Cardiovascular Health in Prediabetics and Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Florida State University"},"collaborators":[{"name":"U.S. Apple Association"}]},"conditionsModule":{"conditions":["Diabetes","Cardiovascular Diseases","Prediabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Apple"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04156685","briefTitle":"Pharmacokinetics, Safety and Tolerability of CKD-387 10/500mg BE Phase1"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chong Kun Dang Pharmaceutical"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Part A, Reference (D635 10/500mg, Astrazeneca)"},{"name":"Part A, Reference (D635 10/500mg, Astrazeneca)"},{"name":"Part B, Reference (D635 10/500mg, Astrazeneca)"},{"name":"Part B, Reference (D635 10/500mg, Astrazeneca)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01964976","briefTitle":"Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Biguanides"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Surveillance"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01964950","briefTitle":"Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Sulfonylurea"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Surveillance"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06667804","briefTitle":"The Effect of Laughter Yoga on Blood Glucose Level, Disease Perception and Stress Level in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Inonu University"}},"conditionsModule":{"conditions":["Diabetes","Laughter Yoga","Glucose","Stress"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Laughter yoga"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02649465","briefTitle":"SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kanazawa University"},"collaborators":[{"name":"Kowa Company, Ltd."}]},"conditionsModule":{"conditions":["Non-alcoholic Fatty Liver Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tofogliflozin"},{"name":"Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04127383","briefTitle":"Effectiveness and Implementation of the Assessment of Burden of Chronic Conditions (ABCC)-Tool"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University"},"collaborators":[{"name":"Netherlands Instititute for Health Services Research"},{"name":"TNO"},{"name":"University of Twente"}]},"conditionsModule":{"conditions":["Chronic Obstructive Pulmonary Disease","Asthma","Diabetes Mellitus, Type 2","Heart Failure"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Assessment of Burden of Chronic Conditions (ABCC)-tool"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00444483","briefTitle":"Structured Patient Education and Quality of Life of Elderly Patients With Diabetes Mellitus- a Prospective Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Heidelberg University"},"collaborators":[{"name":"University of Jena"}]},"conditionsModule":{"conditions":["Impact of Structured DTTP on Quality of Life","Insulin Therapy","Metabolic Control","Psychological Aspects"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Structured diabetes teaching and treatment program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01778348","briefTitle":"Closing the Loop in Children and Adolescents With Type 1 Diabetes in the Home Setting"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Cambridge"},"collaborators":[{"name":"Cambridge University Hospitals NHS Foundation Trust"},{"name":"University College London Hospitals"},{"name":"The Leeds Teaching Hospitals NHS Trust"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 1","Glucose Metabolism Disorders","Endocrine System Diseases","Autoimmune Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Overnight closed-loop"},{"name":"Real-time CGM alone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02693392","briefTitle":"Clinical Evaluation of Fenugreek Seed Extract, a Nutraceutical in Patients With Type- 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"All India Institute of Medical Sciences, Bhubaneswar"},"collaborators":[{"name":"Chemical Resources"}]},"conditionsModule":{"conditions":["Type-2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral hypoglycemic agents (pre-specified) [Metformin, Sulfonylurea]"},{"name":"Fenugreek Seed extract"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00655902","briefTitle":"Copenhagen Obesity Risk Assessment Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Copenhagen"}},"conditionsModule":{"conditions":["Metabolic Syndrome","Abdominal Obesity","Heart Disease","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Trans fat (soy bean oil)"},{"name":"Control fat (sunflower oil)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00004266","briefTitle":"Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},"collaborators":[{"name":"Hennepin County Medical Center, Minneapolis"}]},"conditionsModule":{"conditions":["Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lisinopril"},{"name":"Nifedipine"},{"name":"Simvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02502253","briefTitle":"BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johns Hopkins University"},"collaborators":[{"name":"Icahn School of Medicine at Mount Sinai"}]},"conditionsModule":{"conditions":["Mild Cognitive Impairment","Alzheimer's Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"grape seed polyphenolic extract, resveratrol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02019264","briefTitle":"A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eisai Inc."},"collaborators":[{"name":"Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization"}]},"conditionsModule":{"conditions":["Cardiovascular Disease","High Cardiovascular Risk","Obesity","Overweight","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lorcaserin hydrochloride"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06664099","briefTitle":"Comparison of Weight Loss and Nutritional Deficiency After One Anastomosis Gastric Bypass at 150, 170, and 200 cm From the Duodenojejunal Junction"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cairo University"}},"conditionsModule":{"conditions":["Obesity","Nutritional Deficiency","Type 2 Diabetes Mellitus (T2DM)","Bariatric Surgery (Gastric Bypass)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"One Anastomosis Gastric Bypass (150 cm from Duodenojejunal Junction)"},{"name":"One Anastomosis Gastric Bypass (170 cm from Duodenojejunal Junction)"},{"name":"One Anastomosis Gastric Bypass (200 cm from Duodenojejunal Junction)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02481466","briefTitle":"The Combined Portfolio Diet and Exercise Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Unity Health Toronto"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"},{"name":"University of Toronto"},{"name":"Laval University"},{"name":"University of Manitoba"},{"name":"University of British Columbia"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Hypercholesterolemia","Type 2 Diabetes","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Portfolio diet and structured exercise"},{"name":"DASH-like diet and structured exercise"},{"name":"Portfolio diet and routine exercise"},{"name":"DASH-like diet and routine exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04943614","briefTitle":"Biodex Balance System Training in Diabetic Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Riphah International University"}},"conditionsModule":{"conditions":["Diabetic Neuropathies"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Biodex balance system"},{"name":"conventional exercises"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01472432","briefTitle":"DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Campania \"Luigi Vanvitelli\""}},"conditionsModule":{"conditions":["Chronic Foot Ulcers"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00367978","briefTitle":"Effects of Amlodipine/Benazepril in the Hypertensive African-American Population With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Amlodipine/benazepril"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02852980","briefTitle":"Estimate Rate of the Women Who Have Gestational Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hôpital NOVO"}},"conditionsModule":{"conditions":["Diabetes, Gestational"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"gestational diabetes women"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04026139","briefTitle":"Elastic Band Resistance Exercise on Glycated Haemoglobin and Muscle Strength, Balance, and Physical Function in Patients With Comorbid Type 2 Diabetes Mellitus and Knee Osteoarthritis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shu-Mei Chen"}},"conditionsModule":{"conditions":["Elastic Band Resistance Exercise With Comorbid Type 2 Diabetes Mellitus and Knee Osteoarthritis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Elastic Band Resistance Exercise"},{"name":"active joint range-of-motion exercises and isometric contraction exercises"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01711385","briefTitle":"Undiagnosed Diabetes in a Dental Setting"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Columbia University"},"collaborators":[{"name":"Colgate Palmolive"}]},"conditionsModule":{"conditions":["Prediabetic State","Type 2 Diabetes Mellitus With Oral Complications","Periodontal Pocket","Tooth Loss"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Enhanced intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02775266","briefTitle":"Effect of Antioxidant Intake on Resistin Levels In Patients With Gum Disease and Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Periodontitis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alpha lipoic acid"},{"name":"Scaling and Root planing"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05831644","briefTitle":"A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vicore Pharma AB"}},"conditionsModule":{"conditions":["Type2diabetes","Endothelial Dysfunction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"C21"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04327622","briefTitle":"Prevalence and Risk Evaluation of Diabetic Complications of the Foot in A Large Canadian Population"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LMC Diabetes & Endocrinology Ltd."}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1","Foot Deformities","Onychauxis","Neuropathy, Diabetic","Hyperkeratosis","Onychomycosis","Foot Ulcer, Diabetic"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02353416","briefTitle":"Effect of Low-Glycemic Index Mediterranean Diet on AGEs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Insulin Resistance","Obesity","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low Glycemic Index Mediterranean Diet"},{"name":"INRAM Guidelines' diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01469312","briefTitle":"Effect of Pasta on Blood Glucose Response in Normal Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Minneapolis Veterans Affairs Medical Center"}},"conditionsModule":{"conditions":["Blood Glucose Concentration","Type 2 Diabetes","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"modified pasta"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02276742","briefTitle":"Lifestyle Management of CKD in Obese Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NYU Langone Health"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes","Chronic Kidney Disease (CKD)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Social Cognitive Theory"},{"name":"Monitoring"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01869881","briefTitle":"Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yuhan Corporation"}},"conditionsModule":{"conditions":["Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Anplag(Sarpogrelate)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01472666","briefTitle":"Dairy Lipids, Proteins, and the Metabolic Syndrome - \"DairyHealth\""},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"Aarhus University Hospital"},{"name":"Arla Foods"},{"name":"Wageningen University"},{"name":"University of Dublin, Trinity College"}]},"conditionsModule":{"conditions":["Metabolic Syndrome","Type 2 Diabetes","Cardiovascular Disease","Abdominal Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High content of MC-SFA"},{"name":"Whey"},{"name":"Low content of MC-SFA"},{"name":"Casein"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01689051","briefTitle":"Vasodilatory and Metabolic Effects of Glucagon-like Peptide-1 in Periphery Circulation in Patients With and Without Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"},"collaborators":[{"name":"Danish Heart Foundation"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Blod Pressure","Glucagon-like Peptide-1","Human Physiology","Blood Flow"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"human glucagon-like peptide 1 (7-36)amide"},{"name":"human glucagon-like peptide 1 (9-36)amide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02745613","briefTitle":"Type 2 Diabetes Affect Exercise Induced Improvement in Insulin Sensitivity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Texas, El Paso"}},"conditionsModule":{"conditions":["Insulin Sensitivity/Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"8 weeks of combined exercise intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01818310","briefTitle":"Safety and Efficacy Study of Autologous Bone Marrow Aspirate Concentrate for No-Option Critical Limb Ischemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital Ostrava"},"collaborators":[{"name":"Ministry of Health, Czech Republic"},{"name":"Regional Council of the Moravian-Silesian region, KU MSK"}]},"conditionsModule":{"conditions":["Critical Lower Limb Ischemia","Type-2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Group A: Intramuscular"},{"name":"Group B: Intraarterial"},{"name":"Group C: Intravenous"},{"name":"Group D: Surgical endovascular treatment with maximum medicamentous treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03656744","briefTitle":"A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HighTide Biopharma Pty Ltd"}},"conditionsModule":{"conditions":["Fatty Liver, Nonalcoholic","NAFLD","Nonalcoholic Fatty Liver Disease","Nonalcoholic Steatohepatitis","Digestive System Diseases","Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HTD1801"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01234649","briefTitle":"Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Woman's"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Gestational Diabetes Mellitus","Type 2 Diabetes Mellitus","Metabolic Syndrome","Impaired Glucose Tolerance","Disorder of Glucose Regulation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin XR plus placebo"},{"name":"Metformin XR plus liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01775813","briefTitle":"The Health Influences of Puberty (HIP) Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Denver"},"collaborators":[{"name":"American Diabetes Association"},{"name":"National Institutes of Health (NIH)"},{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)"},{"name":"Children's Hospital Colorado"}]},"conditionsModule":{"conditions":["Obesity","Insulin Resistance","Gonadal Dysfunction","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01354262","briefTitle":"Effect of Vitamin D Supplementation on Hemoglobin A1c"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ascension Health"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Vitamin D Deficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin D"},{"name":"Vitamin D"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01617304","briefTitle":"Effects of Food Cooking on Diabetes-2 Risk Factors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Copenhagen"},"collaborators":[{"name":"The Ministry of Science, Technology and Innovation, Denmark"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes","Insulin Resistance","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dietary intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03588104","briefTitle":"\"POWER2DM Evaluation Campaign\""},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Leiden University Medical Center"},"collaborators":[{"name":"Andaluz Health Service"}]},"conditionsModule":{"conditions":["Type1 Diabetes Mellitus","Type2 Diabetes Mellitus","Diabetes Mellitus","Health Behavior","Self Efficacy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"POWER2DM system"},{"name":"Usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00139659","briefTitle":"A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Asthma","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Inhaled Insulin"},{"name":"Subcutaneous Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06573684","briefTitle":"Differences In The Severity Of Diabetic Neuropathy Based On Electromyography In Type 2 Diabetes Mellitus Patients With And Without Comorbidities"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universitas Diponegoro"}},"conditionsModule":{"conditions":["Diabetic Neuropathies"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Electromyography"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01827280","briefTitle":"Acute and Short-term Chronic Effects of Galvus (Vildagliptin) in Diabetes Type 2 Obese Women"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rio de Janeiro State University"},"collaborators":[{"name":"Laboratory for Clinical and Experimental Research on Vascular Biology"}]},"conditionsModule":{"conditions":["1- Microvascular Function","2-oxidative Stress","3-inflammation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vildagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01496820","briefTitle":"A Randomized Trial to Assess the Efficacy and Safety of GO2KA1(Chitosan Oligosaccharide)on Blood Glucose Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yonsei University"}},"conditionsModule":{"conditions":["Impaired Fasting Glucose, Newly-diagnosed Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GO2KA1"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00608387","briefTitle":"Evaluating a Web-Based Cardiovascular Disease Risk Factor Reduction Program Among American Indians"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Black Hills Center for American Indian Health"},"collaborators":[{"name":"University of Washington"},{"name":"University of Colorado, Denver"},{"name":"NuMedics, Inc."},{"name":"Cheyenne River Sioux Tribe Telephone Authority"},{"name":"Missouri Breaks Industries Research, Inc."},{"name":"Cheyenne River Sioux Tribe"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Diabetes Mellitus, Type 2","Hypertension","Obesity","Tobacco Use Cessation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Chronic disease management Web-based software"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00992043","briefTitle":"Creatine Supplementation and Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Sao Paulo"}},"conditionsModule":{"conditions":["Diabetes","Renal Function"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"creatine"},{"name":"Exercise training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01434407","briefTitle":"Effects of Advanced Glycation Endproducts on Satiety and Inflammation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Copenhagen"},"collaborators":[{"name":"The Ministry of Science, Technology and Innovation, Denmark"}]},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes","Insulin Resistance","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dietary meal intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04313920","briefTitle":"Study of a Carbohydrate Drink in Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Nutrition"}},"conditionsModule":{"conditions":["Glycemic Response"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nutritional Supplement"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00536250","briefTitle":"Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yale University"},"collaborators":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)"}]},"conditionsModule":{"conditions":["Impaired Glucose Tolerance","Pre-diabetes","Childhood Obesity","Insulin Resistance","Metabolic Syndrome"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03670797","briefTitle":"Prevalence Of Oral Mucosal Alterations In Diabetes Mellitus Type2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Alaa Mahmoud abd El kader"},"collaborators":[{"name":"Cairo University"}]},"conditionsModule":{"conditions":["Oral Disease","Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00495885","briefTitle":"Efficacy and Safety of M100907 on Sleep Maintenance Insomnia With a Sub-study in Stable Type II Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Sleep Initiation and Maintenance Disorders"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"volinanserin (M100907)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03329261","briefTitle":"Incidence of Major Cardiovascular Events in Diabetic Patients With ACS Undergoing Coronary Angioplasty and Treated With Clopidogrel 150 mg Versus 75 mg"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Laboratoires Teriak"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","NSTEMI - Non-ST Segment Elevation MI","Coronary Angioplasty"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Clopidogrel"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01038518","briefTitle":"Health2010-14: Monitoring Biomarkers of Chronic Diseases in the General Population"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Glostrup University Hospital, Copenhagen"},"collaborators":[{"name":"Steno Diabetes Centre, Gentofte, Denmark"}]},"conditionsModule":{"conditions":["Cardiovascular Disease","Type 2 Diabetes","Asthma","Allergy","Osteoporosis"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02229396","briefTitle":"Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exantide with Dapagliflozin"},{"name":"Exentide"},{"name":"Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02593032","briefTitle":"Effects of Use of a Connected Pillbox On Medication Adherence"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pennsylvania"},"collaborators":[{"name":"TowerView Health"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Hypertension","Hyperlipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pre-filled trays"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02647905","briefTitle":"Evaluation of the Accuracy of an Implanted Glucose Sensor"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Senseonics, Inc."}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous Glucose Monitoring System"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03807596","briefTitle":"Hyaluronic Acid With Scaling & Root Planing In Chronic Periodontitis Patients With Diabetes Mellitus Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cairo University"}},"conditionsModule":{"conditions":["Chronic Periodontitis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Periodontal treatment with Hyaluronic acid associated with SRP"},{"name":"Scaling & root planning alone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01968044","briefTitle":"A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LG Life Sciences"}},"conditionsModule":{"conditions":["Type 2 DM Patients With Moderate or Severe Renal Impairment"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gemigliptin"},{"name":"Placebo to Linagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05253521","briefTitle":"The Role of South Asian vs European Origins on Circulating Regenerative Cell Exhaustion"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Canadian Medical and Surgical Knowledge Translation Research Group"},"collaborators":[{"name":"Unity Health Toronto"},{"name":"Western University, Canada"}]},"conditionsModule":{"conditions":["Diabetes","Type 1 Diabetes","Type 2 Diabetes","Ischemic Heart Disease","Ischemic Stroke","Cardiovascular Diseases","Peripheral Vascular Diseases"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04048642","briefTitle":"Effects of a Plant-Based Diet on Insulin Requirements and Obesity Markers in Obese Adults With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Rochester"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Insulin Resistance","Obesity","Nutritional and Metabolic Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DASH"},{"name":"Whole-Food, Plant-Based"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00108901","briefTitle":"The Medical College of Georgia PLAY Project: Exercise Dose and Insulin Sensitivity in Obese Children"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Obesity","Type 2 Diabetes Prevention","Executive Function (Cognition)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aerobic exercise program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02808182","briefTitle":"Postprandial Fatty Acid Metabolism in the Natural History of Type 2 Diabetes (T2D)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Université de Sherbrooke"}},"conditionsModule":{"conditions":["Impaired Glucose Tolerance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nicotinic acid"},{"name":"[7,7,8,8-2H]-palmitate"},{"name":"[U-13C]-palmitate"},{"name":"Biopsy"},{"name":"liquid meal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01884545","briefTitle":"Genetic Risk and Health Coaching for Type 2 Diabetes and Coronary Heart Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Duke University"},"collaborators":[{"name":"David Grant U.S. Air Force Medical Center"}]},"conditionsModule":{"conditions":["Coronary Heart Disease, Susceptibility to, 5","Prediabetic State"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Health coaching"},{"name":"Genetic risk counseling"},{"name":"Standard risk assessment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00636766","briefTitle":"Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aristotle University Of Thessaloniki"}},"conditionsModule":{"conditions":["Carotid Atherosclerosis","Stroke","Type 2 Diabetes","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"atorvastatin"},{"name":"rimonabant"},{"name":"rosiglitazone"},{"name":"metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03710083","briefTitle":"A Pivotal Study to Evaluate Guardian™ Connect CGM System Performance in China"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medtronic Diabetes"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Guardian™ Sensor (3)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01397279","briefTitle":"Assessment of Liver Glucose Metabolism in Diabetic Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"German Diabetes Center"}},"conditionsModule":{"conditions":["Newly Diagnosed Type 2 Diabetes (During the Last 12 Months)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"intravenous glucose tolerance test"},{"name":"hyperinsulinemic euglycemic clamp"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01076478","briefTitle":"Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Otsuka Pharmaceutical, Inc., Philippines"}},"conditionsModule":{"conditions":["Polyneuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cilostazol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02324309","briefTitle":"BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 Post-Meal Glucose Control in Patients With Severe Insulin Resistance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Biodel"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BIOD-531"},{"name":"Humalog Mix 75/25"},{"name":"Humulin R U-500"},{"name":"BIOD-531"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00390637","briefTitle":"Diet, Obesity and Genes (DiOGenes)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Copenhagen"},"collaborators":[{"name":"European Commission"}]},"conditionsModule":{"conditions":["Obesity","Metabolic Syndrome","Type 2 Diabetes","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High or low Glycemic Index and high or low Protein Diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04176276","briefTitle":"Determining Serum and Urinary Levels of miRNA 192 and miRNA 25 in Patients With and Without Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pisa"}},"conditionsModule":{"conditions":["Diabetic Kidney Disease","Type2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"no interventions required."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00286572","briefTitle":"Long-term Mortality in Diabetics Undergoing Major Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Basel, Switzerland"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Coronary Heart Disease","Major Non-cardiac Surgery"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00232375","briefTitle":"Intervention to Preserve Beta-Cell Function in GAD Ab-Positive Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tokyo Study Group"}},"conditionsModule":{"conditions":["GAD Ab Positive Clinically Type 2 Diabetic Patients"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00445354","briefTitle":"Randomized Controlled Clinical Trial of Cinnamon to Lower Hemoglobin A1c"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eglin AFB Regional Hospital"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"cinnamon"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00602914","briefTitle":"A Pilot Study to Assess the Safety, PK and PD of Insulin Injected Via MicronJet or Conventional Needle"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NanoPass Technologies Ltd"}},"conditionsModule":{"conditions":["Intradermal Injections"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MicronJet"},{"name":"MicronJet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01041144","briefTitle":"Effects of Health Care Provider-mediated, Remote Coaching System Through the PDA-type Glucometer and the Internet on Diabetes Management"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Catholic University of Korea"},"collaborators":[{"name":"Ministry for Health Welfare and Family Affairs"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Lifestyle Intervention","Glucose Control","Internet Communication"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"lifestyle counseling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00876980","briefTitle":"Obstructive Sleep Apnea and Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Hong Kong"}},"conditionsModule":{"conditions":["Obstructive Sleep Apnea","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"nasal Continuous Positive Airway Pressure"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05396079","briefTitle":"Effect of Tahini in Oxidative Stress and Endothelial Function in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Harokopio University"},"collaborators":[{"name":"National and Kapodistrian University of Athens"}]},"conditionsModule":{"conditions":["Oxidative Stress","Endothelial Function","Blood Pressure","Arterial Stiffness","Blood Glucose","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"tahini and bread"},{"name":"margarine, cheese and bread"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00005479","briefTitle":"Diabetes, Lipoproteins and Accelerated Vascular Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Columbia University"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Heart Diseases","Coronary Disease","Atherosclerosis","Carotid Artery Diseases","Diabetes Mellitus, Non-insulin Dependent","Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01774565","briefTitle":"Closed-loop Insulin Delivery in the General Ward"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Cambridge"},"collaborators":[{"name":"Cambridge University Hospitals NHS Foundation Trust"},{"name":"Insel Gruppe AG, University Hospital Bern"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fully Automated Closed-Loop Insulin Delivery"},{"name":"Conventional insulin therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03251755","briefTitle":"Exercise Using Chinese Yoga Improving Insomnia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Taichung Veterans General Hospital"}},"conditionsModule":{"conditions":["Exercise Promotion"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Yoga"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03839667","briefTitle":"Intensive Diet and Physical Activity on Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Jiao Tong University School of Medicine"}},"conditionsModule":{"conditions":["Type2 Diabetes","Life Style"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"intensive diet intervention"},{"name":"Enhanced physical activity intervention"},{"name":"Standard education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01877590","briefTitle":"Alpha-lipoic Acid Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Wuhan General Hospital of Guangzhou Military Command"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Coronary Artery Disease","Left Ventricular Mass"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"alpha-lipoic acid"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02435329","briefTitle":"Microcirculation and Bone Metabolism in Patients With Type 2 Diabetes Mellitus and Charcot Foot - A Pilot Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tameside General Hospital"},"collaborators":[{"name":"Manchester Metropolitan University"}]},"conditionsModule":{"conditions":["Diabetic Angiopathies","Bone Diseases, Metabolic"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Baseline comparison of microcirculation and bone metabolism"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00024583","briefTitle":"Prenatal Nutrition and Adult Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}},"conditionsModule":{"conditions":["Cardiovascular Diseases","Heart Diseases","Diabetes Mellitus","Diabetes Mellitus, Non-insulin Dependent","Insulin Resistance","Obesity","Hypertension"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01963130","briefTitle":"Does Vildagliptin Affect Portal Vein Pressure In Patients With Type 2 Diabetes Mellitus? A Cross Sectional Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bezmialem Vakif University"}},"conditionsModule":{"conditions":["Drug Mechanism","Drug Usage"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01941290","briefTitle":"BIOFLOW III Asia Registry Orsiro Stent System"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"BIOTRONIK Asia Pacific Pte Ltd"}},"conditionsModule":{"conditions":["Coronary Artery Disease","Myocardial Ischemia","Diabetes Mellitus Type 1 or 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01895712","briefTitle":"BIOFLOW-III Israel Satellite Registry"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"BIOTRONIK Israel"}},"conditionsModule":{"conditions":["Coronary Artery Disease","Myocardial Ischemia","Diabetes Mellitus Type 1 or 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01686828","briefTitle":"T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Washington"}},"conditionsModule":{"conditions":["Insulin Resistance","Type 2 Diabetes Mellitus","Obesity","Androgen Deficiency","Metabolic Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acyline"},{"name":"Testosterone 1.62% gel"},{"name":"Letrozole"},{"name":"Placebo gel (for Testosterone 1.62% gel)"},{"name":"Placebo pill (for Letrozole)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01003236","briefTitle":"Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shiraz University of Medical Sciences"}},"conditionsModule":{"conditions":["Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo"},{"name":"Milk Thistle extract"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03068078","briefTitle":"A Reduced-carbohydrate Diet High in Monounsaturated Fats in Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Odense University Hospital"},"collaborators":[{"name":"Danish Diabetes Academy"},{"name":"Region of Southern Denmark"},{"name":"Odense Patient Data Explorative Network"},{"name":"Novo Nordisk A/S"},{"name":"University of Southern Denmark"}]},"conditionsModule":{"conditions":["Type2 Diabetes","Nonalcoholic Steatohepatitis","Non-Alcoholic Fatty Liver Disease","Atherosclerosis","Dyslipidemias"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low carbohydrate diet high in monounsaturated fats"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01784965","briefTitle":"Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Stanford University"}},"conditionsModule":{"conditions":["Pre-diabetes","Older Adults"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02109978","briefTitle":"RetroMASTER - Retrospective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Royal Devon and Exeter NHS Foundation Trust"},"collaborators":[{"name":"University of Exeter"},{"name":"University of Oxford"},{"name":"Oxford University Hospitals NHS Trust"},{"name":"University of Dundee"},{"name":"NHS Tayside"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02105792","briefTitle":"PROMASTER - PROspective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Royal Devon and Exeter NHS Foundation Trust"},"collaborators":[{"name":"University of Exeter"},{"name":"King's College London"},{"name":"King's College Hospital NHS Trust"},{"name":"University of Glasgow"},{"name":"NHS Greater Glasgow and Clyde"},{"name":"Newcastle University"},{"name":"Newcastle-upon-Tyne Hospitals NHS Trust"},{"name":"Oxford University Hospitals NHS Trust"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"second- or third-line glucose-lowering diabetes treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00031200","briefTitle":"MRI Derived Organ & Tissue Mass Changes With Weight Loss - Ancillary to Look AHEAD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}},"conditionsModule":{"conditions":["Cardiovascular Diseases","Atherosclerosis","Obesity","Diabetes Mellitus, Non-insulin Dependent","Heart Diseases","Myocardial Infarction","Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01420198","briefTitle":"Efficiency and Cost-effectiveness of a Culturally Adopted Lifestyle Intervention Program - the MEDIM Study."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Region Skane"},"collaborators":[{"name":"Lund University"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Impaired Glucose Tolerance","Obesity","Physical Activity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03462017","briefTitle":"Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Microvascular Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SAR247799"},{"name":"Placebo"},{"name":"Sildenafil"},{"name":"Acetylcholine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04027530","briefTitle":"Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Amsterdam UMC, location VUmc"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Diabetic Kidney Disease","Diabetic Nephropathy","Renal Hypoxia","Renoprotection","SGLT2 Inhibitor","Ertugliflozin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ertugliflozin 15 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03840161","briefTitle":"Use of CoG by Patients With Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sciema UG"},"collaborators":[{"name":"Cnoga Medical Ltd."}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"non-invasive tissue glucose prediction"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01099618","briefTitle":"Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dawn Smiley MD"}},"conditionsModule":{"conditions":["Ketosis Prone Diabetes","Diabetes Ketoacidosis","Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"metformin"},{"name":"placebo"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04143945","briefTitle":"A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Healthy Volunteers Diabetes Mellitus, Type 2","Healthy Volunteers Overweight","Healthy Volunteers Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide (administered by DV3396 pen)"},{"name":"Semaglutide (administered by PDS290 pen)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02582736","briefTitle":"Antipsychotics and Risk of Hyperglycemic Emergencies"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Canadian Network for Observational Drug Effect Studies, CNODES"},"collaborators":[{"name":"Drug Safety and Effectiveness Network, Canada"},{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Psychotic Disorders","Schizophrenia","Schizoaffective Disorder","Bipolar Disorder","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Olanzapine"},{"name":"Risperidone"},{"name":"atypical antipsychotics (other)"},{"name":"typical antipsychotics"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01252082","briefTitle":"Non-surgical Periodontal Therapy Effects Metabolic Control in Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mashhad University of Medical Sciences"}},"conditionsModule":{"conditions":["Metabolic Control"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Scaling and Rootplaning"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00327418","briefTitle":"CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"},"collaborators":[{"name":"Diabetes UK"},{"name":"Department of Health, United Kingdom"}]},"conditionsModule":{"conditions":["Major Coronary Event","Cerebrovascular Accident","Coronary Artery Bypass Graft","Angina, Unstable","Revascularization"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Atorvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04143321","briefTitle":"Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory Angina"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Isfahan University of Medical Sciences"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin 25 MG"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04411277","briefTitle":"Time in Range (TIR) and Time Below Range (TBR) in Insulin-Treated Elderly Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cline Research Center"},"collaborators":[{"name":"Abbott Diabetes Care"}]},"conditionsModule":{"conditions":["Continuous Glucose Monitoring"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Application of the FreeStyle Libre Flash Glucose CGM."},{"name":"InBody 270 multifrequency bioimpedance"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00162240","briefTitle":"PPAR - Combination With Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bristol-Myers Squibb"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Muraglitazar"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05190198","briefTitle":"Effect of Ankle Proprioception Training in Type 2 Diabetic Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Riphah International University"}},"conditionsModule":{"conditions":["Diabetic Neuropathies"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Proprioceptive neuromuscular facilitation"},{"name":"conventional therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03643783","briefTitle":"Impact of Plasma Soluble Prorenin Receptor in Obese and Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tulane University"},"collaborators":[{"name":"Tulane University Health Sciences Center"},{"name":"UAB-CCTS Network Mulitdisciplinary Pilot Program"}]},"conditionsModule":{"conditions":["Obesity","Type2 Diabetes","Bariatric Surgery Candidate"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04863872","briefTitle":"Comparing the Effectiveness of Two Approaches to Preventing Severe Hypoglycemia in Patients With Type 2 Diabetes (PHT2)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kaiser Permanente"},"collaborators":[{"name":"Patient-Centered Outcomes Research Institute"}]},"conditionsModule":{"conditions":["Severe Hypoglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Proactive Care Management"},{"name":"my hypo compass education program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03663803","briefTitle":"Live Your Life Without Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"}},"conditionsModule":{"conditions":["Pre Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Brief theory-based health promotion intervention (group-based)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03359590","briefTitle":"Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Profil Institut für Stoffwechselforschung GmbH"},"collaborators":[{"name":"Merck Sharp & Dohme LLC"}]},"conditionsModule":{"conditions":["Pharmacological Action"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin 100 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01859598","briefTitle":"Observational Registry for Basal Insulin Treatment Study (ORBIT)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The George Institute for Global Health, China"},"collaborators":[{"name":"Chinese Diabetes Society"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02263352","briefTitle":"A Clinical Trial to Study the Effect of Lycopene in Patients With Gum Disease and type2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre"},"collaborators":[{"name":"National Institute of Health and Nutrition"}]},"conditionsModule":{"conditions":["Positive Regulation of Oxidative Stress Process"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lycored soft gels Jagsonpal Pharma, Systemic 8mgms/day"},{"name":"Scaling and root planing"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01519102","briefTitle":"Comparison of Closed-loop Operation After Morning Meal With and Without Carbohydrate Counting"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institut de Recherches Cliniques de Montreal"},"collaborators":[{"name":"McGill University"},{"name":"Montreal Children's Hospital of the MUHC"}]},"conditionsModule":{"conditions":["Type-1 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dual Hormone closed-loop system"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01464320","briefTitle":"A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott"}},"conditionsModule":{"conditions":["Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ABT-614"},{"name":"Placebo Comparator"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03240874","briefTitle":"SweetMama: Testing of a Novel Technology for Diabetes Education and Support to Pregnant Women"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Northwestern University"},"collaborators":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus in Pregnancy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SweetMama Focus Groups"},{"name":"SweetMama Individual Testing"},{"name":"SweetMama Feasibility Testing - Pilot Randomized Trial"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04754464","briefTitle":"Clinical Study on the Effect of a Synbiotic on Body Fat Mass"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Slimbiotics"},"collaborators":[{"name":"Clinical Research Center Kiel GmbH"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Metabolic Syndrome","Obesity, Abdominal","Obesity, Visceral"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"synbiotic"},{"name":"microcrystalline cellulose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01109927","briefTitle":"Early Insulin Treatment in Patients With Latent Autoimmune Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lund University Hospital"},"collaborators":[{"name":"Landstinget Kronoberg, Sweden"}]},"conditionsModule":{"conditions":["Diabetes, Autoimmune","Diabetes Mellitus, Adult-Onset"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01071785","briefTitle":"Dietetic Intervention With Soluble Fiber in Type 2 Diabetes Mellitus (DM) Patients With Metabolic Syndrome (MS)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital de Clinicas de Porto Alegre"}},"conditionsModule":{"conditions":["Metabolic Syndrome","Albuminuria"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"guar gum"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02129868","briefTitle":"Automated Closed-loop in Children and Adolescents With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Cambridge"},"collaborators":[{"name":"Cambridge University Hospitals NHS Foundation Trust"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 1","Glucose Metabolism Disorders","Endocrine System Diseases","Autoimmune Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Closed-loop (Android Closed-Loop platform)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01334125","briefTitle":"Adjunctive Metformin Therapy in Double Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Massachusetts, Worcester"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03770767","briefTitle":"Insulin Fiasp vs. Insulin Novorapid During Pregnancy and Laction in Women With Pre-existing Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rigshospitalet, Denmark"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Pregnancy Complications"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Faster-acting Aspart insulin Fiasp"},{"name":"Control (insulin Novorapid)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03738865","briefTitle":"G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Xeris Pharmaceuticals"},"collaborators":[{"name":"Empiristat, Inc."}]},"conditionsModule":{"conditions":["Insulin Hypoglycemia","Type 1 Diabetes Mellitus","Severe Hypoglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"G-Pen"},{"name":"Novo Glucagon"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01766570","briefTitle":"Beneficial Effects of a Polyphenol Enriched Beverage on Type 2 Diabetes Prevention and on Cardiovascular Risk Profile of Men and Women With Insulin Resistance."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Laval University"},"collaborators":[{"name":"Consortium de recherche et innovations en bioprocédés industriels au Québec (CRIBIQ)"},{"name":"Institute of Nutraceuticals and Functional Foods"}]},"conditionsModule":{"conditions":["Diabetes","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Uncontrolled nutritional intervention with a supplemental beverage"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04288778","briefTitle":"A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johnson & Johnson Private Limited"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin + Metformin hydrochloride (Fixed Dose Combination)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00877929","briefTitle":"Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Telmisartan 80"},{"name":"Amlodipine 10"},{"name":"Amlodipine 10"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03823027","briefTitle":"STAR Study Investigating Performance and Safety of the Medical Device SiPore15™"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sigrid Therapeutics AB"}},"conditionsModule":{"conditions":["PreDiabetes","Pre Diabetes","Prediabetic State","Type2 Diabetes","Type2 Diabetes Mellitus","Overweight","Obese"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SiPore15™"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02419612","briefTitle":"A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Saxagliptin"},{"name":"Dapagliflozin"},{"name":"Glimepiride"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00734383","briefTitle":"Propofol Cardioprotection for Type II Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of British Columbia"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Myocardial Injury"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Propofol"},{"name":"Propofol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05449782","briefTitle":"Macro- and Microvascular Response to Cocoa Flavanols in Healthy and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Surrey"}},"conditionsModule":{"conditions":["Microangiopathy, Diabetic","Polyphenol","Optical Tomography","Vascular Endothelium","Arterial Stiffness","Healthy Participants"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cocoa flavanol"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06252051","briefTitle":"Effectiveness of Trivalent Influenza Vaccine (TIV) in Type 2 Diabetes Mellitus (T2DM) Patients With and Without Complications of Chronic Kidney Disease (CKD)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universitas Padjadjaran"},"collaborators":[{"name":"Biofarma"},{"name":"Universiti Sains Malaysia"}]},"conditionsModule":{"conditions":["Influenza","Vaccine Reaction","Diabetes Mellitus","Chronic Kidney Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Trivalent Influenza Vaccine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03017703","briefTitle":"The Role of Aldosterone in Circulatory Disorders Within Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Southern Denmark"}},"conditionsModule":{"conditions":["Endothelial Dysfunction","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Eplerenone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02285231","briefTitle":"Anti-hyperglycemic Effect of Short-term Arginyl-fructose Supplementation in Subjects With Pre-diabetes and Newly Diagnosed Type 2 Diabetes: Randomized, Double-blinded, Placebo-controlled Trial."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yonsei University"}},"conditionsModule":{"conditions":["Pre-diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Arginyl-fructose"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05375656","briefTitle":"The Effect on Metabolism, Food Intake and Preferences of a Knockout Gene Variant Involved in Carbohydrate Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Steno Diabetes Center Copenhagen"},"collaborators":[{"name":"The Novo Nordisk Foundation Center for Basic Metabolic Research"},{"name":"Department of Food Science, University of Copenhagen"},{"name":"Steno Diabetes Center Greenland"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Metabolic Disease","Sucrose Intolerance Congenital","Sucrase Isomaltase Deficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cross-over study"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03252132","briefTitle":"Resistance Training in Patients With Diabetic Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Danish Pain Research Center"},"collaborators":[{"name":"Odense University Hospital"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Polyneuropathy Diabetes","Diabetes Complications","Diabetic Peripheral Neuropathy","Muscle Weakness","Fall Patients"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"12-week resistance training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06197360","briefTitle":"Effects of a Health Intervention on Fear of Hypoglycemia : a Pilot Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yangzhou University"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Fear of Hypoglycemia","Health Education","Impaired Awareness of Hypoglycemia","Self-Management"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Based on BCW Theory of Health Education"},{"name":"General diabetes health education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03869411","briefTitle":"Effects of Exercise Intervention and Confounding Factors on Type II Diabetic Muscles"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Taiwan University Hospital"}},"conditionsModule":{"conditions":["Diabetes and Healthy Control","FTO Gene Expression","Aerobic Exercise Intervention or Home Exercise","Pre-training and Post-training"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"supervised aerobic exercise or home-based aerobic exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00691249","briefTitle":"Resistant Starch on Glucose and Insulin Sensitivity in Individuals With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kansas State University"},"collaborators":[{"name":"MGP Ingredients, Inc."}]},"conditionsModule":{"conditions":["Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Resistant Starch Type 4-Raw"},{"name":"Resistant Starch Type 4-Raw"},{"name":"Resistant Starch Type 4-Cooked"},{"name":"Resistant Starch Type 4-Cooked"},{"name":"Shredded Wheat"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01477112","briefTitle":"Low Dose β-carotene Supplementation Diminishes Oxidative Stress in Type 2 Diabetics and Healthy Individuals"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Instituto Venezolano de Investigaciones Cientificas"},"collaborators":[{"name":"Seguros Caracas Foundation"},{"name":"National Fund for Science and Technology, Science Mission"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Oxidative Stress","Iron Metabolism Disorders"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Betacarotene"},{"name":"Controls. No treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03376698","briefTitle":"Dose-finding Study of Colchicine in Type 2 Diabetic Patients With Coronary Artery Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of the Ryukyus"}},"conditionsModule":{"conditions":["Colchicine","Diabetes Mellitus, Type 2","Coronary Artery Disease","White Blood Cell","Inflammation","Diarrhea"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Colchicine 0.5 mg"},{"name":"Colchicine 0.25 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04157673","briefTitle":"Imagine to Remember: Improving Medication Adherence in Pre- and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"State University of New York at Buffalo"}},"conditionsModule":{"conditions":["Medication Adherence"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Episodic Future Thinking"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02096705","briefTitle":"Phase III Insulin Add-On Asia Regional Program - ST"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Dapagliflozin Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05259475","briefTitle":"Ectopic Fat in Singaporean Women - the Culprit Leading to Gestational Diabetes, Metabolic Syndrome, and Type 2 Diabetes (TANGO Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institute for Human Development and Potential (IHDP), Singapore"},"collaborators":[{"name":"Wilmar International Limited"},{"name":"SATA CommHealth (Singapore)"},{"name":"National University Polyclinics, Singapore"},{"name":"National University of Singapore"}]},"conditionsModule":{"conditions":["Non-Alcoholic Fatty Liver Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle Advice"},{"name":"Diet Intervention"},{"name":"OCFA Meal-Based Diet-Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01034826","briefTitle":"Progression to Impaired Glucose Tolerance and Type 2 Diabetes in the Korean People-based KNDP Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Korea University Guro Hospital"}},"conditionsModule":{"conditions":["Impaired Glucose Tolerance","Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00681278","briefTitle":"Retrospective Survey for Patients With Hypertension and Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Hypertension"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03502109","briefTitle":"Pharmacist-led Medication Review With Follow-up on Primary Care Cardiovascular Older Adult Patients."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pontificia Universidad Catolica de Chile"},"collaborators":[{"name":"University of Technology, Sydney"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Medication Adherence","Drug Use","Hypertension","Type 2 Diabetes Mellitus","Dyslipidemias"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Medication review with follow-up"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03910361","briefTitle":"Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dong-A ST Co., Ltd."}},"conditionsModule":{"conditions":["Type2 Diabetes","Non-Alcoholic Fatty Liver Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Evogliptin"},{"name":"Pioglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03439072","briefTitle":"G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Xeris Pharmaceuticals"},"collaborators":[{"name":"SGS S.A."},{"name":"Integrated Medical Development"}]},"conditionsModule":{"conditions":["Insulin Hypoglycemia","Type 1 Diabetes Mellitus","Severe Hypoglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"G-Pen"},{"name":"Lilly Glucagon"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00927394","briefTitle":"Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Aliskiren"},{"name":"Valsartan"},{"name":"Placebo for Aliskiren"},{"name":"Placebo for Valsartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00819325","briefTitle":"Prevention of Instent Renarrowing With Aggressive Glucose Lowering With Pioglitazone in Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Queen Elizabeth II Health Sciences Centre"},"collaborators":[{"name":"Nova Scotia Health Research Foundation"}]},"conditionsModule":{"conditions":["Coronary Artery Disease","Angina Pectoris","Type 2 Diabetes Mellitus","Percutaneous Coronary Intervention"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pioglitazone"},{"name":"oral hypoglycemic agents"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05358444","briefTitle":"Family Diabetes Prevention Program Pilot Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johns Hopkins University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["PreDiabetes","Overweight and Obesity","Type 2 Diabetes","Overweight, Childhood","Obesity, Childhood","Lifestyle, Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"National Diabetes Prevention Program Lifestyle Intervention (DPP)"},{"name":"Family Diabetes Prevention Program (Family DPP)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04380584","briefTitle":"Relation Between Plasma Apelin Level and Diabetic Nephropathy in Type 2 Diabetes Patients."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cairo University"}},"conditionsModule":{"conditions":["Diabetic Nephropathies"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"plasma Apelin level"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02002091","briefTitle":"Morbidity in Newly Diagnosed type2 Diabetes in Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Algiers"},"collaborators":[{"name":"National Institute of public Health, Algeria"},{"name":"Hopital Ain Taya"},{"name":"Parnet Hospital"},{"name":"Hôpital Mustapha Pacha"},{"name":"Birtraria Hospital"},{"name":"Bab El Oued Teaching Hospital"}]},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus","Complications"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"no specific treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01959334","briefTitle":"Evaluate the Immunogenicity of a Novel Glucagon Formulation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"},"collaborators":[{"name":"Locemia Solutions ULC"}]},"conditionsModule":{"conditions":["Drug-specific Antibodies","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nasal Glucagon (NG)"},{"name":"Glucagon IM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05457933","briefTitle":"Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medanta, The Medicity, India"}},"conditionsModule":{"conditions":["Type2diabetes","Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Glargine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00306696","briefTitle":"Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone"},{"name":"spironolactone"},{"name":"hydrochlorothiazide"},{"name":"frusemide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04523064","briefTitle":"POST-CABGDM: Empagliflozin in Perioperative CABG"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Sao Paulo General Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Coronary Artery Disease","Coronary Artery Bypass Surgery","Acute Kidney Injury"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin 25 MG"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02232503","briefTitle":"Prevalence of DIAbetic RETinopathy and Impact of Genetic Factors in the Development of Diabetic Retinopathy of Patients With Type 1 and 2 Diabetes Mellitus in SlovaKia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Slovakia, s.r.o."},"collaborators":[{"name":"Medirex Group Academy"},{"name":"Slovak Technical University"},{"name":"Comenius University"}]},"conditionsModule":{"conditions":["Diabetic Retinopathy","Diabetic Macular Edema","Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Studied cohort"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03260881","briefTitle":"Liraglutide Effects on Epicardial Fat Inflammatory Genes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Miami"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type2 Diabetes","Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide Pen Injector [Victoza]"},{"name":"matching liraglutide-placebo pre-filled pens"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01823367","briefTitle":"Encourage Healthy Families"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Indiana University"},"collaborators":[{"name":"The JPB Foundation"},{"name":"The YMCA of Greater Indianapolis"},{"name":"Regenstrief Institute, Inc."},{"name":"Indiana Clinical and Translational Sciences Institute"}]},"conditionsModule":{"conditions":["Gestational Diabetes Mellitus","Pre-diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetes Prevention Program (DPP)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05129891","briefTitle":"A Research Study Looking at New Protein-based Tablets in Healthy Male Participants"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Healthy Volunteers","High Blood Cholesterol Levels","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide D"},{"name":"Semaglutide G"},{"name":"Semaglutide H"},{"name":"Semaglutide I"},{"name":"NNC0385-0434 B"},{"name":"NNC0385-0434 C"},{"name":"NNC0385-0434 D"},{"name":"NNC0385-0434 E"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03249974","briefTitle":"Comparison Between Enlite and Flash Glucose Monitoring"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jessa Hospital"}},"conditionsModule":{"conditions":["Type1 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Enlite sensor communicating with Minimed 640G pump"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03939000","briefTitle":"Clinical Profile and Laboratory Finding of DFU From Tertiary Hospitals in Bali"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Udayana University"}},"conditionsModule":{"conditions":["Diabetic Foot Ulcer","Type 2 Diabetes Mellitus","Laboratory Problem","Physical Findings.Skin Ulcer"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05939921","briefTitle":"Effects of Metformin Therapy on Pancreatic and Hepatic Fat Content in Patients of Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diabetes Foundation, India"},"collaborators":[{"name":"National Diabetes Obesity and Cholesterol Foundation"}]},"conditionsModule":{"conditions":["Type2diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00889226","briefTitle":"Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"JW Pharmaceutical"}},"conditionsModule":{"conditions":["Hypercholesterolemia With Type2DM"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pitavastatin"},{"name":"Atorvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02258698","briefTitle":"Insulin Sensitivity, Irisin and Adipokines as Outcome Parameters in Patients Undergoing Cardiac Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Basel, Switzerland"},"collaborators":[{"name":"McGill University"}]},"conditionsModule":{"conditions":["Insulin Resistance","Diabetes Mellitus Type 2","Other Functional Disturbances Following Cardiac Surgery"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cardiac surgery"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03741660","briefTitle":"Konjac-Mannan Improves Glycemia and Other Risk Factors for CHD in T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Unity Health Toronto"},"collaborators":[{"name":"Dicofarm"},{"name":"University of Toronto"}]},"conditionsModule":{"conditions":["Type2 Diabetes","Coronary Heart Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"konjac glucomannan"},{"name":"wheat bran"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03939624","briefTitle":"Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Canadian Network for Observational Drug Effect Studies, CNODES"},"collaborators":[{"name":"Drug Safety and Effectiveness Network, Canada"},{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Type2 Diabetes","Myocardial Infarction","Ischemic Stroke","Cardiovascular Death","Heart Failure","All-Cause Mortality"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors"},{"name":"Dipeptidyl peptidase-4 (DPP-4) inhibitors"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02402985","briefTitle":"Comparison of a Plant Protein Diet to a Animal Protein Diet Emphasized in Type 2 Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"German Institute of Human Nutrition"},"collaborators":[{"name":"Ministry of Food and Agriculture, Germany"},{"name":"Ernst von Bergmann Hospital"},{"name":"University Hospital Tuebingen"},{"name":"Institute of Gain Processing IGV GmbH, Potsdam"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Nutrition Disorders","Obesity","Body Weight","Metabolic Syndrome x","Metabolic Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High animal protein diet group"},{"name":"High plant protein diet group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03736486","briefTitle":"Mil Familias-Santa Barbara's Operational Pilot to Understand Diabetes in the Latino Community"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sansum Diabetes Research Institute"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus","Cardiovascular Diseases"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06131918","briefTitle":"Assessment of Antioxidant Therapy on Oxidative Stress Biomarkers in Type 2 Diabetic Patients With Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Khyber Medical University Peshawar"}},"conditionsModule":{"conditions":["Peripheral Diabetic Neuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Resveratrol, Alpha lipoic acid, Super oxide dismutase"},{"name":"Resveratrol"},{"name":"Alpha lipoic acid"},{"name":"Super Oxide Dismutase"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02421198","briefTitle":"Family Focused Community Program to Prevent Type 2 Diabetes in Peripubertal Youth"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Arizona"}},"conditionsModule":{"conditions":["Pediatric Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"YMCA Family Diabetes Prevention Program (YFDPP)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02686476","briefTitle":"Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medanta, The Medicity, India"}},"conditionsModule":{"conditions":["Non Alcoholic Fatty Liver Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04289753","briefTitle":"Behavioral Economics Applications to Geriatrics Leveraging EHRs R33 Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Northwestern University"},"collaborators":[{"name":"University of Southern California"},{"name":"University of California, Los Angeles"},{"name":"National Institute on Aging (NIA)"}]},"conditionsModule":{"conditions":["Prostate Specific Antigen Screening","Asymptomatic Bacteriuria","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EHR clinical decision support nudges"},{"name":"Brief clinician education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04498156","briefTitle":"Survey of Patient and Physician Awareness and Values to the Diagnosis and Treatment of Reduced Kidney Function (Chronic Kidney Disease) in Patients With High Blood Sugar Level (Type 2 Diabetes) (AWARE-CKD in T2D)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"},"collaborators":[{"name":"LMC Diabetes & Endocrinology"}]},"conditionsModule":{"conditions":["Renal Insufficiency, Chronic"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02957838","briefTitle":"Mitochondrial Effects of C18:0 Supplementation in Humans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital Heidelberg"},"collaborators":[{"name":"German Cancer Research Center"}]},"conditionsModule":{"conditions":["Alteration of Mitochondrial Membrane","Type2 Diabetes","Fatty Acid Deficiency"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"C18:0"},{"name":"mock"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03794232","briefTitle":"Effect of Inulin-type Fructose Extracted From Jerusalem Artichoke on Improving Prediabetic State of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Inuling (Bei Jing) Science and Technology Co. Ltd"},"collaborators":[{"name":"Peking Union Medical College Hospital"},{"name":"Proswell Medical Corporation"}]},"conditionsModule":{"conditions":["Prediabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NIUCHANG"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00736632","briefTitle":"Vitamin D, Insulin Resistance, and Cardiovascular Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Washington University School of Medicine"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"},{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Vitamin D Deficiency","Insulin Resistance","Type 2 Diabetes Mellitus","Cardiovascular Disease","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin D3"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02545049","briefTitle":"Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Diabetic Kidney Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Finerenone (BAY94-8862)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04906226","briefTitle":"Effect of Self-Foot Massage on Diabetic Individuals"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aksaray University"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Self-foot massage"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01847937","briefTitle":"Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aarhus University Hospital"},"collaborators":[{"name":"University of Southern Denmark"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Diabetic Polyneuropathy","Hereditary Axonal Neuropathy","Hereditary Demyelinated Neuropathy","Polyneuropathy, Inflammatory Demyelinating, Chronic"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04973111","briefTitle":"A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Carmot Therapeutics, Inc."}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CT-868 as SC Injection"},{"name":"Placebo as SC Injection"},{"name":"Active Comparator as SC Injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00781547","briefTitle":"Growth Hormone Treatment in Men With High Risk of Developing Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Göteborg University"},"collaborators":[{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Abdominal Obesity","Metabolic Syndrome","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"recombinant human growth hormone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05943899","briefTitle":"Effect of SGLT-2 Inhibitors in Patients With T2DM and Moderate to Severe Liver Fibrosis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diabetes Foundation, India"},"collaborators":[{"name":"National Diabetes Obesity and Cholesterol Foundation"}]},"conditionsModule":{"conditions":["Type2diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01531933","briefTitle":"Efficacy and Safety of DLBS3233 in Prediabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dexa Medica Group"}},"conditionsModule":{"conditions":["Prediabetic"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DLBS3233"},{"name":"Placebo of DLBS3233"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00044148","briefTitle":"The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chromaderm, Inc."}},"conditionsModule":{"conditions":["Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY333531"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00132132","briefTitle":"Study of Impact of Behavioral Intervention- Exercise, Nutrition, Education- on Body Mass Index (BMI)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Steward St. Elizabeth's Medical Center of Boston, Inc."}},"conditionsModule":{"conditions":["Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Behavioral education program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03952000","briefTitle":"Influence of Prior Walking on Postprandial Metabolism in Centrally Obese Men"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Loughborough University"},"collaborators":[{"name":"University Hospitals, Leicester"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Cardiovascular Diseases","Endothelial Dysfunction","Insulin Resistance","Oxidative Stress"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05519163","briefTitle":"A Study on Predictive Model for New-onset Diabetic Foot in Type 2 Diabetes Patients."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yibing Wang"}},"conditionsModule":{"conditions":["Diabetic Foot"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02931630","briefTitle":"The Effect of Whey Protein and Dietary Fibers on Risk Markers of the Metabolic Syndrome and Bone Health"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aarhus University Hospital"},"collaborators":[{"name":"University of Aarhus"},{"name":"Rigshospitalet, Denmark"},{"name":"University of California, Davis"},{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Abdominal Obesity","Metabolic Syndrome","Type 2 Diabetes","Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Whey protein powder"},{"name":"Maltodextrin powder"},{"name":"High fiber bread"},{"name":"Low fiber bread"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01065948","briefTitle":"A Feasibility Study to Assess Critical Aspects of Fluorescence Affinity Sensor (FAS) Performance and Safety Over Several Hours"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"BioTex, Inc."},"collaborators":[{"name":"Endocrinoloogy Associates Houston"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Subcutaneous glucose monitoring device"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03712501","briefTitle":"Influence of Prior Walking on Postprandial Metabolism and Endothelial Function."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Loughborough University"},"collaborators":[{"name":"University Hospitals, Leicester"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Cardiovascular Diseases","Endothelial Dysfunction","Insulin Resistance","Oxidative Stress"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00991549","briefTitle":"Diabetes Prevention In Estrie"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Université de Sherbrooke"},"collaborators":[{"name":"Ministere de la Sante et des Services Sociaux"},{"name":"Novonordisk endocrine fellowship program"}]},"conditionsModule":{"conditions":["Overweight","Glucose Intolerance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"interdisciplinary intervention or meeting-seminars"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01180283","briefTitle":"Efficacy and Safety of Lodenafil Carbonate in the Treatment of Erectile Dysfunction in Patients With Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Cristália Produtos Químicos Farmacêuticos Ltda."}},"conditionsModule":{"conditions":["Erectile Dysfunction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"lodenafil carbonate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01635361","briefTitle":"Understanding and Appraising the New Medicine Service in England"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Nottingham"},"collaborators":[{"name":"Department of Health, United Kingdom"},{"name":"University College, London"},{"name":"University of Warwick"}]},"conditionsModule":{"conditions":["Asthma","Pulmonary Disease, Chronic Obstructive","Diabetes Mellitus, Type 2","Hypertension","Blood Coagulation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"New Medicine Service"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02579395","briefTitle":"A Couples-based Approach for Increasing Physical Activity Among Adults With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Colorado, Denver"}},"conditionsModule":{"conditions":["Collaborative Implementation Intentions","Individual Implementation Intentions","Information Only Control Condition"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Collaborative implementation Intentions"},{"name":"Individual implementation Intentions"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02548767","briefTitle":"Adverse Metabolic Effects of Dietary Sugar"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, Davis"},"collaborators":[{"name":"Touro University, California"},{"name":"University of Southern California"},{"name":"USDA, Western Human Nutrition Research Center"},{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Chronic Disease of Cardiovascular System","Type 2 Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"high fructose corn syrup"},{"name":"aspartame"},{"name":"Energy-balanced diet"},{"name":"Ad libitum diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00561704","briefTitle":"Adiponectin in Obese Women With T2DN and Effects by RAS Blocker"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai Jiao Tong University School of Medicine"}},"conditionsModule":{"conditions":["Obese","Type 2 Diabetes","Diabetic Nephropathy","Glucose Metabolism","Angiotensin II Type 1 Receptor Blockers"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"losartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05564728","briefTitle":"Diabetes Footcare Companion App for Patients and Carers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nanyang Technological University"},"collaborators":[{"name":"Tan Tock Seng Hospital"},{"name":"Ministry of Health, Singapore"}]},"conditionsModule":{"conditions":["Diabetes Mellitus Foot Ulcer","Diabetes Mellitus, Type 2","Diabetic Foot","Diabetic Foot Infection","Ulcer Foot","Ulcer, Leg"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Conversational Agent/Chatbot App"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04230889","briefTitle":"Evaluation of Glucose Control in Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott Nutrition"}},"conditionsModule":{"conditions":["Glycemic Control"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Usual Diet Group"},{"name":"Group 1 Nutritional Shake"},{"name":"Group 2 Nutritional Shake"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02650830","briefTitle":"Seum Bile Acid Profile in Type 2 Diabetes and Association Between Bile Cid Profile and Adipokine or Oxidative Stress"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yonsei University"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Prediabetes","Non-alcoholic Fatty Liver Disease","Metabolic Syndrome"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02290184","briefTitle":"PilAm Go4Health Weight Loss Program to Prevent Heart Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Francisco"}},"conditionsModule":{"conditions":["Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PilAm Go4Health Weight-loss Program"},{"name":"Active Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05658744","briefTitle":"Video Training to Reduce Insulin Administration Errors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Goztepe Prof Dr Suleyman Yalcın City Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Insulin Injection Pad","Injection Site","Insulin Implementation Errors","Educational Problems"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Video group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00741702","briefTitle":"Diabetes Risk Evaluation and Microalbuminuria in Saskatchewan First Nations Peoples"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sunnybrook Health Sciences Centre"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"},{"name":"Pfizer"}]},"conditionsModule":{"conditions":["Hypertension","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nurse administered treatment algorithm"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03717194","briefTitle":"Effect of Ertugliflozin on Cardiac Function in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Soo Lim"},"collaborators":[{"name":"MSD Korea Ltd."}]},"conditionsModule":{"conditions":["Type2 Diabetes","Heart Failure"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ertugliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01272232","briefTitle":"Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Metabolism and Nutrition Disorder","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01492283","briefTitle":"Pathophysiological Implications of the Incretin Hormones in Patients With Liver Disease With and Without Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"}},"conditionsModule":{"conditions":["Non Alcoholic Fatty Liver Disease","Type 2 Diabetes","Liver Cirrhosis"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"OGTT"},{"name":"IIGI"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03673904","briefTitle":"High Sensitive CRP in Prediabetics and Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fayoum University"}},"conditionsModule":{"conditions":["Assess Level of High Sensitive CRP in Diabetics and Prediabetics"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00150410","briefTitle":"Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"},"collaborators":[{"name":"Sanofi"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Inhaled insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06191614","briefTitle":"DEXINEURO® Tab on Blood Glucose Reduction in Patients With Type 2 Diabetes Accompanied by Diabetic Peripheral Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hanlim Pharm. Co., Ltd."}},"conditionsModule":{"conditions":["Diabetic Peripheral Neuropathy"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01448174","briefTitle":"Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Poznan University of Medical Sciences"}},"conditionsModule":{"conditions":["Renal Failure Chronic Requiring Hemodialysis","Metabolic Syndrome","Diabetes Mellitus Type 2","Hyperlipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Atorvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01627340","briefTitle":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Hepatitis B"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Engerix™-B vaccine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00979719","briefTitle":"Improvement of a Physically Active Lifestyle"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Freie Universität Berlin"},"collaborators":[{"name":"Deutsche Rentenversicherung"}]},"conditionsModule":{"conditions":["Pain","Osteoarthritis","Rheumatoid Arthritis","Heart Diseases","Diabetes Mellitus, Type 2","Behavior","Motivation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intervention Group (IG)"},{"name":"Active Control Group (ACG)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00763802","briefTitle":"Validation of a Predictive Model to Estimate the Risk of Conversion to Clinically Significant Macular Edema and/or Vision Loss in Mild Nonproliferative Diabetic Retinopathy in Diabetes Type 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Association for Innovation and Biomedical Research on Light and Image"},"collaborators":[{"name":"Fundação para a Ciência e a Tecnologia"}]},"conditionsModule":{"conditions":["Diabetic Retinopathy"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01440660","briefTitle":"Phenotypes of Nonproliferative Diabetic Retinopathy in DM 2 Patients Identified by OCT, CFP, RLA and mfERG (DIAMARKER)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Association for Innovation and Biomedical Research on Light and Image"},"collaborators":[{"name":"University of Coimbra"}]},"conditionsModule":{"conditions":["Type-2 Diabetes","Diabetic Retinopathy"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00652405","briefTitle":"Effect of Alcohol on Cephalic Phase Reflex and Gene Expression"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"TNO"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Inflammation","Carbohydrate&Lipid Metabolism","Oral Processing"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"alcohol"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06355219","briefTitle":"Macrovascular and Microvascular Morbidity and Mortality After Metabolic Surgery Versus Medicines"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ali Aminian"}},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Obesity","Microvascular Disease","Macrovascular Disease","Major Adverse Cardiovascular Events","Nephropathy","Retinopathy","Heart Failure","All Cause Mortality"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05977465","briefTitle":"Empagliflozin in Treatment of Peripheral Diabetic Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tanta University"}},"conditionsModule":{"conditions":["Diabetic Neuropathy Peripheral"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin 25 MG"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03345004","briefTitle":"Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diamyd Medical AB"}},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus","Autoimmune Diseases","Metabolic Disease","Glucose Metabolism Disorders","Immune System Diseases","Endocrine System Diseases","Juvenile Diabetes","Insulin Dependent Diabetes","Autoimmune Diabetes","Vitamin D","Physiological Effects of Drugs"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diamyd"},{"name":"Vitamin D"},{"name":"Placebo for Diamyd"},{"name":"Placebo for Vitamin D"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01404078","briefTitle":"Study to Compare 2 Doses of Polycap Versus Single Dose of Polycap With or Without Pottasium"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"St. John's Research Institute"},"collaborators":[{"name":"Population Health Research Institute"}]},"conditionsModule":{"conditions":["Ischemic Heart Disease","Ischemic Stroke","Peripheral Vascular Disease","Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Single Dose Polycap"},{"name":"Double dose Polycap"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03440203","briefTitle":"Prevalence of Peripheral Neuropathy and Its Impact on Activities of Daily Living in Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Okayama University"}},"conditionsModule":{"conditions":["Diabetic Neuropathy Peripheral","Activities of Daily Living"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"difficult activities of daily living in each group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00687999","briefTitle":"NIDDM and IR in Combination Therapy for CHC"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kaohsiung Medical University Chung-Ho Memorial Hospital"},"collaborators":[{"name":"National Science Council, Taiwan"}]},"conditionsModule":{"conditions":["Chronic Hepatitis C","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pegylated interferon alpha and ribavirin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06543706","briefTitle":"Metabolic Syndrome and Related Diseases in Healthcare Workers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Peking Union Medical College Hospital"}},"conditionsModule":{"conditions":["Metabolic Syndrome X","Diabetes Mellitus Type 2","Hypertension","Hyperlipidemia","Obesity","Cardiovascular Diseases","Stroke"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02689765","briefTitle":"Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sun Yat-sen University"}},"conditionsModule":{"conditions":["Insulin Resistance","Glucose Metabolism Disorders","Type 2 Diabetes","Lipid Metabolism Disorders"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Anthocyanins"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03388229","briefTitle":"Association Between Dietary Pattern and Glycemic Control Among Type 2 Diabetes Patients in the Unites Arab Emirates"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Rashid Centre for Diabetes and Research"}},"conditionsModule":{"conditions":["Dietary Habits"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"not an intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05199636","briefTitle":"Effect of Dragon Fruit Consumption in Individuals at Risk of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oxford Brookes University"}},"conditionsModule":{"conditions":["Blood Pressure","Glucose Intolerance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dragon fruit product"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00970060","briefTitle":"Exercise and Nerve Function in Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Patricia Kluding, PhD"}},"conditionsModule":{"conditions":["Diabetic Neuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04033705","briefTitle":"DRIVE - Perioperative Period"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Portsmouth Hospitals NHS Trust"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Surgical Procedure, Unspecified"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Freestyle Libre Pro glucose sensor"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05609266","briefTitle":"Validation of Existing Diabetes Risk Models in a Swedish Population"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Umeå University"},"collaborators":[{"name":"University of Cambridge"}]},"conditionsModule":{"conditions":["Type2diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01192373","briefTitle":"Modulation of Free Fatty Acids in Heart Failure Patients With Diabetes: \"Effect on Left Ventricular Function\""},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"Danish Heart Foundation"}]},"conditionsModule":{"conditions":["Heart Failure","Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metabolic substrate modulation"},{"name":"metabolic substrate modulation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05266885","briefTitle":"Prevalence of Hypertension in Type-2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kabul University of Medical Sciences"}},"conditionsModule":{"conditions":["Prevalence of Elevated Blood Pressure in Type-2 Diabetics"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04762251","briefTitle":"What Or When to Eat to Reduce the Risk of Type 2 Diabetes (WOW)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Adelaide"},"collaborators":[{"name":"Australian Catholic University"},{"name":"La Trobe University"}]},"conditionsModule":{"conditions":["Time-restricted Eating","Diet Quality"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Time-restricted eating"},{"name":"Current Best Practice"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02218099","briefTitle":"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Astellas Pharma Europe B.V."}},"conditionsModule":{"conditions":["Healthy Subjects","Pharmacokinetics of ASP8232","Pharmacodynamics of ASP8232","Chronic Kidney Disease (CKD)","Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ASP8232"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04462081","briefTitle":"Non Alcoholic Fatty Liver Disease and Coronary Heart Disease in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Diego"}},"conditionsModule":{"conditions":["Nonalcoholic Steatohepatitis"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01431807","briefTitle":"Long-term Study of SYR-472"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SYR-472"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00064727","briefTitle":"Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}},"conditionsModule":{"conditions":["Congestive Heart Failure"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Avandia (Rosiglitazone)"},{"name":"Avanclia (Rosiqlitazone)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00323349","briefTitle":"A Study of Attitudes About the Risk of Developing Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eastern Virginia Medical School"},"collaborators":[{"name":"Centers for Disease Control and Prevention"},{"name":"Association of Teachers of Preventive Medicine"}]},"conditionsModule":{"conditions":["Prediabetic State"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral Glucose Tolerance Testing"},{"name":"Education tailored to learning style preferences"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03702465","briefTitle":"Assessment of the Impact of a Personalised Nutrition Intervention in Impaired Glucose Regulation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Imperial College London"},"collaborators":[{"name":"DnaNudge Ltd"}]},"conditionsModule":{"conditions":["Pre Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DNA-based dietary intervention"},{"name":"DNA-based dietary intervention using an app"},{"name":"Control arm"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00930956","briefTitle":"Comparison of Different Types of Resistant Starch"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kansas State University"}},"conditionsModule":{"conditions":["Postprandial Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Resistant Starch"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00739180","briefTitle":"Physical Activity in Youth: Implications for Reversing Risk Factors for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pittsburgh"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Abdominal Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Control"},{"name":"Resistance Exercise"},{"name":"Aerobic exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05990205","briefTitle":"Effect of the SCL16A11 Risk Haplotype on Treatments to Prevent Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran"}},"conditionsModule":{"conditions":["PreDiabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Life Style Intervention + Metformin"},{"name":"Life Style Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00370084","briefTitle":"Itopride Hydrochloride in Diabetes: Effects on Gastric Emptying and Glycemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Forest Laboratories"}},"conditionsModule":{"conditions":["Gastroparesis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Itopride"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04547244","briefTitle":"CRTd Responders Optimization"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Campania \"Luigi Vanvitelli\""}},"conditionsModule":{"conditions":["Heart Failure","Heart Failure With Reduced Ejection Fraction","Cardiac Death"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"echocardiographic optimization of CRTd"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00862589","briefTitle":"Glucagon-Like Peptide-1 (GLP-1) Suppression of Alpha Cell Secretion in Type 2 Diabetes Mellitus (T2DM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"},"collaborators":[{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Hyperglycemia","Hyperglucagonemia","Glucose Intolerance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GLP-1 infusion"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01686711","briefTitle":"A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AD-4833 15 mg"},{"name":"AD-4833 30 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05813249","briefTitle":"Semaglutide in Nonalcoholic Fatty Liver Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Zagazig University"}},"conditionsModule":{"conditions":["Non-alcoholic Fatty Liver Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rybelsus Oral Product"},{"name":"Ozempic Injectable Product"},{"name":"Tocopherol and/or Actos"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02228642","briefTitle":"Hypoglycemia in Hospitalized Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pittsburgh"}},"conditionsModule":{"conditions":["Diabetes","Hypoglycemia"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06358846","briefTitle":"Effectiveness of Educational Intervention on Footcare Among Individuals Having Type 2 Diabetes at Slums of Karachi, Pakistan."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"SINA Health Education and Welfare Trust"},"collaborators":[{"name":"Aga Khan University"}]},"conditionsModule":{"conditions":["Diabetic Foot","Educational Intervention","Foot Care","Foot Ulcer, Diabetic","Foot Cellulitis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Self-care behavior to promote foot care through educational guidance among individual with diabetes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02505321","briefTitle":"for Adipose Tissue DIabetes VAriants (fATDIVA)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Royal Devon and Exeter NHS Foundation Trust"},"collaborators":[{"name":"University of Exeter"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral Triglyceride Tolerance Test (OTTT)"},{"name":"Abdominal fat biopsy (optional)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00372086","briefTitle":"Rosiglitazone and Insulin in T1DM Adolescents"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of New South Wales"},"collaborators":[{"name":"Sydney Children's Hospitals Network"},{"name":"National Health and Medical Research Council, Australia"},{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Type 1 Diabetes","Puberty: >Tanner 2 Breast Development or Testis >4ml"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosiglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00642915","briefTitle":"Insulin Glargine Benefits in Japanese Pts Outside of Japan (US or Brazil)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lantus, Amaryl"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03246451","briefTitle":"The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"},"collaborators":[{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Glucose Metabolism Disorders"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo Oral Tablet"},{"name":"Metformin"},{"name":"Saline"},{"name":"Exendin (9-39)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03089333","briefTitle":"Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Campinas, Brazil"},"collaborators":[{"name":"Fundação de Amparo à Pesquisa do Estado de São Paulo"}]},"conditionsModule":{"conditions":["Hypertension","Diabetes Mellitus, Type 2","Blood Pressure","Obesity","Cardiac Hypertrophy","Microalbuminuria","Vascular Stiffness"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin 10mg"},{"name":"Glibenclamide 5Mg Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03925948","briefTitle":"Health Literacy Intervention for African Americans With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johns Hopkins University"},"collaborators":[{"name":"Brancati Center for the Advancement of Community Care"},{"name":"Center for Community Innovation and Scholarship at the Johns Hopkins University"},{"name":"East Baltimore Medical Center"},{"name":"Shepherds Clinic"},{"name":"John Hopkins Aftercare Clinic"}]},"conditionsModule":{"conditions":["Uncontrolled Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PLAN 4 Success-Diabetes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05243238","briefTitle":"Hesperidin and Diosmin Effect on Metabolic Syndrome"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Beni-Suef University"}},"conditionsModule":{"conditions":["Metabolic Syndrome and Diabetic Neuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"dietary supplement flavonoids"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01093833","briefTitle":"A Comparison Study of Prototype Continuous Glucose Sensors in the Intradermal and Subcutaneous Spaces"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Becton, Dickinson and Company"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BD Continuous glucose monitor (BD CGM)"},{"name":"YSI Glucose Analyzer"},{"name":"Medtronic Guardian CGM"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01264523","briefTitle":"Nutritional Intervention With Moderately High-protein, Low-glycemic Load Products in Type-2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Clinica Universidad de Navarra, Universidad de Navarra"},"collaborators":[{"name":"Rovi Pharmaceuticals Laboratories"},{"name":"Equipe Enervit"}]},"conditionsModule":{"conditions":["Type-2 Diabetes","Overweight"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Chronologically scheduled snacking with 40-30-30 products"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02750527","briefTitle":"Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kinderkrankenhaus auf der Bult"}},"conditionsModule":{"conditions":["Type 1 Diabetes","Familial Hypercholesterolemia"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02682901","briefTitle":"Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eastern Virginia Medical School"}},"conditionsModule":{"conditions":["Diabetic Autonomic Neuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cycloset"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04201912","briefTitle":"Role of TLR2 and TLR4 in Stage 2 Periodontitis Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ajman University"}},"conditionsModule":{"conditions":["Periodontal Inflammation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"saliva analysis for Toll like receptor activity"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00883038","briefTitle":"Does a Low-Fat Vegetarian Diet Improve Insulin Resistance in Individuals With Type 2 Diabetes?"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institute for Clinical and Experimental Medicine"}},"conditionsModule":{"conditions":["Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"diabetic diet following the DNSG guidelines"},{"name":"low-fat vegetarian diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04265261","briefTitle":"A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hoffmann-La Roche"}},"conditionsModule":{"conditions":["Diabetic Retinopathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"RG7774"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01260337","briefTitle":"The Effects of a Pre-packaged, Portion Controlled Meal Plan on Type 2 Diabetes and Glycemic Control: A Comparison Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Temple University"},"collaborators":[{"name":"Nutrisystem, Inc."},{"name":"University of Pennsylvania"}]},"conditionsModule":{"conditions":["Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Portion controlled diet"},{"name":"Diabetes Support and Education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00442325","briefTitle":"Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc."}},"conditionsModule":{"conditions":["Coronary Arteriosclerosis","Diabetes Mellitus, Type 2","Cerebrovascular Accident","Dyslipidemia","Peripheral Vascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Atorvastatin (Lipitor)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00403481","briefTitle":"An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo"}},"conditionsModule":{"conditions":["Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"olmesartan medoxomil"},{"name":"Olmesartan medoxomil plus Hydrochlorothiazide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01030978","briefTitle":"Prevention of Type 2 Diabetes in Children With a Family-based Healthy Lifestyle Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yale University"},"collaborators":[{"name":"National Institutes of Health (NIH)"},{"name":"National Center for Research Resources (NCRR)"}]},"conditionsModule":{"conditions":["Impaired Glucose Tolerance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bright Bodies Healthy Lifestyle Program"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04763772","briefTitle":"Clinical Effectiveness of Body Fat Distribution Imaging in Real-World Practice: The BODY-REAL Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospitals Cleveland Medical Center"}},"conditionsModule":{"conditions":["Overweight and Obesity","PreDiabetes","Type 2 Diabetes","Cardiovascular Risk Factor"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Body Fat Distribution Imaging Report"},{"name":"Basic Weight Information"},{"name":"Patient Provided"},{"name":"Physician Provided"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01474603","briefTitle":"Impact of n-3 Polyunsaturated Fatty Acids in a Protein-enriched Diet With Low GI in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Vienna"},"collaborators":[{"name":"Enervit Spa (company)"}]},"conditionsModule":{"conditions":["Overweight","Obese","Insulin Resistance","Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"n-3 PUFA in protein-enriched low-GI diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00442845","briefTitle":"Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc."}},"conditionsModule":{"conditions":["Coronary Arteriosclerosis","Diabetes Mellitus, Type 2","Cerebrovascular Accident","Dyslipidemia","Peripheral Vascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Atorvastatin (Lipitor)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01323088","briefTitle":"Physical Activity in Overweight Girls: Implications for Reversing Risk Factors for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pittsburgh"}},"conditionsModule":{"conditions":["Abdominal Obesity","Physical Activity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Control"},{"name":"Resistance Exercise"},{"name":"Aerobic exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01926938","briefTitle":"Endothelial Function in Young Hispanic Adults at Risk for Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Joslin Diabetes Center"}},"conditionsModule":{"conditions":["Obesity","Insulin Resistance"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00005374","briefTitle":"Genetics of the Metabolic Syndrome in Japanese Americans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Washington"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Coronary Disease","Heart Diseases","Insulin Resistance","Diabetes Mellitus, Non-insulin Dependent","Diabetes Mellitus","Metabolic Syndrome X"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00986700","briefTitle":"The Effect of Late Night Meals on Fasting Glucose in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sheba Medical Center"}},"conditionsModule":{"conditions":["Fasting Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"late night meal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01200394","briefTitle":"A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetic Nephropathies"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-00489791"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02843139","briefTitle":"Circulating microRNAs for Discriminating Obese Preschoolers at Risk of Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nanjing Medical University"}},"conditionsModule":{"conditions":["Discriminate Obese Children at Risk for Diabetes."]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04952766","briefTitle":"Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Régional d'Orléans"}},"conditionsModule":{"conditions":["Kidney Transplant","Myeloma","Cancer","Hematologic Malignancy","Multiple Sclerosis","Hypergammaglobulinemia","Malignant Tumor","Hiv","Diabetes Type 2"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Biological samples"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04201938","briefTitle":"Effect of Probiotic Co-administration With Omega-3 Fatty Acids on Obesity Parameters and Insulin Resistance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bogomolets National Medical University"},"collaborators":[{"name":"Taras Shevchenko National University of Kyiv"}]},"conditionsModule":{"conditions":["Obesity","Insulin Resistance","Insulin Sensitivity","Type2 Diabetes","Visceral Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Symbiter-Omega"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00142701","briefTitle":"Enhancing Support for Women at Risk for Heart Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oregon Research Institute"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Heart Diseases","Coronary Disease","Coronary Heart Disease Risk Reduction","Diabetes Mellitus, Non-insulin Dependent"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"diet"},{"name":"physical activity"},{"name":"stress management"},{"name":"smoking cessation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01424306","briefTitle":"Diet and Systemic Inflammation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fred Hutchinson Cancer Center"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"},{"name":"University of Washington"}]},"conditionsModule":{"conditions":["Low-grade Chronic Inflammation","Intestinal Permeability","Type 2 Diabetes Mellitus","Cardiovascular Disease","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fructose-sweetened beverages"},{"name":"Glucose-sweetened beverages"},{"name":"High-fructose corn syrup-sweetened beverages"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04136951","briefTitle":"Improving Patient Prioritization During Hospital-homecare Transition"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Columbia University"},"collaborators":[{"name":"Visiting Nurse Service of New York"},{"name":"National Institute of Nursing Research (NINR)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Congestive Heart Failure","Obstructive Pulmonary Disease","Dyspnea","Renal Failure"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PREVENT clinical decision support"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03539627","briefTitle":"Azilsartan Medoxomil in Hypertensive pAtients With Stable Ischemic Heart Disease and DiabEtes MEllitus."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Research Institute for Complex Problems of Cardiovascular Diseases, Russia"}},"conditionsModule":{"conditions":["Arterial Hypertension","Diabetes Mellitus","Stable Chronic Angina"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Azilsartan Medoxomil 40 MG Oral Tablet [Edarbi]"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03095196","briefTitle":"Multipolar CRT-d and Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Celestino Sardu"}},"conditionsModule":{"conditions":["Diabetes","Heart Failure","Heart Failure NYHA Class II","Heart Failure NYHA Class III"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Multipolar CRT-d, plus conventional drug therapy for HF."},{"name":"Bipolar CRT-d, plus conventional drug therapy for HF."},{"name":"HF drugs"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02997319","briefTitle":"Shift Work, Heredity, Insulin, and Food Timing Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Massachusetts General Hospital"},"collaborators":[{"name":"Broad Institute"},{"name":"Brigham and Women's Hospital"},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Shift Work Type Circadian Rhythm Sleep Disorder","Diabetes Mellitus, Type 2","Circadian Rhythm Sleep Disorder, Shift Work Type","Insulin Resistance"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01389362","briefTitle":"The Healing Effect of a Two-Herb Recipe on Foot Ulcer in Chinese Patients With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chinese University of Hong Kong"}},"conditionsModule":{"conditions":["Diabetic Foot Ulcer"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Chinese herbal medicine (Radix Rehmanniae and Radix Astragali)"},{"name":"Placebo comparator"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02963922","briefTitle":"Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Metabolism and Nutrition Disorder","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide 3.0 mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05422352","briefTitle":"Role of Carnosine in Combination With Vitamin B Complex in Preventing the Progression of Diabetic Neuropathy in Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Beni-Suef University"}},"conditionsModule":{"conditions":["Diabetic Neuropathies"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Carnosine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01700075","briefTitle":"Physical and Chemical Study of Atherosclerosis Mechanisms"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nazarbayev University"},"collaborators":[{"name":"Ministry of Health, Kazakhstan"}]},"conditionsModule":{"conditions":["Myocardial Infarction","Coronary Artery Diseases","Diabetes Mellitus, Type 2","Atherosclerosis of Femoral Artery"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Conventional treatment"},{"name":"Weight loss treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03768245","briefTitle":"School-Based Program On Metabolic Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado"}},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type 2","Cardiovascular Function","Kidney Diseases","Liver Diseases","Physical Fitness"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Health Education and Physical activity program"},{"name":"Nutrition Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01755351","briefTitle":"Comparative Study About the Influence of Diabetes Diatress and Depression on Treatment Adherence in Chinese Type 2 Diabetes Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shandong Provincial Hospital"}},"conditionsModule":{"conditions":["Compare Diabetes Distress and Depression"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01712061","briefTitle":"A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-04634817"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02192255","briefTitle":"SUPREME-DM (Diabetes Mellitis) Treatment Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"HealthPartners Institute"},"collaborators":[{"name":"Agency for Healthcare Research and Quality (AHRQ)"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intervention Phone Call"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03273140","briefTitle":"The Effectiveness of Gamification Diabetes Education Program for Poorly Controlled Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Healthcare Group, Singapore"},"collaborators":[{"name":"Tan Tock Seng Hospital"}]},"conditionsModule":{"conditions":["Diabetic Patients, Gamification, Diabetic Education"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gamification Diabetes Education Program (GDEP)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02248272","briefTitle":"Effect of Meal Frequency on Glycemic Control of People at High Risk or Diagnosed With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Meropi Kontogianni"},"collaborators":[{"name":"Agricultural University of Athens"},{"name":"National and Kapodistrian University of Athens"}]},"conditionsModule":{"conditions":["Impaired Glucose Tolerance","Hyperinsulinism","Poor Glycemic Control","Hyperglycemia","Insulin Sensitivity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Isocaloric diet with 3 meals"},{"name":"Isocaloric diet with 6 meals"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05030844","briefTitle":"The Effect of IMB Model-Based Diabetes Education and Motivational Interviewing on Care Outcomes in Adults With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pamukkale University"}},"conditionsModule":{"conditions":["Type2 Diabetes","Self Efficacy","Self Management","HbA1c","BMI"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"IMB model based Diabetes Education and Motivational Interviewing"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01046435","briefTitle":"Effects of Periodontal Therapy on Systemic Inflammation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Chile"}},"conditionsModule":{"conditions":["Periodontal Disease","Cardiovascular Disease","Type 2 Diabetes","Obesity","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"metronidazole and amoxicillin"},{"name":"Two placebos"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03859934","briefTitle":"Metabolic Effects of Melatonin Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"},"collaborators":[{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Metabolic Disease","Insulin Sensitivity","Glucose Metabolism Disorders (Including Diabetes Mellitus)","Type 2 Diabetes Mellitus","Blood Pressure","Inflammation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Melatonin"},{"name":"Placebo Oral Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03830840","briefTitle":"Mil Familias Cohort Establishment: a Study to Understand Determinants of Diabetes and Its Complications Among US Latinos"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sansum Diabetes Research Institute"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus","Cardiovascular Diseases"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02068872","briefTitle":"Gastric Sleeve Pilot Study in Morbidly Obese Undergoing Liver Transplantation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Northwestern University"}},"conditionsModule":{"conditions":["Obesity","Cardiovascular Disease","Type 2 Diabetes","Hypertension","Complication of Transplant"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sleeve Gastrectomy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01002547","briefTitle":"Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VA Office of Research and Development"}},"conditionsModule":{"conditions":["Nonalcoholic Steatohepatitis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"pioglitazone-placebo"},{"name":"pioglitazone"},{"name":"Vitamin E"},{"name":"pioglitazone-placebo"},{"name":"Vitamin E"},{"name":"Vitamin E-placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05946148","briefTitle":"Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National and Kapodistrian University of Athens"},"collaborators":[{"name":"Alexandra Hospital, Athens, Greece"},{"name":"Hippocration General Hospital"}]},"conditionsModule":{"conditions":["Non-Alcoholic Fatty Liver Disease","Liver Steatosis"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Dulaglutide"},{"name":"Control Rx"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04423302","briefTitle":"Effect of Totum-63 on Glucose and Lipid Homeostasis in Subjects With Dysglycemia (REVERSE-IT)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Valbiotis"},"collaborators":[{"name":"Biofortis Mérieux NutriSciences"}]},"conditionsModule":{"conditions":["Prediabetic State","Diabetes type2","Dysglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TOTUM-63 3 intakes per day"},{"name":"Placebo 3 intakes per day"},{"name":"TOTUM-63 2 intakes per day"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03299790","briefTitle":"Effect of High-intensity Interval Training on Cardiac Function and Regulation of Glycemic Control in Diabetic Cardiomyopathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hasselt University"},"collaborators":[{"name":"Jessa Hospital"}]},"conditionsModule":{"conditions":["Diabetic Cardiomyopathies","Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"high-intensity interval exercise training (HIIT)"},{"name":"moderate-intensity exercise training (MIT)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05630417","briefTitle":"Investigation of the Effect of Geriatric Massage"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayburt University"}},"conditionsModule":{"conditions":["Nursing Caries"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Feet and Back Massage"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04101383","briefTitle":"A Study to Compare Pharmacokinetics and Pharmacodynamics of RinGlar® to Lantus® in Type 1 Diabetes Mellitus Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Geropharm"}},"conditionsModule":{"conditions":["Clamp Study"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"RinGlar®"},{"name":"Lantus®"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01872611","briefTitle":"Nepafenac Once Daily for Macular Edema - Study 2"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Alcon Research"}},"conditionsModule":{"conditions":["Non-Proliferative Diabetic Retinopathy","Cataract"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nepafenac Ophthalmic Suspension, 0.3%"},{"name":"Vehicle"},{"name":"Prednisolone acetate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00214474","briefTitle":"Improving Diabetes Efforts Across Language and Literacy (IDEALL)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Agency for Healthcare Research and Quality (AHRQ)"},"collaborators":[{"name":"The Commonwealth Fund"},{"name":"California HealthCare Foundation"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ATSM Intervention"},{"name":"GMV Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01530165","briefTitle":"(Pakistan Diabetes Prevention Program PDPP)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aga Khan University"},"collaborators":[{"name":"International Diabetes Federation"},{"name":"University of Helsinki"}]},"conditionsModule":{"conditions":["Prediabetic State & High Risk Individuals on the Basis of Diabetes Risk Score"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Life style intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05021705","briefTitle":"Non Diabetic Causes of Chronic Kidney Disease in Type 2 Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Assiut University"}},"conditionsModule":{"conditions":["Diabetic Kidney Disease"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03042936","briefTitle":"Diabetes Prevention Program in Youth"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Tennessee"}},"conditionsModule":{"conditions":["Pre Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Insulin Superheroes Club Curriculum"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01019642","briefTitle":"Vitamin D, C-reactive Protein and Insulin Resistance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Instituto Nacional de Salud Publica, Mexico"},"collaborators":[{"name":"Instituto Mexicano del Seguro Social"},{"name":"Ellison Medical / International Nutrition Foundation"},{"name":"Tufts University"}]},"conditionsModule":{"conditions":["Diabetes","Low-intensity Chronic Inflammation","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"cholecalciferol"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00508937","briefTitle":"Dietary Protein and Insulin Sensitivity Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"UCSF Benioff Children's Hospital Oakland"},"collaborators":[{"name":"Dairy Management Inc."}]},"conditionsModule":{"conditions":["Insulin Resistance","Type 2 Diabetes","Metabolic Syndrome","Cardiovascular Disease","Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diet"},{"name":"Diet"},{"name":"Diet"},{"name":"Diet"},{"name":"Diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03652480","briefTitle":"Shoulder Corticosteroid Injection in Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Turin, Italy"}},"conditionsModule":{"conditions":["Shoulder Pain","Corticosteroid Injection","Type2 Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MethylPREDNISolone Acetate 40 MG/ML"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03969719","briefTitle":"A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Non-alcoholic Steatohepatitis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"PF-06835919"},{"name":"PF-06835919"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01756703","briefTitle":"A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MT-3995 Low"},{"name":"MT-3995 High"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01874431","briefTitle":"Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Diabetic Nephropathies"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Finerenone (BAY94-8862)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02645448","briefTitle":"Glycemic Responses and of the Autonomic Cardiac Function in Diabetes Type-2 Women Post Resistance Exercise"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidade Federal do vale do São Francisco"},"collaborators":[{"name":"Coordenação de Aperfeiçoamento de Pessoal de Nível Superior."}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Autonomic Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Resistance Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06051565","briefTitle":"Cardiovascular Contrast-enhanced Magnetic Resonance Imaging Using Polysaccharide Superparamagnetic Iron Oxide Injection in Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd."}},"conditionsModule":{"conditions":["Diabetes","Magnetic Resonance Imaging"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Polysaccharide superparamagnetic iron oxide injection"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00449553","briefTitle":"Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"},"collaborators":[{"name":"Eli Lilly and Company"}]},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone and sulphonylurea"},{"name":"Pioglitazone and sulphonylurea"},{"name":"Pioglitazone and metformin"},{"name":"Pioglitazone and metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03994289","briefTitle":"Motor-assisted Cycling and FES Cycling for Postprandial Glucose in Diabetic Patients With ADL Disability"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Arizona State University"}},"conditionsModule":{"conditions":["Type2 Diabetes","Disability Physical"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Motor-assisted cycling"},{"name":"FES cycling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03988140","briefTitle":"Apico-coronal Position of the Implant in Edentulous Diabetics With Implant-retained Overdentures"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Paulista University"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Dental Implants"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dental Implant Placement and subsequent prosthetic reabilithation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03412006","briefTitle":"A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Diabetic Kidney Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fulacimstat (BAY1142524)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05320276","briefTitle":"Predictors of Non-accESs to therapeutiC EducAtion Programs Among Patients With Type 2 Diabetes, and/or Asthma, and/or Chronic Heart Failure in an Emergency Setting"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fondation Hôpital Saint-Joseph"}},"conditionsModule":{"conditions":["Therapeutic Education Program","Emergencies","Diabetes","Asthma","Heart Failure"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02565979","briefTitle":"Long-term Resveratrol and Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"},"collaborators":[{"name":"Diabetes Fonds"},{"name":"DSM Nutritional Products, Inc."}]},"conditionsModule":{"conditions":["Pre-diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"resveratrol"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00734253","briefTitle":"Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NephroGenex, Inc."},"collaborators":[{"name":"Collaborative Study Group (CSG)"},{"name":"Medpace, Inc."}]},"conditionsModule":{"conditions":["Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pyridoxamine Dihydrochloride"},{"name":"Pyridoxamine Dihydrochloride"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02266030","briefTitle":"Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Bundang Hospital"}},"conditionsModule":{"conditions":["Coronary Artery Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cilostazol"},{"name":"Aspirin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00363987","briefTitle":"Controlled Study to Evaluate Efficacy and Safety of α-KA Tab With Low Protein Diet (LPD) in Delaying the Progress of Type 2 Diabetic Nephropathy (DN)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fresenius Kabi"}},"conditionsModule":{"conditions":["Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ketosteril®"},{"name":"diabetic diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04437485","briefTitle":"eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Indiana University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Depression","Major Depressive Disorder","Dysthymic Disorder","Depressive Symptoms","Type 2 Diabetes","PreDiabetes","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Good Days Ahead (GDA)"},{"name":"Problem Solving Treatment in Primary Care (PST-PC)"},{"name":"Antidepressant Medications"},{"name":"Active Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01570946","briefTitle":"Use of Mobile Technology to Promote Sustained Lifestyle Changes to Prevent Type 2 Diabetes in India and the UK"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals"},"collaborators":[{"name":"Indian Council of Medical Research"},{"name":"Medical Research Council"},{"name":"Imperial College London"}]},"conditionsModule":{"conditions":["Prediabetic State"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle Modification"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02345057","briefTitle":"A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With Microalbuminuria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Daiichi Sankyo"}},"conditionsModule":{"conditions":["Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CS-3150"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00549536","briefTitle":"The Effect of Calcium Supplementation on Insulin Resistance and 24h Blood Pressure"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aristotle University Of Thessaloniki"},"collaborators":[{"name":"Hellenic Society of Hypertension"}]},"conditionsModule":{"conditions":["Hypertension","Diabetes","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"tablets each containing of 1000mg elemental calcium (Mega-Calcium Sandoz)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04496154","briefTitle":"Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry \"Bad Cholesterol\" in the Blood"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"May Faraj, PDt, PhD"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Type 2 Diabetes","Insulin Sensitivity/Resistance","Inflammatory Response","Fatty Acids, Omega-3"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Omega-3 fatty acids (2.7 g/d, EPA:DHA, 2:1)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03401697","briefTitle":"Eliminating Hepatitis C Virus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Icahn School of Medicine at Mount Sinai"}},"conditionsModule":{"conditions":["Hepatitis C","HIV","Type2 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01795833","briefTitle":"Diabetes Prevention Using SMS Technology"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Imperial College London"},"collaborators":[{"name":"Barts & The London NHS Trust"},{"name":"Mid and South Essex NHS Foundation Trust"},{"name":"Lister Hospital"},{"name":"Torbay Hospital"},{"name":"Queen Alexandra Hospital"},{"name":"East Surrey Hospital"},{"name":"Pennine Acute Hospitals NHS Trust"},{"name":"West Suffolk Hospital"},{"name":"Derriford Hospital"},{"name":"Exeter Hospital"},{"name":"Milton Keynes University Hospital NHS Foundation Trust"},{"name":"Royal Cornwall Hospitals Trust"},{"name":"Queen Margaret Hospital, Dunfermline"},{"name":"Harrogate & District NHS Foundation Trust"},{"name":"Royal Berkshire NHS Foundation Trust"},{"name":"Rotherham NHS Trust"}]},"conditionsModule":{"conditions":["Prediabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Short text messages"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01473576","briefTitle":"Impact of Nitrate Ingestion on Protein Synthesis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University Medical Center"}},"conditionsModule":{"conditions":["Muscle Protein Synthesis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nitrate"},{"name":"Sodium chloride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02377388","briefTitle":"DPP-4 Inhibitors and Acute Myocardial Infarction:Effects on Platelet Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Sao Paulo General Hospital"},"collaborators":[{"name":"InCor Heart Institute"}]},"conditionsModule":{"conditions":["Platelet Aggregation During Acute Myocardial Infarction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sitagliptin OR saxagliptin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01681173","briefTitle":"OPTIFIT-Optimal Fiber Trial for Diabetes Prevention"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"German Institute of Human Nutrition"},"collaborators":[{"name":"Charite University, Berlin, Germany"},{"name":"German Diabetes Foundation, Munich, Germany"},{"name":"Ernst von Bergmann Hospital"},{"name":"University Hospital Tuebingen"}]},"conditionsModule":{"conditions":["Diabetes","Nutrition Disorders","Obesity","Overweight","Metabolic Syndrome x","Body Weight","Glucose Metabolism Disorders","Metabolic Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fiber"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00130208","briefTitle":"Effect of Sulodexide in Early Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Keryx Biopharmaceuticals"},"collaborators":[{"name":"Collaborative Study Group (CSG)"}]},"conditionsModule":{"conditions":["Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sulodexide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04005287","briefTitle":"A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"WinSanTor, Inc"}},"conditionsModule":{"conditions":["Peripheral Neuropathy","Painful Diabetic Neuropathy","Diabetic Neuropathies, Painful"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"WST-057 (4% pirenzepine) Lose Dose 2mL"},{"name":"WST-057 (4% pirenzepine) High Dose 4mL"},{"name":"Placebo Low Dose"},{"name":"Placebo High Dose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02249897","briefTitle":"PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Chile"},"collaborators":[{"name":"Clinica Alemana de Santiago"}]},"conditionsModule":{"conditions":["DIABETES","DIABETIC RETINOPATHY","DIABETIC NEUROPATHY"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CHOLESTYRAMINE"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00326326","briefTitle":"Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CP-778,875"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03975556","briefTitle":"Culturally-Adapted Diet for Puerto Rican Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Harvard School of Public Health (HSPH)"},"collaborators":[{"name":"FDI Clinical Research"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity","Hypertension","Dyslipidemias","High Triglycerides","High Blood Glucose","Abdominal Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Culturally tailored food and diet advice"},{"name":"Standard healthy eating advice"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00234871","briefTitle":"Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott"}},"conditionsModule":{"conditions":["Hypertension","Diabetes","Proteinuria"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"trandolapril/verapamil"},{"name":"Lotrel (amlodipine/benazepril)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03671915","briefTitle":"Diabeloop for Kids"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète"}},"conditionsModule":{"conditions":["Closed Loop","Diabetes Mellitus, Type 1","Young Children (6 to 12 Years Old )"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Continuous Glucose Monitoring"},{"name":"External Insulin Pump"},{"name":"Diabeloop Software (Model predictive control)"},{"name":"Remote monitoring (Telemedicine)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00351676","briefTitle":"Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alberta"},"collaborators":[{"name":"Capital Health, Canada"}]},"conditionsModule":{"conditions":["Heart Failure, Congestive","Pulmonary Disease, Chronic Obstructive","Pneumonia","Diabetes Mellitus, Type 2","Coronary Arteriosclerosis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Integration of a team based clinical pharmacist"},{"name":"Optimizing therapeutic treatments"},{"name":"Optimizing processes of care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04361097","briefTitle":"Fecal Microbiota Transplantation as a Therapeutic Strategy in the Progression of Chronic Kidney Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital Universitario Dr. Jose E. Gonzalez"}},"conditionsModule":{"conditions":["Chronic Kidney Disease Due to Hypertension","Chronic Kidney Disease Due to Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Faecal microbiota transplant"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04377321","briefTitle":"Colchicine Has Anti-diabetic Effect"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ministry of Health and Population, Egypt"}},"conditionsModule":{"conditions":["Treatment Adherence"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Colchicine Tablets"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00645424","briefTitle":"A Study To Evaluate The Safety And Efficacy Of Atorvastatin In Patients With Diabetes And High Cholesterol"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc."}},"conditionsModule":{"conditions":["Hyperlipidemias"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"atorvastatin"},{"name":"atorvastatin"},{"name":"atorvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03060694","briefTitle":"Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine"}},"conditionsModule":{"conditions":["Non-alcoholic Fatty Liver Disease"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"diabetes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03324737","briefTitle":"Smartphone App to Restore Optimal Weight in Women With Recent Gestational Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National University Hospital, Singapore"}},"conditionsModule":{"conditions":["Gestational Diabetes","Weight Loss","Diet Habit"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Interactive Smartphone App"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03552757","briefTitle":"Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novo Nordisk A/S"}},"conditionsModule":{"conditions":["Obesity","Overweight"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide 1.0 mg"},{"name":"Semaglutide 2.4 mg"},{"name":"Placebo I (Semaglutide)"},{"name":"Placebo II (Semaglutide)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00287183","briefTitle":"6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-04494700 (TTP488)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01725126","briefTitle":"To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"GSK2890457"},{"name":"Metformin"},{"name":"Placebo"},{"name":"Liraglutide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01871207","briefTitle":"Serum and Intraocular Levels of Erythropoietin and VEGF in Type 2 Diabetes Patients With Proliferative Retinopathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Università degli Studi di Brescia"}},"conditionsModule":{"conditions":["Diabetic Retinopathy"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01155050","briefTitle":"Weight Loss in Chronic Disease Patient Population"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pennington Biomedical Research Center"}},"conditionsModule":{"conditions":["Overweight","Obesity","Diabetes","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tele-health Home Monitoring"},{"name":"TrestleTree Telephone Coaching"},{"name":"Tele-health Home Monitoring Plus Trestle Telephone Coaching"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03068065","briefTitle":"Antidiabetic Effects on Intrahepatic Fat"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"}},"conditionsModule":{"conditions":["Non-Alcoholic Fatty Liver Disease","Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Metformin"},{"name":"Gliclazide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00419835","briefTitle":"Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Sao Paulo"},"collaborators":[{"name":"Fundação de Amparo à Pesquisa do Estado de São Paulo"}]},"conditionsModule":{"conditions":["Macroalbuminuric Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"enalapril"},{"name":"losartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05514548","briefTitle":"Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Inversago Pharma Inc."},"collaborators":[{"name":"Worldwide Clinical Trials"}]},"conditionsModule":{"conditions":["Diabetic Kidney Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INV-202"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00771901","briefTitle":"Effect of Endoplasmic Reticulum Stress on Metabolic Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Washington University School of Medicine"}},"conditionsModule":{"conditions":["Insulin Resistance","Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"tauroursodeoxycholic acid"},{"name":"placebo"},{"name":"sodium phenylbutyrate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00829660","briefTitle":"Acarbose Cardiovascular Evaluation Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Oxford"},"collaborators":[{"name":"Bayer"}]},"conditionsModule":{"conditions":["Coronary Heart Disease","Acute Coronary Syndrome","Impaired Glucose Tolerance","Type 2 Diabetes Mellitus (T2DM)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acarbose"},{"name":"Matching Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01549600","briefTitle":"Comparison of Psyllium and Microcrystalline Cellulose on Glycemic Measures in Subjects With Impaired Fasting Glucose"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Procter and Gamble"},"collaborators":[{"name":"Duke University"}]},"conditionsModule":{"conditions":["Impaired Fasting Glucose"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"psyllium"},{"name":"Microcrystalline Cellulose"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01313286","briefTitle":"A Study to Compare Two Forms of LY2608204 in Healthy People"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Healthy Volunteers"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LY2608204 Reference"},{"name":"LY2608204 Test"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06370247","briefTitle":"First-time Usage of SGLT2 Inhibitors in Type 2 Diabetic Patients Who Are Fasting During Ramadan: Safety and Efficacy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sohag University"}},"conditionsModule":{"conditions":["SGLT2 Inhibitors, First Time Use","Type2 Diabetes","Fasting in Ramadan"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"HbA1c, serum creatinine, eGFR urine analysis and serum electrolyte Na and K"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02597127","briefTitle":"Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The Medicines Company"}},"conditionsModule":{"conditions":["Atherosclerotic Cardiovascular Disease","Familial Hypercholesterolemia","Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ALN-PCSSC"},{"name":"Normal Saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00494559","briefTitle":"The Effect of Pioglitazone on Neointima Volume and Inflammatory Markers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Korea University Anam Hospital"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Coronary Artery Stenosis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03078101","briefTitle":"EMPRA (EMPagliflozin and RAs in Kidney Disease)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Vienna"},"collaborators":[{"name":"Attoquant Diagnostics"}]},"conditionsModule":{"conditions":["Diabetic Kidney Disease","Diabetes Mellitus, Type 2","Chronic Kidney Disease stage3","Chronic Kidney Disease stage4"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin 10 MG [Jardiance]"},{"name":"Placebo Oral Tablet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03771066","briefTitle":"Bisphenol A and Muscle Insulin Sensitivity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"California Polytechnic State University-San Luis Obispo"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Insulin Sensitivity","Glucose Metabolism Disorders","Microtia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"bisphenol A"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04509856","briefTitle":"Teach-Back Educational Method On Diabetes Knowledge Level"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ataturk University"}},"conditionsModule":{"conditions":["Patient Empowerment"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Teach-back educational method"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00222807","briefTitle":"Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pittsburgh"},"collaborators":[{"name":"American Association for Geriatric Psychiatry"},{"name":"Janssen Pharmaceuticals"}]},"conditionsModule":{"conditions":["Schizophrenia","Schizoaffective Disorder","Delusional Disorder"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00433628","briefTitle":"Accuracy of Hemoglobin A1C to Predict Glycemia in HIV"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Allergy and Infectious Diseases (NIAID)"}},"conditionsModule":{"conditions":["HIV","Diabetes","Hyperglycemia"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00116831","briefTitle":"Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Atherosclerosis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Glipizide"},{"name":"rosiglitazone maleate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01918345","briefTitle":"Avoiding Diabetes After Pregnancy Trial in Moms"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Women's College Hospital"},"collaborators":[{"name":"The Lawson Foundation"},{"name":"Diabetes Canada"},{"name":"Unity Health Toronto"},{"name":"Sunnybrook Health Sciences Centre"},{"name":"Mount Sinai Hospital, Canada"},{"name":"Michael Garron Hospital"},{"name":"Canadian Institutes of Health Research (CIHR)"},{"name":"Scarborough Rouge Hospital"},{"name":"J.P. Bickell Foundation"}]},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Home-based Physical Activity Program with Health Coach"},{"name":"Home-based Low-GI Diet Program with Health Coach"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02191644","briefTitle":"Dietary Intervention Replacing Carbohydrate With Protein and Fat Has Greater Effect on Peripheral Blood Mononuclear Cell Metabolites Than on Plasma Metabolites in Patients With Prediabetes or Type-2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yonsei University"}},"conditionsModule":{"conditions":["Prediabetes","Type-2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dietary intervention-refined rice"},{"name":"Dietary intervention-whole grains and legumes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01573949","briefTitle":"A Pilot Study: Metformin Therapy in Heart Failure Patients With Early Diabetes or at High Risk of Developing Diabetes (Pre-Diabetes)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, Los Angeles"}},"conditionsModule":{"conditions":["Diabetes","Heart Failure"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00055042","briefTitle":"Laser and Antioxidant Treatment of Diabetic Macular Edema"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Eye Institute (NEI)"}},"conditionsModule":{"conditions":["Macular Edema","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin E"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03646292","briefTitle":"Antidiabetic Drugs for Steatotic Liver Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yonsei University"}},"conditionsModule":{"conditions":["MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","Type 2 Diabetes","Digestive System Disease","Liver Diseases","Fatty Liver","Metabolic Dysfunction-Associated Steatotic Liver Disease","Non-Alcoholic Fatty Liver Disease","Hypoglycemic Agents","Physiological Effects of Drugs","Sodium-Glucose Cotransporter 2 Inhibitors","Pioglitazone","Molecular Mechanisms of Pharmacological Action","Empagliflozin","Thiazolidinediones"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"Empagliflozin"},{"name":"Combination of pioglitazone and empagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02330406","briefTitle":"Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institute for Clinical Effectiveness, Japan"}},"conditionsModule":{"conditions":["Dipeptidyl-Peptidase 4 Inhibitors","LDL Cholesterol","Glycosylated Hemoglobin","Diabetes Mellitus","Coronary Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Anagliptin"},{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03391349","briefTitle":"Quantification of Proteomes: L-plastin , Lipocalin and Adiponectin in Chronic Periodontitis and Diabetic Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Meenakshi Ammal Dental College and Hospital"}},"conditionsModule":{"conditions":["Periodontal Diseases"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05046015","briefTitle":"Comparison Dry Foot Skin Between Diabetic and Non-diabetic Subjects and the Effects of Two Cosmetic Foot Care Products"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Galderma R&D"}},"conditionsModule":{"conditions":["Xerosis Cutis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"10% Urea foot lotion"},{"name":"10% Urea foot ointment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00639457","briefTitle":"Exercise and Pioglitazone for HIV-Metabolic Syndromes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["HIV Infections","Type 2 Diabetes","Obesity","HIV","AIDS","Cardiovascular Disease","Lipodystrophy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"Exercise training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02568384","briefTitle":"Evaluation of an Ascensia Blood Glucose Meter and App System"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ascensia Diabetes Care"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Onyx BG Meter / App System"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06309654","briefTitle":"Home-Based Circuit Training in Overweight/Obese Older Adult Patients With Knee Osteoarthritis and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Princess Nourah Bint Abdulrahman University"}},"conditionsModule":{"conditions":["Aerobic Exercise","Strength Training","Glycemic Control","Blood Pressure","Oxidative Stress","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"12-week home-based circuit training (HBCT)"},{"name":"Standard of care (CONT)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01472640","briefTitle":"The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Flyvbjerg, Allan, DMSc"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Hyperglycemia","Chronic Heart Failure"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00323414","briefTitle":"Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Fatty Liver"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Polyunsaturated fatty acid (Opti-EPA)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01990469","briefTitle":"Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"LG Life Sciences"}},"conditionsModule":{"conditions":["T2DM"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gemigliptin"},{"name":"Gemigliptin placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02556918","briefTitle":"Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Emory University"}},"conditionsModule":{"conditions":["Hyperglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Placebo"},{"name":"Regular Human Insulin"},{"name":"Insulin glargine"},{"name":"Supplemental insulin (Insulin lispro)"},{"name":"Supplemental insulin (Insulin aspart)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02451436","briefTitle":"A Sleep and Media Use Intervention to Improve Adolescents' Weight and Risk of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alabama at Birmingham"}},"conditionsModule":{"conditions":["Sleep"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sleep and Media Use Intervention"},{"name":"Study Skills Control Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02612714","briefTitle":"Statin Lowering Testosterone and Sexual Function"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chang Gung Memorial Hospital"}},"conditionsModule":{"conditions":["Sexual Dysfunction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rosuvastatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01611883","briefTitle":"A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Organon and Co"}},"conditionsModule":{"conditions":["Hypercholesterolemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ezetimibe"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06516705","briefTitle":"The Effectiveness of Multimedia Education on Hypoglycemic Management."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kaohsiung Medical University Chung-Ho Memorial Hospital"}},"conditionsModule":{"conditions":["Type2diabetes","Hypoglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hypoglycemia education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02131948","briefTitle":"Regulation of Endogenous Glucose Production by Brain Insulin Action"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Health Network, Toronto"}},"conditionsModule":{"conditions":["Insulin Resistance, Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Intranasal insulin"},{"name":"Intranasal placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04595396","briefTitle":"Laparoscopic Gastric Bypass as Metabolic Surgery in Obesity Class 1"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"CARLOS ZERRWECK LOPEZ"}},"conditionsModule":{"conditions":["Type2 Diabetes","Bariatric Surgery Candidate","Laparoscopic Gastric Bypass","Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Laparoscopic Gastric Bypass"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04864483","briefTitle":"Sahoor Meal Regimen for Patients With Type1 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"King Abdullah International Medical Research Center"}},"conditionsModule":{"conditions":["Type1diabetes","Fasting Hypoglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Meal timing in relation to time of starting the fast"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01756716","briefTitle":"A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MT-3995 Low"},{"name":"MT-3995 High"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03717207","briefTitle":"Cardiac Autonomic Dysfunction in Diabetics Patients With Syncope"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Campania \"Luigi Vanvitelli\""}},"conditionsModule":{"conditions":["Syncope, Vasovagal"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ecg Holter,"},{"name":"cardiac scintigraphy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03527277","briefTitle":"Orange Juice And Sugar Intervention Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, Davis"},"collaborators":[{"name":"Touro University, California"}]},"conditionsModule":{"conditions":["Cardiovascular Risk Factor","Type2 Diabetes Mellitus","Insulin Sensitivity","Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Naturally-sweetened orange juice"},{"name":"Sugar-sweetened beverage"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04497792","briefTitle":"Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary Interventions"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Research Institute for Complex Problems of Cardiovascular Diseases, Russia"}},"conditionsModule":{"conditions":["Coronary Artery Disease","Diabetes Mellitus","Percutaneous Coronary Intervention"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin 10Mg Tab"},{"name":"hypoglycemic therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03651908","briefTitle":"Comparison Between Bioactive Silica Graft Plus Platelet Rich Fibrin and Only Platelet Rich Fibrin Graft in Intrabony Defects With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre"}},"conditionsModule":{"conditions":["Intrabony Periodontal Defect"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Conventional Flap Surgery"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03254979","briefTitle":"Optimizing the Primary Prevention of Type-2 Diabetes in Primary Health Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Basque Health Service"}},"conditionsModule":{"conditions":["Interprofessional Relations","Primary Health Care/Organization & Administration","Diabetes Mellitus, Type 2/Prevention & Control","Primary Prevention/Methods","Risk Reduction Behavior","Randomized Controlled Trial","Life Style"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Healthy lifestyle prescription"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00570154","briefTitle":"Relation of White Blood Cell Function to Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}},"conditionsModule":{"conditions":["Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02545738","briefTitle":"Antiproteinuric Effects of Liraglutide Treatment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Steno Diabetes Center Copenhagen"},"collaborators":[{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Diabetic Kidney Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00027287","briefTitle":"Laser and Medical Treatment of Diabetic Macular Edema"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Eye Institute (NEI)"}},"conditionsModule":{"conditions":["Diabetes Mellitus","Macular Edema"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin E"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00412165","briefTitle":"PACE-iDP: An Intervention for Youth at Risk for Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, San Diego"}},"conditionsModule":{"conditions":["Obesity","Overweight","Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cell Phone"},{"name":"Weekly access to interactive web site"},{"name":"Group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04265469","briefTitle":"Mobile Application For Educating Diabetics About Foot Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Istanbul Medeniyet University"}},"conditionsModule":{"conditions":["Diabetic Foot, Mobile Application, Patient Education"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diabetic foot education"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01365013","briefTitle":"Evaluation of the Translation of the DE-PLAN Program for the Primary Prevention of Type 2 Diabetes in Routine Primary Care"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Basque Health Service"}},"conditionsModule":{"conditions":["Prediabetic State"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DE-PLAN"},{"name":"Control group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03530644","briefTitle":"Comparative Study Between Two Models of a Non-invasive Glucose Monitoring Device"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"RSP Systems A/S"}},"conditionsModule":{"conditions":["Type1diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"WM3.4NR"},{"name":"P0.1"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04200625","briefTitle":"Semaglutide vs Dulaglutide on Epicardial Adipose Tissue"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Miami"}},"conditionsModule":{"conditions":["Epicardial Fat"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04549324","briefTitle":"Sleep Apnea, Coronary Atherosclerosis and Heart Failure in Diabetes Patients With Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"}},"conditionsModule":{"conditions":["Sleep Apnea","Diabetic Nephropathy Type 2","Coronary Atheroscleroses","Heart Insufficiency","Arterial Stiffness","Kidney Diseases","Vascular Diseases"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05862311","briefTitle":"The Effect of Non-Surgical Periodontal Treatment on Bone Metabolism in Type 2 Diabetes and Systemically Healthy Individuals"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Necmettin Erbakan University"}},"conditionsModule":{"conditions":["Periodontal Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ELISA"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02405949","briefTitle":"GENETIC SUSCEPTIBILITY FACTOR AS A PREDICTOR OF TYPE 2 DIABETES REMISSION AND WEIGHT LOSS AFTER BARIATRIC SURGERY"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital Universitari Vall d'Hebron Research Institute"}},"conditionsModule":{"conditions":["Case-control Study"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Genetic test"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02307279","briefTitle":"Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Gelesis, Inc."}},"conditionsModule":{"conditions":["Overweight","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Gelesis100"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01968668","briefTitle":"Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Diabetic Nephropathies"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BAY94-8862"},{"name":"BAY94-8862"},{"name":"BAY94-8862"},{"name":"BAY94-8862"},{"name":"BAY94-8862"},{"name":"Placebo"},{"name":"BAY 94-8862"},{"name":"BAY 94-8862"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00349128","briefTitle":"Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Solvay Pharmaceuticals"}},"conditionsModule":{"conditions":["Dyslipidemia/Glucose Metabolism Disorder"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"fenofibrate and metformin combination (drug)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04028076","briefTitle":"Improving Diabetes Medication Adherence for African Americans in Madison and Milwaukee Through Peer Support"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Wisconsin, Madison"}},"conditionsModule":{"conditions":["Type2 Diabetes","Medication Adherence","Medication Nonadherence","Peer Support"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Peers Supporting Health-Literacy, Self Efficacy, Advocacy and Adherence"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03301519","briefTitle":"Genetics of Beta Cell Failure in Mexican Americans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Southern California"},"collaborators":[{"name":"Kaiser Permanente"}]},"conditionsModule":{"conditions":["Gestational Diabetes","Diabetes Type 2","Insulin Resistance","Beta Cell Function","Genetics","Nutrition","Physical Activity","Adipokines","Obesity","Air Pollution"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01693510","briefTitle":"Be Healthy in Pregnancy (B-HIP): A Trial to Study Nutrition and Exercise Approaches for Healthy Pregnancy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"McMaster University"},"collaborators":[{"name":"Dairy Farmers of Canada"}]},"conditionsModule":{"conditions":["Excessive Weight Gain in Pregnancy as Antepartum Condition","Obesity","Weight Gain","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise and Nutrition Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03854656","briefTitle":"Effect of Time-restricted Eating on Behaviour and Metabolism in Overweight Individuals at High Risk of Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kristine Færch"},"collaborators":[{"name":"University of Copenhagen"},{"name":"Aalborg University Hospital"},{"name":"IMotions A/S"},{"name":"University of Leeds"},{"name":"Salk Institute for Biological Studies"}]},"conditionsModule":{"conditions":["Overweight and Obesity","PreDiabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Time-restricted eating"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00497003","briefTitle":"Effect of Beta Blocker Treatment on Endothelial Function in Patients With Type 2 Diabetes or Chronic Heart Failure"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bispebjerg Hospital"},"collaborators":[{"name":"Danish Heart Foundation"}]},"conditionsModule":{"conditions":["Endothelial Function","Beta Blocker"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Treatment with either metoprolol or carvedilol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00774904","briefTitle":"Adiponectin and Insulin Resistance in Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Health Science Center of Xi'an Jiaotong University"},"collaborators":[{"name":"Shanghai Jiao Tong University School of Medicine"}]},"conditionsModule":{"conditions":["Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Losartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03790839","briefTitle":"Drug Interaction Study Between Dorzagliatin and Sitagliptin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hua Medicine Limited"}},"conditionsModule":{"conditions":["Patients"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Dorzagliatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03790787","briefTitle":"Drug Interaction Study Between Dorzagliatin and Empagliflozin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hua Medicine Limited"}},"conditionsModule":{"conditions":["Patients"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin"},{"name":"Dorzagliatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00035711","briefTitle":"VA HDL Intervention Trial (VA-HIT) Ancillary Study Data Analysis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}},"conditionsModule":{"conditions":["Coronary Disease","Heart Diseases","Cardiovascular Diseases","Carotid Artery Diseases","Diabetes Mellitus, Non-insulin Dependent","Hypertension","Insulin Resistance","Obesity","Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00233298","briefTitle":"A Study of the Function of Hormones Present In Taste Buds"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute on Aging (NIA)"}},"conditionsModule":{"conditions":["Diabetes","Obesity","Pre-Diabetes","Metabolic Syndrome"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01828931","briefTitle":"Lifestyle Intervention for Diabetes and Weight Management in Psychosis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre for Addiction and Mental Health"},"collaborators":[{"name":"Canadian Diabetes Association"}]},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus","Schizophrenia","Schizoaffective Disorder","Schizophreniform Disorder","Bipolar I Disorder","Substance-induced Psychosis","Psychotic Disorders","Major Depressive Disorder"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle Intervention"},{"name":"Usual Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00730561","briefTitle":"Hematopoietic Stem Cell Transplantation for the Treatment of Limb Ischemia and Diabetic Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital Universitario Dr. Jose E. Gonzalez"}},"conditionsModule":{"conditions":["Limb Ischemia","Diabetic Neuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hematopoietic stem cell transplantation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03497390","briefTitle":"All-encompassing Program Led by Diabetes Specialist Team"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chinese University of Hong Kong"}},"conditionsModule":{"conditions":["Health Care Delivery"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EMERALD intervention"},{"name":"Usual care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02077127","briefTitle":"Monocyte Chemoattractant Protein-1 2518A/G Polymorphism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Harbin Medical University"}},"conditionsModule":{"conditions":["Diabetic Retinopathy"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01310491","briefTitle":"RENEWING HEALTH - RegioNs of Europe WorkINg Together for HEALTH"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"South Karelia, Social and Health Care District"}},"conditionsModule":{"conditions":["Type 2 Diabetes","Coronary Artery Disease","Heart Failure","Atrial Fibrillation","Other Arrhythmias"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Health coaching"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02382159","briefTitle":"A Observational Study to Evaluate Lipid-lowering Drug Its Effect on Parameters in Dyslipidemia of Type 2 Diabetes."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yooyoung Pharmaceutical Co., Ltd."}},"conditionsModule":{"conditions":["Complex Dyslipidemia"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00992641","briefTitle":"The Effect of Nordic Recommended Diet on the Features of Metabolic Syndrome - Multicentre Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Marjukka Kolehmainen"},"collaborators":[{"name":"University of Copenhagen"},{"name":"Aarhus University Hospital"},{"name":"University of Oulu"},{"name":"University of Iceland"},{"name":"University Hospital, Akershus"},{"name":"Uppsala University"},{"name":"Lund University"}]},"conditionsModule":{"conditions":["Abdominal Obesity","Insulin Resistance","Impaired Glucose Tolerance","Type 2 Diabetes","Cardiovascular Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Experimental diet"},{"name":"Control diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03754036","briefTitle":"Sleep Extension and Insulin Sensitivity in Adolescents"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Children's Hospital of Eastern Ontario"}},"conditionsModule":{"conditions":["Sleep"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sleep manipulation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00131846","briefTitle":"Diuretics In the Management of Essential Hypertension (DIME) Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kyoto University"},"collaborators":[{"name":"University of the Ryukyus"}]},"conditionsModule":{"conditions":["Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Thiazide diuretics"},{"name":"No diuretics"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01127659","briefTitle":"Testosterone Replacement in Men With Diabetes and Obesity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University at Buffalo"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Hypogonadism"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"testosterone"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04662398","briefTitle":"Using of Testes' Shocker in Improving Sexual Activity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Baghdad"}},"conditionsModule":{"conditions":["Sexual Dysfunction","Sexual Abstinence","Sexual Desire Disorder","Erectile Dysfunction","Erectile Dysfunction Following Radical Prostatectomy","Erectile Dysfunction Following Cryotherapy","Erectile Dysfunction With Diabetes Mellitus","Erectile Dysfunction Following Radiation Therapy","Erectile Dysfunction Following Urethral Surgery","Erectile Dysfunction With Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"JT Device"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02278068","briefTitle":"COMPLEMENT Study- A First in Human Study of Metabolic Neuromodulation Therapy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Metavention"}},"conditionsModule":{"conditions":["Diabetes","Endocrine, Nutritional and Metabolic Diseases (E00-E89)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metabolic Neuromodulation System (MNS)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05024032","briefTitle":"A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Obesity","Overweight","Metabolism and Nutrition Disorder"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04616014","briefTitle":"A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oramed, Ltd."}},"conditionsModule":{"conditions":["Nonalcoholic Steatohepatitis (NASH)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ORMD-0801 QD"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05857085","briefTitle":"Novel Therapeutics and Endothelial Dysfunction in T1DM Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"General and Teaching Hospital Celje"}},"conditionsModule":{"conditions":["Endothelial Dysfunction","Diabetes Mellitus, Type 1","Biomarkers","Endothelial Progenitor Cells","SGLT 2 Inhibitors","Incretins","Glucose Excursions","FMD","FPF","Arterial Stiffness"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Semaglutide Pen Injector [Ozempic]"},{"name":"Empagliflozin 10 MG"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05144737","briefTitle":"A Virtual Cardiometabolic Health Program for African Immigrants: The Afro-DPP Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johns Hopkins University"},"collaborators":[{"name":"National Institute of Nursing Research (NINR)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 2","PreDiabetes","Hypertension","High Blood Pressure","High Blood Sugar","Obesity","Overweight","Overweight and Obesity","Overweight or Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"The Diabetes Prevention Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03857802","briefTitle":"Efficiency of a Nursing Intervention in Sleep Hygiene"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina"}},"conditionsModule":{"conditions":["Sleep Disorder","Metabolic Glucose Disorders"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sleep hygiene intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03060577","briefTitle":"An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Atherosclerotic Cardiovascular Disease","Symptomatic Atherosclerosis","Type2 Diabetes","Familial Hypercholesterolemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Inclisiran"},{"name":"Evolocumab"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03188263","briefTitle":"Morning Light Treatment to Improve Glucose Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Northwestern University"},"collaborators":[{"name":"Rush University"}]},"conditionsModule":{"conditions":["PreDiabetes","Circadian Dysregulation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bright Light"},{"name":"Dim Light"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00410800","briefTitle":"Insulin Secretory Defects in Pima Indians at High Risk for NIDDM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["NIDDM"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04093856","briefTitle":"Determinants of Bone and Muscle Quality and Strength in Obesity With and Without Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Suzanne Morin"},"collaborators":[{"name":"CHU de Quebec-Universite Laval"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 2","Obesity","Body Weight","Bone Diseases, Metabolic","Fractures, Bone","Osteoporotic Fractures","Osteoporosis","Quality of Life","Fall","Musculoskeletal Diseases"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00005365","briefTitle":"Central Obesity and Disease Risk in Japanese Americans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Washington"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Heart Diseases","Atherosclerosis","Hypertension","Obesity","Diabetes Mellitus, Non-insulin Dependent","Hyperinsulinism","Insulin Resistance","Coronary Arteriosclerosis","Diabetes Mellitus","Metabolic Syndrome X"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02754219","briefTitle":"Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dong-A ST Co., Ltd."}},"conditionsModule":{"conditions":["Liver Dysfunction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Evogliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00542178","briefTitle":"Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Heart, Lung, and Blood Institute (NHLBI)"},"collaborators":[{"name":"National Eye Institute (NEI)"}]},"conditionsModule":{"conditions":["Diabetic Retinopathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hypoglycemic Agents"},{"name":"Standard glycemia control"},{"name":"Intensive BP treatment"},{"name":"Standard BP control"},{"name":"Fenofibrate"},{"name":"Simvastatin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03729479","briefTitle":"The MHERO Study (Michigan's Hypertension, Diabetes, and Obesity Education Research Online)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"}},"conditionsModule":{"conditions":["Type2 Diabetes Mellitus","Hypertension","PreDiabetes","Overweight and Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"DASH diet"},{"name":"Very low carbohydrate, ketogenic diet"},{"name":"Extras"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01147250","briefTitle":"Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"}},"conditionsModule":{"conditions":["Acute Coronary Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide (AVE0010)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03006952","briefTitle":"Add-on Pentoxifylline to Losartan Versus Increasing Dose of Losartan on NT-PRO BNP in Type 2 Diabetics With Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tehran University of Medical Sciences"}},"conditionsModule":{"conditions":["Diabetic Nephropathies"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pentoxifylline"},{"name":"Losartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04287439","briefTitle":"Relaxation and Meditation Techniques on Pain, Fatigue and Quality of Life"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hacettepe University"}},"conditionsModule":{"conditions":["Neuropathy, Diabetic"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Progressive muscle relaxation"},{"name":"Mindfulness meditation"},{"name":"Attention matched control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01237119","briefTitle":"Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Birmingham"},"collaborators":[{"name":"Wellcome Trust"},{"name":"Novo Nordisk A/S"}]},"conditionsModule":{"conditions":["Nonalcoholic Steatohepatitis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide"},{"name":"Liraglutide-placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00603291","briefTitle":"BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eisai Inc."}},"conditionsModule":{"conditions":["Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lorcaserin 10 mg once daily (QD)"},{"name":"Lorcaserin 10 mg twice a day (BID)"},{"name":"Matching Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00604383","briefTitle":"Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chromaderm, Inc."}},"conditionsModule":{"conditions":["Diabetic Retinopathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ruboxistaurin"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00533559","briefTitle":"Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Health Network, Toronto"}},"conditionsModule":{"conditions":["Diabetes","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"sodium phenylbutyrate"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04306406","briefTitle":"Molecular Mechanisms of Raspberries Effect on Insulin Resistance and Inflammation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pennington Biomedical Research Center"},"collaborators":[{"name":"National Processed Raspberry Council"},{"name":"Louisiana State University and A&M College"}]},"conditionsModule":{"conditions":["Inflammation","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Raspberries"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04361799","briefTitle":"Perioperative Closed-loop Glucose Control"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Insel Gruppe AG, University Hospital Bern"}},"conditionsModule":{"conditions":["Perioperative Hyperglycaemia","Insulin Therapy","Elective Surgery","Closed-Loop Glucose Control","Artificial Pancreas"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CamAPS"},{"name":"Standard insulin therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00153023","briefTitle":"1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetic Nephropathies","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Telmisartan"},{"name":"Valsartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05163587","briefTitle":"Composite Flour and Its Antdiabetic Potential"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Veterinary and Animal Sciences, Lahore - Pakistan"}},"conditionsModule":{"conditions":["Blood Glucose, High","Body Weight Changes","Hyperlipidemias","Body Composition"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"low GI composite flour"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00097955","briefTitle":"Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"aliskiren"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04495231","briefTitle":"Sympathetic Activity and Cardiometabolic Complications"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Turin, Italy"}},"conditionsModule":{"conditions":["Catecholamine; Overproduction","Catecholamine; Secretion","Metabolic Syndrome","Hypertensive Heart Disease","Hypertensive Kidney Disease","Diabetes Mellitus, Type 2","Hypertension,Essential"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03312764","briefTitle":"Preventing Diabetes With Digital Health and Coaching"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Omada Health, Inc."},"collaborators":[{"name":"University of Nebraska"},{"name":"Wake Forest University Health Sciences"}]},"conditionsModule":{"conditions":["PreDiabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Online diabetes prevention program"},{"name":"Standard Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02653300","briefTitle":"A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Oramed, Ltd."},"collaborators":[{"name":"Hadassah Medical Organization"}]},"conditionsModule":{"conditions":["Non-Alcoholic Steatohepatitis (NASH)","Type2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Oral Insulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02040441","briefTitle":"Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Peter Rossing"},"collaborators":[{"name":"Mosaiques Diagnostics GmbH"},{"name":"University Medical Center Groningen"},{"name":"University of Glasgow"},{"name":"Istituto Di Ricerche Farmacologiche Mario Negri"},{"name":"Univerzita Karlova v Praze"},{"name":"Geniko Nosokomeio Athinas Ippokrateio"},{"name":"Institut Klinické a Experimentální Mediciny Praze"},{"name":"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz"},{"name":"Klinikum St. Georg Leipzig"},{"name":"Cyril and Methodius University in Skopje"},{"name":"Hannover Clinical Trial Center"},{"name":"European Commission"},{"name":"Diabetes Vascular Research Foundation Hoogeveen"},{"name":"Universitair Ziekenhuis Gent"},{"name":"Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden"},{"name":"Stichting VUMC"},{"name":"Diabetologen Hessen"}]},"conditionsModule":{"conditions":["Diabetic Nephropathy","Diabetic Retinopathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Spironolactone"},{"name":"Placebo"},{"name":"Standard care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03415880","briefTitle":"Light Intensity Physical Activity Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Academisch Ziekenhuis Maastricht"},"collaborators":[{"name":"European Foundation for the Study of Diabetes"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Physical Exercise","Light Intensity Physical Activity","Arterial Stiffness","Aortic Stiffness","Pulse Wave Velocity","Type2 Diabetes","Sedentary Lifestyle","Artery Disease","Physical Activity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Interactive workshops LiPAT intervention group"},{"name":"Wrist-worn feedback physical activity monitor"},{"name":"Smartphone application LiPAT"},{"name":"Telephone Coaching"},{"name":"Workshops control group LiPAT"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00389896","briefTitle":"A Crossover Study to Evaluate the Efficacy of Simvastatin in Elevating HDL-C Levels in Patients With Type 2 Diabetes (0733-216)(COMPLETED)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Organon and Co"}},"conditionsModule":{"conditions":["HDL Cholesterol"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MK0733 / Duration of Treatment: 18 Weeks"},{"name":"Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00627744","briefTitle":"Beta-cell Function in Glucose Abnormalities and Acute Myocardial Infarction"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Karolinska Institutet"}},"conditionsModule":{"conditions":["Myocardial Infarction","Unstable Angina Pectoris","Diabetes Mellitus","Impaired Glucose Tolerance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00314379","briefTitle":"Endothelial Function in a Sample Group of Patients From the ICARE Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Technion, Israel Institute of Technology"},"collaborators":[{"name":"Clalit Health Services"},{"name":"Rambam Health Care Campus"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin E 400IU/day"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00970723","briefTitle":"High Blood Pressure and Sleep Apnea in Diabetic Macular Edema"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Assistance Publique - Hôpitaux de Paris"}},"conditionsModule":{"conditions":["Diabetic Retinopathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"high blood pressure treatment"},{"name":"sleep apnea treatment"},{"name":"diabetic macular edema treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01923350","briefTitle":"Avoiding Diabetes After Pregnancy Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Social & Scientific Systems Inc."},"collaborators":[{"name":"Harvard Pilgrim Health Care"},{"name":"Duke University"},{"name":"Harvard Vanguard Medical Associates"}]},"conditionsModule":{"conditions":["Weight Reduction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Weight Reduction Intervention"},{"name":"Weight Reduction Control Arm"},{"name":"Tested for diabetes"},{"name":"Not tested for diabetes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02318797","briefTitle":"Optimizing Behavioral Health Homes for Adults With Serious Mental Illness"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pittsburgh"},"collaborators":[{"name":"UPMC Center for High-Value Health Care"},{"name":"Western Psychiatric Institute and Clinic of UPMC"},{"name":"Community Care Behavioral Health Organization"},{"name":"Columbia Montour Snyder Union Mental Health"},{"name":"Behavioral Health Alliance of Rural Pennsylvania"}]},"conditionsModule":{"conditions":["Chronic Disease","Mental Health","Behavioral Health","Cardiovascular Disease","Diabetes Mellitus Type 2","Substance-related Disorders","Vascular Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Patient Self-Directed Care"},{"name":"Provider-Supported Integrated Care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03578991","briefTitle":"Diabetes as an Accelerator of Cognitive Impairment and Alzheimer's Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Parc Sanitari Pere Virgili"},"collaborators":[{"name":"Hospital Vall d'Hebron"},{"name":"Consorci Sanitari de Terrassa"},{"name":"Fundació Recerca Mútua Terrassa (FMT)"},{"name":"Clínica Universitària de la Fundació Universitària del Bages (FUB)"},{"name":"Althaia Xarxa Assistencial Universitària de Manresa"},{"name":"Fundació Privada Hospital Asil de Granollers (HAG)"},{"name":"Consorci Hospitalari de Vic"},{"name":"LambdaLoopers"},{"name":"Universitat Politècnica de Catalunya"},{"name":"Leitat"},{"name":"Mixestat"},{"name":"Meditecnologia"}]},"conditionsModule":{"conditions":["Patients Aged 65-85 (Both Included)","Diagnosed of Mild Cognitive Impairment","Diagnosed of Type 2 Diabetes in Active Treatment (Hypoglycemic Agents) for a Period ≥5 Years"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Smart pillbox"},{"name":"Interactive digital platform"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01077323","briefTitle":"A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Eli Lilly and Company"},{"name":"i3 Drug Safety"}]},"conditionsModule":{"conditions":["Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies)","Healthy Subjects (Treated With no Diabetes Therapies)"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"exenatide"},{"name":"Other antidiabetic therapies"},{"name":"No diabetes therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02875782","briefTitle":"Brief Intervention to Promote Smoking Cessation in DM Smokers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Hong Kong"}},"conditionsModule":{"conditions":["Smoking"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Smoking cessation and DM specific component intervention"},{"name":"Control group"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01889810","briefTitle":"Effect of Vitamin D3 Supplementation on Insulin Resistance- The DIR Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Queen's University, Belfast"},"collaborators":[{"name":"HSC Research & Development Division, Public Health Agency, Northern Ireland"},{"name":"The Metabolic Unit Research Fund, The Royal Hospitals, Belfast, Northern Ireland"},{"name":"Northern Ireland Chest Heart and Stroke"}]},"conditionsModule":{"conditions":["Sub-optimal Vitamin D Status","Pre-diabetes","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin D3 supplementation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01884714","briefTitle":"Exploring the Molecular Basis to Healthy Obesity: The Diabetes Risk Assessment Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Guelph"},"collaborators":[{"name":"Public Health Agency of Canada (PHAC)"}]},"conditionsModule":{"conditions":["Obesity","Type-2 Diabetes","Metabolic Syndrome","Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High fat/high calorie meal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00484068","briefTitle":"Chicken-Diet vs. Enalapril to Reduce Albuminuria"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital de Clinicas de Porto Alegre"}},"conditionsModule":{"conditions":["Microalbuminuria","Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"enalapril"},{"name":"chicken diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00663949","briefTitle":"Assessment of the Effect of Captopril Versus Combination of Captopril and Pentoxifylline on Reducing Proteinuria in Type 2 Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shiraz University of Medical Sciences"}},"conditionsModule":{"conditions":["Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Captopril"},{"name":"Captopril + Pentoxifylline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03510000","briefTitle":"Alleviating Carbohydrate-Counting Burden in T1DM Using Artificial Pancreas and Empagliflozin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital"},"collaborators":[{"name":"Canadian Diabetes Association"},{"name":"Institut de Recherches Cliniques de Montreal"},{"name":"McGill University Health Centre/Research Institute of the McGill University Health Centre"}]},"conditionsModule":{"conditions":["Type1diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Empagliflozin 25mg"},{"name":"Single hormone artificial pancreas"},{"name":"Meal strategies"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04647617","briefTitle":"Effects of 12- Weeks of Quantitative Weight-bearing Progressive Resistance Exercise Training on Glycemia Control and Improving Muscle Strength With Type 2 Diabetes Combine Pre-sarcopenia."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Yu- Hsuan Chien"}},"conditionsModule":{"conditions":["Twelve Week Quantitative Weight Bearing of Resistance Training Effect on Glycemic Control and Muscle Strength"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Quantitative weight -bearing and report exercise sign data every weekly"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04621045","briefTitle":"Active You: Feasibility of a Unique Physical Activity Program to Prevent Diabetes and Heart Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Pittsburgh"}},"conditionsModule":{"conditions":["Cardiovascular Risk Factor","Prediabetes","Overweight and Obesity","Sedentary Behavior"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"The Physical Activity for The Heart (PATH) intervention"},{"name":"Be Active Your Way Booklet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02865525","briefTitle":"Development and Validation of a Self-administered QUestionnaire to Identify Levers of Adhesion Behavior to Patient's Medication in Order to Adapt the Educational Monitoring."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Grenoble"}},"conditionsModule":{"conditions":["Patient Education as Topic","Surveys and Questionnaires","Medication Adherence","Pulmonary Disease, Chronic Obstructive","Diabetes Mellitus, Type 2","Heart Failure"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01496443","briefTitle":"TAK-875 Glimepiride Drug-Interaction Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Pharmacokinetics"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"TAK-875 and Glimepiride"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00320060","briefTitle":"Effect of Pyridorin in Patients With Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"BioStratum"}},"conditionsModule":{"conditions":["Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pyridorin (pyridoxamine dihydrochloride)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00940251","briefTitle":"Evaluation of Safety and Efficacy of Mersina, an Ayurvedic Formulation: A Double Blind, Placebo Controlled Study in Type 2 Diabetic Patients With Secondary Failure to Oral Drugs"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jyoti Clinical and Pathological Laboratory"}},"conditionsModule":{"conditions":["Antihyperglycemic Effect in Type 2 Diabetic Patients With Secondary Failure to Oral Hypoglycemic Agents"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mersina"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00920764","briefTitle":"A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AbbVie (prior sponsor, Abbott)"}},"conditionsModule":{"conditions":["Chronic Kidney Disease","Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo for Atrasentan 0.2 mg/mL solution"},{"name":"0.25 mg Atrasentan QD"},{"name":"0.75 mg Atrasentan QD"},{"name":"1.75 mg Atrasentan QD"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00633282","briefTitle":"Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Xin Gao"},"collaborators":[{"name":"Shanghai Jiao Tong University School of Medicine"},{"name":"Shanghai Municipal Science and Technology Commission"}]},"conditionsModule":{"conditions":["Nonalcoholic Fatty Liver Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Life style intervention"},{"name":"pioglitazone"},{"name":"berberine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00555490","briefTitle":"Long-Term Effect of Soy Consumption on Cardio-Renal Indices and CRP in Type 2diabetes With Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Isfahan University of Medical Sciences"},"collaborators":[{"name":"Shahid Beheshti University of Medical Sciences"}]},"conditionsModule":{"conditions":["Kidney Transplantation"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Soy protein"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02827383","briefTitle":"Pilot Stair Climbing Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jennifer Gay"},"collaborators":[{"name":"University of Illinois at Urbana-Champaign"}]},"conditionsModule":{"conditions":["Prediabetic State"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Stair Climbing Frequency"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00422955","briefTitle":"Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Neuropathy, Diabetic"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rosiglitazone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00320021","briefTitle":"Effect of Pyridorin in Patients With Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"BioStratum"}},"conditionsModule":{"conditions":["Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pyridorin (pyridoxamine dihydrochloride)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01237522","briefTitle":"A Pharmacokinetic Evaluation of Metformin in Relation to the Polymorphism A270S in Healthy Caucasian Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Southern Denmark"}},"conditionsModule":{"conditions":["Metformin","Organic Cation Transporter 2","Polymorphism,Single Nucleotide"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00421733","briefTitle":"The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott"}},"conditionsModule":{"conditions":["Diabetic Nephropathy","Chronic Kidney Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Zemplar (paricalcitol ) capsules"},{"name":"Zemplar (paricalcitol) capsules"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02439879","briefTitle":"Alpha Lipoic Acid for Treatment of Diabetic Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidad Popular Autónoma del Estado de Puebla"}},"conditionsModule":{"conditions":["Diabetic Neuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alpha lipoic acid"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03629912","briefTitle":"Bingocize: A Novel Mobile Application for Older Adult Health"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Western Kentucky University"},"collaborators":[{"name":"National Institute on Aging (NIA)"}]},"conditionsModule":{"conditions":["Activities of Daily Living","Accidental Fall","Sarcopenia","Arteriosclerosis","Diabetes Mellitus, Type 2","Hypertension","Cognitive Decline","Executive Function","Cognitive Aging"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Socially-Based Exercise Intervention for Older Adults"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03490747","briefTitle":"Evaluation of a Physical Activity Referral Scheme"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Paula Watson"},"collaborators":[{"name":"University of Bath"},{"name":"University of Gloucestershire"},{"name":"University of Liverpool"},{"name":"Brock University"},{"name":"Radboud University Medical Center"}]},"conditionsModule":{"conditions":["Cardiovascular Risk Factor","Diabetes Mellitus, Type 2","Anxiety","Depression","Musculoskeletal Injury","Cardiovascular Diseases","Cancer","Obesity","Metabolic Syndrome","Physical Activity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Physical activity referral scheme"},{"name":"Usual care exercise referral scheme"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05405244","briefTitle":"Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of North Carolina, Chapel Hill"},"collaborators":[{"name":"American Diabetes Association"}]},"conditionsModule":{"conditions":["Overweight and Obesity","Eating Behavior"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Bromocriptine-QR"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02753491","briefTitle":"The Effect of Motivational Short Interview Model in Type 2 Diabetic Patient in Primary Care in TURKEY"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Marmara University"}},"conditionsModule":{"conditions":["Lifestyle-related Condition"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Motivational short interview"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03889236","briefTitle":"Dietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Leiden University Medical Center"},"collaborators":[{"name":"Dutch Kidney Foundation"},{"name":"Health Holland"},{"name":"Radboud University Medical Center"}]},"conditionsModule":{"conditions":["Diabetic Nephropathy Type 2","Albuminuria","Type2 Diabetes Mellitus","Glucose Metabolism Disorders","Microalbuminuria","Diabetic Nephropathies","Diabetic Complications Renal","Diabetes Mellitus","Kidney Diseases","South Asian"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Fasting mimicking diet Prolon"},{"name":"Food supplement Endocalyx"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01304615","briefTitle":"Foundations for Health"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Tennessee, Knoxville"}},"conditionsModule":{"conditions":["Overweight","Obese"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Decrease Energy Density of the Diet"},{"name":"Increase Steps per Day"},{"name":"Consumption of Self-made Meals"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04293731","briefTitle":"Smectite Gel and Probiotic for Obesity and Insulin Resistance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bogomolets National Medical University"},"collaborators":[{"name":"Taras Shevchenko National University of Kyiv"}]},"conditionsModule":{"conditions":["Obesity","Insulin Resistance","Insulin Sensitivity","Type2 Diabetes Mellitus","Visceral Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Symbiter-Smectite"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01028287","briefTitle":"Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Southeast Renal Research Institute"},"collaborators":[{"name":"Mallinckrodt"}]},"conditionsModule":{"conditions":["Diabetic Nephropathy","Nephrotic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ACTH"},{"name":"ACTH"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00971815","briefTitle":"Effects of 3 Months of Selective Serotonin Reuptake Inhibitor (SSRI)-Treatment on Metabolism and Hypothalamic-pituitary-adrenal (HPA)-Axis in Young Men Born With Low Birth Weight"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"}},"conditionsModule":{"conditions":["Insulin Resistance","Low Birth Weight","Type 2 Diabetes","Cardiovascular Disease","Melancholic Depression","Anxiety Disorders"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Escitalopram"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02695082","briefTitle":"Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Acute Kidney Injury"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00715481","briefTitle":"Renal Insufficiency And Cardiovascular Events"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diabetic Nephropathy Study Group"},"collaborators":[{"name":"Italian Society of Diabetology"}]},"conditionsModule":{"conditions":["Cardiovascular Disease"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00171561","briefTitle":"Valsartan/Hydrochlorothiazide Combination vs Amlodipine in Patients With Hypertension, Diabetes, and Albuminuria."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"valsartan/hydrochlorothiazide"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03512665","briefTitle":"Evaluation of the Impact of a Nutritional Supplement Made of Vegetable Oils in People at Risk of Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Los Andes, Columbia"},"collaborators":[{"name":"Team Foods Colombia S.A."}]},"conditionsModule":{"conditions":["Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Full dose supplement"},{"name":"Low dose Supplement"},{"name":"Control Oil"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05392452","briefTitle":"Fully Closed-Loop Insulin Delivery in Abdominal Surgery (CLAB)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lia Bally"},"collaborators":[{"name":"University Hospital, Basel, Switzerland"}]},"conditionsModule":{"conditions":["Perioperative Hyperglycaemia","Insulin Therapy","Elective Surgery","Closed-Loop Glucose Control","Artificial Pancreas","Liver Diseases","Diabetes Mellitus, Type 2","Colon Disease","Gastric Disease","Pancreatic Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CamAPS HX"},{"name":"Standard insulin therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03122041","briefTitle":"Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Medical Centre Ljubljana"}},"conditionsModule":{"conditions":["PCOS"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sitagliptin"},{"name":"Lifestyle intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00834938","briefTitle":"Comparison Between Patients With or Without Diabetes Recovery After Bariatric Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Campinas, Brazil"},"collaborators":[{"name":"Fundação de Amparo à Pesquisa do Estado de São Paulo"}]},"conditionsModule":{"conditions":["Diabetes","Bariatric Surgery","Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02695095","briefTitle":"Acute Liver Injury in Patients on Dapagliflozin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Acute Liver Injury"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02276196","briefTitle":"Effect of LIXIsenatide on the Renal System"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Amsterdam UMC, location VUmc"}},"conditionsModule":{"conditions":["Diabetic Kidney Disease","Diabetic Nephropathy","Diabetes Mellitus","Glucagon-Like Peptide 1"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lixisenatide"},{"name":"Insulin glulisine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02470403","briefTitle":"Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Elevated Body Mass Index"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LIK066"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03128320","briefTitle":"The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Diabetic Foot"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BAY1193397"},{"name":"BAY1193397"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03363594","briefTitle":"Indian Phenotype Registry"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03403231","briefTitle":"INcreasing Veteran EngagemeNT to Prevent Diabetes (INVENT)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VA Office of Research and Development"}},"conditionsModule":{"conditions":["Prediabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"INVENT Secure Messaging Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02747108","briefTitle":"ForgIng New Paths to Prevent DIabeTes (FINDIT)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VA Office of Research and Development"},"collaborators":[{"name":"VA Ann Arbor Healthcare System"}]},"conditionsModule":{"conditions":["Prediabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Blood Test Group Intervention"},{"name":"Brochure Group Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00456027","briefTitle":"Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Diamyd Therapeutics AB"}},"conditionsModule":{"conditions":["Latent Autoimmune Diabetes in Adult (LADA)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"rhGAD65 formulated in Alhydrogel® (Diamyd®)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01749020","briefTitle":"Effect of Polyphenol-rich Dark Chocolate on Insulin Sensitivity in Normal Weight and Overweight Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Queen Margaret University"},"collaborators":[{"name":"Barry Callebaut"}]},"conditionsModule":{"conditions":["Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Polyphenol-rich Dark chocolate"},{"name":"Placebo Dark chocolate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04631289","briefTitle":"Preadmission Metformin Exposure and Incidence of Acute Kidney Injury"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Second Affiliated Hospital of Guangzhou Medical University"}},"conditionsModule":{"conditions":["AKI"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03769675","briefTitle":"Quantitative Assessment of Painful Diabetic Peripheral Neuropathy After High Frequency Spinal Cord Stimulation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"}},"conditionsModule":{"conditions":["Painful Diabetic Neuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High Frequency Spinal Cord Stimulator"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00005205","briefTitle":"Incidence of Diabetes and Cardiovascular Disease in Mexican Americans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Heart Diseases","Myocardial Infarction","Angina Pectoris","Death, Sudden, Cardiac","Cerebrovascular Disorders","Peripheral Vascular Diseases","Coronary Disease","Diabetes Mellitus, Non-insulin Dependent","Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04080596","briefTitle":"DDI Study to Investigate the Impact of Itraconazole on the Pharmacokinetics of Dorzagliatin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hua Medicine Limited"}},"conditionsModule":{"conditions":["Drug Interaction"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dorzagliatin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00782366","briefTitle":"Predictive Genetic Risk Assessment Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mayo Clinic"}},"conditionsModule":{"conditions":["Colon Cancer","Lung Cancer","Atrial Fibrillation","Diabetes Type 2","Obesity","Breast Cancer","Graves Disease","Osteoarthritis","Celiac Disease","Myocardial Infarction","Prostate Cancer"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SNP analysis"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00241124","briefTitle":"Comparison Of Morning And Evening Dosing Of Valsartan And Lisinopril In Patients With Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis"}},"conditionsModule":{"conditions":["Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"valsartan"},{"name":"lisinopril"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04791267","briefTitle":"ENCOMPASS: Expansion Study C"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Calgary"},"collaborators":[{"name":"University of Alberta"}]},"conditionsModule":{"conditions":["Hypertension","Diabetes Mellitus, Type 2","Chronic Kidney Diseases","Ischemic Heart Disease","Congestive Heart Failure","Chronic Obstructive Pulmonary Disease","Asthma"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Community Health Navigator Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04790617","briefTitle":"ENCOMPASS: Expansion Study B, RCT"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Calgary"}},"conditionsModule":{"conditions":["Hypertension","Diabetes Mellitus, Type 2","Chronic Kidney Diseases","Ischemic Heart Disease","Congestive Heart Failure","Chronic Obstructive Pulmonary Disease","Asthma"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Community Health Navigator Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04790604","briefTitle":"ENCOMPASS: Expansion Study A, RCT"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Calgary"},"collaborators":[{"name":"University of Alberta"}]},"conditionsModule":{"conditions":["Hypertension","Diabetes Mellitus, Type 2","Chronic Kidney Diseases","Ischemic Heart Disease","Congestive Heart Failure","Chronic Obstructive Pulmonary Disease","Asthma"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Community Health Navigator Program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01518205","briefTitle":"HELP-Apheresis in Diabetic Ischemic Foot Treatment (H.A.D.I.F)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universita di Verona"}},"conditionsModule":{"conditions":["Foot Ulcers","Arteriosclerosis Obliterans","Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LDL-apheresis"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04125784","briefTitle":"Lipid Profile and Diabetes Mellitus in People With HIV"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Moritz Oberndorfer"},"collaborators":[{"name":"Merck Gesellschaft mbH, Austria"}]},"conditionsModule":{"conditions":["HIV Infections","Dyslipidemias","Diabetes Mellitus","Cardiovascular Risk Factor"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03741972","briefTitle":"Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart Failure"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Germans Trias i Pujol Hospital"}},"conditionsModule":{"conditions":["Heart Failure"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"iSGTL2"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02642159","briefTitle":"Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"},"collaborators":[{"name":"Regeneron Pharmaceuticals"}]},"conditionsModule":{"conditions":["Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alirocumab"},{"name":"Statins"},{"name":"Ezetimibe"},{"name":"Fenofibrate"},{"name":"Nicotinic acid"},{"name":"Omega-3 fatty acids"},{"name":"Antihyperglycemic Drug"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03689738","briefTitle":"Effects of Potato Resistant Starch Intake on Insulin Sensitivity, Related Metabolic Markers and Satiety"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Midwest Center for Metabolic and Cardiovascular Research"},"collaborators":[{"name":"Alliance for Potato Research and Education"}]},"conditionsModule":{"conditions":["Insulin Sensitivity","Lipid Metabolism","Resistant Starch","Potato"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Potato (Resistant Starch)"},{"name":"CHO-matched (Low-fiber, RS-free)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01399580","briefTitle":"A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AbbVie (prior sponsor, Abbott)"}},"conditionsModule":{"conditions":["Chronic Kidney Disease","Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Atrasentan"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02298556","briefTitle":"An Observational Study to Describe the Effectiveness of Angiotensin Converting Enzyme Inhibitor and Calcium Channel Blocker Combination in the Management of Hypertensive Patients With Elevated Heart Rate and Type 2 Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Abbott"},"collaborators":[{"name":"MonitorCRO"}]},"conditionsModule":{"conditions":["Hypertension"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03077386","briefTitle":"Enhancing Community Health Through Patient Navigation, Advocacy and Social Support"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Calgary"},"collaborators":[{"name":"Alberta Innovates Health Solutions"},{"name":"Canadian Diabetes Association"}]},"conditionsModule":{"conditions":["Hypertension","Diabetes Mellitus, Type 2","Chronic Kidney Diseases","Ischemic Heart Disease","Congestive Heart Failure","Chronic Obstructive Pulmonary Disease","Asthma"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"ENCOMPASS Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03755960","briefTitle":"ACUpuncture in Diabetic Peripheral Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Benno Brinkhaus"},"collaborators":[{"name":"Karl and Veronica Carstens Foundation"}]},"conditionsModule":{"conditions":["Diabetic Neuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"acupuncture"},{"name":"routine care"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00473811","briefTitle":"Diabetic Educational Eating Plan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Massachusetts, Worcester"}},"conditionsModule":{"conditions":["Low-GI Dietary Education","ADA Dietary Education"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low GI"},{"name":"ADA diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01951287","briefTitle":"Impact of Fluid Milk on Post-meal Glycemia and Insulinemia in Overwt/Obese Adults"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Purdue University"},"collaborators":[{"name":"Dairy Research Institute"}]},"conditionsModule":{"conditions":["Blood Glucose","Blood Insulin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acute beverage (water) consumption"},{"name":"Acute beverage (Black Coffee) consumption"},{"name":"Acute beverage (Orange Juice) consumption"},{"name":"Acute beverage (Whole Milk) consumption"},{"name":"Acute beverage (2% Milk) consumption"},{"name":"Acute beverage (Skim Milk) consumption"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02695173","briefTitle":"Complications of UTI in Patients on Dapagliflozin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Severe Complications of Urinary Tract Infections"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04807959","briefTitle":"Evaluation of the Effectiveness of a Comprehensive Visceral Adiposity-Focused Anti-Obesity Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"20Lighter"}},"conditionsModule":{"conditions":["Obesity","Obesity, Morbid","Obesity, Visceral","Central Obesity","Metabolic Disease","Hypertension","Dyslipidemias","Type 2 Diabetes","Visceral Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"20Lighter anti-obesity program"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00362323","briefTitle":"Fenofibrate and Metformin Fixed Combination vs Metformin - FAME METFO"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Solvay Pharmaceuticals"}},"conditionsModule":{"conditions":["Dyslipidemia/Glucose Metabolism Disorder"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"fenofibrate (F) + metformin (M) hydrochloride fixed combination"},{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02279407","briefTitle":"A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Uppsala Clinical Research, Uppsala, Sweden"}]},"conditionsModule":{"conditions":["T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"placebo"},{"name":"Omega-3 carboxylic acids"},{"name":"Dapagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02472236","briefTitle":"Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jiangsu Hansoh Pharmaceutical Co., Ltd."}},"conditionsModule":{"conditions":["Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PEX168"},{"name":"Digoxin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02461914","briefTitle":"Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jiangsu Hansoh Pharmaceutical Co., Ltd."}},"conditionsModule":{"conditions":["Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PEX168"},{"name":"Warfarin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01556594","briefTitle":"Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"},"collaborators":[{"name":"Locemia Solutions ULC"}]},"conditionsModule":{"conditions":["Hypoglycemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nasal Glucagon 1 mg"},{"name":"Nasal Glucagon 2 mg"},{"name":"SC Glucagon"},{"name":"Nasal Glucagon 3 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00348725","briefTitle":"Acceptability of a Fixed Combination of Fenofibrate and Metformin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Solvay Pharmaceuticals"}},"conditionsModule":{"conditions":["Dyslipidemia/Glucose Metabolism Disorder"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"fenofibrate and metformin fixed combination (drug)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04807452","briefTitle":"Strength And Balance Training on Diabetic Peripheral Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Riphah International University"}},"conditionsModule":{"conditions":["Diabetic Peripheral Neuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Strength and balance training"},{"name":"Aerobics training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04436666","briefTitle":"Virtual Reality, Ice Application and Self-injection and Self-test Fair, Pain and State Anxiety"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Inonu University"}},"conditionsModule":{"conditions":["Injection Site Irritation","Fear of Pain"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"motivational video production through virtual reality glasses"},{"name":"Ice Application"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00854113","briefTitle":"Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of EGT0001474 in Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Theracos"}},"conditionsModule":{"conditions":["Safety and Tolerability of EGT0001474 in Healthy Volunteers"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"EGT0001474"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01163591","briefTitle":"To Assess the Accuracy of the eZscan Study in the Screening for Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Chinese University of Hong Kong"}},"conditionsModule":{"conditions":["Diabetic Nephropathy"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01944124","briefTitle":"Exercise and Technology to Reduce Risk in a Rural Population With Metabolic Syndrome"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lawson Health Research Institute"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"},{"name":"Heart and Stroke Foundation of Canada"},{"name":"Canadian Diabetes Association"}]},"conditionsModule":{"conditions":["Metabolic Syndrome X"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Mobile Health"},{"name":"Exercise Prescription"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02585778","briefTitle":"Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sanofi"},"collaborators":[{"name":"Regeneron Pharmaceuticals"}]},"conditionsModule":{"conditions":["Hypercholesterolaemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alirocumab"},{"name":"Placebo"},{"name":"Lipid-Modifying Therapy (LMT)"},{"name":"Antihyperglycemic Drug"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01316016","briefTitle":"Antidiabetic Properties of Rose Hip"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lund University"}},"conditionsModule":{"conditions":["Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rose hip"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01053026","briefTitle":"Evaluation of Effects of Exercise Training and ARB in DM Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Taiwan University Hospital"},"collaborators":[{"name":"Daiichi Sankyo Taiwan Ltd."}]},"conditionsModule":{"conditions":["Vascular Function","Exercise Training"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"olmesartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02210000","briefTitle":"A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GlaxoSmithKline"}},"conditionsModule":{"conditions":["Gastroparesis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Placebo"},{"name":"Camicinal"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05071287","briefTitle":"Metabolism of Low Carbohydrate and Ketogenic Diet"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center at San Antonio"}},"conditionsModule":{"conditions":["Diabetic Kidney Disease","Cognitive Function","Weight Loss","Diabetic Control","Type2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"mHealth + low-fat diet"},{"name":"mHealth + low-carb/ketogenic diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01726816","briefTitle":"Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Korea Otsuka Pharmaceutical Co., Ltd."}},"conditionsModule":{"conditions":["Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Probucol 250mg/day"},{"name":"Probucol 500mg/day"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03332927","briefTitle":"Effect of Egg Consumption on Cardiometabolic Health in Prediabetic Subjects."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Midwest Center for Metabolic and Cardiovascular Research"}},"conditionsModule":{"conditions":["PreDiabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Egg based breakfast foods"},{"name":"Non-egg based breakfast foods"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03219320","briefTitle":"Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aptinyx"},"collaborators":[{"name":"Syneos Health"}]},"conditionsModule":{"conditions":["Diabetic Peripheral Neuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"NYX-2925"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00153088","briefTitle":"INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Diabetic Nephropathies"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Telmisartan capsule 40 mg"},{"name":"Placebo"},{"name":"Telmisartan capsule 80 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05322122","briefTitle":"Creation of Side-to-Side Compression Anastomosis Using the Magnetic Anastomosis System"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GT Metabolic Solutions, Inc."}},"conditionsModule":{"conditions":["Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Side-to-side anastomosis duodeno-ileostomy diversion procedure"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03347968","briefTitle":"Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"MedImmune LLC"}},"conditionsModule":{"conditions":["Healthy Volunteers"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MEDI0382"},{"name":"Warfarin"},{"name":"Esmolol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01690091","briefTitle":"Cardioprotective and Metabolic Effects of Metformin in Patients With Heart Failure and Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Institute for Clinical and Experimental Medicine"}},"conditionsModule":{"conditions":["Insulin Resistance","Chronic Heart Failure"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformini hydrochloridum (Siofor 1000 tbl, Berlin)"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04232995","briefTitle":"Balance Training in Diabetic Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Dow University of Health Sciences"}},"conditionsModule":{"conditions":["Diabetic Neuropathy With Neurologic Complication"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Balance Training"},{"name":"General Exercises"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01614327","briefTitle":"Computer-based Screening for Diabetic Retinopathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"VisionQuest Biomedical LLC"},"collaborators":[{"name":"Project Extension for Community Healthcare Outcomes (ECHO)"},{"name":"Communicare Health Centers of San Antonio"},{"name":"Retinal Institute of South Texas"},{"name":"National Eye Institute (NEI)"}]},"conditionsModule":{"conditions":["Diabetic Retinopathy"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03436693","briefTitle":"Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation"}},"conditionsModule":{"conditions":["Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01794364","briefTitle":"Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-06291874"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00005168","briefTitle":"Hyperapo B and Coronary Heart Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}},"conditionsModule":{"conditions":["Cardiovascular Diseases","Coronary Disease","Heart Diseases","Diabetes Mellitus","Obesity","Hypercholesterolemia, Familial"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03253562","briefTitle":"Metformin Versus Vildagliptin for Diabetic Hypertensive Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"MTI University"}},"conditionsModule":{"conditions":["Reducing the Elevated Blood Pressure for Diabetic Hypertensive Patients"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin Pill"},{"name":"Vildagliptin 50 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04639726","briefTitle":"A Study to Evaluate the Effects of Pre-Meal Whey Protein Microgels Administration on Post-Prandial Glycemic Response."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Société des Produits Nestlé (SPN)"}},"conditionsModule":{"conditions":["Dietary Supplement"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Whey Protein Micro Gel"},{"name":"Water without Whey Protein."}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00935051","briefTitle":"Matrix Metalloproteinase-1/Tissue Inhibitor of Metalloproteinase-1 (MMP-1/TIMP-1) Ratio and Diabetic Foot Ulcers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Grenoble"}},"conditionsModule":{"conditions":["Diabetic Foot Ulcer"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Picture + MMPs and TIMP1 at week 0 and week 4"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03376490","briefTitle":"Study of the Association of Muscle Strength, Balance and Other Factors With Vitamin Levels Among Elderly Diabetics"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"SingHealth Polyclinics"}},"conditionsModule":{"conditions":["Muscle Strength","Vitamin B 12 Deficiency","Folate Deficiency","Vitamin D Deficiency","Hyperhomocysteinemia","Fall"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00375960","briefTitle":"A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic Pain"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Vernalis (R&D) Ltd"},"collaborators":[{"name":"Cita NeuroPharmaceuticals"}]},"conditionsModule":{"conditions":["Pain","Diabetic Neuropathies"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"V3381"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01425905","briefTitle":"Mood and Insulin Resistance in Adolescents At-Risk for Diabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"},{"name":"National Institutes of Health Clinical Center (CC)"}]},"conditionsModule":{"conditions":["Depression","Impaired Glucose Tolerance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"The Blues Program"},{"name":"Hey Durham"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01855282","briefTitle":"Assessment of an Intervention to Prevent Obesity and Diabetes in Latino Farm Workers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of California, Davis"}},"conditionsModule":{"conditions":["Overweight and Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Behavioral Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00041444","briefTitle":"Multi-Ethnic Study of Atherosclerosis (MESA) - Ancillary Eye Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Wisconsin, Madison"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Atherosclerosis","Cardiovascular Diseases","Coronary Arteriosclerosis","Coronary Disease","Cerebrovascular Disorders","Heart Failure, Congestive","Myocardial Infarction","Heart Diseases","Diabetes Mellitus, Non-insulin Dependent","Hypertension","Diabetic Retinopathy","Macular Degeneration","Diabetes Mellitus"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05687812","briefTitle":"Effects of Cephalaria Syriaca Flour-added Bread on Glucose Metabolism and Appetite Parameters in Individuals With Obesity, Diabetes, and Healthy Controls."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Istanbul University"}},"conditionsModule":{"conditions":["Nutrition, Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cephalaria Syriaca flour-added bread"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03241303","briefTitle":"Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"},"collaborators":[{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Glucose Metabolism Disorders"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acarbose"},{"name":"Placebo Oral Tablet"},{"name":"Exendin (9-39)"},{"name":"Placebo Saline"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04019431","briefTitle":"Effect of a Very Low-Calorie Ketogenic Diet on Gut Microbiota and Fat Distribution"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Roma La Sapienza"}},"conditionsModule":{"conditions":["Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Whey protein, vegetable protein or animal protein"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01154478","briefTitle":"Effects of Dietary Polyphenols and ω-3 Fatty Acids on Cardiovascular Risk Factors in High Risk Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Federico II University"}},"conditionsModule":{"conditions":["Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diet rich in omega-3 fatty acids"},{"name":"Diet rich in polyphenols"},{"name":"Control diet"},{"name":"diet rich in omega-3 and polyphenols"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06652867","briefTitle":"Hypoglycemia Biomarkers to Predict Timing of a Hypoglycemic Event"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Royal College of Surgeons in Ireland - Medical University of Bahrain"},"collaborators":[{"name":"King Hamad University Hospital, Bahrain"}]},"conditionsModule":{"conditions":["Hypoglycemia"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00542009","briefTitle":"A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Weight Management","Treatment Of Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CE-326,597 100 mg QD"},{"name":"CE-326,597 50 mg QD"},{"name":"CE-326,597 25 mg QD"},{"name":"Placebo"},{"name":"CE-326,597 5mg QD"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00005761","briefTitle":"Blood Factors and Diabetic Retinopathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Eye Institute (NEI)"}},"conditionsModule":{"conditions":["Diabetic Retinopathy"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03767699","briefTitle":"Medical Nutrition Therapy Program and Eating Behavior Questionnaires on Gestational Weight Gain"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hugo Mendieta Zeron"},"collaborators":[{"name":"Fogarty International Center of the National Institute of Health"},{"name":"Instituto Nacional de Salud Publica, Mexico"}]},"conditionsModule":{"conditions":["Gestational Weight Gain"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Medical Nutrition Therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01853072","briefTitle":"Nepafenac Once Daily for Macular Edema - Study 1"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Alcon Research"}},"conditionsModule":{"conditions":["Non-Proliferative Diabetic Retinopathy","Cataract"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nepafenac Ophthalmic Suspension, 0.3%"},{"name":"Nepafenac vehicle"},{"name":"Prednisolone acetate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00685984","briefTitle":"Peripheral Endothelial Function and Coronary Status in Asymptomatic Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Assistance Publique - Hôpitaux de Paris"},"collaborators":[{"name":"Alfediam"}]},"conditionsModule":{"conditions":["Myocardial Ischemia"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01109212","briefTitle":"The Effects of Bindarit in Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aziende Chimiche Riunite Angelini Francesco S.p.A"},"collaborators":[{"name":"Mario Negri Institute for Pharmacological Research"}]},"conditionsModule":{"conditions":["Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bindarit"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00168857","briefTitle":"A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Boehringer Ingelheim"}},"conditionsModule":{"conditions":["Hypertension","Diabetic Nephropathies"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"telmisartan"},{"name":"losartan"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04382794","briefTitle":"Sitagliptin Treatment in Diabetic COVID-19 Positive Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Milan"},"collaborators":[{"name":"Papa Giovanni XXIII Hospital"},{"name":"Fondazione IRCCS Policlinico San Matteo di Pavia"},{"name":"Humanitas Hospital, Italy"},{"name":"Ospedale dell'Angelo, Venezia-Mestre"},{"name":"University of Pavia"}]},"conditionsModule":{"conditions":["Covid19"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Retrospective case-control analysis"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03700580","briefTitle":"Clinical Trial Using the Proteolytic Fraction P1G10 From V. Cundinamarcensis to Heal Diabetic Foot Ulcer"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Carlos E Salas"}},"conditionsModule":{"conditions":["Diabetic Foot","Neuropathy, Diabetic","Foot Ulcer"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Hydrogel treatment"},{"name":"P1G10"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02104739","briefTitle":"Effects of Antidiabetic Medications on the Postprandial State in Prediabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"The University of Texas Health Science Center, Houston"},"collaborators":[{"name":"The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston"}]},"conditionsModule":{"conditions":["Prediabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exenatide"},{"name":"Saxagliptin"},{"name":"Exenatide extended-release (ER)"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04403945","briefTitle":"The Predictive Value of Sidestream Dark Field Imaging in Diabetic Nephropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Third Military Medical University"}},"conditionsModule":{"conditions":["Microcirculation Detection in Diabetic Patients"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sidestream dark field(SDF) imagining"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02373592","briefTitle":"Implementation of Foot Thermometry and SMS and Voice Messaging to Prevent Diabetic Foot Ulcer"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universidad Peruana Cayetano Heredia"},"collaborators":[{"name":"Johns Hopkins University"},{"name":"Mayo Clinic"},{"name":"University of Southern California"}]},"conditionsModule":{"conditions":["Diabetic Foot"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SMS and voice messaging"},{"name":"Thermometry"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04881123","briefTitle":"SER150 vs Placebo in Diabetic Kidney Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Serodus AS"}},"conditionsModule":{"conditions":["Diabetic Kidney Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"SER150"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04184622","briefTitle":"A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Overweight","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01594333","briefTitle":"Cardiovascular Inflammation Reduction Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Brigham and Women's Hospital"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Cardiovascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Methotrexate"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04735640","briefTitle":"Effectiveness of a Nurse-led Personalized Telephone Intervention on Lifestyle Changes in Diabetes Prevention."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of the Balearic Islands"},"collaborators":[{"name":"Instituto de Salud Carlos III"}]},"conditionsModule":{"conditions":["Prediabetic State"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"nurse-led teleconsultation"},{"name":"SMS"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00552409","briefTitle":"Randomized Controlled Trial of Vitamin D3 in Diabetic Kidney Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Washington"},"collaborators":[{"name":"University of Washington Institute for Translational Health Science (KL2)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Chronic Kidney Disease","Diabetic Kidney Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cholecalciferol"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02228252","briefTitle":"The Effect of Protein Quality and Time-factor by Consumption of a Pre-meal on Postprandial Lipemia in Subjects With the Metabolic Syndrome."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aarhus University Hospital"},"collaborators":[{"name":"University of Aarhus"},{"name":"University of Copenhagen"}]},"conditionsModule":{"conditions":["Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Whey protein"},{"name":"Casein"},{"name":"Gluten protein"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00629213","briefTitle":"Metabolic Syndrome Risk Factor in IGT: STOP-NIDDM Trial"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GWT-TUD GmbH"}},"conditionsModule":{"conditions":["Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"acarbose"},{"name":"placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04877366","briefTitle":"Evaluate Effects of Sprinkled Format REDUCOSE in a Carbohydrate-rich, Mixed Meal on Post-prandial Glycemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Société des Produits Nestlé (SPN)"}},"conditionsModule":{"conditions":["Dietary Supplement"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dietary Supplement: Sprinkled Format REDUCOSE."},{"name":"Reference control"},{"name":"Active comparator"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02087124","briefTitle":"Dose-response Effect of Whey Protein Consumed as Pre-meal on Postprandial Lipaemia in Subjects With Metabolic Syndrome"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Aarhus University Hospital"},"collaborators":[{"name":"University of Aarhus"}]},"conditionsModule":{"conditions":["Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Whey protein"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06407154","briefTitle":"Chronical Illness-related Limitations of the Ability to Cope with Rising Temperatures: an Observational Study, 2nd Wave"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universitätsklinikum Hamburg-Eppendorf"}},"conditionsModule":{"conditions":["Coronary Disease","Myocardial Infarction","Heart Failure","Arrhythmias, Cardiac","Peripheral Artery Disease","Stroke","Ischemic Attack, Transient","Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Pulmonary Disease, Chronic Obstructive","Asthma","Renal Insufficiency","Depressive Disorder","Anxiety Disorders","Schizophrenia","Peripheral Nervous System Diseases"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03369145","briefTitle":"High-fat Overfeeding, Hepatokines and Appetite Regulation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Loughborough University"},"collaborators":[{"name":"Nottingham Trent University"},{"name":"Nottingham University Hospitals NHS Trust"}]},"conditionsModule":{"conditions":["Insulin Resistance","Type2 Diabetes Mellitus","Non-Alcoholic Fatty Liver Disease","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High-fat diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02891928","briefTitle":"Evaluation of Rocker sOles in Diabetis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Brest"}},"conditionsModule":{"conditions":["Diabetic Neuropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Rocker sole shoes"},{"name":"Normal shoes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01955694","briefTitle":"Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Heart Failure"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"BAY94-8862"},{"name":"Eplerenone"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03370237","briefTitle":"Reliability of a Diabetic Foot Ulcer Risk Stratification and Referral Algorithm"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lawson Health Research Institute"},"collaborators":[{"name":"St. Joseph's Healthcare Foundation"}]},"conditionsModule":{"conditions":["Foot Ulcer, Diabetic"]},"designModule":{"studyType":"OBSERVATIONAL"}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02581488","briefTitle":"Use of Santyl in Diabetic Foot Ulcers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Smith & Nephew, Inc."}},"conditionsModule":{"conditions":["Diabetic Foot","Foot Ulcer, Diabetic"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Santyl"},{"name":"Product containing silver"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00727779","briefTitle":"Mechanisms by Which Strength Training Ameliorates the Metabolic Syndrome"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"East Tennessee State University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"strength training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00862433","briefTitle":"Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Diabetes","Fatty Liver","Obesity","Healthy Volunteers"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alpha tocopherol"},{"name":"Vitamin E"},{"name":"Vitamin C"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00001723","briefTitle":"Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jack Yanovski"},"collaborators":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)"},{"name":"Roche Pharma AG"}]},"conditionsModule":{"conditions":["Diabetes Mellitus","Hypertension","Metabolic Disease","Obesity","Sleep Apnea Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Orlistat"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01359241","briefTitle":"Achieving Normal Glucose In Hospital Settings"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Cambridge"},"collaborators":[{"name":"Cambridge University Hospitals NHS Foundation Trust"}]},"conditionsModule":{"conditions":["Dysglycaemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"closed-loop insulin delivery"},{"name":"Usual diabetes treatment regimen"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04167410","briefTitle":"Effect of Perioperative Glycemia Protocol on Glycemic Outcomes in Diabetic Patients Undergoing Abdominal Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Saglik Bilimleri Universitesi Gulhane Tip Fakultesi"}},"conditionsModule":{"conditions":["Hyperglycemia","Perioperative Complication"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"glycaemic management protocol implemented to clinic"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02099929","briefTitle":"Effects of Coffee Consumption on Glucose Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Brasilia"},"collaborators":[{"name":"Conselho Nacional de Desenvolvimento Científico e Tecnológico"},{"name":"MRC Human Nutrition Research"}]},"conditionsModule":{"conditions":["Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Coffee with Sugar"},{"name":"Coffee without Sugar"},{"name":"Decaffeinated Coffee without Sugar"},{"name":"Water with Sugar"},{"name":"Water without Sugar"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01807221","briefTitle":"Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Heart Failure"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Finerenone (BAY94-8862)"},{"name":"Placebo"},{"name":"Inspra (eplerenone)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02065752","briefTitle":"A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Healthy Volunteers"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin, 100 mg"},{"name":"Metformin XR, 500 mg"},{"name":"CANA/MET XR FDC, Formulation 1, 50 mg/500 mg"},{"name":"CANA/MET XR FDC, Formulation 2, 50 mg/500 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04787952","briefTitle":"Insight Into New Brown Adipose Tissue Activators."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Medical University of Bialystok"}},"conditionsModule":{"conditions":["Adiposity","Metabolic Complication","Metabolic Disturbance","Healthy","Obesity","Diet Habit","Nutritional and Metabolic Diseases"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"cold expossure"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04155645","briefTitle":"To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Parexel"}]},"conditionsModule":{"conditions":["Dyslipidemia"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD8233 subcutaneous injection"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00954109","briefTitle":"Acute Cardiovascular and Metabolic Effects of Exercise Training in Individuals With Insulin Resistance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"US Department of Veterans Affairs"}},"conditionsModule":{"conditions":["Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Exercise"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01432509","briefTitle":"Prospective Follow-up of a Cohort of Pre-diabetics in the North of France (DiabeNord)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nantes University Hospital"}},"conditionsModule":{"conditions":["Prediabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Prediabetes screening and prospective follow-up over 5 years"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02895750","briefTitle":"Efficacity and Safety of Metformin XR in CKD Stage 1 to 3"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire, Amiens"}},"conditionsModule":{"conditions":["Renal Insufficiency, Chronic"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02637037","briefTitle":"A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Bioequivalence","Fixed Dose Combination Tablets","Healthy Male and Female Subjects"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)"},{"name":"dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)"},{"name":"dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)"},{"name":"dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04516018","briefTitle":"Shivering and Glucose Homeostasis"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Maastricht University"}},"conditionsModule":{"conditions":["Healthy Overweight/Obese"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cold exposure"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01224054","briefTitle":"Food and Gastrointestinal Habits After Bariatric Surgery"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Campinas, Brazil"}},"conditionsModule":{"conditions":["Bariatric Surgeries"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02073227","briefTitle":"A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Healthy Volunteers"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin, 300 mg"},{"name":"Metformin XR, 500 mg"},{"name":"CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg"},{"name":"CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01819922","briefTitle":"Effect Of Single-Dose PF-05175157 On Metabolic And Cardiopulmonary Parameters"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-05175157"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02325271","briefTitle":"Intra-individual Variability and Circadian Rhythm of VEGF Levels and Interaction With Biomarkers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"GWT-TUD GmbH"},"collaborators":[{"name":"Novartis"}]},"conditionsModule":{"conditions":["Diabetic Macular Edema"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Frequent blood and urine sampling and blood pressure measurement"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04660643","briefTitle":"A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Obesity","Overweight"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04657016","briefTitle":"A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Eli Lilly and Company"}},"conditionsModule":{"conditions":["Obesity","Overweight"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Tirzepatide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03096535","briefTitle":"Cold Induced Activation of Brown Adipose Tissue in Humans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Susanna Søberg"}},"conditionsModule":{"conditions":["Adipose Tissue, Brown","Brown Adipose Tissue","Brown Fat","Uncoupling Protein 1","Adipokines","Proteomics","Infrared Thermography","BAT","Obesity","Type 2 Diabetes","Proteins"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cooling"},{"name":"Thermoneutral"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01156246","briefTitle":"Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy Volunteers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Bristol-Myers Squibb"}]},"conditionsModule":{"conditions":["Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin/Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00708175","briefTitle":"Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Takeda"}},"conditionsModule":{"conditions":["Bone Metabolism"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Pioglitazone"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01451918","briefTitle":"Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Health Network, Toronto"},"collaborators":[{"name":"Canadian Institutes of Health Research (CIHR)"}]},"conditionsModule":{"conditions":["Dyslipidaemia","Insulin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Resveratrol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01356849","briefTitle":"Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AbbVie (prior sponsor, Abbott)"}},"conditionsModule":{"conditions":["Chronic Kidney Disease","Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Atrasentan"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04474496","briefTitle":"Impact of COVID-19 on Marshallese Communities in the U.S."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Arkansas"},"collaborators":[{"name":"Patient-Centered Outcomes Research Institute"}]},"conditionsModule":{"conditions":["COVID-19"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Assessing the impact of COVID-19"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01464073","briefTitle":"Effectiveness of Individualized Exercise Program, Combined With a Balanced Diet on the Evolution of Body Fat"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Centre Hospitalier Universitaire de la Réunion"}},"conditionsModule":{"conditions":["Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LIPOXmax"},{"name":"60% VO2peak"},{"name":"Good Medical Practices"},{"name":"supplementation in fruits and vegetables"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03708887","briefTitle":"The Effect of Omega-3 FA on Glucose and Lipid Homeostasis Disorders in Obese/Diabetic Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Zhejiang University"}},"conditionsModule":{"conditions":["Hyperglycaemia (Diabetic)","Hyperlipidemias"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Low dose omega-3 fatty acid supplementation"},{"name":"High dose omega-3 fatty acid supplementation"},{"name":"Control drug"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03358745","briefTitle":"Impact of Meal Order on Postprandial Cardiometabolic Risk Markers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lund University"},"collaborators":[{"name":"Vinnova"},{"name":"Anti-Diabetic Food Centre"}]},"conditionsModule":{"conditions":["Metabolic Syndrome X","Insulin Resistance","Hyperinsulinism","Glucose Metabolism Disorders","Metabolic Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Standard meal, bread/butter as starter"},{"name":"Standard meal with soup as starter"},{"name":"Standard meal with cheese as starter"},{"name":"Standard meal with salad as starter"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02077803","briefTitle":"A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Canagliflozin, 100 mg"},{"name":"Metformin XR, 500 mg"},{"name":"CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg"},{"name":"CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02039245","briefTitle":"Multiple Dose Pharmacokinetics of Canagliflozin/Metformin 150/1,000 mg Fixed Dose Combination"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Healthy Volunteers"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CANA/MET XR FDC"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02623608","briefTitle":"Effects of Functional Ingredients in an Acute Metabolic Challenge Context"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lund University"},"collaborators":[{"name":"Vinnova"},{"name":"Antidiabetic Food Centre AFC"}]},"conditionsModule":{"conditions":["Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Reference breakfast"},{"name":"Active Ingredient 1"},{"name":"Active Ingredient 2"},{"name":"Active Ingredient 3"},{"name":"Active Ingredient 4"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00668239","briefTitle":"Diffuse Diabetic Maculopathy With Intravitreal Triamcinolone or Laser"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Hospital de Clinicas de Porto Alegre"}},"conditionsModule":{"conditions":["Macular Edema"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"intravitreous triamcinolone"},{"name":"laser therapy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02039258","briefTitle":"Pharmacokinetics of a Fixed Dose Combination of Canagliflozin/Metformin Coadministered With Food"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Janssen Research & Development, LLC"}},"conditionsModule":{"conditions":["Healthy Volunteers"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CANA/MET XR FDC"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01209416","briefTitle":"The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Aarhus"}},"conditionsModule":{"conditions":["Metabolism","Insulin Resistance","Hypopituitarism"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Acipimox"},{"name":"Ghrelin"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04820556","briefTitle":"Gut Microbiota in Chronic Noncommunicable Diseases"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Medical Research Center for Therapy and Preventive Medicine"},"collaborators":[{"name":"Center for Strategic Planning and Management of Biomedical Health Risks of the Federal Biomedical Agency"}]},"conditionsModule":{"conditions":["Arterial Hypertension","Atherosclerosis Occlusive Disease","Heart Failure With Preserved Ejection Fraction","Heart Failure With Reduced Ejection Fraction","Diabetes Mellitus, Type 2","Obstructive Pulmonary Disease","Asthma","Nonalcoholic Fatty Liver Disease"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02115932","briefTitle":"Effect of Physical Therapy in Improving the Health of Patients With Diabetic Peripheral Neuropathy"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National University Health System, Singapore"},"collaborators":[{"name":"National Medical Research Council (NMRC), Singapore"},{"name":"National University Hospital, Singapore"}]},"conditionsModule":{"conditions":["Diabetic Neuropathies","Peripheral Nervous System Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Strength & Balance Training"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01400191","briefTitle":"The Inhibitory Effect of Metformin on Gluconeogenesis in Relation to Polymorphisms in Organic Cation Transporter 1"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Southern Denmark"},"collaborators":[{"name":"Region of Southern Denmark"}]},"conditionsModule":{"conditions":["Pharmacogenetics of Metformin"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04132531","briefTitle":"Effect of Weight Loss Surgery on Stem Cells."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Unity Health Toronto"},"collaborators":[{"name":"Humber River Hospital"},{"name":"University of Western Ontario, Canada"}]},"conditionsModule":{"conditions":["Obesity, Morbid","Stem Cells","Cardiovascular Morbidity"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Bariatric (weight loss) surgery"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02675608","briefTitle":"Vaccine Efficacy in Diabetic and Elderly Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Tulane University"},"collaborators":[{"name":"Louisiana Clinical and Translational Science Center"}]},"conditionsModule":{"conditions":["Inflammation"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Influenza Virus Vaccine"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02313220","briefTitle":"Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Uppsala University"},"collaborators":[{"name":"Uppsala University Hospital"},{"name":"AstraZeneca"}]},"conditionsModule":{"conditions":["Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dapagliflozin"},{"name":"Exenatide"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03857191","briefTitle":"Nutritional Rehabilitation and Sleep Apnea in the Obese"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Grenoble"},"collaborators":[{"name":"Groupe Éthique et Santé"}]},"conditionsModule":{"conditions":["Obese","Sleep Apnea, Obstructive"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Nutritional psychocomportemental rehabilitation"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01818674","briefTitle":"Microclinic Social Network Behavioral Health Trial in Jordan"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Microclinic International"},"collaborators":[{"name":"Royal Health Awareness Society (RHAS)"},{"name":"Jordanian Ministry of Health (MoH)"}]},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Obesity","Hypertension","Hyperglycemia","Blood Pressure","Hyperglycaemia (Diabetic)","Body Weight","Weight Loss","Weight, Body","Weight Change Trajectory","Weight Change, Body","Weight Gain","Blood Pressure, High","Social Behavior","Behavior, Health","Lifestyle Risk Reduction","Lifestyle, Healthy","Diabetes","Diabetes Mellitus","Glucose, High Blood"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Microclinic Behavioral Health Full Program (education curriculum in classroom setting, plus full social interaction program)"},{"name":"Microclinic Behavioral Health Basic Program (education-only in classroom setting; no structured social interactions)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00050479","briefTitle":"Laser and Medical Treatment of Diabetic Macular Edema"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Eye Institute (NEI)"}},"conditionsModule":{"conditions":["Macular Degeneration"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Celecoxib (Celebrex)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00340678","briefTitle":"Renoprotection in Early Diabetic Nephropathy in Pima Indians"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Diabetic Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Losartan"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00236639","briefTitle":"A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."}},"conditionsModule":{"conditions":["Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"topiramate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00331162","briefTitle":"Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Wake Forest University Health Sciences"}},"conditionsModule":{"conditions":["Graft Rejection"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Alemtuzumab"},{"name":"Anti-Thymocyte Globulin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00784745","briefTitle":"Is Insulin Resistance and/or Glucose Intolerance Pathogenetic in the Development of a Reduced Incretin Effect"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Gentofte, Copenhagen"}},"conditionsModule":{"conditions":["Insulin Resistance","Glucose Intolerance"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Dexamethasone"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02203240","briefTitle":"Cocoa and Metabolic Health in Prediabetes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Virginia Polytechnic Institute and State University"},"collaborators":[{"name":"The Hershey Company"}]},"conditionsModule":{"conditions":["Prediabetes"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cocoa"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01718080","briefTitle":"The Effects of Puberty and Weight on Sugar Metabolism in Children"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Baylor College of Medicine"}},"conditionsModule":{"conditions":["Overweight","Leanness","Adolescent"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05081921","briefTitle":"Clinical Trial to Evaluate Safety and Efficacy of MesoCellA-Ortho Tissue-Engineered Advanced Therapy Product in Patients With Osteoarthrosis and Civilisation Diseases"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Jagiellonian University"},"collaborators":[{"name":"National Center for Research and Development, Poland"},{"name":"KCRI"}]},"conditionsModule":{"conditions":["Osteoarthritis of Knee"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"MesoCellA-Ortho administration"},{"name":"HA administration"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01821079","briefTitle":"A Healthy Volunteer Study To Assess Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Pfizer"}},"conditionsModule":{"conditions":["Healthy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"PF-05175157"},{"name":"PF-05175157"},{"name":"PF-05175157"},{"name":"PF-05175157"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00236600","briefTitle":"A Study on Efficacy and Safety of Topiramate in Maintaining Weight Loss in Obese Patients Following an Intensive, Non-Pharmacologic Weight Loss Program"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."}},"conditionsModule":{"conditions":["Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"topiramate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00419497","briefTitle":"Paleolithic Diet in the Treatment of Glucose Intolerance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lund University Hospital"}},"conditionsModule":{"conditions":["Hyperglycemia","Coronary Heart Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Paleolithic diet vs Mediterranean diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06583161","briefTitle":"Emulation of the Moderate Alcohol and Cardiovascular Health Trial (MACH15)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Harvard School of Public Health (HSPH)"}},"conditionsModule":{"conditions":["Myocardial Infarction","Ischemic Stroke","Angina Pectoris","Coronary Revascularization","All-cause Mortality","Cardiovascular Death","Type 2 Diabetes","Heart Failure","Atrial Fibrillation","Cancer","Dementia","Depression","Infections","Injuries","Liver Cirrhosis"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Moderate drinking"},{"name":"Quitting"},{"name":"Social drinking"},{"name":"Heavy/binge drinking"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02941874","briefTitle":"Determining of Normal Values and Conformity Assessment of the Dosage of a Plasmatic Marker of the Cellular Captation of Glucose: the IRAP Protein"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Grenoble"}},"conditionsModule":{"conditions":["Insulin Resistance"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Blood sample collection during an OGTT to assess IRAP blood concentration"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02261831","briefTitle":"Identify Bacteria Associated With Metabolic Diseases That Reside Both in Intestinal Crypts and in Blood"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Hospital, Toulouse"}},"conditionsModule":{"conditions":["Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"obese patients"},{"name":"diabetic patients"},{"name":"patients free of obesity and diabetes"},{"name":"patients free type 2 diabetes"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03514420","briefTitle":"Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Akcea Therapeutics"},"collaborators":[{"name":"Ionis Pharmaceuticals, Inc."}]},"conditionsModule":{"conditions":["Familial Partial Lipodystrophy"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AKCEA-ANGPTL3-LRx"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04142424","briefTitle":"A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"},"collaborators":[{"name":"Parexel"}]},"conditionsModule":{"conditions":["Metabolic Disorders","Non-alcoholic Steatohepatitis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD2693"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00231608","briefTitle":"A Study of Safety and Efficacy of Topiramate in Male Patients With Abdominal Obesity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."}},"conditionsModule":{"conditions":["Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"topiramate"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02147925","briefTitle":"Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sun Yat-sen University"}},"conditionsModule":{"conditions":["Non-alcoholic Fatty Liver Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Liraglutide combined with metformin"},{"name":"Insulin glargine combined with metformin"},{"name":"Sitagliptin combined with metformin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03596983","briefTitle":"P20 Extending Sleep to Reverse Metabolic Syndrome in Middle-Aged Adults: Acceptability and Feasibility of a Sleep Intervention"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"NYU Langone Health"}},"conditionsModule":{"conditions":["Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Sleep Intervention"},{"name":"Week 2 Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03205150","briefTitle":"Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Novartis Pharmaceuticals"}},"conditionsModule":{"conditions":["Obese Patients With Non-alcoholic Steatohepatitis (NASH)"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"LIK066"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT05177172","briefTitle":"Effect of Oat Compounds on Postprandial Glucose Response"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Lund University"}},"conditionsModule":{"conditions":["Healthy Subjects"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High beta glucans"},{"name":"Low beta glucans"},{"name":"Low beta glucans + low polar lipids"},{"name":"Polar lipids"},{"name":"Control"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00387166","briefTitle":"Socioeconomic Status, Psychosocial Factors, and CVD Risk in Mexican-American Women"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"San Diego State University"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Hypertension","Cardiovascular Disease","Metabolic Disorders"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00348855","briefTitle":"Study to Improve Quality of Care and Patient Health in the Field of Cardiovascular Risk Factors in General Practice"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Collège National des Généralistes Enseignants"},"collaborators":[{"name":"Institut National de la Santé Et de la Recherche Médicale, France"},{"name":"Assistance Publique - Hôpitaux de Paris"},{"name":"Laboratoires Takeda"},{"name":"Merck Serono International SA"}]},"conditionsModule":{"conditions":["High Risk Hypertensive Patients"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Cardiovascular drugs strategies"},{"name":"Compliance"},{"name":"Exercise"},{"name":"Stop Smoking"},{"name":"Diet"},{"name":"Feed Back"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00341406","briefTitle":"Fat Cell Size in Insulin Resistance"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}},"conditionsModule":{"conditions":["Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00325962","briefTitle":"A Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"BioMarin Pharmaceutical"}},"conditionsModule":{"conditions":["Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"6R-BH4 (sapropterin dihydrochloride)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03605810","briefTitle":"Study to Develop a Tool to Estimate the Kidney Function in Databases Without Laboratory Data"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Bayer"}},"conditionsModule":{"conditions":["Renal Function"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"No Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00134160","briefTitle":"OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"OSCAR Study"},"collaborators":[{"name":"Japan Heart Foundation"}]},"conditionsModule":{"conditions":["Hypertension","Cardiovascular Diseases"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Olmesartan medoxomil"},{"name":"Calcium channel blockers (amlodipine, azelnidipine)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02108353","briefTitle":"Circadian Phase Adjustment and Improvement of Metabolic Control in Night Shift Workers"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Universitätsklinikum Hamburg-Eppendorf"}},"conditionsModule":{"conditions":["Sleep Disorders, Circadian Rhythm"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Melatonin 2mg"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04554199","briefTitle":"Brain and Cognitive Function of Patients With RPD"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Research Centre, Egypt"}},"conditionsModule":{"conditions":["Missing Posterior Occlusal Contact"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Flexible partial denture"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01318564","briefTitle":"Diabetic Treatment Adherence"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"M.D. Anderson Cancer Center"},"collaborators":[{"name":"Agency for Healthcare Research and Quality (AHRQ)"}]},"conditionsModule":{"conditions":["Endocrine System Diseases"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Metformin"},{"name":"Questionnaires"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03514238","briefTitle":"The Irisin and Metabolic Exercise Training Study"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of New Brunswick"},"collaborators":[{"name":"New Brunswick Health Research Foundation"}]},"conditionsModule":{"conditions":["Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"High Intensity Interval Aerobic Exercise (HIIT)"},{"name":"Continuous Moderate Aerobic Exercise (MOD)"},{"name":"Control Sitting Condition (C)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01170403","briefTitle":"Comprehensive Analyses of Multidetector-row Cardiac Computed Tomography Data in Koreans"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Seoul National University Bundang Hospital"},"collaborators":[{"name":"The Korean Society of Lipidology and Atherosclerosis"}]},"conditionsModule":{"conditions":["Coronary Disease"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01363141","briefTitle":"Effect of a Low Advanced Glycation End Products (AGE) Diet in the Metabolic Syndrome"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Icahn School of Medicine at Mount Sinai"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Metabolic Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Regular AGE Diet"},{"name":"Low AGE Diet"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03998046","briefTitle":"Coordinating Pragmatic Primary Care Population Management for Obesity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Northwestern University"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Obesity","Cardiovascular Risk Factor"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Outreach Support for Weight Loss Goal Setting and Self-Weighing"},{"name":"Outreach Decision Support to Encourage Linkages to Intensive Community Lifestyle Interventions"},{"name":"Adaptive Tailoring of Information Delivery and Intensity of Primary Care Outreach Support"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01463813","briefTitle":"Finnish Vitamin D Trial (FIND)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Eastern Finland"},"collaborators":[{"name":"Academy of Finland"},{"name":"Juho Vainio Foundation"},{"name":"Finnish Foundation for Cardiovascular Research"},{"name":"Finnish Cultural Foundation"}]},"conditionsModule":{"conditions":["Cardiovascular Diseases","Cancer"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Vitamin D3"},{"name":"Vitamin D3"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01075698","briefTitle":"A Trial of Telmisartan Prevention of Cardiovascular Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Kumamoto University"},"collaborators":[{"name":"Japan Foundation for Aging and Health"}]},"conditionsModule":{"conditions":["Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Non-ARB (standard therapy)"},{"name":"ARB (Telmisartan)"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT06254339","briefTitle":"Effects of OAGB and DJB-SG on 10-year and Lifetime Risks of MACE"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"National Defense Medical Center, Taiwan"}},"conditionsModule":{"conditions":["Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"OAGB"},{"name":"DJB-SG"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01503164","briefTitle":"Effects of Continuous Positive Airway Pressure (CPAP) on Glucose Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Johns Hopkins University"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)"}]},"conditionsModule":{"conditions":["Obstructive Sleep Apnea","Sleep Apnea","Sleep-disordered Breathing"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Positive Pressure Therapy (PAP)"},{"name":"LifeStyle Counseling"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00741585","briefTitle":"Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Vigo"},"collaborators":[{"name":"Servicio Gallego de Salud"}]},"conditionsModule":{"conditions":["Essential Hypertension","Cardiovascular Disease","Stroke","Chronic Kidney Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Any antihypertensive medication alone or in combination"},{"name":"Any antihypertensive medication alone or in combination"},{"name":"Ambulatory blood pressure monitoring"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01767441","briefTitle":"Bariatric Surgeries and Glucose Homeostasis During a Mixed Meal Test"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Azienda Ospedaliera Universitaria Integrata Verona"},"collaborators":[{"name":"Universita di Verona"}]},"conditionsModule":{"conditions":["Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Roux-en-Y-gastric bypass"},{"name":"laparoscopic adjustable gastric banding"},{"name":"laparoscopic sleeve gastrectomy"},{"name":"diet treatment"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02804750","briefTitle":"Study to Evaluate CORT125134 in Participants With Cushing's Syndrome"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Corcept Therapeutics"}},"conditionsModule":{"conditions":["Cushing's Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"CORT125134"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01584063","briefTitle":"Healthy Mothers on the Move"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Michigan"}},"conditionsModule":{"conditions":["Pregnancy","Postpartum Period"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Healthy MOMs Healthy Lifestyle Intervention"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00726778","briefTitle":"Admixture Mapping of Ethnic and Racial Insulin Complex Outcomes"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Alabama at Birmingham"},"collaborators":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"}]},"conditionsModule":{"conditions":["Healthy"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04548232","briefTitle":"Clinical Efficacy and Safety of a Laparoscopic Sleeve Gastrectomy in Obese Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Shanghai 10th People's Hospital"}},"conditionsModule":{"conditions":["Obesity"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Laparoscopic sleeve gastrectomy"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT02060279","briefTitle":"Family-based Lifestyle Intervention Program and Carotenoid Supplementation for Children With Obesity"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Nemours Children's Clinic"}},"conditionsModule":{"conditions":["Pediatric Obesity"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Lifestyle intervention and carotenoid supplements"},{"name":"Lifestyle intervention and placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03560505","briefTitle":"High-resolution Ultrasound in Lower Extremity Nerves and Common Fibular Neuropathies."},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Sándor Beniczky"},"collaborators":[{"name":"Aarhus University Hospital"}]},"conditionsModule":{"conditions":["Ultrasonography","Peroneal Neuropathies"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Ultrasound protocol"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04595370","briefTitle":"Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca"}},"conditionsModule":{"conditions":["Heart Failure","Chronic Kidney Disease"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"AZD9977"},{"name":"Dapagliflozin"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03523403","briefTitle":"Obesity-related Health Benefits of Apples"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Guelph"},"collaborators":[{"name":"Ontario Ministry of Agriculture, Food and Rural Affairs"},{"name":"Ontario Apple Growers"},{"name":"Agriculture and Agri-Food Canada"}]},"conditionsModule":{"conditions":["Obesity, Abdominal","Hyperlipidemias","Inflammation","Dysbiosis"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Apples"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04670094","briefTitle":"Comorbidities and Risk Score in COVID-19 Patients"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University of Milano Bicocca"}},"conditionsModule":{"conditions":["Covid19"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT00573781","briefTitle":"Dietary Modulation of Gene Expression and Metabolic Pathways in Glucose Metabolism"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Marjukka Kolehmainen"},"collaborators":[{"name":"VTT Technical Research Centre, Finland"},{"name":"Wageningen University"}]},"conditionsModule":{"conditions":["Metabolic Syndrome","Obesity","Impaired Glucose Tolerance","Impaired Fasting Glucose"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Diet with increased intake of rye bread, berries and fish"},{"name":"Increased intake of whole grain and rye bread"},{"name":"Control diet with decreased intake of rye bread, berries and fish"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT01647776","briefTitle":"Screening and Risk Factors of Colon Neoplasia"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Case Comprehensive Cancer Center"}},"conditionsModule":{"conditions":["Colon Cancer"]},"designModule":{"studyType":"OBSERVATIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Stool DNA Test"},{"name":"biopsies of rectal and colon mucosa"},{"name":"Questionnaires"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT03697109","briefTitle":"A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Corcept Therapeutics"}},"conditionsModule":{"conditions":["Cushing Syndrome"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Relacorilant"},{"name":"Placebo"}]}}},
{"protocolSection":{"identificationModule":{"nctId":"NCT04373265","briefTitle":"Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)"},"statusModule":{"overallStatus":"COMPLETED"},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Corcept Therapeutics"}},"conditionsModule":{"conditions":["Adrenocortical Carcinoma"]},"designModule":{"studyType":"INTERVENTIONAL"},"armsInterventionsModule":{"interventions":[{"name":"Relacorilant"},{"name":"Pembrolizumab"}]}}}
]